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PS1.2
NEW APPROACHES TO THERAPY
A. Christopher Boyd
University of Edinburgh
This review will concentrate on those therapeutic strategies
founded on our growing knowledge of the molecular basis
of CF. These may be divided into four categories.
1. Modifying defective CFTR. The commonest allele,
F508del, results in a protein which is poorly processed
in the cell. Approaches to identify drugs which can
improve the mobilisation of the F508del protein will be
described. How can new technologies help us design or
discover new drugs? Can modifier genes suggest novel
therapeutic targets?
2. Bypassing defective CFTR. Lack of normal CFTR in the
lung results in the appearance of a sticky, immobile
mucus that permits the in situ growth of bacteria, with
subsequent long-term lung damage. Much effort has
been expended in countering these effects, including the
use of antibiotic and mucolytic agents. Also, novel anti-
bacterial strategies that may prevent bacterial colonisa-
tion will be outlined.
3. Replacing defective CFTR. CF is a candidate for gene
therapy because of its monogenic, recessive nature and
the accessibility of the lung epithelium as a target.
Unfortunately, the barriers to effective gene transfer have
proven to be formidable. Two problems with early for-
mulations emerged from the clinical trials of the 1990s:
(i) inefficient delivery and (ii) short-lived expression,
each necessitating a radical overhaul of CF gene therapy
strategies. Novel approaches to CF gene therapy will be
discussed. The use of vectors that contain CFTR control
elements in order to confer long-term, tissue-specific
expression will be summarised.
4. Correcting defective CFTR. Usual approaches to gene
therapy rely on complementing the mutant gene. Meth-
ods that directly repair the mutation have also been
described. An example is the approach followed by Liu
et al. (Nat Biotechnol, 2002; 20: 47), who used a trans-
splicing strategy to correct the F508del defect in mRNA.
The prospects for such approaches to gene therapy will
be outlined.
PS2.1
EARLY LUNG FUNCTION CHANGES IN CYSTIC
FIBROSIS
S. Ranganathan
Institute of Child Health, London, UK
Pulmonary inflammation and infection develop early in
infancy in those with cystic fibrosis (CF), at a time when
the lungs are developing rapidly. Most subjects with CF die
because of progressive lung disease. It remains a challenge
to develop therapeutic strategies aimed at preventing irre-
versible lung damage. If such therapies are to be introduced
in infancy, objective measures of their efficacy are required.
In older subjects with CF, serial measurements of lung func-
tion are essential in the assessment of disease severity, dis-
ease progression and response to treatment in the
individual. Several investigators have attempted to charac-
terise early lung function abnormalities. While some of the
available data contribute to the current understanding of
respiratory physiology in CF, interpretation of other data
has been limited by differences between centres, with
regard to the methods and equipment used, the patients
selected, small numbers of subjects and the lack of appro-
priate reference data. Recently, studies using newer lung
function methods suggest that the raised volume technique
improves the identification of diminished airway function
in infants with CF. This technique has been used to identify
diminished lung function soon after diagnosis in those with
no clinical evidence of prior lower respiratory illness.
Another exciting technique, multiple breath inert gas wash-
out, is being used to detect ventilation inhomogeneities in
early life. The aim of this talk is to summarise available
data, put these into perspective with more recent develop-
ments of lung function testing in infants and to discuss their
implications.
PS2.2
DIAGNOSIS OF INFECTION IN INFANTS
Felix Ratjen
Department of Paediatrics, University of Essen, Hufe-
landstr. 55, D-45122 Essen, Germany
Relevant pathogens such as S. aureus and P. aeruginosa
can colonise the lower airways early in the course of CF
lung disease and reliable diagnostic methods are important
S2 Journal of Cystic Fibrosis 1 (2002) S1–S4
for early and effective treatment. Diagnosis of infection in
infants is difficult as infants do not expectorate sputum and
induction of sputum is not feasible in this age group. Cur-
rently, throat swabs are the methods most commonly used
in CF infants. More recently, studies aiming to define early
infection and inflammation in CF have utilised bronchoal-
veolar lavage (BAL) to obtain material from the lower air-
ways in CF infants. These studies have shown that
approximately 30% of CF patients acquire P. aeruginosa
during the first 3 years of life. Comparative analysis of
BAL and throat swabs found that throat swabs have a low
positive predictive value for lower airway colonisation with
P. aeruginosa and S. aureus. On the other hand, the nega-
tive predictive value is above 90%, indicating that lower
airway colonisation is uncommon in the presence of neg-
ative throat swabs. Even BAL cannot be considered a gold
standard as only a fraction of the lower respiratory tract is
assessed and focal areas of colonisation may be missed.
Serologic antibodies are not useful to diagnose airway
infection with S. aureus in CF; but antibodies against exo-
toxin A; elastase and alkaline phosphatase are used as an
indirect measure for P. aeruginosa infection. While their
precise role in the management of CF patients is yet
unclear, chronically infected patients usually have positive
antibodies to at least one of the epitopes while negative
antibodies indicate the absence of chronic infection. A lack
of time exists between initial airway colonisation and the
development of P. aeruginosa antibodies and negative anti-
bodies do not rule out early P. aeruginosa colonisation.
Therefore, diagnosis of airway infection in CF infants
remains an ongoing challenge. Due to its invasiveness,
BAL is unlikely to become a routine diagnostic procedure,
but it has proven to be a useful tool for research studies. It
is also helpful in individual patients in the clinical setting,
especially in those who fail to respond to empiric therapy
and in whom other techniques have failed to retrieve an
organism.
PS3.1
SEGREGATION–PROS
Christian Koch
Rigshospitalet, Copenhagen University Hospital, Denmark
Cystic fibrosis should be viewed not as a disease, but as a
state of altered properties of exocrine secretions. Excess
morbidity and mortality is not caused by these changes per
se, and patients with CF would live a close to normal life,
was it not for the complicating acute and chronic infections
of the respiratory tract. Among the infecting pathogens,
Pseudomonas aeruginosa takes the most prominent place;
it is present in the lower respiratory tract at a very early
age, probably because it adheres to the altered secretions
lining the bronchial epithelium; and it proliferates at a very
slow rate, but gradually adapts to the environment by form-
ing rather complex colonies, behaving almost like a mul-
ticellular organism. Beyond this transition, it is no longer
possible to eradicate the organism and the ensuing life-long
inflammation will slowly destroy the lung tissue and lead
to premature death. These are the facts which make it
imperative to prevent this infection and this goal is in sight.
What are the factors that influence this process? Acquisition
of chronic P. aeruginosa depends upon the nature of the
mutations in the CFTR gene being delayed in patients with
class IV and V mutations (1). Onset of chronic P. aerugi-
nosa infection is often precipitated by viral infections and
is also dependent upon the degree of exposure from the
environment, in particular from prolonged contact with
chronically infected patients (2). This occurs when patients
are crowded in the hospital wards and outpatient clinics (3)
or crowded during winter or summer camps (2). Cross-
infection depends upon both time and density of contact
since the organisms are transferred from infected to non-
infected patients by direct physical contact and by coughing
at close proximity. Time and density will probably vary
from one camp to another, and from one hospital to another,
which explains why cross-infection is clearly demonstrated
in several—though not all—studies. Perhaps the most com-
pelling evidence comes from the observation that disruption
of the possibility of patient-to-patient transmission by
cohort isolation led to a gradual reduction in the incidence
and prevalence of chronic infection (4). This is the only
report of a decrease in prevalence from any centre
worldwide.
Even more serious is the problem of pathogens belonging
to the Burkholderia cepaciaymultivorans complex and at
least some strains have caused outbreaks among patients
either within a CF centre, or during social contact (2). The
mortality rate of patients chronically infected with these
pathogens is clearly much higher than among patients with
chronic P. aeruginosa infection (2) and other rare organ-
isms leading to chronic infection are likely to come up in
the future as patients survive to an increasing age.
The sum of our knowledge is that: (1) P. aeruginosa, B.
cepaciaymultivorans can cause cross-infection among
patients with CF dependent upon the degree of exposure;
(2) once established it is virtually impossible to cure these
infections; and (3) these infections are the direct cause of
increased morbidity and mortality in the vast majority of
patients. Under these conditions, we must do our best to
protect our patients from undue exposure, and segregation
by cohorting is effective, and not so difficult to carry out
in practice. It is our responsibility to inform our patients of
the risks of cross-infection, and the fear of stigmatising the
infected patient is no excuse for putting an uninfected
patient at risk of contracting a lethal infection. Decreasing
exposure is one of several effective weapons in the ongoing
battle against chronic gram-negative infections in patients
with CF, which we are ultimately going to win.
1. Koch C, Cuppens H, Rainisio M, et al. European Epi-
demiologic Registry of cystic fibrosis (ERCF): comparison
of major disease manifestations between patients with dif-
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ferent classes of mutations. Pediatr Pulmonol 2001; 31: 1–
12.
2. Høiby N, Frederiksen B. Microbiology of cystic fibrosis.
In: Hodson ME, Geddes DM, editors. Cystic Fibrosis,
Arnold, London, 2000, 83–107.
3. Høiby N, Pedersen SS. Estimated risk of cross-infection
with Pseudomonas aeruginosa in Danish cystic fibrosis
patients. Acta Paediatr Scand 1989; 78: 395–404.
4. Frederiksen B, Koch C, Høiby N. The changing epide-
miology of Pseudomonas aeruginosa infection in Danish
cystic fibrosis patients. Pediatr Pulmonol 1998; 28: 159–
166.
PS3.2
SEGREGATION—CONS
Duncan Geddes
Royal Brompton and Harefield NHS Trust, London, UK
Pseudomonas lives in drinking water, plants and vegetables,
flower vases, sinks, etc. (1). As a result, patients with CF
clinic obtain Pseudomonas from different places and almost
always carry their own unique strain that persists for many
years. While siblings may carry the same strain, suggesting
either cross-infection or a common environmental source,
surveys of hospital patients confirm that cross-infection is
so rare that its occurrence suggests a breakdown in simple
infection control. Different things can go wrong, but since
Pseudomonas is acquired by direct contact rather than air-
borne spread, intimate contact between patients, failure of
hand washing by hospital staff or contaminated equipment
are likely causes and the risks are likely to be much greater
for inpatients than outpatients.
How much does it matter anyway? Intuitively, cross-infec-
tion with a multi-resistant strain must be a disadvantage,
and if some epidemic strains of Pseudomonas are particu-
larly virulent then they are likely to enhance lung damage.
However, more generally, the role of different bacteria in
CF lung disease remains unclear. There is good evidence
that some Burkholderia cepacia genomovars worsen prog-
nosis while others do not (2). The acquisition of Pseudo-
monas aeruginosa resulted in no difference in lung function
decline or mortality in the largest reported study (3), while
others have suggested deterioration. None have yet deter-
mined whether the loss of lung function following the
acquisition of Pseudomonas is causal, or merely a marker
of a bad underlying prognosis. Nevertheless, chronic infec-
tion with Pseudomonas is clearly undesirable since treat-
ment is complicated and the patient’s life disrupted by the
need for nebulised and intravenous antibiotics.
What then can be done to delay acquisition of Pseudomon-
as and limit cross-infection? Avoiding environmental con-
tact with the organism is clearly unrealistic, but the claimed
long term benefits of patient segregation are based on com-
parison with historical controls. Similar improvements have
been seen in clinics not using such measures. Cross-infec-
tion in hospitals must certainly be prevented and the choice
lies between the rigorous application of traditional measures
or a more draconian policy aimed at eliminating the risk.
Proponents of the former argue that hand washing, equip-
ment cleaning, sputum disposal and isolation of patients
with known problem organisms will reduce further an
extremely low risk while acknowledging that outbreaks will
occasionally occur. Proponents of the latter want segrega-
tion of all patients according to sputum bacteriology, even
in an outpatient setting. Neither have direct evidence to
support their views. Paradoxically, a cross-infection rate of
1–3% per annum was reported from a unit that used seg-
regation (4). The problems with segregation include the
uncertainty of sputum culture results until after the event,
the human and financial costs, and inconvenience of admin-
istering a policy that can never be 100% effective and will
inevitably result in loss of flexibility in the clinic. Further-
more, segregation by species rather than by strain and anti-
biotic sensitivity is hardly logical, and risks mixing the
most vulnerable patients with the most undesirable organ-
isms. Bacteriological surveillance is an essential part of
either approach, but is costly and must be continuous.
Perhaps the most worrying feature of the debate is the effect
on the families with CF. There is a real risk of stigmatisa-
tion by sputum bacteriology, enhanced anxiety about a rel-
atively benign organism and fear of attending a CF centre
or any social event where another person with CF may be
met. There are risks in doing too little, but it may be worse
to do too much.
(1). Speller DE, Hospital acquired infections, in: Topley &
Wilson Principles of bacteriology, E. Arnold, London,
1990; 142–167.
(2). Jones AM, Dodd ME, Webb AK, Burkholderia cepa-
cia: current clinical issues environmental controversies and
ethical dilemmas, Eur Respir J, 2001; 17: 295–.01
(3). Kerem E, Corey M, Gold R, Levison H, Pulmonary
function and clinical course in patients with cystic fibrosis
after pulmonary colonisation with Pseudomonas aerugino-
sa, J Pediatr, 1990; 116: 714–719.
(4). Ojeniyi B, Frederiksen B, Hoiby N, Pseudomonas
aeruginosa cross infection among patients with cystic fibro-
sis during a winter camp, Pediatr Pulmonol, 2000; 29: 177–
181.
PS3.4
DRUG THERAPY TO CORRECT THE
UNDERLYING CHLORIDE TRANSPORT DEFECT
IN CYSTIC FIBROSIS
Alan S. Verkman , Luis V.J. Galietta and Tonghui Ma1 2
University of California, San Francisco,1
Ist. Giannina Gaslini, Genova2
Cystic fibrosis is caused by mutations in CFTR, which
functions as a regulated chloride channel in epithelial cells
in the airways and other tissues. Although the mechanisms
by which defective CFTR causes lung disease remain poor-
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ly understood, it is generally believed that the restoration
of normal chloride transport in cells expressing mutant
CFTR would provide an effective therapy in cystic fibrosis.
The most common CF-causing CFTR mutant, deltaF508-
CFTR, produces a chloride-impermeable cell because the
mutant protein is retained (in a functional state) at the
endoplasmic reticulum. Other CFTR mutants causing CF,
such as G551D-CFTR, are trafficked normally to the cell
plasma membrane but have impaired chloride transport
function. Theoretically, drugs that correct deltaF508-CFTR
misprocessing and acute activators of mutant CFTRs should
restore chloride permeability in CF epithelial cells. The CF
Foundation in the United States has funded a major effort
to identify such compounds by high-throughput screening
of lead-based and diverse compound collections. Our lab-
oratory has established a cell-based fluorescence assay sys-
tem to rapidly screen compounds for their ability to restore
chloride permeability in CF cells. In an initial study, 7,8-
benzoflavones were identified as a potent class of CFTR
activators by screening of a lead-based combinatorial
library of flavone and benzoquinolizinium analogs (J. Biol.
Chem. 2001; 276: 19723–19728). Utilising robotic instru-
mentation to test 5000–10 000 compounds a day, we are
screening compound collections of )100 000 compounds
against CFTR targets. A number of novel potent CFTR acti-
vators and inhibitors have been identified, some of which
activate CFTR by a direct-interaction mechanism. The new
CFTR activators are potential lead compounds for devel-
opment of new CF therapies to treat the underlying chloride
transport defect.
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S1.1
MODIFYING FACTORS OF CF DISEASE
Frauke Mekus , Manfred Ballmann , Christian Becker , Jan1 1 1
Bijman , Inez Bronsveld , Ulrike Laabs , Margit Ritzka ,2 2 1 1
Henk Veeze , Burkhard Tummler and the European Cystic2 1¨
Fibrosis Twin and Sibling Study Consortium
Klinische Forschergruppe, OE 6711, Medizinische Hochs-1
chule Hannover, Germany;
Erasmus Universiteit Rotterdam, The Netherlands2
The European Cystic Fibrosis Twin and Sibling Study aims
to unravel the relative impact of the CFTR mutation gen-
otype, environmental and other genetic factors on the man-
ifestation of CF disease.
Clinical epidemiology and formal analyses. Patient pairs
were ranked in terms of disease severity and intrapair dis-
cordance by sex- and age-normalized anthropometric and
lung function parameters. Monozygous twins (29 pairs)
were more similar to each other than dizygous twins and
sibpairs (284 pairs). The cohort of F508del homozygotes
exhibited the same range of disease severity as the whole
patient cohort. The clinical status between the younger and
the elder siblings was not significantly different, implying
that the positive family anamnesis did not affect the clinical
course. The more severely affected patient in a pair received
the more aggressive treatment, suggesting that non-compli-
ance to andyor insufficient supply of therapeutic measures
were only of minor importance for the highly variable man-
ifestation of disease in the investigated patient cohort. Gen-
der differentially affects the course of CF pre- and
post-puberty. Amongst sib-pairs with mixed sex, males had,
on average, the better lung function, and females the better
nutritional status. LISREL analysis revealed that the CFTR
mutation genotype influences the clinical course of CF by
approximately 50%. The relative contributions of environ-
mental and other genetic factors are approximately 4:1 for
lung disease and 2:3 for nutritional status.
Basic defect. The F508del homozygous subgroups with
extreme phenotypes (highly discordant, highly concordant
mildly or severely affected) were characterised in epithelial
chloride conductance by nasal potential difference and
intestinal current measurements. cAMP-regulated chloride
conductance was detected in many patients, suggesting, that
in accordance with previous immunocytochemical studies
on patients’ specimens, in vivo, some F508del CFTR can
reach the apical membrane and affect chloride permeability.
The expression of F508del CFTR-mediated chloride con-
ductance in the respiratory and intestinal tracts was identi-
fied as a positive predictor of mild CF disease. Monozygous
twins were significantly more concordant in their electro-
physiological properties than dizygous pairs. Hence, genetic
factors other than CFTR lead to a variable expression of
the basic defect even amongst subjects with the same CFTR
mutation genotype.
Genetic modifiers. An association study in dizygous
F508del homozygotes (sibpairs or single patients with
extreme phenotypes) identified several chromosomal
regions and candidate genes with differential inheritance of
microsatellite or SNP haplo- andyor genotypes in mildly or
severely affected patients. These regions contain genes that
encode epithelial ion channels or elements of host defence,
growth and development. The partially imprinted region of
chromosome 7q that is in linkage equilibrium with, yet
close to CFTR, was found to contain modulators of the
phenotype of patients with CF.
S1.4yP51
COMPLEX MULTIGENIC INHERITANCE
INFLUENCES THE DEVELOPMENT OF SEVERE
CYSTIC FIBROSIS LIVER DISEASE
K. Friedman , S. Ling , M. Macek Jr. , A. Handler , F.1 2 3 1
Zou , D. Mack , J. Colombo , S. Bell , V. Vavrova , A.1 4 4 5 3
Krebsova , D. Zemkova , G. Castaldo , M. Spina , F.3 3 6 7
Salvatore , M. Phillips , J. Zielenski , L.-C. Tsui , P.6 8 8 8
Durie , L. Silverman , M. Knowles8 1 1
University of North Carolina at Chapel Hill,1
Royal Hospital for Sick Children, Glasgow,2
Charles University, Prague,3
University of Nebraska Medical Center, Omaha,4
The Prince Charles Hospital, Chemside, Australia,5
University of Naples,6
University of Molise,7
Hospital for Sick Children and University of Toronto,8
Canada
Severe liver disease afflicts 2–7% of patients with CF. The
risk for CF liver disease (CFLD) is most likely influenced
by genetic factors. Previously, we reported an increased fre-
quency of protease inhibitor (PI) gene mutations, Z and S,
among CFLD patients with portal hypertension and cirrho-
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sis. Most of this association is attributable to the Z allele,
which is more strongly implicated in severe liver disease in
alpha-1-antitrypsin deficiency. This relationship between
CF and PI gene mutations, however, does not preclude
mutations or sequence variants at other loci from contrib-
uting to the development of severe CF liver disease.
We have also evaluated CFLD patients for a variant in the
TGF-Beta gene, as this cytokine mediates the hepatic pro-
fibrogenic cascade initiated by cholangiocytes compro-
mised in CF. A high-expression variant of the TGF-Beta
promoter (T at y509) might exacerbate the fibrogenic
stimuli inherent to CFLD. There was no increased frequen-
cy of genotypes (CT and TT) bearing the TGF-Betay509
T variant among CFLD patients as a whole. However, a
complex genotype including a Z or S allele in the PI gene,
as well as one or two T alleles at y509, was detected in
19% of our patients compared to 6% among CF controls
without liver disease (OR 3.2, 95%CI 1.2–8.2, Ps0.01).
The mannose binding lectin (MBL2) gene has also been
implicated as an adverse modifier of CF liver disease. We
have genotyped 64 CFLD patients for a promoter variant
(y221 XyY) and structural mutations (B, C, D), each
associated with reduced MBL2 serum levels. These MBL2
variants were not significantly elevated among CFLD
patients as a group compared to control subjects. However,
a complex genotype including a Z or S allele in the PI gene,
as well as one MBL2 structural mutation, was detected in
11% of our patients compared to 3% among CF controls
without liver disease (OR 4.6, 95%CI 1.2–19, Ps0.038).
Taken together, the TGF-Beta high-expression variant, and
structural mutations in the MBL2 gene may interact with
PI gene mutations, potentiating their adverse impact on
CFLD. (Supported in part by CFF CFRDP and
SILVER98IO.)
S1.5yP52
CANDIDATE GENE ANALYSIS OF BONE MASS
DENSITY IN CYSTIC FIBROSIS
G. Malerba , A. Sangalli , E. Petrelli , A. Delmarco , M.1 1 1 2
Rossini , B.M. Assael , M. Mottes , P.F. Pignatti , C.3 2 1 1
Castellani2
DMIBG, Biology and Genetics, University of Verona, Italy,1
Cystic Fibrosis Center, Ospedale Civile Maggiore, Verona,2
Italy,
Osteoporosis Center, University-AL of Verona, Italy3
Failure to maintain bone mass density is a major problem
in adults with cystic fibrosis (CF). CF is due to mutations
in the CFTR gene and other genes may contribute to mod-
ifying the disease. Genetic and environmental factors may
play a role in determining the variability of bone mass. A
sample of 75 unrelated Italian CF individuals (males: 37,
females: 38) has been characterized for bone mineral den-
sity (BMD) at femoral neck and spine. The individuals
were genotyped for the following five polymorphisms in
four osteoporosis candidate genes: calcitonin receptor
(CTR, AluI polymorphism), vitamin D receptor (VDR,
FokI polymorphism), estrogen receptor (ER, XbaI and
PvuII polymorphisms) and collagen type I (COL1A1-Sp1,
MscI polymorphism).
Single genotype distribution was compared among osteo-
porotic (BMD t-score-y2.5), osteopenic (BMDy2.5Ft-
scoreFy1.5) and normal (BMD t-score)y1.5)
individuals. The subjects were also stratified according to
insulin dependence and pancreas activity (sufficient or
insufficient).
CTR polymorphism showed a significant difference in gen-
otype distribution for the BMD of the spine in insulin
dependent individuals (Ps0.016), BMD at femoral neck
in insulin independent (Ps0.02) or pancreas insufficient
individuals (Ps0.038).VDR polymorphism showed a sig-
nificant difference in genotype distribution for the BMD of
the spine or femoral neck in pancreas insufficient individ-
uals (Ps0.034 and Ps0.034, respectively). XbaI-ER pol-
ymorphism showed a significant difference in genotype
distribution for the BMD at femoral neck in pancreas suf-
ficient individuals (Ps0.01) and in insulin dependent indi-
viduals (Ps0.03). These are preliminary results and other
clinical markers associated with the severity of the disease
will be investigated.
In conclusion, candidate genes for osteoporosis may be also
involved in bone mass remodeling in CF patients.
S2.2
DISTAL INTESTINAL OBSTRUCTIVE
SYNDROME
C.J. Taylor
Sheffield Children’s Hospital, University of Sheffield, UK
Distal intestinal obstructive syndrome (DIOS) or meconi-
um ileus equivalent is a common complication of cystic
fibrosis (CF). Between 10 and 20% of patients may expe-
rience symptoms which occur more frequently over the age
of 15 years w1,2x. The patho-physiology is incompletely
understood, but differs from meconium ileus of the new-
born. The syndrome is associated with faecal material and
mucus gathering in the distal ileum and proximal colon.
Reports suggest that DIOS is more common in patients tak-
ing inadequate pancreatic enzyme replacement therapy, but
DIOS has also been reported in patients who are pancreatic
sufficient w3x.
DIOS may present as an acute abdomen pain with intestinal
obstruction or sub-acutely with abdominal pain and consti-
pation. Differential diagnosis includes simple constipation,
appendicitis, chronic intussusception, Crohn’s disease and
fibrosing colonopathy. Abdominal ultrasound scan and a
plain abdominal film will help clarify the diagnosis.
Most cases respond to medical therapy, surgery should be
avoided if possible. Suggested treatments include oral Gas-
trografin w4x, polyethylene glycol preparations w5x given
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orally or via a naso-gastric tube and rectal Gastrografin,
however, efficacy data is lacking. No studies have con-
firmed any intervention which prevents recurrence of
DIOS, although dietary modification, optimisation of pan-
creatin dose and timing and osmotic laxatives are widely
used to prevent relapse.
1. Millar-Jones L, Goodchild MC. Cystic fibrosis, pancre-
atic sufficiency and distal intestinal obstruction syndrome:
a report of four cases. Acta Paediatrica 1995; 84 (5): 577–
578.
2. Andersen HO, Hjelt K, Waever E, Overgaard K. The age-
related incidence of meconium ileus equivalent in a cystic
fibrosis population: the impact of high-energy intake. J
Pediatr Gastroenterol Nutrit 1990; 11 (3): 356–360.
3. Gardiner KR, Cranley B. Acute presentation of cystic
fibrosis in an adult. Postgrad Med J 1989; 65 (765): 471–
472.
4. O’Halloran SM, Gilbert J, McKendrick OM, Carty HML,
Heaf DP. Gastrograffin in acute meconium ileus equivalent.
Arch Dis Child 1986; 61: 1128–1130.
5. Koletzko S, Stringer DA, Cleghorn GJ, Durie. Lavage
treatment of distal intestinal obstruction syndrome in chil-
dren with cystic fibrosis. Pediatrics 1989; 83 (5): 727–733.
S2.3
GASTRO-OESOPHAGEAL REFLUX (GOR)
A. Malfroot, I. Dab
Department of Paediatrics, Respiratory and CF Clinic,
Academic Hospital Free University Brussels (VUB)
GOR is clearly more frequent in CF. It is found in approx-
imately 25% of CF children older than 5 years and adults
and in more than 50% of CF babies and infants. It can
worsen respiratory disease. Apart from regurgitations, no
useful clinical predictors of pathological reflux exist.
It is tempting to suggest that GOR is the consequence of
chronic cough, thorax deformation and disturbed thora-
coabdominal pressure gradient. However, most authors did
not find a relationship between the presence of GOR and
the degree of pulmonary disease. GOR is found in a very
high incidence in infants with newly diagnosed CF, in
whom lung disease is often clinically absent. Therefore, a
primary defect or immaturity or motility disorder of the
oesophagus may be responsible for GOR in very young CF.
Some authors showed transient lower oesophageal sphincter
relaxations in CF, which could suggest a disturbed sphincter
function. Mechanisms may be different in the very young
and the older ones and are probably multi-factorial. It is
also known that chest physiotherapy using postural drain-
age and passive percussion vibrations increases GOR. Other
more active techniques such as bouncing were found to be
less GOR provoking and need to be further developed.
Hyperalimentation and gastrostomy are other contributing
factors. However, even if physiotherapy and feeding can
favour GOR, these are essential treatments, which cannot
be omitted in CF. It can only stimulate us for improving
the techniques.
We suggest that all CF babies and infants should benefit
from systematic GOR investigations, and also older patients
whenever they have clinical signs of GOR or if their treat-
ment yields an unexpectedly bad response. Indeed, two dif-
ferent populations might exist: (1) infants who have an
immaturity or a motility disorder of the oesophagus and (2)
patients who reflux as a result of underlying respiratory or
nutritional complications. In both groups adequate anti-
GOR treatment is indicated.
S2.4yP231: HIGHER INCIDENCE OF UPRIGHT
POSITION GASTROESOPHAGEAL REFLUX IN
CYSTIC FIBROSIS CHILDREN IS RELATED TO
POSTPRANDIAL TIME
J. Walkowiak , B. Oralewska , D. Celinska-Cedro , T.1 2 2
Songin , B. Bychowiec , M. Teisseyre , M. Krawczynski ,1 1 2 1
J. Socha2
Institute of Pediatrics, Department of Gastroenterology1
and Metabolism, Karol Marcinkowski University of Medi-
cal Sciences, Poznan,
Department of Pediatric Gastroenterology, Hepatology2
and Nutrition, Memorial Child Health Institute, Warszawa,
Poland
A high frequency of gastroesophageal reflux disease
(GERD) in children with cystic fibrosis (CF) has been
reported. Antibiotics, drug inhalations and chest physio-
therapy have been associated with a significant improve-
ment in lung function and life expectancy in CF. However,
bronchodilators, postural drainage and manual techniques
of percussion and vibrations increase the incidence of
GERD. There are few data regarding the influence of nor-
mal life activity on GERD in CF. In the present study, the
influence of body position and post-prandial time on the
incidence of GERD has been assessed.
Material and methods: Ninety CF patients aged from 2 to
18 years were introduced into the study. Patients with
severe pulmonary involvement (FEV1-40%) were exclud-
ed. In all children, esophageal 24-h pH monitoring was per-
formed. The total number of reflux episodes per hour, the
number of episodes lasting longer than 5 min per hour and
fractional reflux time (RI) were assessed. Selected periods
comprised upright and supine position, as well as 1- and 2-
h post-prandial time.
Results: GERD was detected in 54 patients (60.0%). In 31
patients with GERD (57.4%), RI was higher than 10, and
in seven (13.0%) higher than 20. The total number of
reflux episodes per hour in supine position was significantly
lower than in the remaining time (P-0.001). There were
more episodes lasting longer than 5 min per hour in post-
prandial time than in upright position in the remaining time
(1- and 2-h post-prandial time excluded P-0.004 and P-
0.002, respectively). RI was higher in upright than in supi-
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ne position (P-0.001). However, after exclusion of 2-h
post-prandial time, no significant differences in RI were
found. Age-related differences in the GERD incidence, both
in upright and supine position, were not detected.
Conclusions: Higher incidence of gastroesophageal reflux
disease in the upright position is related to post-prandial
time.
S3.3
PHYSIOTHERAPY IN INFANTS: TIME FOR A
CHANGE
B.M. Button
School of Physiotherapy, The University of Melbourne,
Royal Children’s Hospital, The Alfred Hospital, Melbourne,
Australia
There is controversy about whether asymptomatic infants
with CF should receive daily chest physiotherapy (PT).
There is no evidence to support the treatment of well
infants. Postural drainage (PD) is still widely used with
infants. The aims are to consider the unique anatomy and
physiology of the immature infant’s gastric and respiratory
systems; to determine the prevalence of gastro-oesophageal
reflux (GOR) in infants with and without CF, as well as
predictors and factors that increase or decrease GOR; to
describe the effects of different positions and states of
arousal and non-nutritive sucking (NNS) on GOR; to dis-
cuss the different forms of PT currently used and their
effects on GOR and lung function in infants with CF.
Infants are nose breathers with horizontal ribs and a flatter
diaphragm, reducing the effectiveness of the anti-reflux bar-
rier. They have frequent liquid meals and spend much of
their time horizontal. GOR is common in infants under 1
year and is found in 18–40% of normal infants and
between 40 and 73% of infants with CF. GOR usually
resolves within 1–2 years as feeds become more solid and
less frequent, and the child spends more time in the upright
position with the development of the trunk extensors. The
ribs become more vertically aligned and the diaphragm
more dome shaped. GOR may be associated with burping,
drooling, irritability, crying, frowning, yawning, stretching,
mouthing, stridor and Sandifer’s Sign. Significantly longer
exposure to GOR was found when infants were placed in
an infant seat at an elevation of 608 compared to prone
lying. The 308 elevated prone position, prone horizontal,
and left lateral position have been found to reduce the
reflux index. NNS has not been associated with an increase
or decrease in episodes of reflux. During PT in 2-month-
old well infants with CF, prone 308 head down resulted in
significantly more episodes of GOR than prone flat; supine
flat more than supine 308 elevated; right lateral 308 head
down more than right horizontal. Left lateral 308 head down
was associated with fewer episodes of GOR than right lat-
eral, which may be due to the anatomical ‘sump’ effect of
stomach. Infants had fewer episodes of GOR while asleep
and using NNS than while awake and crying and oximetry
was found to be relatively stable during PT. The uniqueness
of the infant needs to be considered during PT.
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S3.4yP99
EXHALED BREATH CONDENSATE: HOW
VALUABLE TO MONITOR LUNG
INFLAMMATION?
D. Worlitzsch , M. Ulrich , E. Rietschel , F. Ratjen , K.1 1 2 3
Botzenhart , G. Doring1 1¨
Institute of General and Environmental Hygiene, Univer-1
sity of Tubingen,¨
Children’s Hospital, University of Cologne,2
Children’s Hospital, University of Essen, Germany.3
As a consequence of chronic bacterial lung infection,
patients with cystic fibrosis (CF) suffer from chronic lung
inflammation. Exhaled breath condensate (EBC) has been
proposed to monitor inflammation in CF and other inflam-
matory lung diseases as a non-invasive tool. A large num-
ber of markers of inflammation are currently being
discussed in this context ranging in size from small com-
pounds such as hydrogen peroxide (H O ) to larger proteins2 2
such as interleukins. We hypothesized that forces keeping
proteins in the airway surface liquid do not allow proteins
to be present in the gas phase, and consequently, proteins
should not be present in the EBC. We, therefore, measured
H O , neutrophil elastase (NE) and myeloperoxidase2 2
(MPO), derived from inflammatory cells, and alpha-amy-
lase, derived from salivary glands in EBC samples of 34
CF patients with mild lung disease and 10 healthy individ-
uals (HI). In addition, we compared results from EBC with
that obtained in BAL fluids. H O was detectable in EBC2 2
(CF: 0.73"1.21 mM; HI: 1.11"0.78 mM) and BAL (CF:
1.71"1.21 mM) samples. Neutrophil enzymes were absent
in all EBC samples but present in BAL fluids from CF
patients (NE: 5.34"8.40 units; MPO: 0.64"1.18 units).
Alpha-amylase was present in all EBC samples (range 5–
100 ngyml). Besides alpha-amylase, no other protein was
detectable ()3 ngyml) in EBC samples. We conclude that
EBC is a possible tool to monitor lung inflammation when
low molecular weight markers of inflammation are used,
whereas the more invasive technique of BAL is still nec-
essary when information about protein markers of inflam-
mation are needed.
S3.5yP100: BALF NITRITE AS AN INDICATOR
OF LOWER AIRWAY INFLAMMATION IN CF
I. Ilker Cetin , U. Ozcelik , A. Gocmen , N. Kiper , D.4 2 1 1
Dogru , E. Yalcin3 4
Department of Pediatric Chest Diseases, Ihsan Dogramaci1
Children’s Hospital, Hacettepe University Faculty of Med-
icine, Ankara, Turkey
Department of Pediatric Chest Diseases, Ihsan Dogramaci2
Children’s Hospital, Hacettepe University Faculty of Med-
icine, Ankara, Turkey,
Department of Pediatric Chest Diseases, Ihsan Dogramaci3
Children’s Hospital, Hacettepe University Faculty of Med-
icine, Ankara, Turkey
Department of Pediatric Chest Diseases, Ihsan Dogramaci4
Children’s Hospital, Hacettepe University Faculty of Med-
icine, Ankara, Turkey
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Aims: The aim of this study was to evaluate the cytokine
and nitrite levels in serum and bronchoalveolar lavage flu-
ids (BALF) of clinically stable patients with cystic fibrosis
(CF) and patients to whom flexible fiberoptic broncho-
scopy (FFB) was applied because of clinical indications
other than infection and to show the relationship between
the indicators of inflammation and nitrite levels.
Methods: 20 children with CF of mean age 8.2 years and
10 children from control group of mean age 4.2 years
included in the study. BALF and serum samples were stored
at y700 8C. Cytokine levels were measured by using ELI-
SA (Enzyme Linked ImmunoSorbent Assay) and nitrite
levels were measured by using Griess method. Cytokine
and nitrite levels obtained from BALF samples were mul-
tiplied by a factor of serumyBALF urea ratio to get correct
levels.
Results: BALF neutrophil (median 67.5% vs. 14%), TNF-
a (median 133.1 vs. 40 pgyml), IL-8 (median 6.1 vs. 2.8
ngyml) and nitrite levels (median 207.2 vs. 37.5 mMyl)
were significantly higher in patients with CF than in control
patients. The significantly higher BALF nitrite levels also
correlated positively with serum (Rs0.1) and BALF (Rs
0.3) leukocyte counts. There was no such a correlation for
serum levels of these parameters. There was also no cor-
relation between serum and BALF levels of cytokines and
nitrite levels for both groups. There was a strong and sig-
nificant relation between BALF IL-8 levels and BALF
nitrite levels in patients with CF and also control patients.
Conclusions: Inflammatory cytokines and nitrite levels in
the BALF of patients with CF were found to be increased
with a positive correlation. There was no correlation
between serum and BALF levels of inflammatory cytokines
and nitrite levels. These results suggest that BALF nitrite
levels reflect the degree of inflammation localized to lower
respiratory tract and may be a useful indicator of airway
inflammation for patients with CF.
S4.1
SURVIVAL WITHOUT TRANSPLANT
Ilse Goetz
University Children’s Hospital, Vienna, Austria
Patients with cystic fibrosis (CF) who would need lung
transplantation (LTX) but refuse it, challenge the families’
and health professionals’ (HP) capability to confront a like-
ly death that might be prevented. Reasons for refusal are
manifold, including fears of any kind (e.g. unfamiliar doc-
tors, painful procedures, unknown outcome, sustained
dependency), experiences of other patients, contradictory
opinions among significant others, and personal beliefs.
Only seldom does a patient want hisyher life to come to
an end. Rather, as a result of exhaustion and poorly reward-
ed fighting, death may be considered a relief. Clearly,
patients who reject LTX need our understanding and the
best support possible. Often, a decision against LTX is sub-
ject to change. Therefore, HP acceptance of refusal should
be coupled with the awareness of potential doubts and
change of mind in the patients and they should be encour-
aged to re-discuss pros and cons repeatedly. Hope that the
individual course of disease may be different from what is
generally known and the slightest improvements in health
status, even on a very low level, support refusal. Refusal
does not necessarily lead to death within the anticipated
time-span. Although a shocking experience, the communi-
cation of the need for LTX may result in—sometimes for
the first time—intense adherence to treatment recommen-
dations. There are patients who, threatened by the idea of
a transplant, mobilise all their will-power and energy to
improve nutrition, increase physiotherapy, follow medica-
tion, and reduce workload. The experience of actual
improvement usually associated with a better quality of life
motivates some patients to later accept LTX. Many other
reasons can be seen that turn initial refusal into later accep-
tance, such as surviving a life-threatening deterioration that
results in the wish to live on or altered life circumstances
that open a new perspective of life. Because many patients
change their mind, HP must not view an initial refusal as
a definite decision, but a temporary attitude on a continuum
of conflicting wishes influenced by many experiences and
events. Decision-making is a process that requires HP, who
provide information, counselling, and emotional support
and who are respectful and understanding towards contra-
dicting and changing decisions.
S4.2
THE PSYCHOSOCIAL CORRELATES OF
TRANSPLANT SURVIVAL
Drs Esther Serrano-Ikkos and Bryan Lask
Heart and Lung Transplant Unit, Great Ormond Street
Hospital, London, UK
Background: Individual and family characteristics can
increase the risk of adverse outcomes related to diseases of
children or provide protection from them. The literature
provides strong support for the protective effect of good
individual and family functioning. Protective and risk fac-
tors in children with CF receiving lung transplantation have
not been investigated.
Aims: This study prospectively investigated the relation-
ship between pre-transplant assessment of psychiatric diag-
nosis, parent–child relationship, marital satisfaction, family
functioning and parental stress, and an outcome measure of
survival up to 156 months post-transplantation.
Method: Eighty-two children with CF—mean age 11
years, 6 months—admitted between 1988 and 1995 to
assess suitability for transplantation, underwent a semi-
structured standardised psychiatric interview (Rutter and
Graham, 1968). Their parents underwent the Camberwell
Family Interview (Vaughn and Leff, 1976) and completed
two self-reports measures, the Golombock Rust Inventory
of Marital State (Rust et al., 1985) and the General Health
Questionnaire—GHQ-28—(Goldberg, 1978).
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Results: Only half of the children survived to receive trans-
plantation; survivors and non-survivors were comparable in
all pre-transplant measures. Twenty percent of the children
had a psychiatric disorder and 50% of the families had dif-
ficulties in their functioning. A follow up of the transplant-
ed children, ranging from 3 to 156 months
post-transplantation, produced a group of 15 survivors and
19 non-survivors. Family warmth, measured from the Cam-
berwell Family Interview, was the only significant predic-
tors of survival (Ps0.02).
Conclusion: To our knowledge, this is the first study using
survival analysis in children with CF to examine survival
in relation to pre-transplant psychological measures. The
results indicate that family warmth is associated with
increased survival. Preventive interventions aimed at
increasing family strengths are warranted.
S4.4
WHY DO PEOPLE SURVIVE AGAINST THE
ODDS?
Marie Johannesson
Uppsala CF center, Uppsala University Hospital
‘Because I am so stubborn’
‘I laugh a lot with my friends-I try not to take life too
seriously’
‘Is there an option?
‘I have a wonderful family’
‘I have a great job’
‘I have learned to love myself.’
These were statements I received when I asked some of my
older patients what kept them going despite never ending
treatment sessions for their CF.
As a CF-physician, I have followed my older patients for
many years. A few of them survive despite poor lungfunc-
tion and frequent infections during long periods, and they
appear to live on the edge.
Yes, we can argue that medical treatment has much
improved and that there exists other genes that modify the
CF illness. Even so, we have to acknowledge the inner
strength in each patient.
One concept used when discussing resilience is ‘sense of
coherence’.
According to medical psychologist Aaron Antonovsky, this
concept consists of three parts.
1. Comprehensibility
2. Manageability
3. Meaningfullness
During my lecture, I will discuss the parts mentioned
above, and I hope to have a fruitful discussion with the
audience.
S5.1
ASTHMA DRUGS IN CF
Steven Conway
St James’ and Seacroft Hospitals, Leeds, England
People with CF share common ground with asthma
patients. Both suffer from lung disease, in which chronic
inflammatory activity plays an important role. Many with
CF show airway hyper-reactivity and reversible broncho-
constriction. Both may be compromised by excessive
mucus secretion. There is a rationale for the use of asthma
drugs in CF care and bronchodilators and inhaled cortico-
steroids (ICS) are frequently taken by dry powder or meter-
ed dose inhalation, with and without spacer devices, or by
nebuliser. They are prescribed with increasing frequency. In
our unit, there has been a 23% rise in bronchodilator, and
a 186% rise in ICS use over 10 years. Oral corticosteroids
(OCS) are also frequently prescribed, not only as treatment
for allergic bronchopulmonary aspergillosis, but often as a
last resort blanket anti-inflammatory therapy. There have
been a few reports of early experience of the leukotriene
receptor antagonists in CF management and their use is
likely to increase. However, are all these drugs safe, and if
so, are they effective?
Study populations of children and adults show significant
increases in expiratory flow in up to one-third of patients
after bronchodilator therapy, but assessment is complicated
by within patient variability reflecting different clinical con-
ditions at different times. Theoretically bronchodilation
may reduce end expiratory flow and compromise coughing
efficiency. Patients need to be assessed before and after
treatment with B agonist, anticholinergic and combination
therapy.
The Cochrane systematic review states that there is insuf-
ficient evidence to conclude if ICS are beneficial or harm-
ful. OCS have limited application because of side effects,
and then are probably only short term in selected patients.
Further data are needed for the leukotriene receptor
antagonists.
I will discuss the latest evidence for and against asthma
drugs in CF to provide a framework for their rational use
and to highlight areas where further research is needed.
S5.2
MACROLIDES IN CYSTIC FIBROSIS
Andrew Bush
Royal Brompton Hospital, Sydney Street, SW3 6NP, UK
The macrolide antibiotics have become of interest in cystic
fibrosis (CF) for more than their well established antibac-
terial properties. The initial interest arose from observations
in patients with diffuse panbronchiolitis (dpb). This is a
condition seen almost exclusively in middle-aged people in
the Far East, especially Japan, with many similarities to CF.
It is characterised by progressive airflow obstruction with
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sinusitis and distal airway disease, with chronic infection
with mucoid Pseudomonas aeruginosa. Serendipitously, it
was found that treatment with low dose erythromycin
improved 10-year survival from approximately 20% to
more than 90% w1x. So dramatic were these results that an
attempt to mount a randomised controlled trial failed mis-
erably, because no patient wished to take the chance of
entering the placebo limb (Rubin B, personal communica-
tion). This beneficial effect occurred at doses of erythro-
mycin likely to achieve serum and sputum levels well
below the mean inhibitory concentration for the common
CF pathogens Haemophilus influenza, Staphylococcus
aureus and Pseudomonas aeruginosa, nor does it seem like-
ly that the effects were due to treatment of an occult infec-
tion with atypical mycobacteria. It has been speculated that
the effect on prognosis in dpb is mediated by the anti-
inflammatory and not the antibacterial properties of eryth-
romycin. These have been reviewed in detail elsewhere w2x.
CF is known to be characterised, not merely by chronic
bronchopulmonary infection with Haemophilus influenza,
Staphylococcus aureus and Pseudomonas aeruginosa, but
also by an exuberant inflammatory response, with the
recruitment of huge numbers of neutrophils to the airway,
the release of the potent secretagogue neutrophil elastase
(NE), and the propagation of cycles of inflammation which
become destructive to the airway w3x. Anti-inflammatory
strategies which have been tried include oral prednisolone
(beneficial effects, but side-effects unacceptable w4x), non-
steroidal anti-inflammatory agents (indomethacin, benefit
equivocal and only in some age groups w5x) and inhaled
steroids (benefits controversial w6,7x). Thus, the use of
macrolides for their anti-inflammatory properties appears
attractive in CF. Further possible reasons for using these
compounds include potential effects on disrupting the Pseu-
domonas aeruginosa biofilm w8x, favourably modulating
mucus viscosity w9x, interfering with the Pseudomonas
aeruginosa quorum sensing w10x and upregulating other
members of the ATP binding cassette superfamily of which
CFTR is a member w11x, such as the multidrug resistant
protein, and thus improving chloride transfer at the apical
cell membrane. An initial open label study of oral azith-
romycin in seven children over at least 3 months showed
promising results, with improvements in first second forced
expired volume (FEV ) and forced vital capacity (FVC) of1
approximately 10% w12x. Our group subsequently reported
a randomised, placebo controlled, double blind study of
azithromycin in 42 children treated for 6 months with a 2-
month washout period w13x. The results showed a similar
benefit both for the group as a whole (increase in FEV of1
approx. 7%), and for the same proportion of individuals
(approx. two-thirds), as the large randomised controlled
study of rhDNase w14x. There was no effect on sputum IL-
8 or NE levels, nor could we demonstrate any effect on
nasal potential differences, which might have supported a
direct effect of azithromycin on the ATP binding cassette
superfamily. A Danish study of clarithromycin in CF was
underpowered due to large numbers of withdrawals w15x.
An Australian study in CF adults w16x showed reduction in
the need for intravenous antibiotics, better maintenance of
lung function (but no improvement, unlike in our studies
w11,12x) and improvement in quality of life scores. The
differences may relate to their patients having more
advanced disease, although anecdotally, some CF patients
with really severe lung disease may respond dramatically
to treatment with macrolides.
In conclusion, macrolides show promise as a treatment for
CF lung disease. The mechanism of action is unclear, and
their place not yet established. However, a 6-month trial of
oral macrolide is certainly worth considering in CF patients
doing badly on conventional treatment.
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S5.3yP104: CHRONIC TREATMENT WITH
CLARITHROMYCIN MAINTAINS TH1 TYPE
RESPONSE IN CF PATIENTS COLONIZED WITH
P. AERUGINOSA
A. Pukhalsky , G. Shmarina , S. Kokarovtseva , N.1 1 1
Kapranov , N. Kashirskaja .2 2
Laboratory of Immunogenetics, Research Centre for Med-1
ical Genetics. Russia,
Department of Cystic Fibrosis, Research Centre for Med-2
ical Genetics, Russia
Twelve CF pediatric patients (the mean age 10.5 years)
were enrolled into the study. All patients were chronically
colonized with P. aeruginosa. Beside the basic therapy, the
patients were treated with clarythromycin in a dose of 250
mg every other day orally. The patients were examined
before clarythromycin prescription and after 3, 6 and 12
months of the treatment. During 1 year before the start of
the therapy, the most patients had experienced a decline in
FEV1 and FVC (y3.6 and y4.9% predicted, respective-
ly). Following clarythromycin treatment, the lung disease
progression become slower: annual changes in the pulmo-
nary function test parameters amounted to 9.3 and 10.4%
predicted, respectively (both P-0.02). Inflammatory mark-
er investigation revealed both local and systemic anti-
inflammatory effects of the drug. Thus, a marked decrease
of the sputum TNF-alpha level from 75.8 to 14.5 IUymg
protein has been found (Ps0.04). A significant increase of
peripheral blood lymphocyte sensitivity to glucocorticoids
was also shown. These data confirm the results of previous
investigations demonstrating the anti-inflammatory effect
of 14-membered macrolide antibiotics. Moreover, it was
shown that 6-month treatment with clarythromycin resulted
in the marked reduction of the sputum IL-4 (Th2 type cyto-
kine), whereas no change in the sputum IFN-gamma (Th1
related cytokine) was found. IFN-gammayIL-4 ratio sig-
nificantly increased during clarithromycin treatment (P-
0.03). In the plasma specimens, the similar shift in the
cytokine profile as well as IFN-gammayIL-4 ratio elevation
have been revealed. These changes in plasma cytokine lev-
els remained during 1 year, whereas in the sputum, a sig-
nificant decrease of IFN-gamma and IL-4 has been
observed. During clarythromycin treatment all patients
showed a significant increase of peripheral blood lympho-
cyte response to phytohemagglutinin. The data show that
beneficial effect of clarythromycin is associated with the
prevalence of Th1 type response.
S5.4yP105: STIMULATION OF PULMONARY
DENDRITIC CELLS WITH GM-CSF INDUCES A
TH1 RESPONSE IN MICE WITH CHRONIC
PSEUDOMONAS AERUGINOSA LUNG
INFECTION
C. Moser, PØ. Jensen, R. Shirai, H. Calum, A. Kharazmi,
N. Høiby
Department of Clinical Microbiology; Copenhagen,
Denmark
Aims: Previously, a Th2-dominated response in cystic
fibrosis (CF) patients with chronic Pseudomonas aerugi-
nosa lung infection has been described. Moreover, a more
Th1-dominated response has been shown to be related to
the GM-CSF levels and to correlate with better lung func-
tion. Therefore, we speculated whether GM-CSF treatment
could induce a Th1 response in susceptible Th2 reacting
BALByc mice with chronic P. aeruginosa lung infection.
The effect would presumably be mediated by subsets of
dendritic cells (DC).
Methods: Chronic P. aeruginosa lung infection was estab-
lished in 18 BALByc mice. The mice were divided into
three groups with six mice in each group: high dose (0.2
mgyday), low dose (0.02 mgyday) and controls. Mice were
treated from day 3 until day 6, and killed day 7. The cyto-
kine release by lung cells was investigated, and the frac-
tions and subsets of dendritic cells were estimated by flow
cytometry.
Results: Both the IFN-gyIL-4 and the IFN-gyIL-5 ratio
increased significantly (P-0.02) in the high dose treatment
group, indicating a Th1 dominated response. Magnetic cell
sorting revealed that both CD4 and CD8 cells contributed
to the IFN-g production, whereas the IL-4 production orig-
inated from CD4 cells. Moreover, the IFN-gyIL-4 ratio
doubled in CD4 cells in the high dose treatment group.
CD8a and CD11b were used to distinguish between differ-
ent subsets of DCs. The fractions of double positive CD8ay
CD11b DCs wLangerhans cell (LC) -derived DCx increased
significantly in the high treatment group (P-0.04), where-
as the fractions of CD8a or CD11b single positive DCs did
not differ between the three groups.
Conclusions: The present findings indicate a possible Th1
inducing role for GM-CSF in patients with chronic P. aeru-
ginosa lung infections. The results further indicates that the
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modulation of the Th1yTh2 balance is mediated by GM-
CSF effects on the pulmonary LC-derived DCs.
S6.1
AN UPDATE ON THE BURKHOLDERIA CEPACIA
COMPLEX
John R.W. Govan
Medical Microbiology, University of Edinburgh Medical
School, Edinburgh, UK
The Burkholderia cepacia complex (Bcc) describes a
diverse group of bacteria whose natural habitats include
soil, water, and the rhizosphere of plants. Interest in these
highly versatile microbes stems primarily from their impor-
tance as pathogens for plants, human and animals, and iron-
ically, as biopesticides to control plant or fertilisers in poor
soils (1). The Bcc provide a particular challenge to the CF
community as a cause of life-threatening lung infections
with intrinsic resistance to antibiotic therapy and the poten-
tial for epidemic spread. To understand the epidemiology
and hostypathogen interactions of ‘B. cepacia’, it is nec-
essary to take into account the evolving taxonomy of these
closely related bacteria (2). At present, the Bcc comprises
least nine genomic species (genomovars). Although all
members of the Bcc have been cultured from CF sputum,
it is important to note the following. First, B. cepacia gen-
omovar III and B. multivorans account for over 90% of
clinical isolates. Second, spread of individual strains, in
particular the genomovar III lineage known as ET12, can
occur at local, national and intercontinental level. Third,
clinical outcome cannot be predicted even when a group of
individuals are infected by the same epidemic strain. These
factors continue to thwart attempts to make generalisations
on Bcc issues concerning virulence, transmission, antibiotic
resistance and infection control.
This update will draw on recent research, including the
expertise and collaborations of the International B. cepacia
Working Group (http:yygo.toycepacia), to discuss progress
in the microbiology of the Bcc and in the management of
Bcc infections.
(1). Parke JL, Gurian-Sherman D. Diversity of the Burk-
holderia cepacia complex and implications for risk assess-
ment of biological control strains. Ann Rev Phytopathol
2001; 39: 225–258.
(2). Coenye T, Vandamme P, Govan JRW, LiPuma. Tax-
onomy and identification of the Burkholderia cepacia com-
plex. J Clin Microbiol 2001; 39: 3427–3436.
S6.3
ASPERGILLUS
Martin H. Schoni, M.D. Prof of Pediatrics,¨
Department of Pediatrics, University of Berne, Switzerland,
CH-3010 Berne
Approximately 130 ubiquitous mold species are known, but
in 80% of the cases, Aspergillus fumigatus (Asp. f) is the
causing agent for disease in humans; other species as Asp.
niger, Asp. flavus or Asp. nidulans are very rarely cultured
and are not responsible for a immune reaction such as aller-
gic broncho-pulmonary aspergillosis (ABPA). In some
patients, a combined type I and type III allergic reaction is
elicited with the production of serum IgA, IgE and IgG
antibodies to Asp f. Recently, cloning, characterisation and
production of recombinant allergens (rAsp. f 1,3,4 and 6)
from Asp. f improved the diagnostic precision. All sensi-
tized patients expresse significant levels of IgE to rAsp. f1
and rAsp. f3, whereas only rAsp. f 4 and rAsp. f 6 are sig-
nificantly elevated in ABPA. Of 74 CF patients whose
serum was screened for IgG and IgE antibodies to Asp. f,
23 were identified to have serologically defined ABPA, 40
were diagnosed to be sensitised (sensABPA) and only 11
had completely normal serum antibody concentrations
(noABPA). The concentrations of total serum IgE and spe-
cific IgE serum antibodies to rAsp. f were significantly dif-
ferent between the ABPA and sensABPA and the noABPA
patients, respectively. However, lung function test results
did not statistically differ between these groups. From the
23 patients serologically identified having ABPA, only 11
showed clinical symptoms fulfilling Nelson’s cirteria (clas-
sic ABPA) and 12 (seroABPA) did not.
We found that the single determination of a total serum IgE
value higher than 1000 kUyl offers a specificity of 92% for
the accurate diagnosis of patients with clinical signs of
ABPA with a low sensitivity and a low positive predicted
value. The combination of high ()1000 kUyl) total serum
IgE and elevated rAsp. f 4 andyor 6 for an accurate diag-
nosis of classic ABPA in CF patients increased specificity
and positive predictive value to 100%.
In our study, sevenof 11 patients with classic ABPA were
treated with oral corticosteroids for 12 months; the others
with itraconazole. Under this treatment, IgE antibodies to
rAsp. f antigens 4 andyor 6, total serum IgE and IgG levels
decreased slightly, but none normalized. Whether CF
patients with ABPA need oral corticosteroids in addition to
inhaled steroids for the therapeutic control with or without
anti-fungal treatment is questioned.
S6.4yP207: PROSPECTIVE STUDY OF
NONTUBERCULOUS MYCOBACTERIA
ISOLATES IN CHILDREN WITH CYSTIC
FIBROSIS
M. Ballmann, S. Junge
Medical School Hannover Paediatric Department, Hanno-
ver, Germany
The aim of this prospective study was to determine the
prevalence of positive cultures for NMT in children with
CF. In a prospective study over 1 year (from 01.03.2000 to
28.02.2001), we screened all sputa of children with CF for
NMT when they had their routine visit in the outpatient
CF-centre. We have seen 169 children (90 female, 78 male)
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at an age of 9"5 (mean"S.D.) during the 1-year period,
this were 415 consultations. The patients had a FEV1 of
86"21.3% predicted, a weight for height of 97.4"10.9%,
a C.N.-score of 7.4"4.3 and 73 (43.2%) were colonised
with Pseudomonas aeruginosa. Sixty-seven (40.9%)
patients expectorated sputum, which was tested for NMT.
These patients were 12.8"3.4 years old and had a FEV1
of 80.5"21.7% predicted, a weight for height of
96.8"13% and a C.N.-score of 9.8"5.1. Forty-two
(62.7%) of them were colonised with Pseudomonas aeru-
ginosa and 41 (61.2%) had 2–4 annual intravenous anti-
biotic courses. We screened 157 sputa for NMT and had
additional costs of 74750. In four out of the 67 patients
(6%) with an age of 13"1.5 years, we found six positive
cultures for NMT (3=M. abscessusychelonae, 1=M.
avium, 1=M. intracellulare, 1=M. fortuitum). In these
patients, we found a FEV1 of 71.7"25.5% predicted
(range: 44–97.1), a weight for height of 94.7"13.4%
(83.2–116) and a C.N.-score of 9.25"3.59 (6–14). All
patients were colonised with Pseudomonas aeruginosa and
got antibiotic i.v. therapies regularly. None of them showed
a clinical deterioration in the time of positive culture for
NMT, that is why nobody was treated with antimycobac-
terial drugs. Conclusions: The prevalence of NMT in chil-
dren with CF is lower than in adults (6% of children who
produce sputum vs. 9% of adults, same laboratory meth-
ods). A clinical disease is rare and the costs of screening
for NMT are high. It might be sufficient to test for NMT
if there is clinical deterioration or there are specific changes
in thorax X-ray.
S7.2
EXTENSIVE GENETIC ANALYSIS FOR
NEONATAL SCREENING
Carlo Castellani
Cystic Fibrosis Center, Ospedale Civile Maggiore; Verona,
Italy
CF screening is based on the immunoreactive trypsinogen
(IRT) assay on dried blood spots. In order to reduce the
false positives, different strategies have been developed and
applied to newborns positive to the IRT assay, including
analysis for gene mutations. As a consequence, a few car-
rier newborns are detected.
As the main advantage of heterozygote detection is
informed reproductive decision-making, newborns will
have no benefit from this information until they reach
reproductive age. Even then, this benefit is only hypothet-
ical, since the genotype information could not be preserved
over such a long stretch of time.
The finding of a carrier newborn might instead be of poten-
tial value to parents and relatives, as some couples at high
risk for having a child with CF can be identified. However,
this applies only to a minority of cases; usually, only one
of the parents is found to carry a CF mutation, while the
negative-testing partner will still have a chance of being a
carrier. Therefore, the couple is left with a risk of having
an affected child which, depending on the detection rate of
the panel of tested mutations, can be sometimes similar to,
but some other times considerably higher than that for the
general population.
Another issue is that non-affected IRT positive babies have
been found to carry CF mutations much more often than
the general population. It has been suggested that neonatal
hypertrypsinemia could indirectly detect healthy carriers,
who may have some subclinical impairment of exocrine
pancreatic function as early as the first days of life. Con-
versely, at least some hypertrypsinemic carrier newborns
have, on the other chromosome, an undetected mild muta-
tion, and possibly suffer from an atypical form of CF, char-
acterized by a negative sweat test.
The decision on how extensive genetic analysis for neonatal
screening should be cannot be taken without considering all
these issues.
S7.3
INTERNATIONAL QUALITY CONTROL OF IRT
SCREENING PROGRAMMES
G. Travert
Department of Biophysics and Nuclear Medicine, Neonatal
screening laboratory of Normandy, Caen University Hos-
pital, 14033 Caen, France
Newborn baby population screening for cystic fibrosis is
primarily done by measurement of immunoreactve trypsin
(IRT) in dried blood spots; when IRT is elevated, some
combination of DNA analysisyrepeat sampling on the same
or a new sample is used to determine which patients are to
be referred for diagnostic testing. The most common pro-
tocols are IRT, followed by IRT on a second sample, or
IRT followed by DNA analysis on the same sample or a
combination of both. Quality assurance of CF screening has
the same requirements as other screening, i.e. quality assur-
ance of the sampling and screening processes, and quality
assurance of the analyses (internal, external and population
quality control).
IRT is an ill-defined molecule. It is known that different
molecular forms exist in serum, and that the distribution of
forms in CF and not-CF differs. There is no certified ref-
erence IRT preparation. Commercially available trypsin dif-
fers between companies, and there is little correlation
between lots of immunogenicity, protein content and tryptic
activity.
External quality assurance materials for IRT assays are
obtainable from the HGSA (Human Genetics Society of
Australasia) and IRTIQAS (IRT International Quality
Assurance Scheme-France). HGSA uses purified human
cationic trypsin from different sources and IRTIQAS uses
blood from patients with pancreatitis or normal individuals,
but neither of these provide an appropriate, consistent mate-
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rial which suits all assays. There is a diversity of antibodies
in IRT kits so that different kits may react differently to
different quality assurance samples and the significance of
this to false negative cases of CF is difficult to estimate,
since the molecular form of IRT in CF neonates has not
been characterised.
Population parameters, such as the mean value in a batch
and false positive rates at different cut-off levels can be
used to monitor the analytical stability of IRT assays.
The addition of PCR products of different regions of the
CFTR gene to 55% hematocrit blood samples enriched with
IRT and spotted onto filter paper enables blind quality
assurance of both process and analyses of the single-sample
two-tier IRTyDNA screening strategy.
The materials supplied by IRTIQAS and the HGSA, as well
as the handling of data and statistical analysis they provide,
have been found satisfactory by many screening pro-
grammes for several years. However, the absence of a ‘gold
standard’ IRT material and the lack of knowledge about the
molecular form of IRT elevated in CF newborns are sig-
nificant barriers to the provision of a totally adequate exter-
nal quality assurance programme for CF neonatal screening.
S7.4yP94
PULMONARY DISEASE AFTER DELAYED OR
WITH EARLY DIAGNOSIS THROUGH
NEONATAL SCREENING
P. Farrell , M. Kosorok , M. Rock , M. Splaingard , A.1 2 1 4
Laxova , L. Zeng , Z. Li , J. Collins , C. Green1 2 2 3 1
Department of Pediatrics,1
BiostatisticsyInformatics,2
Department of Radiology, University of Wisconsin-3
Madison,
Pediatrics, Medical College of Wisc, Milwaukee, USA4
Neonatal diagnosis of cystic fibrosis (CF) through screen-
ing provides an opportunity to prevent malnutrition and also
offers potential pulmonary benefits. Using a randomized
clinical trial designed to avoid selection bias, we have
investigated since 1985 pulmonary outcomes in a screened
(early diagnosis) group compared to patients who experi-
enced delayed diagnosis (control group); both were man-
aged with the same evaluation and treatment protocol. The
results of assessing the two groups with the Wisconsin chest
radiograph scoring system (normals0; most severes100)
revealed the following distribution of values in patients
averaging 10 years of age: 1) 0–5 (very mild)s30%; 6–
10 (mild)s40%; 11–15 (moderate)s16%; )15 (more
severe)s14%. Serial spirometry showed that the majority
of FEV-1yFVC ratio values were normal and obstructive
dysfunction of clinical significance was uncommon. A
comparative analysis of lung disease in the two groups was
completed recently. Eliminating those with meconium ileus,
there were 54 patients in the screened group and 47 controls
available for quantitative chest radiology shortly after the
time of diagnosis, at mean ages of 5.9 and 27 months (P-
0.001); the chest radiographic scores of both groups
revealed relatively mild lung disease but were significantly
better in the early diagnosis group. Specifically, we found
that the Wisconsin additive scoring system yielded values
of 4.4"3.8 vs. 7.1"6.0 (Ps0.0089) when average scores
were computed using chest films from the screened and
control groups, respectively. Longitudinal analysis over 15
years suggests that the two groups become similar and con-
tinue to have relatively mild disease. Examining pulmonary
function data (735 observations) revealed that mild abnor-
malities persisted in the two groups. Although a delay in
diagnosis appears to be associated with initially greater
severity of lung disease in children with CF, aggressive
therapy is effective in retarding progression, especially
when coupled to early diagnosis.
S8.2
INNATE IMMUNITY OF THE RESPIRATORY
TRACT
Robert Bals
Hospital of the University of Marburg, Marburg, Germany
This aim of this presentation was to give an overview about
innate immune mechanisms involved in CF lung disease.
The innate immune system is a universal and ancient form
of host defense against infection. Innate immune recogni-
tion relies on a limited number of germline-encoded recep-
tors that recognize pathogen-associated molecular patterns
(PAMPs) and on a variety of effector molecules that
orchestrate inflammation and exert direct antimicrobial
activity. Various cell types contribute to innate immunity,
including epithelial and connective tissue cells as well as
professional phagocytes and inflammatory cells such as
granulozytes, macrophages, dendritic cells, mast cells, and
NK cells. This presentation focuses on the role of the res-
piratory epithelium in the respiratory innate immune sys-
tem. Respiratory epithelial cells are equipped with
mechanisms to detect microorganisms and to induce a host
defense reaction. Epithelial cells express a variety of pattern
recognition receptors (PRR), including CD14 and toll-like
receptors 1–10. The function of these receptors seems to
be different from their role in macrophages or dendritic
cells. Additionally epithelial cells secrete a variety of effec-
tor molecules including interleukins, chemokines and anti-
microbial peptides. Antimicrobial peptides are cationic
peptides that are secreted from epithelial and inflammatory
cells and have a direct microbicidal activity. Furthermore,
antimicrobial peptides have various other functions such as
attraction and activation of inflammatory cells, angiogene-
sis and regulation of cell growth. Defects of the innate
immune system are important for the pathogenesis of CF
lung disease: (a) a classic hypothesis claims a CF-specific
breach in antimicrobial function as cause of CF lung dis-
ease. (b) Inflammation as functional component of innate
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immunity is a hallmark of CF lung disease. A significant
part of inflammation is triggered by microorganisms. (c)
Antimicrobial peptides are effector molecules of innate
immunity with beneficial (antibacterial) and harmful (pro-
inflammatory effects).
S8.3
DYNAMIC INTERACTIONS BETWEEN
BACTERIA AND AIRWAY EPITHELIAL CELLS
E. Puchelle , J.M. Zahm , M. Milliot , M. Merten , C.1 1 1 3
Hologne , L. Edabbra , N. Bonnet , O. Bajolet1 1 1 1,2
UMRS 514, INSERM, Reims, France,1
Laboratoire de Bacteriologie, Virologie, Hygiene, CHU,2 ´ `
Reims, France,
EPI 0014, INSERM, Vandoeuvre-les-Nancy, France3
The different steps of bacteria and airway cell interactions
have been generally analyzed using conventional fluores-
cence or electron microscopy which do not allow visuali-
zation and kinetic characterization of the infection
pathways of living bacteria in living airway cells. We used
a real-time imaging technique, allowing bacteria (S. aureus
reference strain 8325-4) and airway glandular epithelial
cells (MM 39) to be labeled with fluorescent probes in
order to simultaneously analyze their physiological state at
single cell level. We used a Bac Light (Molecular Probes)
kit, composed of two nucleic acid binding stains: SYTO 9
which stains in green airway cells and bacteria; and pro-
pidium iodide, which only penetrates cells and bacteria with
damaged membranes, the combination of the two stains
producing red fluorescence. Using a time-lapse fluores-
cence microscope, images were acquired every 5 min dur-
ing a 1-h incubation period of S. aureus (2.7–8.6=10 cfu8
ml ) with airway cells in culture. We observed that they1
bacterial adherence to airway cells was faster than previ-
ously described and began within 5 min of incubation. The
number of damaged (red) bacteria rapidly increased (95–
98% after 1 h). Bacterial counts demonstrated that, after 1
h, the loss of bacterial membrane integrity was associated
with a marked decrease of viable bacterial counts (-105
cfu ml ), whereas no alteration of airway epithelial celly1
permeability could be observed.
These results suggest that, after a short period of contact
with bacteria, the airway cells are able to actively secrete
antibacterial molecules. Dynamic imaging of interactions
between CF clinical strains of S. aureus and CF airway cells
after longer periods of incubation will allow us to study the
process of bacterial internalization and the host CF cell
response.
Supported by INSERM and Association Vaincre la
Mucoviscidose.
S8.4yP42
RELATIVE ROLE OF CFTR AND ACIDIC
SPHINGOMYELINASE IN P. AERUGINOSA
INTERNALISATION AND KILLLING BY
RESPIRATORY EPITHELIAL CELLS.
E. Copreni , A. Bragonzi , M. Di Cicco , G. Doering , M.1 2 3 2
Conese1
Institute for Experimental Treatment of Cystic Fibro-1
sis,H.S. Raffaele, Milano, Italy,
Hygiene-Institut, University of Tuebingen,2
Tuebingen,Germany,
II Clinica Otorinolaringoiatrica, University of Milano,3
Milano, Italy
The role of respiratory epithelial cells in P. aeruginosa
clearance from the airways has not been established yet.
We undertook this study to demonstrate the relative role of
CFTR and the intracellular enzyme acidic sphingomyeli-
nase (ASM) in P. aeruginosa internalisation and apoptosis.
F508del cells (sigmaCFTE29o-) were able to internalise P.
aeruginosa significantly less than non-CF 9HTEo- cells, as
evaluated by crystal violet staining. To follow the fate of
internalised bacteria, a gentamicin exclusion assay was
used.
Syngeneic CF (16HBE-AS3; stably transfected with an
antisense to CFTR mRNA) and non-CF (16HBE-S1; con-
trol with sense) cells were incubated with 10e8 cfu (MOI
1000) of P. aeruginosa, and incubated with gentamicin (0.4
mgyml) for 2 h to kill extracellular bacteria. Serial dilutions
of cell lysates were plated and viable bacteria counted. CF
null cells showed a significant increased number of viable
bacteria at all time points. These results could be explained
either by a defect of intracellular killing of bacteria or by
a decreased apoptotic rate in CF cells. Apoptosis was eval-
uated by quantification of fragmented DNA by ELISA and
it was not different between the two cell lines. A
w Cxsphingomyelin degradation assay showed that CF cells14
were not able to activate ASM upon infection. Lipofection
of CFTR or ASM cDNA recovered the bacterial internali-
zation activity in F508del cells.
CF cells obtained from nasal polyps showed a reduction of
viable internalised bacteria after transfer of CFTR cDNA.
These results show that CF cells fail to internalise and kill
intracellular bacteria. ASM may have a role other than the
induction of apoptosis and cooperate with CFTR in the bac-
terial internalisation process.
Funded by ItalianTelethon grant A.179.
S9.1
CFTR GENOTYPE AND AIRWAY EPITHELIAL
FUNCTIONAL CORRELATES AS ASSESSED BY
NASAL POTENTIAL DIFFERENCE
Michael R. Knowles
The University of North Carolina at Chapel Hill
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Studies of nasal epithelial bioelectric parameters of Naq
and Cl transport have demonstrated clear-cut differencesy
between CF and normal. Specifically, CF patients with
‘classic’ disease associated with ‘severe’ (pancreatic insuf-
ficient) mutations have an accelerated rate of Na transportq
(absorption) and little (or no) CFTR-mediated Cl secre-y
tion. These observations have been buttressed by a recent
multicenter study in the US, sponsored by the CFF Ther-
apeutic Development Network (TDN) (Standaert TA, et al.,
Pediatr Pulmonol Suppl 22: 213, 2001). This TDN study
was performed in 40 normal and 40 CF subjects at eight
sites validated to measure NPD by a standard operating
procedure. Baseline NPD (index of Na transport) was yq
19.7 for normal subjects, as compared to y42.6 mV for
CF subjects. The CFTR-mediated Cl conductance in nor-y
mal subjects was y23.6 mV (delta PD with perfusion of
zero Cl solution, plus isoproterenol), whereas CF patientsy
had no measurable Cl conductance (delta PD,q2.2 mV).y
In CF patients who have ‘milder’ (pancreatic sufficient)
mutations with residual function in CFTR, there is a modest
CFTR-mediated Cl conductance (delta PD, y2 to y8y
mV, hyperpolarization), as compared to ‘classic’ CF
patients. Mutations in CFTR manifest as mono-organ dis-
ease (congenital bilateral absence of the vas deferens,
CBAVD; idiopathic pancreatitis) are associated with normal
basal PD (index of Na transport), and a CFTR-mediatedq
Cl conductance (delta PD, y10 to y12 mV) that isy
approximately half the normal value (delta PD, y24 mV).
In conclusion, there is a rough correlation between the
CFTR genotype and airway epithelial bioelectric parame-
ters of Na and Cl transport. Specifically, the ‘milder’q y
mutations are associated with lower (or normal) Na trans-q
port rates, but with larger CFTR-mediated Cl conductancey
than ‘null’ mutations that are associated with the classic CF
phenotype. (Supported by CFFTI KNOWLE98Y0 and
RR0046).
S9.4yP54
SPLICING FACTORS AS MODULATORS OF THE
CFTR FUNCTION IN CELLS CARRYING
SPLICING MUTATIONS
M. Nissim-Rafinia, B. Kerem
Department of Genetics, The Hebrew University, Jerusa-
lem, Israel
The molecular basis for the variability in CF severity has
been suggested to involve genetic modifiers and environ-
mental factors. We studied the molecular basis for the var-
iability among patients carrying splicing mutations. A wide
variability in the level of the aberrantly spliced pre-mRNA,
transcribed from such alleles, is found in the respiratory
epithelium of different patients and among different organs
of the same individual. The variability correlates with the
variability in disease severity. We hypothesized that the
molecular basis for the phenotypic variability involves fac-
tors known to regulate alternative splicing in vivo. We have
shown that the cellular and viral splicing factors can mod-
ulate the splicing pattern of minigenes carrying CFTR splic-
ing mutations (3849q10 kb C™T, which can lead to the
inclusion of a cryptic exon, or 5T, which can lead to the
skipping of exon 9).
Here, we studied the effect of splicing factors on endoge-
nous CFTR alleles carrying the 3849q10 kb C™T muta-
tion, in epithelial cell lines from nasal polyps of two CF
patients carrying the mutation. We found that the splicing
pattern of RNA transcribed from the endogenous alleles
could be modulated by over expression of splicing factors.
The cellular factor ASFySF2 led to almost a complete abol-
ishment of the aberrantly spliced transcripts. The viral fac-
tor E4-ORF3 and the cellular factor Htra2-b1 promoted
exon inclusion and led to a significant increase in the level
of aberrantly spliced transcripts. We further analyzed the
effect of splicing modulation on the function of the CFTR
protein using chloride efflux measurements. Our prelimi-
nary results show that the CFTR channels in these cells are
inactiv, similar to the inactivity found in cells carrying two
severemutations. We further studied the effect of over-
expression splicing factors on the chloride efflux in these
cells. The results of these experiments and their significance
for the development of new therapeutic approaches will be
discussed.
S9.5yP58
CPG METHYLATION OF THE CFTR PROMOTER
REGION IN PATIENTS WITH CYSTIC FIBROSIS
B. Steiner , J. Sanz , A. Schaller , R. Kraemer , S.1 1 1 2
Gallati1
Human Molecular Genetics, Department Clinical1
Research,
Department of Paediatrics2
Aims: The genotype–phenotype relation in cystic fibrosis
(CF) is known to be very complex. Disease severity even
varies among CF patients carrying the same CFTR geno-
type. Factors that contribute to this variability are topics of
intense study. Little work has been done regarding the ques-
tion of whether there exists a relationship between DNA
methylation and CFTR gene expression. Three publications
from 1993 (Koh et al.) and 1995 (Smith et al. and Denamur
et al.) examined tissues and cell lines that vary with respect
to CFTR expression using the methylation sensitive restric-
tion endonuclease HhaI. Analysis of the chromatin structure
and methylation status of the CFTR promoter region
revealed cell line differences which correlated with expres-
sion levels, suggesting that the physical context of the
CFTR gene in vivo may contribute significantly to appro-
priate regulation of CFTR transcription. In contradiction to
the growing interest on DNA methylation, no further meth-
ylation-specific analysis of the CFTR promoter was done.
Methods: Sequencing of bisulphite modified genomic DNA
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is a powerful method to determine methylation patterns of
chromosomal DNA, but due to the limited amount of tissue
material available, we established a special bisulphite treat-
ment, which ensures an optimal reactivity of small amounts
of DNA. We performed Na–bisulphite treatment and pol-
ymerase chain reaction single-strand conformation poly-
morphism analysis (BiPS) using three sets of primers
spanning the CFTR promoter region. Results: In a clinically
well-described group (ns21) of DF508 homozygous CF
patients, we examined the methylation status of the pro-
moter CpG sites. Furthermore, cell culture experiments
treating EBV transformed lymphocytes with an increasing
concentration of 5-aza-2 deoxycytidine (AZA), a potential
inhibitor of the methyltransferases, showed a significant
increase in CFTR mRNA expression. Conclusions: Taken
together, these findings indicate that the control of CFTR
gene expression is lik.
S10.2
ASSESSMENT OF THE NEED FOR
PANCREATIC SUPPLEMENTS
Diana Costantini
CF Centre, Paediatric Department, University of Milan,
Italy
Correlation between nutritional status and pulmonary func-
tion in CF has been well documented for some years and
it is suggested that improved survival is associated with
changes in dietary management.
Regular nutritional surveillance has became an important
phase of clinical evaluation of the patients, but periodic
assessment of fat malabsorption is needed to ensure an
appropriate balance between energy intake and faecal loss,
according to our experience. Faecal elastase determination
is performed to recognize pancreatic insufficiency first at
the time of diagnosis and then yearly in patients with resid-
ual pancreatic function.
In infants with CF, nutritional counselling is provided every
2 months together with a faecal sample for steatocrit anal-
ysis in order to adequate enzymes dosage, achieve weight
gain and control steatorrhea.
Toddlers and pre-school-age children present additional
challenges due to age-related behavioural disturbances and
they often need caloric supplementation. School-age chil-
dren begin to have a more active and independent lifestyle
with increased caloric requirements. From this age, mal-
absorption is monitored by means of two stable isotope
breath tests, which are dependent on pancreatic lipase (1).
Adolescents show typical problems related to the develop-
ment of autonomy, leading to the lack of regular meal times
and increase of energy requirements for their often intensive
physical activity. Periodic individual nutritional counselling
is performed taking into account daily dietary records,
amount of exercise and steatocrit data. In case of malab-
sorption, a calculation of lipase units needed per gram of
ingested fat per meal is made and enzyme capsules are tai-
lored to the quality of each meal instead of prescribing
fixed dosages for meals or snacks. Problems arise with
teenagers dealing with counter-peers or with doctors and
dieticians; these problems have to be discussed with other
members of CF team. Pancreatic function assessment by
means of a stable isotope breath-test or measuring the coef-
ficient of fat absorption are useful tools to achieve a regular
weight gain. In adulthood, along with a better understand-
ing of nutritional guidelines and requirements and a better
compliance with therapy, the frequency of respiratory exac-
erbations increases; higher energy intakes are, therefore,
needed, leading to a frequent need for caloric supplemen-
tation, by an oral or enteral route.
When the correct amount of pancreatic enzyme is pre-
scribed, and nevertheless, malabsorption still seems uncor-
rected, other pivotal factors are to be addressed, such as
acid gastric pH, low duodenal pH, sticky mucus plastering
intestinal surfaces, and bile acid deficiency. The use of anti-
acid drugs or H2 inhibitors or even simple sodium bicar-
bonate can allow a better management of malabsorption
without increasing enzyme dosage. Adjuvant therapy with
Taurine was demonstrated to be useful in patients with bile
acids dysfunctions. In some patients, the use of oral muco-
lytic drugs seems to help in decreasing the mechanical bar-
riers that mucins can create in the digestive tract.
Only an individual approach in patients at different ages
and with various life styles and nutritional behaviours,
together with help from skilful and CF devoted dieticians,
can allow correct dealing with the dietary hazards of CF,
which are always present and very different according to
the patients’ age and the severity of the disease.
Colombo C. Comparison of 2 stable isotope BT to assess
pancreatic status in CF. Ped Pulmonol Suppl. 2001; 22: 339.
S10.3
DECLINE OF EXOCRINE PANCREATIC
FUNCTION IN PANCREATIC SUFFICIENT
PATIENTS
Jaroslaw Walkowiak , Sanda Nousia-Arvanitakis1 2
Department of Gastroenterology and Metabolism, Institute1
of Pediatrics, Karol Marcinkowski University of Medical
Sciences, Poznan, Poland;
Department of Pediatrics, Aristotle University, Thessalon-2
iki, Greece
Direct pancreatic function tests such as the secretin–cho-
lecystokinin-test remain the gold standard in the assessment
of exocrine pancreatic function (EPF). However, they are
invasive and not acceptable as a repeatable procedure in
children. Indirect tests are used routinely in clinical practice
because they are non-invasive, simple, less time-consuming
and less expensive. The most popular among them—steat-
orrhea—presents with low sensitivity. Considering time,
expenses, the proven clinical value of the test in the assess-
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ment of EPF and patients’ acceptance, the fecal elastase-1
(E1) test seems to be the most reasonable indirect test.
Howewer, the E1 test has limited sensitivity in patients with
mild to moderate exocrine pancreatic insufficiency. There
are few data concerning longitudinal assessment of the pro-
gressive decline of EPF in cystic fibrosis (CF). Therefore,
the aim of the present study was to evaluate the usefulness
of the E1 test in this respect.
Material and methods: 184 CF patients were included into
the study. In all subjects, E1 concentrations and fecal fat
excretion were measured. PS patients with normal E1 val-
ues were followed for 5 years.
Results: At the beginning of the study, 36 (19.6%) CF
patients were pancreatic sufficient (PS) and 32 (17.4%)
had normal E1 concentrations. Longitudinal measurements
of E1 concentrations in 27 PS CF patients demonstrated
stable enzyme output in 19 and essential decrease in eight
of them. The decrease was fast and mutual in five younger
(infants) and gradual in three older patients. The decrease
of E1 concentrations preceded the presence of steatorrhea
in all eight subjects.
In conclusion, the decline of exocrine pancreatic function
in CF appears more frequently in first months of life; how-
ever, late PSyPI conversion is also possible. Fecal elastase-
1 test is a helpful screening tool in the longitudinal
assessment of declining exocrine pancreatic function in
individual pancreatic sufficient CF patients.
S10.4yP232: DHA AND AAyDHA RATIO IN
ERYTHROCYTE MEMBRANE PHOSPHOLIPIDS
(PC, PE) OF CF PATIENTS WITH PANCREATIC
SUFFICIENCY AND PANCREATIC
INSUFFICIENCY
C. Galabert , C. Legay , M-R. Vericel , J-C. Freiche , J-P.1 1 2 2
Chazalette2
Laboratoire de Biologie-CERM, Hopital Renee Sabran,1 ˆ ´
Centre de Soins pour la Mucoviscidose-CERM, Hopital2 ˆ
Renee Sabran´
Membrane lipid imbalance has been reported in cftr yyy
mice, characterized by an increase in phospholipid bound
arachidonic acid (AA) and a decrease in phospholipid
bound docosahexaenoic acid (DHA). AAyDHA imbalance
in cell membranes has been suggested to be responsible for
the phenotypic expression of cystic fibrosis.
Aim: In this study we investigated the polyunsaturated fatty
acid profile and AAyDHA ratio in serum and red blood
cell (RBC) membrane phospholipids of CF patients with
pancreatic inssufficiency (CF–PIs) or pancreatic sufficien-
cy (CF-PSs). Fatty acid composition of phosphatidyl cho-
line (PC) and phosphatidyl ethanolamine (PE) was
examined in 14 CF-PS patients (aged 5–57 years), 33 CF–
PI patients (aged 3–51 years) and 24 non-CF control sub-
jects (aged 18–46 years). All CF–PI patients continued to
take pancreatic enzyme supplements during the study.
Methods: Serum and membrane phospholipids were
extracted by solvent partition and separated by HPTLC.
Fatty acids (methylesters) of PC and PE were analyzed by
gas phase chromatography. Results:
CF–PIs CF–PSs Ctrls
Linoleic RBC-PC 17.7"2.6% 20.5"2.7% 21.1"2.1%
AA RBC-PE 25.0"2.8% 24.8"2.4% 23.9"2.9%
DHA RBC-PE 5.45"1.33% 5.71"1.53% 6.8"1.8%
AAyDHA RBC-PE 4.91"1.58% 4.62"1.25% 3.75"1.03%
As reported earlier, linoleic acid (C18:2ny6) was
significantly lower in serum and RBC membrane PC of
CF–PIs as compared to control subjects (P-0.001) and
to CF–PIs (P-0.01); arachidonic acid (AA) was
significantly higher in RBC-PE and serum-PC of CF–
PIs as compared to control subjects (P-0.03);
docosahexaenoic acid (DHA) was significantly lower in
RBC-PE of CF–PIs as compared to controls (P-0.02);
most interestingly, AAyDHA ratio was significantly
higher in RBC-PE of CF–PIs (P-0.001) and CF–PSs
(P-0.05) as compared to control subjects.
Conclusion: These results show an increased production
of arachidonate and an imbalance of the AAyDHA ratio
in cystic fibrosis, particularly in pancreatic insufficient
patients.
S10.5yP241: WEE, WEIGH, POO, WEIGH, WEIGH
POO—THE USE OF ACCURATE WEIGHING
SCALES TO DETERMINE STOOL LIPID LOSSES
AMONG CF PATIENTS
J. Gavin , S. Ogilvie-Goddard , D. Rowe , S. Struthers , G.1 2 2 1
Connett1
Regional Cystic Fibrosis Service, Department of Paedia-1
trics, Southampton University Hospital Trust, UK,
Department of Biochemistry, Southampton University Hos-2
pital Trust, UK
Pancreatic insufficiency affects over 85% of individuals
attending CF centres. In clinical practice, doses of pancre-
atic enzymes are often titrated against the reporting of gas-
trointestinal symptoms such as the passage of, bulky, oily
stools. Few centres routinely perform lab measurements to
assess malabsorption. Assays are time consuming and
unpopular among lab staff. We have previously shown lin-
ear correlations between stool weight and stool energy
losses. In this study, we have calculated stool weights by
weighing patients immediately before and after defecation
over a 3-day period and determined the usefulness of such
measures as an estimate of fat malabsorption.
Twenty-seven children aged 4–16 years (16 CF, 11 control
subjects) were recruited. Two children (controls) chose not
to complete the study protocol. Twenty-five children suc-
cessfully completed a 3-day faecal fat collection (14 CF,
11 control subjects). Children were asked to micturate
immediately prior to defecation. They were then weighed
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using high resolution scales calibrated to within 1 g accu-
racy before and after defecation. Measurements were used
to derive stool weights. The fat content of the 3-day stool
collection was assayed using the gravimetric method. Twen-
ty-one children successfully completed the weighing pro-
tocol. There was good correlation between weights using
the two methods (Rs0.99, P-0.001) although weighing
patients tended to over estimate actual stool weight. There
was good correlation between wet weight and stool lipid
(Rs0.682, P-0.01). Urgency of defecation and stress uri-
nary incontinence affected some families ability to follow
the study protocol. This method for estimating stool lipid
was acceptable to the majority of patients and might prove
useful for assessing the benefits of interventions to reduce
malabsorption in CF.
S11.1
INTENSIVE EXERCISE IN CF, POSITIVE
EFFECTS VS. LIMITATIONS
Johan K. Stanghelle, MDPhD
Sunnaas Rehabilitation Hospital, 1450 Nesoddtangen,
Norway
This presentation will be a survey on Norwegian studies
performed during strenuous physical activity in CF patients.
Since the 1980s, several studies have shown that regular
physical exercise is favourable for patients with CF, espe-
cially as an effective lung drainage method.
We have, during several studies, also shown that some of
these patients can perform strenuous exercise, such as mar-
athon running, without detrimental effects.
The biochemical, metabolic and endocrine responses to pro-
longed exercise indicated no untoward changes compared
with from those in healthy control subjects. The psycho-
logical effects of completing a marathon event were
obvious.
One of the CF patients (man, born 1966) completed New
York City Marathon 12 times during the period 1983–1995.
He had a lung transplant in 1997, and completed the mar-
athon again in 1998 and 1999 with a bilateral lung trans-
plant. He had only minor problems and similar responses
as expected in healthy marathon runners in 1998. After the
race in 1999, he developed an infection in his metatarsal
joint of his first toe, and after 4 days he expired due to
septicaemia caused by beta-haemolytic Streptococcus.
Based on these experiences, this presentation will discuss
the positive effects vs. limitations during intensive exercise
in CF patients.
S11.2
ANAEROBIC PERFORMANCE IN CHILDREN
WITH CYSTIC FIBROSIS.
P.H.C. Klijn , W. Gruber , D. Kiosz , C.K. van der Ent , J.1 2 2 1
van der Net , P.J.M. Helders1 1
Wilhelmina Children’s Hospital, University Medical Cen-1
tre, Utrecht, The Netherlands;
Hospital Satteldune for children and adolescent with2 ¨
chronic disease, Amrum, Germany
In many children with cystic fibrosis (CF), aerobic exercise
capacity is reduced. This limitation has been related to pul-
monary impairment and malnutrition. It has been shown
that in children with CF, anaerobic exercise performance is
reduced compared to healthy children. This underlines the
importance of measuring anaerobic performance in children
with CF.
The aim of this study was to determine the anaerobic per-
formance of children with CF in relation to pulmonary
function, fat free mass (FFM) and muscle force, and to
study the effects of an in-patient anaerobic training program
in CF on anaerobic and aerobic exercise tolerance, pul-
monary function and FFM.
Anaerobic performance in 25 children with CF (age
12.8"2.6 wS.D.x years) was assesed with the Wingate test
(WanT). FFM was determined using bioelectrical impe-
dance techniques. Pulmonary function testing was per-
formed before the WanT (FEV1 87.3"17.2% pred).
Maximal isometric muscle force was measured for six mus-
cle groups. Multiple regression analysis indicated that 80–
86% of the variability in anaerobic performance was
explained by FFM. In correlation, analysis peak power (PP)
and mean power (MP) were significantly correlated with
quadriceps, biceps and shoulder abductor force (Rs0.73–
0.87; P-0.0001). No significant correlations were found
between anaerobic performance and pulmonary function.
Preliminary results of a study in 18 CF patients (age
14.2"1.8 years, FEV1 76.2"24.3% pred) showed a higher
PP and MP after anaerobic training (PF0.05). There was
a significant increase in FFM, P , and a slight non-sig-max
nificant increase in VO . At VAT (respiratory anaerobic2max
threshold), there was an increase (PF0.05) of VO . Heart2
rate and VO at 1-min and 3-min after exercise were sig-2
nificantly lower.
In conclusion, FFM is the major determinant of anaerobic
performance in CF-patients. Futhermore, the anaerobic per-
formance of children with CF can be improved by anaer-
obic training.
S11.3
HOME-BASED EXERCISE TRAINING
PROGRAMME FOR CF PATIENTS
Helge Hebestreit
Universitats-Kinderklinik, Josef-Schneider-Str. 2, 97080¨
Wurzburg, Germany¨
There is increasing evidence that exercise is beneficial in
patients with cystic fibrosis (CF) with regards to fitness,
lung function and quality of life. Since most CF-patients
live far from large centers andyor are afraid of transmission
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of bacterial pathogens, well-controlled training programs
are not feasible for the majority of patients. Therefore, a
home-based exercise program is recommended by many
CF-centers, although there is concern that such a program
may have less—if any—beneficial effects than controlled
training. However, it was shown that a home-based physical
training (three times, 20 min per week, heart rate approx.
150 bpm) may have a positive impact on vital capacity
(VC) and forced expiratory volume in 1 s (FEV1) (Schnei-
derman-Walker et al., J. Pediatr. 2000; 136: 304–310). Cur-
rently, the multi-center training study MUKOTRAIN
evaluates the effects of various modes of individual home-
based training. CF-patients from Switzerland engage either
in aerobic training or weight training, both taking place in
fitness clubs near their homes, while patients from Germany
can choose any form of physical training they want. Pre-
liminary data analysis after 6 months of training shows that,
compared with control subjects, CF-patients in the training
groups experience a benefit in fitness and lung functions.
It appears that weight training is especially effective in
decreasing residual volume while aerobic training improves
FVC and FEV1. Home-based exercise training is, thus, fea-
sible and effective in CF patients. Patients should, however,
be advised to contact their physician before engaging in
strenuous activities to identify possible individual risks
associated with exercise.
S11.4yP141: DESATURATION ON A 12-MIN
WALK—IS THIS IMPORTANT IN PREDICTING
SURVIVAL?
N. Marks , S. Charman , E. Gunn , A. Jackson , J.1 2 1 1
Parmar , D. Bilton1 1
Adult CF Centre, Papworth Hospital, Cambridge, UK,1
MRC Biostatistics Unit, Cambridge, UK2
An assessment of exercise tolerance is frequently used in
addition to spirometric data at assessment for transplanta-
tion to aid decisions regarding timing of transplantation for
CF patients. At an annual review (AR) in the CF Adult
Unit, a 12-min walk is routinely performed. It was noted
that some patients achieved good distances on the 12-min
walk, but with severe desaturation. We, therefore, studied
all the patients at their first AR in the adult clinic from
1997 to 1999, in order to address the question as to whether
desaturation could be predicted at a certain level of FEV1
impairment, and furthermore, whether desaturation on a 12-
min walk predicted 2-year survival. Ninety-six patients
were studied (41F), mean (S.D.) ages21 (7) years,
BMIs20 (2.8) kgym , distance walkeds794 (158) m.2
FEV1% pred median (IQR)s42 (32,75)%. On exercise,
38 patients desaturated (end O sats-90%). Using a2
receiver operating characteristic curve, the area (95%CI)
under the ROC curve was 0.77 (0.67, 0.86) P-0.001 indi-
cating that FEV1 is a statistically significant predictor of
desaturation. Comparing the patients who desaturated and
those who did not there were significant differences
between FEV1% (P-0.001) and BMI (P-0.05) but not
in the distance walked (Ps0.34).
There were six transplants and 17 deaths in total in this
series. Two-year actuarial survival (95% CI) from trans-
plant or death was 83% (74, 90). Desaturation was signif-
icantly associated with poorer survival (P-0.001) in
univariate analysis as was BMI (P-0.001) and FEV1%
(P-0.001). In multivariate analysis, only percentage FEV1
(FEV1%) remained significant (P-0.001). The resulting
relative risk wRR (95% CI)x of death (for a fall in %FEV1
of 10%) was 3.5 (2.1, 5.9).
In conclusion, desaturation on a 12-min walk is associated
with poorer survival, but %FEV1 remains the most useful
prognostic indicator.
S11.5yP139: VALIDITY OF A MODIFIED
SHUTTLE WALK TEST AS A MEASURE OF
EXERCISE TOLERANCE IN PAEDIATRIC CF
PATIENTS
D. Rogers , P. Smith , N. John , W. Oliver , I.J.M. Doull1 2 1 3 1
Paediatric CFyRespiratory unit, Department of Child1
Health,
Cardiology Department,2
UWCM, University Hospital of Wales, Cardiff, Wales3
Background: The modified shuttle walk test (MSWT) is
a valid measure of exercise capacity in adult patients with
cystic fibrosis (CF)1. Aims: To assess the validity of the
MSWT in paediatric patients with CF by comparing dis-
tance achieved during MSWT with peak oxygen consump-
tion (VO peak) measured during a treadmill test. We have2
previously demonstrated a significant relation between
MSWT distance and leg length.
Subjects and methods: Fourteen CF patients (9 m), mean
age 14.7 years (range 10.0–19.0), with stable disease
(mean FEV1 64% predicted; range 32–113%) performed,
in random order on separate days, a ramped maximal tread-
mill test (STEEP protocol) and a MSWT within 14 days
of each other. Outcome measures were VO peak as raw2
data and corrected for height, weight and age, while for
MSWT, raw data (Dist) and distance achieved were cor-
rected for leg length (DistLL).
Results: Dist was significantly correlated with VO peak2
(Rs0.663, P-0.01) and VCO (Rs0.638, Ps0.014).2
Both VO corrected for weight and corrected for age, weight2
and height were significantly correlated with DistLL (Rs
0.54, Ps0.05 and Rs0.739, Ps0.003, respectively), but
neither were related to Dist. Correlations were stronger in
those with more severe lung disease.
Conclusions: MSWT is a valid objective measure of exer-
cise tolerance in paediatric patients with CF.
1. Bradley J et al. (1999). Validity of a modified shuttle
test in adult cystic fibrosis. Thorax 1999; 54: 437–439.
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S12.3
ATYPICAL CF AND THE CLINICAL
CONSEQUENCES
C. Wallis
Great Ormond Street Hospital for Children, London, UK
For the majority of patients with CF, the diagnosis is
straight forward. There is a classical phenotype of sinu-
pulmonary disease, pancreatic insufficiency, failure to
thrive and male infertility. The constellation of clinical
signs and symptoms are confirmed with a positive sweat
test and two disease-causing mutations in the gene for
CFTR. Ironically, it has been the advent of widely available
genetic testing for CFTR mutations that has highlighted a
small but disproportionately challenging group of children
and adults who have atypical forms of CF. It is useful to
consider them in two groups:
(1) Patients who have two mutations with or without evi-
dence of CFTR dysfunction (e.g. a positive or intermediate
sweat chloride level; abnormal responses to nasal potential
difference measurements), but who do not have any clinical
evidence of end organ disease; and
(2) Patients who have some clinical symptoms or signs
traditionally associated with CF (often single organ
involvement), but for whom there is insufficient corrobo-
rative evidence to fulfil the criteria for a CF diagnosis.
Examples of such conditions include male infertility with
two CF mutations, but no evidence of any other end organ
involvement; chronic pancreatitis with pancreatic sufficien-
cy, a border line sweat test and one identifiable CFTR muta-
tion; chronic sinusitis with a positive sweat test, etc.
For both these groups of ‘atypical CF’, it does not seem
appropriate to apply the traditional CF label with all its
implications on future prognosis, treatment regimens and
lifestyle decisions.
Atypical CF needs to be considered as a separate diagnostic
category. Those children with two mutations but no evi-
dence of disease need not undergo treatments that are bur-
densome and of dubious long term benefit. CF is a clinical
disease and two abnormal mutations do not mean you will
necessarily get the disease. It may be reasonable to adopt
a well-known oncological concept and label these individ-
uals as having ‘pre-CF’: i.e. you have the genetic potential
to develop CF, but may not do so. CF is not necessarily an
all-or-nothing disease and the phenotype may emerge with
time. These children and adults will need to be monitored
for the development of CF complications but do not require
either the label or the intensive therapy.
For patients with atypical CF involving single organ sys-
tems, it is hoped that they will be accommodated separately
in future international classifications of diseases. No longer
will their particular form of CF be lumped with ‘classical
CF’ and all the implications that the label of a life-threat-
ening disorder carries. Treatment for these patients needs to
be individualised. CF is not one disease but many. Each
patient, in conjunction with their clinician, will need to
identify a therapeutic regimen that is appropriate for their
individual form of atypical CF.
S12.4yP322: CYSTIC FIBROSIS; SOON TO BE A
GERIATRIC PROBLEM
M. Ninkovic, C. Milla, W.J. Warwick
Minnesota Cystic Fibrosis Center, Minneapolis, MN, USA
At the Minnesota CF Center, 70 patients have reached age
40. Of these, 55 (78%) are still alive. After the age of 40,
the average per year mortality rate had been 0.7% for
females and 1.5% for males. We project that 65% of these
males and 86% of these females will reach age 60. If our
observed mortality rates only double after age 60, we pre-
dict that 41% of males and 69% of females who reach 40
will reach age 75. Since genetic CF extends only to the cell
membrane and clinical complications are all ‘normal’ dis-
eases frequently acquired, we need to prepare for excesses
of some diseases of aging as CF patients age. In 1969, 1975
and 1977, we defined CF as a new-expanding challenge for
internal medicine. In the next 20 years, CF will become
such a challenge for geriatric medicine. We propose a mul-
ticenter protocol to monitoring the aging of CF patients, a
collaboration with CF Centers in Europe and North Amer-
ica to ensure that these, now few, aging patients will prepare
the future health of the future large stream of geriatric
patients.. We estimate that, in the United States, the number
of patients over 60 will be at least 80 by 2005, 180 by
2010, 360 by 2015 and 720 by 2020. Focusing on geriatric
diseases for CF patients will gradually eliminate patients
dying at notable ages, i.e. ages 30, 40 and 50. At these
ages, we observe a five-fold greater mortality than the aver-
age for each whole decade. Focusing on a long view for
each patient and on therapy with the goal of becoming a
healthy old person may make the prescription of prophy-
lactic therapy acceptable to physicians and perhaps even
popular with patients. We need to design tools to monitor
aging, to manage of clinical, personal, nutritional, genetic
and other data and to prevention and to treat the acquired
diseases of aging in patients with cystic fibrosis. A rela-
tional database, such as our Minnesota CF Database, has
the power to monitor and test diagnostic and therapeutic
strategies as CF patients age.
S13.4yP210: NOVEL PSEUDOMONAS
AERUGINOSA ADHESINS INVOLVED IN
ATTACHMENT TO AIRWAY EPITHELIUM
S. de Bentzmann, M. Aurouze, I. Vallet, A. Filloux, A.
Lazdunski
UPR 9027, Marseille, France
A recent study has shown the existence of three fimbrial
gene clusters (cup A, B and C) in the PAO genome and
the involvement of the CupA system in attachment and ear-
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ly stage biofilm formation on plastic surfaces (Val-
let,PNAS,2001,98:6911). Since it has also been
demonstrated that in CF airways, P. aeruginosa exists as
biofilm (Singh, Nature, 2000; 407: 762), we wondered
whether Cup systems could be involved to attachment to
bronchial epithelial cells. The mutant strains PAKcup A3,
cup B3, cup C3, PAKpil A(type IV pili) and the wild-type
PAK strain were grown up to stationary phase in the pres-
ence of H3-adenine and were incubated for 0 up to 1 h with
the human bronchial epithelial cell line, 16HBE140–. The
fraction of attached bacteria to the host cell surface was
measured from radioactive counts. Interestingly, attachment
has occurred during the first 30 min of incubation. As
expected, the non-piliated strain exhibits a significant
reduced adherence level as compared to the parental strain
PAK. Very interestingly, PAKcup A3 and PAKcup B3
attachment to bronchial epithelial cells was also signifi-
cantly reduced compared to PAK, whereas we did not
observe any difference between PAKcup C3 and PAK.
From these results, it appears that apart from type IV pili,
additional adhesins are involved in attachment to airway
epithelium. These adhesins may present surface or tissue
specificity. Genome sequence analysis revealed additional
putative adhesins. We selected a gene cluster involved in
assembly of bundle type of pili called Tad in A. actino-
mycetemcomitans (Kachlany, J Bact, 2000; 182: 6169) and
five genes encoding filamentous hemagglutinin-like pro-
teins, called Fha in B. pertussis (Jacob-Dubuisson, Mol
Microbiol, 201; 40: 306). Tad and Fha are known to be
involved in the attachment process of those organisms. The
Fha protein is transported to the cell surface via a so-called
two-partner secretion pathway (TPS). The role of these
adhesins is currently under investigation. Supported by
VLM.
S14.2
PROCESSING AND INTRACELLULAR
TRAFFICKING OF NORMAL AND MUTANT CFTR
Margarida D. Amaral
Carlos M. Farinha, Paulo Alves, Isabel Vieira, Deborah
Penque
Department of Chemistry and Biochemistry, Faculty of Sci-
ences, University of Lisboa, Portugal
Centre of Human Genetics, National Institute of Health,
Lisboa, Portugal
As happens with other multi-domain glycoproteins, CFTR
is co-translationally inserted into the endoplasmic reticulum
(ER) membrane and N-linked to glycosyl groups. The addi-
tionytrimming of these groups, and rounds of bindingy
release with the ER-chaperone calnexin, facilitate folding
until the protein acquires its native conformation. Only
properly folded proteins, assessed by the ER quality con-
trol, proceed through the secretory pathway across the Gol-
gi, where they are fully glycosylated.
Wild-type (wt) CFTR maturates inefficiently and F508del
causes an even greater maturation and trafficking defect.
Indeed, studies in heterologous expression systems, fail to
detect the fully-glycosylated form and protein at the cell
membrane. In native tissues (respiratory epithelium), some
F508del-CFTR (significantly less than wt) localizes api-
cally, thus evidencing a trafficking defect as well. ER-reten-
tion of F508del-CFTR probably results from misfolding
that is recognised by the cellular quality control with the
participation of molecular chaperones.
We examined the in vivo effect of overexpressing the
Hsp70 chaperone and its modulator co-chaperone Hsp40
upon the biosynthesis and processing of wt- and F508del-
CFTR and found a significant stabilization of the core-gly-
cosylated form (band B) of wt-CFTR, but not of
F508del-CFTR. Conversely, when we overexpressed cal-
nexin, the degradation rate of the immature form of
F508del-CFTR, but not of wt-CFTR, is increased.
Overexpression of Bag-1, another co-chaperone that mod-
ulates the in vitro activity of HscyHsp70 by promoting sub-
strate release and ATP hydrolysis, results in a reduction in
the degradation rate of F508del-CFTR band B, but not of
wt-CFTR.
Together with observations at low temperature, these results
suggest that two different conformations occur for wt- and
F508del-CFTR, being differently recognized and modulated
by the various chaperones that participate in its biogenesisy
processing.
Work supported by grant Sapiens 99y35737y99.
S14.3
A ROLE FOR PROTEASOME ATPASE ACTIVITY
IN THE EXTRACTION AND RELEASE OF CFTR
FROM THE ER MEMBRANE
Jon Oberdorf and William R. Skach
Division of Molecular Medicine, Oregon Health Sciences
University, Portland, OR 97201
To better understand events that govern the early fate CFTR
in the endoplasmic reticulum, we developed a cell-free sys-
tem that reconstitutes CFTR synthesis, core glycosylation,
membrane integration and ATP-dependent degradation via
the ubiquitin-proteasome pathway. Under physiological
conditions, immature CFTR is efficiently polyubiquitinated,
degraded and released from the ER membrane solely in the
form of trichloroacetic (TCA) acid soluble peptide frag-
ments. All three active proteasome b subunits, b1 (Y), b2
(Z), and b5 (Z), contribute to CFTR degradation as dem-
onstrated by active site inhibitors. Inhibiting b subunit
activity by )95% significantly blocks (;90%) the rate of
CFTR conversion into TCA soluble fragments. However,
in the presence of active site inhibitors, CFTR is released
from the membrane as heterogeneous TCA insoluble frag-
ments (20 to ;50 kDa in size) as well as higher MW
fragments that resemble polyubiquitinated species. These
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cytosolic fragments contain N- C- and R-domain epitopes
and remain associated with a large protein complex similar
in size to that of the proteasome. Moreover, N- C- and R-
domain epitopes are all released from the ER membrane at
similar rates, suggesting that CFTR degradation involves
endoproteolytic cleavage. Generation of TCA insoluble
CFTR fragments correlates directly with the extent of beta
subunit inhibition and is completely blocked when protea-
some AAA–ATPase activity is inhibited by hemin. These
results provide evidence that proteasome ATPases facilitate
dislocation of CFTR from the ER membrane and its transfer
into the catalytic core of the 20S subunit. Active site inhib-
itors uncouple protein unfolding from peptide cleavage,
thus allowing membrane extraction to exceed the rate of
degradation, which results in aberrant release of cytosolic
degradation intermediates. wSupported by NIH (DK 51818)
and CFF.x
S14.4yP31: ROLE OF THE C-TERMINUS IN THE
TARGETING AND FUNCTIONING OF CFTR
Jie Cheng , Garry R. Cutting , Bruce A. Stanton , Min1 2 3
Li , William B. Guggino1 1
Department of Physiology,1
Center for Medical Genetics, The Johns Hopkins Univer-2
sity School of Medicine, Baltimore, MD 21205.
Department of Physiology, Dartmouth Medical School,3
Hanover, NH 03755
CFTR is regulates a number of ion channels and cellular
processes wE.M. Schwiebert, D.J. Benos, M.E. Egan, M.J.
Stutts, W.B. Guggino, Physiol Rev. 1999; 79: S145–S166x.
The proper localization of CFTR is a prerequisite for CFTR
to regulate other processes. In addition, vectorial chloride
movement through CFTR itself requires its presence at the
plasma membrane. Recently, CFTR-associating PDZ
domain proteins have emerged as central molecules in scaf-
folding, targeting and regulating CFTR within macromo-
lecular complexes. PDZ domain is a modular domain that
interacts with other proteins (M. Sheng, Neuron 1996; 17:
575–578). PDZ domains bind to a consensus sequence at
carboxy terminus of a variety of membrane proteins and
play an important role in establishing and maintaining epi-
thelial polarity. We have studied two PDZ domain proteins,
CAL and CAP70, that are involved in scaffolding, traffick-
ing and regulating of CFTR. CAL contains one PDZ
domain and two coiled-coil domains. CAP70 contains four
PDZ domains. CAL is primarily localized to the Golgi
apparatus whereas CAP70 is concentrated to the apical
compartment. CAL is detected in the Golgi of serous and
duct cells of the submucosal glands. The Golgi localization
suggests that CAL may be involved in the trafficking of
CFTR. Indeed, over-expression of CAL inhibits CFTR traf-
ficking to the plasma membrane. CAP70 has been localized
to the brush border of kidney and small intestine. Three of
the four PDZ domains are capable of binding to the C-
terminus of CFTR. Linking at least two CFTR molecules
by CAP70 potentiates the CFR chloride channel activity.
Thus, CAL and CAP70 have distinct subcellular localiza-
tion and function. These findings suggest an involvement
of CAL in the trafficking of CFTR from Golgi to the apical
membrane, as well as a role for CAP70 in regulating CFTR
channel activity at the apical membrane.
S14.5yP30: IDENTIFICATION AND FUNCTIONAL
CHARACTERIZATION OF TRANSCRIPTION
FACTORS INVOLVED IN THE
TRANSCRIPTIONAL ACTIVATION OF THE CFTR
GENE
J. Doudement, C. Gerbon, M. Claustres, M.C. Romey
Laboratoire de Genetique Moleculaire, IURC, 641 Avenue
duDoyen Gaston Giraud, 34093 Montpellier, France
Regulation of expression of the CFTR gene is complex.
Very little is known about the regulatory elements that are
involved in CFTR transcription including those controlling
tissue specificity. We recently presented the first evidence
for a compensatroy mutation (y102T)A) in the CFTR
minimal promoter that up-regulates its expression and
recruits specifically an additional nuclear protein, YY1.
Sequence analysis of the CFTR proximal promoter (WT
and mutated) suggested potential regulatory roles for a vari-
ety of ubiquitous and lung-restricted transcription factors.
We performed an extensive immunological analysis (via
EMSA) with specific antibodies against factors having the
potential to bind various sites in the studied region, level
with CArG-like motif.
We demonstrated that:
● the wild-type sequence (y102T) recruits specifically
nuclear proteins immunologically related to SRF and Cy
EBPbeta
● the y102A allele, in addition to the YY1 transcription
factor, binds to SRF and CBP ubiquitous factors, and to
FOXA, a factor known to regulate respiratory epithelial
cell differentiation. This last complex, DNA–FOXA, is
only observed with nuclear extracts from cell lines,
which express CFTR protein.
This study is the first to demonstrate specific cis-acting ele-
ment in the human CFTR gene.
To determine the functional relevance of these proteins on
the CFTR basal transcriptional activation, we selectively
mutated these sites and compared the activity of WT and
mutant constructs in transient transfection assays. Unex-
pectedly, we showed that a consensus CArG box in both
CFTR promoter WT and mutated constructs causes a sig-
nificant decrease in basal CFTR expression. We addressed
the possibility that the SRF factor, more strongly bound to
the generated consensus CArG box, could interact with a
repressor factor such as p20-CyEBPbeta.
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We are currently investigating the mechanisms involved in
transactivation of the CFTR mutated gene (y102A allele)
via YY1, SRF, CBP and FOXA.
S15.2
EARLY USE OF DORNASE ALPHA IN CYSTIC
FIBROSIS—CON
Andrew Bush
Royal Brompton Hospital, Sydney Street, SW3 6NP, UK
Dornase Alpha (rhDNase) has become an established treat-
ment in patients with cystic fibrosis (CF), both with mod-
erate w1x and severe w2,3x lung disease. There are clearly
marked and unpredictable individual differences in
response, with only some patients gaining benefit w4,5x, and
some actually getting worse w5x despite feeling better. It is
well known that there is evidence of inflammation and
increase in DNA in lavage fluid in early lung disease w6–
8x and lung function is impaired very early, even in a group
of babies which appear to be free of any respiratory disease
w9x. The recent publication of an impressive paper w10x has
challenged us to consider the use of this medication in early
disease. As always, the issues are safety and efficacy.
● Is rhDNase safe in early stage CF in young children?
The safety record in older children and adults is impressive
w1–3x. The unknown in infants and young children is the
potential effect on in particular alveolar development (the
first 2 years of life in particular). These children are, in the
main, well, with the likelihood of many years of life ahead
of them, and therefore, have much more to lose than adults
with severe lung disease, in whom the intense infection and
inflammation are far more likely to wreak severe damage
than any medication.
● How do we monitor efficacy?
The issues have been reviewed recently w11x. Mortality is
the endpoint, which might concern patients’ families at
diagnosis w12x, but current survival curves are too flat w13x
to make this a useful endpoint; a study to show a change
would need to last decades, with thousands of children
enrolled. The most common surrogate is lung function, in
particular, first second forced expired volume (FEV ). Even1
in advanced disease, lung function is only as accurate as
tossing a coin to determine mortality w13x. In young chil-
dren, a significant change in FEV is 190 ml or 8% of1
baseline w14x, a change unlikely to be achieved in young
children in this sort of study. The use of flow at low lung
volumes is even more fraught with difficulty; variability
may be as much as 20–30% w15x. The use of infective
exacerbations as an endpoint is dogged by difficulties in
definition w16x. There are clearly major difficulties in trial
work in very young children.
● What are the data and what do they mean today?
A 2-year study completed by 410 children w10x showed
reduced time to first exacerbation (but did not comment on
total exacerbations) and maintained lung function in the
treatment group. Criticisms of what is by any standards a
herculean task may seem churlish, but the following points
must be considered w17x:
1. Were the children early stage; more than one-third had
digital clubbing, and calculation from their own data
show that some would have had an FEV as low as 66%,1
and a Brasfield score as low as 18, assuming their group
statistics are correctly calculated.
2. By the same calculations, some children would not have
met entry criteria (forced vital capacity )85%)
3. Was the use of 1983 normal ranges for lung function
justified; why not use more modern data w18x?
4. Does time to first exacerbation equate to fewer
exacerbations?
5. Why the early and non-sustained peak in lung function
on rhDNase?
6. The study, as the authors state, was underpowered to
detect a rate of change in lung function.
7. The lack of individual data, or an attempt to correlate
response with initial lung function, is a weakness; if all
those with FEV -80% responded, and those with better1
lung function did not, this tells us little more than pre-
vious studies w1–3x.
● Summary and conclusions
rhDNase cannot be recommended for all CF infants at the
time of diagnosis on the current evidence. The data would
certainly support its use on an ns1, trial basis in young
children who are doing badly. Monitoring of response in
the individual is essential, but difficult in practice, and the
best means is not clear. We need better ways to detect dete-
rioration, and monitor therapeutic response early, so that
subgroups who are doing badly can be targeted early. Final-
ly, the equivalence of daily and alternate day rhDNase has
recently been shown w19x, and future studies should bear
this in mind.
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S15.4
DRY POWDER INHALERS
P.P.H. Le Brun , J.P. de Koning , A.H. de Boer , H.W.1 2 2
Frijlink , H.G.M. Heijerman2 3
Central Hospital Pharmacy The Hague,1
GUIDE: Groningen University Institute for Drug Explo-2
ration, Department of Pharmaceutical Technology,
Adult Cystic Fibrosis Center Leyenburg Hospital, The3
Hague, The Netherlands
CF patients use various types of aerosolized drugs. The aim
of pulmonary drug administration is to reach a high lung
deposition with a rapid local onset while avoiding high sys-
temic drug concentrations.
Lung deposition is determined by the device, the particle
size distribution of the released drug and patient related
factors. Currently, three basic types of devices are available:
pressurized metered dose inhalers (pMDI’s), nebulizers and
dry powder inhalers (DPI’s). pMDI’s are most popular, but
not always applicable. A nebulizer is used in the case where
no alternatives are available (e.g. young children); it is a
practical but inefficient dose system (on average, approx.
10% of the nominal dose is inhaled).
Dry powder inhalation forms a proper alternative. A high
efficiency (up to 50% of the nominal dose) is combined
with a short inhalation time. The primary functional ele-
ments of the device are the powder formulation, the dosing
system, the powder de-agglomeration principle and the
mouthpiece. The design of each of these elements, as well
as their combination, is relevant to the properties of the
released aerosol during inhalation. To reach the lung effec-
tively, aerodynamic diameters of pulmonary drug particles
have to be within the range between 0.5 and 7.5 mm. To
date, it is unclear which excact size fraction is optimal in
CF therapy. For reaching the small airways, a much more
narrow fraction of approximately 1 mm may be necessary.
The inspiratory flow as the driving force for discharge, de-
agglomeration and deposition of dose is an important
patient related parameter. The air flow finally transports the
particles into the lung. The actually reached flow curve
depends, beside the patient’s lung function, on the instruc-
tion to the patient, a proper understanding by the patient
and the air flow resistance of the device. Various flow par-
ameters, such as the peak inspiratory flow rate (PIFR), flow
increase rate (FIR) and inspiration time, can be relevant to
good DPI performance. In general, the fine particle fraction
released varies with PIFR. However, in some cases (e.g.
Pulmicort Turbuhaler) acceleration to peak flow determines
the performance. For capsule inhalers, inhalation time has
to be long enough for all particles to be released through
the narrow holes pierced in the capsule.
In conclusion, with a proper design of the device and a
good understanding of its performance and the factors relat-
ed to that, DPI seems to form an attractive and efficient
dose administration principle for pulmonary drugs.
S16.1
CYSTIC FIBROSIS AS A MULTIFACTORIAL
DISEASE: LIVER DISEASE
Carla Colombo, Pier Maria Battezzati
CF Center, Department of Pediatrics, University of Milan
and *Cattedra di Medicina Interna II (Ospedale San
Paolo), University of Milan, Milan, Italy
CF-associated liver disease is the first inherited disease of
the liver in which the primary defect, consisting of lack of
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functional CFTR, is known to affect cholangiocytes rather
than hepatocytes. Its pathogenesis is dependent on the
impaired secretory function of the biliary epithelium, lead-
ing to reduced biliary fluidity and alkalinity and obstruction
of bile ductules by inspissated secretions. However, liver
disease develops in no more than one-third of CF patients,
shows a great degree of variability in terms of severity, and
although its incidence is higher among patients harbouring
severe mutations, no clear association with specific CFTR
mutations could be established. All these findings suggest
that additional factors andyor concurring events may wors-
en the secretory defect, further damage cholangiocytes and
play a significant pathogenetic role. The search for factors
associated with the development of liver disease has been
actively pursued. In a cohort study involving 177 CF
patients monitored prospectively for hepatic status for a
mean period of 14 years, we have found that CF patients
with a history of meconium ileus were five times as likely
to develop liver disease as the patients with no such history
and were diagnosed earlier in life. In these patients, addi-
tional risk factors for liver disease may include extensive
surgical management and prolonged total parenteral nutri-
tion. However, patients with a history of meconium ileus
represent a minority of the CF population and search for
additional risk factors for liver disease should be pursued.
A preponderance of male subjects among CF patients with
liver disease has been consistently reported. Interestingly,
all female patients in our prospective cohort study devel-
oped liver disease before the age of 11, while liver disease
continued to be diagnosed up to the age of 18 in male
patients. It is well known that estrogens and their receptors
play a critical role in modulating proliferative and secretory
activities as a response to liver damage. The gender differ-
ences we have observed invite consideration of the possible
role of endocrine factors in the development or in the rec-
ognition of liver disease in CF. An increased susceptibility
to infectious agents or drugs seems unlikely: in our pro-
spective study, frequencies of viral hepatitis (A, B and C)
did not differ between CF patients who developed (ns48)
and who did not develop liver disease (ns129); there was
no difference in the severity of lung disease and number of
intravenous antibiotic treatments between the two groups,
suggesting that drug hepatotoxicity is not relevant in liver
disease pathogenesis.
Recently, attention has been focused on the possible role of
genetic factors other than CFTR. Presence of human leu-
cocyte antigen 4HLA7 type DQ6 has been linked to
increased risk of development of liver disease in British CF
patients, but this finding was not confirmed in an ethnically
different population. More recently, candidate modifiers
genes for liver disease have been selected among genes
associated with inherited liver diseases or because the
encoded proteins are relevant to CF-liver disease pathophy-
siology. There is some evidence that the protease inhibitor
and the MBL2 genes may be involved, but the issue
requires further study on large patient populations. The
search for further factors implicated in the pathogenesis of
this complication or conditioning its progression rate is
warranted.
S16.3
INTESTINAL COMPLICATIONS OF CYSTIC
FIBROSIS (CF)
C.J. Taylor
Sheffield Children’s Hospital, University of Sheffield, UK
The gastrointestinal epithelium exhibits the same ion trans-
port anomalies seen in the CF airway. Moreover, the lack
of alternative Ca activated Cl channels in the CF intes-2q y
tine indicates a more severe defect in the gut than the lung.
This perhaps explains both the earliest clinical manifesta-
tion of the disease-intestinal obstruction in the newborn CF
infant (meconium ileus), and the phenotype seen in the
dF508 CF mouse.
In addition to problems resulting form defective Cl trans-y
port and pancreatic exocrine failure, CF patients appear to
be at increased risk of gastrointestinal disease. Disorders
including cow’s milk allergy, coeliac disease and lactose
intolerance have all been reported in association with CF.
An increased risk of digestive tract tumours has also been
described, with an overall odds ratio of 6.5, increasing to
20 in the 20–29-year age group.
Gastro-oesophageal reflux disease (GRD) appears to be
common, having been demonstrated in 19% of infants
under 6 months and up to 76% of children under 3 years.
Reflux symptoms are also frequent in CF adults and have
been linked to pulmonary allograft dysfunction after lung
transplantation.
Dysfunction of the ileum and colon are also common. Both
appear thickened on ultrasound and show functional chang-
es including abnormal motility and enhanced sodiumyglu-
cose absorption. Defective bile acid uptake and loss of bile
acid induced secretion have both been described in the ter-
minal ileum. Crohn’s disease was said to be17 times more
common in CF patients but this was prior to the description
of fibrosing colonopathy. This disorder should now be con-
sidered in any patient exposed to high doses of pancreatin
presenting with abdominal pain, distension, chylous ascites,
change in bowel habit—particularly bleeding, or poor
weight gain.
S16.4yP48: SEVERITY OF CYSTIC FIBROSIS IS
ASSOCIATED WITH POLYMORPHISM OF ANTI-
OXIDIZING GLUTATHIONE-S TRANSFERASE
GENE
C. Flamant , A. Henrion-Caude , A. Flahault , M.1* 1* 2
Roussey , K. Chadelat , M.C. Miesch , R.C. Strange , A.3 1 1 4
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Reactive oxygen species (ROS) in conjunction with abnor-
malities in protective antioxidants are important mediators
of tissue damage in patients with cystic fibrosis (CF). Our
work was undertaken to test the hypothesis that polymor-
phism of the detoxifying enzymes glutathione-S transferase
GSTM1 and GSTM3 could influence phenotypic hetero-
geneity in CF.
We have examined, using the standard PCR-RFLP method,
polymorphism of those genes in 106 CF children (mean
age 11.5"5.25 years old) and gathered clinical data for
each patient. We assessed endocrine pancreatic status and
subdivided our population (ns65) into two groups, accord-
ing to the oral glucose tolerance test. We found that the
GSTM3 AA genotype was significantly correlated with CF-
diabetes mellitus (Ps0.017). Interestingly, our study fur-
ther revealed the association of this GSTM3 AA genotype
with greater severity in CF. In a subpopulation of CF
patients either homozygous or heterozygous for deltaF508
CFTR mutation, we found that the mean FEV1% at 8 years
old (ns52) was significantly decreased amongst patients
having the GSTM3 AA genotype (mean FEV1s79.7%) as
compared with the group of AB or BB genotype (mean
FEV1s95.2%) (mean difference 15.5%, Ps0.008). In
order to narrow down this correlation, we subdivided the
group according to the median value (89.5%) into patients
having an FEV1 inferior to or greater than the median val-
ue. The frequency of GSTM3 AA was significantly
increased amongst patients with an FEV1-89.5% as com-
pared with the other group (Ps0.02). No correlation
between the GSTM1 genotype and clinical data were iden-
tified. These data suggest that the AA genotype for GSTM3
is associated with greater severity of CF, particularly with
abnormal glucose metabolism and increased degradation of
respiratory function.
*These authors have contributed equally to this work.
S16.5yP50: CFTR GENE AND ASTHMA: A
LINKAGE AND TDT STUDY
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The genetic factors involved in atopic asthma are largely
unknown. Some recent evidence suggested an increase of
CFTR gene mutations for asthma patients relative to control
subjects.
We have collected 211 families (940 subjects) with atopic
asthmatic children from North-East Italy. The subjects were
characterized for total serum IgE levels, Skin Prick Test
(SPT) reactivity to common allergens, bronchial hyperres-
ponsiveness (BHR) to methacholine, and clinical asthma.
Six DNA markers, located inside the CFTR gene (IVS8-
TGm, IVS8-polyT, M470V and 2694 TyG) or very close
to it (MP6-d9 and J3.11), and 3 CFTR gene mutations
(deltaF508, G576A, R668C) were studied by multipoint
non parametric linkage analysis on 117 families (572 sub-
jects) with affected sibpairs and by transmission disequilib-
rium tests (TDT) in all the 211 families. All traits were
treated as qualitative.
Non-parametric linkage analysis results has indicated no
evidence for linkage with any phenotype. No significant
transmission disequilibrium of the polymorphisms, or of the
mutations, or of the haplotypes formed by the polymor-
phisms in the 211 families was observed.
The frequency of the three CFTR gene mutations analysed
in the asthmatic families, which were previously described
in asthma or in other pulmonary diseases related to CF, is
not different from controls (a sample of blood donors of
the same population; Bombieri et al., Hum Genet 2000;
106: 172–178).
In conclusion, presently available data indicate no evidence
for linkage or allele transmission disequilibrium for the
CFTR gene in atopic asthma in a North-East Italian
population.
S17.1
FUNCTION OF CFTR IN ERYTHROCYTES
P. Verloo, C. Kockena, A. Thomasa, B. Hogema, B.C. Tilly,
M. Sinaasappel, H.R. de Jonge
Department of BiochemistryySophia Children’s Hospital,
Faculty of Medicine & Health Sciences, Erasmus Univer-
sity, 3000DR Rotterdam, and aTNO-Biomedical Primate
Research Centre, Department of Parasitology, Rijswijk, The
Netherlands
Until shortly, anion conductive pathways in the red blood
cell (RBC) membrane have been poorly characterized. The
recent notion that deformation-induced ATP release from
human RBCs is defective in cystic fibrosis (Sprague et al.,
1998), and that infection of RBCs by Plasmodium falci-
parum resulted in the induction of novel, voltage-dependent
anion channels, possibly functioning as a new permeation
pathway (NPP) for nutrients and waste products (Desai et
al., 2000) prompted us to investigate the expression of
CFTR chloride channels in RBCs, its possible role in ATP
release, and its potential relevance in malaria.
A first indication for the expression of CFTR in human
RBCs was obtained on the basis of RT-PCR, showing a
low level of CFTR mRNA in nucleated precursor cells, the
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erythroblasts, obtained from bone marrow puncture. More
direct evidence for the presence of tonically active CFTR-
Cl channels in human RBCs was attained by whole celly
patch clamp recordings. Basal Cl currents measured undery
isotonic conditions (80 pA at 100 mV; ns34) showed (1)
a linear I–V relationship, (2) dependence on Mg-ATP in
the pipette; (3) a slight activation by cyclic AMP (1.1–1.3
fold); (4) complete inhibition by the protein kinase-A
inhibitor PK-I; (5) inhibition by the CFTR blockers gli-
benclamide (100 mM) and DPC (500 mM); and (6) inhi-
bition by G449, an R domain-directed CFTR antibody.
Most importantly, this Cl conductance was virtuallyy
absent ()90% reduction) in RBC from DF508 homozy-
gous CF patients (ns15), arguing against its identity as a
‘pseudo-CFTR’ Cl channel.
Aside CFTR, another anion channel was identified by
whole-cell patch clamping under hypertonic bath conditions
(600 mOsm). This chloride conductance (termed IR) was
CFTR-dependent, i.e. absent in CF RBCs and inhibitable
by PK-I, G449, glibenclamide and DPC, but differed from
CFTR in its mode of activation (i.e. cell shrinkage), its
biophysical properties (strong inward rectification; 5–6
fold larger conductance), and its sensitivity to the NPP-
inhibitor furosemide ()90% inhibition at 100 mM). A
channel with similar biophysical properties appeared toni-
cally active in P. falciparum-infected RBCs from healthy
control subjects, but likewise failed to become activated in
malaria-infected RBCs from DF508 homozygous CF
patients. To test the hypothesis that the Plasmodium-
induced, CFTR-dependent chloride current is an essential
component of the NPP, predicting a poor survival of the
malaria parasite in CF patients, control and CF RBCs were
infected with P. falciparum and both the parasite survival
in vitro (cell count and 3H-hypoxanthine incorporation)
and NPP-dependent isotonic lysis (Hb release in response
to 0.3 M glucose, 0.3 M alanine or 0.15 M choline chlo-
ride) were compared. Remarkably, no significant differenc-
es were found, arguing against a role of the IRy
Plasmodium-activated Cl channel in the NPP pathway.
However, our finding that (1) cAMP-, cell shrinkage- and
cell deformation-induced ATP release from RBCs is defec-
tive in CF (Verloo et al., 2000), and (2) the pharmacolog-
ical inhibition profile of ATP release and of the IRy
Plasmodium-activated Cl conductance are similar in control
RBCs, strongly suggest a role of the CFTR-dependent IRy
Plasmodium-activated anion channel in cellular ATP
release. The possible consequences of defective ATP
release in CF RBCs for the survival of the malaria parasite
in vivo and for the regulation of microvascular resistance
is presently under investigation in a CF mouse model.
Sprague, RS, Ellsworth, ML, Stephenson, AH, Kleinhenz,
ME, Lonigro, AJ. Am J Physiol 1998; 275: H1726–H1732.
Desai, SA, Bezrukov, SM, Zimmerberg, J. Nature 2000;
406: 1001–1005.
Verloo, P, Sinaasappel, M, Schinkel, AH, De Jonge, HR.
Pediatric Pulmonol, 2000; Suppl. 20: 190–191.
S17.2
IMPACT OF CFTR ON VECTORIAL
BICARBONATE TRANSPORT BY AIRWAY
SEROUS CELLS
M. Hug , A. Waltz , R. Bridges1 1 2
Institute of Physiology, University of Muenster, D-481491
Muenster, Germany;
Department of Cell Biology and Physiology, University of2
Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
Impaired HCO and fluid secretion is the hallmark in they3
pathophysiology of the pancreas of CF patients. However,
this defect is not only restricted to the pancreas but also
affects most other tissues known to express CFTR. We have
previously shown that the airway serous cell line Calu-3
transports bicarbonate (HCO3-) ions upon stimulation with
agonists increasing cAMP. In our present study, we inves-
tigated whether functional CFTR is required for the vec-
torial transport of HCO . Calu-3 cells were subjected toy3
measurement of the intracellular pH (pHi) by microfluori-
metry and to whole cell patch clamp. When cells were
exposed to a solution containing HCO yCO , a rapidy3 2
acidification accompanied by a depolarization were
observed. pHi recovered in the presence of the buffer to
slightly more alkaline values and membrane voltage (Vm)
hyperpolarized. Clamping Vm to hyperpolarized values
using ATP, Ionomycin or EBIO acidified the cells and pre-
vented pHi recovery in the presence of HCO yCO indic-y3 2
ative for electrogenic HCO transport. To understandy3
HCO exit, cells were exposed to gradients for Cl andy y3
HCO . Replacement of extracellular Cl by gluconate iny y3
the presence of HCO resulted in a modest increase iny3
pHi suggesting the presence of a Cl yHCO exchanger.y y3
Stimulation with Forskolin decreased pHi, depolarized the
membrane and increased Gm. However, when Cl wasy
replaced in the presence of Forskolin, a marked alkalini-
zation was observed that could not be inhibited by a typical
inhibitor of anion exchangers, DIDS. In contrast, addition
of Glibenclamide, an inhibitor of the CFTR Cl conduc-y
tance, abolished the alkalinization induced by Cl replace-y
ment. We conclude that Calu-3 airway serous cells utilize
rheogenic transporters for HCO import and export.y3
HCO extrusion is stimulated by Forskolin and requiresy3
the activity of CFTR. Defective CFTR could result in
impaired HCO and fluid secretion of airway serous cellsy3
and thus affect the properties of the secreted mucins.
S17.3
REGULATION OF CFTR CHANNEL GATING BY
THE FLUORESCEIN DERIVATIVE PHLOXINE B
Z. Cai, H. Li, D.N. Sheppard
Department of Physiology, University of Bristol, Bristol
BS8 1TD, UK
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Cystic fibrosis (CF) is caused by a malfunction of the cys-
tic fibrosis transmembrane conductance regulator (CFTR),
a Cl channel with novel regulation. The activity of CFTR
is tightly controlled by protein kinases and phosphatases
that regulate the phosphorylation status of the R domain
and intracellular nucleotides that interact with the nucleo-
tide-binding domains (NBDs) to open and close the chan-
nel pore.
In the search for new activators of CFTR, we tested the
effects on the CFTR Cl channel of the fluorescein deriva-
tive phloxine B, an agent that interacts with ATP-binding
sites to modulate the function of transport proteins. When
added to the intracellular side of excised inside-out
membrane patches from C127 cells expressing wild-type
human CFTR, phloxine B (0.1–5 mM) increased channel
activity, whereas higher concentrations of the drug blocked
the channel. Phloxine B (1 mM) stimulated channel activity
by augmenting the affinity of phosphorylated CFTR Cl
channels for ATP and altering channel gating. The drug
increased opening probability by slowing the rate of chan-
nel closure without altering the opening rate. To learn
whether phloxine B enhances cAMP-stimulated Cl secre-
tion in polarised epithelia, we studied MDCK cells. When
added to the outside of MDCK epithelia, higher concentra-
tions of phloxine B (EC s19 mM) were required to aug-50
ment cAMP-stimulated short-circuit current (I ), a measuresc
of Cl secretion. However, the drug accelerated the activa-
tion and dramatically slowed the deactivation of cAMP-
stimulated I . Like its effect on wild-type CFTR, phloxinesc
B (1 mM) enhanced the P of the most common CF muta-o
tion DF508 by prolonging the duration of channel opening.
We conclude that phloxine B is a novel activator of the
CFTR Cl channel that might stimulate CFTR by binding to
the ATP-binding site of NBD2 to slow the dissociation of
ATP from NBD1. It or related agents might be of value in
the development of new treatments for CF.
Supported by the CF Trust and NKRF.
S17.4yP32: MODULATION OF CFTR BY
EXTERNAL ANION CONCENTRATION
A. Wright, B. Argent, M. Gray
Department of Physiological Sciences, University Medical
School, Newcastle Upon Tyne, NE2 4HH UK
We have shown that external HCO ions cause a dose-y3
dependent inhibition of Cl efflux through CFTR (O’Reil-y
ly et al., Gastro, 2000; 118: 1187–1196). However, the
mechanism underlying this ‘trans’ inhibition is unknown.
Aims: To test if trans inhibition is specific for HCO , andy3
to elucidate the mechanism of block. Methods: CFTR trans-
fected CHO cells were studied by fast or slow whole cell
recording (WCR) techniques. The total Cl concentrationy
in pipette and bath solutions was 114 and 155.5 mM,
respectively. Results: CFTR channels were activated by 5
mM forskolin, which increased basal currents (;10 pAy
pF) between 20- and 40-fold. After stable activation, 100
mM external NaCl was replaced with 100 mM NaBr,
NO , Aspartate or HCO . Mean percentage inhibition of3 3
inward current (measured at E y60 mV) was: Br,rev
58"13 (ns6); NO , 25"9 (ns7); aspartate, 40"3y3
(ns10) and HCO , 53"6 (ns9), giving an inhibitoryy3
sequence of BrsHCO )Asp)NO . As the P yPCl3 3 x
sequence was Br (1.53))NO (1.37))Cl (1.0))HCO3 3
(0.54))Asp (0.25), the extent of trans inhibition is not
related to relative permeability of the anion. Iso-osmotic
replacement of external NaCl with mannitol (down to 10.5
mM NaCl) caused a dose-dependent inhibition of inward
current, with 100 mM NaCl replacement causing a 49"6%
(ns6) reduction. Similar experiments using slow WCRs
gave comparable results, but the dose–response for
wCl xext was shifted to the left by;50 mM. Finally, reduc-y
ing internal Cl from 114 down to 54 mM had no effecty
on current levels. Conclusion: (i) changes in external, but
not internal, wCl x affects Cl efflux through CFTR. (ii)y y
the extent of trans inhibition by reduced wCl xext can bey
modulated by other anions. (iii) The sensitivity of CFTR
to wCl xext is dependent on recording configuration sug-y
gesting a cytosolic factor is involved in the response. We
speculate that external wCl x may be a novel ‘signal’ thaty
couples changes in the luminal ionic environment to secre-
tory activity of CFTR. Supported by the Wellcome Trust.
S18.3
ANTI-VIRAL AND VACCINATION STRATEGIES
A. Malfroot (Brussels), G. Adam (Athens), O. Ciofu
(Copenhagen), I. Dab (Brussels), G. Doring (Tubingen),¨
C. Knoop (Brussels), A. Lang (Bern), P. Van Damme
(Antwerp)
ECFS Vaccination Group
Health care in CF may be improved by a specific vacci-
nation protocol, although no special recommendations for
CF exist. Moreover, CF adults, vaccinated in early infancy,
might be at risk to get ‘vaccine-controlled’ diseases such
as measles or pertussis, which can be harmful in adult CF
and in immunocompromised transplanted subjects so that
booster vaccinations may be considered. Based on a review
of the literature, we have attempted to establish guidelines.
CF children should follow national immunisation programs
so that optimal vaccination coverage is obtained. They
could escape normal programs due to frequent hospital
admissions and school absenteeism. Unfortunately, there is
no uniform European immunisation schedule for vaccines
against hepatitis A (HAV) and B (HBV), varicella (VZ)
and some boosters. HBV and HAV are recommended in
general in patients with chronic liver disease (CLD). As
CLD is a complication of CF, it can be expected that CF’s
run a higher risk of fatal hepatitis A or B. The most appro-
priate time to vaccinate CF patients (if not implemented in
the national schedule), is as soon as the diagnosis of CLD
is made or, as soon as CF is diagnosed. VZ vaccination is
not recommended in all European countries. There are no
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data about possible worsening of pulmonary status follow-
ing VZ in CF, but it is known to cause pulmonary damage
in non-CF adults. This issue needs further investigation. In
addition to the standard vaccines, CF patients will benefit
from influenza vaccination, given either )6 months (two
doses) or )6 years (one dose). RSV infection might play
a role in the initial Pseudomonas colonization and decline
pulmonary function. An RSV vaccine is still not available
(soon in the future?). There are no recommendations for
palivizumab in CF as an alternative but expensive
prophylaxis.
More studies are needed to complete these recommenda-
tions especially for adults and CFs on a transplantation list.
Vaccines of interest for the future are RSV and CMV.
S18.4yP173: MORE THAN 7 YEARS WITH ANTI-
PSEUDOMONAS IgY WITHOUT CHRONIC
COLONISATION
H. Kollberg , M. Johannesson , H. Olesen , D. Carlander ,1 1 2 3
A. Larsson3
University Children’s Hospital, Uppsala, Sweden;1
Aarhus University Hospital, Skejby Sygehus, Denmark;2
Department of Medical Sciences, University Hospital,3
Uppsala, Sweden
Aims. Chronic Pseudomonas aeruginosa (PA)infection
ultimately occurs in nearly all CF-patients. It is impossible
to eradicate PA once established. We have previously
shown that treatment with oral anti-Pseudomonas-IgY
(antiPA-IgY) can prevent PA chronic colonisation.
Methods and material. Specific antiPA-IgY is purified
from eggs of hens immunised with PA. Ten CF-patients are
enrolled in our ongoing study. At their first colonisation
with PA, they received antibiotics to eradicate PA. There-
after, they have gargled every night with antiPA-IgY solu-
tion. By January 2002, these patients had gargled for a total
of 470 months (mean: 47; range: 26–82). For comparison,
we have retrospectively observed a group of 21 patients of
similar age for 761 months (mean 36; range: 12–74). As
in the study group, these patients had their first colonisation
with PA whereafter they were given PA antibiotics to erad-
icate PA. They did not receive antiPA-IgY.
Results. In the treated group, only 12 out of 265 sputum
cultures (4.5%) were positive for PA, i.e. only 2.6 per 100
months of observation. No patients have become chroni-
cally colonised with PA. In the control group, 19% obtained
PA positive cultures, i.e. 14 per 100 months of observation
and 5y21 became chronically colonised with PA during the
time of observation.
Conclusions. This study shows that chronic colonisation
with PA can be postponed after the first PA colonisation. It
also shows less positive PA cultures and a decreased need
for antibiotics. These results are promising, but more obser-
vations are needed. We have started a multicenter, double
blind, randomised, placebo controlled study, but due to the
limited number of patients available in Sweden, we have to
find new collaborators for future studies.
S20.2
ESSENTIAL FATTY ACID METABOLISM IN CF
Birgitta Strandvik
Dept of Paediatrics, Institute of the Health of Women and
Children, Goteborg University, Sweden.¨
Essential fatty acid (EFA) deficiency is a common finding
in patients with CF, especially related to ‘severe’ genotypes
(1) and more prevalent in infancy, puberty, pregnancy and
lactation. Also, in first grade relatives, the EFA concentra-
tion in serum phospholipids have been shown to be influ-
enced (2) and in a screened population it has been found
to gradually decrease during the first year of life (3). In
malnourished patients it is aggravated and shown to influ-
ence lung function (4). In long term studies it has been
shown to influence liver steatosis and renal function (5,6).
Sweat chloride concentration was not influenced (7) but
short term effect has been suggested during intravenous lip-
id therapy (8). Regular corrections of EFA deficiency as a
part in the treatment policy of patients with CF may con-
tribute to the successful survival rate in our country (9).
The cause of the EFA deficiency is still obscure. Although
CFTR is a protein located in the cell membrane and belong-
ing to the ABC casett protein family, which is characterized
by both having functions as channels and transport proteins
(10), a specific transporting function of CFTR has not been
recognized. In cell cultures the dF508 mutation has been
shown to increase the incorporation of linoleic acid in tri-
glycerides at the expense of the incorporation in phospho-
lipids (11). However, this finding might be related to the
observation that the most common phospholipid in the
membranes, phosphatidylcholine, has an increased turnover
in CF cells (12). The arachidonic acid releasing enzyme
phospholipase A2 has been reported to be increased in
serum (13) and arachidonic acid release has been found
exaggerated in at least two cell systems (14,15). The arach-
idonic acid release is rate limiting for the eicosanoid syn-
thesis and it is therefore further support for an increased
arachidonic acid release that the excretion of prostanoids
are increased in CF patients (16). All these factors would
contribute to an accelerated metabolism of linoleic acid
(17).
Also the metabolism of n-3 fatty acids are influenced and
in patients with linoleic acid deficiency, docosahexaenoic
acid is also decreased in serum phospholipids (1). The ratio
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between arachidonic acid and docosahexaenoic acid is
increased and the metabolic disturbance behind this abnor-
mality is at present not clarified.
To summarize, it is at present not known how the lipid
abnormalities are related to the basic defect in CF, but many
clinical symptoms are related to EFA deficiency and the
status of the patients seem to benefit from correction of the
deficiency.
References will be given on request to the author.
S20.3
FAILURE OF NUTRITIONAL TREATMENT
Sue Wolfe
Regional Paediatric CF Unit, St James’s University Hos-
pital, Leeds, UK
A close relationship between nutritional status, pulmonary
function and survival is well established . Recently, body1
wasting has been found to be an independent risk factor for
impaired survival , adding further evidence of the impor-2
tance of nutritional management.
Nutrient inadequacy is the result of inadequate intake or
excessive loss. There are two distinct categories of nutri-
tional failure. Studies repeatedly show that patients fail to
achieve an adequate macronutrient status, resulting in
growth failure, wasting, deteriorating respiratory function
and mortality. Patients may also have a suboptimal intake
of micronutrients, leading to consequential deficiency
symptoms. With increasing longevity, this type of nutri-
tional failure could contribute to a poorer quality of life and
greater morbidity within patient groups.
Staged intervention programmes are widely used to min-
imise nutritional failure. It is common for patients to pass
through the stages of normal eating, oral supplement use,
invasive nutritional support and in some cases parenteral
nutrition. The need to pass from one stage to the next could
be viewed as nutritional failure. In the UK and Europe,
recently developed guidelines on the nutritional manage-
ment of CF give clear indications when to instigate nutri-
tional support, and therefore, will hopefully help to
minimise nutritional failure.
Some treatments are well established, such as supplemen-
tation with vitamins A, D and E; even so, there is still
debate about optimal plasma levels. Others are still under
investigation. These include the need for routine supple-
mentation with vitamin K, calcium, essential fatty acids and
antioxidant nutrients. Until we have the answers to these
questions we are possibly unknowingly missing important
aspects of nutritional care.
References
1. Corey M, et al. J Clin Epidemiol 1988; 41 (6): 583–
591.
2. Sharma R, et al. Thorax 2001; 56: 746–750.
S20.4
ARTIMINO 2001: THE ECFS CONSENSUS ON
NUTRITION
Martin Stern for the ECFS Consensus Committee
University Children’s Hospital, Tuebingen, Germany
Based on available evidence and practice a European con-
sensus on nutrition in patients with cystic fibrosis has been
agreed upon by 33 experts in the field after a consensus
conference which took place in Artimino (Italy) in March
2001.
The consensus paper (to be published in the first edition of
the new Journal of Cystic Fibrosis) summarises nutrition
and growth deficiencies in CF with a special focus on def-
inition of malnutrition and its assessment by anthropometry
and laboratory investigations. Increased energy expenditure,
pancreatic enzyme deficiency and other factors contributing
to malabsorption and malnutrition in CF are shifting energy
balance into a negative direction. Macronutrient and micro-
nutrient deficiencies are summarised. In many cases, lack
of appropriate studies had to be conceded.
Practical advice based on the prevention of malnutrition and
early intervention is given by the consensus paper. This
applies to infant feeding, high-fat diet, high-energy supple-
ments and tube feeding if required. A new guideline for
nutritional intervention is given, based on relative weight
for height and on body mass index parameters, as well as
on fine indicators of failure to thrive. Pancreatic enzyme
dosage and gastrointestinal management have been given
in some detail, as well as supplementation guidelines for
vitamins A, D, E and K and for minerals and trace
elements.
Conclusions. The consensus is concluded by 18 important
questions and answers summarising basic needs and strat-
egies to prevent and correct malnutrition in CF. The con-
sensus is pointing out 30 topics for further study to improve
knowledge and strategies in CF nutrition, particularly on
the use of antioxidants, on patient compliance and reasons
for therapy failure, on basic gastrointestinal mechanisms,
fatty acid metabolism, diabetes mellitus, neurological and
bone development.
S21.1
TRANSCULTURAL CHALLENGES IN CYSTIC
FIBROSIS
A.J.A. Duff
Regional Cystic Fibrosis Unit, St James’s University Hos-
pital, Beckett St, Leeds, UK
The incidence of cystic fibrosis (CF) and the frequency of
disease-causing genetic mutations varies amongst different
ethnic and geographic populations. It remains so rare in
non-Caucasians that it has been suggested that certain
groups should be excluded from screening programmes
(Phillips et al., 1995). However, increasingly more is
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becoming known about the spectrum of mutations in the
CFTR gene in different populations (e.g. African, African–
American, Jewish, South American, Japanese and Chinese),
and consequently, other studies have questioned whether
the disease is under-reported or misdiagnosed (e.g. Padoa
et al., 1999).
This paper will review the literature on such developments
and consider the new challenges that are beginning to face
those who treat the disease. For example, in the US, CF
patients of African–American decent, identified with the
delta F508 mutation, have been shown to have a signifi-
cantly poorer nutritional status than their age- and sex-
matched Caucasian counterparts (Hamosh et al., 1999).
Implications for patient-education, clinical practice and
research will be discussed in detail. Particular focus will be
on ‘inclusivity’ with respect to patients accessing services
and treatment (especially those that are nutritionally-based)
and on considering how differing ethnic and cultural beliefs
may impact on traditional CF interventions.
References
Hamosh et al., J Pediatr 1999; 132: 255–259.
Padoa et al., J Med Genetics 1999; 36: 41–44.
Phillips et al., J Nat Med Assoc 1995; 87: 433–435.
S21.3
PSYCHOTHERAPEUTIC INTERVENTIONS IN A
MULTI-ETHNIC SOCIETY
Mervyn S. Miller, D. Katznelson, A. Augarten, A. Szein-
berg, O. Efrati, A. Barak, J. Yahav
National Center for Cystic Fibrosis, Pediatric Division,
Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
The complex management and treatment of CF, a life-long,
life-threatening and life-curtailing incurable disease, is fur-
ther complicated when the treated population is of diverse
ethnic, religious and cultural origins. While effective med-
ical treatment may be administered to diverse populations
without modification, the implementation of culture-related
psychotherapeutic interventions based on western models
may be inappropriate, ineffective and even adverse. Sensi-
tive, informed and respectful regard for ethnic, religious and
cultural factors is necessary. Frequent reasons for referral
may include: emotional crises following initial diagnosis
and later exacerbations, problems of parent–child relation-
ships, adherence (nutrition and physiotherapy), behavior,
body-image, anxiety, depression and social relationships.
Addressing these difficulties requires culture-relevant and
culture sensitive psychotherapeutic interventions including
modifications in technique, theory and philosophical con-
siderations (Tseng, 1999). It is also necessary to consider
the socio-cultural setting of the therapy, patient’s expecta-
tions, communication style, culturally adjusted theories of
psychopathology, therapeutic models, culture-specific cop-
ing patterns and goals of therapy. Further important factors
are language, health–belief systems, familial and religious
values and customs, the evolving therapeutic alliance and
attitudes towards professional figures and dependency. Var-
ious modes of intervention will be compared and their basic
assumptions, orientations, techniques and mechanisms
analyzed.
Therapists should be flexible, open, and curious and should
acquire cultural sensitivity, knowledge, empathy and
insight. Awareness and reflection on the impact of their
personal value systems towards patients is important to
monitor tendencies toward stereotyping and prejudice that
may emerge in the counter-transference. These processes
are relevant to all members of the multidisciplinary CF
team.
S21.4
PATIENT–CLINICIAN CONFLICTS
Bryan Lask
Department of Psychiatry, St George’s Hospital Medical
School, London SW 17 0RE, UK
Conflict is an everyday phenomenon, a part of normal life.
It is not surprising, therefore, that it should occur in a clin-
ical setting, not only between clinicians and within teams,
but also between patients and clinicians. This is all the more
likely in a setting that deals with a chronic disease such as
CF. The physical, emotional, social and practical burdens
of the illness are such that coping mechanisms are stretched
to their limits. Disagreements, misunderstandings, impaired
trust, and different expectations may all challenge the
patient–clinician relationship. In a context in which chil-
dren and adolescents form at least half the clientele, the
potential for conflict is intensified because of the involve-
ment of parents. Where there are socio-cultural differences,
this understandably becomes even more the case. It is not
at all surprising, therefore, that conflicts may occur.
This paper emphasises the normality of such conflicts, illus-
trates common conflict-laden scenarios, explains the rea-
sons for them, and explores how best to resolve them. The
basic principles of conflict-resolution are outlined, and use-
ful techniques, readily applicable in everyday practice, are
described.
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WS1.1yP7
STABILIZATION OF CFTR TRANSCRIPTS
INDUCED BY EXTRACELLULAR STIMULI VIA
ACTIVATION OF MAP KINASE CASCADES
A. Jaulmes , M. Baudouin-Legros , B. Coste , P. Fanen ,1 1 2 2
A. Edelman1
INSERM U.467, Faculti de midecine Necker, 75015 Paris,1
France,
INSERM U.468, Hopital Henri Mondor, 94000 Creteil,2 ˆ
France
A good stability of transfected CFTR mRNAs is required
for the success of an eventual gene therapy of cystic fibro-
sis, but various extracellular stimuli, such as cytokines,
hyperosmolarity, or ouabain, the Na , K -ATPase inhibi-q q
tor, control the degradation of endogeneous CFTR mRNAs.
We study here the post-transcriptional reactions involved in
the control of CFTR gene expression.
The work is performed on human colic (HT-29) and pul-
monary (Calu-3) cell lines which express CFTR, then on
HeLa cells stably transfected with CFTR cDNA completed
by the 3-untranslated sequence of the gene. It includes: (1)
measurements, by Northern blots, of the rate of degradation
of the CFTR mRNAs under inhibition of gene transcription;
and (2) analysis of the in vitro degradation of CFTR m-
RNAs (contained in total RNAs isolated from Calu-3 cells
or transfected HeLa cells) incubated with cytosolic proteins
extracted from Calu-3 cells in basal state or submitted to
extracellular stimuli.
Northern blots show that hyperosmolarity and ouabain sta-
bilize the CFTR transcripts in HT-29 and Calu-3 cells,
respectively.
The in vitro experiments show that cytosolic proteins
extracted from untreated Calu-3 cells degrade the CFTR
mRNAs of control Calu-3 cells and transfected HeLa cells.
The degradation of the CFTR transcripts is significantly
less important when the cytosolic proteins are extracted
from cells pre-treated for 24 h with either ouabain
(2=10 M), interleukine 1b (250 pgyml), or TNFa (10y7
ngyml), and the protection is particular to CFTR, since it
does not affect the b actin mRNAs. Activation of MAP
kinase cascades mediates this protection, since the CFTR
mRNAs are not stabilized by proteins extracted from cells
treated by ouabain in the presence of inhibitors of p38 or
p42y44 MAP kinases.
Characterization of the protective protein should bring
interesting data for gene therapy improvement
WS1.2yP8
SYNTAXIN8 INHIBITS CFTR CHANNEL
ACTIVITY AND TRAFFICKING
F. Bilan , V. Thoreau , R. Derand , A. Cantereau , F.1 1 2 2
Becq , A. Kitzis2 1
Laboratoire de Genetique Cellulaire et Moleculaire,1
UPRESEA 2622, CHU de Poitiers, Poitiers, France;
Laboratoire de Biomembranes et Signalisation Cellulai-2
re,CNRS UMR 6558, Universite de Poitiers, Poitiers,´
France
We have previously reported the cloning of a cDNA encod-
ing human syntaxin8 (STX8 gene), using the R domain of
CFTR as a bait in a two-hybrid screening. Syntaxin8 is a
member of the t-SNARE protein superfamily, which is
involved in vesicle trafficking and membrane fusion events
within the cell. Syntaxin8 has been shown to be a compo-
nent of the endosomal SNARE complex. In order to inves-
tigate the physiological relevance of an interaction between
CFTR and syntaxin8, we have generated cell lines co-
expressing these proteins. We have selected a CHO-K1 cell
clone harboring CFTR and overexpressing syntaxin8. In
this clone, we have established, by iodide efflux and whole
cell patch clamp experiments, that overexpression of syn-
taxin8 induces a dramatic inhibition of CFTR chloride
channel conductance. To visualize syntaxin8 effects upon
CFTR trafficking, we have transfected a GFP-CFTR fusion
protein in COS-7 cells. By confocal microscopy, the fluo-
rescence was localized in perinuclear compartments, in ves-
icle-like structures and in the plasma membrane. When
co-transfected with syntaxin8, GFP-CFTR was only
observed in the perinuclear area. These data suggest that
over-expression of syntaxin8 could inhibit CFTR channel
activity by impairing its trafficking towards the plasma
membrane or its recycling by the endocytic pathway. More-
over, we can provide arguments suggesting a direct pro-
tein–protein regulation, as it has been shown with
syntaxin1A, since we found physical interactions between
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CFTR and syntaxin8. GFP-CFTR present in transfected
COS-7 lysates was retained by immobilized recombinant
GST-syntaxin8, although with a weaker affinity than syn-
taxin1A. Nevertheless, we co-immunoprecipitated CFTR
with syntaxin8 antibody in HT29-19A cells. Therefore,
these two proteins appear to be present in the same com-
plex, whether their interaction is direct or not. Taken togeth-
er, our results strengthen the idea that the SNARE
machinery directly regulates CFTR trafficking and activity.
WS1.3yP9
CORRELATION BETWEEN C-SRC TYROSINE
KINASE ACTIVITY AND GAP JUNCTION
MEDIATED INTERCELLULAR COMMUNICATION
IN CFTR-EXPRESSING AIRWAY CELLS
S. Huang, T. Dudez, I. Scerri, S. Suter, M. Chanson
Department of Pediatrics, Laboratory of Clinical Investi-
gation III, Geneva University Hospitals, 1211 Geneva,
Switzerland
We previously reported that rapid down-regulation of gap
junctional communication (GJC) by the pro-inflammatory
mediator TNF-alpha was defective in human cystic fibrosis
(CF) airway cell lines. Adenovirus-mediated transfer of
wild-type CFTR into CF cells was associated with the
recovery of TNF-alpha-induced closure of gap junction
channels. To examine the mechanisms by which the pro-
inflammatory mediator regulates GJC in non-CF airway
cells, we tested several inhibitors known to selectively
block signal transduction pathways. PD98059, a potent
inhibitor of MAP kinase pathway, did not affect the gap
junction channel closure mediated by TNF-alpha in the
CFTR-expressing Beas2B cells. In contrast, TNF-alpha-
induced uncoupling of Beas2B cells was prevented by tyro-
sine kinase inhibitors (tyrphostins and PP1). Similar
observations were made in Beas2B cells exposed to LPS
from Pseudomonas aeruginosa. In addition, the activation
of c-Src by TNF-alpha was detected within minutes as
revealed by Western blots using specific phospho-antibod-
ies against the active form of the tyrosine kinase. Transfec-
tion of Beas2B cells with a dominant-negative version of
c-Src kinase abrogated the down-regulation of GJC induced
by TNF-alpha and LPS. Finally, exposure of non-CF airway
cells in primary cultures to tyrphostin strongly attenuated
the decrease in GJC normally evoked by TNF-alpha. Taken
together, the data suggest that c-Src mediates GJC down-
regulation induced by pro-inflammatory mediators in
CFTR-expressing airway cells. Failure of gap junction
channels to close in CF airway cells may contribute to the
enhanced inflammatory response characteristic of the CF
pathogenesis.
Supported by the Swiss National Science Foundation, Vain-
cre la Mucoviscidose and the Swiss Society for Cystic
Fibrosis.
WS1.4yP10: TYROSINE KINASE C-SRC
CONSTITUTES A BRIDGE BETWEEN MUC1
OVEREXPRESSION AND CFTR CHANNEL
FAILURE IN CYSTIC FIBROSIS
T. Santa-Coloma , A. Gonzalez-Guerrico , E. Cafferata , F.1 1 2
Marcucci , M. Radrizzani , D. Gruenert , O. Pivetta1 2 3 2
Fundacion Campomar, UBA, CONICET, Buenos Aires,1 ´
Argentina;
Centro Nacional de Genetica Medica, Buenos Aires,2 ´ ´
Argentina;
Human Molecular Genetics Unit, Department of Medicine,3
University of Vermont, Burlington, VT, USA
Cystic fibrosis (CF), a disease caused by mutations in the
cystic fibrosis transmembrane regulator (CFTR) chloride
channel, is associated in the respiratory system with accu-
mulation of mucus and impaired lung function. The role of
the CFTR channel in the regulation of the intracellular path-
ways that determine the overexpression of mucin genes is
unknown. Applying differential display to CFDE cells (CF
cells) and to CFDEy6RepCFTR cells (CFDE transfected
with wt-CFTR), we have isolated several differentially
expressed cDNA fragments the might correspond to m-
RNAs of different CFTR-dependent genes. One of them
was further characterized and corresponded to the tyrosine
kinase c-Src. Northern blot analysis confirmed that the c-
Src mRNA is modulated by NPPB or CFTR-antisense oli-
gonucleotide. In addition, c-Src protein and activity, which
increased in CFDE cells, could be modulated by the CFTR
inhibitor glibenclamide. On the other hand, MUC1 protein
and mRNA levels were found to be elevated in CFDE cells.
The MUC1 levels returned to normal after c-Src inhibition
with the inhibitor PP2 or by transfection of CFDE cells
with a c-Src dominant negative mutant. Also, overexpres-
sion of c-Src with a plasmid expressing wt c-Src in CFDEy
6RepCFTR cells raised the MUC1 protein and mRNA
levels as determined by confocal immunocytochemistry and
confocal FISH. Finally, CFTR inhibition with NPPB or gli-
benclamide showed no effects on CFDE cells although the
inhibition increased MUC1 levels on CFDEy6RepCFTR
cells, suggesting a CFTR™c-Src™MUC1 link in CF. The
results also suggest that c-Src is a central element in the
pathway connecting the CFTR channel with MUC1 over-
expression and that the overexpression of mucins is a pri-
mary response to CFTR malfunction in cystic fibrosis,
which occurs even in the absence of bacterial infections.
This work was supported partially by grants from the Uni-
versity of Buenos Aires (to TASC), the National Research
Council of Argentina (to TASC) and the Asociacion FIPAN´
(to OHP and TASC).
WS1.5yP11: ISOLATION AND
CHARACTERIZATION OF HUMAN AIRWAY
EPITHELIAL STEM CELLS
A. Avril-Delplanque , I. Khazaal , C. Delenda , O.2 1 2
Danos , E. Puchelle , B. Peault2 3 1´
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Inserm U506, Villejuif, France;1
Genethon III, Evry, France; (3) Inserm U514, Reims,2
France
Development, turnover and repair of the human respiratory
epithelium are still poorly understood. Up to now, airway
epithelial stem cells have not been clearly identified; but it
is generally accepted that both secretory and basal cells
have the capacity to divide and differentiate.
We have previously developed an in vivo assay for pro-
genitor cells of the human tracheobronchial epithelium rely-
ing on the transplantation of human fetal respiratory tissues
into severe combined immunodeficiency (SCID) mice.
Using this model, we studied the progenitorial potentialities
of human airway epithelial basal and apical cell subpopu-
lations. Epithelial single-cell suspensions were obtained by
enzyme digestion from mature airway xenografts. Detection
by flow cytometry of the CD166 adhesion molecule and
the aquaporin-3 water channel expressed by apical cells and
basal cells, respectively, led to sorting of the two epithelial
cell subpopulations. Potentialities of sorted cells were eval-
uated in vivo in our xenograft model. While both cell sub-
populations reconstituted epithelial structures after 4 weeks
of engraftment, remarkably, only aquaporin-3q basal cells
exhibited the ability to restore a normal pseudostratified
airway epithelium on long term (12 weeks). We have trans-
duced dissociated epithelial cells by a lentiviral vector
encoding green fluorescent protein (GFP) driven by the
internal human phosphoglycerate kinase promoter (hPGK)
and pseudotyped with the vesicular virus glycoprotein
(VSV-G), and studied their fate in vivo. After 10 weeks of
engraftment, epithelial cells restored a normal human air-
way epithelium with submucosal glands, both structures
showing persistent and stable GFP expression.
These results suggest that airway stem cells are present
among the basal cell subpopulation and sorting of these
epithelial progenitors reveals new opportunities for celly
gene therapy in CF.
Supported by INSERMy AFM and Association Vaincre la
Mucoviscidose (AVLM) grants.
WS1.6yP1
BASAL KC PRODUCTION IN TRACHEAL
SURFACE LIQUID OF CF MICE ENGRAFTED IN
NUDE MICE
S. Escotte, V. Laplace, S. Benoit, J. Hinnrasky, J.M. Zahm,
D. Gaillard, E. Puchelle
INSERM UMRS 514, IFR53, Reims, France
We have earlier shown in an in vivo (cftrm1Hguy
cftrm1Hgu) murine model (Zahm et al., 1997) and in CF
fetal humanized airway xenografts in SCID mice (Tirou-
vanziam et al., 2000) that a pro-inflammatory state is pres-
ent, before any infection in CF airways. There is currently
controversy about whether the basic cellular defect is asso-
ciated with an inflammatory response or whether this
response occurs secondary to airway infection. In this study,
we used female CFTR-deficient mice (cftrm1Uncy
cftrm1Unc) aged 4–5 weeks and backcrossed on C57BLy
6 during three generations. We first performed a
histological analysis of the airway and intestinal epithelium
in the CF mice and littermates. The tracheae were dissected
and tied at their distal end to sterile polyethylene tubing,
and implanted in the nude mice flanks during 1 week. Cul-
ture medium was inoculated in the lumen of the grafted
tracheae. After 4 h of contact with the tracheal surface, we
collected the intraluminal liquid. We measured the basal KC
secretion in six CF tracheae and littermates mice. We ana-
lyzed the CF chloride efflux and littermates on tracheal
explant outgrowths by videomicroscopy analysis using SPQ
probe after sequential incubation with amiloride, forskolin
and ATP (10, 25 and 10 mM, respectively). No evidence
of inflammatory state could be seen in the native CF tra-
cheae, but marked abnormalities in intestinal epithelium
and meconium ileus were frequently identified. We meas-
ured an abnormally low chloride efflux in CF tracheal epi-
thelial cells. Furthermore, we observed a significantly (Ps
0.004) higher basal KC protein level (1826.6"536 pgymly
mg proteins) in CF mice as compared to littermates mice
(133.6"131.3 pgymlymg proteins).
These results add weight to the hypothesis that the airway
epithelium inflammation may be initiated very early before
infection by the CF basic defect.
S. Escotte is a Ph.D. student supported by Inserm and Asso-
ciation Vaincre la Mucoviscidose.
WS2.1yP339: PROMOTING A POSITIVE IMAGE
IN ADULTS WITH CYSTIC FIBROSIS
A. Nicholas , H. Kitchen , P. Winslow , I. Lumley , M.E.1 2 2 2
Dodd , A.K. Webb1 1
Adult Cystic Fibrosis Unit, Manchester, UK;1
Lime (Formerly Hospital Arts)2
Our annual consumer survey showed a demand for activi-
ties to reduce boredom among patients affected by frequent
or prolonged hospitalisation.
In response we set up the ‘Me, Myself, I’ project with the
help of an arts co-ordinator (HK) from LIME, an organi-
sation which works chiefly in health service contexts,
engaging patients and staff in arts projects designed to pro-
mote well being. Patients explored themes of self and iden-
tity in words and photographs in a 1-week series of daily
workshops. Patients worked as a group with a creative writ-
er (PW) and a photographer (IL). A patient segregated due
to B. cepacia had individual sessions.
The CF social worker provided continuity for the project,
helping to overcome difficulties caused by admissions and
discharges. Inspired by images, models and words each
patient wrote a poem, and worked individually with the
photographer to produce a self-portrait they felt comfort-
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able with. Patients, staff and relatives were invited to com-
ment on the project.
Patients, staff and relatives reported a positive change in
mood and self esteem among patients, with increased co-
operation over care and treatment. Those involved in the
project felt more confident as a group and tackled other
ward-based problems, e.g. catering. Patients felt that shar-
ing their thoughts and feelings with the group generated a
sense of pride in their achievement and in the CF
community.
The patients’ enthusiasm was the best indication of success.
The sessions were eagerly anticipated and ran for longer
than planned at patients’ request. The project met and
exceeded its original aims.
The work is of a high standard and has been published as
a set of limited edition hand bound books, which act as a
reminder of the thoughts and feelings of those who shared
in the project. The work was displayed in a public area of
the hospital and drew many compliments from visitors. It
will also be displayed permanently on the CF unit.
Patient demand for similar activities remains high. We now
have artists working with groups and individuals in a wide
variety of media: including digital, writing, sculpture, paint-
ing and music.
WS2.2yP341: EMBRYONIC STEM CELL
RESEARCH TO TREAT CF: A MODEL FOR
REASONED ETHICAL DISCUSSION
B. Leclerc , M. Melancon , M. De Braekeleer1 2 3
College de Rimouski & Institut de recherche sur l’ethique1
et la regulation sociale, Universite du Quebec a Rimouski,
Quebec, Canada;
Universite du Quebec a Chicoutimi, Quebec, Canada;2
Universite de Bretagne Occidentale & CHU Morvan Brest,3
France
The purpose of this interdisciplinary research is to develop
a process of reasoned analysis of the ethical and social fac-
tors in the use of human embryonic stem cell therapy. We
know that basic research on cellular production and differ-
entiation is ongoing in some countries and that this will
eventually lead to initial therapeutic trials, potentially to
treat CF. We know as well that this research will be pre-
ceded and accompanied by debate within associations such
as the CF European Association, the medical and scientific
communities, and also the public. We are of the conviction
that these debates must be rationally structured so as to be
both careful and constructive.
Methodologically, this research involves the application of
a structured analysis based on recurring ethical and social
factors in recent literature dealing with human embryonic
stem cell research. This analytical process, developed by
professor Leclerc in the perspective of discourse ethics,
includes three levels: those of utility, beneficence, and
justice.
Our research results are systematized in order to permit the
organization of the debates in three successive, interrelated
steps from the simplest to the most complex. Here is a
preview.
The level of utility: establish the facts on possible thera-
peutic use, security, the possibility of cloning, cost analysis,
the availability of embryos, etc. The level of beneficence:
analysis of competing values, especially the recovery of
patients, the advancement of knowledge, economic devel-
opment, the value of human life at conception, etc. The
level of justice: the resolution of value differences in a
social ethics perspective, protection of research subjects and
of the embryo, public monitoring of research, etc.
Funded by Genome QuebecyGenome Canada.
WS2.3yP342: FERTILITY COUNSELLING ISSUES
IN MALES WITH CYSTIC FIBROSIS
C. Cowperthwaite , B. Govin , M. Ledson , M. Walshaw1 1 1 1
Regional Adult CF Unit
Whilst nearly all males with CF are infertile due to
CBAVD, recent developments in fertility treatment (ICSI
and MESA) mean that many can now father their own chil-
dren. However, it was our impression that whilst many are
aware that this is a common complication of their CF dis-
ease, many are unaware of the possible fertility therapeutic
options. We, therefore, used a structured interview tech-
nique to assess the fertility knowledge and approachability
of 33 male patients (mean age 25, range 17–46) attending
our adult CF unit (150 patients). All were interviewed by
one of two CF nurses, who also used the interview to pro-
vide a counselling service. All patients knew that they
might be infertile: 33% had been informed by their doctor,
9% by another patient, 21% by the UK CF Trust, 12% by
the CF nurse, 18% by their parents, and the remaining 3%
at school. The preferred route, however, was from the CF
team (87% of cases). Whilst 30 (91%) were aware that a
fertility (sperm) test was available, only five (15%) had
undertaken this, and few expressed a wish to undergo it.
Only 24% were aware of ICSI and MESA as a treatment,
and whilst the general response to this new information was
positive, 30% did not find it helpful. Overall, 91% were
happy that the interview information was useful, but 9%
wanted written supplementation. As regards broaching this
sensitive issue, 91% of patients were happy to discuss fer-
tility issues, and 40% felt this was an unappreciated need.
57% of patients wished to discuss fertility with their CF
doctor, 87% with the CF nurse, 27% with the general prac-
titioner, 21% with the physiotherapist, and 21% with ward
staff. Thus, we have shown that, in our unit, whilst male
patients are aware of their infertility, few have had it inves-
tigated and few know about the new therapeutic options
available. Despite this, most patients were happy to talk
about fertility issues and welcomed discussion about this
distressing aspect of the CF condition for adult males.
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WS2.4yP344: ASSESSMENT OF EATING
DISORDER SYMPTOMATOLOGY IN PATIENTS
WITH CYSTIC FIBROSIS
L. Meloff , N. Brager1 1
University of Calgary Medical Clinic of the Foothills Med-
ical Centre
Rationale: Chronic illnesses such as CF have been pro-
posed as being precursors to eating disorder (ED) symp-
tomatology due to the emphasis on food and weight. The
presence of an ED or ED symptomatology could compro-
mise the precarious nutritional balance of CF. The investi-
gation into this link seems essential, however, the only
measures available to assess ED are those that have been
specifically developed for use with ED populations. Hence,
ED measures need to be evaluated for use with disease
specific populations such as CF.
Aim: To evaluate the validity of current ED measures for
detecting ED symptomatology in patients with CF. Method:
Thirty-four patients from the Adult CF Clinic completed
two self-report questionnaires (Eating Attitudes Test wEATx
and Eating Disorder Inventory-2 wEDI-2x), and a semi-
structured interview (Eating Disorder Examination wEDEx).
Forty-four non-clinical psychology students completed the
EAT and EDI-2. Exploratory factor analyses, a modified
multivariable multimethod correlational matrix, and a dis-
criminant function analysis were utilized.
Results: Factor analyses revealed varied factor structures
for the instruments that did not support the constructs orig-
inally posited for ED samples. Correlational analyses
revealed convergence between the instruments indicating
overlapping constructs. The discriminant function analysis
showed that the instruments were able to discriminate
between the CF and non-clinical groups with the Oral Con-
trol subscale from the EAT being the most important
variable.
Conclusions: The ED assessment instruments presented
with distinctly different factor structures when utilized with
non-ED samples questioning their construct validity for use
with non-ED populations and specifically with CF patients.
The findings provide a potential foundation from which to
build assessment protocols for the identification of ED
symptomatology in patients with CF.
WS2.5yP345: A MULTI-FOCAL
PSYCHOLOGICAL INTERVENTION (MFPI) AS A
MEANS OF INCREASING ADHERENCE IN
REBELLIOUS CF CHILDREN
Y. Neumann , E. Kerem , M.S. Miller1 2 3
CF center, Shaare Zedek,1
Department for Pediatric Pulmonary Disease in Shaare2
Zedek’s Goldwurm Pediatric Institute,
Senior Clinical Psychologist3
Aim: Negativism and rebelliousness regarding adherence
frequently manifests. Complex psychodynamic factors
affect adherence, including difficulties in exercising paren-
tal authority due to feelings of guilt, unconscious anger, etc.
and difficulties in allocation attention between healthy and
sick children. This study evaluates a MFPI that aimed at
optimizing allocation of parental attention among children,
and promoting adherence.
Method: A MFPI intervention (individual and couple-ther-
apy, parental guidance) was applied. This MFPI comprised
6 months, of weekly double sessions of 90 min.
Results: The family history revealed multiple traumas, e.g.
Holocaust and births of three CF siblings. Chronic states of
mourning disrupted normal separation–individuation proc-
esses. The mother experienced helplessness with the anti-
social behavior of two of her CF children. Our intervention
succeeded in enhancing adherence behavior by addressing
the multiple difficulties. The MFPI contributed to the artic-
ulation of elements of the medical treatment and the atten-
dant psychological experiences. The parents renunciation of
an aspiration for total control led to a more flexible
approach. Attunement to the different children’s psychic
needs facilitated cooperation, self-care and renewed clinic
visits. Manifestations of impulsiveness and acting-out were
transformed to socially acceptable behavior. One child
returned to school after a long absence and another obtained
his driving license and renewed formerly abandoned social
relationships.
Conclusion: MFPI is labor-intensive but has important
long-term benefits for children with CF. This MFPI com-
bined diverse psychological interventions for all family
members including parental guidance and individual and
couple-therapy. MFPI successfully enhanced adherence
(medication, clinic visits, physiotherapy and nutrition).
Multi-problem families necessitate complex multi-dimen-
sional approaches, such as MFPI, and may thereby be suc-
cessfully treated.
WS2.6yP346: ADHERENCE TO PULMOZYME
AND VITAMINS IN ADULTS WITH CYSTIC
FIBROSIS: DO OPINIONS ABOUT TREATMENT
MATTER?
L. Kettler , H. Winefield , H. Greville , S. Sawyer1 1 2 3
Adelaide University,1
Royal Adelaide Hospital,2
Royal Children’s Hospital, Adelaide, Australia3
Aims: Research indicates that many adults with CF adhere
poorly to their prescribed treatments. Reasons for poor
adherence among adults remain poorly understood due to
problems with measurement and research methods. In this
research project, we aim to investigate links between adher-
ence to treatment in CF and the opinions and beliefs which
people hold about their CF and its treatment.
Method: Participants for this study are being recruited from
two adult outpatient CF clinics in Australia. In all, 50 con-
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secutive attendees (25 from each site), prescribed both Pul-
mozyme and Vitamin D will be recruited. Electronic
monitors are being used to track participants adherence to
Pulmozyme and Vitamin D over 3 months. The Cystic
Fibrosis Perceptions Inventory (CFPI), the Beliefs about
Medicines Questionnaire and a set of demographic ques-
tions will also be completed. The CFPI provides a measure
of the perceived importance of CF treatments and the opin-
ions that patients hold about CF and its treatment.
Results: This study is ongoing. Early findings indicate a
discrepancy in adherence to Pulmozyme and Vitamin D of
between 7 and 76%. As recorded by the electronic moni-
tors, participants took their Pulmozyme on average on 81%
of days. Adherence to Vitamin D was much lower, with
adherence on average on 40% of days in the recording peri-
od. Poor adherence to one medication was not necessarily
linked to poor adherence to the other. In 72% of cases,
participants rated the medication that they adhered to on
more days as more important than the other medication
monitored in the study.
Conclusions: Electronic monitoring of two concurrent
treatments appears to support earlier self-report research
findings indicating differential adherence to treatments in
adults with CF. It seems increasingly likely that individual
beliefs about treatment have an important association with
adherence to treatment in adults with CF.
WS3.1yP115: THE FUNCTIONAL ANTIBODY
RESPONSE TO IMMUNISATION AGAINST
HAEMOPHILUS INFLUENZAE TYPE B AND
PNEUMOCOCCUS IN CHILDREN WITH CYSTIC
FIBROSIS AND LOW IGG2
J. Garside , D. Kerrin , K. Brownlee , J. Gooi , S.1 2 1 1
Conway1
Yorkshire Regional Paediatric Cystic Fibrosis Unit, St.1
James’s University Hospital, Leeds, UK,
Barnsley District General Hospital, Barnsley, UK2
The aim of this study was to document the response of
patients with low IgG2 levels to immunisation against
Pneumococcus and Hib. IgG2 levels were measured by
radial immunodiffusion (binding site). Functional antibody
levels to Pneumococcus and Hib were measured by ELISA
kit (binding site). Data were collected for age, Shwach-
mann–Kulczycki score, Northern chest X-ray score, FEV1,
Pseudomonas infection status and height, weight and BMI
z-scores. Ninety-four patients with sub-optimal levels of
functional antibodies to Hib and or Pneumococcus were
immunised. Of these, 28 had low levels of IgG2. The func-
tional antibody levels were measured again 1–3 months
post-immunisation, and at an annual review.
Patients were divided according to their response to immu-
nisation: non-responders; those who had an initial good
response that was not sustained at least 6 months following
immunisation; and those who had and maintained a good
response.
Sixty-one out of 66 patients immunised against Hib had
data on the response to immunisation. All of these had a
rise to adequate levels ()1.0 mgyml). Data were available
for 51 patients more than 6 months after immunisation.
Four out of 13 patients who did not maintain a response
had low levels of IgG2. Fourteen out of 39 patients who
maintained a response had low levels of IgG2. Eighty-one
out of 83 patients immunised against Pneumococcus had
data on the response to immunisation. Three out of four
patients who did not respond had low levels of IgG2. Twen-
ty-three out of 77 who mounted an adequate response ()
30 mgyml) had low levels of IgG2. Data were available for
64 patients more than 6 months after immunisation. Seven
out of 15 who did not maintain a response had low levels
of IgG2. Fifteen out of 49 patients who maintained a
response had low levels of IgG2. These differences were
not significant. There was no difference between the groups
for the other variables measured.
The results suggest that IgG2 level is not a good predictor
of immunisation response in children with cystic fibrosis.
WS3.2yP110: ROLE OF P38 MAP AND ERK
KINASES IN ELEVATED IL-8 AND RANTES
PRODUCTION IN CF HUMAN BRONCHIAL
EPITHELIAL CELLS
C. Muselet , O. Tabary , K. Chadelat , J. Jacquot1 2 1 1
EMI, Inserm, Pediatric Pneumology, Hopital Trousseau,1 ˆ
75012, Paris, France,
Inserm U514, IFR53, 51092, Reims, France2
We have previously shown that CF human bronchial (CF
HBG) gland epithelial cells produce elevated chemokine
IL-8 mRNA and protein concomitant with constitutively
activated NF-kB. To characterize other signaling pathways,
we investigated the role of p38 MAP (mitogen activated
protein) and extracellular signal-related protein (ERK)
kinases in the regulation of IL-8 and RANTES expression
by cultured CF and non-CF HBG cells. We compared the
effects of specific inhibitors for p38 MAP (SB203580 and
SB202190) and ERK (UO126 and PD98059) kinases at
one 5 M and 10 5 M concentrations for 1, 4 and 16 h on
the IL-8 and RANTES expression. Using RT-PCR and ELI-
SA methods, we confirmed that IL-8 and RANTES gene
and protein expression were significantly increased in CF
HBG cells compared to non-CF HBG cells. In both cell
types, IL-8 mRNA expression was significantly reduced
with p38 MAPK specific inhibitors (20% and 40% with
SB203580 and SB202190, respectively) and less strongly
with the ERK specific inhibitors (20% and 5% with UO126
and PD98059, respectively) after 1 h treatment. The secre-
tion of IL-8 was significantly reduced with p38 MAPK spe-
cific inhibitors (40% and 50% with SB203580 and
SB202190, respectively) and less strongly with the ERK
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specific inhibitors (40% and 20% with UO126 and
PD98059, respectively) after 4 h treatment. No significant
decrease of IL-8 secretion was observed with p38 MAPK
and ERK inhibitors after 16 h treatment. Surprisingly, no
p38 MAPK and ERK inhibitors significantly reduced RAN-
TES secretion in CF and non-CF HBG cells after 4 and 16
h treatment.
Our results suggested that (1) IL-8 and RANTES expres-
sion are differently regulated in both cell types, and (2)
p38 MAPK pathway is involved in elevated IL-8 produc-
tion in CF HBG cells. Consequently, p38 MAP kinase
inhibitors may be of potential interest in the treatment of
airway inflammation in CF patients.
Supported by Association Vaincre la Mucoviscidose. C.
Muselet is funded by Goemar Laboratories.
WS3.3yP111: S100A12 (EN-RAGE)
EXPRESSION IN ACUTE EXACERBATIONS OF
CYSTIC FIBROSIS
I.D. Foell , S. Seeliger , H.G. Koch , T. Vogl , C. Sorg , J1 1 1 2 2
Roth1
Department of Pediatrics1
Institute for Experimental Dermatology, University Hos-2
pital Muenster, Germany
Aims: Chronic airway inflammation is a core phenomenon
in cystic fibrosis (CF). Identifying states of acute exacer-
bations is important for necessary therapeutic adaptations.
S100A12 (EN-RAGE) is a calcium-binding protein
expressed by granulocytes. It acts via interaction with the
multiligand receptor for advanced glycation end products
(RAGE). This receptor and its activation by S100A12 is
implicated in the pathogenesis of various chronic disorders
in murine models. Blocking agents provided insight into
the key role of this pro-inflammatory cytokine in inflam-
matory processes. We investigated a possible role of
S100A12 as serum marker for acute CF exacerbations.
Methods: S100A12 serum levels were analyzed using a
newly established sandwich-ELISA in 21 cases of acute
exacerbations at start and end of intravenous antibiotic ther-
apy. C-reactive protein, erythrocyte sedimentation rate and
leukocyte count were monitored as conventional parameters
for inflammation. Additionally, we analyzed S100A12 in
18 CF out-patients in stable condition and 34 healthy con-
trol subjects.
Results: S100A12 serum levels of patients with acute exac-
erbations were significantly elevated compared to controls
(381 ngyml vs. 57 ngyml; P-0.01). After 2 weeks of
intravenous antibiotic therapy mean S100A12 level
decreased significantly (381 ngyml vs. 130 ngyml; P-
0.01). There is also a significant difference between
S100A12 levels of patients with acute exacerbations and
CF out-patients without exacerbations (381 ngyml vs. 126
ngyml; P-0.01). Immunhistochemical studies of CF lung
biopsies revealed S100A12 expression by infiltrating gran-
ulocytes in inflamed lung tissue.
Conclusions: S100A12 is a potent serum marker for CF
exacerbations. It is superior to conventional indicators of
inflammation, especially for the differentiation of acute and
chronic processes. The pathophysiologic role of S100A12
expression in inflammatory disorders might serve as a target
for therapeutic interventions.
WS3.4yP101: INDUCIBLE NO SYNTHASE AND
ARGINASE IN LUNG EPITHELIAL CELLS
M. Bustami , A.W. Smith , M.L. Watson2 1 1
Pharmacy & Pharmacology, University of Bath, UK;1
Pharmacy and Medical Technology, University of Petra,2
Amman, Jordan
Nitric oxide (NO) plays an important role in host defence,
and the increased susceptibility of CF patients to lung infec-
tions may be explained, in part, by defective NO produc-
tion. This study investigates the regulation of nitric oxide
production by iNOS, and substrate competition by arginase,
in lung epithelial cells.
Stimulation of A549 cells (type II alveolar epithelial cell
carcinoma line) for 24 h with a three cytokine (3C) mixture
(IL-1beta 3 ngyml, TNF-alpha 30 ngyml, and IFN-gamma
50 uyml) resulted in a marked increase in supernatant
nitrite levels (a measure of NO synthesis) from 0.74"0.2
mM (mean"S.E.M., ns3) to 3.5"0.15 mM (ns3). This
production was completely inhibited by co-incubation with
the selective iNOS inhibitor 1400W (100 mM). The argi-
nase inhibitor L-norvaline (20 mM) did not change 3C-
stimulated nitrite production. Furthermore, arginase activity
in A549 was undetectable by colorimetric assay of urea
production from L-arginine.
Expression of iNOS by 3C-stimulated A549 cells can be
inhibited by IL-13, but this is not due to a reduction in
substrate availability. Co-addition of L-norvaline or excess
(2 mM) L-arginine (the common substrate for iNOS and
arginase), failed to reverse IL-13 inhibited nitrite
production.
We conclude that impaired NO production in lung epithelia
is unlikely to be due to an increased arginase activity. Nei-
ther arginase inhibition nor enhanced substrate provision
increase iNOS-dependent NO production. Alternative strat-
egies to increase epithelial NO production may help restore
antimicrobial activity in iNOS-deficient CF epithelia.
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WS3.5yP112: CHANGES OF G-CSF AND PMNS
IN THE BLOOD, AND LUNG FUNCTION DURING
ELECTIVE ANTIBIOTIC TREATMENT OF CYSTIC
FIBROSIS PATIENTS WITH CHRONIC
PSEUDOMONAS AERUGINOSA LUNG
INFECTION
P.Ø. Jensen , C. Moser , A. Kharazmi , S. Lanng , T.1 1 1 2
Pressler , C. Koch , N. Høiby2 2 1
Department of Clinical Microbiology, Rigshospitalet,1
Copenhagen, Denmark,
Danish CF Center, Rigshospitalet, Copenhagen, Denmark2
The persistent accumulation of PMNs in the lungs of CF
patients with chronic Pseudomonas aeruginosa lung infec-
tion is regarded as a major cause of premature death in CF.
G-CSF is a major mobilizing cytokine for PMNs, and pre-
viously we found increased levels of G-CSF and a number
of PMNs in the peripheral blood from CF patients with
chronic P. aeruginosa lung. These parameters were corre-
lated to poor lung function. In the present study, we aimed
to characterize the effect of elective antibiotic treatment on
the PMNs in peripheral blood and the lung function of
chronic infected CF patients with out exacerbations. Blood
samples and lung function before and at the end of anti-
biotic treatment from 15 chronic infected CF patients were
compared using blood cell counting, FACS, ELISA, and
lung function measurement.
The lung function was improved in 12 patients (FEV1 and
FVC, P-0.05) during antibiotic treatment. Simultaneously,
the concentration of G-CSF (P-0.05) and the number of
PMNs (P-0.002) was decreased in the blood. In addition,
the number of activated PMNs as judged by their phago-
cytic activity (P-0.04) and oxidative burst (P-0.01) in
the blood was reduced. Moreover, the surface expression
on the PMNs of L-selectin (P-0.03) and FcgRIII (P-
0.01) was increased during treatment.
The decreased level of G-CSF, paralleled by the changes in
number, activity, and phenotype of PMNs, emphazises a
central role of this cytokine in CF patients with chronic P.
aeruginosa lung infection. The clinical importance of G-
CSF in the blood is supported by the relation to poor lung
function. Furthermore, our results suggest that the PMNs
are less activated at the end of treatment. In conclusion, the
mechanisms of improvement of the lung function by anti-
biotic treatment is possibly due to a reduced bacterial load,
and thus, a decreased release of G-CSF into the blood. In
turn, fewer and less activated PMNs are mobilized from the
bone marrow, resulting in reduced immigration to the lungs.
WS4.1yP33: PAC BASED ENGINEERING AND
EXPRESSION OF A GENOMIC CFTR–GFP
FUSION GENE
A. Laner , A. Ramalho , S. Cattani , S. Christan , B.2 3 2 2
Marques , S. Beck , M. Amaral , D. Schindelhauer3 3 3 1
Institute of Human Genetics, Technical University,1
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Ricardo Jorge, Lisboa
In order to generate a genomic expression marker for stud-
ying CFTR gene transfer, we engineered a fusion gene
encoding enhanced green fluorescent protein (EGFP) and
a portion of the CFTR protein. The construct aims at
expression under the control of the endogenous CFTR pro-
moter within its chromatin context. Either green fluores-
cence, or detection of transgene product with EGFP
antibodies, would ease the analysis of functional gene trans-
fer in CF models.
Towards this end, we engineered and initially analyzed the
expression from our 145 kb construct prototype CG2. Start-
ing from a P1 artificial chromosome (PAC) containing
genomic CFTR sequences, and from the plasmid pEGFPN1
(Clontech) containing EGFP cDNA, a seven-step cloning
procedure was applied. The resulting construct contains
approximately one-half of the entire genomic CFTR gene
locus from position y60 kb to exon 10, the EGFP cDNA
replacing CFTR exons 10–24, and 2 kb of 39 sequences of
the CFTR gene. Lipofection into the human lung sarcoma
cell line HT1080 resulted in integration of one or possibly
few copies of the construct into a host chromosome.
Expression and correct splicing of the synthetic 10 exon
gene has been confirmed using RT-PCR. Since expression
of the primary transcript of CG2 requires intact transfer of
a minimum of 77 kb, the reporter should be useful for the
development of large DNA transfer protocols. In addition,
the reporter now allows the analysis of transgene expression
regulation within target tissues. The work shows that con-
ventional PAC cloning can be used as an accurate and
workable alternative to homologous recombination based
engineering.
WS4.2yP35: NON-VIRAL GENE THERAPY OF
CELL LINES WITH REFERENCE TO CYSTIC
FIBROSIS
A. Dragomir , L. Hjelte , G.M. Roomans1 2 1
Department of Medical Cell Biology, Uppsala University,1
Sweden,
Stockholm Cystic Fibrosis Center, Huddinge University2
Hospital, Karolinska Institute, Sweden
Cationic liposomes are widely used as gene transfer agents
in in vitro and in vivo studies of cystic fibrosis. In this
study, we report comparative results of cationic liposomal
transfection in several airway cell lines.
We used established cell lines that were immortalised and
cultured under similar conditions from normal subjects or
from cystic fibrosis patients. The cells were transfected with
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a green fluorescent protein plasmid (pEGFPLuc) complex-
ed with cationic commercial liposomes wGeneporter2 and
25 kD Polyethylenamine (PEI)x when 50–70% confluent.
At the end of the incubation, in some of the experiments,
low molecular weight heparin was added in order to reduce
the toxicity of the lipoplexes. After 24–96 h the transfec-
tion efficiency and the cell viability were measured by
flow-cytometry. Lipid analysis of the cell membrane was
performed by capillary gas chromatography, after methanol
lipid extraction and methylation.
As a general observation, the level of expression of fluo-
rescent green protein and the viability of the cells were
constant over time. PEI-lipoplex treated cells had lower
transfection efficiency and viability compared to GP2 in all
tested cell lines. DeltaF508 CFTR carrying cells seem to
be easier to transfect, but have lower viability compared to
their healthy counterparts. This might be explained by their
different membrane lipid composition, as observed by gas
chromatography analysis. The membrane lipid differences
may be intrinsic to the cell metabolism, since the exogenous
contribution is similar for all cells.
Low molecular mass heparin added at the end of the lipo-
plex incubation time could help to maintain the viability of
the cells, without interfering with the transfection efficien-
cy. This effect is under ongoing investigation for determin-
ing the optimal dosage.
WS4.3yP37: EFFICIENT LENTIVIRAL VECTOR
TRANSDUCTION IN 3-D HUMAN FETAL AIRWAY
EPITHELIUM
N. Castillon , A. Avril-Delplanque , C. Delenda , J.1 2 3
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Most of the viral vectors exhibit poor transduction efficien-
cy when applied to human airway epithelium. Recently
developed lentiviral vectors have been reported to transduce
non-dividing rabbit and murine airway epithelial cells. We
addressed the question of whether lentiviral vectors could
induce a sustained expression in human airway fetal epi-
thelium during tubulogenesis formation and in well-differ-
entiated 3-D cultures. We used an HIV-1-derived lentiviral
vector encoding the enhanced green fluorescent protein
(eGFP) whose expression is driven by the internal human
phosphoglycerate kinase promoter (hPGK) and pseudoty-
ped with the vesicular virus glycoprotein (VSV-G). Airway
epithelial cells were isolated from mature human fetal tra-
chea and airway xenografts developed in SCID mice. After
enzymatic dissociation, the cells were incubated with per-
manent rotating in the presence of lentiviral vector particles
at different multiplicities of infection. Maximal eGFP stain-
ing was achieved with a MOI 100 and the presence of HIV-
1 proviral genome contents was controlled by quantitative
PCR. Airway epithelial cells transduced with a MOI 100
were used for the formation of 3-D spheroids. After 25
days, ciliary activity and c-AMP Cl efflux were observed.y
By flow cytometry, 12% of epithelial cells appeared trans-
duced after 24 h. The eGFP expression was maintained for
more than 80 days in epithelial cells forming spheroids.
Incubation of HIV-1-derived lentiviral (MOI 10) with
mature 3-D spheroids and with a 3-D culture model of
human fetal tubular structures allowed an efficient trans-
duction. These results suggest the potential relevance of
HIV-1-derived lentiviral vectors to efficiently and stably
transduce CFTR in in vivo mature human fetal airway
epithelium.
Supported by INSERMyAFM and Association Vaincre la
Mucoviscidose.
WS4.4yP41A: CHARACTERIZATION OF SFHR-
MEDIATED MODIFCATION OF CFTR IN VITRO
AND IN VIVO
K.K. Goncz , E. Bruscia , G. Novelli , D.C. Gruenert1 1,2 5 1
Human Molecular Genetics, Department of Medicine, Uni-1
versity of Vermont, Burlington, VT,
Laboratory of Biopathology and Diagnostic Imaging Tor2
Vergata University, Rome, Italy
Gene therapy has held a great deal of promise for the future
of medical treatment. However, there has been limited suc-
cess, especially in the treatment of cystic fibrosis (CF).
This limited progress has, in part, been due to the fact that
the field is in its infancy. The optimistic projections of suc-
cess were, somewhat naively, based on in vitro studies in
model systems that had only a vague relationship to the
target organs. These projections did not take into account
the complexity of an intact biological system or the impor-
tance of genomic integrity in the cell-specific regulation of
gene expression. As an alternative to these cDNA-based
approaches to CF gene therapy, a strategy that targets the
mutant region of the endogenous CFTR gene for correction
was developed. This strategy of small fragment homolo-
gous replacement (SFHR) directly replaces this mutant
region with wild-type sequences and maintains the integrity
of the CFTR gene in terms of the relationship between the
protein coding sequences and the gene-specific regulatory
elements. Numerous in vitro studies have been carried out
in human airway epithelial cells that have demonstrated
both genotypic and phenotypic SFHR-mediated modifica-
tion of CFTR. Recent studies have shown that such gene
targeting will occur in mouse airway epithelial cells in vivo.
The data indicate that SFHR-mediated modification can
occur in the mouse airways and intestine in those cells that
express mouse CFTR (mCFTR) mRNA following trans-
fection with various cationic lipid and dendrimer complex-
es. Further in vivo studies are underway to quantify SFHR
in mice and evaluate mCFTR expression and function
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WS4.5yP40: SITE-SPECIFIC MODIFICATION OF
CFTR IN CF EPITHELIAL CELLS BY SFHR-
MEDIATED TARGETING. ISOLATION OF
ISOGENIC CF-BASED CELL LINES WITH LONG-
TERM EXPRESSION OF SFHR-MODIFIED CFTR
E. Bruscia , F. Sangiuolo , E. Bonifazi , M. Lais , P.1 1 1 1
Sinibaldi , K. Goncz , D.C. Gruenert , G. Novelli2 3 3 1
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The experiments reported here test the effectiveness of
small fragment homologous replacement (SFHR) for
inducing the long-term replacement of a 3-bp sequence on
the deltaF508 locus of CFTR and for the development of
isogenic cell lines with different CFTR mutations. A trans-
formed human epithelial cell line (CFBE41oy), homozy-
gous for deltaF508 mutation, was modified in vitro by
introduction of 3-bp, using SFHR-mediated targeting. This
technique produced a mixed population of SFHR-modi-
fiedyunmodified cells. Isogenic cell lines generated from
the parental deltaF508y deltaF508 CF cells were isolated
from the heterogeneous population by subcloning. The
wild-type replacement sequences were detected in four col-
onies and showed WTy deltaF508 genotype. To confirm
that the colonies were isogenic and derived from the
CFBE41oy cell line, genomic fingerprinting was per-
formed. The CFTR mRNA expression in these clones was
assayed by allele-specific and non-allele-specific PCR. The
expression of the WT allele in one isogenic cell line pre-
dominated over the mutant deltaF508 allele. This expres-
sion profile could be the result of a more robust expression
of the wild-type allele in this particular colony. These
clones were cultured for more than 1 year and were peri-
odically analyzed, showing a long-term and stable expres-
sion of SFHR-modified CFTR. Restoration of chloride ion
transport from the CFTR channel was investigated by the
36 Cl efflux assay. This work indicates that SFHR hasy
potential, not only for gene therapy of CF, but also for
development of isogenic cell lines with different CF muta-
tions. The isogenic cell lines and the parental CFBE differ
from each other only at the deltaF508 locus and represent
a powerful system for investigating the role of the CFTR
in cystic fibrosis pathology and in its interactions with other
cellular gene products. Supported by CFF, CFRI, PCFI and
Ministero Italiano della Sanita
WS4.6yP41: FUNCTIONAL HUMAN CFTR
PRODUCED BY A STABLE MINICHROMOSOME
C. Auriche , D. Carpani , M. Conese , E. Caci , O. Zegar-1 2 2 3
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Gene therapy protocols for cystic fibrosis (CF) have been
developed based both on viral and non-viral transfection
systems. Some of the problems raised by the current pro-
tocols for gene therapy could be overcome by the use of
large fragments of DNA containing the transgene and its
regulators, and by the use of a MAC (mammalian artificial
chromosome), as vector for the transgene.
We have used a structurally defined mini-chromosome to
clone the human CFTR locus. To guarantee the presence of
the proper regulatory elements, we used the 320 Kb YAC
37AB12 with the intact CFTR gene and upstream sequenc-
es. The resulting mini-chromosome was analyzed for the
presence of the entire CFTR gene and for its functional
activity by means of molecular and functional methods. We
have identified clones showing the presence of both the
transcript and the CFTR protein. Indirect immunofluoresc-
ence revealed that CFTR-MC1-containing clones presented
CFTR at intracellular sites reminiscent of either Golgi or
endoplasmic reticulum. A cytofluorimetric analysis showed
that all clones presented plasma membrane staining in
approximately 2–3% of cells. Unlike clones P37 and P38,
in the presence of forskolin, clone P39 exhibited a 1.7-fold
increase in CFTR surface signal. Moreover, in these clones,
a chloride secretory response to cAMP was detected.
In order to determine the mitotic stability of the mini-
chromsome after prolonged growth in the absence of selec-
tion, metaphase chromosomes were analyzed by FISH with
a CFTR probe. To monitor possible structural rearrange-
ments of the mini-chromosome, the Alu PCR profile was
analyzed in the presence and absence of selection for many
generations. These experiments demonstrated that the mini-
chromosome is stable in the absence of selection without
any evident structural variation, as also confirmed by func-
tional analysis. This is the first example of a structurally
known mini-chromosome made to contain an active thera-
peutic gene.
This work was supported by Telethon-Onlus, grant N
A.164.
WS5.1yP47: PRIMARY SCLEROSING
CHOLANGITIS (PSC): ASSOCIATION WITH THE
CYSTIC FIBROSIS TRANSMEMBRANE
CONDUCTANCE REGULATOR (CFTR)
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PSC is a progressive cholestatic liver disease with similar-
ities to cystic fibrosis liver disease (CFLD). It is charac-
terized by fibro-obliterative inflammation of the biliary tract
leading to cirrhosis and portal hypertension. Although the
etiology of PSC is unknown, it is strongly associated with
ulcerative colitis and Crohn’s disease. Similar to CFLD, it
has been hypothesized that PSC could be due to defective
CFTR-associated ion transport across the bile duct epithe-
lial cells leading to cholestasis. Our aim was to study pos-
sible association of the CFTR gene with PSC by genetic
and functional tests in PSC patients (Ns18) and disease
controls (Ns35). Disease controls were cases with inflam-
matory bowel disease and primary biliary cirrhosis. CFTR
gene screening, with estimated mutation detection rate of
95%, was conducted by multiplex heteroduplex analysis,
which included the promoter area, all 27 exons and flanking
introns. In addition, two intragenic polymorphic loci (T-
tract in intron 8 and 1540AyG in exon 10) were analyzed.
Nasal potential difference (PD) measurements were per-
formed using the technique described by Knowles et al.
Complete CFTR gene screening of PSC patients demon-
strated increased rate of mutationsyvariants compared to
disease control group (33% vs. 6%; Ps0.014). In addition,
the distribution analysis of 1540AyG (470MyV) genotypes
demonstrated an excess of less active CFTR 470V variant
(1540G) in PSC patients compared to that observed in the
control group (no statistical significance; Ps0.064). On
the functional level, significantly higher proportion of PSC
patients than disease controls had abnormal or border line
nasal chloride conductance or sweat chloride (50% vs.
11%; Ps0.005). Since the majority (67%) of PSC patients
had either abnormal genetic or functional test (vs. 17% in
the control group) both genetic and functional data suggest
involvement of CFTR in pathophysiology of PSC, most
likely via defective CFTR-mediated ion transport.
WS5.2yP280: AN AUDIT OF
URSODEOXYCHOLIC ACID THERAPY FOR THE
TREATMENT OF CYSTIC FIBROSIS RELATED
LIVER DISEASE
A. Verma , M. Cove , G. Evans , J. Redfern , D. Clough ,1 1 2 1 1
A. Webb1
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Introduction: There is compelling evidence that cystic
fibrosis (CF) patients who are commenced early on urso-
deoxycholic acid (UDCA) for cystic fibrosis related liver
disease (CFRLD) have improvement in deranged liver bio-
chemistry at 12 months (Colombo, 1996)
Aims: To ensure all patients with known CFRLD andyor
gallstones are prescribed UDCA and are on the appropriate
dosage regimen of 15–20 mgykgyday. To observe the
effect of treatment on normalising the LFTs and US
changes.
Methodology: A retrospective proforma based audit was
devised with all patients attending the cystic fibrosis unit
being included in the audit (ns175). The audit period was
from 1 March 2001 to 28 February 2001.
Results: A total of 55y175 (31.4%) patients had LFT
abnormalities. Out of the total number of 55 patients with
abnormalities on LFTs, 32 (58.2%) were on UDCA. On
follow-up LFTs, 11 of these 32 (34.3%) were found to have
improvement. A total number of 53y175 (30.3%) patients
were found to have US abnormalities, of which only 23
(43.3%) were on UDCA. Eighty-foury175 (48.0%) had
abnormalities on ultrasound andyor liver function tests; 45y
51 (88.2%) were on 15–20 mgykgyday; 33y84 (39.3%)
who had an abnormality did not receive UDCA; only four
patients suffered side effects in the form of abdominal pain
which resolved after treatment was ceased. Fifty-oney84
(60.7%) of patients with abnormalities suggestive of
CFRLD received UDCA. Thirty-threey84 (39.3%) were
not offered UDCA. Forty-sixy51(90.2%) were on the
appropriate dosage regimen. Eleveny32 (34.4%) had
improvement of their LFTs on UDCA therapy. Follow-up
data for US was incomplete as the audit period had ended.
Recommendations: The audit identified patients who have
abnormalities suggestive of CFRLD and are currently not
on appropriate treatment. Patient with fatty change should
stop their UDCA (Linblad, 2001). A re-audit will be per-
formed to complete the follow-up data and demonstrate
expected improvement in the appropriate treatment of
UDCA.
WS5.3yP284: USE OF URSODEOXYCHOLIC
ACID FOR CYSTIC FIBROSIS RELATED LIVER
DISEASE IN A PAEDIATRIC CLINIC IN THE UK
M.A. Jardine , L.J. Heaf , K.W. Southern1 2 1
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Aims
To examine the use of ursodeoxycholic acid (UDCA) for
cystic fibrosis (CF) related liver disease in a Regional Pae-
diatric CF Clinic in the UK. Clinic Policy for UDCA
prescription;
a. two or more abnormal biochemical tests;
b. abnormal liver texture on ultrasound scan; and
c. evidence of portal hypertension or abnormal portal vein
flow.
UDCA is discontinued if these parameters are normal for
more than 12 months. Recommended dose is 20 mgykgy
day.
Methods
Retrospective case note study. Clinical data collected from
most recent annual assessment. Data stored anonymously.
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Results presented as mean"S.E.M. Non-parametric tests
used to compare groups (Mann–Whitney).
Results
Complete data collected from 97 patients. Twenty-nine
(29.9%) were taking UDCA (all were taking UDCA appro-
priately). Four of these 29 were due to discontinue UDCA
at next annual assessment. The average dose of UDCA was
19.1 mgykgyday (range 12.7–24.7). Median duration of
treatment was 2.8 years. In seven (7.2%) patients, UDCA
had been discontinued. To date, no patient with abnormal
US scan has been able to discontinue UDCA. Sixty-one
(62.9%) patients have never been prescribed UDCA
(appropriately in all). Patients on UDCA were younger
than those not (11.1"0.8 vs. 13.2"0.3, P-0.03) and had
significantly higher liver enzymes (ALT, 42"7.5 vs.
23.2"1.6, P-0.001) at the most recent assessment; how-
ever, there was no significant difference in clinical status
of these patients (e.g. CXR and clinical scores).
Conclusions
A systematic review of randomised controlled trials dem-
onstrated evidence of short-term benefit from UDCA ther-
apy for CF liver disease, but no data are available from
RCTs for long-term outcomes. A significant proportion of
children attending our clinic are prescribed UDCA, appro-
priately according to clinic policy. If these data reflect the
prevalence of UDCA use in the paediatric CF population,
there is an urgent need for further analysis of the long-term
outcomes of UDCA therapy.
WS5.4yP285: LONG-TERM EFFECTS OF LIVER
TRANSPLANTATION IN PATIENTS WITH
CYSTIC FIBROSIS
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Liver transplantation (OLT) is increasingly performed in
CF patients, but the long term effects of OLT on pulmonary
function and nutritional status need to be better defined.
Since 1990, 18 Italian CF patients with biliary cirrhosis,
esophageal varices and hypersplenism, were referred for
OLT to our Center. Ten patients (six males, 15.5"5.6
years) with decompensated cirrhosis underwent OLT, seven
of whom are presently alive and on regular post-OLT fol-
low-up (12–135 months). The other eight patients (six
males, 17.6"7.0 years) with relatively preserved hepatic
function were offered regular follow-up (14–144 months)
and portosystemic shunt procedures in the case of variceal
bleeding (three cases).
After initial evaluation, all patients were reviewed once a
year and dual energy X-ray absorptiometry scan was per-
formed at least every other year to determine body com-
position. In transplanted patients, the mean Z-score for
weight increased from y1.14"0.98 before OLT to
0.68"0.68 at last visit (P-0.02); the increase in body
weight was associated with an increment in total body fat
(q5.1"6%, P-0.05) and in bone mineral density Z-score
(q0.96"0.85%). In contrast, the mean Z-score for weight
in non-transplanted patients was y0.72"0.71 at initial
evaluation and y0.80"0.90 at last visit, with decreasing
total body fat (y1.73"5.12%) and bone mineral density
Z-score (y0.4"0.5). After OLT, there was also an increase
in plasma vitamin E (q3.72"2 mgyl) and vitamin A (q
0.30"0.25 mgyl), which did not occur in non transplanted
patients (vitamin E: y0.27"2.3 mgyl; vitamin A: y
0.08"0.09 mgyl) (P-0.02). Two severely compromised
patients had striking improvement of pulmonary function
after OLT, however, long-term follow-up revealed minor
degrees of deterioration in both transplanted (FEV1% from
a mean of 68.8 to 64.3; FVC from 83.4% to 79.0%) and
non-transplanted patients (FEV1 from 79.0 to 76.8; FVC
from 83.2% to 81.3%). OLT has long-term beneficial
effects in CF patients with end-stage liver disease.
WS5.5yP287: LIVER TRANSPLANTATION (LT)
IN CYSTIC FIBROSIS (CF): A EUROPEAN
SURVEY
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Liver failure is a cause of death in CF and LT might be
needed although in a small number of cases. Of the patients
included in the European LT Registry, only 89 had CF.
Through a questionnaire sent to all CF and LT European
centers (sponsored by ESCF and ELTR) we were able to
collect data concerning 56 patients transplanted between
1989 and 2001 (40 M; 16 F).
Results: The follow up period was 0.3–11 years. LT was
performed prevalently in males (73.2%) and in the pedi-
atric age (median age 12.2 years; range 2–27). DF508 was
highly represented (64%). Kaplan–Meier analysis showed
that 82.3% of the patients survived 3 years after LT; eight
patients died after a median period of 0.4 years from LT
(0–1.1). This mortality level is not higher than what
expected after LT for other diseases. Only patients with
slight-moderate respiratory disease were transplanted and
the patients who died had lower FEV1% 6 months pre-LT
waverage FEV1% of 53 (S.E. 24) vs. 64 (S.E. 20) in the
whole groupx. In 29 cases, pre- and 6-month-post-LT FEV1
were available and showed a significant improvement with
an average increase of 6% (Ps0.033, paired t-test).
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Although the mortality of LT in CF is not higher than in
other diseases, poorer respiratory function might be a risk
factor for early death. On the other hand LT may ameliorate
respiratory function in CF patients with slightymoderate
respiratory disease.
The following colleagues contributed sending data of their
patients: H.E. Castro, C. Colombo, J. Dapena, F. De Roer-
tis, J. Doull, B.G. Ericson, B. Gunson, L. Hjelte, P. Jara,
D.A. Kelly, F. Lacaillem V. Lucidi, J. Manzanares, F. Parisi,
F. Pardo, F. Perez-Aguilar, G. Picherot, J. Pirenne, S. Quat-
trucci, T. Repetto, G. Rossi, J. Socha, Teissevre, A. Wet-
tergrew, J.P. Zarski.
WS6.1yP59: MISSENSE MUTATION D565G
CAUSES SKIPPING OF EXON 12: IN VIVO
STUDIES
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Missense mutation D565G (A)G@1826), located in exon
12, has been found in seven Greek subjects in cis with the
common polymorphism R668C in exon 13. mRNA studies
in one patient, showed production of transcripts lacking
exon 12 comparable to those from the true splicing muta-
tion 1818q1G)T. The missense mutation possibly affect-
ed an exonic splicing enhancer sequence and further
weakened exon 12 inclusion. Analysis of mRNA transcripts
from other D565G carriers, have been completed. Our aim
was to device a method that readily distinguishes between
the transcripts produced from the normal (1826A) and
mutant (1826G) alleles. Taking advantage of the presence
of the R668C polymorphism cis to the mutation, we
designed allele specific primers containing at their 39 end
(n2134) either C or T, discriminating between the R and C
alleles, which allows discrimination between the two types
of transcripts derived from each CFTR allele in individuals
heterozygous at the R668C locus. Two PCR s are set up
for each sample with a common forward primer and dif-
ferent reverse primers. We expected the production of two
types of transcripts, containing or lacking exon 12, from
both the normal (D565; n1286A) and mutant (565G;
n1286G) alleles. cDNA from nasal epithelial cells of six
individuals heterozygotes for D565G and four controls
were amplified with primers spanning exons 11–13. Anal-
ysis of the cDNA products revealed the presence of two
aberrantly spliced transcripts from both alleles (449bp con-
taining exon 12 and 362bp lacking exon 12). The 565G
allele produced a high percentage of transcripts lacking
exon 12, average 65.419.2%, compared to 12.117.7% from
the normal allele of individuals heterozygous for the
D565G mutation. The control subjects produced low
amounts of transcripts lacking exon 12 (4.9–8.6%) from
both of their alleles. In conclusion, D565G is a missense
mutation which affects the splicing mechanism producing
high percentage of transcripts lacking exon 12.
WS6.2yP68: DIAGNOSIS OF CYSTIC FIBROSIS
IN ADULT PATIENTS WITH DIFFUSE
BRONCHIECTASIS
D. Hubert , I. Fajac , T. Bienvenu , N. Desmazes-Dufeu ,1 2 3 1
M. Ellaffi , J. Dall’Ava , D. Dusser1 2 1
Service de Pneumologie, Hopital Cochin, Paris, France;1
Service de Physiologie Respiratoire, Hopital Cochin, Par-2
is, France;
Service de Biochimie Ginitique, Hopital Cochin, Paris,3
France
We assessed the contribution of sweat testing, genotyping
and nasal potential difference (NPD) measurements, alone
or in combination, in the diagnosis of cystic fibrosis (CF)
in adult patients with diffuse bronchiectasis (DB).
We studied 46 adult patients with DB who were diagnosed
as CF after sweat testing, genotyping and NPD measure-
ment. Sweat test was positive in 37 patients (80%) and
normal in nine patients. Two cystic fibrosis transmembrane
conductance regulator (CFTR) mutations were identified in
18 patients (39%) by screening 31 mutations, and in 36
patients (78%) by completing the genetic analysis. NPD
was suggestive of CF in 71% of the patients. Combination
of sweat test and genetic analysis led to diagnosis in 42
patients (91%) by screening 31 mutations, and in 45
patients (98%) after complete screening. In the nine
patients with normal sweat test, diagnosis could be proved
by molecular genetic analysis in five patients by screening
31 mutations, and in three additional patients by complete
screening. NPD allowed the diagnosis of CF in one patient
with intermediate sweat test and only one mutation
identified.
Sweat test is indicated in all adult patients with DB without
causative factors. If it is normal, CF cannot be excluded
and genetic analysis with screening of the 31 mutations
must be done. A complete analysis of the CFTR gene is
indicated when only one mutation is detected andyor when
other clinical features, such as obstructive azoospermia or
pancreatic insufficiency, are suggestive of CF. Nasal poten-
tial difference measurement is indicated in controversial
cases.
WS6.3yP69: QUANTIFICATION OF CFTR SPLICE
VARIANTS IN ADULTS WITH DISSEMINATED
BRONCHIECTASIS, USING THE TAQMAN
FLUOROGENIC DETECTION SYSTEM
J. Andrieux , M.P. Audrizet , I. Frachon , C. Leroyer , C.1 1 3 3
Rogi , V. Scottet , C. Ferec4 2 1´
Laboratoire de Genetique Moleculaire—CHU Brest;1 ´ ´ ´
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INSERM, EMI 0115-Brest;2
Service de Medecine Interne et Pneumologie—CHU Brest;3 ´
Service de Pneumologie—CH Morlaix4
Mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene are associated with different cystic
fibrosis related disorders, such as congenital bilateral
absence of the vas deferens, chronic idiopathic pancreatitis,
or disseminated bronchiectasis (DB). Many different dis-
ease-causing mutations are associated with DB, particularly
the 5T allele (IVS8 poly T tract, variant of the splice accep-
tor site at the end of intron 8, which affects the efficiency
with which the site is used. It thus affects accuracy of exon
9 splicing, and hence the expression of functional CFTR
protein.
In this study, we focus on quantifying transcript in nasal
biopsies of DB patients, compared with normal control sub-
jects. We developed a real time quantitative reverse tran-
scription PCR assay (using the Taq Man system) to
evaluate the relative amounts of accurately sliced transcript,
and transcript lacking exon 9. People with the 5T allele had
increased amounts of aberrant transcript: in genotypes 5Ty
7T, 7Ty7T and 9Ty7T, the mean fractions of transcripts that
had been spliced incorrectly were 38.4%, 3.5% and 0.6%.
The proportions of incorrectly sliced transcripts in nasal cell
swabs and bronchic biopsies were similar, suggesting that
nasal biopsy could be used as a source of tissue for study.
This q functional test is of interest to monitor the amount
of CFTR transcript in different clinical situations or to mon-
itor the effect of drugs on CFTR transcription.
WS6.4yP78: PRE-IMPLANTATION GENETIC
DIAGNOSIS FOR CYSTIC FIBROSIS IN
POPULATIONS WITH MOLECULAR
HETEROGENEITY, BASED ON MULTIPLEX
SEQUENCE VARIATION DETECTION
THROUGHOUT THE CFTR GENE
Ch. Vrettou , M. Tzetis , J. Traeger-Synodinos , G.1 1 1
Palmer , E. Kanavakis2 2
Medical Genetics, Athens University, St. Sophia’s Chil-1
dren’s Hospital, Athens 11527, Greece;
Centre for Reproductive Medicine, Alpha Lab, Athens2
11524, Greece
Cystic fibrosis (CF) is targeted as one of the priority genet-
ic diseases for prevention programmes. Pre-implantation
genetic diagnosis (PGD) represents an alternative approach
to prenatal diagnosis, especially for couples with an unsuc-
cessful reproductive history andyor undergoing assisted
reproduction for male infertility who have the additional
risk of transmitting CF. The clinical application requires
optimization of single cell genotyping protocols to mini-
mize PCR failure, allelic drop out (ADO) and contamina-
tion. In addition, the protocol should allow detection of the
wide spectrum of potential CF-affected genotypes, espe-
cially relevant for Southern European populations. To this
end, we developed a flexible multiplex PCR protocol allow-
ing analysis of sequence variations in any combination
amongst seven CFTR gene exons (4, 10, 11, 13 in two
parts, 14b, 17b and 21) by nested-PCR and DGGE analysis,
along with the intragenic dinucleotide microsatellite
IVS8CA. The experiments were carried out on 390 single
lymphocytes from three compound heterozygous CF
patients: one heterozygote and one non-CF individual. PCR
efficiency between exons varied from 90% to 100%, and
ADO from 0% to 3.8%. IVS8CA was co-amplified with
PCR efficiency of 92.4% and 10.8% ADO (evaluated by
sizing the fluorescent PCR product). No contamination was
observed in any set of experiments. The present method
overcomes the need for separate assays for each CFTR gene
mutation, and additionally, allows analysis of linked poly-
morphic sequence variations (when informative), useful for
minimizing misdiagnosis andyor indirect diagnosis. This
method proved robust and flexible for diagnosing diverse
CF genotype combinations in single cells.
WS6.5yP57: DETERMINATION OF THE
RELATIVE CONTRIBUTION OF THREE GENES,
THE CYSTIC FIBROSIS TRANSMEMBRANE
CONDUCTANCE REGULATOR GENE, THE
CATIONIC TRYPSINOGEN GENE, AND THE
PANCREATIC SECRETORY TRYPSIN
INHIBITOR GENE TO THE ETIOLOGY OF
IDIOPATHIC CHRONIC PANCREATITIS
M.P. Audrizet , J.M. Chen , C. Le Marichal , P.1 2 2
Ruszniewski , M. Robaszkiewicz , O. Raguinhs , I. Quiri ,4 5 1 1
V. Scotet , C. Ferec3 1´
Laboratoire de Ginitique Moliculaire—CHU Brest;1
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Universiti de Bretagne Occidentale, Brest, France;3
Service de Gastroenterologie, Hopital Beaujon, Clichy,4
France;
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Over the last 5 years, mutations in three genes, the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene, the cationic trypsinogen (PRSS1) gene, and the pan-
creatic secretory trypsin inhibitor (PSTI) gene, have been
found to be associated with chronic pancreatitis (CP). In
this study, using established mutation screening methods,
we systematically analysed the entire coding sequences and
all exonyintron junctions of the three genes in 39 patients
with idiopathic CP (ICP), with a view to evaluating the
relative contribution of each gene to the etiology of the
disease. Our results demonstrate that, firstly, ‘gain-of-func-
tion’ mutations in the PRSS1 gene may occasionally be
found in an obvious ICP subject. Secondly, presumably,
‘loss-of-function’ mutations in the PSTI gene appear to be
frequent, with a detection rate of at least 10% in ICP, and,
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finally, abnormal CFTR alleles are common: at least 20%
of patients carried one of the most common CFTR muta-
tions, and approximately 10% of patients were compound
heterozygotes, having at least one ‘mild’ allele. Thus, in
total, approximately 30% of ICP patients carried at least
one abnormal allele in one of the three genes, and this is
the most conservative estimate. Moreover, a trans-hetero-
zygous state with sequence variations in the PSTIyCFTR
genes was found in three patients. However, an association
between the 5T allele in intron 8 of the CFTR gene and
ICP remains unproven.
WS6.6yP34: AN ENGINEERED GENOMIC CFTR-
GFP FUSION GENE IS EXPRESSED AND
CORRECTLY SPLICED ON HUMAN ARTIFICIAL
CHROMOSOMES
D. Schindelhauer , A. Laner , S. Christan , S. Cattani , A.1 2 2 2
Ramalho , B. Marques , S. Beck , M. Amaral3 3 3 3
Institute of Human Genetics, Technical University,1
Munich, Germany;
Department of Medical Genetics, Ludwig Maximilians2
University, Munich, Germany;
Centre of Human Genetics, National Institute of Health Dr.3
Ricardo Jorge, Lisboa, Portugal
To assess co-lipofection of telomerized components cloned
into a ditelomeric P1 phage based artificial chromosome
vector (pTAT) as a means to incorporate genomic genes
into human artificial chromosomes (HAC), we use our
recently engineered, telomerized CFTR-EGFP fusion gene
construct CGT21 (138 kb) which expresses a 77-kb pri-
mary transcript under the control of the CFTR promoter.
Comparably small amounts (100 ng) of CGT21 and telom-
erized alpha satellite DNA of chromosome 17 (a17T, 200
kb) where sufficient to generate a large number of co-trans-
fected, blasticidin S resistant clones.
The presence of the centromere efficiently changed the fate
of the transferred gene from integration to HAC formation
in five out of five lines analyzed, out of which three
expressed and correctly spliced all 10 exons. The HACs
bind antibodies against the centromere binding protein A,
indicative for functional centromeres, and are devoid of
centromere DNA other than the transfected, as determined
by competition studies. Low copy HACs were detected by
fluorescence in situ hybridization (FISH) in only 10–50%
of metaphases, regardless whether on or off selection. Nev-
ertheless, the majority ()87%) of single cell derived sub-
clones which have been isolated after having been off
selection for 30 generations, grew upon re-selection, indi-
cating stable HACs in virtually all cells.
While two of the lines presented stable HACs without inte-
gration after 60 generations, one HAC line showed an
increasing proportion of metaphases (up to 40%) with inte-
grations in two independent (painting probe) host chro-
mosomes, indicating secondary events in this cell clone of
the tumor cell line HT1080 used. The data suggest that de
novo HAC formation from naked DNA is an efficient
means to stably transfer genomic copies of genes which can
be accurately engineered in PACs beforehand.
WS7.1yP26: THE ROLE OF LIPID RAFTS IN THE
REGULATION OF ION TRANSPORT IN HUMAN
AIRWAY EPITHELIAL CELLS
M. Duszyk , R. Lam , A. Szkotak1 1 1
Department of Physiology, University of Alberta, Edmon-
ton, Alberta, T6G 2H7, Canada
Cholesterol is an essential constituent in the plasma mem-
branes of most eukaryotic cells, where it is distributed in
structural and kinetic pools, called lipid rafts. The current
model for the function of lipid rafts is that they act to bring
proteins together to improve the kinetics of signal trans-
duction. In particular, lipid rafts help to cluster ion channels
with signaling molecules such as G-proteins, thereby mak-
ing ion channels dependent on cholesterol for normal func-
tion. Since people with cystic fibrosis have low levels of
plasma cholesterol, the present study was undertaken to
explore the modulatory role of cholesterol on ion transport
in the human airway epithelial cell line, Calu-3. The pres-
ence of lipid rafts was investigated using cell sub-fraction-
ation. To determine the amount of cholesterol present in the
epithelial plasma membranes, lipid extraction was per-
formed, and an assay kit was used to determine the total
cholesterol content of both untreated and methyl-beta-
cyclodextrin (CD) treated epithelia. Short-circuit current
(I ) measurements were performed with cell monolayerssc
mounted in an Ussing chamber, and bathed with Krebs–
Henseleit solution containing glucose, and bubbled with
95% O y5% CO . After a stable baseline current was2 2
achieved, the epithelium was treated with 10 mM CD, and
the measurements were performed for up to 6 h. Our data
indicated that disruption of lipid rafts by CD significantly
reduced I activation by adenosine receptor stimulation.sc
Similarly, cholesterol removal reduced I responses to car-sc
bachol. Since carbachol is known to activate calcium-
dependent signaling pathways, we measured the effect of
CD treatment on intracellular calcium. Carbachol increased
intracellular calcium in normal but not cholesterol depleted
cells, while the response to thapsigargin remained in both
control and CD treated cells. In summary, our data indicate
that cholesterol is an important regulator of transepithelial
ion transport.
WS7.2yP27: INTERACTION BETWEEN CFTR
AND P2Y PURINERGIC RECEPTOR SIGNALING
PATHWAYS
B. Marcet , B. Verrier1 2
University,1
INSERM, Marseille, France2
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Extracellular nucleotides can exert autocrineyparacrine
effects on ion transport by acting on both ionotropic P2X
and metabotropic P2Y purinergic receptors. P2Y receptors
are often coupled to stimulation of phospholipase C and
intracellular calcium concentration (wCa x ) increase. The2q i
cystic fibrosis transmembrane conductance regulator
(CFTR) is a cAMP-activated Cl channel which has beeny
shown to be involved in the regulation of wCa x subse-2q i
quent to P2Y receptor activation. Here, we have studied the
effects of extracellular nucleotides on CFTR activation.
Experiments were performed on recombinant CFTR over-
expressing Chinese Hamster Ovary CHO-BQ1 cells, and
CFTR activity was measured using the iodide 125I efflux
technique. We showed that ATPyUTP, but not ADP or
adenosine exposure, inhibited CFTR activation induced by
forskolin (10 5M). This inhibition was prevented by the
P2Y receptor antagonist Reactive Blue-2. The Ca ion-2q
ophore A23187 did not mimic the ATP effect, indicating
that wCa x increase was not the mediator of the CFTR2q i
inhibition. Characterization of P2Y receptors using reverse
transcriptase-polymerase chain reaction (RT-PCR), molec-
ular cloning, western blot and wCa x measurement showed2q i
that CHO-BQ1 cells expressed functional P2Y1 receptors
(2MeSADP)ADP) coupled to Pertussis toxin (PTX)-sen-
sitive G-proteins and P2Y2 (ATP)UTP) receptors linked
to PTX-insensitive G-proteins, but not P2Y4 receptors,
whereas, in control cells, which do not express CFTR, both
P2Y1 and P2Y2 receptors used PTX-insensitive G-proteins.
Knock-down of P2Y1 receptors by specific oligodeoxynu-
cleotide antisense fully inhibited ADP-induced Ca2q
responses but did not alter ATP-induced Ca responses,2q
suggesting that ATP responses involved P2Y2 receptors.
Taken together, these data suggest that CFTR activation was
inhibited by PTX-insensitive-G-protein linked P2Y2 recep-
tor activation and that CFTR expression induced a change
in G-protein selectivity of P2Y1, but not P2Y2 receptors.
WS7.3yP28: PROTEINASE-ACTIVATED
RECEPTOR-2 (PAR-2) MEDIATED CLI
SECRETION IN HUMAN COLON REQUIRES
FUNCTIONAL CFTR
T. Gonska , J. Thomas , S. Hirtz , J. Kuehr , R.1 1 1 1
Schreiber , M. Brandis , K. Kunzelmann , M. Mall2 1 2 1
University Children’s Hospital, Mathildenstrasse 1, D-1
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Recent studies on various epithelia have demonstrated acti-
vation of Ca -dependent Cl secretion by stimulation of2q y
proteinase-activated receptor-2 (PAR-2). In the present
study, we determined the effect of PAR-2 activation in
human rectal mucosa from normal individuals and CF
patients by measuring bioelectric responses in a perfused
micro Ussing chamber.
In non-CF tissues, basolateral addition of the PAR-2 agonist
trypsin (1 mmolyl) induced large Cl secretory responsesy
(DI sy66.6"22.8 mAycm ; ns10). In contrast, luminal2sc
trypsin had no effect on trans-epithelial ion transport. Tryp-
sin-mediated anion secretion was inhibited by pre-treatment
with indomethacin, and further increased by co-activation
with IBMX and forskolin (DI sy99.8"29.5 mAycm ,2sc
ns10). Furthermore, trypsin-mediated responses were
inhibited by bumetanide, low Ca , and basolateral K2q q
channel blockers. Similar responses were observed using a
specific PAR-2 activating peptide (AP). In CF rectal tis-
sues, PAR-2 activation failed to induce Cl secretion. They
data are in agreement with previous studies demonstrating
that Ca -dependent activation of colonic secretion requires2q
functional CFTR for Cl exit across the luminal membrane.y
While cAMP- and Ca -dependent secretion are defective2q
in intestinal tissues from patients with ‘severe’ CFTR muta-
tions, further studies will focus on the role of Ca agonists2q
as potential activators of residual CFTR function associated
with ‘mild’ mutations. The PAR-2 pathway may serve as a
possible target in this strategy.
Supported by Zentrum Klinische Forschung Freiburg and
Muko e.V.
WS7.4yP29: ION TRANSPORT IN HUMAN NON-
CF AND CF DISTAL AIRWAY EPITHELIUM
S. Blouquit , E. Naline , T.C. Chinet1 2 1
Universite Paris V, UFR Paris Ouest, Laboratoire de Bio-1 ´
logie et Pharmacologie des Epitheliums Respiratoires,
UPRES EA 220,
Universite Paris V, Laboratoire de Pharmacologie, Insti-2 ´
tutdes Cordeliers, Paris, France
Disease-causing mutations in the CFTR gene induce epi-
thelial ion transport abnormalities. These abnormalities
have been thoroughly described in proximal airways. We
report here the first description of ion transport properties
of non-CF and CF human bronchiolar epithelial cells. Seg-
ments of bronchioles were dissected from surgically
removed lung pieces from 11 non-CF subjects and four
homozygous deltaF508 CF patients. Primary cultures of
bronchiolar epithelial cells were established using enzy-
matic procedures, grown to confluence and studied in Uss-
ing chambers. Basal short circuit current (I ) of 12 non-CFsc
bronchiolar epithelial cultures studied in KBR was
34.5"9.8 mAycm (mean"S.E.). The addition of amilor-2
ide decreased I by 19.7"8.6 mAycm (P-0.05). Sub-2sc
sequent additions of forskolin and ATP increased I bysc
2.6"0.4 and 15.9"3.2 mAycm , respectively (P-0.05).2
Twelve non-CF bronchiolar cultures bathed in low-Cl KBR
exhibited similar basal I and amiloride-induced decreasesc
in I compared to regular KBR; in contrast forskolin- andsc
ATP-induced increases in I were smaller (P-0.01 forsc
both). Basal I of 27 CF bronchiolar epithelial cultures wassc
28.9"3.6 mAycm (NS compared to non-CF cultures stud-2
ied in KBR). Addition of amiloride decreased I bysc
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18.7"2.4 mAycm (NS); subsequent additions of forskolin2
and ATP increased I by 0.0"0.0 and 10.4"1.2 mAysc
cm (P-0.01 for both). We conclude that: (1) normal2
human cultured bronchiolar epithelial cells exhibit amilor-
ide-sensitive Na absorption and forskolin- and ATP-acti-
vated Cl secretion; (2) basal I and amiloride-sensitive Nasc
absorption are similar in CF and in non-CF preparations;
(3) the forskolin-activated Cl secretion is inhibited in CF
bronchioles; and (4) the ATP-activated Cl secretion is
decreased in CF bronchioles. These results suggest that the
abnormalities in CF epithelial ion transport differ in prox-
imal and distal airways. Supported by Vaincre la
Mucoviscidose.
WS8.1yP229: EARLY TREATMENT OF
BRONCHIAL COLONISATION WITH P.
AERUGINOSA. TWELVE-YEAR EXPERIENCE
C. Vazquez , J. Elorz , F. Baranda , A. Sojo , J.I. Pijoan1 1 2 1 3
CF Unit, Hospital Infantil de Cruces;1
CF Unit, Pulmonology Department, Hospital de Cruces;2
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Aims: To review our experience with such therapy on 52
CF patients in whom P.a. was first isolated (sputum or
throat swab), between 1988 and 1999 (colonisation). All
had a normal number (0–1) of serum precipitins against
P.a. surface antigens (Dr Høiby, Copenhagen). The time of
the review was April 2000, at least 1 year after colonisation.
Two were excluded (one died with liver failure, and another
had poor adherence to therapy). Forty-one (82%) lived in
our region and got all their medications from our Hospital
Pharmacy. No significant compliance problems were
noticed.
Methods: Patients older than five, and all from 1996,
received oral ciprofloxacin 40–50 mgykyday 2–3 times
daily for 2–3 weeks and nebulised Colomycin 1 million
units plus Tobramycin 100 mg twice daily. Those younger
than 5 years, up to 1996, were administered nebulised anti-
biotics only. Aerosol antibiotics were discontinued once all
cultures were (y) for at least 1 year (2 years up to 1992)
and the number of serum precipitins to P.a., remained nor-
mal. In case of new (q) cultures, patients had a further 3-
week courses of Ciprofloxacin and aerosol antibiotics were
increased for the same time to thrice-daily. In the case of
failure, aerosol Ceftazidime 1 g b.i.d. was tried. We con-
sidered patients to have CBIPa when most cultures over 6
months or longer (minimum 3) were (q) and serum pre-
cipitins against P.a. were two or more. Median age at colon-
isation was 6.7 years (2 months–27 years). Median age at
CBIPa was 16 years (4–21). Age in April 2000 was
13.5"6.9 years (2–33). Follow-up since colonisation up
to the time of the review or the onset of CBIPa was
5.6"3.3 years (1–11.5). FEV1 at colonisation (ns26)
was 98.7% Pred (52–140). Nine (19%) had increased
number of serum precipitins to S. aureus (3–8).
Results: Throat swabs (1533) and 688 sputums were
obtained and 0.9%, and 9.5% respectively were (q) for
Pa. Thirty-seven (74%) were free from CBIPa in April
2000, but 13 (26%) had CBIPa. The percentage of patients
free from CBIPa was 89% at 2 years, 81% at 4 years and
76% at 6 years. We performed analysis of survival to CBIPa
(Kaplan–Meir) and in order to investigate potential risk
factors for treatment failure we split patients at colonisation
into different groups according to age (younger or older
than 10), sex, genotype, pancreatic function, BMI Z-score
(below or above y1.5), and serum precipitins to S.a. (nor-
mal or elevated). Survival of the different groups was com-
pared by log–rank and Mantel–Hanszel tests. The only
relevant variables were age and number of serum precipi-
tins to S.a. Those older than 10 at colonisation had a 9.17
(3.2–26) times higher risk of developing CBIPa. The nine
patients with elevated serum precipitins to S.a. also had an
increased risk (x 34.2). However, as they were older at2
colonisation (14"8 vs. 5"4), the independent effects of
both variables is difficult to assess. We did not observe
emergence of multi-resistant organisms. Seven (14%)
developed Allergic Bronchopulmonary Aspergillosis.
Conclusion: Early treatment of bronchial colonisation with
P.a. was efficacious in delaying the onset of CBIPa for
years in most patients. Older age and increased number of
serum precipitins to S.a. were risk factors for treatment fail-
ure. Controlled trials with other treatment methods (macrol-
ids?) are necessary to improve the efficacy of early
treatment of P.a. colonisation in CF.
WS8.2yP228: LOW PREVALENCE OF CHRONIC
P. AERUGINOSA COLONIZATION IN THE CF
CENTRE OF TUSCANY: IS IT THE RESULT OF A
MULTI-FACTORIAL INFECTION CONTROL
STRATEGY?
F. Festini, G. Taccetti, S. Campana, E. Procopio, M.L.
Cioni, S. Zuffo, S. Farina, T. Repetto, M. de Martino
Cystic Fibrosis Center of Tuscany, Department of Pediat-
rics, University of Florence, Meyer Hospital, Florence,
Italy
Chronic P. aeruginosa (PA) colonization has been associ-
ated with a decline of clinical conditions. As there is well
documented evidence of cross-infections among patients,
since 1994, the Tuscan CF Center has carried out a strategy
for infection control based on the combined implementation
of five policies regarding: segregation, disinfection, reduc-
tion of environmental contamination, behavioral rules for
patients and eradicating treatment in case of first PA
colonization.
Segregation policy includes the partition of patients in six
groups according to their colonization. Appointments are
scheduled so that the patients of one group never meet
patients of other groups. One visiting room and separate
medical equipment are reserved to each group.
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Disinfection policy is based on the extensive daily use of
chlorine based disinfectants. Room ventilation and adequate
intermissions between visits are provided; environmental
microbiological controls of rooms, medical devices and
sinks are performed monthly.
Patients are taught the rules that reduce the risk of cross
contamination during their stay at the Center and a strict
observance of appointments time is expected.
As for eradicating treatment (carried out since 1992), when
PA is isolated for the first time, patients are treated with
aerosolized colistin and oral ciprofloxacin. So far, eradica-
tion has succeeded in 76.9% of cases.
When we introduced the described strategy, the Center had
100 patients (mean age 11.7 years, adults 24%) and the
prevalence of chronic PA colonizations was 46%.
We are now following 158 patients (mean age 15.9 years,
adults 39.2%) and the prevalence of chronic PA coloniza-
tion is currently 38.6%.
Molecular analysis of PA isolates performed by PFGE
allows the exclusion of a common source of infections or
a cross-colonization among patients.
These data suggest the hypothesis that this strategy for
infection control helps to maintain a low prevalence of
chronic PA colonizations.
WS8.3yP13: AZITHROMYCIN INDUCES OVER-
EXPRESSION OF THE MULTIDRUG
RESISTANCE-ASSOCIATED PROTEIN (MRP)
AND RESTORES CHLORIDE CONDUCTANCE IN
CYSTIC FIBROSIS
U. Pradal , A. Delmarco , M. Morganti , M. Cipolli , E.1 1 2 1
Mini , G. Cazzola2 1
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The role of azithromycin (AZM) in the treatment of cystic
fibrosis (CF) lung disease is matter of debate. The mech-
anisms by which AZM works have not been fully eluci-
dated. Anti-bacterial as well as anti-inflammatory activity
can be postulated. AZM could also induce the over-expres-
sion of proteins homologous to the CFTR, such as the mul-
tidrug resistance-associated protein (MRP), a protein
involved in cell detoxification, which could play a role in
chloride conductance as well.
The purpose of the present study was to verify if AZM
could induce MRP over-expression in CF airway cells and
if it could improve the ion transport, typically defective in
CF. We studied ion transport in vivo by measuring nasal
potential difference (NPD), and MRP mRNA expression in
nasal cells of seven CF patients before and after 4 weeks
of AZM treatment (500 mg once daily). NPD was abnor-
mal in all patients before treatment. After treatment, sodium
conductance remained abnormal, while chloride transport
stimulation with the chloride-free solution determined a
shift towards hyperpolarization, reaching values that were
statistically different from baseline (0.6"3.5 mV and y
4.8"4.2 mV respectively, Ps0.03). In four out of seven
patients the degree of hyperpolarization reached values not
typical for CF, ranging from 4.4 to 6.3 mV. In these patients
a significant increase in MRP mRNA was also documented
(Ps0.03). A statistically significant direct correlation was
found between MRP mRNA expression levels and the NPD
response to chloride-free solution after AZM treatment
(Ps0.04, Rs0.78).
These results show that AZM may upregulate MRP expres-
sion and restore chloride conductance in the airways of CF
patients. These findings identify a new potential role of
AZM, i.e. the possibility to upregulate proteins whose func-
tion may, at least in part, overcome the basic defect of CF.
WS8.4yP211: EFFECT OF SUB-INHIBITORY
CONCENTRATIONS OF AZITHROMYCIN ON
ADHERENCE OF PSEUDOMONAS
AERUGINOSA TO BRONCHIAL MUCINS
COLLECTED FROM CYSTIC FIBROSIS
PATIENTS
M.O. Husson, P. Gerardin, G. Carfantan
Laboratoire de Bacteriologie, Hopital Calmette, Bd J.´ ˆ
Leclercq, CHRU, 59037 Lille, France
Several previous investigators have been reported that long-
term administration of AZT is effective in patients with
pulmonary PA infections. Clinical benefits may be an indi-
rect result on host defense systems andyor on production
of virulence factors of PA. AZT is not bactericidal for PA,
but at sub-inhibitory concentrations, it can reduce synthesis
of various exoproducts and improve alterations in cell sur-
face structures and outer membrane proteins (OMPs). Since
some of these proteins are implicated in adherence to res-
piratory mucins, the aim of this study was to evaluate the
action of sub-inhibitory concentrations of AZT (achievable
at therapeutic use) on the synthesis of OMPs of PA, and
on the adherence of PA to respiratory mucins from CF
patients. Three methods were analysed: the comparison of
PAGE-SDS patterns of OMPs from strains grown with 2 or
4 mgyl of AZT, the binding of mucins to these, and an
adherence assay of PA to mucins fixed in microtiter plates.
A decrease of 4–6 OMP was observed when strains (four
tested) were grown with 2 or 4 mgyl of AZT. Some of
OMPs were shown to react with mucins, and AZT reduced
the amounts of 3–4 of them. A significant reduction of
adherent bacterial cells number by AZT confirmed these
results. However, when this assay was evaluate on 10 other
strains, AZT did not affect adherence of three strains. Sub-
inhibitory concentrations of AZT can thus reduce the adher-
ence of PA to mucins. This result means intracellular AZT
storage, and AZT action on protein synthesis. However, this
appears dependant on strains. Further studies are necessary
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to determine how bacteria may be AZT resistant, and what
are consequences in clinical use of AZT.
WS8.5yP15: INFLUENCE OF IPRATROPIUM
BROMIDE ON APICAL TRANSEPITHELIAL
CHLORIDE TRANSPORT
D. Schuler, J. Wagner, G. Huls, H. Lindemann¨ ¨
CF-Center, University of Giessen, Germany
Aims: Ipratropiumbromide is often used as a mild bron-
chodilator to treat chronic pulmonary obstructive disease.
Aim of the study was to examine the effect of ipratropium-
bromide on alternative and CFTR-dependent chloride chan-
nels in the apical membrane of respiratory epithelia using
measurement of nasal transepithelial potential difference.
Methods: Nasal transepithelial potential difference was
determined below concha nasalis inferior in 19 healthy sub-
jects (16–33 years). Blocking apical sodium channels,
nasal mucosa was sequentially superfused with (1) chloride
buffer, (2) chloride-free solution and (3) salbutamol or
ipratropiumbromide (in chloride-free buffer). The effect of
ipratropiumbromide and salbutamol on nasal transepithelial
potential difference was investigated on separate occasions
with an interval of at least one day. In a pre-study without
blockage of sodium channels, ipratropiumbromide in chlo-
ride free buffer was compared with single chloride-free
buffer.
Results: In 19 healthy subjects, during blockage of apical
sodium channels, ipratropiumbromide increased nasal tran-
sepithelial potential difference (mean"S.D.; 12.9"7.6
mV; 102.6"68.8%). The effect of salbutamol was not sig-
nificantly different (P)0.05; 11.6"5.2 mV;
95.3"29.6%). Even without initial sodium channel block-
age, ipratropiumbromide increased nasal transepithelial
potential difference to a similar extent than chloride-free
buffer (13.0"10.9 vs. 17.5"8.5).
Conclusions: The effect of ipratropiumbromide on nasal
transepithelial potential difference during blockage of api-
cal sodium channels suggests an additional specific effect
of ipratropiumbromide on CFTR-function in healthy
subjects.
WS8.6yP17: N-ACETYLCYSTEINE INHIBITS NAH
ABSORPTION ACROSS CULTURED HUMAN
NASAL EPITHELIAL CELLS
T. Rochat , J.S. Lacroix , L. Jornot1 2 1
Respiratory Division, University Hospitals;1
Department of Otorhinolaryngology, University Hospitals,2
Geneva, Switzerland
The thiol agent N-acetylcysteine (NAC) is prescribed in a
variety of respiratory disorders including cystic fibrosis
(CF). Little is known, however, about the effects of NAC
on ion transport in the respiratory epithelium. In this study,
we investigated the effects of NAC on the bioelectric prop-
erties of human nasal epithelial cells obtained from surgery
in non-CF patients. Untreated cells had a transepithelial
potential difference (Vt) of y73"7 mVycm and a tran-2
sepithelial resistance (Rt) of 410"23 ohmycm , corre-2
sponding to an equivalent short-circuit current (I ) ofsc
124"17 mAycm (ns10). The magnitude of the amilori-2
de-sensitive current wI (amil)x, which represents the con-sc
tribution of electrogenic Na absorption to transepithelialq
transport, was 80"14 mAycm . A 24-h basolateral treat-2
ment with 10 mM of NAC resulted in a 40% decrease in
Vt and I , and a 50% reduction in I (amil) without affect-sc sc
ing Rt. Similar effects were observed with epithelial cells
from one CF patient. When the basolateral membranes of
cells were permeabilized with amphotericin B in the pres-
ence of a mucosal-to-serosal Na gradient (145:25 mM),q
the amiloride-sensitive fraction of the amphotericin B-
induced current was lower in NAC-treated cells than in
untreated cells. After permeabilization of the apical mem-
branes, the I , which is a measure of Naq–Kq–ATPasesc
activity, was similar in NAC-treated and untreated cells. We
conclude that NAC decreased Na absorption acrossq
human nasal epithelial cells by inhibiting the amiloride-sen-
sitive Na channels. Given the importance of epithelialq
Na channels in controlling the thin layer of fluid thatq
covers the surface of the airways, we suggest that this effect
of NAC might contribute to the increase of the fluidity of
airway mucus in vivo.
WS9.1yP171: CHARACTERISATION OF
BACTERIAL DIVERSITY IN CYSTIC FIBROSIS
LUNG INFECTIONS USING 16S RDNA
TERMINAL RESTRICTION FRAGMENT LENGTH
G. Rogers , D. Serisier , M. Carroll , T. Hart , M.1 2 2 3
Walshaw , K. Bruce3 1
King’s College London;1
Southampton University Hospital;2
Liverpool University Hospital, UK3
Inflammation resulting from chronic pulmonary infection is
the primary cause of morbidity and mortality in cystic
fibrosis (CF) and optimal management of CF lung disease
centres on suppressing bacterial load. The assessment of
pulmonary bacteriology currently requires identification of
organisms following culture. This approach is poorly rep-
resentative of the complex bacterial environment of the CF
lung, fails to detect changes in pulmonary bacteriology dur-
ing periods of flux, and takes several days to complete. We
are investigating a method that has the potential to rapidly
provide specific data on pulmonary bacteriology that is both
qualitative and quantitative, and is sensitive to changes dur-
ing periods of infection and treatment. In the current study,
we characterised the bacterial community present in CF
sputum by analysing DNA extracted directly from 37 con-
secutive sputum samples, collected from 16 CF patients,
using a unique rapid molecular profiling-based method.
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This profiling method used PCR products generated by bac-
teria-specific primers from the 16S rDNA region. For each
individual CF sample, 16S rDNA sequences from different
bacterial species were resolved in a single electrophoretic
profile using automated Terminal Restriction Fragment
Length Polymorphism (T-RFLP). T-RFLP profiling was
highly reproducible. A wide range of bacterial species was
indicated by T-RFLP analysis, with profiles varying
between different individuals and for the same individual
over the time course of an infection. T-RFLP profiling, cou-
pled with 16S rDNA clone library analysis, indicated the
presence of both recognised CF pathogens and other bac-
terial species not previously characterised in the CF lung.
CF lung infections may, therefore, involve more complex
microbial interactions than previously supposed. The rapid
analytical approach described here is currently being
extended to look at other aspects of CF infections including
analysis at different levels of phylogenetic resolution.
WS9.2yP205: GENETIC POLYMORPHISM OF
CYSTIC FIBROSIS AND ENVIRONMENTAL
BURKHOLDERIA CEPACIA COMPLEX
ISOLATES
A. Bevivino , V. Peggion , G. Manno , S. Tabacchioni , C.1 1 2 1
Dalmastr , S. Piana , M.L. Belli , L. Chiarini1 3 2 1
Biotechnology Unit, ENEA-C. R. Casaccia, Via Anguilla-1
rese, 301-00060 S. Maria di Galeria, Rome, Italy;
Infectious Diseases Research and Diagnosis Laboratory,2
Department of Pediatrics, University of Genoa, Gaslini
Children’s Hospital Genoa, Genoa, Italy;
Cystic Fibrosis Centre, Department of Pediatrics, Univer-3
sity of Genoa, Gaslini Children’s Hospital Genoa, Genoa,
Italy
Bacteria of the Burkholderia cepacia complex are recog-
nized as important opportunistic pathogens in patients with
cystic fibrosis (CF). The worldwide increase of B. cepacia
infection in CF patients suggests its epidemic spread, but
the source and transmissibility of strains remain controver-
sial. The environment is regarded as a potential source of
strains capable of infecting CF patients. Thus, determining
the genetic polymorphism of the different species consti-
tuting the B. cepacia complex in clinical and environmental
samples has become important in order to study the epi-
demiological and genetic relatedness of B. cepacia complex
isolates and to evaluate the role of natural habitats as poten-
tial reservoir of pathogenic strains. In this study, we exam-
ined a large Italian collection of clinical and environmental
B. cepacia complex isolates. Clinical isolates were recov-
ered from sputum samples from CF patients who attended
the Cystic Fibrosis Centre of Gaslini Hospital (Genoa, Ita-
ly). Environmental strains were isolated from the rhizo-
sphere of maize, where the B. cepacia complex represents
one of the predominant groups, in three different locations
in northern, central, and southern Italy. The genetic diver-
sity among B. cepacia complex isolates was analysed by
means of the random amplified polymorphic DNA (RAPD)
technique; the analysis of molecular variance method
(AMOVA) was applied to estimate the genetic differences
among the various species and genomovars identified with-
in the B. cepacia complex populations. Preliminary results
indicate that clinical isolates show RAPD fingerprints that
are generally distinct from environmental isolates. Further-
more, RAPD fingerprints of isolates from CF patients
exhibited a much higher genetic homology than environ-
mental isolates did. These data suggest that the B. cepacia
complex isolates recovered from clinical sources may be
genetically different from environmental ones.
WS9.3yP199: BURKHOLDERIA CEPACIA
COMPLEX (BCC) INFECTIONS IN PATIENTS
WITH CYSTIC FIBROSIS: CORRELATION
BETWEEN GENOMOVARSySPECIES AND
CLINICAL OUTCOME
G. Manno , L. Minicucci , C. Dalmastri , L. Chiarini , S.1 2 3 3
Tabacchioni , M.L. Belli , E. Ugolotti , A. Giannatasio , M.3 1 1 2
Strozzi , A. Bevivino2 3
Infectious Diseases Research and Diagnosis Lab.,1
2nd Pediatric Clinic, University Department of Pediatric,2
G. Gaslini Institute, Genova, Italy
Biotechnology and Agriculture Division, ENEA Casaccia,3
Rome, Italy
Aim: To determine correlation between distinct genomo-
vars (gmv)yspecies and clinical outcome on Bcc infected
patients (pts) attending the CF center of Genova from 1984
to 2001.
Methods: Bcc strains recovered from 76 patients were
assigned to the complex by means of (i) conventional tests,
i.e. API 20 E, API NE Systems (BioMerieux), OF basal
medium (Difco) for six sugars, oxidase test, growth at 42
8C, pigment and hemolysis production; (ii) PCR-based
techniques, such as Restriction Fragment Lenght Polymor-
phism Analysis (RFLP) of Amplified 16S rDNA
(ARDRA) and recA gene, and genomovar specific PCR
tests of the recA gene. In the pts, age of Bcc acquisition,
persistent or transient infection, previous bacterial coloni-
zation, Bc syndrome, lung function evolution and mortality
rate were evaluated.
Results: Twenty-seven patients (35.5%) were infected by
gmv IIIA, 31 patients (40.8%) by unclassified strains (UN)
(assigned to the complex but failing to be subclassified by
molecular analysis), seven patients (9.2%) with gmv IIIB,
5 patients (6.6%) with B. stabilis; B. cepacia (gmv I), gmv
III, and B. pyrrocinia were present in only one patient
respectively; three patients had multiple gmv (two IIIAq
UN, one IIIqIIIA). Transient infection was present in 6y
31 patients with UN, 2y7 patients with IIIB, 5y5 patients
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with B. stabilis. Mean age of Bcc acquisition, mean dura-
tion of infections and mortality rate were: 5.9 years"4.8
S.D., 10.6 years"19 S.D. and 74% in IIIA patients; 5.5
years"4.7 S.D., 16.1 years"6.2 S.D. and 14.3 6% in IIIB
patients; 6.8 years"2.7 S.D., 20.7 years"8.8 S.D. and
48.4% in the UN group. Bc syndrome occurred in one
patient with gmv I, two patients with gmv IIIA, and three
patients with gmv UN. Pts with gmv IIIA were the preva-
lent from 1984 (66.7%) to 1991 (59%) while patients with
UN from 1992 (52%) to 2001 (55%).
Conclusions: Patients with Bcc gmv IIIA showed a signif-
icantly high mortality rate (P-0.01). Patients with UN
gmv showed longer duration of infection compared with
patients with other gmvyspecies.
WS9.4yP187: EFFECT OF STAPHYLOCOCCUS
AUREUS MACROCOLONY FORMATION ON
PHAGOCYTOSIS
M. Ulrich , K. Ziegler , S. Crampton , G. Doring1 1 2 1¨
Department of General and Environmental Hygiene, Med-1
ical Faculty,
Department of Microbial Genetics, University of Tubin-2 ¨
gen, Tubingen, Germany¨
Biofilm and macrocolony formation of S. aureus may be
the basis of persistent lung infection in cystic fibrosis
patients (CF). We investigated the phagocytosis of single
S. aureus cells and macrocolonies by polymorphonuclear
neutrophils (PMN). The polysaccharide intercellular adhes-
in (PIA) positive strain ATCC 35556 and its PIA negative
mutant 35556D ica::tet and a patient isolate (SA7) were
used. We incubated the strains for 2 h at 37 8C in collagen
coated chamber slides to reveal the attachment of single
cells. After depletion of non-attached bacteria we incubated
the chamber slides for 2 days under anaerobic conditions
for macrocolony formation. Single attached S. aureus cells
and macrocolonies were incubated with PMN for 2 h. Phag-
ocytosis was quantified by plate count. Additionally we
investigated phagocytosis with planctonic cells grown
under aerobic and anaerobic conditions. Ingestion of S.
aureus single cells or macrocolonies by PMN was dem-
onstrated by SEM and TEM. Macrocolony formation
resulted in a significant reduction of phagocytosis (macro-
colonies vs. single cells: ATCC 35556: 11.35"22.7%
vs. 68.9"19.9%; SA7: 13.61"41.1% vs. 77.3"17.6%).
Phagocytosis of planctonic cells revealed no significant dif-
ferences (aerobic vs. anaerobic: SA7: 76.9"10.3% vs.
69.9"2%; 35556: 75.4"6.5% vs. 80.8"15%; 35556D
ica::tet: 58.8"10.8% vs. 47.9"14.7%). Macrocolony for-
mation in CF induces resistance against phagocytosis and
contributes to chronic lung infection in CF patients.
WS9.5yP172: USE OF SUBTRACTIVE
HYBRIDISATION TO IDENTIFY NOVEL
GENOMIC REGIONS OF AN EPIDEMIC STRAIN
OF PSEUDOMONAS AERUGINOSA
Yasmin Parsons , M. Walshaw , C. Hart , C. Winstanley1 2 1 1
Department of Medical Microbiology, University of Liv-1
erpool, Liverpool L69 3GA, United Kingdom,
Regional Adult Cystic Fibrosis Unit, Cardiothoracic Cen-2
tre, Liverpool L14 3PE, United Kingdom
Chronic colonisation with Pseudomonas aeruginosa occurs
in up to 80% of adult CF patients and is associated with
increased morbidity and mortality. Unlike Burkholderia
cepacia, reports of highly transmissible strains of Ps. aeru-
ginosa are rare. A strain of Ps. aeruginosa exhibiting high
levels of antibiotic resistance has spread amongst patients
at a CF clinic in Liverpool and also from an adult CF
patient at the clinic to her healthy parents. Recent evidence
also suggests that this strain can cause ‘superinfection’ of
already colonised patients. The aim of this study was to
compare the genetic make-up of this highly transmissible
‘epidemic’ strain with that of the laboratory strain PAO1,
for which the genome sequence is available.
Suppression subtractive hybridisation (SSH) is a polymer-
ase chain reaction (PCR)-based technique used to identify
sequences present in one strain (the tester) but absent from
another (the driver). SSH was used with the Liverpool CF
epidemic strain as the tester and PAO1 as the driver. Eleven
sequences present in the tester but absent from the driver
were identified, nine of which share homology of varying
significance to sequences in the database, including a sid-
erophore receptor, a putative adhesin, and a genomic island
reported previously as common to pathogenic strains of Ps.
aeruginosa. PCR amplification and DNA hybridisation
assays have been used to screen a panel of 15 genetically
different CF sporadic isolates. Four of the sequences iden-
tified using SSH were present only in epidemic strains and
a further three were present only rarely in non-epidemic
strains.
Our data indicate that SSH can be used to identify sequenc-
es present in the CF epidemic strain of Ps. aeruginosa but
absent or rare amongst CF sporadic isolates. This technique
should be a useful tool for identifying genetic factors con-
tributing to the greater transmissibility of the CF epidemic
strain.
WS9.6yP175: EXOS AND EXOT ARE SECRETED
BY PSEUDOMONAS AERUGINOSA IN THE
ABSENCE OF THE PUTATIVE CHAPERONE
ORF1
L. Quenee, B. Toussaint, D. Lamotte, F. Morel, B. Polack
GREPI, EA2938, Universite Joseph Fourier; Grenoble,
France
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P. aeruginosa is an opportunistic pathogen responsible for
severe infections in cystic fibrosis (CF) patients. Its type
III secretion system (TTSS) allows a direct toxin transfer
into the cytosol of target cells. In most species, cytosolic
chaperones are required for secretionytranslocation of
TTSS effectors. To date, four TTSS proteins of P. aerugi-
nosa have been identified, ExoS, ExoT, ExoY and ExoU.
The region downstream exoU is essential for a maximal
secretion and encodes a small protein, SpcU, that functions
as a chaperone. There is no known chaperone for ExoT and
ExoY. The putative chaperone orf1, directly upstream exoS,
is regulated by the SSTT promotor.
CHA is a CF clinical isolate of P. aeruginosa which induces
cell death in human PMNs in a TTSS dependant manner.
In this work we constructed an orf1-exoS deleted mutant
strain (CHA-LQ1) by allelic exchange. This strain is una-
ble to secrete ExoS via the TTSS. In addition, there is no
putative chaperone close to exoT, but this toxin has more
than 70% homology with ExoS, and therefore, could share
the orf1-encoded chaperone. However, the lack of orf1 in
mutant strain CHA-LQ1 does not decrease ExoT secretion.
When CHA-LQ1 is complemented in trans with a plasmid
containing exoS, the secretion of the toxin is restored in the
supernatant. Conversely, orf1 complementation in trans
does not modulate the secretion of ExoT.
Therefore, Orf1 is not required for ExoS and ExoT secre-
tion. Nevertheless, Orf1 may avoid the aggregation of ExoS
or ExoT into the bacterial cytosol, thus lowering their tox-
icity. Indeed, the CHA-LQ1 mutant strain exhibits a faster
growth than the wild type strain. In addition, an overex-
pression of ExoS induces a lower growth than the one of
the wild type strain.
In order to clarify the role of this putative chaperone a
mutant defective for orf1 alone will be produced in CHA,
and the protein-protein interaction between the chaperone,
ExoS and ExoT will be analysed with bacterial two-hybrid
method.
WS10.1yP258: VITAMIN SUPPLEMENTATION
AND MONITORING PRACTICES IN PATIENTS
WITH CF IN THE UK
A. Morton , S. Wolfe1 2
Regional Adult CF Unit, Seacroft Hospital, Leeds, UK,1
Regional Paediatric CF Unit, St James’s University Hos-2
pital, UK
Malabsorption of fat soluble vitamins is common in patients
with CF. Overt symptoms of vitamin deficiency are rare.
With improved survival, the consequences of suboptimal
vitamin levels may become clinically important.
Sixty-seven questionnaires regarding vitamin supplemen-
tation practices were mailed to the UK Dieticians’ CF Inter-
est Group members (response 61%). 25 hospitals treated
children (48% treating)50 patients), 16 treated adults
(75% treating)50 patients).
Results: All gave routine vitamin A, D and E supplemen-
tation to PI patients. Five (12%) gave routine vitamin K.
Fourteen different preparations were routinely advised.
Most hospitals (81%) advised vitamins were taken with
food and enzymes. Monitoring: Annually; vitamins A and
E 95% of hospitals, vitamin D 76%, PTH 10%. If doses
were changed, 51% rechecked levels within 6 months, 44%
less frequently. Twenty percent measured fasting vitamin
levels and only 17% omitted supplementation the day of
monitoring. Vitamin A: Although all hospitals measured
plasma levels, only one routinely used retinol binding pro-
tein (RBP) to aid interpretation, a further five used RBP
occasionally.
There was a wide variation in the level considered toxic
(range 2–13.5 mmolyl). Eighty-one percent of adult hos-
pitals monitored vitamin A more frequently during preg-
nancy due to its teratrogenicity. Vitamin D: There was
inconsistency in the desired minimum level (range 15–125
nmolyl). Only 20% considered seasonal variation. Eighty-
one percent of adult hospitals, but no paediatric hospitals,
routinely measured BMD. Vitamin E: Only 24% considered
vitamin E: lipid ratio to interpret plasma levels. Vitamin K:
56% give vitamin K in CF liver disease, 41% for extended
clotting times. The range and frequency of dosing was
large. The full results will be discussed in detail.
Conclusion: This survey shows wide diversity in vitamin
supplementation and monitoring practices in the UK. The
introduction of Nutritional Guidelines in the UK and
Europe will encourage greater consistency of practice.
WS10.2yP263: ASSESSING THE VITAMIN K
STATUS OF PATIENTS WITH CYSTIC FIBROSIS
(CF) USING UNDERCARBOXYLATED
OSTEOCALCIN (UO) TO TOTAL OSTEOCALCIN
(TO)
A. Verma , B. Keevil , R. Bright-Thomas , M. Dodd , A.1 2 1 1
Jones , A. Webb1 1
Adult Cystic Fibrosis Unit, Wythenshawe Hospital,1
Manchester;
Biochemistry Department, Wythenshawe Hospital,2
Manchester
Introduction: Osteocalcin (OC) is a member of the extra-
hepatic Gla-containing proteins. OC is synthesised by oste-
oblasts as pro-osteocalcin, which then undergoes proteolytic
cleavage to the uncarboxylated form, which is carboxylated
using Vitamin K (VK) as a co-factor. The carboxylated OC
has a high affinity for calcium and will bind to hydroxy-
lapatite forming the organic matrix of bone. Measuring the
percentage of UO to TO (% UO) is an indirect measure of
VK deficiency w1x. Warfarin is a potent VK antagonist and
will prevent the carboxylation of UO to carboxylated OC
w2x. Patients treated with warfarin have higher a %UO to
control subjects w3x. CF patients with exocrine pancreatic
insufficiency (PI) have reduced serum concentrations of
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fat-soluble vitamins. At our unit, we do not routinely sup-
plement VK.
Aim: To ascertain if CF patients who had ceased growing
have VK deficiency using OC assays.
Method: Electrochemiluminescens immunoassays of TO
and UO were measured in 54 CF patients (50y54, 92.5%
PI) wGroup Ax, 10 warfarinised, non-CF patients wGroup Bx
and nine non-warfarinised, non-CF patients wGroup Cx. CF
patients also had dual energy X-ray absorptometry to assess
bone mineral density (BMD). Group means were compared
by the Student’s t-test.
Results: Groups A, B and C had a mean (S.E.M.) %UO
of 8.66% (0.55), 22.74% (1.43) and 10.24% (1.18),
respectively. There was no significant difference between
Group A and Group C and a difference between Group A
and Group B (P-0.01). There was no difference in VK
status as assessed by %UO for patients in Group A with
osteoporosis and with normal BMD. We did identify the
osteoporotic CF patients as having a significantly higher
mean TO (P-0.05) to the normal BMD CF patients. This
perhaps signifies increased bone turnover.
Conclusions: CF patients did not have a significant degree
of VK deficiency, as assessed by %UO.
1. Knapen et al., Ann Int Med 1989; 111: 1001–1005.
2. Sokoll et al., Clin Chem 1995; 41: 1121–1128.
3. Menon et al., J Clin Endo Metab 1987; 64: 59–61.
WS10.3yP247: USE OF BIOELECTRICAL
IMPEDANCE ANALYSIS FOR ASSESSMENT OF
THE NUTRITIONAL STATUS IN ADULT
PATIENTS WITH CYSTIC FIBROSIS
C. Lehmann, T. Rabisch, M. Heilmann, A. Altenburg*, S.
Bischoff*, J.M. Hohlfeld
Departments of Respiratory Medicine and
Gastroenterology*,
Hannover Medical School, 30623 Hannover
In cystic fibrosis patients, pulmonary function and long-
term survival has been strongly related to nutritional status.
To assess the nutritional status of adult CF patients, we
examined the relationship between body mass index (BMI),
bioelectrical impedance analysis, resting energy expenditure
(REE), quantitative energy intake determined by 3-day die-
tary records, pulmonary status and diagnosis of diabetes in
57 adult CF patients and 22 healthy control subjects.
Adult patients with CF had a significantly increased resting
energy expenditure (105.8"10.3 vs. 94.6"4.8% of pre-
dicted values; P-0.001) and a significant higher caloric
intake per day (3184"1206 vs. 2528"648 kcalyday; P-
0.05) compared to the control subjects. Among the CF
patients, BMI was positively correlated with pulmonary
function while the extracellular massybody cell mass
(ECMyBCM) was negatively correlated with pulmonary
function. Patients with abnormal glucose tolerance had
more severe malnutrition indicated by a lower body cell
mass (21.7"5.7 vs. 29"5.3 kg; P-0.001) and an
increased ECMyBCM (1.01"0.24 vs. 0.86"0.09; P-
0.01) already in patients with a normal BMI. REE and daily
caloric intake were not different in underweight to normal
weight patients. Female CF patients compared to male had
a significant lower caloric intake per day (2596"656 vs.
3616"1339 kcalyday; P-0.001) and a significant reduced
body cell mass and ECMyBCM ratio, whereas BMI or rest-
ing energy expenditure were not different.
A loss of BCM (malnutrition) had already occurred in
symptomless CF patients, particularly in females and
patients with an abnormal glucose tolerance. The use of
bioelectrical impedance analysis in CF patients may help to
elucidate differences in nutritional status that are not dis-
cernible with BMI alone.
WS10.4yP245: NUTRITIONAL PROFILE OF A
LARGE ADULT CYSTIC FIBROSIS UNIT
S. Pandya , M. Ledson , M. Walshaw1 1 1
Regional Adult CF Unit
Most patients with CF have from pancreatic insufficiency,
and adequate replacement therapy is essential to maintain
good nutrition. Furthermore, nutritional status can be taken
as an index of the patient’s health. We, therefore, undertook
a nutritional profile of 140 patients (mean age 25 years
wrange 17–56x, mean BMI 21.5 wrange 14–33x, mean FEV1
68% predicted wrange 16–120%x, 60 females) attending our
large CF unit, to give an indication of the overall health of
the clinic. Whilst six (4%) were diagnosed later in life, the
remainder (96%) were transferred from paediatric clinics.
Twenty-four (14%) were colonised by B. cepacia.
Although 23 (16%) were enzyme sufficient, the remainder
took supplemental pancreatic enzymes: 56 (40%) Creon
10 000 (average 25 capsules w2805 iuykgx), 20 (14%) Cre-
on 25 000 (average 28 capsules w5274 iuykgx), 33 (24%)
Pancrease (average 37 capsules w3093 iuykgx), seven (5%)
Pancrease HL (average 22 capsules w5945 iuykgx) and one
(1%) Nutrizym (average six capsules w1053 iuykgx). The
average lipaseykg was 4273 iuykg. Of those requiring
enzymes, only nine (8%) regularly took nutritional supple-
ments, and a further five (4%) had overnight enteral feed-
ing (one via nasogastric tube and four via button
gastrostomy). Six (4%) had obvious liver disease, and one
(1%) had undergone liver transplantation. Although several
had glucose intolerance, a further 26 (19%) had frank dia-
betes mellitus and used regular insulin.
Thus, it can be seen that, in our clinic, patients appear to
be well nourished, as reflected by their BMI. Few patients
require nutritional supplements or NGyPEG feeding, and
for the majority who take pancreatic enzymes, the average
daily dose is within the approved range. In keeping with
the UK CF Trust’s recommendations, we provide a com-
prehensive annual dietary assessment for our patients, and
these results show that, by fully utilising the skills of a
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dedicated CF dietician, the overall nutritional health of our
clinic is maintained.
WS10.5yP262: CHRONIC INFLAMMATION IS A
RISK FACTOR FOR ANTIOXIDANT DEFICIENCY
M. Heilmann , C. Lehmann , A. Altenburg , T. Rabisch ,1 1 2 1
J. Hohlfeld , H. Fabel1 1
Department of Pulmonary and Critical Care Medicine,1
Hannover Medical School;
Department of Gastroenterology2
Aims: Recent studies have demonstrated protective effects
of antioxidant vitamins and co-factors as selenium, b-car-
otene and zinc in obstructive airway diseases. The aim of
the study was to correlate dietary antioxidant-levels in adult
cystic fibrosis (CF) patients with clinical status and to iden-
tify patients at risk for deficiencies.
Methods: This was a prospective cohort study of 107
adults aged 18–43 with CF, mild to severe pulmonary dis-
ease (forced expiratory volume in 1 s (FEV1) within 17–
123% of predicted value) and pancreatic insufficiency.
Standard vitamin substitution included E (400 mgyday)
and vitamin A as part of a multivitamin prescription. Serum
levels of vitamin A, vitamin E, selenium, zinc, ferritin and
b-carotene were correlated with sex, genotype, nutritional
status, use of enzymes, lung function, diabetes, liver cir-
rhosis, Pseudomonas colonisation, IgE and inflammatory
parameters.
Results: Median body mass index (BMI) of all adult
patients was 20.4 kgym (range 14.5–28) with 71% having2
a BMI)19. One patient (1%) was deficient for vitamin A,
13.5% for vitamin E. Only 3.2% had lowered zinc levels,
but 62.6% presented with b-carotene-deficiency and 74.5%
with selenium-deficiency. Though anemia was rare, 44% of
the patients had significantly lowered ferritin-levels indi-
cating iron-deficiency. Statistical analysis revealed no cor-
relation of any deficiency with sex, BMI, amount of
enzymes taken, lung function, diabetes, BMI or Pseudo-
monas colonisation. Eleveted levels of IgG and CRP had a
negative correlation with vitamin and antioxidant-levels
(P-0.05).
Conclusion: Deficiency of dietary antioxidants in adult CF
patients is common. In this study, elevated inflammatory
parameters had a negative correlation with levels of dietary
antioxidants, but not lung function or BMI. Also patients
with normal body weight are likely to have micronutrient
deficiencies. The role of antioxidants in the inflammatory
process of CF needs to be evaluated.
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OP1.1yP164: PROTEOME ANALYSIS OF
PSEUDOMONAS AERUGINOSA CYSTIC
FIBROSIS ISOLATE STRAIN C WITH
REFERENCE TO PAO
S.D. Dinesh, M. Nimtz, U. Kaerst, U. Roemling
German Research Centre for Biotechnology, Braunschweig,
Germany
Aims:
Cystic fibrosis (CF) lung isolates of Pseudomonas aeru-
ginosa develop a common phenotype irrespective of the
genetic background. The common phenotype includes defi-
ciency of lipopolysaccharides, mucoidy and amino acid
auxotrophy. The aim of this study was to compare the pro-
teome of a strain with frequently occurring genotype C (1),
which was isolated during the onset of the colonization
process with that of a burn-wound isolate P. aeruginosa
PAO.
Methods:
Two-dimensional separation of whole-cell proteins in com-
bination with mass spectrometry methods MALDI-TOF
(Matrix assisted laser desorptionyionization-time of flight),
Q-TOF (Quadruple-time of flight), and finally, N-terminal
sequencing enabled us to compare efficiently the overall
protein expression profile of different strains under defined
growth conditions.
Results:
The whole-cell proteome of these strains revealed that pro-
teins involved in DNA-replication, protein-turnover (trans-
lation, post-translational modification and degradation),
chaperones, heat-shock and stress proteins were found to
be expressed at the same level. In contrast, the expression
of outer membrane proteins, hypothetical proteins, and also
the proteins involved in amino acid metabolism were found
to vary significantly. Proteins involved in amino acid bio-
synthesis were down-regulated and OMPs are up-regulated
in strain C. In line with those findings, strain C was found
to utilize additional extra-cellular amino acids when com-
pared to the strain PAO in rich medium.
Conclusions:
These features of a CF isolate colonizing an amino acid
rich environment can be attributed to mutations in the cor-
responding structural or regulatory genes. Such mutational
events might lead to auxotrophy as a strategy towards adap-
tation in a nutrient-rich habitat during the course of chronic
infection.
OP1.2yP208: ROLE OF EFFLUX SYSTEM
MEXXY-OPRM IN THE RESISTANCE OF CF
ISOLATES OF PSEUDOMONAS AERUGINOSA
TO AMINOGLYCOSIDES
C. Vogne, D. Hocquet, F. El Garch, P. Plesiat´
Laboratoire de Bacteriologie, Centre Universitaire de´
Besancon, France¸
Active efflux system MexXY-OprM is known to play a
major role in the natural resistance of Pseudomonas aeru-
ginosa to aminoglycosides. To investigate whether this sys-
tem is also responsible for high-level aminoglycoside
resistance in isolates colonizing cystic fibrosis (CF)
patients, we analyzed three pairs of isogenic susceptibley
resistant (SyR) bacteria recovered sequentially from the
sputums of three patients. The resistant isolates were 2.5–
3-fold less susceptible to aminoglycosides (gentamicin,
amikacin, tobramycin) than their susceptible counterparts.
Immunoblot analysis of membrane extracts demonstrated a
correlation between the development of resistance and an
increased production of MexXY. In addition, alterations in
the regulatory gene mexZ that normally represses the efflux
operon mexXY were seen in two out of three resistant iso-
lates. To confort these results indicating a role for MexXY-
OprM in the resistance of CF strains to aminoglycosides,
we subsequently examined two unrelated isolates obtained
from two other patients. Again, these bacteria were found
to overproduce MexXY and to harbor deletions in gene
mexZ. In conclusion, several lines of evidence tend to dem-
onstrate that the active efflux system MexXY is a key
mechanism in the resistance of CF strains of P. aeruginosa
to aminoglycosides. In some isolates, upregulation of the
efflux appears to result from mutations occuring in the
repressor gene mexZ.
OP1.3yP170: CHRONIC LUNG INFECTION IN CF
MICE CAN BE ESTABLISHED WITH STABLE
MUCOID P. AERUGINOSA STRAIN 57388
N. Hoffmann , C. Stub , H.K. Johansen , N. Høiby1 2 1 1
Department of Clinical Microbiology, afsnit 9301, Rigs-1
hospitalet, Copenhagen, Denmark;
Royal Veterinary and Agricultural University, Copenha-2
gen, Denmark
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Chronic P. aeruginosa (PA) lung infection in patients with
CF requires that the bacteria avoid host defences by estab-
lishing an alginate containing biofilm. Planktonic PA was
cleared in 1–2 days after challenging the lungs of rodents.
Thus, in order to achieve a chronic lung infection in animal
models, the bacteria must be entrapped in agar or seaweed
alginate beads mimicking the biofilm mode of growth. In
the present study, a stable CF mucoid PA isolate (57388)
hyperproducing alginate was instilled in the lungs of Cftr
(yyy) knockout mice (5=10 CFUylung) but without6
the use of beads, and in spite of that, the bacteria continued
to proliferate for 1 week. Histopathological examination of
lung sections revealed bronchi heavily blocked with micro-
colonies of PA embedded in a layer of slime, resembling
the biofilm seen in the lungs of CF patients. Alginate could
be precipitated chemically from lung homogenate, whereas
appropriate controls were negative. Replication inside mac-
rophages and only few leucocytes were observed. The new
experimental model of chronic PA lung infection will hope-
fully allow more reliable studies of the initial interaction of
PA and the defence mechanism of the host mimicking the
situations in CF patients.
OP1.4yP209: THE LONG PENTRAXIN PTX3
BINDS P. AERUGINOSA AND PROMOTES ITS
INTERNALIZATION BY RESPIRATORY
EPITHELIAL CELLS
S. Francisconi , B. Bottazzi , S. Carrabino , G. Peri , F.1 2 1 2
Pasqualini , A. Mantovani , M. Conese2 2 1
Institute for the Experimental Treatment of Cystic Fibrosis,1
H.S. Raffaele, Milano, Italy;
Istituto Mario Negri, Milano, Italy2
PTX3 is a prototypical long pentraxin, structurally related
to, but distinct from, C-reactive protein and serum amyloid
P component. Pro-inflammatory signals, including LPS, IL-
Ibeta, and TNF-alpha, induce the release of PTX3 by endo-
thelial cells and mononuclear phagocytes. PTX3 can bind
several ligands, including C1q, and apoptotic cells. In this
report, we investigated whether PTX3 could have any anti-
bacterial activity against P. aeruginosa. FACS analysis
demonstrated PTX3 binding (0.01–0.1 mgyml) to several
bacterial strains, including P. aeruginosa PAO1. Incubation
of PAO1 with various concentrations of rhPTX3 (2–200
ngyml) resulted in a dose-dependent decrease in the num-
ber of viable bacteria. Maximal inhibition of growth was
observed after 3 h of incubation. The synthesis and secre-
tion of PTX3 by human respiratory epithelial cells was
evaluated by an ELISA assay on conditioned media. IL-
1betayTNF-alpha could induce PTX3 levels by 2–26-fold
depending on the cell line (basal level, 3–13 ngyml), while
E. coli LPS had negligible effects. Since human respiratory
epithelial cells are able to internalize P. aeruginosa, we
investigated whether PTX3 could influence cell adhesion
and uptake of bacteria through the crystal violet assay.
PTX3 (1000 ngyml) increased adhesion and internalization
of bacteria to 9HTEo- tracheal cells, respectively, of 42%
and 28% after 15 and 30 min of incubation. These results
indicate that human airway epithelial cells secrete PTX3,
which can bind to P. aeruginosa and increase bacterial
internalization. It is under evaluation whether PTX3 could
have a protective effect on P. aeruginosa-induced cellular
apoptosis. The synthesis and secretion of PTX3 by human
respiratory cells suggest that PTX3 may have a role in the
innate immunity in the respiratory tract.
OP1.5yP201: BURKHOLDERIA CEPACIA
COMPLEX IN CYSTIC FIBROSIS AND NON-
CYSTIC FIBROSIS PATIENTS: IDENTIFICATION
OF A CLUSTER OF EPIDEMIC LINEAGES
A. Agodi , M. Barchitta , V. Giannino , A. Collura , T.1 1 2 3
Pensabene , M.L. Garlaschi , C. Pasquarella , E.3 4 5
Mahenthiralingam , S. Stefani6 2
Department of Biomedical Sciences, University of Catania,1
Italy;
Department of Microbiological and Gynaecological Sci-2
ences, University of Catania, Italy;
Ospedale G. Di Cristina, ARNAS, Palermo, Italy;3
Istituti Clinici di Perfezionamento, Milan, Italy;4
Department of Hygiene of Perugia Italy;5
School of Biosciences, Cardiff University, Cardiff, Wales,6
UK
This study was performed in order to compare B. cepacia
complex strains from CF and non-CF patients at the gen-
omovar, genetic and epidemiological levels. A total of 92
B. cepacia isolates were obtained from a previous investi-
gation from the respiratory tract of patients attending the
following CF centers: Catania and Palermo, Sicily; Gualdo
Tadino, Central Italy, and Milan, Northern Italy. A total of
23 B. cepacia isolates were obtained from various sources
(blood, surgical wounds and intravenous catheter) of
patients without CF hospitalised in Catania and Varese,
Northern Italy. Genomovar status identification, clonality
and genetic relatedness determination, antibiotic suscepti-
bility pattern determination and electron microscopy were
performed. Transmission of infection was shown in CF and
in non-CF patients, by identifying clonality of responsible
strains. A total of 13 clones were involved in cross-trans-
mission episodes. No outbreak was described involving
both CF and non-CF patients. The present study showed
the existence of a distinct cluster of strains responsible for
epidemics in CF and non-CF patients, based on their genet-
ic relatedness, distinct from strains associated with none or
negligible transmissibility. This result suggests that trans-
missibility is not only associated to a specific genomovar
in CF patients, but it is also significantly associated with a
group of genetically related lineages in CF and non-CF
patients. A key role is shown for both segregation measures
and careful surveillance of infection, based on selective cul-
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ture, molecular identification and epidemiological charac-
terisation of individual isolates.
OP1.6yP191: PERSISTENT PULMONARY
INFECTIONS WITH BURKHOLDERIA CEPACIA
IN PATIENTS FROM THE MAJOR PORTUGUESE
CYSTIC FIBROSIS CENTER
C.M. Vunha , J.H. Leitao , S. Sousa , L. Lito , M.J.1 1 1 2
Salgado , C. Barreto , I. Sa-Correia2 3 1´
Centro de Engenharia Biologica e Quımica, Instituto1 ´ ´
Superior Tecnico, Av. Rovisco Pais, 1049-001 Lisboa;´
Laboratorio de Bacteriologia;2 ´
Consulta de Fibrose Quıstica, Hospital de Santa Maria,3 ´
Lisboa, Portugal
The first epidemiological survey of Burkholderia cepacia,
involved in pulmonary infections among the cystic fibrosis
(CF) patients who attended the major Portuguese CF treat-
ment center at the Santa Maria Hospital in Lisbon w1x, was
extended to more than 100 isolates recovered from 22 CF
patients since 1995 until the end of 2001. The present study
confirms first indications suggesting that: (1) the environ-
ment is an important source of acquisition; (2) the Portu-
guese clinical isolates are not genetically related with
strains representative of the EdinburghyToronto and Man-
chester epidemic outbreaks; and (3) more than 75% of the
isolates examined do produce significant amounts of exo-
polysaccharide (EPS), suggesting that this may play a role
in the colonization and persistence of B. cepacia in the CF
lung. The EPS characterised is composed of a branched
heptasaccharide repeating unit with D-glucose, D-rhamnose,
D-mannose, D-galactose and D-glucuronic acid (1:1:1:3:1);
two acetyl groups are present per repeating unit w2x. The
pathway leading to the nucleotide sugar precursors neces-
sary to EPS biosynthesis was proposed w3x. Two out of 11
persistently infected patients were colonized with strains
which do not produce EPS, at least under standard labo-
ratory conditions. Furthermore, only one of the persistently
infected patients harboured serial isolates with the cblA
gene, thought to be involved in the colonization and per-
sistence of B. cepacia in the CF lung w4x. These results
suggest that other factors besides EPS and the cable pili
may be involved in B. cepacia persistence in CF. Studies
are underway to gain insights into the possible contribution
of these two putative virulence determinants in bacterial
adhesion to surfaces and biofilm formation.
w1x Richau et al., J Clin Microbiol, 2000; 38: 1651–1655.
w2x Cescutti et al., Biochem Biophys Res Commun, 2000;
273: 1088–1094.
w3x Richau et al., Biochem Biophys Res Commun, 2000;
276: 71–76.
w4x Sajjan et al., J Bacteriol, 1995; 177: 1030–1038.
OP1.7yP203: EXOPOLYSACCHARIDES FROM
BURKHOLDERIA CEPACIA: A COMPARATIVE
STUDY OF CLINICAL AND ENVIRONMENTAL
STRAINS BELONGING TO GENOMOVAR III
P. Cescutti , L. Drigo , R. Rizzo , G. Impallomeni , S.1 1 1 2
Piana , G. Manno , A. Bevivino , C. Dalmastri , S.3 3 4 4
Tabacchioni , L. Chiarini4 4
Dipartimento Biochimica, Biofisica e Chimica delle1
Macromolecole, Universita di Trieste, Italy;`
Istituto per la Chimica e la Tecnologia dei Materiali Poli-2
merici, CNR, Catania, Italy;
Laboratorio di Ricerca e Diagnostica Infettivologica,3
Dipartimento di Pediatria, Istituto G. Gaslini, Genova,
Italy;
Unita Biotecnologie, Protezione della Salute e degli Ecos-4 `
istemi, C.R. Casaccia, ENEA, Roma, Italy
B. cepacia comprises at least nine distinct genomovars,
referred to collectively as the B. cepacia complex. B. cepa-
cia genomovar III is the one seemingly best adapted to the
lungs of CF patients and the one that includes the major
epidemic strains. Its wide diffusion in soil habitats raises
serious concern about infection in vulnerable humans.
Recently, among the virulence determinants of B. cepacia,
exopolysaccharides (EPS) have attracted great interest as
possible candidates. Investigations carried out both in our
laboratory w1x and in other countries w2–4x revealed the
production of a common EPS. However, a detailed study
of both the number of EPSs produced by B. cepacia and
their correlation with the genomovar is strongly needed to
explore the clinical relevance of these biopolymers.
The aim of this study was to investigate more systemati-
cally the kind of EPS produced by isolates of B. cepacia
genomovar III and to assess the differences between EPS
of clinical and environmental origin. Six CF and six envi-
ronmental strains of B. cepacia belonging to genomovar III
were selected on the basis of their mucoid phenotype. They
were grown on solid medium and the EPSs produced were
isolated and purified. The 12 polymers were characterised
in terms of type and molar ratios of the sugars present by
means of chemical and spectroscopic analysis. The results
indicated that all the strains examined produced the EPS
already described in the literature. However, other polysac-
charides exhibiting different chemical characteristics were
also biosynthesised.
w1x Cescutti et al., Biochem Biophys Res Comm, 2000;
273: 1088–1094.
w2x Cirantola et al., Eur J Biochem, 1999; 260: 373–383.
w3x Linker et al., Carbohydr Res, 2001; 335: 45–54.
w4x Cirantola et al., FEMS, 2000; 185: 243–246.
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OP1.8yP193: IMMUNO-DETECTION OF
PROTEINS EXPRESSED IN VIVO BY
BURKHOLDERIA CEPACIA
H. Ryley, J. Weeks, A. Rose
Department of Medical Microbiology, UWCM, Cardiff
CF14 4XN, UK
Over the last decade, there has been an increased focus on
the contribution to bacterial virulence of proteins that are
only expressed in vivo by bacterial pathogens. The methods
used to investigate such expressions are complex, expen-
sive, usually require an animal model and are generally not
applicable to the more common pathogens of patients with
CF.
Recently, Handfield et al. (Trends Microbiol 2000; 8: 336–
339) suggested that patients who acquire bacterial infection
will have antibodies to in vivo-only expressed proteins in
their antibody repertoire. In this preliminary study, we
report on our findings concerning changes in the protein
phenotype by a B. cepacia isolate that has been grown
intracellularly in an epithelial cell line, as detected using
serum from a patient who carried the same strain. An ET12
isolate of B. cepacia was grown in a confluent pnuemocyte
cell line, A549, using conditions similar to that described
by Martin and Mohr (Infect Immun, 2000; 68: 24–19); the
resultant intracellular bacteria being harvested after 24 h. A
control (in vitro) growth of bacteria in tissue culture media
alone was harvested and investigated in parallel with the in
vivo isolate. The bacterial proteins from both types of iso-
late were analysed by electrophoresis on sodium dodecyl
sulfate-polyacrylamide gel followed by electro-blotting
onto nitrocellulose sheets. The blots were probed with
serum from a patient who was carrying an ET12 strain of
B. cepacia. The serum was either unabsorbed or made spe-
cific for in vivo expressed protein by absorption with B.
cepacia grown in vitro. A second antibody, antihuman IgG-
lactoperoxidase conjugate, together with a chemilumines-
cence method was used to detect bound antibody. Using
this method, up to 20 in vivo expressed proteins could be
detected. There was also a marked change in the phenotype
pattern between in vitro and in vivo grown bacteria, indi-
cating in vivo down regulation of some proteins.
OP1.9yP196: BURKHOLDERIA CEPACIA
GENOMOVAR III: IS THE SUBDIVISION IN TWO
RECA GROUPS RELATED TO DIFFERENT
DEGREE OF VIRULENCE?
L. Chiarini , S. Tabacchioni , A. Bevivino , C. Dalmastri ,1 1 1 1
G. Manno , E. Ugolotti , S. Piana2 2 3
Biotechnology Unit, ENEA C.R. Casaccia, 00060 S. Maria1
di Galeria, Rome, Italy;
Infectious Diseases Research and Diagnosis Laboratory,2
Department of Pediatrics, University of Genoa, Gaslini
Children’s Hospital, Genoa, Italy
Cystic Fibrosis Centre, Department of Pediatrics, Univer-3
sity of Genoa, Gaslini Children’s Hospital, Genoa, Italy
B. cepacia genomovar III is the genomovar seemingly best
adapted to the lungs of cystic fibrosis patients and the one
that includes the major epidemic strains of the B. cepacia
complex. Recently, B. cepacia genomovar III has been phy-
logenetically divided into two recA groups, namely III-A
and III-B. The taxonomic and functional significance of this
subdivision has still to be determined. In particular, it is not
clear if isolates belonging to different recA groups have
different degrees of virulence. In an attempt to approach
these questions, a panel of bacterial isolates representative
of these two recA groups was established. All isolates were
subjected to molecular fingerprinting and characterised with
respect to a number of candidate virulence determinants.
Molecular fingerprinting was carried out by means of the
RAPD technique. All patterns were statistically analysed by
means of the AMOVA program. Preliminary results indicate
that the two recA groups have a quite different genetic
structure. Among traits related to virulence, proteolytic and
haemolytic activity, antibiotic susceptibility, and ability to
produce exopolysaccharides, were evaluated. Moreover, the
presence of genetic markers associated with transmissibility
such as the B. cepacia epidemic strain marker (BCESM)
encoded by esmR gene and the cable pilus gene was inves-
tigated. Evaluation of preliminary results indicates, again,
that there are some significative differences between these
two groups of bacteria, in particular, with respect to anti-
biotic susceptibility and BCESM distribution.
These results suggest that the subdivision in two recA
groups of the isolates belonging to the most virulent gen-
omovar of the B. cepacia complex may reflect not only
taxonomic differences but also functional ones related to
different degrees of virulence.
OP1.10yP186: HIGH INCIDENCE OF
ERYTHROMYCIN RESISTANCE IN S. AUREUS
ISOLATED FROM CYSTIC FIBROSIS PATIENTS
REVEALS THE PRESENCE OF
HYPERMUTABLE STRAINS
A.L. Prunier , B. Malbruny , M. Laurans , J. Brouard , J.F.1 1 2 2
Duhamel , R. Leclercq2 1
Microbiology,1
Pediatric department, Caen, France2
Incidence of erythromycin resistance in S. aureus strains
isolated from 70 cystic fibrosis (CF) patients has increased
from 26.7% to 72% between 1997 and 1999 in our hospital.
We have studied 21 bronchial isolates of erythromycin-
resistant S. aureus from nine CF patients previously treated
with macrolides. Acquired genes conferring macrolide
resistance by ribosomal target methylation (erm) or by anti-
biotic efflux wmsr(A)x were searched for by PCR. Only five
strains contained an erm gene and two an msr(A) gene.
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Nucleotide sequence of ribosomal structures forming the
binding site of erythromycin, ribosomal proteins L4 and
L22, and 23S rRNA (domains II and V) revealed numerous
mutations. Overall, 43 mutations in domain V, 15 in domain
II, 22 in L4 and 2 in L22 gene sequences were detected.
Most mutations have been reported in E. coli and have been
used to identify the binding site of erythromycin but have
never been observed in S. aureus, so far. This high preva-
lence of mutation led us to suspect the presence of hyper-
mutable strains in CF patients. The study was enlarged to
the characterization of hypermutable phenotype in 91 CF
S. aureus strains compared to 66 strains isolated from non-
CF patients. We found a significant difference (P-0.025)
in rifampin resistance mutation frequency between the two
samples. These results led us to analyse the mutS gene
which has been previously identified as a mutator gene in
E. coli. In two out of six strains studied, the gene could
not be amplified by PCR or detected by Southern blotting,
while in another strain, a 41-amino-acid deletion was found.
In conclusion, erythromycin resistance in S. aureus strains
from CF patients from our region is mostly due to riboso-
mal mutations. The sudden emergence of resistance that we
observed might be related to the frequent use of macrolides
in CF patients infected or colonized with hypermutable
strains of S. aureus.
OP1.11yP189: STAPHYLOCOCCUS AUREUS
FROM CF AIRWAY SECRETIONS ENTER INTO
AND INDUCE AIRWAY EPITHELIAL CELL
DEATH
M.C.A. Silva , R. Nishi , O. Bajolet , M. Abely , E.1 2 3 4
Bingen , E. Puchelle , M.C. Plotkowski5 3 2
UFRJ, Rio de Janeiro, Brazil;1
UERJ, Rio de Janeiro, Brazil;2
U 514 INSERM, IFR 53, Reims, France;3
CHU Reims, Reims, France;4
CHU R. Debre, Paris, France5 ´
S. aureus is usually associated with early lung disease in
CF and may potentially contribute to airway damage. In
this report, 16 HBE cells grown in culture conditions giving
origin to poorly differentiated cells were exposed for 1 h
to S. aureus strains isolated from CF airway secretions of:
(i) recently infected infants; (ii) chronically infected
patients; and (iii) patients infected simultaneously by S.
aureus and P. aeruginosa. High concentrations of adherent
extracellular (EC) and intracellular (IC) bacteria were
detected in host cells, as determined by the gentamicin
exclusion assay. Concentration of IC bacteria ranged from
15.5 to 44.7% of the EC bacteria concentration. By light
microscopy, bacterial interaction with host cells were seen
to be heterogeneous, some cells being heavily infected
whereas others remained almost untouched. In cells infect-
ed by 40% of the strains, the concentrations of IC bacteria
increased significantly from 1 to 5 h of IC residence. The
ability to multiply inside host cells was not different in S.
aureus strains from the three groups studied. Between 5 and
24 h of IC residence, the bacterial viability decreased sig-
nificantly in cells infected by 90% of the strains. The
decrease in the bacterial IC concentration ranged from 32
to 90%. Cytotoxicity toward infected cells was detected by
the LDH assay in 40% of the strains after an IC infection
period of 24 h. However, with our culture conditions, no
relationship could be established between the bacterial cyto-
toxicity and the origin of the S. aureus strains. The role of
infection by S. aureus CF clinical strains on the fate of
airway cells will be further analyzed by dynamic imaging.
Supported by CAPES (Brazil) and Association Vaincre la
Mucoviscidose (France).
OP2.1yP248: IMPACT OF INTRAVENOUS
ANTIBIOTIC THERAPY ON TOTAL DAILY
ENERGY EXPENDITURE AND PHYSICAL
ACTIVITY IN CYSTIC FIBROSIS CHILDREN WITH
PSEUDOMONAS AERUGINOSA PULMONARY
EXACERBATION
L. Beghin , F. Gottrand , L. Michaud , G.-A. Loeuille , N.1 2 2 2
Wizla-Derambure , A. Sardet , D. Guimber , A.2 2 2
Deschildre , D. Turck2 2
Gastroenterlogy, Hepatology and Nutrition Unit, Pediatric1
Department and Clinical research Center CIC-9301-
INSERM-CHU of Lille, France;
Gastroenterlogy, Hepatology and Nutrition Unit, and Cys-2
tic Fibrosis Center, Pediatric Department, Jeanne de Flan-
dre University Children’s Hospital, France
Aims: Resting energy expenditure (REE) increases during
pulmonary exacerbation by Pseudomonas aeruginosa (PA)
in cystic fibrosis (CF) patients, and decreases after intra-
venous anti-PA antibiotic therapy (IVAT). However, the
impact of IVAT on total energy expenditure (TEE) is
unknown.
The aim of this study was to assess the changes in TEE
and its main components after IVAT administered at home.
Methods: Body composition, energy intake, physical activ-
ity, REE, and TEE were measured in 16 patients (nine boys
and seven girls) aged 12.1"2.3 years (range, 7.1–14.6
years), before and after a 14-day IVAT course.
Results: After IVAT, weight and fat mass increased by
1.9% (32.1"7.5 vs. 32.7"7.6 kg; P-0.05) and 9.8%
(5.7"2.3 vs. 6.3"2.7 kg; P-0.05), respectively. Energy
intake increased by 4.6% (10 797"3039 vs. 11 320"3074
kJyday; P-0.05). REE decreased by 4.1% (5295"909 vs.
5093"837 kJyday; P-0.05), whereas TEE remained sta-
ble (7002"1929 vs. 7081"1478 kJyday). Physical activ-
ity, when assessed by an activity diary using metabolic
equivalent tasks (MET) or accelerometry, increased by
9.3% (37.0"3.1 vs. 40.7"4.5 MET; P-0.05) or 20.2%
(175 035"52 474 vs. 219 392"88 708 countsyday; P-
0.02), respectively.
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Conclusions: The improvement in nutritional status after
IVAT is not related to a decrease in TEE, but probably to
an increase in energy intake. After IVAT, the reduction in
REE is probably compensated by an increase in physical
activity in CF patients.
OP2.2yP266: AN AUDIT OF INVESTIGATIONS
AND MANAGEMENT RELATING TO BONE
MASS IN CF
C. Harvey, D. Honeybourne
Cystic Fibrosis Unit, Birmingham Heartlands Hospital,
Birmingham, UK
In CF poor nutrition, pancreatic insufficiency, reduced sex
steroids, use of corticosteroids and increased osteoclast acti-
vating factors may all cause reduced bone density. We per-
formed an audit to look at the investigation, management
and prevention of osteoporosis. Forty case notes were ran-
domly selected from the 224 adult CF patients. Information
included: age, latest FEV1, BMI, corrected blood calcium,
alkaline phosphatase, fasting 25-hydroxyvitamin D and
PTH levels, previous fracture, steroid use and dose, DEXA
scan and current treatments (vitamin D, calcium,
bisphosphonates).
Risk factors: at the time of audit, 23.3% of the population
were taking oral, 60% inhaled and 10% nasal steroids. Vita-
min D: only 33% of our patients achieved the suggested
level of 15 mcgyl. This was despite the fact that 93% were
documented to be taking vitamin D supplementation. Only
40% had had a vitamin D level checked within the last year.
DEXA scans: eight patients had had a scan requested, five
having had a DEXA scan carried out. Of those who had
had a scan, four were found to have a reduced bone density,
two being classified as osteoporotic (T-score-y2.5) and
two as osteopenic, (T-score-y1.0). Treatment: all patients
with reduced bone density were taking vitamin D supple-
mentation. Both classified as osteoporotic had been pre-
scribed bisphosphonates.
This audit demonstrated that correct vitamin D levels were
often not achieved and that vitamin D level monitoring was
too infrequent. While some units recommend that all CF
patients should have a DEXA scan, only 20% of those
audited had had a scan requested. Of those investigated, a
high proportion were found to have a reduced bone density.
Appropriate treatment was prescribed for osteoporosis in
those in whom it was found. A formal protocol of assess-
ment for osteoporosis has been introduced.
OP2.3yP264: VITAMIN D LEVELS IN CHILDREN
WITH CYSTIC FIBROSIS
R. Chavasse, J. Francis, I. Balfour-Lynn, M. Rosenthal, A.
Bush
Department of Paediatrics, Royal Brompton Hospital, Lon-
don, UK.
Morbidity from bone disease is an increasing concern in
adults with cystic fibrosis (CF). Inadequate bone mineral-
isation during childhood and adolescence may predispose
individuals to fractures in later life. Vitamin D, a fat soluble
vitamin, is important in regulating bone accretion. Vitamin
D is routinely supplemented in pancreatic insufficient chil-
dren in our centre. We assessed vitamin D status in children
who had attended our specialist CF clinic for their annual
review.
Methods: Patients who had an annual assessment between
1999 and 2001 were identified from the local CF database.
Twenty-five hydroxyvitamin D (25-OHD) levels were com-
pared to age, growth, pulmonary function and other bio-
chemical indices recorded at the same annual review.
Results: 290 of 320 patients (median age 9 years, 0.9–
19.3) had 25-OHD levels recorded, median 65 nmolyl
(range 9–190). Only 1% were lower than the laboratory
reference range for adults (15–100 nmolyl). Median 25-
OHD levels were significantly lower in adolescents (age)
13 years, 52 nmolyl) compared to children aged 1–5 (76
nmolyl) and 5–12 (71 nmolyl) years (P-0.001). Median
25-OHD was significantly lower between October and
March (59 nmolyl) compared to April to September (77
nmolyl) (P-0.001) with 75% of low levels being meas-
ured during these months. There was no relationship
between 25-OHD and vitamin A or E levels, FEV1% pre-
dicted or weight and height Z-scores. There was no differ-
ence in 25-OHD level between pancreatic sufficient (ns
13) and pancreatic insufficient patients (ns26) matched
for age, gender and season.
Conclusion: 25-OHD was usually normal in children with
CF compared to the adult reference range. There is no
accepted paediatric range, nor optimal level for adequate
bone accretion. The lower levels in adolescence potentially
reflect either normal physiology or disease. The interpre-
tation of 25-OHD levels in children is unclear, and there-
fore, deficiency cannot be excluded as a cause of bone
disease in adults.
OP2.4yP270: DETERMINANTS OF REDUCED
BONE MINERAL DENSITY (BMD) IN ADULTS
WITH CYSTIC FIBROSIS (CF)
S.J. King , D.J. Topliss , T.C. Kotsimbos , M Bailey , I.B.1 2 3 4
Nyulasi , J.W. Wilson1 3
Nutrition Department, Alfred Hospital;1
Department of Endocrinology and Diabetes, Alfred2
Hospital;
Cystic Fibrosis Service, Alfred Hospital;3
Department of Epidemiology and Preventive Medicine,4
Monash University
Reduced BMD is recognised as a complication of CF and
has the potential to impair quality of life in CF patients as
survival improves. Multiple factors have been implicated.
Aim: To identify determinants of reduced BMD in an adult
CF population.
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Subjects: Eighty-eight adults w60% male, mean age 29.9
years (range 19–59 years)x, with mean FEV1 of 58.2%
predicted (range 14–126) who were not being treated for
reduced BMD were studied.
Methods: BMD in the lumbar spine (LS) and femoral neck
(FN) and body composition wfat-free mass (FFM) and fat
mass (FM)x were measured using Dual Energy X-Ray
Absorptiometry (DEXA) (Lunar). FEV1% was measured,
and body mass index (BMI) was calculated. Blood was
analysed for 25-hydroxy vitamin D3 (vit D), osteocalcin,
TNF-a, IL6, IL-1b, calcium, phosphate, albumin, parathy-
roid hormone and ALP and urine was analysed for N-tel-
opeptide (NTX).
CF genotype, a history of diabetes or liver disease, need
for enteral nutrition (EN) (a marker of previous malnutri-
tion or high energy needs), history of growth, development
or weight gain delays (GDW) and oral or IV corticosteroid
use were analysed.
Results: Mean (S.D.) BMD Z-scores were y0.58 (1.31)
at the LS andy0.24 (1.19) at the FN. Mean BMD Z-scores
were significantly lower in males at both sites compared
with females wy0.87 (1.35) vs. 0.15 (1.11) at the LS; y
0.46 (1.13) vs. 0.08 (1.22) at the FN; P-0.05 for both
comparisonsx. Multiple linear regression of all variables
showed that gender, deltaF508 genotype, fat mass, phos-
phate, ALP, GDW, EN, liver disease and vitamin D were
significantly associated with LS Z-score (R s0.48); while2
gender, FEV1%, deltaF508 genotype and fat-free mass
were significantly associated with FN Z-score (R s0.34).2
Conclusion: Reduced BMD in CF appears to be associated
with a number of factors including male gender, deltaF508
genotype, lower FEV1%, need for EN, lower vitamin D,
GDW delay and poorer nutritional status.
Supported by the Australian Cystic Fibrosis Research Trust.
OP2.5yP46: THE USE OF NASAL POTENTIAL
DIFFERENCE MEASUREMENTS IN RECURRENT
PANCREATITIS
M. Wilschanski , Y. Yaakov , H. Blau , H. Bibi , N.1 1 2 3
Weisman , R. Arnon , A. Klar , E. Broide , E. Kerem4 5 6 7 1
CF Center, Shaare Zedek Medical Center, Jerusalem;1
CF Center, Schneider Children’s Hospital, Petach Tiqva;2
Pediatric Pulmonology, Barzilai Medical Center,3
Ashkelon;
Clinical Nutrition Unit, Sorasky Medical Center, Tel Aviv;4
Pediatric Gastroenterology, Sorasky Medical Center, Tel5
Aviv;
Department of Pediatrics, Bikur Cholim Hospital,6
Jerusalem;
Pediatric Gastroenterology, Assaf Harofeh Hospital,7
Tzriffin
An emerging number of patients present with an atypical
phenotype of CF expressing only partial features or even
single-organ disease. The association between the pheno-
type of recurrent pancreatitis and CFTR dysfunction is
unclear. Nasal potential difference (NPD) measurements
may be a useful diagnostic tool. Aim: To investigate a
cohort of patients with previously undiagnosed recurrent
pancreatitis. Methods: Seven patients (six males) aged
18"11 years (range 8–40) with recurrent pancreatitis
underwent extensive investigations to establish a diagnosis.
One patient had mild asthma and one had Crohn’s disease;
no patient was alcoholic. There was no family history of
CF and all patients had normal spirometry and negative
sputum cultures. Four patients had imaging of the pancre-
atic duct (ERCPyMRCP) and in one patient mild pancre-
atic duct stenosis was found. No patient was PI. Mean
sweat chloride values were 45"15 mmolyl (range 20–66).
Nasal PD was diagnostic in two patients (sweat chloride
44 and 60); basal PD was y26.5"12 mV (normal range),
but there was an abnormal response to chlorideyfreeqiso-
proterenol solutions. The diagnostic ratio: e response to
chloride-free and isoproterenolyresponse to amiloride with
value)0.7 predicting a diagnosis of CF (Eur Resp J 2001;
17: 1208–1215) was pathological. In the other five
patients, the basal PD was also in the normal range (y
19"5 mV), but the diagnostic ratio was normal. Mutation
analysis revealed W1282Xy5T and W1282Xy? in the
patients with abnormal PD only. Nasal PD is a more useful
diagnostic test in recurrent pancreatitis, and in this group
of patients, it is more sensitive than sweat testing.
OP2.6yP45: CF DIAGNOSIS: INTESTINAL
CURRENT MEASUREMENTS ON RECTAL
SUCTION BIOPSIES VS. THE SWEAT TEST
I. Bronsveld , H. de Jonge , M. Sinaasappel1 2 1
Department of Pediatric Gastroenterology, Sophia Chil-1
dren’s Hospital, Rotterdam, The Netherlands;
Department of Biochemistry, Erasmus University, Rotter-2
dam, The Netherlands
Aims: When a patient is suspected to have CF from his
clinical presentation, the first diagnostic test performed is
the sweat test. However, since CF patients have presented
with sweat chloride levels in the borderline (30–60 mmoly
l) or normal range (-30 mmolyl), additional approaches
are necessary. To determine the importance of the intestinal
current measurement (ICM) as a diagnostic method for CF
in addition to the sweat test, we compared the results in
patients suspected with CF but with inconclusive sweat test
results, with previously reported ICM results in CF and
control groups (Veeze et al., Gastroenterology, 1991;
Bronsveld et al., Gastroenterology, 2000).
Methods: In a Ussing chamber, a rectal suction biopsy is
mounted between two volumes of salt solution. By adding
secretagogues and inhibitors of different chloride secretory
pathways to the mucosal andyor serosal side of the rectal
tissue, chloride currents can be determined and separated
into cAMP and Ca -mediated chloride currents.2q
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Results: Forty-nine patients with clinical symptoms vary-
ing from chronic upper airway infections, nasal polyps, ste-
atorrhoea or pancreatic insufficiency were investigated by
ICM. On the basis of their sweat chloride levels
(39.6"20.1), CF diagnosis could not be determined.
Therefore, we compared their ICM values with the reported
ICM values, which were 43.9"18.9 5Aycm (range 11.9–2
110.2) for control subjects and 4.6"7.4 5Aycm (y35.2–2
8.43) for the CF group. In our 49 patients, 14 had ICM
values in the CF range 1.6–6.9 5Aycm , while the other2
ICM results were consistent with control values 37.3"18.
Conclusion: In patients that are suspected to have CF from
their clinical presentation, but have inconclusive sweat test
results, the ICM can distinguish those with normal and
abnormal intestinal chloride currents, to substantiate the
diagnosis of CF.
OP3.1yP123: HIGH RESOLUTION CT SCANS
SHOW PROGRESSIVE STRUCTURAL
ABNORMALITIES IN THE PRESENCE OF
STABLE PULMONARY FUNCTION TESTS IN
CHILDREN WITH CYSTIC FIBROSIS
P. de Jong , Y. Nakano , M. Lequin , R. Woods , P. Pare ,1 2 3 2 2´
H. Tiddens1
Sophia Children’s Hospital, Erasmus Medical Centre, Rot-1
terdam, Department of Pediatric Pulmonology, Rotterdam,
The Netherlands;
UBC McDonald Research Laboratories and iCAPTURE2
Centre, St. Paul’s Hospital, Vancouver, BC, Canada;
Sophia Children’s Hospital, Erasmus Medical Centre Rot-3
terdam, Department of Pediatric Radiology, Rotterdam, The
Netherlands
Pulmonary function tests (PFT) and high resolution CT
(HRCT) are different methods to monitor severity of lung
disease in CF. Abnormalities on HRCT can be scored repro-
ducible with various semi-quantitative scoring systems.
Aim:
To investigate the sensitivity of various HRCT scoring sys-
tems to detect structural changes over time and to compare
these changes with the changes in PFT. We hypothesized
that HRCT is a more sensitive method to detect lung dam-
age compared to lung function.
Methods:
Children in our CF centre have an annual check-up that
includes the following routine PFT from the age of 5:
FEV1, FVC, FEF25-75, FEV1yFVC, Raw, RV, TLC, and
RVyTLC. Since 1996, HRCT is done biennially from the
age of 4. Fifty-eight children had two CT scans (CT1 and
CT2) that were done combined with one or two PFT (PFT1
and PFT2). CT scans were scored using five scoring sys-
tems: Bhalla (Bh); Santamaria (S); Helbich (H); Brody
(Br); and Castile (C). The difference in CT scores (CTDs
CT2yCT1) was correlated with the difference in PFT
(PFTDsPFT1yPFT2) using Spearman’s correlation (R).
Structural changes over time were evaluated by correlating
CT1 with CT2 using the paired t-test, functional changes
over time by correlating PFT1 with PFT2. A P-value -
0.05 was considered significant, data are given as
mean"S.D.
Results:
Age at CT1 was 9.9"3.9 years, FEV1 was 74.6"17.9%
pred. The time interval between CT1 and CT2 was
1.98"0.57 years. CTD (Bh, S, H, Br) correlated signifi-
cantly but weakly with PFTD for FEF 25–75% pred and
FEV1yFVC (R-values between 0.28 and 0.44). All HRCT
scores worsened significantly with time (P-0.01). PFT
improved for RV% pred and RVyTLC (P-0.005) but
remained unchanged for other PFT.
Conclusions:
HRCT and PFT reflect different aspects of the pulmonary
condition of CF patients. HRCT shows progressive struc-
tural damage over a 2-year period, even though lung func-
tion remains unchanged. We recommend including HRCT
in the routine evaluation of lung damage in young CF
patients.
OP3.2yP134: CF DIAGNOSIS IN ADULTS: BOTH
ATYPICAL AND CLASSIC FORMS OF THE
DISEASE
R. Padoan , D. Costantini , C. Fredella , G. Pizzamiglio ,1 1 1 2
A. Bassotti , M. Seia , E. Madonini1 3 4
CF Center,1
CF Center, Adult Unit,2
Molecular Genetic Dept.,3
Respiratory Physiopathology, Villa Marelli, Milano, Italy4
CF has become a disease relevant to adult pneumologists
as well as to paediatricians, and some patients may reach
adult age undiagnosed, usually attending Respiratory
Departments due to the prevalence of chronic lung disease.
We present a survey of 54 patients diagnosed after the age
of 16 years for respiratory symptoms and regularly fol-
lowed in the Milan CF Centre. Forty-foury54 had a positive
history of lung disease from childhood. Mean age of diag-
nosis was 24.4 years (range 16–45), with 23.3% subjects
diagnosed after the age of 30. All patients but one had an
abnormal chest X-ray film, upper lobes involvement being
the most common finding. Upper airway disease was pres-
ent in 53.7% of the patients, all the patients had positive
sputum coltures, with Ps. aeruginosa recovered in 33 pts
(61.1%) and S. aureus in 27 pts (50%). Pulmonary func-
tion at diagnosis (available in 49 pts) showed a high prev-
alence of normality: FVC was )80% of predicted value in
27y49 (54,1%), FEV1 was)80% in 16y49 (32,6%). Thir-
teeny54 (24%) showed the classic form of the disease with
pancreatic insufficiency.
Three patients had a sweat test value -60 mEqyl, and CF
was diagnosed by genetic analysis. Molecular analysis of
CFTR gene by means of PCRyOLA assay and DGGE
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sequencing showed a high allelic variability: 22 mutations
account for 80% of CFTR abnormalities. Thirty-oney52 pts
(60%) bear two CFTR mutations, 21 with only one known
CFTR alteration, and in the remaining four, no mutation
was identified.
The most common diagnostic mistakes were Tb and sar-
coidosis (11 and eight cases, respectively). CF diagnosis
during adulthood is performed in pts presenting atypical
disease, but also patients with the classic form of the dis-
ease may receive a a delayed diagnosis.
CF must be considered in the differential diagnosis of adult
patients with chronic respiratory symptoms, chest X-ray
abnormalities and characteristic sputum microbiology, even
in subjects with normal pulmonary function, andyor normal
chloride sweat values.
OP3.3yP122: OPTIMIZING AEROSOL LUNG
DEPOSITION IN CF PATIENTS
G. Scheuch , T. Meyer , B. Muellinger , K. Sommerer , P.1 1 1 1
Brand , K. Haeussinger , J. Heyder2 3 2
Inamed—Intelligent Aerosol Medicine, Gauting, Germany;1
GSF—National Research Center for Environment and2
Health, Neuherberg, Germany;
Asklepios Fachkliniken, Munich-Gauting, Germany3
Aerosol systems used for inhalation therapy should be able
to deliver the drugs into different regions of the respiratory
system. The efficiency and reproducibility of lung deposi-
tion of most commercially aerosol systems is limited by the
delivered particle size distribution and breathing pattern of
the patients. Even if particle size is optimised (between 2
and 4.5 m aerodynamic particle diameter, dae), the effi-
ciency and variability of lung deposition will be determined
by the patient’s breathing pattern. In this study, the varia-
bility in peripheral lung deposition should be limited by a
controlled inhalation with the AKITA delivery device.
Intrathoracic deposition should be optimised to )80% of
the delivered dose. The AKITA device controls the aerosol
inhalation flow and the inhalation volume of the patient. It
can be combined with available jet nebulizers.
Methods:
In an in vivo lung deposition study in six CF patients
(FEV1s69%) with the AKITA delivery system intrathor-
acic lung deposition was determined with Fe O aerosol3 4
particles labelled with 99mTc. Lung deposition was meas-
ured using a gamma camera and a human body scintillation
counter. Patients inhaled slowly and deeply. The inhalation
volume was individualized, taking into account the patient’s
vital capacity. The inhalation flow rate was limited to 200
mlys. The peripheral lung deposition was determined by
measuring particle retention in the lungs over a period of
24 h after inhalation.
Results:
The intrathoracic lung deposition and the intersubject var-
iability in a group of six CF patients was found to be
86"2% of delivered aerosol dose. Peripheral lung deposi-
tion was 78"5%. When patients inhaled spontaneously,
lung deposition usually ranged from 10% to 50%.
Conclusion:
It can be concluded that the controlled inhalation of parti-
cles in the size range of dae 2–5.5 m with the AKITA
delivery system in CF patients results in high intra-thoracic
deposition with very low intersubject variability.
OP3.4yP161: COMPARISON OF COMPLIANCE
IN CYSTIC FIBROSIS PATIENTS USING EITHER
A HALOLITE ADAPTIVE AEROSOL DELIVERY
(AAD) SYSTEM OR A CONVENTIONAL HIGH
OUTPUT NEBULISER SYSTEM
S. Conway , M. Dodd , R. Marsden , E. Paul , P. Weller1 2 3 4 5
St. James Hospital, Leeds, UK;1
Wythenshawe Hospital, Manchester, UK;2
Profile Therapeutics, UK;3
Wolfson Institute of Preventive Medicine, London, UK;4
The Birmingham Childrens Hospital, Birmingham, UK5
CF patients may use conventional high output nebulisers
(NEB) for up to 1 hyday to aerosolise therapies aimed at
preserving lung function. Poor techniques such as nose
breathing, talking and inadequate lip seal compromise the
time spent breathing correctly on the mouthpiece (1), and
hence, the amount of drug delivered to the lungs. HaloLite
(AAD) has been designed to generate aerosol only whilst
patients breathe correctly through the mouthpiece. The sys-
tem provides feedback to the patient during treatment and
signals once the pre-programmed dose has been success-
fully delivered. The aim of this study was to compare com-
pliance with AAD to compliance with NEB.
Patient Logging System (PLS) monitoring technology was
used in a device study comparing AAD with NEB to overt-
ly monitor 50 of 259 patients over 182 days. ‘Adherence’
(doses startedyby the number of doses prescribed) and
‘compliance’ (the percentage of doses taken correctly)were
recorded. For AAD a correctly taken dose was defined as
delivery of)90% of the pre-programmed dose, and for the
NEB when the Porta-NebO PLS compressor was run for`
)6 min. ‘True compliance’ is adherence=compliance.
FEV1 was recorded on day 0 and 28 for patients who did
not exacerbate.
The sample included 30 AAD and 20 NEB patients. Pro-
visional data show that adherence was 62% for AAD and
47% for NEB (P)0.05). Compliance was 84% for AAD
and 43% for NEB. ‘True compliance’ was significantly
higher for AAD (51%) compared to NEB (27%) (Ps
0.006). There was no correlation between true compliance
and percentage change in FEV1 after 28 days for NEB (ns
14), however, there was a correlation between the percent-
age change in FEV1 and true compliance for AAD (ns
17) (Rs0.53) (P-0.03). These data show that the AAD
system increases true compliance and may contribute to the
maintenance of FEV1.
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1. Denyer J, et al. Does inhalation duty cycle in-vitro pre-
dict inhaled dose during domicillary nebulizer use? Drug
delivery to the lungs VIII, 1997.
OP3.5yP62: CLINICAL FEATURE AND THE
MEASUREMENT OF NASAL POTENTIAL
DIFFERENCES IN TWO 63- AND 61-YEAR-OLD
SIBS WITH GENOTYPE F508DELy2789H5G)A
J. Mainz , U. Hammer , C. Rokahr , U. Claussen , F.1 2 3 2
Zintl , M. Ballmann1 3
CF-Centre of the University of Jena at the Department of1
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We report the clinical features and the measurement of nasal
potential differences (nPD) of two 61- and 63-year-old
male sibs with cystic fibrosis (CF) who are heterozygous
for delta F508del and 2789q5G)A. Clinically, both are
characterised by late diagnosis at the age of 43 and 45
years, mild to moderate pulmonary deterioration (FEV1
39% and 62%), mild pancreatic insufficiency and infertility.
CF diagnosis was based on positive sweat tests and con-
firmed by genotyping, which resulted in compound heter-
ozygosity (delta F508del and 2789q5G)A).
The measurement of the nPD, according to the protocol of
Knowles et al., revealed a CF-typical voltage change (79%
and 69%) from basal values induced by the Na-channel-
blocker Amiloride. The voltage changes (y12.8 and y
13.8 mV) induced by superfusion with chloride free
solution indicated significant remaining chloride channel-
function This is the first documented accordance of elec-
trophysiologically demonstrated residual chloride
conductance and the results from nasal epithelial mRNA-
analysis published by Highsmith et al. who suspected the
synthesis of small amounts of normal CFTR protein in
patients with this genotype.
Besides the electrophysiologically detected remaining
CFTR-function the patients high physical activity and con-
sequent lifestyle may have reduced the disease progression
decisively.
OP3.6yP126: VENOUS SERUM CHLORIDE AND
BICARBONATE MEASUREMENTS AS
BIOCHEMICAL MARKERS OF EXACERBATION
OF PULMONARY DISEASE IN ADULT CYSTIC
FIBROSIS
P. Ferrara , V. Carnovale , D. de Santis , A. Bloise , L.1 1 1 1
Viati , P. Capaccio , G. Gerundo , N. Ferrara , P. Abete ,1 1 1 2 1
F. Rengo1
Universita di Napoli ‘Federico II’, Cattedra diGeriatria,1 `
Unita Specialistica Fibrosi Cistica dell’adulto;`
Seconda Universita di Napoli, Cattedra di Geriatria2 `
Classical markers of exacerbation of pulmonary disease in
adult Cystic Fibrosis (CF) are both clinical, functional and
biochemical. Moreover, exacerbation of pulmonary disease
in adult CF induces alveolar hypoventilation, and therefore,
respiratory acidosis. The changes in PaCO induce com-2
pensatory alterations of renal bicarbonate transport: hyper-
capnia stimulates renal reabsorption of bicarbonate, and in
order to preserve the anion gap, increases chloride excre-
tion. Thus, as the serum bicarbonate rises, serum chloride
falls. The aim of this study was to assess the use of venous
serum chloride (Cl ) and bicarbonate (HCO ) measure-y y3
ments in the evaluation of exacerbation of pulmonary dis-
ease in adult CF. We retrospectively examined 25 adult CF
(10 male and 15 female; mean age 24.9"15.4) admitted
to our hospital for an exacerbation of pulmonary disease
(20 Pseudomonas aeruginosa, five Pseudomonas aerugi-
nosa and Burkholderia cepacia). The following parameters
were monitored:
Parameter Admission Discharge P
Cl (mmolyl)y 95.413.6 99.213.3 0.000
HCO (mmolyl)y3 30.516.6 26.916.0 0.01
pH 7.4110.05 7.3810.02 0.002
PaO (mmHg)2 64.1116.6 88.1113.3 0.000
PaCO (mmHg)2 47.1113.8 46.3110.1 0.721
SatHbO (%)2 92.615.7 95.613.7 0.007
C-reactive protein (mgydl) 6.817.9 0.911.2 0.001
White blood cells (=1000y5 l) 11.514.4 8.612.6 0.002
FEV1 (% predicted) 38.4110.3 50.6115.9 0.002
Except for PaCO , we observed a significant difference2
among all the parameters considered at the admission
vs. discharge. Interestingly, low venous chloride and
raised bicarbonate were significantly associated with the
classical indexes of exacerbation of pulmonary disease
of adult CF. Thus, venous chloride and bicarbonate,
markers of metabolic compensation in respiratory
acidosis, may have important prognostic implications in
adult CF.
OP3.7yP127: LUNG FUNCTION CHANGES
AFTER ANTIBIOTIC THERAPY IN CF PATIENTS
G. Pisi, G.L. Grzincich, C. Spaggiari, G. Attanasi, R. Mar-
vasi, A. Battistini
Cystic Fibrosis Center, University of Parma, Italy
The aim of the study was to evaluate the effect of antibiotic
therapy on lung function of 58 CF patients (27 male; age
range 9 to 41 years; BMI range 12 to 26 kgym , medians2
19.7) with moderate to severe lung disease. Their forced
expiratory volume at 1 s (FEV1, % predicted values) and
Schwachman score ranged, respectively, between 30 and
80% (medians71%) and between 35 and 90 (medians
70). All patients were treated at the hospital with b-lactams
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plus aminoglycosides, intravenously administered for 2
weeks.
In all patients, baseline (B)and after treatment (AT) values
of forced vital capacity (FVC, l), FEV1 (l), forced expi-
ratory flow at 25–75% of FVC (FEF 25–75, lys), residual
volume (RV, l), total lung capacity (TLC, l), and airway
resistance (Raw, cmØH Oylys) were measured. Results,2
expressed as mean(S.D.), are reported in the table.
FVC FEV1 FEF 25–75 RV TLC Raw
B 2.8 (0.9) 1.9 (0.8) 1.4 (1.0) 2.0 (1.1) 5.0
(1.2) 6.2 (2.6)
AT 3.0 (0.9) 2.1 (0.8) 1.6 (1.2) 1.8 (1.1) 5.0
(1.0) 5.6 (2.6)
P* 0.001 0.001 0.001 0.001 ns 0.001
*By Student’s paired t-test.
No correlation was found between the change of lung
function values, expressed as a percentage of baseline,
and age, gender, BMI and Schwachman score.
The results of this study showed that, in CF patients with
moderate to severe lung disease, an antibiotic treatment
lasting for 2 weeks can significantly increase both
airway obstruction and lung hyperinflation parameters.
Moreover, this change was not related to antropometric,
clinical and functional characteristics of the patients.
OP3.8yP148: CMV INFECTION IN A CF PATIENT
L. Mared, L. Eriksson
Department of Respiratory Medicine, Lund, Sweden
A young woman, 23 years old, living far away from the
centre, was diagnosed with CF at 2 years of age. She had
lung disease from the beginning, as well as pancreatic
insufficiency, colonisation with P. aeruginosa, pathological
OGTT, and difficulties in weight keeping. Port-a-cath. VC
2.4, FEV1 1.8 l att the latest yearly check up. Sputum cul-
tures showed two strains of non-mucoid P. aeruginosa, both
sensitive to aminoglucosides. One strain was resistant to
piperacillin and both to imipenem. Nu funghi, Pneumocys-
tis or Mycobacteria.
Fever up to 39.5 8C and increased sputum for 4 weeks
before arrival to the centre was reported. A 2-week treat-
ment with piperacillin and tobramycin iv was commenced
after 1 week of symptoms. Weight loss was 3 kg. Vertigo
due to tobramycin was reported. On arrival, the patient had
undulating fever and massive sputum production. An X-ray
showed increasing infiltrates bilaterally, mostly in the left
lower lobe. Cultures from blood, port-a-cath and urine were
negative. Sputum showed only P. aeruginosa; WBC
19=10 yl, CRP 147 mgyl. There was slight liver affection,9
elevated glutamyltransferase and alkalic phosphatase.
Transferases were higher than her usual values, but still
within the normal range. The patient was initially treated
with piperacillin, ceftazidim iv and inhaled colimicin. No
change was noted; if anything, the state worsened. Treat-
ment with ciprofloxacin was added. Fever was now )40
8C, and the patient desaturated continuously. Oxygen treat-
ment was started, but the patient had difficulties in accept-
ing both mask and prongs. New cultures showed the same
pattern. Then virus serology was checked; PCR in serum
as well as serology (IgM and IgG) were positive for CMV.
Treatment with ganciclovir was started on day 11 after hos-
pitalising. After 5 days of treatment, the patient improved:
the fever disappeared, blood tests were normalised. Total
weight loss during the episode was almost 8 kg. The patient
left hospital in relatively good condition.
We have never seen any reports on CMV infections in CF
patients. When do you test for viruses? Should we be more
generous in testing for CMV and maybe other viruses?
OP3.9yP145: CASE REPORT: CMV PNEUMONIA
IN AN IMMUNOCOMPETENT INFANT WITH
CYSTIC FIBROSIS
R. Padoan , M. Barbi , P. Barbaccia , E. Fossali , P.1 2 3 4
Guidotti1
Cystic Fibrosis Center, Department of Pediatric, A.O. Isti-1
tuti Clinici di Perfezionamento, Milan, Italy;
Institute of Virology, University of Milan;2
Department of Pediatric Radiology, A.O. Istituti Clinici3
diPerfezionamento, Milan, Italy;
Department of Pediatric, A.O. Istituti Clinici di Perfezion-4
amento, Milan, Italy
We present the first case of CMV pneumonia in an immu-
nocompetent infant with cystic fibrosis.
The child was diagnosed soon after birth (3 weeks) because
of positive neonatal screening, genetic analysis performed
on Guthrie card (delF508yN1303K) and positive sweat test
(Cl : 99.42 mmolyl). Adequate therapy was started withy
pancreatic enzyme and vitamins supplementation, and chest
physiotherapy (by means of PEP mask). At 5 months of
age, she showed failure to thrive and progressive worsening
of respiratory symptoms despite oral and intramuscular
antibiotic administration according to sputum microbiology.
When 7 months old, she presented with tachypnoea,
dyspnoea and hypoxyemia. Her chest X-ray film showed
focal thickening and dysventilating areas, which worsened
despite an apparently adequate therapy with intravenous
antibiotic drugs (ceftazidime and tobramicin) and intensive
chest physiotherapy (BiPAP). Gastro-oesophageal reflux
was excluded together with RSV infection, EBV, rubella,
HSV1 and HSV2, and fungi; a skin test for M. tuberculosis
was also negative. The patient was found positive for anti-
CMV serum IgM and IgG. CMV antigens could be found
in urine and sputum. On the basis of these data, a bron-
choalveolar lavage was performed. BAL fluid proved high-
ly positive for CMV immediate early protein p72,
demonstrating the presence of a pulmonary infection due to
CMV. The patient was then treated with a 17-day course of
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intravenous ganciclovir and high dose immunoglobulins.
Her clinical conditions, chest X-ray film and respiratory
function promptly responded to therapy. A 4-year follow up
shows a 5-year-old girl in good clinical conditions, with
normal growth and lung function and no Pseudomonas lung
infection.
In infants with CF-associated lung disease not improving
on antimicrobial therapy targeted according to sputum anti-
microbial sensitivities, BAL should be considered and the
possibility of CMV infection should be investigated.
OP3.10yP158: INHALED STEROIDS FOR THE
TREATMENT AND PREVENTION OF
ANASTOMOTIC GRANULATION STENOSIS IN A
CF PATIENT AFTER LUNG TRANSPLANTATION
S. van Koningsbruggen , K. Wassermann , K. Paul , D.1 2 3
Michalk , E. Rietschel1 1
Children’s Hospital, University of Cologne, Germany;1
2 IIIrd Medical Department, University of Cologne,2
Germany;
Pediatric Pulmonology, Charite, Humboldt University3
Berlin, Germany
Introduction: Airway complications such as tracheobron-
chial stenosis due to anastomotic scar formation or granu-
lation tissue remain a source of significant morbidity after
lung transplantation (LTX). The current incidence of such
complications is 12–15%.
Case report: We report a 12-year-old girl with cystic fibro-
sis who underwent bilateral lung transplantation 2.5 years
ago. Post-transplant complications were three rejection epi-
sodes and a chronic systemic infection with Mycobacterium
abscessus, requiring multiple daily iv-antibiotic treatments.
After almost 2 years of stable condition steroids were
tapered to 4 mg daily, when she developed gradually dete-
riorating shortness of breath verified by a drop in the forced
expiratory volume in 1 s (FEV1) and a progressive
decrease of quality of life. Bronchoscopy revealed near
complete occlusion of the left main stem anastomosis by
granulation tissue. The right main stem bronchus was also
substantially narrowed by granulation tissue, however, to a
lesser extent than the left. Subsequent to extensive debri-
dement using rigid broncoscopy, there was symptom relief
and normalization of the anastomosis. Endoscopic debri-
dement was required every 2–3 weeks. Histologic work up
of this tissue showed granulomas with fibrinoid necrosis
and polypoid granulation tissue. BAL cultures were positive
for Mycobacterium abscessus. Acute infection andyor
rejection was excluded as a reason for deterioration.
To prevent further recurrences of hyperplastic tissue causing
airway obstruction the patient was started on high dose
inhaled steroids (fluticason 2000 ygyd). For the past 4
months, she has reached a stable condition without relapse.
Discussion: The management of intrabronchial granulation
tissue after LTX includes debulking, endoscopic stent
placement, laser-, cryo- and brachytherapy. There is some
evidence that, apart from these invasive measures, topical
steroids may prevent recurrence and potentially suppress
the development of excess granulation and fibrotic stenosis
of susceptible anastomotic segments.
Conclusion: Symptomatic benign airway obstruction due
to intrabronchial growth of hyperplastic tissue after LTX
can be successfully treated or prevented with the aid of
topical (inhaled) steroids.
OP4.1yP12: THE EFFECT OF CHLORIDE ON
THE GATING BEHAVIOUR OF HUMAN CFTR
Z. Cai, D. Sheppard
Department of Physiology, University of Bristol, Bristol,
UK
The cystic fibrosis transmembrane conductance regulator
(CFTR) is a Cl channel with complex regulation. Recent
work by Wu et al. (J Biol Chem, 2001; 276: 6473–6478)
demonstrated that cytosolic electrolytes are essential co-fac-
tors for CFTR gating. In this study, we examined the effect
of Cl ions on the gating behaviour of CFTR using excised
inside-out membrane patches from mouse mammary epi-
thelial cells (C127 cells) stably expressing wild-type human
CFTR. Membrane patches were bathed either in symmet-
rical 147 mM Cl solutions or symmetrical 51 mM Cl solu-
tions and the intracellular solution contained PKA (75 nM)
and ATP (1 mM) at 37 8C; voltage wasy50 mV. Decreas-
ing the Cl concentration from 147 to 51 mM caused a
reduction in single-channel current amplitude, but no effect
on open probability (ns4–6). However, visual inspection
of single-channel traces suggested that channel gating was
altered. In 147 mM Cl, the burst duration was 162"3 ms,
ns6; whereas, in 51 mM Cl, burst duration was 144"7
ms, ns4; P-0.05 (mean"S.E.M.; Student’s t-test). To
better understand this effect, we examined gating kinetics
using a simple C1–C2–O model (Winter et al., Biophys J,
1994; 66: 1398–1403). Our data indicate that decreasing
the Cl concentration from 147 to 51 mM reduced the tran-
sition rate from C2 to C1 from 181"12 lys to 76"4 lys
(ns4–6; P-0.05). In contrast, the transition rate from O
to C2 was increased from 22"2 lys to 47"8 lys (ns4–
6; P-0.05). Other transition rates were not affected by
decreasing the Cl concentration. Thus, in the presence of
low Cl concentrations, CFTR prefers to reside in the short-
lived closed state (C2). This might explain the observed
reduction of burst duration observed in 51 mM Cl. Further
studies are required to identify the amino acid residues
responsible for this Cl-dependent gating.
Supported by the CF Trust.
OP4.2yP14: MIMETIC PEPTIDES AS BLOCKERS
OF CONNEXIN-DEPENDENT ATP RELEASE IN
EPITHELIAL CELLS
C. Folli , L. Musante , E. Caci , R. Ravazzolo , L.J.V.1 2 1 1
Galietta , O. Zegarra-Moran1 1
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ATP release is an autocrine mechanism that may regulate
chloride and sodium transport in airway epithelia. This
mechanism could be important in CF, in which alternative
chloride channels activated by ATP are functional.
Recent studies suggest that ATP may cross the cell
membrane through connexin hemichannels. We have inves-
tigated the expression of connexins in human cultured bron-
chial epithelia by RT-PCR, finding that connexin 26 and 43
are highly expressed. In HeLa cells overexpressing connex-
in 43, we found that basal ATP efflux, measured by a luci-
ferineyluciferase assay, was significantly higher than in
non-transfected cells (94.9"14.4 vs. 31.9"7 fmolymin,
P-0.001). Application of a hypotonic shock increased
ATP release in both types of cells. ATP efflux was also
measured in polarized bronchial epithelial cells. ATP
release on the apical side was eight times higher than on
the basolateral side (901"106 vs. 111"22 fmolymin) and
was also increased by hypotonic shock. To assess the role
of connexins, we designed two mimetic peptides with
sequence homology to an extracellular loop of connexins
(Gap26y63–75 and Gap26y57–75) and measured ATP
efflux through HeLa and epithelial cells with or without
incubation with different concentrations of peptides. The
longest peptide (Gap26y57–75) significantly decreased
ATP efflux in both types of cells. For example, after 1 h
incubation with 300 mM, basal efflux in airway epithelial
cells decreased to 255"58.2 fmolymin (P-0.05). These
data indicate that ATP is released through connexins and
that this mechanism can be inhibited by using peptides with
homology to an extracellular loop of these proteins. Exper-
iments are in progress to better characterize this mechanism
and its importance for ion transport and homeostasis in air-
way epithelia.
OP4.3yP16: DIRECT BLOCK OF THE CFTR CL
CHANNEL BY NIFLUMIC ACID
T. Scott-Ward , H. Li , A. Schmidt , D. Sheppard1 1 2 1
Department of Physiology, University of Bristol, Bristol,1
UK;
Centre of Human Genetics, National Institute of Health Dr2
Ricardo Jorge, Lisboa, Portugal
Niflumic acid is widely used to inhibit calcium-activated
Cl channels.
However, some studies suggest that it inhibits other Cl
channels including the cystic fibrosis transmembrane con-
ductance regulator (CFTR). To investigate the effect of
niflumic acid on CFTR, we used Ussing chambers and the
patch-clamp technique. For Ussing chamber studies, we
examined cAMP-stimulated, bumetanide-sensitive short-
circuit current (I ) of MDCK epithelia that endogenouslysc
express CFTR. MDCK epithelia were bathed in symmet-
rical 149 mM Cl solutions at 37 8C; voltage was 0 mV.
Addition of niflumic acid (200 mM) to the apical and baso-
lateral solutions decreased I by 55"3% (ns7), suggest-sc
ing that the drug might inhibit CFTR. To understand better
channel block, we studied CFTR Cl channels in excised
membrane patches.
For these experiments, the bath (internal) solution con-
tained 147 mM Cl, 0.3 mM ATP and 75 nM PKA at 37
8C and the pipette (external) solution contained 10 mM Cl;
voltage was y50 mV. Addition of niflumic acid to the
internal solution caused a concentration-dependent decrease
of CFTR Cl current with a K of 205"44 mM and a Hilli
coefficient of 0.95"0.03 (ns5); inhibition was readily
reversible.
Visual inspection of single-channel traces suggested that
niflumic acid caused a very fast flickery block of CFTR.
At y50 mV, niflumic acid decreased dramatically current
amplitude (control, y0.80"0.03 pA; niflumic acid (200
mM), y0.36"0.04 pA, ns5; P-0.01; Student’s t-test),
but was without effect on open probability (ns5; P)
0.35). These data suggest that niflumic acid interacts direct-
ly with CFTR to inhibit channel activity. They also indicate
that caution is warranted when using micromolar concen-
trations of niflumic acid to block calcium-activated Cl
channels because these concentrations of the drug will also
inhibit CFTR.
Supported by the CF Trust and NKRF.
OP4.4yP18: THE EFFECT OF R555K OR G550E
TRAFFIC RESTORING SUBSTITUTIONS UPON
A561E-CFTR PROCESSING
M. Roxo Rosa, F. Mendes, C.M. Farinha, S. Beck, M.D.
Amaral, D. Penque
Centro de Genitica Humana, Instituto Nacional de Sazde1
Dr Ricardo Jorge, Lisboa, Portugal;
Department Qummica e Bioqummica, Faculdade de Cijnc-2
ias, Universidade de Lisboa
The A561E mutation found in Portuguese CF patients caus-
es, like F508del, the loss of CFTR Cl channel functiony
by disrupting the biosynthetic processing so that the mutant
does not reach the plasma membrane.
Here, we investigated the kinetics of biosynthesis and proc-
essing of this mutant by metabolic labeling experiments fol-
lowed by immunoprecipitation in BKH cell lines stably
expressing A561E cDNA-CFTR. The results indicate that
A561E-CFTR is synthesized as an immature form (;150
kDa), which is rapidly degraded with similar kinetics as the
one described for F508del-CFTR. By contrast with wild-
type CFTR, A561E-CFTR fails to acquire complex N-
linked glycans since no mature form (;170 kDa) was
observed like for F508del-CFTR.
We also evaluated here whether the traffic restoring CFTR
substitutions R555K and G550E are able to correct the mis-
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processing defect of A561E, as described for F508del (1,2).
The pulse-chase assays followed by immunoprecipitation
showed that, in contrast to CFTR solely with A561E, the
conversion of the immature precursor to mature form is
readily apparent for either A561EyR555K or A561Ey
G550E CFTR. Densitometric analysis indicates that, for
both restoring substitutions, approximately 5–10% of the
immature A561E-CFTR present at the end of pulse under-
goes processing after 3 h of chase. These results suggest
that the traffic restoring effect of R555K and G550E is not
specific for F508del because they also partially correct
processing defect of A561E. We are further investigating
whether each of these substitutions also generates A561E-
CFTR functional Cl-channels at the cell surface. In sum-
mary, we identified another critical residue (A561) for the
acquisition of CFTR functional conformation.
1. Teem et al., Receptors and channels, 1996; 4: 63–72.
2. DeCarvalho et al., Pediatric Pumonol, 2000; Supp 20,
Abst 8
Work supported by PRAXIS XXI PySAUy55y96 and Sapi-
ens 99y357737y99 grants.
MRR, FM, CMF have FCT fellowship, We thank G.
Lukacs for BHK stable cells.
OP4.5yP19: THE CYSTIC FIBROSIS-
ASSOCIATED MUTATION L206W LOCATED IN A
TRANSMEMBRANE DOMAIN IMPAIRS CFTR
PROCESSING
J. Clain , J. Lehmann-Che , N. Arous , M. Goossens , A.1 1 1 1
Edelman , J. Teulon , P. Fanen2 3 1
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L206W mutation located in the third transmembrane seg-
ment of CFTR accounts for approximately 1% of French
Canadian cystic fibrosis (CF) chromosomes. The aim of
this study was to decipher the molecular mechanisms of
this mutation. Wild-type and mutant CFTRs were transient-
ly expressed in HeLa cells and we analyzed: (i) protein
processing by immunoprecipitation, pulse-chase experi-
ments, and immunocytochemistry; and (ii) chloride channel
function by a fluorescent dye assay and the single-channel
patch-clamp technique. Immunoprecipitation experiments
at steady-state revealed that the amount of the fully-gly-
cosylated band C was largely decreased for the mutant
wratio band Cy(band Bqband C): 37.5% vs. 92%; P-
0.001x, whereas pulse-chase experiments showed that the
kinetics of the core- and fully-glycosylated proteins were
similar to the wild-type. The processing defect was con-
firmed by the large decrease in cell surface staining eval-
uated by immunofluorescence microscopy.
To better characterise the L206W misprocessing, other
mutants were generated and analysed at steady-state. Our
data suggest that the presence of a polar side chain at res-
idue 206 was the misprocessing determinant. The cAMP-
dependant Cl conductance at the cell plasma membraney
showed a 40% decrease compared to the wild-type (P-
0.005), consistent with the CF phenotype. However, no dif-
ference in conductance (L206W: 7.62"0.61 pS, ns6;
wild-type: 7.18"0.36 pS, ns6) nor I–V relationships was
observed using the single-channel patch-clamp technique.
Altogether, our results indicate that the CF-associated
L206W mutation resulted in CFTR misprocessing because
of the polar property of the tryptophan side chain residue,
and did not impair the single-channel conductance although
located in a transmembrane segment supposed to line the
channel pore.
This work was supported by grants from INSERM and
Vaincre la Mucoviscidose.
OP4.6yP20: CFTR FUNCTION IN
HETEROZYGOTES SUBJECTS
I. Sermet-Gaudelus, M. Dechaux, B. Vallee, R. Marianov-´ ´
ski, J.L. Bresson, G. Lenoir, A. Edelman
INSERM U467, Federation de Pediatrie, Hopital Necker,´ ´ ´ ˆ
France
In recent years, the ability to detect cystic fibrosis (CF)
mutations and to measure transepithelial ion transport has
greatly expended the CF clinical spectrum. Of particular
interest are the CFTR mutation heterozygotes because of a
high prevalence in this population of CF-related symptoms
such as pancreatitis, disseminated bronchectiasis and aller-
gic bronchopulmonary aspergillosis. This suggests that
CFTR may have functional defect in heterozygotes.
To test this hypothesis, we explored nasal potential differ-
ence (NPD) and the anion conductive pathway in nasal
ciliated epithelial cells (NCC) of 30 CFTR mutations het-
erozygotes, nine control subjects and 50 CF patients. The
transmembrane Cl CFTR dependant conductive pathwayy
was measured by a halide sensitive fluorescent dye assay
SPQ (6-methoxy-N-39-sulfopropylquinolinium) after addi-
tion of the cAMP agonists according to the method decri-
bed by Verkman et al. (1).
NPD measurements evidenced a decreased hyperpolariza-
tion in response to isoproterenol in heterozygote patients
(mean Disuprelsy3 mv (y8–0) compared to control
subjects wmean deltaisuprelsy5 mv (y10 to y1) (Ps
0.004)x. Most CF patients did not demonstrate a response
to isoproterenol.
The percentage of NCC per subject displaying a cAMP-
stimulated anion conductive pathway was, respectively:
75% (50–100) in control subjects, 52% (0–100) in het-
erozygotes and 20% (0–100) in CF patients (Ps0.0001).
Our results suggest the existence of an abnormal cAMP-
regulated pathway in NCC of CFTR mutations heterozy-
gotes. This could explain the high prevalence of CF-related
manifestations in this population.
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(1) Verkman AS, Development and biological applications
of chloride-sensitive fluorescent indicators, Am J Physiol,
1990; 259: C375–C388.
OP4.7yP22: ALTERATION OF CL AND KI H
SWELLING-ACTIVATED CHANNELS BY CFTR
KNOCK-OUT IN PRIMARY CULTURES OF
RENAL TUBULES
H. Barriere, R. Belfodil, M. Tauc, C. Poujeol, P. Poujeol
Laboratoire de physiologie cellulaire et moliculaire, Univ-
ersiti de Nice Sophia Antipolis, Faculti des sciences de
Nice, Parc Valrose, France
Aim: Several studies demonstrated that cells expressing
mutated CFTR protein exhibit altered channel regulation.
Transgenic CFTRyyy mice were used to study alterations
of different Cl and K channels in renal cells.y q
Methods: Primary cultures of proximal convoluted (PCT),
distal convoluted (DCT) and cortical collecting tubules
(CCT) were obtained from wild type (CFTRqyq) and
CFTR knock-out (CFTRyyy) mice. Cl and K con-y q
ductances were characterised using whole cell clamp tech-
nique in 7-day-old cultures.
Results: In CFTRqyq mice, cAMP activated Cl andy
K conductances were measured in cultured DCT andq
CCT, but not in PCT cells. As expected, cultured DCT and
CCT from CFTRyyy mice did not exhibit cAMP-acti-
vated Cl and K conductances. Swelling-activated Cly q y
and K conductances were also studied. In cultured PCT,q
DCT and CCT from CFTRqyq mice, a hypo-osmotic
shock induced outwardly rectifying currents, which were
strongly inhibited by hyper-osmotic solution, and classical
inhibitors in three segments. Extracellular adenosine or
ATP mimicked the swelling-activated Cl and K conduc-y q
tance. A1 receptor antagonist DPCPX blocked the effects
of ATP, adenosine or hypotonic shock. Hypotonic shock or
adenosine produced a Ca influx which b swelling con-2q
ductances. In CFTRyyy mice, hypotonic shock failed to
induce Cl currents whatever the segment and failed toy
induce K currents in DCT and CCT. Perfusion of ATP,q
adenosine or ionomycin restored swelling-activated
conductances.
Conclusions: From CFTRqyq mice, swelling-activated
channels are controlled by A1 receptors and Ca influx2q
across cell membranes. Inactivation of CFTR suppresses
both swelling-activated conductances. This could be due to
the absence of adenosine production resulting from the loss
of ATP release.
UMR-CNRS 6548 Universiti de Nice Sophia Antipolis Parc
Valrose 06108 Nice, France.
OP4.8yP23: LOW TEMPERATURE EFFECT
UPON CFTR TURNOVER AND PROCESSING
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Reduced temperature has been widely described as a poten-
tial modulator of the endoplasmic reticulum (ER) quality
control responsible for the inefficient maturation of the cys-
tic fibrosis transmembrane conductance regulator (CFTR)
protein. In particular, it was described that low temperature,
conjugated with chemical chaperones, allows the relocation
of mutant F508del CFTR from the ER to the plasma
membrane. However, the mechanism by which low tem-
perature makes the cellular quality control become leaky is
not well understood. In the present study, we examined the
effect of low temperature (26 8C) upon CFTR biosynthesis,
turnover and processing.
CHO cells stably expressing wt- or F508del-CFTR were
incubated at 26 8C for either 24 or 48 h. Pulse-chase assays
(3 h pulse at 26 8C with wSxmethionine, chase at 0.5, 1,35
2 and 3 h either at 37 or 26 8C) followed by CFTR immu-
noprecipitation were then performed. Samples were ana-
lysed by 7% SDS-PAGE and autoradiographs analysed by
Imagemaster 1D. After quantification of bands B (immature
form) and C (mature form) of CFTR, results show that at
26 8C:
(1) the degradation rate of wt- and F508del-CFTR band B
is decreased relatively to cells at 37 8C, but for F508del-
CFTR only when chase is performed at 26 8C; and (2) for
F508del no band C is detected and for wt the efficiency of
conversion of band B into band C is increased by 3.5-fold
when chase is at 37 8C.
Low temperature thus seems to slow down the degradation
and processing rates of CFTR, leaving biosynthesis rate
apparently unchanged. Although the observed effects can
be partly due to a general decrease in the cellular metabo-
lism (degradation and processing but not biosynthesis), the
accumulated wt-CFTR immature form is a stable confor-
mation which is later, at 37 8C, converted into band C,
whereas F508del (only occuring at 26 8C) is an unstable
conformation form, which is rapidly degraded when cells
are shifted to 37 8C.
OP4.9yP24: LOW TEMPERATURE CORRECTION
IN CELLS EXPRESSING F508del CFTR
E. Caci , C. Folli , P. Fanen , R. Ravazzolo , O. Zegarra-1 1 2 1
Moran , L.J.V. Galietta1 1
Laboratorio di Genetica Molecolare, Istituto G. Gaslini,1
Largo G. Gaslini 5, Genova-16148, Italy;
Institut National de la Sante et la Recherche Medicale2 ´ ´
U.468, Service de Biochimie et Genetique, Hopital Henri
Mondor, AH-HP, 94010 Creteil, France
Up to date there is no effective therapy to correct the traf-
ficking defect caused by F508del. The aim of our work was
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to generate a cell model for F508del useful for biochemical
studies and drug screening. We have chosen the Fisher Rat
Tyroid cells (FRT) because of their ability to form polarised
epithelia when grown on permeable supports and because
it has no endogenous CFTR-like activity. We generated sta-
ble cell lines by transfecting FRT with the pTracer-CMV
vector containing F508del CFTR. Expressing clones were
studied in an Ussing chamber after permeabilization of the
basolateral membrane and application of a transepithelial
Cl gradient. Other investigators have shown that incuba-y
tion of F508del cells at low temperature increases the CFTR
expression at the cell surface although this behavior is not
always reproduced. Cells were incubated at 37 and 27 8C
for 48 h and CFTR activity was measured in short-circuit
experiments upon sequential stimulation with 500 microm-
olar Cpt-cAMP and 50 micromolar genistein, a flavonoid
which has been found to potentiate F508del activity.
F508del clones kept at 37 8C showed cAMP-dependent cur-
rents that were less than 1–2% that of wild-type CFTR
expressing cells. At low temperatures, one of the six clones
expressing F508del showed a cAMP-activated current of
97.45"30 mAycm , eight times larger than the value of the2
same cells kept at 37 8C. Genistein further increased the
current by 37%. The other clones showed a much smaller
degree of low temperature correction or no correction at all.
However, in these clones acute stimulation with genistein
increased cAMP-dependent current by four-fold. Our data
show that the low temperature correction of F508del mutant
is a variable phenomenon which could be dependent on
expressionyactivity of other cell proteins. This heteroge-
neity seems to modulate also the sensitivity to acute stim-
ulation with CFTR openers. Studies are in progress to
characterize these clones at the functionalybiochemical
level.
OP4.10yP25: TWO-DIMENSIONAL
ELECTROPHORESIS OF THE PROTEOME OF
NASAL AIRWAY CELLS
M. Roxo Rosa , M.D. Amaral , D. Penque1 2 1
Centro de Genetica Humana, Instituto Nacional de Saude1
Dr Ricardo Jorge, Lisboa, Portugal;
Department Quimica e Bioquimica, Faculdade de Cien-2
cias, Universidade de Lisboa, Lisboa, Portugal
Superficial cells from nasal mucosa, recovered by brushing,
are a useful native biological material in the assessment of
chronic respiratory diseases, including cystic fibrosis (CF)
(1). We have recently confirmed that ;87% of all nasal
cell type recovered by brushing from either CF and non-
CF patients are epithelial cells (2). By immunocytochem-
istry, using three distinct CFTR antibodies, we also reported
a decreasing gradient for the percentage of epithelial cells,
ciliated or not, with CFTR in the apical region from the
group of healthy controls (56%), F508del-carriers (42%)
to the CF patients homozygous for F508del (22%). In order
to observe the functional consequences of those findings to
the airway, we have generated protein expression profiles
of nasal brushing cells using two-dimensional (2D) elec-
trophoresis. Nasal brushing cells from healthy individuals
(ns6) were suspended in the isoelectric focusing (IEF)
lyses buffer and loaded onto immobilized pH 3–10 gradient
strips. After IEF, the strips were applied to 7–16% (wyv)
SDS-PAGE gradient polyacrylamide gels for a second
dimension run. The proteins in the 2D gel were visualized
by silver staining and the 2D patterns obtained were ana-
lyzed by computer software. No significant differences
were observed among the 2D-MAPs of nasal cells proteins
isolated from the same individual more than once at a dis-
tinct time, neither from the six different healthy individuals.
The 2D-gel electrophoresis of nasal brushing cells from CF
patients homozygous for F508del is under progress to be
compared with those of healthy individuals. Changes in the
abundance or position in the 2D-gel patterns will suggest
an involvement of those proteins in the CF pathology.
1. Danel C, et al., Am J Respir Crit Care Med, 1996; 153:
362–368.
2. Penque D, et al., Lab Invest, 2000; 80: 857–868.
Work partially supported by PCOTIy1999yMGIy35737
and POCTIyMGIy40848y2001 research grants. MR is a
recipient of PRAXIS BDy19869y99 doctoral fellowship.
OP5.1yP335: TOWARDS A ‘PAIN FREE’
TRANSITION: THE INTRODUCTION OF A
PATIENT CONTROLLED HANDBOOK
J. Dyer , K. Fare , K. Wedlock1 2 3
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Adolescence is a time of rapid change physically and emo-
tionally. In combination with chronic illness, the process of
transition into adult life proves particularly difficult. Tran-
sition of CF patients from children’s services to adult care
in even the most organised centres can be a challenge to
all concerned.
To enhance transition to our recently established adult serv-
ice, we have taken the opportunity to audit practice against
national standards and survey patient views on how to
improve the process. Our aims were to ensure that national
and local standards were met and identify the needs of
patients in relation to transition. All patients in the transi-
tion clinic (in their last year at the children’s centre), plus
those who had been transfered within the last year, were
approaching ns18, and 12 agreed to be interviewed.
In general, it was felt that the process could be improved
by better definition of the transition period, more patient
control in the process and allocation of a key team member
to guarantee a smooth handover.
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Our results combined with previously published evidence
were used to inform a patient hand book. To allow a gradual
transition period, the handbook is introduced at the age of
13 years. The handbook outlines issues surrounding CF
management. These include self management of treatment
such as IV antibiotics and physiotherapy; fertility and adult
relationships; plans and prospects; and psychosocial issues
including education and employment. It affords the oppor-
tunity and direction to ensure all the issues that need to be
discussed during the transition period of 3–4 years have
been addressed satisfactorily prior to transfer. Individual
patient concerns can be highlighted and managed
appropriately.
OP5.2yP340: GENDER AND INTER-PERSONAL
RELATIONSHIPS IN CYSTIC FIBROSIS: DO MEN
AND WOMEN DIFFER IN THEIR SELF-RATINGS
ON RELATIONSHIP ISSUES?
L. Gee , J. Abbott , S.P. Conway , C. Etherington , A.K.1 1 2 2
Webb3
Faculty of Health, University of Central Lancashire, Pres-1
ton, PR2 2TQ, UK;
Adult CF Unit, Seacroft Hospital, Leeds, L514 6UH;2
Adult CF Unit, Wythenshawe Hospital, Manchester, M233
9LT, UK
It has been reported that there are differences in clinical
outcome for males and females with cystic fibrosis (CF)
and related factors regarding disease status that may affect
relationship issues. The present study aims to examine rela-
tionship difficulties in men and women with CF. This study
utilises four items from the Cystic Fibrosis Quality of Life
Questionnaire (CFQoL)* which ask respondents to self rate
the following four statements: (1) My CF makes it difficult
for me to establish intimate relationships; (2)My CF makes
it difficult for me to maintain intimate relationships; (3) I
find that my CF interferes with me having a satisfactory
sex life; (4) It concerns me that I may not be able to have
anyyhave more children. Two hundred and twenty-three
adolescents and adults with CF completed the four items
(102 men and 121 women). Differences between men and
women were analysed using independent groups t-tests. No
differences were found for age or FEV1. A significant dif-
ference was found for BMI with females having a lower
BMI (Ps0.04). Significant differences were found for
statements regarding establishing and maintaining intimate
relationships (Ps0.027 and Ps0.042) with males dem-
onstrating more difficulties. There were no differences
between men and women for items regarding difficulties
with sex life or concerns about having children. However,
30% of men and 26% of women reported difficulties with
their sex life and 71% of men and 73% of women expressed
concerns about their ability to have children. In conclusion,
issues surrounding intimate relationships and reproduction
are of concern to both men and women with CF. Men with
CF are significantly more likely to be concerned about ini-
tiating and maintaining intimate relationships. It is, there-
fore, imperative that patients are offered support with
disease related issues that impact on relationship issues,
including optimising their ability to reproduce.
* For copies of the CFQoL and scoring equations, contact
J. Abbott (e-mail: jabbott@uclan.ac.uk).
OP5.3yP338: GENDER DIFFERENCES IN
HRQOL AMONG PATIENTS WITH CF
A. Quittner, A. Modi, M. Davis
University of Florida, Gainesville, FL, USA
Significant differences in morbidity and mortality have
been found between males and females with cystic fibrosis
(CF), with males living approximately 3–4 years longer
than females. Although several reasons for this difference
have been proposed (e.g. nutritional status), this ‘gender
gap’ in survival has not yet been explained. One area that
has received little attention is the psychosocial impact of
these differences in health outcomes. The aim of the current
study was to identify gender differences across specific
dimensions of health-related quality of life (HRQOL) and
determine when these gender differences emerge across the
developmental trajectory. The Cystic Fibrosis Questionnaire
is a reliable, valid, disease-specific HRQOL instrument
assessing several domains of functioning for individuals
with CF (e.g. physical, social, body image). Participants
included 541 individuals (51% female) with CF. The sam-
ple was divided into four age groups: 6–13, 14–17, 18–
31 and 31–53. It was hypothesized that statistically
significant gender differences would be found on the CFQ,
with the largest differences emerging in adolescence. MAN-
OVAs were conducted on the scaled scores of the CFQ by
age group. For younger children, females reported signifi-
cantly lower HRQOL (Hotelling’s Ts45.7; P-0.05) on
the Physical, Treatment Burden, and Respiratory scales. For
adolescents, females reported higher HRQOL (Hotelling’s
Ts65.6; P-0.05) on Body Image and Weight, but higher
HRQOL for Vitality. Similar differences (Hotelling’s Ts
40.5; P-0.05) were found for individuals 18–31 years,
with females also reporting lower HRQOL on Physical
functioning. Among the oldest age group, t-tests were con-
ducted, revealing few gender differences (Physical and
Emotional), likely reflecting the ‘survivor’ status of those
adults whose life expectancy has exceeded the median. In
sum, HRQOL adds valuable information to the health out-
come data on gender differences and suggests areas for
intervention.
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OP5.4yP329: PARENTAL COPING AFTER A
NEW DIAGNOSIS OF CYSTIC FIBROSIS:
BASELINE CHARACTERISTICS AND SUMMARY
STATISTICS FOR A PROSPECTIVE STUDY
C. Glasscoe , J. Hill , R. Smyth , G. Lancaster1 1 2 1
University Department of Child Mental Health, Royal Liv-1
erpool Children’s Hospital-Alder Hey;
Department of Child Health, Institute of Child Health,2
Royal Liverpool Children’s Hospital-Alder Hey, UK
Aims: There are no prospective studies that examine paren-
tal coping from the point of diagnosis of cystic fibrosis
(CF), few studies with a matched control group, and few
studies that are conceptually based such that a clinical
application emerges from the findings. This study aims to
test a model of parental adaptation to a new diagnosis of
CF. The model contends that diverging beliefs and modes
of responding are less likely to yield a co-ordinated
response and more likely to be associated with psychosocial
distress.
Method: A pilot case-control study of 30 matched pairs of
parents comparing study (CF), and control groups over a
9-month period with baseline and follow-up data. Couples
in the study group have recently received a diagnosis of CF
and couples in the control group are matched for age, sex
and position in the family of the affected child. Baseline
characteristics are reported together with summary statistics
for locus of control beliefs, parental role division, depres-
sion and partner satisfaction.
Results: Sample characteristics demonstrate that the groups
are equivalent at baseline. Fathers of children with CF have
significantly higher levels of depression and partner dissat-
isfaction than fathers of control children and there is a non-
significant trend in the same direction in mothers.
Depression and partner satisfaction are inversely related in
CF parents (Spearman rhosy0.514, Ps0.004 for mothers
and Spearman rhosy0.504, Ps0.007 for fathers) There
are no such associations in parents of control children.
Conclusions: Group equivalence at baseline suggests this
sample offers a sound basis to examine changes over time
of family adaptation to having a child with CF. Differences
in correlations between depression and partner satisfaction
in the two groups may indicate a protective function of a
supportive relationship in stressed parents. Prospective
analyses will be used to clarify interpretations of these
cross-sectional associations.
OP5.5yP328: PATIENT INFORMATION-GIVING
THEM WHAT THEY WANT, WHEN THEY WANT
IT
J. Dyer , K. Wedlock1 2
CF Clinical Nurse Specialist;1
CF Clinical Nurse Specialist, Bristol Royal Hospital for2
Children, Bristol, UK
There are many excellent sources of patient literature avail-
able regarding cystic fibrosis pathophysiology, treatment
and care. However, some families in particular parents of
the younger age group find this information fragmented and
not fully addressing their needs. We have consulted with
our patients and families to determine their views on the
current literature in circulation and how to improve it. Com-
mon concerns are that leaflets do not give enough infor-
mation on some aspects, provide irrelevant or inappropriate
information (usually too much about the complications of
advanced disease) or that information does not ‘match’ the
care practises of their CF centre. This can produce undue
worry and confusion.
Families have expressed a desire to have staged information
tailored to their individual needs, in patient friendly terms
that answer those questions most frequently raised. We have
introduced a range of ‘add to’ literature that can be stored
in a personal folder provided, building into an individual
portfolio of information as and when patients require or
request it. Each sheet of information covers just one aspect,
for example ‘How to look after your port’ or ‘Bugs and
Anti-bugs’. This system means that individual sheets can
be updated and replaced as developments or changes are
made in CF management without making whole booklets
redundant. Patients are able to relate the information to
national standards in general and to the current practice of
their CF centre.
OP5.6yP327: YOUR CHILD HAS CYSTIC
FIBROSIS!
F. Thornhill , A. Dewar1 1
Paediatric Department, Poole Hospital NHS Trust, UK1
Parents of children with cystic fibrosis have strong mem-
ories of the day their child was diagnosed. Breaking this
kind of news is difficult for all concerned and medical staff
receive little training in how to do it well.
Aim: To assess parents views and experiences so that we
can improve the practice of our team in breaking news to
families in the future.
Methods: A confidential questionnaire was distributed to
35 families within the East Dorset area.
Results: Parents recall of the moment of diagnosis was very
clear in 23 cases and quite clear in 12 cases. Sixteen chil-
dren were over 13 years of age at the time of the study,
and age at diagnosis ranged from pre-natally to 10 years.
Twenty-six parents suspected a medical condition prior to
diagnosis, four families had a younger child born before
their CF child was diagnosed and three were pregnant at
the time of diagnosis. Twenty-four of 35 parents had both
partners present at diagnosis and only 23 were given an
opportunity to have a friend or relative with them. Twenty-
one were told in a private room, but six were told on the
open ward and six were told by telephone. Twenty-one par-
ents felt they were given enough time and 17 felt they were
given an opportunity for questions. Twenty-one parents felt
S77Journal of Cystic Fibrosis 1 (2002) S59–S77
the CF consultant should give the diagnosis, six felt it
should be their General Practitioner and 32 felt the CF
nurse specialist should be present.
Conclusions: Parents recall of the way in which bad news
is broken is extremely good and can have an impact on
families and future relationships. We can learn from our
own patients ways of improving how we manage the proc-
ess. Parents appreciate honesty, but all want time for ques-
tions, written information and to know whom their support
team will include. Many aspects of our current management
were commended but this study provides good evidence
upon which to base future practice.
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Presented at the International Physiotherapy Group (IPGyCF) Meeting
Training programmes in Scandinavia
S. Gursli
National Center for Cystic Fibrosis, Ullevaal University
Hospital, Kirkev. 166, 0407 Oslo, Norway
Background and aims: Physical exercise has been a part
of the treatment in cystic fibrosis since the early 1980s. The
focus has been on improvement in working capacity and
lung function. Physical exercise can be used as an Airway
Clearance Technique, combining principles from endurance
training with principles from airway clearance techniques.
The aim of this presentation was to focus on physical exer-
cise with regard to the following principles: FIT (frequency,
intensity, time), and LMR (loosen, move, remove bronchial
secretions).
As a part of the project: ‘Chest physiotherapy and airway
clearance’, guidelines for chest physiotherapy in CF have
been established, which link treatment to age, degree of
obstruction and amount of secretions. Physical exercise
used in airway clearance is a dynamic change between
activity to loosen secretions, and rests to checkyremove it.
Methods: Methods from quality development and quality
assurance have been used in a National working group to
identify problems and solutions. The work is further based
on literature review, visit to centers, and clinical observa-
tions of responses in individual treatments.
Results: Adjusted to the individual patient, physical exer-
cise can fulfil the quality-criteria for treatment to be gentle,
efficient, motivating and self supporting (GEMS).
Alternative ways of using physical exercise in regard to
airway clearance:
● Preventive (FIT"LMR);
● Loosen and remove secretions during the exercise
(LMR"FIT);
● Loosen secretions, move and remove it after exercise
(FITyLyMR);
● Airway clearance before physical exercise (LMRyFIT).
Conclusions: Physical exercise is used as ACT, and is the
first choice if possible. Physical exercise can be used in the
treatment to cover both principles, but not necessarily at the
same time. In some patients, physical exercise will not rep-
resent a gentle and efficient way of clearing the lungs. Indi-
vidual adaptations have to be considered. The patient needs
to participate in identifying solutions to be able to adhere
to daily treatment.
Evidence based physiotherapy practice—an
overview
Esta-Lee Tannenbaum, Clinical Specialist Physiotherapist,
Great Ormond Street Hospital for Children, London, UK
Evidence-based medicine is the conscientious, explicit and
judicious use of current best evidence in making decisions
about the care of individual patients . An integration of1
clinical expertise and evidence from systematic research
enables clinicians to provide the highest standard of care.
Physiotherapists caring for patients with cystic fibrosis
(CF) make decisions regarding treatment based on the age
of the patient and severity of disease, yet the evidence upon
which these decisions are based is of variable quality. Cur-
rent practice relies mainly on conventional sources of infor-
mation such as personal experience, peeryexpert advice or
medical textbooks, and although extremely useful, these
may be subject to bias.
Systematic reviews of physiotherapy for CF undertaken to
date have failed to draw conclusive evidence regarding the
efficacy of airway clearance interventions . This may, in2,3
the main, be due to the quality of studies available for anal-
ysis. It is important that the balance between evidence and
traditionyclinical expertise is redressed in order to equalise
the basis upon which clinical decisions are made. In order
to do this, trials need to be of robust scientific methodology
with outcome measures which are repeatable, reliable and
meaningful.
Research evidence provides a common foundation upon
which physiotherapists should collaborate in order to imple-
ment findings to clinical practice. However, these recom-
mendations need to be tailored to the individual patient.
References:
Sackett DL, Rosenberg WM, Gray JA. et al. Evidence
based medicine: what it is and what it isn’t. Br Med J 1996;
312: 71–72.
Thomas J, Cook DJ, Brooks D. Chest physical therapy
management of patients with cystic fibrosis: a met-analysis.
Am J Respir Crit Care Med 1995; 151: 846–850.
van der Schans C, Prasad SA, Main E. Chest physiotherapy
compared to no chest physiotherapy for cystic fibrosis
(Cochrane review). In: The Cochrane library, 2,
2001.Oxford: Update Software.
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P2
TISSUE-SPECIFIC GENE TARGETING OF CFTR
GENE IN MOUSE LUNG BY CREyLOX SYSTEM
G. Bertin, L. Hasseine, C. Poujeol, P. Poujeol, M. Tauc
CNRS UMR 6548 Laboratoire de Physiologie Cellulaire et
Moleculaire´
Cystic fibrosis transmembrane conductance regulator
(CFTR) is a chloride channel implicated in cystic fibrosis
and localized in the apical membrane of various tissues
including lung. Since complete gene inactivation of CFTR
leads to rapid postnatal death in mouse, consequences of
CFTR-deficiency cannot be addressed. In fact, it does not
exist animal models that reproduce the major pulmonary
disease encountered in cystic fibrosis. To overcome this
problem, we have decided to engineer a transgenic mouse
expressing a specific inactivation of CFTR in lung. To inac-
tivate CFTR we used the promoter of mouse Clara cell
secretory protein which is specific of the Clara cells (which
express CFTR) in the airway epithelium.
Firstly, 2.1 kb of the mouse promoter have been cloned
upstream of Cre gene and microinjected in mouse fertilized
eggs pronuclei. The first mice obtained are being exten-
sively characterized for tissue specific expression. A second
transgenic mouse strain is created by electroporation of ES
cells with a transgene containing a floxed CFTR gene.
Eight kilobases of the CFTR gene have been cloned and
two loxP sites were added to flank CFTR gene exon 11
together with selection genes (Thymidine kinase and
NeomycineR).
The inactivation of CFTR in lung will be obtained by the
mating of this two different transgenic mouse lines. Such a
model will be useful for the study of infectious and inflam-
matory processes and could help in therapeutic studies.
P3
EVALUATION OF DIFFERENT CFTR
ANTIBODIES FOR IMMUNOLOCALIZATION OF
CFTR IN NASAL EPITHELIAL CELLS FROM
HEALTHY AND CF PATIENTS
I. Carvalho Oliveira , A. Efthymiadou , M.D. Amaral ,1,4 1,2 1,3
M. Tzetis , E. Kanavakis , R. Malhos , D. Penque2 2 4 1
Centro de Genetica Humana, Instituto Nacional de Saude1
Dr Ricardo Jorge, Lisboa, Portugal, Department of Medi-2
cal Genetics, University of Athens, Aghia Sophia Chil-
dren’s Hospital, Athens, Greece, Departamento de3
Quimica’e Bioquimica, Departamento de Biologia Vegetal,4
Faculdade de Ciencias de Lisboa, Universidade de Lisboa,
Portugal
The intracellular detection of CFTR in native tissues is one
of the major issues concerning the study of mutation effects
on the CFTR processing and trafficking as well the evalu-
ation of therapeutic strategies regarding the restoration of
those effects.
In this study, we compared by immunofluorescence tech-
nique, using various fixation procedures, a panel of ten dif-
ferent CFTR antibodies (Abs: 169, 1061, M13-1, CC24-R,
MP-CT1, M3A7, MM13-4, L12B4, MAB25031,
MAB1660, Lis1) for the intracellular localization of CFTR
protein in freshly nasal epithelial cells collected by brushing
from healthy individuals and CF patients homozygous for
the most common CF mutation, F508del.
The results indicate that: (1) the CFTR signal patterns
obtained for each of those antibodies did not alter signifi-
cantly when cells were fixed by acetone, formaldehyde or
formaldehyde plus methanol; (2) most of the Abs are capa-
ble of detecting CFTR in the apical region of tall columnar
epithelial (TCE) cells isolated from either healthy or CF
patients as, previously demonstrated by us using the 169,
MATG1061 and M13-1 Abs (Penque et al. 2000, Lab
Invest 80, 857–9; 3). In opposition, the M3A7 and MM13-
4 Abs detect, almost exclusively, the intracellular CFTR of
the majority of TCE cells isolated from healthy individuals
but not of the TCE cells from CF patients.
Indeed, a very fewer CF TCE cells present intracellular
signal with those CFTR Abs. It seems that, those Abs react
mostly with the intracellular CFTR that escape degradation
by the ER quality control.
Work partially supported by PCOTIy1999yMGIy35737
and POCTIyMGIy40848y2001 research grants. The
authors wish to thank CF doctors, patients with CF and
their families for their cooperation, Dr W. Guggino (Bal-
timore, Maryland) for 160 Ab, Dr de Jonge H. (Rotterdam,
Netherland) for CC24-R, Dr R.L. Dormer (Cardiff, UK)
for MP-CT1, Transgene (Stransbourg, France) for
MATG1061 Ab and to Carolina Cunha for technical
assistance.
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P4
CHARACTERISATION OF Ca -STIMULATED2H
Cl SECRETION BY A HUMAN BRONCHIALI
CELL LINE
K. Bernard, S. Lindenthal, S. Bogliolo, O. Soriani, J.
Ehrenfeld
CNRSyUMR 6078 Villefrancheymer
The human bronchial cell line 16HBE14o- was used as a
model of airway epithelial cells to determine factors affect-
ing the Ca -dependent Cl secretion. When grown on per-2q y
meable supports these cells form a tight and polarised
monolayer. The transepithelial Cl secretion was measuredy
using the short-circuit current (I ) technique and the Kqsc
permeability was assessed using Rb efflux. The resting86
transepithelial resistance of the monolayer was 930"126
V cm (ns25) and the resting current was 0.6"0.2 mAy2
cm (ns25). Ionomycin and ATP both stimulated I with2 sc
different profiles. A transient peak was observed with both
agents (24.2"4.1 and 49.2"5.9 mAycm ; ns4 for iono-2
mycin and ATP, respectively). In contrast, a plateau phase
(4.8"0.8 mAycm ; ns4) following the initial peak was2
only observed with ionomycin. The use of anion channel
inhibitors confirmed the presence of at least two compo-
nents mediating Cl secretion: CFTR (glybenclamide sen-y
sitive) and CaCC (DIDS sensitive). We found that the
electrochemical gradient for Cl through the apicaly
membrane was determinant for overall Cl secretion.y
Indeed, a specific K channel inhibitor (TPA) blockedCa( )
Cl secretion and the transport could be restored by ay
favourable electrochemical Cl gradient. The presence ofy
K channels located on the basolateral membranesCa( )
(BLM) was confirmed by Rb efflux. Our study demon-86
strates also the presence of a significant apical K per-q
meability that could be stimulated by Ca and blocked by2q
TPA. An increase of intracellular cAMP enhanced the iono-
mycin-induced I peak by 80.8"30.5% (ns4) withoutsc
significant change of the plateau phase. This stimulation
was not due to the activation of BLM K channels sinceCa( )
Rb efflux were insensitive to intracellular cAMP. Our86
findings suggest a direct regulation of CaCC by cAMP.
P5
QUANTITATIVE ASSESSMENT OF BRONCHIAL
EPITHELIAL CELL POPULATIONS IN CONTROL
SUBJECTS
A. Mariassy , B. Hyma1 2
Nova Southeastern University, Ft. Lauderdale, FL, Dade1 2
County Medical Examiners Office, Miami FL, USA
Pathogenesis of respiratory disease is reflected in the
remodeling of the airway wall and the lining mucosa. There
is a singular lack of baseline quantitative data concerning
the airway epithelial cell populations in control subjects.
Aim: We aim to quantify the bronchial epithelium of
healthy subjects and present here the assessment of the epi-
thelial cell abundance in the bronchi of respiratory disease
free subjects.
Methods: We used the Image-Pro. Plus, a morphometry
program on digitized images of paraffin embedded H&E
and PAS stained tissues. Random, stratified samples were
taken at autopsy from the airways of 9 male and 9 female
individuals who died of trauma not involving thorax. None
of the subjects had a history of chronic bronchitis. The air-
way basement membrane lengths, thickness, epithelial
heights, and differential epithelial cell counts were deter-
mined in 69 mm of 78 bronchi ranging in calculated airway
diameter from 3 to 6 mm.
Results: The bronchial surface epithelium consisted of a
population of ciliated, 53.4"5.9% ("S.D.), mucous,
9.1"3.2% ("S.D.), intermediate, 13.4"5.7% ("S.D.),
basal, and 23.4"5.5 ("S.D.), and migrating cells
2.5"2.0% ("S.D.). The epithelial height, ranged from 22
to 64 mm, basement membrane was 3.4"3.9 mm thick.
Conclusions: Bronchial epithelium exhibits a considerable
variation in the epithelial cell populations as indicated by
the relatively high S.E.M. Nevertheless, a quantitative base-
line of data have been presented for interpretation of the
airway remodeling in disease affected bronchi. We are cur-
rently investigating the bronchial epithelial cell and sub-
mucosal gland secretions and their involvement in the
airway remodeling as related to the pathogenesis of asthma
and cystic fibrosis.
P6
EFFECT OF COLCHICINE ON CHLORIDE
SECRETION BY CYSTIC FIBROSIS CELL LINES
A. Dragomir, G.M. Roomans
Department of Medical Cell Biology, Uppsala University,
Box 571, S-75123, Uppsala, Sweden
Colchicine has long been known and used for its anti-
inflammatory effects. Recently colchicine was proposed as
an alternative drug for the alleviation of chronic inflam-
mation symptoms in cystic fibrosis (CF) patients. It is also
known that colchicine can upregulate the multidrug resis-
tance (MDR) proteins which are closely related both evo-
lutionary and functionally to the cystic fibrosis
transmembrane conductance regulator, the defective protein
in CF. Our aim was to investigate whether the chronic expo-
sure of CF cell lines with colchicine can affect their ability
to transport chloride in response to cAMP.
We have used the CFSMEo- cell line homozygous for the
deltaF508 mutation and its normal analogue, the Calu3 cell
line. Colchicine-resistant clones were selected by growing
cells in medium containing nanomolar concentrations of the
drug, and steadily increasing the concentration after each
passage, up to 10 nM. Quantitative Westernblot was used
to determine the amount of MDR protein present in each
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clone. Chloride efflux was determined by loading the cells
with the chloride-sensitive fluorescent dye MQAE and
measuring the changes in cell fluorescence during cells per-
fusion with chloride free solutions. The basal efflux was
compared with the stimulated efflux in the presence of for-
skolin and isobutyl-methylxanthine.
Colchicine-resistant clones had a higher expression of MDR
proteins compared to the untreated cells, but a reduced
amount of total cell protein. Their morphology was slightly
affected, the treated cells being larger than the controls. The
basal chloride efflux of the treated cells increased by 50%
compared with the untreated cells, while for the cAMP-
stimulated Cl-efflux there was no significant change. This
may suggest that the colchicine treatment may affect the
ion permeability of the cell membrane but does not specif-
ically increase cAMP-induced chloride efflux. Higher con-
centrations of colchicine are under investigation.
P17A
PROTEOMIC APPROACH IN THE ANALYSIS OF
PROTEIN EXPRESSION AFFECTED BY THE
CYSTIC FIBROSIS GENE
B.K.A. Thomson, M.T. Clandinin
Nutrition and Metabolism Research Group, Department of
Agricultural, Food and Nutritional Sciences and Depart-
ment of Medicine, 4-10 Agriculture-Forestry Centre, Uni-
versity of Alberta, Edmonton, Alberta, Canada
The protein identified as responsible for cystic fibrosis (CF)
is a cAMP-activated Cl channel (CFTR). To identify ify
other proteins are expressed to a different degree in CF
cells, a proteomic, approach was used to determine quan-
titative differences in proteins expressed between
CFTE29o- (dF508ydF508) and 9HTEo- (wild-type) tra-
cheal epithelial cells grown in culture. Cells were grown in
minimum essential medium for 7 days until confluent. Total
cell homogenates were isolated and pelleted and cellular
proteins were quantitated then separated using high reso-
lution two-dimensional gel electrophoresis. The use of
immobilized pH gradient strips of pH 6–11 showed repro-
ducible and significant differences in protein expression,
specifically between pH 6 and 8. Using Adobe Photoshop
to visually scan for quantitative protein differences, the
expression of 6 proteins was upregulated in wild-type cells
and 3 proteins were upregulated in CF cells. While defin-
itive protein identification will require MALDI-TOF and Q-
TOF mass spectrometry, proteomics clearly indicates that
expression of the CF gene product may alter the expression
of other proteins in the cell that might explain cellular
mechanisms for this disorder.
P21
LEVELS OF CFTR TRANSCRIPTS BEARING
NONSENSE MUTATIONS IN NATIVE TISSUES
A. Ramalho , S. Beck , D. Penque , H. Seydewitz , M.1 1 1 2
Mall , M.D. Amaral2 1,3
Centro de Genetica Humana, Instituto Nacional de Saude,1 ´ ´
Lisboa, Portugal, Universitats-Kinderklinik Freiburg, Frei-2 ¨
burg, Germany, Dept Quımica e Bioquımica, Faculdade de3 ´ ´
Ciencias da Universidade de Lisboa, Portugalˆ
From the 996 mutations reported in the CFTR gene 13%
are nonsense mutations and approximately 5% of all CF
chromosomes cause a premature stop codon in the respec-
tive transcript due either to a stop codon or to a frameshift.
The fate of the majority of transcripts bearing these muta-
tions is its selective degradation by the cellular control
mechanism, termed nonsense-mediated decay.
For a better understanding of the consequences of these
mutations, we have analysed RNA samples from the colon
of 9 CF patients and nasal epithelium of 1 CF patient all
bearing F508del in one allele and one of 6 different non-
sense or frameshift mutations in the other allele, namely:
Q39X (2 patients), G542X (1p-nasal epithelium), R553X
(1 p) (2 p), 2183AA™G, 3905insT (2 p) and W1282X
(1 p).
Total RNA was extracted and used for RT-PCR amplifica-
tion in the region of exons 8–10 with primers previously
described, being the forward Fam-labeled. The two tran-
scripts present in the RT-PCR products were quantitatively
analysed by a sensitive and reproducible method based on
automatic sequencer analysis. The extent of degradation of
nonsense transcripts was estimated relatively to F508del-
mRNA (assuming that if they were wt-alleles they would
yield 100% transcripts) and based on previous estimate of
F508del- vs wt-transcripts in which the former was shown
to be expressed at 87.1"6.3% (ns30) of wt. The esti-
mated percentages of degradation are
Mutation Q39X G542X R553X 2183AA™
G
3905insT W1282X
%
Degradation
y
12%,
y7%
86% 40%,
50%
78% 49%,
56%
61%
These results demonstrate that in the colon, as in other
tissues, there is no correlation between the degradation
levels of nonsense CFTR transcripts and the position of
stop codons along a 39™59 gradient. Higher levels of
Q39X transcripts (7–12%) vs. wt-transcripts opposes
such a correlation. This data may have impact for the
use of aminoglycoside antibiotic therapies aimed at
restoring CFTR function in patients with CFTR
nonsense or frameshift mutations by reading through the
premature stop codons.
P36
LACTOSYLATED POLYETHYLENIMINE AS AN
EFFICIENT VECTOR FOR GENE TRANSFER
INTO CYSTIC FIBROSIS AIRWAY EPITHELIAL
CELLS
S. Grosse , Y. Aron , L. Bedouet , A.-C. Roche , M.1 1 2 2
Monsigny , I. Fajac2 1
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Lab. Physio. Resp., Faculte Cochin, Paris, France, Gly-1 2
cobiologie-VTI, CBM-CNRS, Orleans, France
Polyethylenimine (PEI) is a synthetic cationic polymer
with endosome buffering capacity that mediates efficient in
vitro and in vivo gene transfer into various mammalian
cells. In order to target airway epithelial cells, we have
developed lactosylated PEI and studied its ability to transfer
genes into immortalized cystic fibrosis airway epithelial
cells (sigmaCFTE cells). The requested amount of lacto-
sylated or sugar-free PEI (25 kDa; branched form) was
complexed to a plasmid (2.5 mg) encoding the green flu-
orescent protein in order to obtain a NyP ratios10.
SigmaCFTE cells were incubated in the presence of com-
plexes for 1 h at 370 8C and the number of transfected cells
was determined by flow cytometry 24 h later. Intracellular
trafficking of complexes was studied using lactosylated or
sugar-free fluorescein-labeled PEI complexed to a biotiny-
lated plasmid DNA and confocal microscopy. After a single
transfection, lactosylated PEI and sugar-free PEI allowed
an efficient gene transfer into 33.7"4.3% and 15.5"3.2%
of cells, respectively (P-0.05). After three transfections
performed daily using lactosylated PEI as a vector,
60.8"1.7% cells were transfected.
As assessed by flow cytometry, the cellular uptake of lac-
tosylated complexes was greater than that of complexes
made with sugar-free PEI. Endosomal, lysosomal or nuclear
locations of both types of complexes was similar. Our
results show that lactosylated PEI is more efficient for gene
transfer into immortalized cystic fibrosis airway epithelial
cells than sugar-free PEI. As intracellular trafficking was
similar for both complexes, the greater gene transfer effi-
ciency of lactosylated PEI compared to that of sugar-free
PEI may be attributed to the greater cell uptake of lacto-
sylated complexes. The efficiency of gene transfer based
on lactosylated PEIyplasmid complexes into human pri-
mary airway epithelial cells and in vivo in mice are under
investigation.
Supported by Association Vaincre la Mucoviscidose.
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GENE TRANSFECTION ACTIVITY OF
PEGYLATED AND NON-PEGYLATED
LIPOPLEXES AFTER EXPOSURE TO
COMPONENTS OF CF MUCUS
N. Sanders , S. De Smedt , S. Cheng , J. Demeester2 1 2 1
Laboratory of General Biochemistry and Physical Phar-1
macy, Faculty of Pharmacy, Ghent University, Ghent, Bel-
gium, Genzyme Corporation, Framingham, MA, USA2
In general, lipoplexes are positively charged and built up
by cationic lipids that bind the therapeutic pDNA by elec-
trostatic interactions. Consequently, negatively charged CF
mucus components might bind to the lipoplexes and neu-
tralize their surface charges, which could cause aggregation
of the lipoplexes and release of therapeutic pDNA.
We examined the influence of CF mucus components and
CF sputum on the physicochemical stability and gene trans-
fection activity of cationic DOTAP lipoplexes and neutral,
pegylated GL67 lipoplexes, which were previously used in
CF clinical studies. Exposure of the cationic DOTAP lipo-
plexes to the CF mucus components albumin, linear DNA
and mucin, at concentration ratios expected to occur in
vivo, significantly lowered their gene transfection activity.
This decrease was primarily due to aggregation of the cat-
ionic lipoplexes induced by these CF mucus components.
Additionally, the DNA in the sputum was able to release
small amounts of therapeutic pDNA from the cationic lipo-
plexes. In contrast to the cationic DOTAP lipoplexes, expo-
sure of neutral, pegylated GL67 lipoplexes to the CF mucus
components did not affect their gene transfection activity.
Indeed, we confirmed that the CF mucus components did
not interact at these concentration ratios with pegylated
GL67 lipoplexes. However, albumin was able (although
artificially due the electric field during gel electrophoresis)
to release pDNA (;25%) from the lipoplexes. The disso-
ciation of DOTAP:DOPE lipoplexes by linear DNA and the
dissociation of GL67 lipoplexes by albumin was confirmed
in experiments using native CF sputa.
These results indicate that charge shielding of cationic gene
complexes by polyethylene glycol favors their physico-
chemical stability in CF sputum and thereby aids in pre-
serving their transfection activity.
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GENE TRANSFECTION INTO THE MOUSE
AIRWAYS IN VIVO USING PEGYLATED
LIPOPLEXES
N. Oudrhiri , P. Belmont , B. Pitard , A. Aissaoui , M.1 2 3 1
Hauchecorne , S. Julia , J. Navarro , J.P. Vigneron , J.M.1 1 1 2
Lehn , P. Lehn2 1
INSERM U458, Hospital Robert Debre, Paris, France,1 ´
Laboratoire de Chimie, College-de-France, Paris, France,2 `
INSERM U533, Faculte de Medecine, Nantes, France3 ´ ´
Over the last several years, cationic lipids have emerged as
attractive alternatives to recombinant viruses for use in gene
therapy. In order to avoid precipitation of the lipoplexes at
the high DNA concentrations required for in vivo gene
delivery, we have directed our efforts towards the devel-
opment of cationic lipid systems involving polyethylene-
glycol (PEG) conjugates. Indeed, PEG coating may
sterically stabilize the lipoplexes by hindering their inter-
actions. The results of our studies clearly show that incor-
poration of adequate lipophilic PEG derivatives allows to
prepare concentrated solutions of colloidally stable lipo-
plexes obtained by mixing plasmid DNA with bis-guani-
dinium-tren-cholesterolydioleoylphosphatidylethanolamine
(BGTCyDOPE) liposomes, a type of cationic liposomes we
have previously reported to mediate gene transfection into
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the mouse airways via direct intratracheal instillation of low
doses of DNA complexes. Most importantly, we also found
that PEG-mediated steric stabilisation permits enhanced
transfection of the mouse airways via intranasal adminis-
tration of concentrated BGTC lipoplex solutions. In addi-
tion, we have recently discovered the transfection properties
of novel cationic cholesterol derivatives characterized by
an aminoglycoside-bearing headgroup. Interestingly, pegy-
lated kanamycin-cholesterolyDOPE lipoplexes also allow
efficient gene transfection into the mouse airways in vivo.
In ongoing experiments, we attempt at present to identify
the cell types actually transfected in the trachea and lung
epithelium and to assess the toxicity of these novel cationic
lipid formulations.
Supported by Vaincre la Mucoviscidose and Aventis
Gencell.
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EMPLOYING THE NASAL POTENTIAL
DIFFERENCE AS A DIAGNOSTIC TEST FOR
CYSTIC FIBROSIS IN NEONATES; POTENTIAL
PITFALLS
E.A. Gaillard , N.J. Shaw , H.L. Wallace , N.V.1 1 2
Subhedar , K.W. Southern1 2
Liverpool Women’s Hospital, Liverpool, UK, Institute of1 2
Child Health, University of Liverpool, Liverpool, UK
Aims: To highlight the potential for misdiagnosis of cystic
fibrosis (CF) by employing nasal potential difference (PD)
studies on the first day of life.
Background: Ion transport studies have been used to sup-
port the early diagnosis of CF in infants. Nasal PD meas-
urements are technically possible soon after birth and
results immediately available. A maximal baseline PD
greater than y40 mV in combination with a PD change of
less than y5 mV following perfusion with a zero chloride
solution are consistent with a diagnosis of CF.
Methods: As part of an ongoing study we measured nasal
PD in infants during the first 24 h of postnatal life using a
modified perfusion protocol suitable for neonates. We
determined:
1. Maximal PD following perfusion of a physiological iso-
tonic solution
2. Change in PD following perfusion with amiloride 10–4
M
3. Change in PD, after perfusion with a zero chloride
solution.
Results: From 72 infants we identified three with nasal PD
profiles consistent with a CF diagnosis. Mean maximal
baseline PD was 47, y49 and 51 mV, respectively. The
change in PD following perfusion with a zero chloride solu-
tion was less than 5 mV in both nostrils in all infants. Two
infants were born preterm at 33 and 35 weeks. The other
infant was delivered by elective caesarean section at term
without labour. They were referred to a Paediatric Respi-
ratory Consultant. They had no clinical features suggestive
of CF and sweat electrolytes were normal with adequate
sweat weights.
Conclusion: The airway ion transport profiles in these
infants likely reflect normal adaptive processes on the first
day life. Nasal PD studies should not be used to make an
early diagnosis of CF on the first day of life. The use of
this measurement in the older neonate as a diagnostic tool
needs further evaluation.
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IMPACT OF ADDITIONAL TOOLS ON THE
DIAGNOSIS OF CYSTIC FIBROSIS
C. Barreto , A. Lopes , L. Pereira , J. Thomas , M. Mall ,1 1 1 2 2
M. Amaral3
Cystic Fibrosis Centre, Pediatric Department, University1
of Hospital Santa Maria, Lisbon, Portugal, Universitats-2
Kinderklinic, Albert-Ludwigs Universitat Freiburg, Ger-
many, Centro de Genitica Humana, Instituto Nacional de3
Saude, Lisbon, Portugal
The phenotypic variation observed in CF patients raises
problems in diagnosis and prognosis. In order to confirm
the diagnosis, a group of patients with atypical CF (bor-
derline or low sweat test results or non-informative geno-
type) and another group with confirmed CF but uncommon
mutations or variable clinical evolution were assessed.
Altogether 28 patients were included (aged 2 to 33—19
female). Patients were grouped by sweat test results. Group
1, 21 patients with sweat conductivity test values 085
mEqyl. Group 2, 7 patients with values -85 mEqyl.
All patients were characterized according to age at diag-
nosis, Shwachman–Kulczyzki and Crispin–Norman scores,
pulmonary functions and recovery of pathogens in bron-
chial secretions. Further molecular and function analysis
included: (1) transepithelial short-circuit current in rectal
biopsies; (2) chloride concentration (instead of conductiv-
ity) in sweat; (3) extended genotype screening; (4) deter-
mination of faecal elastase-1 (EL-1).
Results: For Group 1 patients, measurements of transepi-
thelial short-circuit currents showed lack of chloride secre-
tion (compatible with CF) in 12 out of the 21 patients. All
these 12 patients evidenced pancreatic insufficiency (EL-
1-200 mcgyg) variable clinical scores (33–96) and vari-
able genotypes. In the remaining 9 patients, residual
chloride secretion was observed in 7, and a normal secre-
tion in 2. All 9 patients had normal pancreatic function and
better clinical scores.
For Group 2, 6 patients evidenced normal chloride secretion
in the intestine (thus excluding CF) and for one no secre-
tion was detected. All the former 6 had normal pancreatic
function and very good clinical scores. The patient without
chloride secretion had EL-1-1 mcgyg.
Conclusions: With the combination of additional diagnos-
tic methods it was possible to exclude or confirm a CF
diagnosis in these atypical patients.
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Results evidence a good correlation of pancreatic function
with intestinal chloride secretion.
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TNF2 GENE AND SEVERITY OF LUNG DISEASE
IN CYSTIC FIBROSIS: A POSSIBLE
CORRELATION?
M. Rossi , M. Mazzi , E. Bigagli , M.A. Bernardi , R.1 1 1 2
Bini , A. Miano , F. Battistini , V. Perez , A. Cosimi , P.2 1 3 4 5
Moretti , E.G. Barlocco , M. Bartolozzi6 2 1
Medical Genetic Service, Cystic Fibrosis Service, Gros-1 2
seto, Cystic Fibrosis Service, Cesena, Cystic Fibrosis Ser-3 4
vice, Livorno, Cystic Fibrosis Service, Gualdo, Cystic5 6
Fibrosis Service, Teramo, Italy
Tumor necrosis factor alpha (TNFa) is a pro-inflammatory
cytokine produced predominantly by macrophages, it
enhances neutrophil oxidative and secretory responses; it
eases the release of proteases and lysosomal enzymes which
are necessary to break down and digest the bacterial rem-
nants, but, if they are in excess, they can digest connective
and normal tissue. A polymorphism exists in the promoter
region of TNFa gene, and this polymorphism is important
for the levels of TNFa. Because of this polymorphism, two
alleles exist, TNF1 and TNF2: the latter is associated with
higher levels of TNFa. If it is true that higher TNFa levels
are associated with an increased and excessive inflamma-
tory reaction, we can conclude that the patients with TNF2
genotype have a worse lung disease. The aim of our study
is to verify if in the cystic fibrosis population those with
genotype TNF2 present a worse clinical course of pulmo-
nary disease. Our study is based on 46 patients. The pres-
ence of the 308 polymorphism was detected by the
amplification of a 345 base pair (bp) fragment of DNA
flanking the 308 polymorphic site, using the polymerase
chain reaction from each sample of genomic DNA. The 39
primer used in the PCR reaction incorporates the 308 pol-
ymorphic site in a NcoI restriction site. If the TNF1 allele
is present, NcoI enzyme will give two fragments, the first
of 325 bp and the other of 20 bp; if the TNF2 is present
the NcoI site is destroyed and no cutting occurs. The frag-
ments were resolved using a 2% NuSieve GTG agarose gel
and visualised by ethidium bromide staining. Lung function
evaluated for FEV1; chest radiographs scored using Chris-
pin–Norman system; colonised by P. aeruginosa: organism
isolated from sputum at least for 6 months. We have select-
ed patients over 15 years old. FEV1 and Chrispin–Norman
score were analysed using Student’s t-test, while we used
x -test for analysis of presence or absence of P. aeruginosa.2
We present our preliminary data.
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AMINOGLICOSIDE-INDUCED OTOTOXICITY IN
PATIENTS WITH CYSTIC FIBROSIS: DOES IT
DEPEND ON GENETIC MUTATIONS?
T. Repetto , R.A. Casano , E. Pelo , C. Centrone , M.L.1 2 2 2
Cioni , E. Procopio , G. Taccetti , F. Torricelli1 1 1 2
Cystic Fibrosis Center of Tuscany, Department of Pediat-1
rics, University of Florence, Meyer Hospital, Florence, Ita-
ly, Cytogenetic and Genetic Unit, Careggi Hospital,2
Florence, Italy
Patients with cystic fibrosis (CF) who are chronically col-
onized by Pseudomonas aeruginosa, often require repeated
courses of aminoglycoside antibiotics (AA) for lung infec-
tions. Ototoxicity is the major irreversibile toxicity of AA,
occurring in a dose-dependent and idiosyncratic fashion.
The idiosyncratic pathway appears to be genetically deter-
mined in some individuals. In fact in the mitochondrial 12S
ribosomal DNA some mutations were identified which
cause non-syndrome maternally inherited hearing impair-
ment after AA exposure. The aim of this study is to deter-
mine the role of genetic alterations in AA-induced deafness.
In our centre we have been following 158 CF patients, 60
out of whom require intermittent AA i.v. therapy. Most of
the patients had more than 3 parenteral AA antibiotic a year
(10–15 mgykgydie) and only one had documented toxic
levels during treatment. Five patients (8.3%) out of 60
became deaf. Two out of them had severe hearing impair-
ment on speech threshold. We studied the most common
mitochondrial 12S ribosomal RNA gene mutations causing
maternally inherited deafness in five CF and deaf patients
only.
In our experience 8% of CF patients treated with repeated
i.v. AA developed neurosensory hearing loss, as demon-
strated by audiometry, consisted white AA-induced ototox-
icity. We observed no genetic predisposition to
mitochondrial DNA mutation. Perhaps a high cumulative
dose cause inner ear injury even though there were no spe-
cific episodes of toxic serum levels.
In CF patients long exposure to very high cumulative AA
doses enhances the risk of ototoxicity, and thus require ade-
quate audiometric monitoring and serum drug concentration
determination during AA therapy.
Although our study did not show a genetic prevalence of
AA susceptibility in CF populations, we do suggest that
physicians do a careful medical history of CF patients to
look for familial deafness, in an effort to identify patient at
risk and screen certain drugs before starting AA therapy.
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THE 1237G™A ENHANCER POLYMORPHISM
OF ALPHA-1 ANTITRYPSIN GENE AS MODIFIER
OF PULMONARY DISEASE IN CYSTIC FIBROSIS
PATIENTS
A. Sobczyqska-Tomaszewska , D. Sands , D. B9k , A.1 2 3
Nowakowska , J. Bal2 1
Department of Medical Genetics, Institute of Mother and1
Child, Pediatric Clinic, Institute of Mother and Child,2
Department of Genetics, Warsaw University3
There is significant difference in lung disease severity
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among CF patients and a lot of studies suggest that genetic
factors unrelated to mutations in the CFTR gene are likely
contributors to these variations. Alpha-1 antitrypsin (AAT)
inhibits several proteinases, including neutrophil elastase
(NE). The genetic deficiency of AAT leading to emphy-
sema demonstrates an important physiological role of AAT
in protecting the respiratory tract from NE induced injury.
We studied the 1237G™A enhancer polymorphism of AAT
gene to examine the hypothesis that this polymorphism
could be associated with pulmonary disease severity in CF.
The 1237G™A polymorphism were identified in DNA
samples from 60 CF patients, homozygotes for delF508.
Sixteen patients were found to be heterozygotes GyA,
one—homozygote AyA and 42 patients—homozygotes for
more frequent G allele. Monitoring of lung disease progress
suggests smaller and slower range of changes in CXRyRTG
studies. In the GyG group 6 patients suffered from a very
severe course of pulmonary disease and died. In the GyA
group one patients died. A mild form of lung disease was
found in 62.5% of the GyA patients, whereas in the GyG
group only 24.4% were classified as a mild form, 29% had
the severe form of pulmonary disease. In 4-graded scale of
change in pulmonary tissue (I—emphysema, II—hyperpla-
sia of interstitium, III—bronchiectasis, IV—pulmonary
fibrosis) 31% of the GyA patients were counted to the
group I, none patients were classified into the group IV,
whereas 24.5% of the GyG patients were recognized as the
groups III and IV. We did not find difference between fre-
quency of Pseudomonas aeruginosa infection, but more of
the GyG patients had chronic Staphylococcus sp. infection.
Our results indicate that better pulmonary prognosis in CF
could be associated with the AAT gene enhancer polymor-
phism. These data need to be confirmed by large case
studies.
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ANALYSIS OF CFTR GENE IN PATIENTS WITH
CFTR RELATED MONOSYMPTOMATIC
DISORDERS (MALE INFERTILITY AND
CHRONIC PANCREATITIS)
A. Nikolic , J. Kusic , D. Radojkovic , S. Niksic , V.1 1 1 2
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This study was undertaken to test the possible involvement
of CFTR gene in the aetiology of male infertility and chron-
ic pancreatitis in Yugoslav patients.
We analyzed 21 infertile men (11 with infertility due to
reduced sperm quality and 10 with obstructive azoosper-
mia) and 39 patients with chronic pancreatitis (alcohol-
related in 29 and idiopathic in 10) using the combination
of PCR and subsequent direct (HA, PSM) and indirect
(SSCP, DGGE) mutation detection methods.
Six men with infertility, 1 of 11 with infertility due to
reduced sperm quality and 5 of 10 with obstructive azoos-
permia, had at least one mutation in CFTR gene—F508del
(one azoospermic male was a compound heterozygote—
F508dely711q3AyG). Among chronic pancreatitis
patients 3 had a mutation in CFTR gene, 2 of 29 with
alcohol-related and 1 of 10 with idiopathic pancreatitis. Of
those three, two mutations were F508del, while mutation
found in exon 6a remains to be defined through sequencing.
5T allele at Tn polymorphic site was present in 3 men with
obstructive azoospermia and in 2 with reduced sperm qual-
ity, but it was not found in any patient with chronic pan-
creatitis. Many patients in both groups were found to be
carriers of common polymorphisms 2694TyG andyor
4002AyG.
The frequency of mutations in our sample of infertile males
(16.7%) was significantly higher, while frequency in a
group of chronic pancreatitis patients was only slightly
increased (3.8%), compared to the frequency in general
population (2%). Degree of correlation between CFTR gen-
otype and phenotype was higher for obstructive azoosper-
mia and idiopathic pancreatitis then for infertility due to
reduced sperm quality and alcohol-related pancreatitis.
These findings suggest that CFTR protein may be involved
in aetiology of male infertility and chronic pancreatitis, but
further investigations on a larger cohort of patients would
confirm this conclusion.
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A GENOTYPEyPHENOTYPE CORRELATION
STUDY OF THE G85E MUTATION IN A LARGE
COHORT OF EUROPEAN CF PATIENTS
K. Decaestecker , E. Decaestecker , C. Castellani , M.1 1 2
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So far, it is not clear whether the G85E CFTR mutation is
associated with a mild or a severe phenotype. In a large
European study, in which 17 CF centres from 7 European
countries participated, the phenotype was investigated in 70
patients homozygous or compound heterozygous for the
G85E-mutation. Strict definitions were used to standardise
the clinical parameters. Each index case was compared with
two CF patients from the same clinic, matched for age and
gender: one with pancreatic sufficiency (PS) and one with
pancreatic insufficiency (PI). For continuous traits, the dif-
ferences between the groups were tested by a Wilcoxon
matched pairs signed rank test; for discontinuous traits the
Fisher exact test was used. A Spearman rank correlation
was calculated to determine the FEV1 course over time in
each patient; these values were then used in a Wilcoxon
matched pair test. There was a significant difference
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between the G85E group and the PS group with regard to
sweat chloride concentration, weight for height, age at first
P. aeruginosa colonisation and at chronic P. aeruginosa
colonisation, rate of decline of FEV1, occurrence of abnor-
mal liver function tests, liver cirrhosis and CF related dia-
betes mellitus. For all these parameters, patients with the
G85E-mutation had a similar phenotype as the one seen in
PI patients. Failure to thrive andyor steatorrea as presenting
symptom were significantly more common in the G85E
group than in the PS group. PI was observed in 57% of the
G85E patients. One patient homozygous for the G85E
mutation was PS. Pulse-chase experiments revealed that the
G85E mutation, either on a M470 or V470 background,
fails to mature. G85E therefore is a class II mutation.
Although the clinical presentation is quite variable, it can
be concluded that the G85E-mutation tends to have a severe
phenotype.
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VARIOUS CF PHENOTYPES IN RELATION WITH
FOUR NOVEL MUTATIONS IN PATIENTS FROM
DIFFERENT ETHNIC ORIGINS
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While relationships between gene defects and disease sever-
ity has been extensively studied in classical form of CF, or
in congenital bilateral absence of the vas deferens
(CBAVD), in CF with normal or borderline sweat chloride
levels, a high degree of phenotypic variability is observed,
depending on the nature and location of the CFTR muta-
tions. In this case, the diagnosis of CF remains difficult and
is mostly based on extensive screening of the CFTR gene.
Here we report four unknown mutations in unrelated
patients affected either with typical (patient 1), mild
(patient 2) or atypical CF (patients 3, 4). CFTR gene anal-
ysis by DGGEysequencing, identified: (A) two homozy-
gous mutations, -n 1) 459T™A (Y109X) in exon 4,
resulting in a severe form of CF in a girl of Cameroon
origin with a positive sweat test and failure to thrive, -n 2)
(4268q3G™A) in intron 22, detected in a girl from Guy-
ane with a positive sweat chloride level, recurrent pulmo-
nary infections and severe hypotrophy born to
consanguineous parents; and (B) two heterozygous muta-
tions -n 3) 1687A™G (S519G) in exon 10, observed in a
French girl with borderline sweat test (56 mmolyl), recur-
rent bronchitis, rhinitis and pansinusitis, born after IVF
(due to oligospermia in her father) and -n 4) 481C™G
(R117G) in exon 4, detected in a CBAVD affected French
man without any additional clinical features.
This study was supported by the Association Mucovisci-
dose ‘ABCF proteines’.´
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COMPOUND HETEROZYGOTE GENOTYPE
DELTAF508yG551D WITH DIVERGENT
PHENOTYPE IN A SIBLING PAIR
A. Hofmann, A. Busch, R. Ziebach, M. Stern
University Children’s Clinic, Tubingen, Germany¨
Introduction: We present a sibling pair (male, age 26,
female, age 18) with divergent clinical features in spite of
their identical CF mutation. Both patients received CF cen-
tre care since their date of diagnosis.
Case reports: Both were diagnosed in 1983 (male: age 8
years, female: age 1 month).
The male patient showed pulmonary problems. His sweat
tests were positive. His sister was tested directly after birth,
her sweat tests were positive, too.
At present, the lung function of the brother has deteriorated
severely (FEV1: 17%, FVC: 21%). He needs oxygen 24 h
a day and his sputum shows more than one strain of mucoid
Pseudomonas aeruginosa since many years and Staphylo-
coccus aureus. He has taken a classic CF-course and has
been treated by intravenous antibiotics many times.
His sister has a FEV1 over 100% and her sputum shows
one strain of mucoid Pseudomonas aeruginosa only since
February 2001. Staphylococcus aureus has been found in
her lung. She has a very mild course of CF including addi-
tional clinical features like enterocolitis and polyarthritis.
In their nutritional state there are very important differenc-
es, too. His BMI is 16 (178 cm; 50.7 kg). Her BMI is 26.2
(176 cm; 81.3 kg). The energy intake in both siblings is
almost identical. She eats approximately 3341 kcal per day
and he eats 3687 kcal per day. They are both pancreatic
insufficient. While he is on 250 000 IU lipase per day, she
refuses to take any pancreatic enzymes because of abdom-
inal discomfort.
Conclusion: Clinical features and the course of the disease
may vary widely in siblings with identical CF mutation. In
our case report this was true for pulmonary and gastroin-
testinal symptoms, and also for the nutritional status.
Beyond CF mutation, time of diagnosis and quality of ther-
apy, there must be other factors influencing disease severity
and also quality of life in CF.
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ISOLATED IDIOPATHIC CHRONIC
PANCREATITIS IN A PATIENT WITH A
COMPOUND HETEROZYGOZITY (G542Xy
S1235R) FOR THE CFTR GENE
A. Iron , M.P. Reboul , D. Laharie , M. Amouretti , D.1 1 2 2
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There is a significantly high prevalence of CFTR gene
mutations in idiopathic chronic pancreatitis (ICP). The
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CFTR genotype-ICP phenotype relations are not easy to
establish due especially to interference with alcohol pan-
creatitis, limitation in the exclusion rate of mutations. Up
to now, 7 cases of nonalcoholic patients suffering from ICP
and bearing 2 mutations of the CFTR gene have been
reported; but only 3 of them have a pathology limited to
pancreas and are compound heterozygotes with a rare muta-
tion giving a moderate deleterious effect.
The ICP patient, 35 years old, has been thoroughly inves-
tigated by clinical examinations and followed up for 10
years. A hereditary pancreatitis was excluded (no other case
in the family, no mutation in the cationic trypsinogen gene).
Pancreas MRI and CT scan confirmed the diagnosis. The
CFTR gene investigation consisted in a direct mutation
detection and polymorphism determinations (wTGxm, Tn,
codon 470).
The history of our patient and the clinical features of his
disease obviously evoke an isolated ICP without any usual
sign generally linked with a CFTR gene abnormality (bron-
chectasia, nasal polyposis, congenital bilateral absence of
vas deferens). The CFTR gene analysis has revealed a com-
pound heterozygosity i.e. a G542X allele and a wTGx12-T7-
M470-R1235 allele. The patient has a normal sweat test.
G542X is a frequent and severe CF mutation. S1235R is a
rare mutation, recently reported as bringing very probably
a moderate deleterious effect when it is found on the hap-
lotype wTGx12-T7-M470.
In conclusion, the mutation S1235R (in the haplotype back-
ground wTGx12-T7-M470) located in trans of G542X) must
certainly be responsible for the phenotype of ICP. The case
reported here could contribute to a better knowledge of the
specificity of some CFTR gene abnormalities in the ICP
phenotype.
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THE MUTATION 1811H1.6 kb A™G OF THE
CFTR GENE: A SEVERE CLASS V MUTATION
AS SUGGESTED BY THE CLINICAL DATA OF 12
CF PATIENTS (2 HOMOZYGOTES ET 10
COMPOUND HETEROZYGOTES)
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Practically absent in CF patients from other parts of France,
the mutation 1811q1.6 kb A™G of the CFTR gene is not
rare in patients genotyped in the Southwest of France. With
a 3–4% frequency of CF alleles, its appears as the 4th
mutation after F508del, G542X and N1303K and referred
to the effective of CF chromosomes with a Southwest geo-
graphic origin, it represents more than 5%.
The mutation 1811q1.6 kb A™G, located in the intron 11
of the CFTR gene, creates a new splicing site. It was pre-
viously ranked in class I mutations (i.e. no production of
normal CFTR protein) whereas it allows—as class V muta-
tions (responsible for moderate phenotypes)—a reduced
synthesis of normal protein.
There are few data on the phenotypic consequences of
1811q1.6 kb A™G; the present study aims at a better
knowledge of the mutation.
We have collected the clinical features of 12 CF patients
originated from the Southwest region of France and bearing
1811q1.6 kb A™G, 10 compound heterozygotes and
especially 2 homozygotes for the mutation. The genotyping
of the mutation was obtained either by PCR-sequencing or
PCR-digestion.
The data (age of diagnosis, height and weight, sweat test,
pancreatic status, colonisation by Pseudomonas aeruginosa,
other clinical signs) indicate that patients with 1811q1.6
kb A™G present a severe form of CF comparable to homo-
zygotes for F508del.
Our results are in good agreement with previous data from
Spanish CF patients who are compound heterozygotes with
severe phenotype. We can conclude that 1811q1.6 kb A™
G has to be definitely considered as a class V mutation
(with residual normal CFTR protein) responsible for a typ-
ical cystic fibrosis with pancreatic insufficiency.
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3849H10 kb (C to T) HOMOZYGOTE: CLINICAL
FEATURES
R. Messineo , A. Cannuscio , M. Collura , L. Iapichino ,1 1 2 2
C. Di Girgenti1
Laboratorio di Biologia Molecolare-Ospedale G. Di-1
Cristina, Palermo, Italy, Centro Regionale Fibrosi Cistica-2
Ospedale G. Di Cristina, Palermo, Italy
Clinical features of the patient: The patient is a 27-year-
old man. Main symptoms: nasal polyposis from childhood,
disseminated bronchiectasis, chronic bronchitis. Good nutri-
tional status, oligo and astenospermia.
Laboratory tests: Sweat test was: Chloride 52y56 meqyl;
the ultrastructural cilia examination (brush) was normal.
Genotype was 3849q10 kb (C to T) homozygous (molec-
ular analysis of 31 mutations performed by Cystic Fibrosis
Assay Kit-Applied Biosystem).
Genotype was confirmed by INNO-LiPA CFTR 17qTn Kit
(Innogenetics).
Discussion: The clinical features, strongly suggesting an
Immotilia cilia syndrome are instead those of a mild form
of CF, diagnosed by molecular analysis.
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MOLECULAR-GENETIC ANALYSIS OF
POLYMORPHIC VARIANTS OF GSTM1, CYP1A1
GENE AND CFTR GENE MUTATIONS IN
PATIENTS WITH CHRONIC PULMONARY
DISEASE FROM BASHKORTOSTAN
D. Yanbaeva, G. Korytina, T. Victorova, E. Khusnutdinova
Institute of Biochemistry and Genetics, Ufa, Russia
Chronic pulmonary disease are one of the major widespread
cause of ill health. The search for pulmonary disease sus-
ceptibility genes is a complex issue, owing to the influence
of environmental factors in the pathogenesis of these dis-
orders. Nevertheless, a large number of epidemiologic stud-
ies suggest that genetic factors might play a role. One
possibility to account for a susceptibility to the effects of
environmental pollutants may be the genetic variations in
the xenobiotic metabolising enzymes such as glutatyon-S-
transferase M1 (GSTM1) and cytochrome P4501A1
(Cyp1A1). The null allele of GSTM1 that does not have a
protein product or mRNA due to expanded deletion of the
gene. The mutation of (Cyp1A1) gene (Ile 462Val)
increase enzyme activity in lung. The recent reports have
suggested that heterozygosity for predominant delF508
mutation of CFTR gene is associated with pulmonary dis-
ease such chronic bronchitis and asthma. In order to deter-
mine the possible role of detoxifying enzymes gene
mutations and mutation delF508 of CFTR gene in the path-
ogenesis of pulmonary disease we studied 45 patients (22
with bronchopneumonia, 12 with chronic bronchitis, 7 with
astma and per 2 with bronchiectasis and bronchoobstructive
syndrome) and compared results to 68 subjects from
healthy control group. The GSTM1 0y0 genotype was
found in 37% of affected individuals and in 49% in control
subjects. There is no significant differences (P)0.05). For
Cyp1A1 locus the Val allele was detected in 7% of affected
individuals and only in 3% in control, but the differences
not significant (P)0.05). Cyp1A1 IleyVal genotype
approximately twofold increased in affected individuals
(15%). We not found individual with delF508 mutation of
CFTR gene. In future studies of multiple gene polymor-
phisms we should be include other candidate genes and will
augment number of affected patients.
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NO FALSE POSITIVES OR CROSS-REACTIONS
WITH BENIGN VARIANTS OR RARE
MUTATIONS: EVALUATION OF THE PROBE
SPECIFICITY USED IN INNO-LIPA CFTR
P. Hendrix , C. Van Loon , G. Verpooten1 1 1
Innogenetics
INNO-LiPA CFTR12 and INNO-LiPA CFTR17qTn,
respectively, identify 12 and 17 CF-related mutations and
their wild-type sequences, as well as the CBAVD-related
polymorphism Tn. The technology used is a simple reverse
hybridisation of amplified product on a nitro-cellulose strip
carrying specific oligonucleotide probes as parallel lines.
The amplified product is the result of an optimised multi-
plex amplification. Hybridisation and stringent wash occur
at the same temperature and can be performed either man-
ually or using Auto-LiPA. Both assays were successfully
validated in a European multicenter study.
Individuals, homozygous for a mutant or a wild-type allele,
will only hybridise with the corresponding probe, whereas
individuals heterozygous for a particular mutation will
hybridise with both the mutant and wild type probe for this
mutation. We undertook to test the INNO-LiPA CFTR
assay specificity for samples containing benign variants or
rare CF-related mutations, of which the sequences are, cov-
ered by the INNO-LiPA CFTR mutant and wild type
probes. The benign sequence variants were introduced by
mutagenesis and controlled by sequence analysis. In addi-
tion, three clinical samples with proven presence of F508C
and linked with the S1251N mutation were included. For
the rare mutations, clinical samples were available. None
of the benign variant sequences tested showed any false-
positive reaction with the corresponding mutant probe on
the strip; in all these cases, the wild-type probe remained
positive. For the rare mutations, no cross-reactivity with the
mutant probes was observed. We could conclude that in all
these samples, the INNO-LiPA probe reactivities allowed
correct clinical interpretation.
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HIGH FREQUENCY OF CFTR MUTATIONS IN
CHRONIC PULMONARY DISEASES IN
CHILDHOOD
R. Padoan , C. Corbetta , D. Coviello , T. Mariani , A.1 2 3 2
Bassotti , F. Rusconi , M. Seia1 4 3
CF Center, Neonatal Screening Center, Molecular Genet-1 2 3
ic Department, Paediatric Department, AO Istituti Clinici4
di Perfezionamento, Milano, Italy
The role of the CFTR gene is well known in the pathogen-
esis of several lung diseases in adults (bronchiectasis,
ABPA, sinusitis). Few data are available for paediatric
patients suffering of chronic respiratory diseases. In order
to verify if CFTR gene has a pathogenetic role, we per-
formed a wide molecular analysis in a cohort of 85 patients
(aged 4 months to 17 years), not related and with no famil-
ial history for CF, referred to our paediatric department
because of chronic respiratory symptoms (chronic cough
andyor wheezing). All patients presented a sweat test chlo-
ride value -60 mmolyl.
Clinical and radiological evaluations identified several
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causes of symptoms: nasal polyposis, chronic sinusitis,
ABPA, disseminated bronchiectasis, lobar actelectasia,
COPD, asthma and bronchiolitis.
The molecular analysis of the CFTR gene was performed
by means of DGGE technique and sequencing.
Five compound heterozygotes were identified (delF508y
S1252N, delF508yD1152H, D1152Hy3849q10 kb C™T,
delF508y3849q10 kb C™T, A120TyF1052V).
27y170 (15.8%) mutated alleles were identified, showing
a high allelic heterogeneity (16 different mutations). The
frequency of CFTR alterations is approximately eight times
more elevated than expected (2% in the normal
population).
These results suggest the involvement of the CFTR gene in
determining chronic lung disease in the paediatric popula-
tion. A relevant number of CF diagnoses were made in
patients presenting normal sweat test, thus the molecular
study of the gene is recommended in children to clarify
their risk to have a chronic lung disease.
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TEN YEARS OF MOLECULAR GENETIC
DIAGNOSIS OF CYSTIC FIBROSIS IN RUSSIAN
PATIENTS
N. Kapranov, N. Petrova, E. Ginter, N. Kashirskaya
Research Centre for Medical Genetics RAMS, Moscow,
Russia
Since 1990 466 CF patients and more than 1000 members
of their families which were clinically diagnosed in the
Department of CF of the Research Centre for Medical
Genetics have been examined for 20 mutations in the CFTR
gene. More than 80% of the patients were originated from
the European part of Russia. The relative frequencies of 13
screened CF mutations were as follows: delF508, 53%;
CFTRdele2.3 (21 kb), 6.4%; N1303K, 2.6%; G542X,
2.0%; W1282X, 1.9%; 3849q10 kb C™T, 1.9%; 2143DT,
1.8%; 2184insA, 1.8%; R334W, 0.7%; S1196X, 0.7%;
394DTT, 0.4%; 1677DTA, 0.5%; G551D, 0.3%. Other
screened mutations have not been identified in our sample.
The above mentioned 13 mutations account for 75% of all
CF alleles of Russian patients. It seems that it is possible
to distinguish a nucleos of common ‘Slavic’ mutations
(CFTRdele2.3 (21 kb), 2143DT, 21S4insA) but their origin
and history of distribution should be clarified further. Still
approximately 25% of CF alleles are remained to be iden-
tified in Russian population and only for 56% of CF
patients the full CF genotype could be recognized. In fam-
ilies where one or both parents have unidentified mutations
analysis of inter- and intra-genic DNA markers have been
exploited to complete genetic testing. As a result the infor-
mativity close to 100% could be obtained for all families
with the CF child.
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DEVELOPMENT OF A PCR-BASED, LINE
PROBE ASSAY FOR THE DETECTION OF 76
ALLELES IN THE CYSTIC FIBROSIS
TRANSMEMBRANE CONDUCTANCE
REGULATOR (CFTR) GENE
Angela Myers , Rhea Nersesian , Randall K. Saiki1 1 3
Roche Molecular Systems INC, Alameda, CA 94501,1
Celera Diagnostics, Alameda, CA 945023
Genetic testing for molecular defects in the CFTR gene has
become an important area in laboratory testing. However,
because of the large number of documented molecular
defects in the CFTR gene, only a small number of labora-
tories have implemented the techniques necessary to
exhaustively analyze a patient’s CF locus. The geographical
distribution of mutations and their relative frequencies vary
considerably. In a European study of more than 27 000 CF
chromosomes only one mutation (delta F508) was present
in the majority of CF chromosomes (66.8%), while four
others had relative frequencies of between 1.0 and 2.6%,
and 17 mutations had frequencies between 0.1 and 0.9%.
To provide a cost-effective CF test and optimize the CF
detection rate, the selection of a subset of mutations to be
analyzed must be carefully considered and appropriate to
the target population. Genetic analysis by hybridization
with sequence-specific oligonucleotide probes is the bases
for the research prototype CF EU-38. The assay is capable
of detecting 38 CF-related mutations and their wild-type
sequences, as well as the Tn and exon 10 polymorphisms.
Testing for these 38 mutations will lead to a detection rate
of 80–80% in the Scandinavian and Western European
countries and significant detection levels in remaining Eur-
opean counties. This may be sufficiently sensitive for rou-
tine carrier screening and for the majority of diagnostic
requests. The ability to test for CFTR mutations at the
molecular level has already improved the diagnosis of
symptomatic patients and expanded the reproductive
options for family members of CF patients. The same tech-
nology also holds promise of identifying asymptomatic car-
riers and at-risk couples without family history. Genomic
DNA is amplified in a single 18-plex polymerase chain
reaction amplification system followed by detection of the
38 mutations and 4 polymorphisms (intron 8 Tn locus,
I506V, I507V, and F508C) using a low-density oligonu-
cleotide probe array. The format of the assay permits the
simultaneous screening of many samples for multiple muta-
tions and can be readily modified to combine the detection
of the most frequent mutations with other allelic variants
common to specific ethnic groups. Expanding the panel of
screened mutations only marginally increases the sensitivity
of the assay. This molecular diagnostic assay is simple and
accurate. The assay identifies most of the carriers and
affected persons (high sensitivity) with few false positives
(high specificity) and may be used in carrier screening and
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in conjunction with conventional tests for newborn
screening.
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FIRST LINE STRATEGIES FOR CFTR
GENOTYPING DEPENDING ON COVERED
MUTATIONS
L. Naehrlich , C. Kraus , B. Boewing , M. Wagner , A.1 2 1 1
Reis2
University Hospital for Children and Adolescents, Univer-1
sity Erlangen-Nuremberg, Germany, Institute for Medical2
Genetics, University Erlangen-Nuremberg, Germany
CFTR genotyping is an important diagnostic tool and the
base for genetic counsel of CF-patients and their families.
Therefore, optimization is a crucial challenge.
Methods: CFTR mutations of all CF-patients diagnosed
according to the criteria of Rosenfeld and seen on a regular
basis in our CF-center in the year 2001 were analyzed. In
patients with one or two unknown mutations we examined
a 21 kb genomic deletion (del 2.3), the ‘5T-allele’ of Intron
8 and used a 15 plex PCR to amplify different fragments
of the CFTR-genome to examine the following 31 muta-
tions by oligonukleotid-ligations-assay (OLA) (Applied
Biosystems, Foster City, USA): deltaF508, deltaI507,
Q493X, V520F, 1717y1G™A, G542X, G551D, R553X,
R560T, S549R, S549N, 3849q10 kb C™T, 3849q4A™
G, R1162X, 3659delC, W1282X, 3905insT, N1303K,
G85E, 621q1G™T, R117H, Y122X, 711q1G™T,
1078delT, R347P, R347H, R334W, A455E, 1898q1G™A,
2183AA™G, 2789q5G™A. The rate of informative anal-
ysis was judged according to the covered mutations: All
mutations covered by our strategy (A) versus strategies
covering the 24 (B) or 10 (C) most common mutations in
German CF-patients.
Results: We examined 135 patients out of 125 families.
Two mutations could be detected in 90% (A) versus 86%
(B) versus 81% (C) of all families. Non-deltaF508 muta-
tions were diagnosed in 78% (A) versus 69% (B) versus
60% (C).
Conclusion: The analysis of the CFTR genome by ampli-
fication and OLA including the 21 kb genomic deletion and
the 5T allele is superior to the examination of the 10 or 24
most common mutations according to the detection of both
mutations in German patients. Optimal first line strategies
need to be evaluated for every population.
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THE EPIDEMIOLOGY OF CF GENE IN ROMANIA
I. Popa , L. Pop , Z. Popa , L. Dracea , P. Grigorescu-1 1 2 3
Sido , M. Filip , Gh. Benga , L. Frentescu , M. Schwarz ,4 4 4 4 5
Z.L. Popa1
University of Medicine and Pharmacy Timisoara, CF1 2
Centre Timisoara, Children’s Hospital Brasov, University3 4
of Medicine and Pharmacy Cluj-Napoca, Romania, Royal5
Manchester Children’s Hospital, Genetic Unit, UK
The aim of the paper is to show the current data regarding
the epidemiology of CF gene in Romania. Study lot: 45 CF
patients (20 male and 25 female) from different areas from
Romania, followed by the CF Center Timisoara. We
excluded the cases with non-conclusive clinical findings if
the sweat test were normal or borderline, respectively, we
included the cases with conclusive clinical findings even
with sweat test normal or borderline. The sweat test was
performed with electronic machine ‘Wescor’. The genetic
tests were performed at Royal Manchester Children’s Hos-
pital, Genetic Unit, UK. DNA was obtained from integral
blood samples.
Results: Five patients (11%) had normal or borderline val-
ue of chloride. Four of them were confirmed by genetic
test. The genotype structure of the evaluated cases was:
delta F508ydelta F508, 31.1%; delta F508ynon-delta F508,
22.2%; delta F508yunknown, 8.88%; non-delta F508ynon-
delta F508, 2.22%; non-delta F508yunknown, 4.44%;
unknown genotype, 31.1%. Delta F508 has a frequency of
46.6%. About non-delta F508 mutations, we identified 15
alleles from which: 20% most frequent in Central and East-
ern Europe, 33% most frequent Western European Coun-
tries or other areas and populations far away from Romania,
46.6% sporadic and rare mutations.
Conclusions: The frequency of delta F508 mutation is sim-
ilar to the neighbor countries with a majority Caucasian
population; the complex structure of the identified alleles
emphasizes its heterogeneous character; the importance of
genetic test in CF diagnoses, if the sweat test is normal or
borderline.
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THE MUTATION SPECTRUM OF CFTR GENE IN
THE CF PATIENTS FROM BASHKORTOSTAN
G. Korytina , T. Victorova , T. Ivaschenco , D. Yanbaeva ,1 1 2 1
V. Baranov , E. Khusnutdinova2 1
Institute of Biochemistry and Genetics, Ufa, Institute for1 2
Obstetrics and Gynecology, St. Petersburg
Cystic fibrosis (CF) is one of the most common autosomal
recessive disorders A mutations in the CFTR gene causes
this disorder. The aim of our study was to identify the most
common mutations and create a CF-screening programme
that would enable complete CF mutations detection among
our patients. We have screened 141 CF chromosomes for
18 previously reported mutations: delF508, 1677delTA
CFTRdele2.3 (21 kb), 394delTT, 1154insTC, R347P,
R334W, G542X, G551D, R553X, S549N, 2184insA,
2143delT, S1196X, 3737delA, 3849q10 kb T C, W1282X,
N1303K. We also used SSCP-analysis for exons 3, 7, 10,
11, 13, 19 and 20, to find other mutations. The results of
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molecular analysis revealed the following frequency of
detected mutations: delF508 (34%), 394delTT (3.5%),
CFTRdele2.3 (21 kb) (1.4%), R334W (1.4%), G542X
(0.7%), 2184insA (0.7%), S1196X (0.7%), 3849q10 kb
T™C (1.4%), W1282X (0.7%), N1303K (1.4%). Six nov-
el mutations are detected I488M (0.7%) Q493E (0.7%) in
10 exon, 1811q12A C (1.4%)—11 intron, T663S (1.4%)
13 exon, I1226R (0.7%)—19 exon, 4005q9A™C
(0.7%)—20 intron. And two new polymorphisms was
found: 2097A C (A655A)—13 exon (0.7%), 3996G™C
(V1288V)—20 exon (2.1 %). This leading study resulted
in the identification of 16 different mutations accounting
for almost 50% of CF alleles.
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DELTAF508 HOMOZYGOSIS: TWO CASES OF
MISDIAGNOSIS
A. Cannuscio , L. Iapichino , R. Messineo , C. Di1 2 1
Girgenti1
Laboratorio di Genetica Molecolare – Ospedale G. Di-1
Cristina, Centro Regionale Fibrosi Cistica – Ospedale G.2
Di Cristina, Paleermo I-90100, Italy
Among genetic analysis performed in our laboratory in CF
families, two relatives of propositus (a maternal aunt, RR,
and a sister, BV) turned out to be homozygous for the
deltaF508 mutation (molecular analysis of 31 mutations
carried out by Cystic Fibrosis Assay Kit—Applied Bios-
ystem). The electropherograms showed an irregular peak
within plot of deltaF508 normal allele. Generally this peak
is not present on deltaF508 homozygous subjects.
Both subjects are adult, healthy and show normal sweat test
(chloride concentration: 38–40 mEqyl).
Genotype molecular characterisation by INNO-LiPA
CFTR12 Kit identified both subjects as DF508 heterozy-
gous. Furthermore, RR’s father was DF508 heterozygous
and the mother was normal for the studied mutations. BV’s
parents were not available.
We hypothesised that the detection of only a mutant
deltaF508 allele in the RR and BV’s electropherograms was
caused by a DNA sequence variation of exon 10. This
sequence variation might prevent detection of the normal
allele.
We proceeded sequencing PCR product exon 10 by BigDye
Terminator Cycle Sequencing Ready Reaction Kit (Applied
Biosystem). We identified the substitution at nucleotide
position 1716 G to A in the three subjects RR, BV and in
RR s mother. Nucleotide substitution does not appear to
affect the encoded amino acids (G or A).
This observation was helpful in the interpretation of genetic
tests. The interaction of deltaF508 mutation with the sub-
stitution at nucleotide position 1716 may lead to a misdi-
agnosis of deltaF508 homozygosity.
It is also important to note that Cystic Fibrosis Assay Kit
detects other mutations (V520F, deltaI507, Q493X) located
in exon 10. Also these mutations can present the same prob-
lem and this may be cause misdiagnosis.
Seen in this light, the identification of other alterations on
CFTR gene will be an essential part in understanding the
structure and function of the protein and to provide useful
information to set up genetics test.
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CANADIAN GUIDELINES FOR HUMAN STEM
CELL RESEARCH (2002) : POSSIBLE
APPLICATION TO CF RESEARCH
M.J. Melancon , B. Leclerc , M. De Braekeleer1 2 3´ ¸
Universite du Quebec a Chicoutimi, Quebec, Canada,1 ´ ´ ` ´
Member of the Canadian Working Group on Stem Cell
Research, Departement de philosophie, College de2 ´ `
Rimouski, Quebec, Canada, Universite de Bretagne Occi-3´ ´
dentale and CHU Morvan, Brest, France
Although the treatments have increased the life expectancy
of patients with cystic fibrosis (CF), it is still a lethal dis-
order with no curative therapy. Much efforts have been put
into the development of gene therapy. One can ask whether
pulmonary stem cells graft could be an other alternative and
a promising CF research avenue.
The aim of this communication is to present important rec-
ommendations for research on stem cells made by the ad
hoc Working Group on Stem Cell Research (WG) (2002)
of the Canadian Institutes of Health Research (CIHR).
The WG, (9 experts in clinics, science, law and ethics), has
met several times since November 2000, reviewed the
Canadian and international literature in the evolving inter-
national situation, and prepared a Discussion paper (March
2001) for public consultation before writing the Final report
(January 2002).
This report provides 18 recommendations on areas of stem
cell research eligible or ineligible for CIHR funding.
Among them we selected important ones with regard to CF.
Research involving the grafting of human embryonic stem
cells, embryonic germ cells or other human cells of a plu-
ripotent nature into non-human animals (from birth to
adulthood) is eligible for CIHR funding, under 3 conditions
(R.4.6).
Research involving the grafting of human stem cells or oth-
er human cells of a pluripotent nature into legally compe-
tent humans is eligible for CIHR funding provided that: (a)
there is overwhelming evidence from pre-clinical models
for safety and efficacy; (b) the research is carried out in
well-designed clinical trials; (c) there is free and informed
consent from the prospective research participants (R.4.7).
CIHR should immediately establish a National Stem Cell
Oversight Committee responsible for the ethics review of
human pluripotent stem cell research (R.8.1).
The Canadian guidelines for human stem cell research
(2002) could be relevant and useful for CF research involv-
ing stem cells grafting.
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PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS:
THE EXPERIENCE OF THE MILAN CENTER
M. Seia , P. Capasso , R. Padoan , A. Giunta , A. Canty-1 1 2 2
Rajnoldi , D. Coviello1 1
Laboratorio di Genetica Medica, A.O. ICP Milano, Italy,1
Centro FC Regione Lombardia, A.O. ICP Milano, Italy2
Over the last 10 years prenatal diagnosis (PND) of cystic
fibrosis (CF) using DNA based methods has moved from
linkage analysis to direct mutations detection.
PND and molecular testing of CF started in our Centre in
1987.
Molecular analysis performed in 624 CF patients followed
at the regional CF Centre of Lombardia showed a great
heterogeneity of CF molecular defects. In 83% of chro-
mosomes 67 mutations were detected. In the remaining
17% of CF chromosomes the mutation was not detected
and PND could be performed using linkage analysis by
intragenic microsatellite markers.
To date 190 PND in family at risk 1:4 of CF has been
performed using increasingly specific techniques to study
foetal DNA extracted from chorionic villi. Since 1992 the
genetic study protocol, which previously covered only the
molecular segregation of the gene responsible for the
pathology in question, has been expanded to forensic
markers.
Among 190 PND: 43 were affected, 121 heterozygous and
26 normal.
In 2 cases of affected foetus the parents decided to continue
the pregnancy.
Among the 190 PND performed in 175 cases the couples
were already parents of an affected child, in 9 couples one
subject was carrier already known (family history) and the
second was identified as carrier during to DNA analysis at
our Centre, 2 cases had as a positive marker for hyperech-
ogenic bowel, 2 couples were identified at risk tank to neo-
natal screening program and in the last period two cases of
PND were carried to check the result of preimplantation
genetic diagnosis.
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PRENATAL DIAGNOSIS AND GENETIC
COUNSELLING: 1992–2002 ACTIVITY OF
TUSCANY REGIONAL CENTRE FOR GENETIC
DIAGNOSIS OF CYSTIC FIBROSIS
E. Pelo , B. Minuti , C. Centrone , S. Bernabini , F.1 1 1 1
Sbernini , E. Periti , T. Repetto , M. De Martino , F.1 2 3 3
Torricelli1
U.O. Citogenetica e Genetica, Azienda Ospedaliera Car-1
eggi, Firenze, Dipartimento di Ginecologia e Ostetricia,2
AziendaOspedaliera Careggi, Firenze, Centro Regionale3
Fibrosi Cistica, Azienda OspedalieraMeyer, Firenze
Assessing the reproductive choices of parents of children
with cystic fibrosis (CF) is important in getting a greater
insight into the possible needs for counseling of carrier cou-
ples in the reproductive decision-making process.
Genetic counseling is an important part of health care in
patients with CF or respiratory diseases associated with the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene. The basic goal is to provide patients with
information on the transmission of CF and to assess the
risk of recurrence. This risk is determined from molecular
biology analyses examining the CFTR gene. Genotyping is
the only means of screening for the heterozygous state, fre-
quent in the Tuscany population (;1y30).
More than 900 mutations and more than 200 different pol-
ymorphisms have now been reported in the CFTR gene.
Because of the large number of mutated alleles not covered
entirely by the genetic tests, there remains a question of
probability expressed as a residual risk of a heterozygous
state. A prenatal genotype diagnosis should be proposed to
heterozygous couples who have a 25% risk of having a
diseased child. Technically, this is almost always possible
and the results are highly reliable. Nevertheless, there
remains the risks related to sample taking and the ethical
issue about which the patients must be informed. Manage-
ment of these at risk couples who desire a child must be
based on a multidisciplinary approach, particularly impor-
tant when one of the parents has overt CF.
Based on our results, genetic counseling clearly benefits
families. This study also confirms that parental reproductive
plans are influenced by the identification of a child who is
a carrier of a mutated CFTR gene. This finding further
demonstrates the need for accurate counseling about het-
erozygote status. Genetic counseling is imperative for the
success of prenatal diagnosis for CF and other congenital
diseases.
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TOWARDS A GENERAL QUALITY STANDARD
IN GENETIC TESTING
E. Dequeker, J.J. Cassiman
KU Leuven, Leuven, Belgium
Genetic diagnostic laboratories show a growing interest in
the systematic application of quality assurance (QA) in
genetic diagnostic laboratories. Many laboratories now par-
ticipate in external quality assessment (EQA) schemes. In
order to evaluate the status of QA implementation in genet-
ic diagnostic laboratories, a survey on QA and accreditation
was sent to 206 laboratories from 32 European countries
and 5 laboratories in Australia and the USA.
One hundred and fifty one participants responded (73%) to
the survey. In order to minimise errors, an appropriate QA
system needs to be worked out for the whole procedure of
a genetic analysis. Such system is established in 110 of the
surveyed laboratories (73%): 45 laboratories follow an
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international standard, 52 a local or national standard, and
13 laboratories did not specify which guidelines are being
used. However, only 82 laboratories are officially inspect-
ed: 52 are inspected by a national body, and 30 are accred-
ited by an internationally recognised accreditation body.
Thus, it is clear that at present there is no harmonisation
on QA among laboratories. The new ISO 17025 standard,
which is accepted by most national and international
accreditation bodies, could therefore be an important step
towards harmonisation of laboratory practice. This new
standard also includes requirements for reporting the
results. The reporting results of the latest CF EQA schemes
illustrate that less than 15% of the laboratories include all
the items required by this new standard.
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DHPLC ANALYSIS PROTOCOL FOR THE
CHARACTERISATION OF CF ALLELES IN THE
ITALIAN POPULATION
R. D’Apice, F. Sangiuolo, S. Gambardella, G. Novelli
Department of Biopathology and Diagnostic Imaging, Tor
Vergata University, Rome, Italy
CF molecular diagnosis and heterozygotes screening in Ita-
ly have become even more difficult because an elevated
CFTR allelic heterogeneity and a different regional distri-
bution of CF mutation and polymorphisms. We successfully
applied denaturing ion-pair reverse-phase high performance
liquid chromatography (DHPLC) technology to develop a
rapid and accurate analysis protocol able to characterise
nearly all CF chromosomes in Italian population. Using this
protocol we analysed the complete coding sequence of the
CFTR gene, after optimising temperature conditions
required for the analysis of 27 amplicons. We tested 100
CF patients and characterised their CF alleles, successively
confirmed by sequence analysis (see Table)
Test Mutation detection rate (%) Individuals
by no. of
causing allele
disease
2 1 0
DHPLC 90 75 22 3
Innolipa CF12yCF17 77 56 38 6
Innolipa CF12 60 29 52 19
Our data confirm and extent the usefulness of DHPLC
in CF allele characterisation. Our experience strongly
support the efficacy of this technique to reveal CF
mutations even in a more allelic heterogeneous
population. By this protocol the CF detection rate is
increased from 77 to 90%.
Supported by Regione Lazio, Fondo Sanitario Nazionale
per la Prevenzione e la Cura della Fibrosi Cistica (Legge
23 dicembre 1993, N. 548).
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PYROSEQUENCING TO ASSESS THE MOST
COMMON CYSTIC FIBROSIS MUTATIONS
Anna Lotta Schiller, Jenny Dunker, Ulrika Larsson, Maria
Storgards, Rhiannon Sanders, Anders Alderborn¨
Thirteen years after the discovery of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene and
the characterization of over 990 mutations, CF is now to
become the first disease targeted for population-wide genet-
ic screening.
Pyrosequencing AB (Sweden) offers a PSQ96MA System
well suited to meet the demand for research and routine
testing of mutations in the CFTR gene, providing simple,
rapid, cost efficient and extremely accurate detection of all
relevant mutations, including internal controls for each
analyzed position. Pyrosequencing is a DNA sequencing
technology based on real-time detection of pyrophosphate
released upon nucleotide incorporation. Highly reliable CF
assays have been designed and developed for CFTR muta-
tions with a population frequency of00.1% including point
mutations as well as insertions and deletions, for example
?F508, ?I507, 1717y1G?A, G85E, R117H, Y122X, I148T,
621q1G?T, 711q1G?T, 1078delT, R334W, R347P, A455E,
G542X, G551D, R553X, R560T, 1898q1G?A, 2184delA,
2789q5G?A, 3120q1G?A, R1162X. 3659delC, 3849q
10kbC?T, W1282X, N1303K, 394delTT as well as 5Ty7Ty
9T. No additional reflex test has to be performed to
distinguish severe mutations from any neighboring benign
variants. The assays are greatly condensed including mul-
tiplex design of both PCR and sequencing reactions. The
assays have also been optimized to even include less com-
mon mutations in the same analysis simply by extending the
number of nucleotide dispensations in each pyrosequencing
reaction. In addition to these two approaches, the same
assays have been used for population-based determination
of carrier frequencies using allele quantification.
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3-YEARS EXPERIENCE IN CF NEONATAL
SCREENING
D. Sands, A. Nowakowska, R. Piotrowski, K. Zybert, A.
Milanowski, M. Oltarzewski
Institute of Mother and Child – Pediatrics Department
Despite its relative frequency, cystic fibrosis (CF) is diffi-
cult to diagnose in infancy and delays may lead to severe
malnutrition and advanced lung disease. In Poland the aver-
age age of diagnosis is approximately 4 years (median-12
months) and has not improved over the past decade. The
aim of neonatal screening programme for CF is early diag-
nosis in presymptomatic period. Since 1999 CF neonatal
screening programme has been started in Poland (1y4 of
the population) different method were used. IRTyIRT
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(recall method) with confirmation by sweat test was finally
introduced.
Results of CF neonatal screening.
In 1999, 2000 and 2001 (until September) we screened
85710, 99261 and 64223 newborns, respectively. We con-
firmed 47 cases of CF (14 in 1999, 21 in 2000 and 12 in
2001)—one case of CF was missed. This gives the follow-
ing frequencies: 1:6122, 1:4511 and 1:5352, respectively.
Age of diagnosis: means3.8 weeks, medians4 weeks.
The following genotypes were found:
dF508ydF508s29
dF508ydele2.3s4
dF508y3849q10 kb C Ts1
dF508yR553s1
dF508yN1303Ks2
dF508y?s7
N1303Ky?s1
dele2.3y?s1
?y?s1
Forty-one children are followed-up in Warsaw CF Centre.
Twelve patients did not ever need to be hospitalised. Clin-
ical course was characterised by pancreatic insufficiency
(most of our patients) and metabolic alkalosis (9 patients).
Less children suffered of respiratory symptoms.
Conclusions: Neonatal screening for CF enabled earlier
diagnosis and introduction of prophylactic strategy and
complex therapy. Normal somatic development may be
achieved thanks high caloric diet and early supplementation
with pancreatic enzymes. CF Patients should be followed
up in the specialised centers.
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NEONATAL SCREENING FOR CYSTIC
FIBROSIS MUTATION IN TUSCAN POPULATION
C. Centrone , B. Minuti , E. Pelo , S. Bernabini , G.1 1 1 1
Taccetti , T. Repetto , M. De Martino , F. Torricelli , L.2 2 2 1
Marianelli2
U.O. Citogenetica e Genetica, Azienda Ospedaliera Car-1
eggi, Firenze, Centro Regionale Fibrosi Cistica, Azienda2
OspedalieraMeyer, Firenze
The newborn screening for cystic fibrosis (CF) that it
comes executed in the Tuscany, from 1991, is based cur-
rently on the dosage of the trypsina on spot of blood and
on the dosage of the lattasi on sample of meconium. The
present research is proposed to place side by side to these
analyses the study of the mutations of CFTR gene more
frequently characterised in Tuscany patients with CF, in
order to increase and to improve the specificity of the
screening. The conduct genetic analyses from 1987 to
today, on 186 afferent CF patients to the From Tuscany
Centre for Cystic Fibrosis, have allowed to characterise the
79.6% of CF chromosomes. Analyzing the data, it emerges
that mutation L1065P, described in literature like rare muta-
tion, represents 4% of chromosomes FC of Tuscany origin.
The sampling begun in March 2001; from this date to the
end of December they have been analyzed 24.487 Tuscany
newborn. The positive IRT are 318. Between these they
have been characterized five subjects with genotype CF,
two homozygous deltaF508 and three heterozygous com-
posed (one of these with deltaF508yL1065P and two with
deltaF508yG542X); 21 introduce a single mutation,
between those analyzed, positive in heterozygous.
The frequency of the identified mutations is 4.9%. The
genetic analysis on positive champions IRT is in a position
to characterizing patients CF with greater reliability regard-
ing the methodologies of screening in use therefore sending
to the sweat test a reduced number of false cases and there-
fore to reduce the number of the positive ones. To charac-
terize subjects heterozigous and to establish eventual
relations of causality with hypertripsinemie in order to
define meant clinical of the IRT with one mutation CFTR.
The result of the screening can also evidence prematurely
not only classic shapes of CF but also mild shapes for
which a clinical one can be previewed for specific
management.
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NEONATAL SCREENING OF CYSTIC FIBROSIS
IN CASTILLA AND LEON (SPAIN)
J.J. Telleria, M.J. Alonso, J.A. Garrote, I. Fernandez, A.
Blanco
Department of Pediatrics and Immunology and Instituto de
Biologia y Genetica Molecular, Universidad de Valladolid
Aims: To analyse the efficiency of the method used in the
neonatal screening of cystic fibrosis (CF) in Castilla y
Lesn, carried out with blood from the Guthrie spots.
Material and methods: We have studied 44.710 samples
from newborns from January 1999 to December 2001
obtained between the 4th and 6th day of life and submitted
by post to our lab.
Immunorreactive trypsinogen (IRT) was quantified in all
samples and genetic study covering 87.5% of the CFTR
mutations in our population was carried out when IRT lev-
els were higher than 60 ngyml. Children in which one
mutation detected, were tested by sweat test.
Results: IRT values)60 ngyml were observed in 384 chil-
dren (0.86%), diagnosis of CF was reached in 11 cases
(3.8%), and one mutation was detected in other 19 (4.9%),
being the sweat test negative, and classified as healthy car-
riers. CF was diagnosed in 1y4.064 newborns. We did not
notice any false negative, until now.
Conclusions: The two-tier screening method we have used
fulfill the required criteria showing a 98.5% sensibility. The
basic model can be used in other regions, although, the
genetic search should be optimized by means of pilot pro-
grams in order to identify the local spectrum of CFTR
mutations.
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THE FRENCH NATIONAL SCREENING
PROGRAM FOR CF
C. Grosskopf , J.P. Farriaux , M. Vidailhet , M.L. Briard ,1 1 1 1
G. Travert , V. Belot , P. Roussel , D. Turck , J. Navarro ,1 2 3 4 5
J. Bloch6
AFDPHE, CNAMTS, Lille University, CHU Jeanne de1 2 3 4
Flandre, Lille, Hopital Robert Debre, DGS, France5 6´
Sufficient evidence from Wisconsin, Australia and the
western part of France now exist to confirm the interest of
implementing neonatal screening for CF. The French Asso-
ciation for Neonatal Screening (AFDPHE) obtained the
reimbursement by the social security (CNAMTS) for
screening CF in December 2000. During the year 2001,
different expert groups (IRT, DNA, Information, Ethics and
genetics, criteria for CF Centre, Protocol of Care of a new-
born with CF) issued recommendations to establish a
national program which would guarantee efficacy and ade-
quate CF management and care from diagnosis. An IRTy
DNA strategy was chosen. Due to relative regional
heterogeneity, the number of mutations selected is 29 which
provide a 85% coverage. The ethics and genetics committee
recommended that informed consent according to French
bioethics regulation should be obtained on all neonates at
birth directly on the blotting paper in order to decrease the
anxiety of parents if recalled. Implementation of the screen-
ing program was an unique opportunity to be able to organ-
ize the French CF care in creating CF centres recognized
by the Health Ministry where children diagnosed should be
referred and receive adequate care by a trained staff with
sufficient means. A protocol for screened CF babies was
established. It includes frequent visits, daily chest therapy,
nutrition care and rapid intervention if problems. This pro-
gram will be implemented region by region in France from
beginning 2002 till 2003.
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NEWBORN SCREENING FOR CF: THE WELSH
WAY
S. Hall , K. Azzopardi , I. Doull1 1 1
Paediatric CF Unit, Department of Child Health, Univer-
sity Hospital of Wales, Cardiff, Wales
Wales has had newborn screening for Cystic Fibrosis by
measurement of bloodspot immunoreactive trypsin (IRT)
since December 1996. Newborns with the top 0.5% of
bloodspot IRT values are then screened for 31 common CF
mutations (accounting for 93% of Welsh CF mutations),
and if one or more mutations are detected, the families are
invited for a sweat test.
We have developed the standard that all infants should have
a sweat test, and the results explained to the family, within
24 h of the possibility of CF being broached with the fam-
ily. The CF Nurse Specialist and the infant’s own Health
Visitor undertake a joint visit 24 h prior to the sweat test,
where parents are told there is a possibility of CF, but that
a sweat test is needed for definitive diagnosis. Appropriate
written information and contact numbers are left with the
family.
During 2001, nine infants were identified in Cardiff as hav-
ing 1 or 2 CF mutations: 2 infants with CF mutations, and
7 infants with a single mutation. Sweat testing confirmed
CF in 2 infants, and the remaining 7 were unaffected car-
riers. In all cases, a diagnostic sweat test was performed
within 24 h of the possibility of CF being broached. Of
these 6 parents opted for genetic counselling and cascade
testing.
The present protocol minimised the period of stress for
most parents to 24 h, while allowing the families time to
come to terms with the possibility of CF, and arrange for
both parents to be present for the sweat test result. The
sweat test remains pivotal as a focus for a definitive diag-
nosis. Although this remains to be a stressful time for par-
ents, they have reported satisfaction at the information they
have been given and are fully aware of reasons for
attending.
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NEWBORN SCREENING PROGRAM FOR
CYSTIC FIBROSIS IN LIGURIA REGION
P. Vannini , L. Minicucci , L. Romano , U. Caruso , C.1 1 1 1
Corbetta , F. Dagna-Bricarelli , R. Lorini2 3 1
University Department of Pediatrics and CF Centre – Gas-1
lini Institute, Genoa, Italy, Istituti Clinici di Perfeziona-2
mento – Milan, Italy, Centro di Genetica Umana –3
Ospedali Galliera, Genoa, Italy
Newborn screening for CF was started in the Liguria
Region in October 1997, after a short period of pilot pro-
grammes aimed to study feasibility and method set-up.
Immunoreactive trypsin (IRT) is measured on 3 mm of
diameter blood spots by time resolved fluoroimmunoassay
(Delfia., followed by Autodelfia. in June 2000). Due to
method changes, the cut-off value (70 ngyml at the begin-
ning) has been adjusted during the time, being now 55 ngy
ml. Blood spots showing IRT concentration over the cut-off
are re-tested in duplicate. If the abnormal value is con-
firmed (two positive results among the three) the baby is
called at age 2 months for the sweat test. Up to December
31st 2001, 48 100 newborns have been tested (coverage:
99.5%). 378 newborns (0.79%) have been called for sweat
test and 12 new CF patients (1:4008 newborns) have been
identified. Newly identified patients are referred to the CF
Centre for clinical evaluation and follow-up. The relative
allele frequencies were (9y12 patients) DF508: 9 (50%),
N1303K: 3 (17%), G542X: 3 (17%), others or unknown:
3 (17%). This distribution closely mimics that of the Italian
CF patients. One false negative patient was found, showing
at birth IRTs59 ngyml. The patient is DF508 homozygote.
Accordingly with the literature and the experience of other
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Centres, babies showing borderline sweat test result (high
normal value considered: Cl 40 mEqyl) are clinically eval-
uated and inserted in a special follow-up program, looking
especially to changes in sweat test results. In these patients
the genetic testing for CF mutations is performed on the
blood spot, after parental informed consensus. 8 babies out
of the 19 showing borderline sweat test result are etheroz-
ygote for CFTR mutations. Genetic testing is also per-
formed on the blood spot when it is impossible to perform
the sweat test on the child (deceased or impossible to con-
tact, 18 patients, one CF).
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CYSTIC FIBROSIS IN GREECE: MOLECULAR
DIAGNOSIS, PRENATAL DIAGNOSIS AND
CARRIER IDENTIFICATION AMONGST HIGH-
RISK INDIVIDUALS
M. Tzetis , A. Efthymiadou , S. Doudounakis , E.1 1 2
Kanavakis1
University of Athens, Department of Medical Genetics, St.1
Sophia’s Children’s Hospital, Athens, 11527, Greece, Cys-2
tic Fibrosis Clinic, St. Sophia’s Children’s Hospital, Athens
11527, Greece
Since the identification of the CF gene more than 1000
mutations have been discovered, few common in all pop-
ulations but the majority being ethnic specific. We have
conducted CF mutation analysis on 437 patients, character-
izing 83 different mutations (21 specific to our population)
accounting for 91% of CF genes and generating 103 dif-
ferent genotypes. The most common were F508del
(53.4%), 621q1G™T (5.7%), G542X (3.9%), N1303K
(2.6%), 2789q5G™A (1.7%), 2183AA™G (1.4%),
E822X (1.4%), R1158X (1%). Fourteen show frequencies
between 0.5 and 1%, while the rest (61) were found on 3
to one alleles. DGGE screening of 7 exons (4, 10, 11, 13,
14b, 17b and 21) detects 80.6% and expanding the search
to 5 more (3, 7, 16, 19 and 20) increases the percentage of
detectable CF alleles to 85.5%. During this period we have
also performed 165 prenatal diagnoses (including 49 due
to bowel hyperechogenicity) using a combination of DGGE
CFTR mutation screening and the intragenic markers
IVS8TA, 17BTA and 17BCA, testing a total of 39 different
parental genotypes. 116 prenatals resulted in 24 affected,
58 heterozygous and 34 normal fetuses. Of the 49 echo-
genic bowel fetuses tested, 3 were heterozygotes. With the
aim of reducing the number of CF births through recogni-
tion of parental heterozygosity carrier screening was initi-
ated, with emphasis on individuals and couples in high-risk
groups—with a family history of CF, one partner with CF,
couples with male fertility seeking IVF. We have completed
mutation analysis on 552 individuals (including 120 cou-
ples, 91 unaffected CF siblings, 283 CF family relatives
and 58 general population subjects). We identified a total
of 175 heterozygotes and 7 couples where both members
were carriers. Prenatal diagnosis was performed in 4 cases
and 3 were counseled on the need for prenatal diagnosis
upon pregnancy. We have thus shown the feasibility of pop-
ulation screening for CF in Greece, by DGGE screening of
12 CFTR exons, identifying 85.5% of CF alleles.
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PREVALENCE OF THE CFTR MUTATION IN
NEWBORN WITH INCREASE IRT, DETECTED
THROUGH A PILOT NEONATAL SCREENING
FOR CYSTIC FIBROSIS IN THE PIEMONTE
REGION, ITALY
G. Restagno , E. Bignamini , L. Anfossi , L. Sbaiz , A.1 2 2 1
Gomez , S. Bosso , L. Leone1 1 3
Molecular Genetics Service, Azienda Ospedaliera1
Oirm.s.Annatorino, Italy, Cystic Fibrosis Centre Azienda2
Ospedaliera Oirm’s, Anna-Torino Italy, Department of3
Clinical Pathology Azienda Ospedaliera Oirms, Anna Tori-
no, Italy
Neonatal screening strategy. A two-step combines the assay
for immunoreactive trypsinogen (IRT) with the analysis of
30 mutations in the CFTR gene through OLA-PCR SCS.
Neonates with two mutations are referred directly for clin-
ical assessment and confirmatory sweat test, to the CF cen-
tre; those with one mutation are recalled for sweat test in
order to understand if they have or have not CF. A genetic
counseling benefit is offered to parents when trypsinogeny
DNA screening is performed. This strategy results in an
early and accurate diagnosis of CF but it has been reported
that hypertrypsinemia is more frequently found in
heterozygotes.
Prevalence of heterozygosity in hypertrypsineminaemic
newborns.
Heterozygosity frequency has been assessed in 50 956 chil-
dren born from July 2000 to December 2001. Nine hundred
and ninety six (996) of those tested had an IRT level great-
er than the decisional threshold (1.95%, 1 of 51) and were
analysed for mutations. Nineteen (19) were CF (repeated
positive sweat test) and 80 were healthy carriers. Incidence
of CF was 1y2682, leading to a carrier frequency of 1y26,
while the estimated frequency of heterozygotes in children
with hypertrypsinaemia was 1y9, three time greater than
general population (1y26). The number of different muta-
tions in carriers is greater than CF children (13 versus 10).
The identification of an excess of heterozygotes in hyper-
trypsinaemic newborns remains an important matter that
can only be managed with effective counseling strategies.
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CFTR GENE:FREQUENT HAPLOTYPES
INVOLVED IN AZOOSPERMIC PATIENTS AND
IRT RAISED SAMPLES
M.J. Alonso, E. Dominguez, J.J. Telleria, J.A. Garrote, I.
Fernandez, A. Blanco
S99Journal of Cystic Fibrosis 1 (2002) S81–S180
Departamento de Pediatria, IBGM (Instituto de Biologma
y Genetica Molecular), Fac. Medicina. Avda Ramon y
Cajal 7 Valladolid, Spain
Aims: To analyse the frequency of the IVS8-5T variant in
CBAVD (Congenital Bilateral Absence of Vas Deferens),
CUAVD (Congenital Unilateral Absence of Vas Deferens)
and CBASV (Congenital Bilateral Absence of Seminal
Vesicles) patients and neonatal screening samples with IRT
elevated, and extend the haplotypes in order to stabilise the
differences and similarities between these phenotypes.
Methods: We analysed 23 exons from the CFTR gene in
19 azoospermic patients (16 with CBAVD, 2 with CUAVD
and 1 with CBASV). Two hundred and twenty five neonatal
blood samples with raised IRT were also studied for 12
CFTR exons, including the 90% of the mutations causing
Cystic Fibrosis in our population. The screening methods
were PAGE, DGGE and direct sequencing.
Results: F508del was the most frequent mutation in both
cases, but the IVS8-5T variant is the second in the azoos-
permic patients but not in IRT raised samples. There exist
differences too when we extend the haplotype and analyse
the (TG)m variant: (TG)12 is the most frequent in CBAVD
phenotypes and (TG)11 in CUAVD and neonatal samples
with elevated IRT.
Another important difference is the linkage desequilibrium
found between 5T-11TG haplotype and the 875q40 A–G
polymorphism in IRT elevated samples.
Conclusions: The penetrance of the IVS8-5T variant could
be affected not only by the (TG)m but another polymor-
phisms as 875q40 A–G, raising the IRT values at birth,
or it is also possible that this haplotype is linked to another
not detected mutation.
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CF SCREENING: A FOLLOW-UP OF CYSTIC
FIBROSIS (CF) PATIENTS IDENTIFIED BY
NEONATAL SCREENING
I. Eichler, R. Rath-Wacenovsky, S. Renner, S. Stockler-¨
Ipsiroglu
University Children’s Hospital, Vienna, Austria
Aims: In November 1997 nationwide neonatal screening
programme for CF has been started in Austria. We retro-
spectively sampled clinical data of patients diagnosed dur-
ing the screening period and followed at the University
Children’s Hospital (UCH) to characterise their clinical
course.
Methods: Neonatal screening is performed by two tier IRT
testing (flourimmunoasssay DELFIA Wallace, Turku, Fin-
land). After the second IRT being positive quantitative
sweat testing is performed.
Results: In Austria 248 638 newborns have been screened
for CF since 1997. One thousand four hundred and forty
one infants had a positive first IRT test (0.57%). 368 of
those infants also had an increased IRT value at the second
sample (0.15%). Subsequently 80 infants were diagnosed
as cystic fibrosis patients by quantitative sweat testing and
clinical evaluation (1:3108). In the UCH-CF Center 20
children with CF were diagnosed since screening pro-
gramme was started. 18y20 infants had two increased IRT
values. 19y20 infants had two positive sweat test results,
one patient had repeated normal sweat tests. 10y20 patients
were found to be DF508 homozygous, 7y20 DF508 het-
erozygous in molecular genetic analysis. In 3 patients no
CFTR mutations could be detected so far. Mean age of
diagnosis was 70.3 days compared to 15.3 months prior to
the screening programme. 2y20 infants presented with
meconiumileus, 14y20 patients presented with symptoms
(bronchitis, pneumonia, failure to thrive) prior to CF diag-
nosis and 6y20 patients were asymptomatic. Mean weight
at the time of diagnosis was 3.89 kg. 19y20 infants were
diagnosed as pancreatic insufficient and pancreatic enzyme
supplementation was started. P. aeruginosa was detected in
10y20 infants at the mean age of 7 months. 11y20 patients
are colonized with Staph aureus. Mean FRC flow (18y20)
at age of diagnosis was at the 23rd percentile.
Conclusion: Neonatal screening for CF allows early diag-
nosis and intervention, families get a chance to deal with
it from early age on.
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CF CARRIER IDENTIFICATION IN SOUTHERN
FRANCE: A GREATER FREQUENCY THAN
EXPECTED
M. Des Georges , C. Guittard , A. Bouchut , J. Feingold ,1 1 1 2
M. Claustres1
Laboratoire de Genetique Moleculaire et Chromosomique1
IURC, 641 Avenue du doyen Gaston Guiraud, 34093 Mont-
pellier cedex5 France, Department of Medical Genetics2
and INSERM U393, HopitalNecker Enfants Malades,
75015 Paris, France
Cystic fibrosis has an incidence of 1y2500 to 1y3000 and
a carrier rate estimated to 3.5–4% in Caucasians. The prev-
alence of mutations has been defined by the frequency of
CF mutations in affected individuals. The aim of this work
was to evaluate the frequency of carriers in Languedoc-
Roussillon by scanning CFTR sequences by DGGE and
sequencing in 300 subjects.
Results: We detected 4.66% heterozygotes for one of four
confirmed mutations that were identified in the tested sam-
ple (F508del, G542X, D443Y, R117H) and 3.33% hetero-
zygotes for one of three ‘potentially’ CF-related mutations
(S1235R, L997F, V562I). In addition, 4y50 carried one
haplotype TG11T5.
Conclusion: If we consider only F508del and G542X, the
carrier rate in our population is 1y27. If we add D443Y
and R117H-7T (associated with CBAVD only in South of
France), the prevalence of CFTR mutations is 1y21. If
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S1235R, S1235R, L997F and V562I are considered as path-
ogenic mutations, the frequency of carriers is increased to
1y12, which was unexpected.
This finding suggests several hypothesis:
(1) Two types of CFTR mutations are present in the pop-
ulation: mutations causing CF and mutations causing
‘CFTR-opathies’.
(2) Some mutations can be, alone, neutral polymorphisms,
but may become deleterious when they are associated in cis
with other(s) variation(s). S1235R may be a CBAVD-caus-
ing mutation when associated in cis with TG13T5 in infer-
tile men carrying a confirmed mutation in trans. We suggest
that some ‘deleterious haplotypes’ might confer a higher
risk to express CFTR defects.
(3) Having just one copy of an abnormal CFTR may pre-
dispose some individuals to a variety of phenotypes includ-
ing idiopathic bronchiectasis or pancreatitis, sinusitis,
ABPA, asthma, OATS, neonatal hypertrypsinemia, in which
a higher that expected frequency of heterozygotes has been
reported. However, these studies should be reevaluated for
the prevalence of CFTR mutations in the general population
from which the patients are originating.
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SIMULTANEOUS BILATERAL SWEAT
TESTING—TWO FOR THE PRICE OF ONE?
C. Pao, C. Wallis
Portex Respiratory Unit, Great Ormond Street Hospital for
Children NHS Trust and Institute of Child Health
Background: A unilateral sweat test is performed as part
of the diagnostic workup for cystic fibrosis (CF). A mini-
mum sweat rate of 1 gym ymin is required. It is recom-2
mended to repeat the test if (1) insufficient sweat volume
is obtained or (2) genotyping for CFTR mutations is non-
confirmatory and a second positive test is required for diag-
nostic certainty. In an attempt to overcome the need to recall
patients for repeat sweat testing we undertake simultaneous
bilateral testing on each forearm.
Aims and methods: To audit the results of consecutive
simultaneous bilateral sweat tests (chloride concentration
and sweat weight) performed between August 1998 and
March 2001 to determine:
1. How often there was a discrepancy between the 2 sites
2. How often was it possible to report a result despite a
unilateral failure
Tests were analysed for sweat weight and chloride concen-
trations from each site.
Results: Results from 206 tests were analysed. There were
41 (19.9%) bilateral failures and 22 unilateral failures (2
CF, 13 normal and 7 equivocal). On repeat testing 5 failed
unilaterally. There was no difference in sweat weight; medi-
an right sweat weight 119 mg (interquartile range, IQR 78–
180 mg), left 125 mg (IQR 77–190 mg), (Ps0.46). There
was no difference in chloride concentration; median right
chloride concentration 18 mmolyl (IQR 13–27 mmolyl),
left 17 mmolyl (IQR 17–27 mmolyl), (Ps0.92). In our
institution a bilateral test costs 69.9 EUR compared to
approximately 63.54 EUR for a single test. The difference
in analytical time taken is minimal.
Conclusions: Simultaneous bilateral sweat testing produces
clinically useful, diagnostic information and has a cost ben-
efit that effectively provides two tests for the price of one.
By performing two simultaneous sweat tests we were able
to reassure 13 families that their child did not have CF and
commence treatment in 2 children subsequently confirmed
to have CF on genotyping.
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POSITIVE SWEAT TEST FOLLOWING
MENINGOCOCCAL SEPTICAEMIA
M. Eisenhut, K. Southern
Institute of Child Health, University of Liverpool, Alder
Hey Childrens Hospital, Eaton Road, Liverpool, Great
Britain
Aims: To highlight the finding of temporarily raised sweat
electrolytes following meningococcal septicaemia.
Methods: Case report and literature review.
Results: A 2-year old presented with petechial rash, fever
and signs of septicaemic shock. Investigations confirmed
meningococcal septicaemia. She required prolonged venti-
latory support. A chest radiograph on day 9 demonstrated
appearances consistent with right upper lobe and left lower
lobe consolidation. Weight was 12 kg (50th centile).
Because of a previous history of wheeze, a sweat test was
undertaken on day 13. Sweat Na and Cl concentrationsy
were raised (83 and 76 mmol l ), consistent with a diag-y1
nosis of cystic fibrosis (CF). Blood was sent for DNA anal-
ysis for common mutations associated with CF. The child
was extubated on day 16 and discharged home on day 21.
She has since been well and thriving (75th centile). Three
further sweat tests (with adequate sweat weight) demon-
strated a gradual reduction in sweat electrolytes to normal
values (Na, 78, 43 and 20 mmol l , Cl , 68, 32 and 15y1 y
mmol l ). Extended DNA analysis did not demonstrate ay1
CF mutation.
Conclusions: This case highlights the need for caution in
interpreting sweat test results shortly after meningococcal
septicaemia. In addition, this finding may give insight into
the pathophysiology of Gram-negative septicaemia.
Transient pseudohypoaldosteronism (PHA), in the form of
reduced renal tubular responsiveness to aldosterone with
normal serum electrolytes, has been reported with pyelo-
nephritis caused by Gram-negative organisms.
The temporary elevation of sweat electrolyte concentrations
in this case following meningococcal septicaemia may rep-
resent a transient PHA with the sweat gland being the
insensitive end-organ. Transient PHA in children with
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Gram-negative septicemia may represent a mechanism for
the respiratory compromise that can occur in this patient
group.
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HUMAN EOSINOPHIL PEROXIDASE IS
NITRATED
M. Ulrich , F. Promm , P. Schmid , D. Worlitzsch , M.1 1 2 1¨
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Although eosinophil peroxidase (EPO), a highly cationic
heme protein, located in the granules of eosinophils has
been shown to nitrate protein tyrosyl residues, physiological
substrates of this enzymatic reaction have not been char-
acterized. Immunostaining of eosinophils with nitrotyrosin
antibodies revealed high reactivity. Separation of eosinophil
proteins by gel electro-phoresis, Western blotting and the
application of MALDITOF led to the identification of two
nitrated proteins: EPO (62.4 kD) and a 24.8 kD ribonucle-
ase, eosinophil cationic protein (ECP). Nitration of protein
tyrosyl residues seems to be a dominant reaction in human
eosinophils, since immunostaining for nitro-tyrosin in other
immunocompetent cells such as human neutro-phils, mast
cells, monocytesymacrophages and T lymphocytes was
negative. Immunostaining of chronically inflamed lung tis-
sue of cystic fibrosis patients revealed no further nitroty-
rosy-lated proteins. The data suggest that the EPO-mediated
nitration of protein tyrosyl residues is a specific reaction
within resting eosinophils which may involve EPO auton-
itration and nitration of ECP.
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CYTOKINE PRODUCTION IN WHOLE BLOOD
AND TNF-A PROMOTOR POLYMORPHISMS IN
CYSTIC FIBROSIS
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Aims: Polymorphonuclear leukocytes and cytokines play a
key role in immune mediated inflammation in progressive
pulmonary damage in cystic fibrosis.
The aim of this study was to assess the correlation between
a TNF-308 promoter polymorphism and ex vivo cytokine
production.
Methods: Patients with the Delta F508 (homozygous)
mutation were grouped according to the presence (A, ns
10) or absence of the allele TNF2 of the TNF-a-308 pro-
moter polymorphism (B, ns23). Whole blood cells were
stimulated with 5 ng of lipopolysaccharide (LPS). The fol-
lowing tests were performed: Interleukin-8 (IL-8) and
tumor necrosis factor a (TNF-a) using a chemiluminescent
immunometric assay (DPC Bad Nauheim, Germany).
Results: Though there was evidence of higher TNF-a val-
ues at baseline (median group AyB: xs60.8y46.6 pgyml,
n.s. (Mann–Whitney-U-Test)) in those carrying the muta-
tion, there was no difference after stimulation with LPS
(median group AyB: xs556.7y553 pgyml). Slightly lower
IL-8 values before (median group AyB: xs6.8y10.2 pgy
ml, n.s.) and after stimulation with LPS (median group Ay
B: xs481y518 pgyml, n.s.) were observed for those who
carried the mutation.
Conclusions: The TNF-308 promotor polymorphism does
not seem to influence interleukin release in whole blood
cells before and after stimulation with LPS.
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DIFFERENT CYTOKINE RESPONSE OF
NATURAL KILLER CELLS FROM RESISTANT
C3HyHEN AND SUSCEPTIBLE BALByC MICE
WITH PSEUDOMONAS AERUGINOSA LUNG
INFECTION
H. Calum, C. Moser, P.Ø. Jensen, N. Høiby
Department of Clinical Microbiology, Rigshospitalet,
Copenhagen University hospital, Denmark
The immune response in cystic fibrosis patients with chron-
ic Pseudomonas aeruginosa lung infection is known to be
important for the prognosis. Apart from NK cells defense
mechanisms, NK cells has important immunoregulatory
functions by releasing cytokines such as IFN-g, TNF-a and
GM-CSF.
The purpose of the present study was to investigate whether
NK cells from the resistant C3HyHeN and susceptible
BALByc mice showed difference in release of regulatory
cytokines and expression of surface molecules during lung
infection caused by biofilm embedded P. aeruginosa. Two
pooled lung cell suspensions from five mice of each strain
were depleted for lymphocytes by magnetic cell sorting.
The cells were stimulated with IL-2 for 24 h, and super-
natants were analysed for IFN-g, TNF-a and GM-CSF con-
centration by ELISA at day 1 and 2 after infection.
Non-infected mice of both strains were used as controls.
Futhermore, flow cytometry was used to estimate the acti-
vation of the NK cells by surface expression of the integrin
molecule LFA-1 (CD11a) and the Fc receptors (CD16y
CD32).
IFN-a production was at comparable levels at day 1 (568
vs. 934 pgyml). However, at day 2 IFN-g levels increased
in C3HyHeN mice (1755 vs. 22 pgyml), but decreased in
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BALByc mice, and was approximately 90 times higher in
C3HyHeN mice. The GM-CSF levels increased only in the
C3HyHeN mice, and was 2 times higher (46 vs. 20 pgy
ml) and 4.5 times (101 vs. 23 pgyml) higher at day 1 and
2, respectively, as compared to BALByc mice. NK cells
from both mice strains only produced low levels of TNF-
a.
The expression of LFA-1 on the NK cells was higher in
C3HyHeN mice as compared to BAL.
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CYSTIC FIBROSIS-ASSOCIATED
PSEUDOMONAS AERUGINOSA STIMULATES
MAST CELLS TO PRODUCE INTERLEUKIN 6
THROUGH PROTEIN KINASE C ALPHA
Tong-Jun Lin , R. Boudreau , R. Garduno1 2 2
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Pseudomonas aeruginosa is the major cause of lung infec-
tion in cystic fibrosis. P. aeruginosa infection is character-
ized by massive airway inflammation, which comprises
significant cytokine production. Although mast cells are
abundant in the lung and are potent sources of various cyto-
kines, a role of mast cells in P. aeruginosa infection remains
undefined and P. aeruginosa-induced signaling mechanisms
in mast cells have not been studied previously. Here we
demonstrate that human cord blood-derived mast cells,
mouse bone marrow-derived mast cells (BMMC) and the
mouse mast cell line MCy9 produce significant amounts of
interleukin 6 (IL-6) in response to cystic fibrosis-associated
P. aeruginosa. This response was accompanied by a stim-
ulation of PKCalpha phosphorylation and PKC activity, and
was significantly blocked by the PKC inhibitors Ro 31-
8220 and PKC pseudosubstrate. Interestingly, mast cells
treated with P. aeruginosa had reduced protein levels of
phosphatase 2A catalytic unit (PP2Ac), which prompted us
to determine whether a direct association between PKCal-
pha and PP2A occurs in mast cells. In BMMC and MCy9
cells, as well as in the human mast cell line HMC-1, PP2A
co-immunoprecipitated with PKCalpha either using PKCal-
pha- or PP2Ac-specific antibodies, suggesting that PKCal-
pha and PP2Ac are physically associated in mast cells. The
PP2A inhibitor okadaic acid induced P. aeruginosa-like
responses in mast cells including increased PKCalpha phos-
phorylation, stimulated PKC activity, and augmented IL-6
production; the latter being blocked by the PKC inhibitor
Ro 31-8220. Finally, okadaic acid potentiated the P. aeru-
ginosa-induced IL-6 production. Collectively, these data
provide, to our knowledge, the first evidence of both a
direct physical association of PP2A and PKCalpha in mam-
malian cells, and their co-involvement in regulating mast
cell activation in response to P. aeruginosa.
P108
THE IMMUNOSTIMULATORY ACTIVITY OF THE
LUNG SURFACTANT PROTEIN-A (SP-A)
INVOLVES THE TOLL-LIKE RECEPTOR 4
Loıc Guillot , Viviane Balloy , Francis X. McCormack ,1 1 2¨
Douglas T. Golenbock , Michel Chignard , Mustapha Si-3 1
Tahar1
Unite de Defense Innee et Inflammation, Institut Pasteur,1 ´ ´ ´
Paris, France, Division of Pulmonary and Critical Care2
Medicine, Department of Medicine, University of Cincin-
nati, Cincinnati, OH, USA, Division of Infectious Dis-3
eases, Department of Medicine, University of
Massachusetts Medical School, Worcester, MA, USA
Cystic fibrosis is associated with functional impairment and
biochemical alterations of surfactant proteins in the air-
ways. The most abundant among them, surfactant protein-
A (SP-A), is a member of the collectin family of
preimmune opsonins. Recent studies suggest an integral
role for SP-A in innate host defense and regulation of
inflammatory processes in the lung. Although a number of
SP-A binding cell surface proteins have been identified,
their contribution to SP-A-induced cell activation remains
controversial. Here, we investigated the molecular mecha-
nisms related to the immunostimulatory activity of SP-A
using macrophages from C3HyHeJ mice which carry an
inactivating mutation in the toll-like receptor 4 (TLR4)
gene and TLR4-transfected chinese hamster ovary cells. We
demonstrate that SP-A-induced activation of the NF-kB
signaling pathway and upregulation of cytokine synthesis
such as TNFa and IL-10 are critically dependent on the
TLR4 functional complex. These findings support the con-
cept that TLR4 is a pattern recognition receptor that signals
in response to both foreign pathogens and endogenous host
pulmonary mediators.
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PAR-2 AND HUMAN LUNG EPITHELIAL CELLS:
EXPRESSION, AND EFFECTS OF SERINE
PROTEINASES
S. Dulon, C. Candi, D. Pidard, M. Chignard
Institut Pasteur, Defense Innee et InflammationyINSERM´ ´
U485, France
Proteinase-activated receptor-2 (PAR-2), which belongs to
an emerging subfamily of G protein-coupled receptors, is
most likely involved in inflammatory processes. Trypsin
cleaves the aminoterminal extracellular extension of human
PAR-2 unmasking a new amino terminus starting with
SLIGKV, acting as a tethered ligand which binds intramo-
lecularly and activates the receptor. The synthetic peptide
corresponding to the tethered ligand domain activates PAR-
2 without the need for receptor cleavage. In the present
study, we provide evidence that PAR-2 is expressed by
human alveolar (A549) and bronchial (16HBE) epithelial
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cell lines, based on the analysis of mRNA by RT-PCR and
protein by flow cytometry using an anti-PAR-2 antibody
whose recognized epitope maps over the trypsin cleavage
site. We show that PAR-2 activation by trypsin and by the
activating peptide SLIGKV-NH2 leads to intracellular cal-
cium mobilization in both lung epithelial cell lines. During
inflammation, lungs are burdened by neutrophils and their
serine proteinases, elastase and cathepsin G, are released in
the airspaces. We here demonstrate that these poteinases are
unable to activate PAR-2 but rather disable it. Thus, elastase
and cathepsin G prevent any further activation of cells by
trypsin but not by SLIGKV-NH2. We hypothesize that leu-
kocyte proteinases proteolyse PAR-2 downstream of the
trypsin cleavage site but upstream of the SLIGKV-NH2
binding site. These findings suggest that these proteolytic
activities may contribute to the regulation of lung
inflammation.
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Autoimmune phenomena, represented for example by the
positivity of autoantibodies associated with diabetes melli-
tus, anti-sperm antibodies or antineutrophil cytoplasmic
antibodies (ANCA), among others, were repeatedly report-
ed in patients with cystic fibrosis. In the last years we are
constantly finding the positivity of ANCA in a subset of
children with CF. Here we report the frequent positivity of
anti-gliadin antibodies of IgG isotype in children with CF.
Out of 130 investigated children, 58 were tested positive
for anti-gliadin IgG antibodies, while only 5 were positive
for anti-gliadin antibodies of IgA isotype and just once we
detected positive anti-endomysium antibodies (EMA).
Anti-gliadin IgG antibodies were thus not associated with
celiac disease. We hypothesized that anti-gliadin IgG anti-
bodies represent epiphenomenon, resulting from the differ-
ent uptake of antigens by the mucosa of CF gut and
subsequent abnormal antigen processing by gut immune
system. The tested possible association of anti-gliadin IgG
positivity with meconium ileus was not confirmed (17 out
of 130 children had meconium ileus, but only 4 out of these
had anti-gliadin antibodies). We further looked for the asso-
ciation of anti-gliadin antibodies and ANCA. ANCA direct-
ed against bactericidalypermeability increasing protein are,
besides CF, typically found in inflammatory bowel diseases,
particularly ulcerative colitis, implicating the more probable
association of ANCA with CF gastrointestinal rather than
lung disease. There were 45 ANCA positive children in the
tested group, however, only 16 children were positive for
both anti-gliadin antibodies and ANCA, making such asso-
ciation not probable.
We conclude that frequent presence of anti-gliadin IgG anti-
bodies is not associated with celiac disease in CF children
and might result from abnormal reaction of CF intestinal
mucosal system.
Supported by Czech Ministry of Health (IGA 5865-3) and
Ministry of Education (111300001, 111300003).
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Introduction: Pneumocystis carinii is an atypical fungus
with lung tropism and world-wide distribution. Recent
Western blot (WB) serological studies have demonstrated
a high prevalence of Ab. against this pathogen in Seville s
child population, which suggests a spread penetration of
this infection in our environment. Objectives: To determine
de Ab. prevalence against P. carinii in subjects with cystic
fibrosis (CF) whom show a high rate of respiratory
infections.
Method: A prospective epidemiological study was carried
out among 42 patients with CF attended in a Unit speci-
alised in this disorder. A random population of 223 school
children was used as control group. An epidemiological
survey was done among all these children and samples for
serological studies were obtained. A serological sample was
stored at 20 8C until its processing. Samples were blindly
analysed by the WB technique using as antigen extract from
rat’s P. carinii. A commercial Ab. monoclonal (Dako, Glos-
trup) was used as positive control.
Results:
Group n Negative WB
(%)
Positive WB
(%)
Indetermined WB
(%)
Control 233 30 (13%) 163 (70%) 40 (17%)
C.F. 42 20 (47.6%) 16 (38%) 6 (14.4%)
Conclusions: These results demonstrate that the Ab’s
production rate against P. carinii is lower among CF
patients than among general population. It is possible
that this pathogen cannot colonise the respiratory tract
of CF patients either due to a phenomenon of
competitiveness with other microorganisms, or because
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the bronchial inflammation and obstruction caused by a
mucus blockage that stops this pathogen s access to the
alveolus; which could make difficult the immune
response
Supported by Eurocarinii Project QLK2-CT-2000-01369.
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TO MEASURE THE ACTIVITIES OF NEUTRAL
SERINE PROTEASES OF
POLYMORPHONUCLEAR NEUTROPHILS
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Polymorphonuclear neutrophils are the major inflammatory
cells involved in chronic inflammatory lung pathologies.
Upon degranulation at sites of inflammation they release
cathepsin G, neutrophil elastase (HNE) and proteinase 3
(PR3) from their azurophil granules. Proteases are released
extracellularly andyor translocated to the surface of plasma
membranes where they display secretagogue and lytic activ-
ities on airways tissues. However, the participation of free
or membrane-bound proteases in inflammation chronicity
remains to be elucidated: on one hand, the low activity of
cathepsin G on synthetic substrates impairs studies aiming
at clarifying its biological function; on the other hand, the
relative contribution of HNE and PR3 to the overall inflam-
matory process is hardly distinguishable because of their
similar substrate specificity (all PR3 synthetic substrates
used so far are hydrolyzed faster by HNE).
We used here part of the peptide sequence of putative pro-
tein targets of these proteases to design new sensitive sub-
strates with intramolecularly quenched fluorescence for
each of them. These substrates were mainly derived from
the reactive site loop sequence of inhibitors of the serpin
family. They allowed to measure and to quantify
membrane-bound and free cathepsin G, PR3 and HNE spe-
cifically, even when these proteases were present in low
amount in lung secretions or in BAL fluids of patients with
lung inflammatory diseases.
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LEVEL OF SECRETORY PHOSPHOLIPASE A2
AND DELTAF508 MUTATION IN HUMAN
EPITHELIAL TRACHEAL CELL LINE
S. Medjane, L. Touqui
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Phospholipases A2 (PLA2) catalyse the hydrolysis of phos-
pholipids at the sn-2 position to generate lysophospholipids
and free fatty acids such as arachidonic acid (AA), which
is a precursor of major lipid mediators involved in inflam-
mation. It is well known that cystic fibrosis (CF) pathology
is associated to chronic airway infection and inflammation.
In particular, increased levels of AA metabolites have been
observed in the sputum from CF patients. Prostaglandin
E (PGE ), a metabolite derived from AA, has been shown2 2
to modulate the expression of secretory PLA2 (sPLA2) in
various cell types. Previous studies have demonstrated that
primary cultures of tracheal epithelial cells and skin fibro-
blasts from CF patients, as well as CF epithelial cell lines,
release more AA when stimulated by the hormonal stimulus
bradykinin. This led us to study the expression of different
types of sPLA2s in human tracheal epithelial cell lines:
CFT-2 (CFTR DF508qyq cell line) and NT-1 (control
line) and its potential relationship with AA metabolism.
Thin layer chromatography analysis show that the CFT-2
cell line incorporates exogenous AA at a lower rate and
presents a distinct pattern of AA incorporation in the
membrane phospholipids as compared to the NT-1 cell
lines. Quantification of sPLA2-IIA and sPLA2-X mRNAs
by semi-quantitative RT-PCR showed that CFT-2 cells con-
stitutively expressed a higher transcript level compared to
unstimulated NT-1 control cells. This expression could still
be increased by pro-inflammatory stimuli (TNF alpha,
Pseudomonas aeruginosa’s lipopolysacharride) and PGE .2
These studies suggest a possible relationship between
DF508 mutation and increased expression of sPLA2 in epi-
thelial airway cell line CFT-2. Because sPLA2 are known
to play a pivotal role in inflammation, their increased
expression might have an important physiopathological sig-
nificance in the context of CF.
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PROTEIN KINASE B AND GLYCOGEN
SYNTHASE KINASE 3 SIGNALLING IN AIRWAY
EPITHELIAL CELLS
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Aberrant regulation of the inflammatory response is impli-
cated in CF airway disease. Downstream effectors of phos-
phatidylinositol 3-kinase (PI3K) signalling, namely protein
kinase B (PKB) and glycogen synthase kinase 3 (GSK3),
are known to regulate gene expression and cell survival in
a number of systems. This study investigates the activity
and regulation of these pathways in deltaF508 (CFTE) and
non-CF (HTE) human tracheal epithelial cells.
Cells were grown on extracellular matrix-coated plates
under immersion culture conditions. Whole cell lysates
were collected after 1–30 min stimulation and PI3K sig-
nalling assessed by immunoblotting for the presence of ser-
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ine phosphorylated (p) PKB and GSK3. Under basal
conditions pPKB levels were low in both cell lines. Incu-
bation with the PI3K activator IL-13 (30 ngyml) produced
a large increase in the levels of pPKB, peaking at 15 min.
This response was completely inhibited by the co-incuba-
tion of the cells with the PI3K inhibitor LY294002 (10
mM). Neither the p38 MAPK inhibitor SB203580 (10
mM), the MAPKyERK kinase inhibitor PD98059 (10 mM),
nor the PKC inhibitor Ro320432 (10 mM) had any effect
on pPKB levels. pGSK3 was present in both cell lines
under basal conditions and was increased upon stimulation
with IL-13. This phosphorylation was partially reduced by
LY294002 and unaffected by SB203580. The combination
of LY294002 and PD98059 virtually abolished GSK3 phos-
phorylation in CFTE cells but not in HTE cells. This pattern
was also observed with Ro320432.
These data suggest that there are differences in the regu-
lation of GSK3 in CF and non-CF tracheal epithelial cells.
Such differences may contribute to altered inflammatory
and apoptotic activity in the CF lung.
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During cystic fibrosis, infiltration of the airway epithelium
by neutrophils occurs, and release of noxious compounds
destroy the surface epithelium. We used cDNA microarrays
to profile wound healing during lung inflammatory dis-
eases. To monitor differential gene expression a microarray
containing ;1500 probes were built. It was spotted with
PCR fragments of ;250 nucleotides, originating from
human sequences. Each fragment boring an identity of 80%
with its murine ortholog, the same array was useable in
human, mouse, or in any mammalians. The list of genes
was first restricted to CFTR, related ion transport proteins,
cytokines, growth factors, and metalloproteinases. It was
then extended and the design of ;6000 probes has been
performed. We validated the ‘mammalian’ characteristic of
this array by hybridizing cDNA issued from wounded
human and canine keratinocytes. Some control genes, c-fos,
c-jun, zinc finger protein, or serine protease inhibitor,
indeed covaried in the two cell types: at 30 mn, c-fos ratios
(woundyctr) of 6.6- and 5.4-fold were observed in human
and canine keratinocytes, respectively; c-jun: 1.5- and 1.8-
fold; zinc finger protein: 2.72- and 2.76-fold. Three hours
after the wound, the serine protease inhibitor was expressed
with ratios of 3.52- and 3.34-fold in human and canine
keratinocytes, respectively. We then analyzed primary cul-
ture of airway epithelial cells, A549 cell lines, keratinocytes
and fibroblasts primary cells. In fibroblasts, IL6 was sur-
expressed (3.15-fold) 1 h after wounding, and IL8 (3-fold)
3 h after the wound, when in keratinocytes IL8 was sur-
expressed only 2-fold after 3 h. Collagens type I, IV, V, VI,
and IX all appear inhibited in the first 6 h after wounding.
MMP2 was inhibited during the first hours, showed a 4.3-
fold increase at 24 h, and returned to its normal levels 30
h after the wound. These results demonstrate that cDNA
biochips are useful in analyzing molecular mechanisms
associated with lung inflammation.
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The HaloLite AAD system (AAD) has been developed to
improve inhaled medication delivery by giving feedback
during treatment and will not deliver aerosol for nose
breathing, talking, or poor mouthpiece lip seal. A multi-
centre randomised parallel study comparing AAD with con-
ventional high efficiency nebulisers (NEB) was conducted
in Australia, Canada, USA, and Europe. Patients estab-
lished on DNase and inhaled antibiotics were randomised
to AAD or NEB after an exacerbation and used the study
device to take their inhaled medications for 182 days. The
primary outcome variable was change in FEV1 from day 0
to 182. Secondary outcome variables were days antibiotic
use, exacerbation frequency, time to first exacerbation, safe-
ty, adherence to prescribed regimen, and compliance with
device (by overt electronic monitoring in 20% of the sam-
ple). Patients completed a questionnaire to assess device
acceptability.
Two hundred and fifty nine patients were randomised (133
AAD, 126 NEB) median age 17 years, median FEV1 56%
predicted. Preliminary analysis of change in %predicted
FEV1 was y3.5% for AAD and y2.4% for NEB (Ps
0.7). There was no statistically significant difference
between AAD and NEB for secondary outcome variables
except for a significantly higher incidence of chest tightness
(a known potential effect of inhaled antibiotics) for AAD
(P-0.05). Completed questionnaires showed that the per-
ceived dose received from the device, patient wellbeing and
preference versus their pre-study device were significantly
better for the AAD group (P-0.0001). Fifty-one percent
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of prescribed doses were taken beyond 90% of the pro-
grammed dose for AAD compared with 26% of prescribed
doses where the compressor was run for )6 min for NEB
(P-0.006).
Acceptability for AAD was higher than for NEB. A higher
incidence of chest tightness for AAD may be indicative of
more successful delivery of antibiotic to the lung. Patients
take more doses to an acceptable level using AAD.
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OUTPUT CONVENTIONAL NEBULISER SYSTEM
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Chest tightness is a recognised side effect of nebulised anti-
biotics (AB). We describe a sub group of patients who
nebulised colistin in a clinical trial. Patients using nebulised
AB and DNase for )90 days were randomised to use the
HaloLite AAD system (AAD) or a conventional high out-
put nebuliser (NEB) over a 182 day period. All patients
used bronchodilators, some of the patients in each nebuliser
group used a pMDI or DPI (INHL) others used a solution
(SLN) form through the study device. This abstract reports
preliminary analysis of %predicted FEV1 mean change
from baseline to day 28, and to day 182 for each combi-
nation of nebuliser (AAD or NEB) and bronchodilator
(SLN or INHL).
Results: 189 of 259 patients used colistin. For SLN 51
patients median age 19 baseline FEV1 50% pred used AAD
and 43 patients median age 19 baseline FEV1 53% pred
used NEB. At day 28 mean (95% confidence interval) %
change in % pred FEV1 was 6.6 (1.0 to 12.1) and y3.9
(y8.6 to 0.8) for AAD and NEB, respectively. At day 182
change in FEV1 was 0.5 (y6.6 to 7.7) and y3.7 (y11.7
to 4.3) for AAD and NEB, respectively. For INHL 43
patients median age 13 baseline FEV1 65% pred used AAD
and 41 patients median age 15 baseline FEV1 64% pred
used NEB. At day 28 change in FEV1 wasy7.3% (y12.5
to y2.1) and y0.8% (y4.7 to 3.2) for AAD and NEB,
respectively. At day 182 change in FEV1 was y7.0% (y
12.1 to y2.0) and y5.1% (y11.3 to 1.1) for AAD and
NEB, respectively. The interaction between device type and
bronchodilator type was statistically significant (Ps0.001).
Conclusions: The use of a bronchodilator prior to nebulis-
ing antibiotics is recommended practice to prevent inhaled
antibiotic induced chest tightness in adult and paediatric
patients. These data suggest that the use of a bronchodilator
solution with colistin in patients using AAD has a positive
effect on maintaining both short and long-term FEV1. This
effect was not seen in the NEB group, nor was it evident
in patients using INHL.
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THE COMPUTER TOMOGRAPHY IS AN
IMPORTANT INSTRUMENT IN THE DIAGNOSTIC
OF THE CYSTIC FIBROSIS
A. Holcıkova, D. Horak´ ´ ´
Children’s University Hospital, Brno, Czech Republic
The leading pathologic disorders in cystic fibrosis are in
connection with the respiratory tract. We can find bronchi-
ectasis in the lung as a typical symptom very often. Such
affliction gives out information about the grade of the dam-
age caused by the illness. We can also check the progress
of the disease. In advanced stages of the illness the typical
opacities or brightness are visible on the sagittal chest X-
ray. More often we can see only augmentation of the central
structures on the X-ray but bronchiectasis could be
observed only by HRCT. Thus, using HRCT we can follow
the disease better, we can advise the physiotherapeutist on
the more problematic part of the lung and we can use this
information for diagnostic purposes—for example in a case
with not completely clear genetic information or in a case
with the marginal sweat test.
We perform LDHRCT on 5–6-year-old children, as soon
as the cooperation with the child is possible and we repeat
it every 2 or 3 years.
Attached, there are nine examples of radiological docu-
mentation–chest X-rays in comparison to LDHRCT.
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QUANTITATIVE MEASUREMENT OF AIRWAY
WALL THICKNESS ON HIGH RESOLUTION CT
SCANS IS A SENSITIVE MARKER OF
PROGRESSIVE STRUCTURAL LUNG DAMAGE
IN CHILDREN WITH CF
P. de Jong , Y. Nakano , M. Lequin , P. Pare , H.1 2 3 2´
Tiddens1
Department of Pediatric Pulmonology, UBC McDonald1 2
Research Laboratories and iCAPTURE Centre, St Paul’s
Hospital, Vancouver, BC, Canada, Department of Pediatric3
Radiology, Rotterdam, The Netherlands
In CF the severity of the airway inflammation correlates
with airway wall thickness and bronchial obstruction. In
high resolution CT (HRCT) scoring systems for CF airway
wall thickening is measured in a semi-quantitative fashion.
However, the technology is available to measure airway
wall area (Aaw) in an automated fashion.
Aims: To measure Aaw, HRCT score (Castile), and lung
function tests (PFT) over a 2-year interval in a cohort of
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children with CF. To compare changes in Aaw to those in
HRCT score, and PFT. We hypothesized that Aaw is a sen-
sitive marker of disease progression.
Methods: Twenty-seven CF-children had two CT scans
(CT1 and CT2) in combination with PFT (PFT1 and
PFT2). PFT were: FEV1; FVC; FEF25-75; FEV1yFVC;
Raw; RV; TLC; and RVyTLC. Two observers matched
identical airways on CT1 and CT2. Aaw of matched air-
ways was measured with an automated multi-ray edge
detecting computer program. The mean percentage change
in Aaw (DAaw) was calculated for scans with more than
5 matched airways. All scans were scored (Castile). DAaw
was compared with DHRCT scores (HRCT2-HRCT1) and
DPFT (PFT1–PFT2) using paired samples statistics. Data
given are mean"S.D.
Results: Age at CT1 was 10.1"4.1 years, time interval
between CT1 and CT2 was 1.8"0.36 years. Four hundred
and eighteen matched airway pairs were measured, 20 chil-
dren had )5 matched airways on CT1 and CT2. Changes
over the study period were: DAawq4.3% (P-0.0001);
DHRCTq4.3 points (Ps0.004); DFEV1q4.0% predicted
(n.s.); DFVCq2.4% predicted (n.s.); DFEF25-75 y1.3%
predicted (n.s.). Correlation between DAaw and DHRCT
was weak (Rs0.42, Ps0.07). There was no correlation
between DPFT and DAaw.
Conclusions: Airway wall thickness and other structural
abnormalities on HRCT increase with time in CF. DAaw
and HRCT score may be useful markers of structural lung
damage in longitudinal studies. Lung function is an indirect
and less sensitive marker of structural lung damage relative
to HRCT score and Aaw.
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LUNG FUNCTION TESTS IN INFANTS WITH
CYSTIC FIBROSIS (CF) DIAGNOSED FOR
NEONATAL SCREENING: PRELIMINARY
RESULTS
G. Tancredi, S. Cingolani, F. Midulla, F. Scalercio, G. Cim-
ino, M. Zaccagnini, S. Bertasi, S. Quattrucci
Cystic Fibrosis center, Department of Pediatrics, Univerity
of Rome ‘‘La Sapienza’’
The role of lung function tests in early infancy is less clear
than in older children with CF. The aim of our study was
to evaluate the lung function of asymptomatic infants with
CF, diagnosed for neonatal screening, respect to healthy
infants. In 6 CF patients (5 males) and 3 healthy subjects
(2 males) we measured, by an infant respiratory function
testing device (Exhalizer. Eco Medics), the following par-
ameters: RR (respiratory rate), VTykg (tidal volume pro
kg), TptefyTe (ratio of time to peak expiratory time divided
by the expiratory time), Rrs (resistance of the respiratory
system), Crs (compliance of the respiratory system), Grs
(conductance of the respiratory system). The measured val-
ues are reported in the table
FC Healthy subjects
Mean"S.D. Mean"S.D. p
Age week 38.3"25.3 25.3"17.6 n.s.
Weight (g) 7667"2307 7166"2401 n.s.
Height (cm) 62.5"14.8 63.33"9.6 n.s.
RR (brymin) 76.9"46.4 59.4"18.2 n.s.
VT (mlykg) 7.7"2.6 7.8"1.8 n.s.
TptefyTe (%) 33.7"6.1 37.2"6.8 n.s.
Rrs kP (lys) 0.892"0.78 0.829"1.02 n.s.
Crs (mlykPa)ykg 29.3"20.7 35.86"8.7 n.s.
Grs 1y(kPa syl) 0.410"0.25 1.06"0.21 n.s.
We observed highest values of TptefyTe and Grs and
lowest Rrs in healthy subjects respect to CF infants, that
indicate an early airways obstruction in CF patients,
even if the statistical differences were not significant
between the two groups, ought to the small number of
cases. Our preliminary findings evaluate the important
question about the onset of impaired airways function
and the natural history in cystic fibrosis infants respect
to healthy subjects.
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MEASURING LUNG HYPERINFLATION IN
CHILDREN WITH CYSTIC FIBROSIS
C. Pao, R. Dinwiddie
Portex Respiratory Unit, Great Ormond Street Hospital for
Children NHS Trust and Institute of Child Health
Introduction: We previously reported a modified Chris-
pin–Norman score w1x for scoring lung hyperinflation in
children with cystic fibrosis using a single frontal chest
radiograph (CXR) instead of frontal and lateral views w2x.
Aims: To measure hyperinflation scores using modified and
classical Chrispin–Norman scores and to compare the
results to measurements of lung volumes taken on the same
day as the CXRs.
Methods: In a randomised blinded study a single scorer
(RD) scored CXRs using both the Chrispin–Norman score
(CN): sternal bowing, diaphragmatic depression, spinal
curvature and the modified Chrispin–Norman score
(modCN): diaphragmatic depression, chest wall shape,
lucency of lung fields. Each parameter scored 0 for normal,
1 for mildly abnormal and 2 for severely abnormal, giving
a maximum total score of 6. Scores were compared to lung
volumes-percent-predicted total lung capacity (%TLC) and
residual volume (%RV).
Results: CXRs of 50 children (age range 1–16 yr) were
scored. There was no difference between CN and modCN;
mean difference 0.26 (95% confidence interval y3.16 to
q3.68, Ps0.29). There was no correlation between either
score and %TLC or %RV: modCN correlation with %TLC
rs0.26 and %RV rs0.05; CN correlation with %TLC rs
0.28 and %RV rs0.43.
Conclusions: We have demonstrated that although there is
no significant difference between lung hyperinflation
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scored using CN and modCN, neither accurately reflects
measured lung volume. It may be time to discontinue the
use of lateral films for measurement of progress of under-
lying lung disease and consider alternative imaging such as
CT at annual review.
References
1. Evans RE, Dinwiddie R. ECFS 2001.
2. Chrispin AR, Norman AO. Pediatric Radiology 1974; 2:
101–106.
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LONG TERM EFFICACY OF AEROSOLIZED
AMILORIDE IN PEDIATRIC PATIENTS WITH
CYSTIC FIBROSIS
G. Huels , M. Mueller C. von Bredow , E. Heuer , K.2 2 4 3
Paul , K. Ulbrich , H. Lindemann1 3 2
CF-Zentrum Dresden, Giessen, Hamburg, Munich,1 2 3 4
Germany
Background: Hyperabsorption of sodium and subsequent
water loss are believed to account for the high sputum vis-
coelasticity in cystic fibrosis (CF). Aerosolization of ami-
loride, a sodium channel inhibitor, was shown effective in
improving mucociliary clearance in short-term trials. How-
ever, the long-term efficacy is unknown. A retrospective
analysis of an 8-year open trial at four German CF Centers
was conducted to compare the long-term effects of amilor-
ide treatment on pulmonary function in pediatric patients
with CF.
Methods: Thirty-six children with CF (age 6–12 years)
from two CF centers were treated with high dose aerosol-
ized amiloride (AM) (1.8 or 3.0 mgyml, bid or tid) for at
least 5 years. Conventional treatment was continued. Age-
matched controls treated with aerosolized N-acetylcysteine
(NAC) (ns20) at a third CF center and age-matched con-
trols receiving standard treatment at a fourth CF center (ns
30) served as control groups. Inclusion criteria were ability
to perform lung function testing and reliable compliance
with amiloride inhalation (deep inspiration maneuvers, end-
expiratory break). Safety was monitored by serum electro-
lytes, urea and creatinine measured annually and amiloride
serum levels. Pulmonary function test parameters including
FEV1 and inspiratory vital capacity (IVC) and specific
conductance (sGaw) were evaluated.
Results: Significantly higher values of IVC and sGaw were
found in the AM treatment group (median IVC 104.5 ver-
sus 90.5%, P-0.05; median sGaw 1.42 versus 1.0 kPays,
P-0.05; FEV1 values did not differ (Table 1). The find-
ings of the groups on standard therapy und on aerosolized
NAC were not different. Electrolytes and urea were not
influenced by amiloride therapy.
Conclusions: Chronic inhalation of amiloride appears to be
a safe and useful supplementary therapy in young CF
patients. More sensitive parameters of lung function than
FEV1 demonstrate an improvement over standard therapy.
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FAILURE OF RECOMBINANT HUMAN
DEOXYRIBONUCLEASE I THERAPY IN CYSTIC
FIBROSIS: THE ROLE OF MAGNESIUM AND
POTASSIUM
N.N. Sanders, S.C. De Smedt, J. Haustraete, J. Demeester
Laboratory of General Biochemistry and Physical Phar-
macy, Faculty of Pharmacy, Ghent University, Ghent,
Belgium
In the management of cystic fibrosis (CF), recombinant
human deoxyribonuclease I (rhDNase I) is widely used to
facilitate the removal of the highly viscoelastic mucus from
the lungs. It is, however, known that an important group of
CF patients does not benefit from rhDNase I therapy (so-
called non-responders). The reasons for this failure are
unknown.
We found that sputa from non-responders had a significant
lower potassium and magnesium concentration compared
to sputa from responders. It is known that globular actin,
which is present in CF sputa, inhibits rhDNase I activity.
Additionally, other groups reported that magnesium and
potassium enhance the polymerization of globular actin into
filamentous actin which does not inhibit rhDNase I. More-
over, we showed that the decrease in viscosity by rhDNase
I of DNAyactin solutions increased at higher magnesium
andyor potassium concentrations, while the decrease in vis-
cosity by rhDNase I of DNA solutions without actin was
independent of the magnesium andyor potassium concen-
trations. Based on these observations we hypothesize that
failure of rhDNase I therapy in non-responders is probably
due to the low magnesium and potassium concentrations,
which limits the polymerization of the rhDNase I inhibitor
globular actin in their sputa.
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ONE YEAR EXPERIENCE WITH RHDNASE
(PULMOZYME) THERAPY IN BULGARIAN CF
CHILDREN
I. Galeva, A. Kufardjieva, V. Brussarska, E. Elencheva, I.
Kalev
Pediatric Clinic, Alexander’s State University Hospital,
Sofia, Bulgaria
Aim: To evaluate the effectiveness of a long-term therapy
with rhDNase (Pulmozyme) and its tolerance in Bulgarian
CF patients.
Methods: 46 CF patients (25 male and 21 female) aged
from 5 to 22 years (mean age 13.1 years) received daily in
addition to their regular CF therapy schelude, 2.5 mg
rhDNase (Pulmozyme) by nebulisation for a period of 1
year. Of all patients 43.5% were homozygous for F508,
compound heterozygous and non-delta F508 were 34.8 and
21.7%, respectively. In the beginning of the study 11
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patients (23.9%) showed FVC less than 60% of predicted.
Schvachman scores less than 70 were found in 24.6% of
the patients and 58.7% were diagnosed permanently posi-
tive for Ps. aeruginosa. Body mass index (BMI), Schvach-
man score, clinical, X-ray and functional lung parameters,
as well as, frequency of lung exacerbation, drug tolerance
and disease outcome were followed during that period.
Results: Upper airway irritation, voice alternance andyor
bronchospasmus were not seen in any of the patients. The
expected 3–5% lung function decline was established in
19.3% of the patients, mostly among those with Schvach-
man scores less than 60. More than one-third of the patients
(most of them compound heterozygous) showed strong
improvement in FVC and FEV1. No progression in lung
X-rays was established in 63% of the patients younger than
12 years of age. BMI was more satisfactory in half of the
patients (54y4%), mostly non-homozygous. Only two
patients needed hospitalization more than twice and just one
(17 year boy) died (2.1%) during the same period.
Conclusions: Pulmozyme increases efficacy of CF man-
agement and improves patient’ life quality and survival. It
is well tolerated.
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THE TREATMENT WITH RHDNASE IN THE
CHILDREN WITH CF FROM ROMANIA
I. Popa , L. Pop , Z. Popa , Z.L. Popa1 1 2 1
University of Medicine and Pharmacy Timisoara, Roma-1
nia, CF Centre Timisoara, Romania2
Objective: The assessment of the therapy efficiency with
rhDNase at the CF children with and without a secondary
infection Staphylococcus aureus—(Staph. aur.) and Pseu-
domonas aeruginosa—(P. ae.) Study lot: 6 patients fol-
lowed by the Center of CF Timisoara, with their age
between 5 and 16 years (average 11.6 years), to whom we
administered rhDNase for 12 months. Selection criteria:
chronic chest modifications, clubbing, intense productive
coughing, scarring on the whole pulmonary area, but with-
out being necessary hospitalization, FEV1 50% at least (in
the children older than 6 years). Four patients showed
chronic respiratory infection (3 with P. ae. aged 6, 7,
respectively, 16 years and one 13 years old with Staph.
aur.). One patient (16 years) showed ABPA. One case (12
years) did not present respiratory infection. Assessment
parameters: clinical general state, coughing and sputum fea-
ture, clinical examination of the respiratory system, chest
X-ray, FEV1, bacteriologic examination of the sputum. In
the case with ABPA we did not notice favorable results;
the therapy was interrupted after 3 months. The case with-
out a secondary infection as well as 3 of the cases with a
secondary infection had a favorable evolution: significant
amelioration of the general clinical state, coughing reduc-
ing, reducing of the sputum as well as of the pulmonary
scarring, a better reaction to the antibiotherapy related to
the episodes of the respiratory disease exacerbation, FEV1
improvement on an average basis with 7.6%. We did not
notice significant improvements of the X-ray images. Bac-
teriological examinations maintained positive. One case
with P. ae. had not significant positive answer at the treat-
ment and it was interrupted after 6 months.
Conclusions: The rhDNase treatment was beneficial even
under the conditions of a bacterial secondary infection; an
assessment of the efficiency treatment in these situations
may be done after 6 months of treatment; ABPA case had
no favorable response.
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CF DIAGNOSIS IN ADULTS: BOTH ATYPICAL
AND CLASSIC FORMS OF THE DISEASE
R. Padoan , D. Costantini , C. Fredella , G. Pizzamiglio ,1 1 1 2
A. Bassotti , M. Seia , E. Madonini1 3 4
CF Center, CF Center, Adult Unit, Molecular Genetic1 2 3
Department, Respiratory Physiopathology, Villa Marelli,4
Milano, Italy
CF has become a disease relevant to adult pneumologist as
well as to paediatricians, and some patients may reach undi-
agnosed the adult age, usually attending Respiratory
Departments due to the prevalence of the chronic lung dis-
ease. We present a survey of 54 patients diagnosed after
the age of 16 yr for respiratory symptoms and regularly
followed in Milan CF Centre. 44y54 had a positive history
of lung disease from childhood. Mean age of diagnosis was
24.4 years (range 16–45), with 23.3% subjects diagnosed
after the age of 30. All patients but one had an abnormal
chest X-ray film, upper lobes involvement being the most
common finding. Upper airway disease was present in
53.7% of the patients, all the patients had positive sputum
coltures, with P. aeruginosa recovered in 33 pts (61.1%)
and S. aureus in 27 pts (50%). Pulmonary function at diag-
nosis (available in 49 pts) showed a high prevalence of
normality: FVC was )80% of predicted value in 27y49
(54.1%), FEV1 was )80% in 16y49 (32.6%). 13y54
(24%) showed the classic form of the disease with pancre-
atic insufficiency.
Three patients had a sweat test value -60 mEqyl, and CF
was diagnosed by genetic analysis. Molecular analysis of
CFTR gene by means of PCRyOLA assay and DGGE
sequencing showed a high allelic variability: 22 mutations
account for 80% of CFTR abnormalities. 31y52 pts (60%)
bear two CFTR mutations, 21 only one known CFTR alter-
ation, and in the remaining 4 no mutation was identified.
The most common diagnostic mistakes were Tb and sar-
coidosis (11 and 8 cases, respectively). CF diagnosis during
adulthood is performed in pts presenting atypical disease,
but also patients with the classic form of the disease may
receive a delayed diagnosis.
CF must be considered in the differential diagnosis of adult
patients with chronic respiratory symptoms, chest X-ray
S110 Journal of Cystic Fibrosis 1 (2002) S81–S180
abnormalities and characteristic sputum microbiology, even
in subjects with normal pulmonary function, andyor normal
chloride sweat values.
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DNA-QUANTIFICATION AND -QUALIFICATION
IN SPUTUM OF CF-PATIENTS FOR
MONITORING RHDNASE-THERAPY?
J. Riethmueller , H. Grassme , R. Ziebach , T. Borth-1 2 1
Bruhns , J. Wessels , M. Eyrich , M. Stern , E. Gulbins1 1 1 1 2
Department of Pediatrics, University Hospital, Hoppe-Sey-1
ler Str. 1, 72076 Tubingen, Germany, Department of2¨
Molecular Biology, University of Essen, 45122 Essen,
Germany
Aims: In large clinical trials the positive effect on outcome
of inhalative rhDNase therapy was usually measured with
pulmonary function methods (FVC, FEV1). These studies
revealed that only a limited number of patients revealed an
increase of lung function. We therefore analysed whether
DNA-quantification and -qualification in sputum with gel-
electrophoresis is suitable to answer the question why rh-
DNase is not effective in patients in good clinical
conditions?
Methods: Aliquots (15 ml) from 43 sputa of CF-patients,
50 BAL of postoperative incubated pediatric patients and
33 reference DNA-samples of T-lymphocytes (Jurkat-cells)
were analyzed by agarose gel-electrophoresis. Sputa of CF-
patients were also incubated 60 min with 10 mM Dithio-
treitol (DTT). Further aliquots were incubated in vitro with
10 5l rhDNase (Pulmozyme) and also analysed on the aga-
rose gels. The qualifications of fractioned DNA was done
with a gel-analysis-program (Analysis Dokub, SIS Leinfel-
den) in kilobase-sizemarker and in each aliquot.
Results: In ns5 CF-patients we detected no measurable
DNA in sputum, in ns10 CF-patients we detected intact
cells on baseline and in ns30 CF-patients we measured
0.11 mgyml median (0.013–1.19) fractioned DNA. Ns20
control-patients revealed only baseline DNA, ns34
patients exhibited median 0.014 (0.002–0.07) mg frac-
tioned DNA. Prior to in vitro DNase-application T-lympho-
cytes showed a distribution of almost equal percentage in
each kb-sizes (-12 000, 12 000, 4000, 3000, 2000, 1600,
1000, 500, 200, -200 kb). After DNase application we
detected a significant decrease of high kb-sizes and an
increase of small kb-sizes. In CF- and control-aliquots all
kb-sizes were completely cut after in vitro application of
rhDNase.
Conclusions: (1) DNA-quantification of CF-sputa might
be an activity marker on pulmonal inflammation; and (2)
might be helpful for starting DNase-therapy. (3) DNA-
qualification might be helpful in monitoring effective DNa-
se-therapy in vivo. All the questions have to be verified in
further clinical trials.
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ASSOCIATION BETWEEN ACTIVITY OF
GLYCOPROTEIN DEGRADATIVE ENZYMES IN
CF SPUTUM AND LUNG FUNCTION
H.A. Wyatt , K.A. Homer , R.G.G. Ruiz , D. Beighton1 2 1 2
Department of Child Health, King’s College Hospital,1
London, Department of Oral Microbiology, GKT Dental2
Institute, King’s College, London
Glycoproteins (mucins) in CF sputum are altered by chron-
ic infection. In the mouth bacteria obtain nutritional sub-
strates by degrading mucins. Inhibition of the enzymes
required may offer novel anti-infective strategies. We pos-
tulate that if the release of nutritional substrates from
mucins in CF sputum by bacterial or host enzymes contrib-
utes to the multiplication and persistence of the organisms
in the lung, then these enzyme activities may correlate with
the severity of lung damage.
Aim: To determine how glycosidase and protease activity
in sputum from CF patients varies with the patients’ lung
function.
Methods: Sputa from 12 CF patients aged 5.7–22.9 years
(median 15.6 years) were collected and spirometry record-
ed during routine clinic visits. All patients had chronic
infection with Pseudomonas aeruginosa andyor Staphyloc-
cocus aureus. Sputa were extracted into Tris–HCl buffer
and enzyme activities measured using sensitive fluorogenic
substrates, with determination of released fluorophore and
quantitation using authentic standards. Glycosidases meas-
ured included sialidase, N-acetyl-b-D-hexoaminidases, and
a-L-fucosidase. Proteases measured included elastase and
glycylprolyl dipeptidase. Spearman correlation coefficients
between individual enzyme activities and FEV1 and FVC
were calculated.
Results: The median FEV1 was 52.5% predicted (range
32–66%) and FVC was 73.5% predicted (range 50–89%).
The glycosidases, N-acetyl-b-D-glucosaminidase, N-acetyl-
b-galactosaminidase and a-L-fucosidase activities were sig-
nificantly (P-0.05) inversely correlated with FVC (rsy
0.741, rsy0.713 and rsy0.657, respectively). These
activities were also inversely correlated with FEV1 but just
failed to reach statistical significance perhaps due to small
sample size. Protease activity did not correlate with lung
function.
Conclusion: In this preliminary study, increased activities
of glycosidases with mucin-degrading activity were asso-
ciated with diminished lung function.
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THE 6-MIN-WALK TEST AS AN INDICATOR OF
DISEASE SEVERITY IN CF
D. Costantini , A. Brivio , D. Brusa , M. Fo , G.1 2 2 2
Romano , M. Russo1 1
CF Center, Department of Pediatrics, University of Milan,1
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ICP, Italy, CF Center, Physiotherapy Service, University of2
Milan, ICP, Italy
Exercise tolerance plays an important role in determining
quality of life of pts with respiratory impairment.
The 6-min-walking test is considered a simple and reliable
method to assess exercise tolerance, it has been validated
in adults and children.
Aim of the study was to determine if the test is related to
extent of lung disease.
Materials and methods: We studied 51 CF pts (26 CF)
with a mean age of 16.6"5.9 (range 5–31 yrs) and mean
FEV1 of 74.86%"24.9 predicted (range 22–127%). All
subjects performed the 6-min walk test, all of them had one
or more previous walking test and were in stable clinical
conditions. Outcome measures were walked distance, mean
and maximal heart rate (HR), mean and minimal arterial
oxygen saturation and SaO at rest.2
Results: No relation was found between distance walked
and FEV1 in the whole group (mean 573 m) in the group
with mean FEV1 68%. Max HR is inversely related to
FEV1 being 172 bpm vs 147 in the group with worse vs
better function (Psn.s.) weaker is the relationship between
mean HR and FEV1. Resting SaO has no correlation with2
respiratory function, but mean SaO during walk is directly2
related to FEV1 varying from 95.78 in the mild pts to
90.25% in the most severe ones (P-0.01). Same results
are demonstrated in minimal SaO being 93.17 vs 85.25%2
in those groups of pts (P-0.01).
In conclusion the presence of desaturation is strongly relat-
ed to the degree of respiratory impairment, similarly does
the rise of HR during walk, therefore 6-min-walk test is to
be considered a useful indicator of the severity of the dis-
ease and may help in the pre-transplantation evaluation.
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EXERCISE TOLERANCE IN HYPOXIEMIC CF
PATIENTS
G. Pizzamiglio , G. De Grandis , A. Brivio , M.A.1 1 2
Monti , D. Costantini1 2
CF Adult Center, Department of Internal Medicine, Milan,1
Italy, CF Center, Department of Pediatrics, University of2
Milan, Italy
Chronic respiratory failure and deconditioning of muscle of
locomotion impairs physical activity in CF patients.
In a previous study* we presented data about a program of
reconditioning training program in 10 hypoxiemic adult CF
pts, concluding that only a slight decrease in max heart rate
(HR) and a good response in dispnoea score were observed
at the end of rehabilitation.
Material and metods: With this study we are able to report
results of 18 pts (12 F–6 M), mean age 26941727, mean
FEV1 48.33%114.7, who where hypoxiemic during a 6
walking test (WT) or overnight; 3 pts were 02 dependent,
6 pts required 02 during the training program. The exercise
program consisted of an interval training by bicycle with
constant workload and increasing working time for 3–5
days per week for 6 weeks. Individual workload was based
upon 85% of their max HR during the initial WT.
Results: We evaluated during the WT, before and after the
rehabilitation program: walked distance (meters
5533916622 vs 5684417806), min SaO (86.5%13.07 vs2
8661494), max HR (bpm 1666111345 vs 1590511449, Ps
0.03), respiratory rate (33331949 vs 311660) and exertion-
al dispnoea measured by visual analogic scale (552212056
vs 484412035, Ps0.05).
In conclusion our data show an improvement of all para-
meters we evaluated; a training program on exercise toler-
ance in hypoxiemic CF pts seems to be helpful and
advisable in a global program of care. An improvement as
well in the quality of life of these pts could be achieved;
further studies are needed to study this aspect.
* XIIIth International CF Congres, 4–8 June 2000, Stock-
holm, p. 140.
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BLOOD OXYGENATION PARAMETERS AND
ACID–BASE BALANCE IN PATIENTS WITH
CYSTIC FIBROSIS
A. Mianrowska, M. Kaczmarski
III Department of Children’s Diseases, Medical Academy
in Bialystok, Poland
Background: Cystic fibrosis is the most common, multi-
system disease of the white race. Regardless of form as the
disease advances, signs of chronic anoxia are observed.
This indicates adaptation of organism to poor accessibility
of oxygen for tissues.
Aims: The assessment of acid–base balance and blood oxy-
genation parameters in patients with CF in every clinical
manifestation.
Methods: In the study, assessment of oxygenation para-
meters and acid–base balance was performed in 18 patients
aged 2–21 years with CF treated in 3rd Department of Chil-
dren s Diseases. Taking clinical assessment according to
Shwachman score into account, two groups of patients were
created: with cinical efficiency (group I) and clinical inef-
ficiency (group II). In both groups following measurements
of gasometry and acid–base balance in venous blood were
carried out: partial pressures of oxygen and carbon dioxide,
pH, base excess (BE) were measured by using 278 Blood
Gas System; concentration of haemoglobin, blood oxygen
content, blood oxygen capacity, concentration of oxyhae-
moglobin, blood oxygen saturation were measured by using
270 CO-oxymeter.
Results: Blood oxygenation parameters: in patients with
CF with clinical inefficiency and clinical efficiency a sig-
nificant disturbance in blood oxygenation parameters was
found. O2cap in 3 patients of group I and in 4 patients of
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group II was lowered. O2Hb and sO2 in 7 patients in both
groups were lowered. Acid–base balance: pO in 2 patients2
in both groups was lowered. No significant disturbance was
found in other values.
Conclusions: Oxygen distribution in CF is considerably
disturbed. The measurements of acid-base balance para-
meters give a possibility to prognose a metabolic disorders
with intensity of disturbance of oxygen distribution in case
of incorrect values in this range. The assessment of oxy-
genation and tissue metabolism is important in both groups
of patients with CF and give a possibility to monitor these
parameters and to modify the treatment.
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ROLE OF ASPERGILLUS FUMIGATUS IN CF
PATIENTS
D. Costantini , C. Fredella , G. Pizzamiglio , G. Romano ,1 1 2 1
M. Russo , M.A. Monti1 2
CF Center, Department of Pediatrics, University of Milan,1
ICP, Italy, CF Center, Department of Internal Medicine,2
University of Milan, ICP, Italy
The relationship between Aspergillus fumigatus and cystic
fibrosis is extremely complex. We wanted to study the prev-
alence and the clinical relevance of A. fumigatus sensitis-
ation in a cohort of pts in care at the CF Center of Milan.
Materials and methods: We evaluated 124 pts (60 M, 64
F), mean age 20.7 yrs (range: 1–50 yrs) followed at the
outpatient Department of our Clinic and assessed for all the
parameters of A. fumigatus sensitisation: skin test, total and
specific IgE, precipitating antibodies to A. fumigatus, spu-
tum culture, chest X-ray findings.
Results: We divided pts in two groups depending on total
IgE levels: group AsIgE within the normal range and
group Bshigh IgE levels; the characteristics of both groups
are listed below:
Group n Age FEV1% IgEkUAy
IRAST class
Precipitins
M M M M (% pts)
A 85 21.0 y 69.6% 91.4 0.6 18.8%
B 39 19.8 y 73.5% 1237.7 3.55 41%
Fifty-six percent of patients of group A vs 61.5% of
group B live at country side. Both age and respiratory
function are similar in the group with low and high IgE,
but positivity of precipitins and elevation of specific IgE
seem to be related to Aspergillosis. Prevalence of ABPA
defined on the basis of 3 criteria at least in our series is
31.4%. Sputum is frequently colonised by Aspergillus
77.6% in group A vs 58.9% in group B. The need for
steroid treatment is higher in group B 46% of pts vs
4.7% in group A. Itraconazole was administered to the
majority of pts affected by ABPA 61.5% versus 18.8%
in group A.
In conclusion Aspergillosis in our series seems to be not
related to age nor to the severity of the disease nor to
rural environment; further studies are required to
determine the role of A. fumigatus in CF.
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MANAGEMENT OF ABPA COMPLICATED BY
ENDOCRINOLOGICAL DEFICIENCIES IN A
CHILD WITH CF
S. Higgs , H. Thomas , E. Crowne , S. Langton Hewer1 2 3 4
Cystic Fibrosis Fellow, Consultant Respiratory Paediatri-1 2
cian, Consultant Paediatric Endocrinologist, Consultant3 4
Respiratory Paediatrician, Bristol Royal Hospital for Chil-
dren, Bristol, UK
Presenting the case of a 15-year-old adopted boy who was
diagnosed with cystic fibrosis (CF) aged 2 years. He
became chronically infected with Pseudomonas aeruginosa
in his sputum and raised antibody titres. Aged 9 his lung
function deteriorated PEFR 80% expected, FEV1 74% and
FVC 115%.
Allergic bronchopulmonary Aspergillosis (ABPA) was
diagnosed on the basis of elevated IgE ()1000 IUyl),
RAST 4 IUyl to Aspergillus, strongly positive Aspergillus
precipitins, isolates of Aspergillus fumigatus (and later
Aspergillus niger) in his sputum and flitting infiltrates on
CXR. He was treated with oral prednisolone (1–2 mgykgy
day) and inhaled Budesonide 1200 mcg bd later changed
to Fluticasone 750 mg bd.
It was not possible to wean him off high dose oral pred-
nisolone without relapse. Additionally he developed evi-
dence of growth failure at 11 years when bone age was 6–
7 years. Oral Itraconazole was started in an attempt to
decrease his steroid dependency. Serum Itraconazole levels
were monitored until it reached the therapeutic range at a
dose of 600 mg od.
Aged 12 he presented with symptoms of acute adrenal
insufficiency. Synacthen test displayed an inadequate
response and Glucagon test showed no response. Replace-
ment hydrocortisone was started.
Growth hormone (GH) assays revealed deficiency and GH
was started in July’99 and has resulted in accelerated
growth with resultant pubertal changes.
While on high dose prednisolone he developed a severely
impaired glucose tolerance which persisted after reduction
in prednisolone and insulin therapy commenced in July’99.
As a result of these interventions there have been fewer
acute exacerbations and improvement in lung function
PEFR 101% expected, FEV1 102% and FVC 128%.
Points for discussion:
1. Criteria for diagnosis of ABPA
2. Treatment of ABPA and the role of oral Itraconazole
3. Monitoring of Itraconazole dosage
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4. Timing of referral to an Endocrinologist for assistance
with growth stasis?
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PREVALENCE OF ALTERNARIA
SENSITIZATION IN ADULT CYSTIC FIBROSIS
P. Ferrara , R. Calvanese , V. Carnovale , G. Testa , P.1 2 1 1
Capaccio , L. Viati , V. Del Villano , D. de Santis , P.1 1 1 1
Abete , F. Rengo1 1
Unita Specialistica Fibrosi Cistica dell’Adulto-Centro di1 `
Riferimento Regione Campania, University of Naples
‘‘Federico II’’, Presidio Sanitario ‘‘S.Maria della Pieta’’,2 `
Unita Operativa di Pneumologia, Casoria (Naples)`
In Cystic fibrosis, viscous secretions and altered mucocili-
ary clearance lead to endobronchial trapping of inhaled fun-
gal spores. Aspergillus fumigatus is frequently cultured
from respiratory secretions of CF adult. Although the inva-
sive disease of Aspergillus is rare in CF patients, allergic
bronchopulmonary aspergillosis (ABPA) may occur in as
many as 5 to 15% of CF adult. The finding of Aspergillus
in sputum and the presence of antiaspergillus IgE, IgA, IgG
can occur in patients with CF without ABPA. Several mul-
ticenter studies emerged of a non-negligible frequency of
sensitization to Alternaria mold in respiratory allergic
patients in Europe. A previous study provided the first and
unique demonstration that Alternaria, in addition to Asper-
gillus, is an important allergen causing a bronchial response
in CF patients. In a recent study, 25% of 20 CF patients
having high IgG ab to AsfI (the major Aspergillus allergen)
also had IgE binding to recombinant Alt a 1 (the major
Alternaria allergen) and RAST IgE to Alternaria. The pur-
pose of this study was to evaluate the prevalence of sen-
sitization to Alternaria with the determination of serum
specific IgE by the CAP method in adult CF. Patient data
were obtained by retrospective review of the records of 65
adult CF followed in our Center in 2001. We observed that
36.9% of patients (24y65) were positive to Alternaria and
Aspergillus fumigatus; 3.1% of patients (2y65) were sen-
sitized to only Alternaria. According to Alternaria CAP
score, we observed that 66.7% of patients (16y24) was in
CAP class 1–2 (0.35–3.50 IUyml) and 33.3% of patients
(8y24) was in CAP class 3–4 (3.50–50.0 IUyml). None
of patients was in CAP class 5–6 (50–100 IUyml). The
clinical relevance of this positivity in CF adult is still uncer-
tain. Further studies are needed to better establish the clin-
ical relevance and the prognostic value of Alternaria
sensitization in adult CF.
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FOLLOW-UP OF INFILTRATES AND
ATELECTASIS IN CYSTIC FIBROSIS BY MRI
Alexandra Hebestreit , G. Schulz , A. Trusen , H.1 2 2
Hebestreit1
Universitats-Kinderklinik, Institut fur Rontgendiagnostik,1 2¨ ¨¨
University Wurzburg, Germany¨
To avoid multiple chest X-rays in the follow-up of patients
with pulmonary atelectasis or pneumonic infiltrates, mag-
netic resonance imaging (MRI) of the lung may prove to
be a valuable tool. Eight patients with cystic fibrosis and
one girl with bronchiectasis who presented with atelectasis
andyor with pulmonary infiltrate participated. All but two
patients were initially examined using chest X-rayyCT-scan
and MRI. All patients were followed clinically and by MRI
until the acute lung pathology was resolved. Patients were
examined in a 0.2 Tesla Siemens Magnetom Open system
using a true fisp sequence and a slice thickness of 20–35
mm. All patients could be examined in the MRI without
sedation. Chest X-raysyCT-scans and MRI provided iden-
tical information in all cases. The MRI proved sufficient to
monitor the pulmonary complications in all cases so that
no additional chest X-rays or CT-scans were required. In
several cases, therapeutic intervention was guided by the
MRI findings. In conclusion, MRI of the lung is a feasible
and valuable tool in the follow-up of lung pathologies, i.e.
infiltrates and atelectasis. In the future, MRI may be helpful
to identify optimal treatment strategies for atelectasis.
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REFRACTORY ATELECTASIS IN CHILD WITH
CYSTIC FIBROSIS. CASE REPORT
R.T.T. Ramos, S.A. Machado Jr., M.A. Santana
Unit of Cystic Fibrosis, Hospital Octavio Mangabeira, Sal-
vador, Bahia, Brazil
Introduction: CF lung disease is characterized by early
colonization of the airways by several bacteria and by
relapsing infectious re-exacerbations leading to respiratory
failure. Because most often atelectasis is caused by airway
inflammation, optimal treatment of the causative disease
may be an effective prophylactic measure against
atelectasis.
Case report: We report a male, 10 years old patient with
exocrine pancreas insufficiency, poor nutritional status, por-
tal hypertension, chronic P. aeruginosa and S. aureus lung
infection and severe pulmonary obstruction. CF diagnosis
was made at 18 months old. During his 10th year of life
he had his 3rd admission with subtle worsening of pul-
monary status. Chest HRCT showed total right lung col-
lapse and diffuse interstitial shadows, over inflation,
mucus-impacted bronchi and bronchiectasis in the left side.
At that time 2 bronchoscopies were performed, though
copious purulent mucus had been aspirated and repeated
lavages done. Despite of these efforts pulmonary expansion
was not achieved. At the 3rd endoscopy a naso-bronchial
catheter was placed in right main bronchus followed by
resolution of the right lung collapse after 1 day. It was
removed after 4 days.
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Conclusion: Management of refractory atelectasis is based
on physiotherapy and bronchoscopy. Suctioning and lavage
can remove mucus plugs. Attempts at insufflating the ate-
lectatic lung segment have been made using a catheter or
a fiberoptic bronchoscope, in spite of hazards. Placing an
endobronchial catheter is an easy procedure and can be
guided during the bronchoscopy or by fluoroscopy. In such
case, bronchial washings, instillations of mucolytic agents
and repeated aspirations can be done. Despite this simple
method the authors did not find the description of the
approach in literature.
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STAPHYLOCOCCUS AUREUS SEPTICEMIA AS
PRESENTING EVENT IN A YOUNG CF INFANT
(CASE REPORT)
L. Dracea, L. Petrescu, E. Georgescu, O. Falup-Pecurariu
Children’s HospitalyUniversity Hospital of Brasov,
Romania
Staphylococcus aureus has long been recognised as a path-
ogen in Cystic Fibrosis. It is often the first bacterial species
isolated from pulmonary secretions, but extended infections
beyond the lung are uncommon in CF patients. A premature
female infant, was admitted to the ICU with failure to
thrive, severe dehydration and respiratory distress at the age
of 1 month. There was no previous history of disease, but
a low socio-economic condition of the family. The patient
presented severe hypoxemia, bilateral patchy atelectasis and
hyperinflation of the lungs. There was rapidly developing
a multiple organ failure consistent with the diagnosis of
Staphylococcus aureus septicemia. Intensive antibiotic ther-
apy, nutritional support, oxigenotherapy, i.v. immunoglob-
ulins were immediately started. The recovery was very
slow. After the life threatening staphilococcal infection,
weight gain was very poor and there were intermittent epi-
sodes of diarrhea. In the forthcoming months there were
several episodes of pulmonary exacerbations with bronchial
obstruction and persistent atelectasis on the chest X-ray.
First isolation of Pseudomonas aeruginosa from pulmonary
secretions was at the age of 2.6 months. Gathering the data,
there was a high suspicion for the diagnosis of Cystic Fibro-
sis. Genotyping revealed deltaF508ydeltaF508 mutation.
The patient is now on a regular treatment program, but with
very frequent pulmonary exacerbations, intermittent colon-
isation with P. aeruginosa and poor nutritional status. We
presume that septicemia was precipitated by prematurity
and poor weight gain in the first month of life. Slow
improvement of clinical status may be caused by the early
damage of the respiratory tract produced by the S. aureus
which thereby paved the way for Pseudomonas aeruginosa.
Conclusions: Even Staphylococcus aureus septicemia is a
rare condition in CF patients, the early acquisition of this
bacterial species in selected individuals could affect
morbidity.
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AIR TRAVEL IN ADULTS WITH CYSTIC
FIBROSIS: PREDICTING THE RESPONSE TO
THE HYPOXIA INHALATION TEST
E. Ross , D. Cramer , S. Ward , M.E. Hodson1 2 2 1
Department of Cystic Fibrosis, Department of Lung func-1 2
tion, Royal Brompton Hospital, London, UK
Low barometric pressure during air travel may cause sig-
nificant hypoxaemia (PaO -6.6 kPa (50 mmHg)) in sub-2
jects with cystic fibrosis (CF). The hypoxia inhalation test
(HIT) simulates commercial aircraft cabin hypoxic condi-
tions during flight at 2440 m, equivalent to breathing 15%
oxygen at sea level. The test is not widely available. The
aim of the study therefore was to assess whether the PaO2
during HIT could be predicted from lung function or arte-
rial blood gases on air.
Methods: 66 studies were performed in 55 adults with CF
(34 F, mean age 27.1 yrs) from May 1997 to September
2001. Subjects underwent full lung function and hypoxia
inhalation testing. During the HIT, subjects breathe 15%
oxygen for 20 min with arterialised blood gas sampling
before (on air) and at the end of the test (while still
breathing 15% oxygen).
Results: Reported as mean"S.D. Lung Function: FEV1
1.23L"0.52 (36.99"13.90% pred), FVC 2.36L"0.70
(60.87"14.73% pred). ABGs: On air: SaO 94.9%"1.9,2
PaO 9.62 kPa"1.54, PaCO 4.98 kPa"0.58;On 15% oxy-2 2
gen: SaO 86.8%"5.1 PaO 6.59 kPa"0.97, PaCO 4.682 2 2
kPa"0.58.
In 34 studies, the PaO on 15% oxygen was less than 6.62
kPa. Compared to those with a PaO above 6.6 kPa, this2
group had a significantly lower FEV1% (29.24 vs 44.86,
P-0.01), FVC% (53.38 vs 68.92, P-0.01), SaO % (93.62
vs 96.1) and PaO on air (8.71 kPa vs 10.69, P-0.01) and2
higher PaCO on air (5.23 kPa vs 4.71, P-0.01). By2
receiver operating characteristic curve analysis, baseline
PaO (area under curve 0.914) SaO (auc 0.90) and2 2
FEV1% (auc 0.84) most accurately predicted whether
PaO on 15% oxygen was below 6.6 kPa. To exclude a2
PaO on 15% oxygen below 6.6 kPa, the best cut-points2
were FEV1)50% (sensitivity 97.4%, specificity 31%),
PaO on air)10.6 kPa (sens 97%, spec 53%) and SaO on2 2
air )96% (sens 97.1%, spec 62.5%). Below these levels,
hypoxia testing may be helpful.
Conclusion: In CF adults, FEV1% predicted and ABGs on
air may be helpful in excluding significant hypoxaemia dur-
ing the HIT.
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SIMULATION OF A LONG-DISTANCE FLIGHT IN
PATIENTS WITH CYSTIC FIBROSIS
K. Brueckner, R. Fischer, S. Meyer, R.M. Huber
Pneumology, Medizinische Klinik Innenstadt, Ludwig-Max-
imilians-University, Munich
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Background: Due to the increasing age and mobility of
patients with cystic fibrosis, the number patients performing
long-distance flights increases. We, therefore, performed a
study about the cardio-pulmonary risk of an exposition for
several hours to an altitude of approximately 2600 m in
these patients, equivalent to the pressurized cabin of an air-
craft at cruising altitude.
Methods: We examined patients with cystic fibrosis at an
altitude of 2660 m over a period of 8 h, performing lung
function tests, capillary blood gas analysis and echocardi-
ography at rest. To evaluate the effect of moderate exercise
at altitude, we draw additional blood gas samples during
cycling at 60 W.
Results: We included 34 patients in the study, average age
30.1 years (19–47), 14 women.
Variable 500 m 2660 m 2660 m 2660
m(mean values) (at
arrival)
(after 8
h)
(moderate
exercise)
FEV1% pred. 66.3 71.1 70.4
R (kPa syl)tot 0.4 0.35 0.37
ITGV, % 118.4 133.5 136.8
VC (l)max 3.97 3.96 3.95
PEF %pred. 71 84.9 82.2
MEF25 %pred. 25.96 32.52 30.33
PaO (mmHg)2 75.9 52.8 52.8 47.8
PaCO2
(mmHg)
38.3 35.2 37.8 34.2
Thirty-two percent of our patients had a PaO of 502
mmHg or lower at rest after 8 h. However, none of them
had to be treated with oxygen or felt subjectively sick.
We found no significant increase in pulmonary pressure
signs in echocardiography. The correlation coefficient
between low altitude PaO and high altitude PaO was2 2
0.69 (P-0.01). In multivariate analysis, MEF25
(percent predicted) was the best predictor of PaO at2
altitude.
Conclusion: Even with moderate exercise, patients with
cystic fibrosis are able to tolerate PaO -values below 502
mmHg over a period of up to 8 h. Therefore, some of
the international guidelines concerning fitness to fly in
these patients may be too rigorous.
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FACTORS ASSOCIATED WITH DISEASE
SEVERITY IN A COHORT OF ADULT PATIENTS
WITH CYSTIC FIBROSIS (CF)
N.A. Jarad
Adult CF Unit, Bristol Royal Infirmary, Bristol BS2 8HW
Aim: To assess factors associated with disease severity in
a cohort of adult CF patients.
Methods: Factors which determine disease severity were
investigated reterospectively in 53 adult CF patients (22
female), average age 23.4 year, range: 17–39 years. Dis-
ease severity was divided into 4 categories according to the
need for intravenous antibiotics with and without hospital-
isation and the level of lung function tests. The contribution
of the following factors to the disease severity was
assessed: genetic profile, age, sex, body mass index, and
colonisation with pseudomonas aeroginosa.
Results: There was no difference in age distribution, sex
and genetic profile in different grades of disease severity.
Patients with a more advanced disease had a significantly
reduced body mass index and increased incidence of colon-
isation with pseudomonas aeroginosa compared with those
with milder disease.
Disease severity 1 2 3 4
Female:Male 5:11 7:7 6:8 4:3
PAqve PA-ve* 6:9 6:8 10:6 6:1
Homo D508:other 7:8 5:9 6:10 4:3
Mean age 24.9 23.4 24.6 22.4
Mean BMI* 23.1 21.2 20.7 18.1
PA: Pseudomonas aerogenosa. *P-0.01.
Conclusion: In our adult CF patients, reduced body
mass index and colonisation with pseudomonas
aeroginosa are the only two factors which appear to be
associated with increased disease severity.
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IS POOR OUTCOME PREDICTABLE IN EARLY
MANIFESTATIONS OF CYSTIC FIBROSIS IN
YOUNG CHILDREN?
L. Dracea , O. Falup-Pecurariu , S. Buzinschi , S. Rogoz ,1 1 1 1
G. Benga , M. Schwarz , I. Popa2 3 4
Children’s HospitalyUniversity Hospital of Brasov, Roma-1
nia, Genetic Department, University Hospital Cluj-Napo-2
ca, Romania, Genetic Department, Royal Manchester3
Children’s Hospital, UK, IInd Pediatric Clinic, National4
CF Center Timisoara, Romania
It is recognised that the age at diagnosis and the type and
severity of symptoms at the initial presentation reflect the
heterogenicity of CF. Early detection of the functional
abnormalities in CF patients entirely depend upon an accu-
rate clinical diagnosis as early as possible.
Aims: To determine the correlations between poor outcome
and type and severity of CF symptoms at initial
presentation.
Methods: In a 3 years follow up period, we assessed 15
CF patients diagnosed in the Respiratory Department of the
Children’s Hospital of Brasov. Mean age at diagnosis was
2.5 years (age range 5 months–10 years, excluding MI
patients); 50% being infants. We analysed the possible risk
factors for poor outcome as it follows: —severe presenta-
tion (including important nutritional impairment) at the
time of diagnosis—5 patients-homozygots for delta F508
mutation—2 patients-early colonisation with Ps. Aerugi-
nosa—6 patients-delay of diagnosis despite suggestive clin-
ical features—5 patients-association with specific pathology
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findings—4 patients-chronic metabolic alkalosis—3
patients.
Results: All deaths encountered (5 patients) were under the
age of 1 year and presented all the evaluated risk factors.
Ten patients are under continuous survey and treatment reg-
imens—two of them presenting severe respiratory symp-
toms (recurrent atelectasis, early acquisition of Ps.
aeruginosa, high degree of hyperinflation) and impaired
growth. Clinical diagnosis was delayed in more than 50%
of patients when lung damage was important and closely
correlated with nutritional status.
Conclusions: Early recognition of CF phenotype and active
treatment regimens, despite long hospitalisation periods,
significantly improved the clinical outcome in most
patients. Identifying individual young CF patients at high
risk of developing progressive lung disease could be a
measure for targeting them for appropriate preventive treat-
ment which should influence long term survival.
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FACTORS INFLUENCING THE COURSE OF CF
IN CZECH PATIENTS
D. Zemkova , M. Hladmkova , J. Bartosova , A.1 2 1
Zapletal , M. Macek Jr. , V. Vavrova1 3 1
2nd Paediatric Department, Charles University 2nd Med-1
ical School and University Hospital Motol, Institute of2
Medical Informatics, Charles University 2nd Medical
School, Institute of Biology & Medical Genetics, Charles3
University 2nd Medical School
The overall course of CF is predominantly determined by
genetic factors, pancreatic status, level of therapy, chr.
infection by P. aeruginosayB. cepacia, lung functions
(PFTs), nutritional status (NS) and gender. The aim of the
study was to assess the proportional role of these factors in
Czech patients (pts) that have been longitudinally moni-
tored since 1985. In 108 pts we had clinical data at 8 and
12 years of age, while 54 of them were followed also at
the age of 18. F508del homozygotes (61y108—56.5%) and
compound heterozygotes for Class I–III mutations account-
ed for most genotypes, 9y108 (8.3%) were F508delyunk
and 3y108 (2.8%) were carriers of a class IV–V alleles
102y108 (94.4%) pts were pancreatic insufficient. Since
the mean FEV1 at 12 yrs of age was 74.4q21.4% predicted
(8.3% pts -40%) and at 18 yrs 58.2q26.5 (31.5%), this
parameter is an important risk factor. From 9 pts with
FEV1-40% at 12 yrs 5 died after 1.7–12.5 yrs (median
6.0) and 4 have lived 0.2–7.0 yrs (2.6), while from 18 pts
with FEV1-40% at 18 yrs 11 died after 0.5–6.7 yrs (2.3)
and only 6 have lived 0.3–7.2 yrs (1.8). Based on these
initial findings we evaluated factors influencing FEV1 at
12 and 18 yrs by simple regression, partial correlation coef-
ficients and step-wise multiple regression analyses. FEV1
at 12 yrs correlates closely with FEV1 at 8 yrs (rs0.73,
P-0.001). Controlling for FEV1 at 8 yrs, FEV1 at 12 yrs
correlates with NS at 8 yrs (mid-arm circumference Ps
0.02) and modern therapy duration Ps0.05. FEV1 at 18
yrs depends especially on FEV1 at 12 yrs and modern
intensive treatment duration (P-0.001). FEV1 at each age
depends on duration of P. aeruginosa infection. B. cepacia
infection deteriorates FEV1 at 18 yrs. We did not prove the
influence of sex on the course of CF. In conclusion, our
study proved the importance of NS, PFts, chr. infection and
modern intensive treatment.
Supported by MZCR: 5067-3, LN00A079, ME457, and
00000064203.
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MONITORING OF CYTOMEGALOVIRUS (CMV)
INFECTION IN LUNG TRANSPLANT
RECIPIENTS WITH CYSTIC FIBROSIS
A. Grzejdziak, M. Rolla, P. Canuzzi, C. Mancini, A. Gaeta,
C. Nazzari, M. Zaccagnini, S. Cingolani, S. Quattrucci
Cystic Fibrosis Center, Department of Pediatrics, Univer-
sity of Rome ‘‘La Sapienza’’, Italy
Introduction: CMV infection and disease are common in
lung transplant recipients (LTR). Rapid and sensitive meth-
ods are necessary for an early diagnosis and management
of antiviral treatment.
Methods: From 1996 to 2001, 41 LTR with cystic fibrosis
were examined. CMV antigenemia and qualitative CMV
PCR were performed routinaly. Competitive PCR ELISA
assay was used to quantitate CMV DNA in peripheral blood
polymorphonuclear leucocytes (PMNLs). Treatment with
ganciclovir (GCV) i.v. alone or plus CMV-specific immu-
noglobulins (Ig) i.v. was started if positive antigenemia was
shown andyor CMV DNA levels were above 100 copiesy
100 000 PMNLs.
Results: 37 patients (pts) developed CMV infection with
wide variation in the CMV DNA levels; only 18 pts had
positive antigenemia. 30 pts underwent treatment with GCV
during infection (11 pts were also given CMV-specific Ig).
7 pts did not undergo GCV for low CMV DNA levels.
Clinical findings were: CMV duodenal ulcer (1 patient);
CMV pneumonitis (1 patient); symptoms related to a mon-
onucleosis-syndrome (5 pts). Complications associated
with CMV infection were: opportunistic pneumoniae (5
pts); fungal colonization (7 pts).
Four patients developed obliterative bronchiolitis. No mor-
tality directly related to CMV was reported.
Conclusions: Our findings suggest that PCR is a reliable
assay for an early diagnosis of CMV infection. The routine
quantitation of CMV DNA by PCR is useful in monitoring
and management of CMV infection. We were able to avoid
unnecessary treatments in patients with low viral load and
to control CMV infection and disease through a good tim-
ing of antiviral treatment. Cystic fibrosis has not influenced
our results; we have only noted that opportunistic infections
were caused by agents colonizing our patients.
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TELEMETRIC MONITORING SYSTEM (TMS)
FOR DOMICILE NON INVASIVE MECHANICAL
VENTILATION (DNIMV) IN END STAGE CYSTIC
FIBROSIS (CF) PATIENTS WAITING FOR
DOUBLE LUNG TRANSPLANTATION (DLT)
G. Cimino , S. Bertasi , F. Alatri , L. Graziano , S.1 2 3 4
Cingolani , S. Quattrucci5 6
Medical Doctor, Medical Doctor, Physiotherapist, Phy-1 2 3 4
siotherapist, Medical Doctor, Medical Doctor, Pediatrics5 6
Department Policlinico Umberto I University of RomeLa
Sapienza, Rome, Italy
Domicile application of Non Invasive Mechanical Ventila-
tion (DNIMV) for patient affected by chronic obstructive
lung disease is widely employed in order to improve res-
piratory fatigue, hypercapnia and hypoxemia. Mechanical
ventilation is frequently indicated in those patients with
inadequate alveolar ventilation. Many Authors have dem-
onstrated that NIMV may increase the survival rates in end
stage CF patients waiting for double lung transplantation
(DLT) both by reducing the respiratory distress and by
improving the patient general status. End stage CF patients,
on waiting list for DLT at the Department of CF, University
of Rome ‘la Sapienza’, were treated by means of DNIMV
with Bilevel Positive Airway Pressure device. A telemetric
monitoring system (TMS) via modem was employed in 2
cases in order to achieve continuos data regarding the res-
piratory parameters. The aim of the study was to verify the
efficiency of a telemetric monitoring system in patients
with DNIMV. Our data (PO2, respiratory rate, ventilation
parameters) suggest that DNIMV, supported by TMS, by
improving the control of the respiratory conditions, may
contribute to reduce mortality rates in end stage CF patients
waiting for DLT.
Results:
Patient A Patient B
pre VMD with VMD pre VMD with VMD
Sat. O (average)2 90% 96% 89% 95%
PaO (mmHg)2 55 65 51 69
PaCO (mmHg)2 67 52 70 59
Respiratory rate 34ymin 22ymin 35ymin 22ymin
VDyVT 0.65 0.48 0.7 0.45
MIP 40 45 34 41
FRyVT 106 56 110 53
Conclusions: Increased waiting time for DLT among CF
patients is frequently accompanied by high mortality
rates. In these cases, domicile NIMV with TMS are very
helpful to reduce the hospitalization rates and to improve
the patient and the patient s family quality of life.
P160
DOPPLER ECHOCARDIOGRAPHIC INDEX OF
RIGHT VENTRICULAR FUNCTION IN CYSTIC
FIBROSIS ADULTS
R.J. Bright-Thomas , M.I. Burgess , M.E. Dodd , A.K.1 2 1
Webb1
Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Man-1
chester, United Kingdom, Department of Cardiology,2
Wythenshawe Hospital, Manchester, United Kingdom
Introduction: Abnormalities of both right ventricular (RV)
systolic and diastolic function have been reported in CF
adults. A non-invasive Doppler index of myocardial per-
formance (IMP) has been described which incorporates
important periods of systole and diastole. A raised RV IMP
predicts adverse outcome in primary pulmonary hyperten-
sion but its use has not previously been reported in CF. The
purpose of this study was to assess the feasibility of meas-
uring the RV IMP in CF patients and to assess its corre-
lation with clinical status, oxygen status and pulmonary
artery pressure.
Methods: Patients were studied by two-dimensional and
Doppler echocardiography. All were stable and none had
clinical evidence of RV failure. Doppler measurements
were taken at end-tidal apnoea. The tricuspid closing to
opening time was measured as the interval between end and
onset of tricuspid inflow (a). The RV ejection time was
measured from the onset to the end of the RV outflow pro-
file (b). The RV IMP was calculated as (ayb)yb.
Results: 32 patients (19 male) were studied. Age
(mean"S.D.) 27"7 years, BMI 19.9"2.3, FEV1% pre-
dicted 46"22, resting awake PaO 67"11 mmHg. RV2
dimensions were normal in all subjects. Twenty-three
patients (72%) had tricuspid regurgitation. Pulmonary
artery systolic pressure in these 23 patients was 39"9
mmHg. Measurement of the RV IMP was feasible in all
patients. RV IMP was 0.44"0.15. There was a significant
inverse correlation between the RV IMP and resting awake
PaO (Ps0.013) and FEV1% predicted (Ps0.026). There2
was no correlation between the RV IMP and nocturnal oxy-
gen saturation or pulmonary artery systolic pressure.
Conclusion: Measurement of the RV IMP, which allows
assessment of global RV function, is feasible in CF adults.
Preliminary results suggest that it is correlated with resting
awake PaO and FEV1% predicted. Larger scale studies are2
needed to assess its use and the relationship between oxy-
gen status, RV function and survival in CF patients.
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A SURVEY TO INVESTIGATE HOME
PHYSIOTHERAPY PRACTICE IN AN ADULT CF
UNIT
R. Tattersall, J. Dance, M. Ledson, M. Walshaw
Regional Adult CF Unit
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Whilst patients are taught appropriate chest clearance tech-
niques and have supervised physiotherapy in hospital, most
treatment is carried out at home and in adults is unsuper-
vised. It can be onerous, and we had the impression that
some patients were reluctant to carry it out or modified their
technique when at home. To explore this, we interviewed
25 adult CF patients (mean age 23 years wrange 16–39x,
13 female) using a structured questionnaire, conducted by
a physiotherapist (JD) who was unknown to the patients to
obtain accurate responses. When well, 36% undertook no
physiotherapy, 28% 1 treatment daily and 36% 2 treat-
ments. However, when ill 8% undertook no treatment, 20%
1 treatment, 44% 2 treatments, 16% 3 treatments and 12%
4 times daily and the length of treatment increased (when
ill, 26% of treatments )20 min compared to 18% when
well). Whilst 64% had at least one treatment in the morn-
ing, most (73%) varied the timing to fit in with their daily
routine. 29% were independent with treatment, but 21%
always had help and the remainder occasionally. Of these,
partners (24%) and relatives (76%) helped, with a good
technique in 65% of cases and only poor in 6%. ACBT was
the most widely used technique (70% of cases), and 65%
of these incorporated postural drainage. 70% added in man-
ual techniques such as percussion and vibrations and a fur-
ther 20% when sputum was sticky. 80% of patients were
aware of problematic areas in their chests and 86% of these
adapted their treatment accordingly. 92% of patients exer-
cised at least weekly. Thus most adult patients with CF will
carry out some from of chest clearance whilst at home, but
adapt the methods they have been taught in hospital. In
particular, patients increase the frequency and length of
treatment when ill. We believe that although patients should
be encouraged to carry out domiciliary physiotherapy, to
improve compliance they should be encouraged to adapt
their technique to suit their needs and lifestyle.
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USE OF PHYSIOTHERAPY AIDS AND
ADJUVANT INHALED THERAPY BY CF ADULTS
IN DOMICILIARY PRACTICE
R. Tattersall, J. Dance, M. Ledson, M. Walshaw
Regional Adult CF Unit
Chest physiotherapy, coupled with inhaled therapies, is
important in maintaining pulmonary function in CF
patients. Whilst they are taught clearance techniques and
have supervised physiotherapy in hospital, most treatment
is carried out at home and in adults is unsupervised. In
recognition of this, many patients are provided with aids to
assist with home chest clearance. We wished to assess the
use of such home aids, and also patients understanding of
the importance of adjuvant inhaled therapy. We surveyed
25 CF adults (mean age 23 years wrange 16–39x, 13
female) by detailed questionnaire. For postural aid, 17
patients (68%) had a tipping frame: 8 (46%) used it all the
time, 1 (6%) occasionally and the 8 (46%) never; of the 4
(16%) who had a physiotherapy wedge, only 2 used it reg-
ularly. To aid sputum production, 18 (72%) had a flutter
valve: 3 (17%) always used it, 10 (56%) occasionally and
the 5 (27%) never; of the 7 (28%) with a PEP mask only
5 (57%) used it occasionally. A further 2 had a Cornet, and
both used it. 95% reported that they had received instruc-
tion in home physiotherapy equipment cleaning., but only
45% cleaned it after each treatment, and 15% cleaned it
rarely, if at all. Regarding adjuvant use of inhaled therapies,
82% understood to take bronchodilators before, 14% after,
and 4% in between treatments. 52% rated their knowledge
of this therapy to be good, 16% excellent, 12% acceptable
and 20% poor. Of those who inhaled saline, 70% did so
before and 30% after treatment. Whilst 96% of patients said
their knowledge of inhaled antibiotics was excellent, 50%
still took inhaled antibiotics prior to physiotherapy despite
advice to the contrary. Thus, we have shown that in our
unit, CF patients knowledge on the use and cleaning of
physiotherapy aids and the timing of inhaled medication
needs to be improved. We have now adopted a policy of
regularly reinforcing these issues in clinic and in-patient
situations.
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PROBING P. AERUGINOSA BIOFILMS WITH
PROTEOMICS
S. Vilain , P. Cosette , M. Hubert , C. Lange , G.A.1 1 2 2
Junter , T. Jouenne1 1
UMR 6522 CNRS, Faculte des Sciences de Rouen, 768211 ´
Mont-Saint-Aignan, France Spectrometrie de masse Bioor-´
ganique, UMR 6014 CNRS, Faculte des Sciences de Rou-2 ´
en, 76821 Mont-Saint-Aignan, France
The discovery of a novel molecule involved in a particular
pathological condition offers a potential target for drug
design. Proteomic approaches involve the study of large
numbers of proteins at the same time, and represent one the
most promising strategies for drug target discovery. Pro-
teomic methodology consists of separating thousands of
proteins by 2D electrophoresis, followed by quantitative
image analysis and protein identification using mass spec-
trometry. We used proteomics strategies to identify proteins
involved in bacterial biofilms and resistance to antibiotics.
Patients with cystic fibrosis (CF) accumulate viscous
mucous in their lungs. This offers a favourable biological
nidus for bacterial colonization, particularly Pseudomonas
aeruginosa. The bacteria organize themselves into biofilms
that protect them from the host immune system, hiding
them from engulfing macrophages and providing them
resistance to antibiotics. We have investigated changes in
protein expression of bacteria organized in biofilms. We
found that approximately one quarter of the proteome
changes when P. aeruginosa are cultivated in biofilms. Fig-
uring out which of these are involved in antibiotic resis-
S119Journal of Cystic Fibrosis 1 (2002) S81–S180
tance will lead to the development of novel anti-microbial
agents to treat CF patients.
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PATTERNS OF ISOLATION OF RESPIRATORY
PATHOGENS IN A GEOGRAPHICAL
POPULATION OF CF PATIENTS OVER 6 YEARS
K. Giles , J. Tyrrell , S. Murray , S. Langton Hewer1 2 2 3
South and West Cystic Fibrosis Database, Bath, England,1
Royal United Hospital, Bath, England, Bristol Royal Hos-2 3
pital for Children, Bristol, England
Since 1995 data on all known cystic fibrosis patients in the
South–West of England have been supplied to a local reg-
istry database, providing a 6 year follow-up on a complete
geographical population. Data on bacterial pathogens iso-
lated from one or more respiratory specimens in each year
were analysed to identify changes in patterns of isolation.
Comparing 1995 (ns548) to 2000 (ns699), there was
increased prevalence of MRSA (0.5% to 5.4%, P-0.001)
and Staphylococcus aureus (40.8% to 49.2%, Ps0.03).
There were also non-significant increases in the prevalence
of Pseudomonas aeruginosa (51.3–56%) and Burkholderia
cepacia (2.4–4.1%) and a non-significant decrease in Hae-
mophilus influenzae (31.3–28.6%). The proportion of
patients with normal respiratory flora only over the whole
year has dropped (12.1–8.1%, Ps0.02). The number of
clinics affected by B. cepacia and MRSA has risen (10y47
to 16y39 for B. cepacia; 3y47 to 18y39 for MRSA). Some
of the increase in isolation rates may be explained by more
frequent or more diligent sampling, or improved laboratory
protocols.
Prevalence at individual clinics is highly variable. In 2000,
P. aeruginosa varied from 20 to 80%, S. aureus from 15 to
70%, and H. influenzae from 5 to 60%. There was no rela-
tionship between clinic size and rate of P. aeruginosa
isolation.
Despite the apparent increase in respiratory pathogen iso-
lation, the population’s health as characterised by weight
SDS (Z-scores) and FEV1% of predicted has not worsened
during the 1995–2000 period; for most age groups there
has been no change, and among teenagers there has been
some slight improvement. As this study does not differen-
tiate between chronic and intermittent or one-off infection,
one contributing factor may be good prevention of chronic
P. aeruginosa infection. We found that 38% of those with
P. aeruginosa infection in 1995 were free of it in 2000.
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DNA FINGERPRINTING OF PSEUDOMONAS
AERUGINOSA IN CYSTIC FIBROSIS PATIENTS:
RISK ASSESSMENT OF CROSS-
COLONISATION IN A CF REVALIDATION
CENTRE
F. De Baets , S. Van Daele , P. Schelstraete , A.S.1 1 1
Moring , G. Claeys , M. Vaneechoutte , H. Franckx3 2 2 3
Department of Pediatric Pulmonology University1
HospitalGhent, Belgium, Department of Bacteriology Uni-2
versity Hospital Ghent, Belgium, CF Revalidation Centre3
De Haan, Belgium
In Belgium many CF patients become residents of a CF
revalidation centre during prolonged or short annual periods
in order to learn the ‘autogenic drainage’ technique.
Although Pseudomonas aeruginosa (Pa) colonised patients
are segregated during physiotherapeutic treatment sessions
and meals, social contacts are not prohibited. We studied
the risk of cross-colonisation. During the periods of 8 Jan-
uary to 31 April and 1 September to 17 December 2001, a
total of 583 Ps. a. isolates from 44 CF patients (23 years,
range 5–34), all residents at the CF revalidation centre
were typed using random amplified polymorphic DNA fin-
gerprinting PCR technique (RAPD-analysis-primer
ERIC2). Evenso 11 Pa isolates from environmental sources
from the centre were typed. A total of 61 different geno-
types were established. Of the 35 patients for whom more
than three isolates were typed, 15 patients carried a single
genotype, 14 two, 4 three and 2 patients carried four dif-
ferent genotypes. Twenty five of the 32 patients for whom
sufficient data were available, carried a single or a predom-
inant genotype. Each patient came to the centre and went
with the same Pa strains. Cross infection did not occur dur-
ing the study time. Nineteen patients (8=2 and 1=3)
shared isolates from a common RAPD-genotype with at
least one other patient. One pare of patients were siblings.
Seven children, belonging to the same age group, had a
prolonged overlapping stay (234–812 days). In 10 children
there was an simultaneous residency ranging from 1 to 80
days. None of the genotypes isolated from the 11 environ-
mental sources could be linked to genotypes of the patients.
It is clear that there was no general cross contamination
with a highly transmissible strain between these patients
and there was not a single source of environmental contam-
ination, though cross colonisation did occur in 36% of the
regular residents.
Funded by the Belgian CF association and FWO.
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DNA-FINGERPRINTING OF PSEUDOMONAS
AEROGINOSA IN CYSTIC FIBROSIS
PATIENTS:RISK ASSESSMENT OF CROSS-
INFECTION IN A CF-CENTRE
S. Vandaele , F. Haerynck , P. Schelstraete , M.1 1 1
Vaneechoutte , G. Claeys , F. De Baets2 2 1
Paediatric Pulmonology, University Hospital, Ghent, Bel-1
gium, Department of Microbiology, University Hospital,2
Ghent, Belgium
Introduction: The means, by which P. aeroginosa (P. a.)
in CF patients is acquired and transmitted, are not well
understood. Cross-infection between CF patients should be
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avoided, therefore colonized patients are segregated in our
CF centre.
Aim: To assess the diversity of P. a. genotypes and the risk
of cross-infection among CF patients in our centre.
Patients and methods: Sputum samples were obtained
from P.a. colonized CF patients. The genotype of P.a. strains
was identified by random amplified polymorphic DNA fin-
gerprinting technique.
Results: 38y124 CF patients (31%) are colonized with P.a.,
which corresponds with other centres (40%). DNA finger-
printing was done in 34y38 colonized patients. 20y34 har-
boured a unique strain. 15y34 had shared genotypes. Since
it is known that siblings and partners commonly carry the
same genotype, we excluded those, which gave an overall
risk of cross-infection of 5y25 (20%).
Of the 34 patients 19 attended exclusively our CF depart-
ment. 4y19 had shared genotypes. Excluding 1 pair of sib-
lings, 2y17 had the same genotype (12%). These 2 patients
are close friends with frequent contact outside our CF cen-
tre (sharing the same classroom, the same physiotherapist,
the same car, while coming to the CF centre).
15y34 had a prolonged stay in a CF rehabilitation clinic in
the past. 11y15 had shared genoypes. Excluding 3 couples
of siblings and 1 couple of partners, 3y8 had the same
genotype (38%).
Conclusions: A large diversity of genotypes of P.a. in CF
patients is found. The risk of cross-infection is low in an
outpatient CF clinic (12%). Prolonged stay in a CF reha-
bilitation clinic increases the risk of cross-infection (38%).
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THE PREVALENCE OF BACTERIAL STRAINS
ISOLATED FROM RESPIRATORY TRACT
SPECIMENS IN CHILDREN WITH CYSTIC
FIBROSIS
Y. Navesnakova , A. Feketeova1 2
Department of Clinical Microbiology, University Hospital1
UPJS Kosice, Department of Pediatric, University Hospital2ˇ ˇ
UPJS Kosiceˇ ˇ
Patients with cystic fibrosis (CF) suffer from recurrent and
chronic endobronchial lung infections. The thick dehydrat-
ed and viscous mucus which adheres to the epithelial sur-
face in the patients respiratory tract is a very good
environment for bacteria and viruses. Bacteria are the most
important microorganisms responsible for the progression
of the lung pathology and the prognosis of the patients.
The aim of this study was to analyse the colonization with
bacterial flora of the respiratory tract in the group of 51
patients (29 F, 22 M) with CF in the CF Center in Kosiceˇ
(Eastern Slovakia). We analysed the sputum in patients
who can produce and expectorate it and the throat swabs
in small children and patients who are minimaly productive.
Methods: All sputa was Gram-stained and diagnosed by
microscopy to ensure that specimens are adequate and not
predominately saliva ()25 neutrophils). Sputum was liq-
uefied with 2% N-acetylcystein and diluted 103, 105, 107y
ml. 0.1 ml of each dilution and of undiluted sputum was
inoculated on to agar culture media such as Blood agar,
Chocolate blood agar (CBA), McConkey agar, Sabourad
glucose agar and Cepacia Medium agar (or OFPBL agar).
Plates were incubated aerobically at 37 8C with exception
of CBA, which were incubated in an atmosphere of 5%
CO . Bacterial growth should be visible within 24 h but the2
confirmation of mucoidy in Pseudomonas aeruginosa may
reguire 48 h or longer. In the case of Burkholderia cepacia
incubation may need to be extended to 72 h. Identification
of the microbial strains was made by conventional bio-
chemical test using standard laboratory techniques.
Results and conclusion: The most frequently strains of
bacteria isolated from sputum in all age groups of our
patients was St. aureus (87.5%), Ps. aeruginosa (68.8%),
H. influenzae (34.4%) and Burkholderia cepacia genomo-
var III (12.5%)—genomovar typing was made by PCR. In
the throat swabs cultures the most frequently isolates were
St. aureus (89.5%) and H. influenzae (36.8%).
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PSEUDOMONAS AERUGINOSA: SEEK AND
YOU SHALL FIND
S, Patel , M, Turner , G, Hambleton , P, Ashcroft , B,1 1 2 3
Sanyal , T, David , L, Patel3 1 1
Department of Child Health, University of Manchester,1
Department of Respiratory Paediatrics, Booth Hall Chil-2
drens Hospital, Department of Microbiology, Booth Hall3
Childrens Hospital
Background: Airway colonisation with Pseudomonas
aeruginosa (PA) is a major factor contributing to lung dis-
ease in cystic fibrosis (CF). Early recognition and treatment
of airway pathogens may delay and minimise lung damage.
We studied whether the frequency of sputum microbiology
testing influenced the age at first isolation of PA in children
with CF.
Methods: Sputum results obtained by a single laboratory
of all patients under 16 years age managed at two regional
CF units were studied. For each patient we calculated the
median number of samples per year over all the years
available.
Results: From 158 patients (90 males) a total of 25 733
sputum results were studied. The number of samples per
year for each patient did not vary with time. A median of
20 sputum results were collected per patient per year (inter-
quartile range 9–37, range 1–93). The age at 1st isolation
of PA correlated with the median number of sputum results
per patient per year (Spearman rsy0.34, P-0.0001). In
order to assess further the relationship between number of
samples per year from each patient and the age at 1st iso-
lation of PA, we examined the deciles of number of sputum
results. For each decile, the number of sputum samples per
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patient per year (SPY) covered by the decile and the medi-
an age at 1st isolation of PA in years (AGE) are shown in
the table.
Deciles 1 2 3 4 5
SPY 0–8 9–10 11–12 13–16 17–24
AGE 9.3 4.0 5.4 4.9 1.5
Deciles 6 7 8 9 10
SPY 25–31 32–37 38–47 48–51 52q
AGE 1.5 3.0 3.3 1.5 2.8
The age at 1st isolation of PA differed significantly for
the 1st 5 deciles (Kruskal–Wallis, Ps0.02) but not for
deciles 6 to 10 (Kruskal–Wallis, Ps0.7).
Conclusions: More frequent sputum microbiology
testing was associated with earlier identification of 1st
PA. There was no additional advantage of more than 25
samples per patient per year. We recommend a minimum
sampling frequency of every 2 weeks.
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DYNAMIC IMAGING APPROACH TO ANALYZE
BACTERIA AND AIRWAY EPITHELIAL CELL
INTERACTIONS
J.M. Zahm , M. Milliot , O. Bajolet , L. Addabra , C.1 1 2 1
Hologne , N. Bonnet , E. Puchelle1 1 1
INSERM UMRS 514, IFR53, Reims, France, Laboratoire1 2
de Bacteriologie, Virologie, Hygiene CHU Reims, France´ `
The ability of bacteria to adhere to airway epithelial cells
is important in the pathogenesis of airway bacterial infec-
tions, particularly in cystic fibrosis (CF). The adherence to
airway epithelium has been generally studied by static
approaches using immunofluorescence, scanning and trans-
mission electron microscopy. We have developed a dynamic
videomicroscopic approach where the interaction between
bacteria and airway cells can be continuously analyzed.
Staphylococcus aureus is early identified in CF airway
secretions and preferentially adhere to injured and repairing
airway epithelium (Mongodin et al., Infection and Immu-
nity, 2002). We therefore investigated the dynamic inter-
action of S. aureus to airway epithelial cells. We used a S.
aureus reference strain (8325-4) able to adhere through
fibronectin-binding proteins to airway cells. Bacteria and
airway cells were stained with a viability kit and incubated
at a concentration of 5=10 CFUyml with airway epithelial8
cells (16HBE14o-) grown up to confluency. The culture
dish was then placed on the stage of an inverted microscope
at 37 8C and fluorescent images were recorded. After 1 h
of incubation, numerous bacteria were seen to adhere to
airway epithelial cells. The non-adherent bacteria were then
washed away and the culture dish was further incubated for
24 h. After 24 h, we clearly observed many alive airway
epithelial cells, with a condensed and granulated nucleus.
In these altered airway epithelial cells, large intracytoplasm-
ic bacterial clusters were present, reflecting the internalis-
ation of bacteria within the airway cells. The dynamic
imaging of bacteria and airway epithelial cell interactions
represents a powerful tool and will be further applied to
answer the question whether the adherence and internalis-
ation of S. aureus clinical strains differ according to the
source (CF or non CF) of airway cells. Supported by
INSERM and Association Vaincre la Mucoviscidose.
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PGFE OF PS. AERUGINOSA IN PATIENTS WITH
CHRONIC AND INTERMITTENT PSEUDOMONAS
COLONISATION AT THE WEST SWEDISH CF
CENTER
A. Lindblad , C. Wellinder-Olsson , S. Seeberg1 2 2
Department of Pediatrics, Queen Silvias Childrens’ Hos-1
pital, Gothenburg, Sweden, Department of Microbiology,2
Sahlgrenska University Hospital, Gothenburg, Sweden
Many centres segregate patients with chronic Pseudomonas
aeruginosa (PA) infection from non-colonised patients due
to fear of cross-infection. In our center the patients are not
segregated in the outpatient clinic. The aim was to inves-
tigate if there are signs of cross-infection in the outpatient
clinic.
Methods: To type the PA strains isolated from the chroni-
cally colonised (CC) patients, all newly isolated PA in
intermittently colonised (IC) or patients growing Pseudo-
monas aeruginosa for the first time by pulse field gel elec-
tropheresis (PFGE). Isolates with the same pattern "2
bands on the PFGE were considered to belong to the same
strain or closely related.
Results: 115 patients excluding the transplanted patients
(59 M, median age 15.4 years, range 1–52 years) attended
the CF center during the period. 70 patients had never or
only intermittently (NCyIC group) grown PA (median age
11.2, range 1–48.2 years) while 37 patients were CC with
PA (median 22.3, range 6.7–49). Eight patients were
chronically colonised with St. maltophilia or B. cepacia.
During a period of 15 months 31y37 of the CC patients
and 17y70 NCyIC patients had PA isolates analysed with
PFGE. A total of 32 different strains were identified. Six
of the strains included more than one isolate (9sgroup A,
4sB, 3sC, 2sD, 2sE and 2sF strains, respectively).
All 9 with PA group A were chronically colonised, seven
for more than 10 years (before the start of the center) or
colonised at the first visit at the center. The other two
became colonised approximately 3–4 years earlier. Only 2
of 17 isolates in the NCyIC groups were similar to any
other strain (group B and D, respectively).
Twenty-three patients were typed a second time (21 CC and
2 IC). Two patients with CC and both patients who were
NCyIC had another stain at follow-up. All other were
unchanged.
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Conclusion: No evidence for significant cross infection
was found. Only 12% of the isolates in the NCyIC group
were not unique.
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COUGH PLATE VERSUS COUGH SWAB
S. Maiya, M. Desai, A. Baruah, J. Clarke, P. Weller, J. Gray
Birmingham Children’s Hospital, Birmingham, UK
Accurate identification of lower respiratory tract pathogens
is of the utmost importance in the clinical management of
cystic fibrosis (CF) patients, but is difficult in patients who
cannot expectorate sputum. Cough swabs may detect upper
airway rather than lower respiratory tract pathogens. The
aim of this study was to look at the cough plate as an
alternative method of obtaining respiratory samples for
microbiological culture.
Methods: A prospective audit was conducted in patients
aged between 8 and 16 years, attending our tertiary CF
clinic between April and December 2001. Sputum, cough
plate (5% horse blood agar), dry and wet cough swabs were
collected in a random order from patients who could spon-
taneously expectorate sputum. These samples were proc-
essed on the day of collection.
Results: Pathogenic microorganisms were cultured from
sputum in 20 of 31 patients. Pathogenic microorganisms
were not isolated in the remaining eleven patients by any
method. Isolates by different techniques were:
Cough
plate
Dry
cough
swab
Wet
cough
swab
Positive cultures (compared with
sputum)
16y20 7y20 7y20
Sensitivity (confidence interval) 80%
(56–
94%)
35%
(15–
59%)
35%
(15–
59%)
When comparing cough plate with cough swabs, the
cough plate method identified significantly more positive
cases than either dry or wet cough swabs (Ps0.012 for
both dry swab and wet swab (Mcnemar test)). All
patients preferred cough plate to cough swab.
Conclusion: In patients who can expectorate sputum,
cough plates appear to be more sensitive than cough
swabs in isolating lower respiratory pathogens. As there
is no additional cost to the department and patients
prefer it, cough plate merits further evaluation
particularly in non-sputum producers. Isolation of
pathogens in this study may have been limited by only
using one medium (blood agar). Further studies using a
combination of specialised media are required.
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DIRECT SPUTUM SENSITIVITY TESTING (DSST)
IN CYSTIC FIBROSIS (CF)
D.J. Serisier , G. Jones , A. Tuck , M.P. Carroll1 2 2 1
Adult Cystic Fibrosis Unit, Southampton University Hos-1
pital, Public Health Laboratory, Southampton University2
Hospital
In CF patients with chronic pulmonary colonisation by
Pseudomonas aeruginosa (PsA), the clinical applicability
of antibiotic selection guided by standard sputum sensitivity
techniques is questionable. Considerable heterogeneity in
antibiotic susceptibility between different PsA colonies
exists and clinical response to antibiotics correlates poorly
with standard disc sensitivity testing of individually cul-
tured PsA colonies. Additionally, the use of cultured colo-
nies does not consider the impact of the physical
characteristics of CF sputum and PsA biofilms upon bac-
terial sensitivity and antibiotic penetration. We have
devised a novel, homogenised, whole sputum technique
(DSST) that also enables an assessment of the efficacy of
antibiotic combinations, using antibiotic gradient E-tests
(AB Biodisks, Sweden). DSST involves surface spreading
50 ml of homogenised sputum directly onto Iso-sensitest
agar using a swab. E-tests are placed directly onto the inoc-
ulum prior to incubation. Minimal inhibitory concentration
(MIC) values are determined at 24 and 48 h. Combination
tests are performed by placing the first antibiotic E-test on
agar for 30 min to establish an antibiotic gradient and then,
following removal, overlaying the second antibiotic E test
and proceeding as above. Evidence for synergy is deter-
mined by comparison of MIC values derived from the com-
bination with those achieved by individual antibiotics. A
standard panel of antibiotics is routinely tested, individually
and in combination and novel combinations may be select-
ed for testing. DSST is simple to perform, provides quan-
titative data (MIC’s) and information on antibiotic synergy,
and results are available within 24–48 h. The use of whole
sputum, as opposed to individually cultured colonies, the-
oretically provides more clinically applicable sensitivity
data and our early anecdotal clinical experience suggests
that DSST can effect management decisions that enhance
clinical outcomes.
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USE OF DEEP THROAT SWAB AFTER
PHYSIOTHERAPY FOR ISOLATION OF
MICROBIAL AGENT FROM LOWER
RESPITRATORY TRACT
S.K. Kabra , A. Alok , A. Kapil , M. Kabra , Sridevi K. ,1 1 2 1 1
R. Lodha1
Department of Pediatrics, Department of Microbiology,1 2
All India Institute of Medical Sciences, New Delhi 110029,
India
Cough swab or sputum cultures are commonly used meth-
ods for identification of microbial agents of lower respira-
tory tract. Both the methods may not be applicable in young
infants and children.
Methods: We compared isolation of microbial agents by
three methods (deep throat swab (DTS), cough swab (CS),
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deep throat swab after chest physiotherapy (DTSAP)) with
sputum examination as gold standard in children with cystic
fibrosis who had pulmonary exacerbation. All the samples
were processed for isolation of staphylococcus and pseu-
domonas species by standard techniques.
Results: From 168 episodes of pulmonary exacerbation in
71 patients (mean age 7.011, 4.84 years) all four specimens
could be collected over a period of 3 years. The culture of
sputum revealed pseudomonas sp. in 125 (74%), staphy-
lococcus in 24 (14%) and normal flora were present in 19
(11%). Out of 125 pseudomonas from sputum, the isolation
from cough swab, deep throat swab and throat swab after
physiotherapy was 65%, 61% and 88%, respectively.
Organisms Sputum CS DTS DTSAP
Pseudomonas 125 81 (65%) 76 (61%) 110 (88%)
Staphylococcus 24 10 (40%) 5 (20%) 24 (100%)
Normal flora 19 9 (50%) 9 (50%) 9 (50%)
Considering sputum to be representative of lower air-
ways microbials, we found that throat swab after
physiotherapy had better correlation with sputum as
compared to cough swab and deep throat swab.
Conclusion: Throat swab after physiotherapy has an
acceptable sensitivity for identification of pseudomonas
and staphylococcus in children with CF.
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RESULTS OF DIRECT SPUTUM SENSITIVITY
TESTING (DSST) DIFFER FROM STANDARD
SPUTUM CULTURE AND SENSITIVITY IN
CYSTIC FIBROSIS (CF)
D.J. Serisier , G. Jones , A. Tuck , P.M. Hockey , M.P.1 2 2 1
Carroll1
Adult Cystic Fibrosis Unit, Southampton University Hos-1
pital, Public Health Laboratory, Southampton University2
Hospital
In vitro antibiotic sensitivity testing of whole, homogenised
sputum (as opposed to sensitivity testing of only selected
colonies from culture) may theoretically be more represen-
tative of in vivo antibiotic sensitivity of pulmonary patho-
gens in CF.
Aims: To compare antibiotic sensitivity results obtained by
DSST performed on whole sputum with standard culture
and disc sensitivity testing (CqS) of Pseudomonas aeru-
ginosa (PsA), Burkholderia cepacia (BC) and Stenotro-
phomonas maltophilia (StM) isolates.
Methods: Retrospective review of results of concurrent
DSST and CqS performed on consecutive sputum samples
collected from patients with chronic PsA or BC colonisa-
tion where requested by clinicians, between January and
December 2001.
Results: Concurrent DSST and CqS results were available
for 72 sputum samples (71 CF and 1 bronchiectasis), from
40 patients. 67 samples contained predominant PsA, 2 pre-
dominant BC, 1 StM and 2 mixed organisms. 27 isolates
(40%) were multi-resistant (MR) by CqS. Comparison of
DSST with CqS for all samples demonstrated discordant
sensitivity results in 35 (49%), with DSST detecting sen-
sitivity to an antibiotic that was resistant by CqS in 18
samples (51% of discordant samples), and resistance to an
antibiotic that was sensitive by CqS in 16 (49%). Using
a model for theoretical selection of antibiotics by both
methods, DSST suggested an alternative antibiotic combi-
nation to CqS in 48 cases (67%). DSST suggested an
alternative combination in 23 (82%) of 28 MR isolates
compared to 25 (54%) of 46 sensitive isolates (P-0.04).
In 8 cases (11%), DSST was unable to provide adequate
data for selection of an effective antibiotic combination.
Conclusion: Results of sensitivity testing by DSST differ
considerably from those of standard CqS, particularly for
MR isolates, and this potentially alters antibiotic selection.
Our early clinical experience that this also enhances clinical
outcomes is undergoing further prospective evaluation.
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CLINICAL APPLICATION OF DIRECT SPUTUM
SENSITIVITY TESTING (DSST) IN A SEVERE
INFECTIVE EXACERBATION OF CYSTIC
FIBROSIS (CF)
D.J. Serisier , G. Jones , A. Tuck , M.P. Carroll1 2 2 1
Adult Cystic Fibrosis Unit, Southampton University Hos-1
pital, Public Health Laboratory, Southampton University2
Hospital
DSST is a form of whole sputum sensitivity testing that
provides information on antibiotic synergy and may more
accurately reflect in vivo antibiotic sensitivity patterns in
CF. We have anecdotally noted clinical benefits using this
method to select antibiotics and report one such patient who
improved dramatically following the use of DSST. A 16-
year-old CF male with severe lung disease was admitted
with an infective exacerbation. During the preceding 12
months he had required almost continual intravenous (IV)
antibiotics and repeated hospital admissions for recurrent
infective exacerbations. Standard sputum culture grew 2
colonies of multiresistant Pseudomonas aeruginosa (PsA)
and tobramycin, piperacillinytazobactam and clarithromy-
cin were commenced. On day 5 non-invasive ventilation
was commenced for acute hypercapnoeic respiratory failure
and his piperacillin was changed to meropenem, however
he continued to deteriorate. DSST was performed and sug-
gested an optimal antibiotic combination of tobramycin,
meropenem and cotrimoxazole and on day 12 his antibiotics
were amended. Within 72 h he had improved significantly,
and he was discharged home on day 26. He subsequently
did not require IV antibiotics for 6 weeks (his longest peri-
od off IV antibiotics for over 12 months). Antibiotic selec-
tion for his next course of IV antibiotics was not guided by
DSST and he again required IV antibiotics after only 2
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weeks. At this point, DSST was again performed and this
course resulted in another 6 week period off IV antibiotics.
With the guidance of DSST over this 4 month period, this
patient has had more time off IV antibiotics than in the
entire 8 months preceding it, associated with an increase in
weight from 45 kg (body mass index wBMIx 18.5) to 51
kg (BMI 21.2). This current case and our early clinical
experience with the use of DSST in other patients suggests
that this technique offers real clinical advantages over stan-
dard sputum sensitivity testing.
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DETECTION OF ANTIBIOTIC SYNERGY WITH
DIRECT SPUTUM SENSITIVITY TESTING (DSST)
D.J. Serisier , G. Jones , A. Tuck , M.P. Carroll1 2 2 1
Adult Cystic Fibrosis Unit, Southampton University Hos-1
pital, Public Health Laboratory, Southampton University2
Hospital
We have incorporated the use of a novel whole sputum
sensitivity test into our clinical practice that also enables an
assessment of the efficacy of antibiotic combinations
(DSST). We sought to review our early experience with the
detection of antibiotic synergy using this technique.
Aims: To evaluate synergistic antibiotic combinations using
DSST on whole sputum from patients colonised with Pseu-
domonas aeruginosa (PsA) or Burkholderia cepacia (BC).
Methods: Retrospective review of results of DSST per-
formed on consecutive sputum samples between January
and December 2001. Samples were collected from patients
with chronic PsA or BC colonisation and DSST was per-
formed where requested by clinicians.
Results: DSST was performed on 103 sputum samples
(102 Cystic Fibrosis samples and 1 bronchiectasis sample).
Results from 16 samples (16%) were discarded due to
insufficient PsA growth (8 samples), isolation of Staphy-
lococcus aureus only (7), and overgrowth by yeast (1). 87
remaining DSST results from 45 patients were reviewed,
with 82 containing predominant PsA, 2 predominant BC, 1
Stenotrophomonas maltophilia, and 2 mixed organisms. No
antagonistic antibiotic combinations were detected. Anti-
biotic synergy was detected for 41 samples (47%), with
90% of these (37) demonstrating multiple synergy. Of syn-
ergistic samples, 20% (8) required a 3 drug combination
for demonstration of synergy. Of the 2 drug combinations
tested, gentamicinymeropenem demonstrated synergy most
frequently (16 samples, 39% of samples with synergy). Of
the 3 drug combinations tested, tobramycinyceftazadimey
cotrimoxazole demonstrated synergy most frequently (6
samples, 15% of samples with synergy). Of the third drugs
used, cotrimoxazole most frequently added synergy to a 2
drug combination (11 of 41 samples, 27%).
Conclusions: Antibiotic synergy is frequently detected with
the use of DSST on whole sputum, and is currently under-
going further prospective microbiologic and clinical
evaluation.
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CLINICAL EFFICACY AND SAFETY OF
AZITHROMYCINE IN CF PATIENTS
H. Kayserova , L. Langsadl1 2
CF Centre, National Institute of TB and Respiratory Dis-1
ease, Department of Mikrobiology, National Institute of2
TB and Respiratory Disease
Aims: To evaluate the clinical efficacy and safety of
macrolid antibiotics (azithromycin) in long-term treatment.
Methods: Fifty-eight CF patients (maleyfemale: 29y29,
mean age 12.9 yrs) were treated with AZI in dose 5 mgy
kgydaily for 3 months (12 pts for 6 months). Standart ther-
apy (rhDNAse, inhalated Colistin, enzymes, vitamins,
physiotherapy, UDCA.) of each patient was continued with-
out changes. The patients were examinated every 1–3
months (LFT, physical examination, sputum microbiology,
inflammatory markers, liver tests). Follow-up period of an
open prospective study was 9 months.
Results: We found an improvement in FVC (q6%) and
FEV1 (5%) in 49 pts (84.5%) after 3 months and 14%y
8% after 6 months of treatment (12 pts) with clinical
improvement (sputum production, caught) and positive
changes in sputum mikrobiology. In remaining 12 pts
(15.5%) we observed no clinical improvement and FVCy
FEV1 decline (9%y15% resp.).
No significant changes we observed in inflammatory mark-
ers (IgG, IK, PMN, CRP) nor in liver tests (ALT, AST,
ALP). In 63.7% chronically colonised pts. (Pseud. aer.,
Haem. infl., Staph. aur.) no exacerbation of inflammatory
process (no need of i.v. ATB) was observed during 9
months after beginning of treatment (decline of hospitality
days).
We conclude, that macrolides might be a therapeutical
obtion for some of CF patients (also chronically colonized
with Pseud. aer.), as a long-term treatment results in clin-
ical (QoL) and laboratory improvement without any
adverse events.
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PREDICTORS OF STAPHYLOCOCCUS AUREUS
INFECTION IN ADULT CYSTIC FIBROSIS
J. Courtney , S. Elborn1 1
Adult Cystic Fibrosis Unit, Belfast City Hospital, Belfast,
UK
Staphylococcal aureus is a frequent cause of respiratory
tract infection in cystic fibrosis. Treatment options in chil-
dren are continuous prophylactic antistaphylococcal treat-
ment or intermittent antibiotics with each isolation.
However there is no evidence for the continued use of pro-
phylactic treatment in adults. The aim of the study was to
examine if there is a group of adult patients who have fre-
quent infections with S. aureus.
Patients attending the adult CF centre in Belfast were ret-
rospectively studied during 1999. Age, sex, BMI, FEV1
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value (% predicted) and Pseudomonas aeruginosa status
were compared with the number of isolations of S. aureus.
All patients who isolated S. aureus from sputum were treat-
ed immediately with antistaphylococcal antibiotics for 14
days.
72 patients (40 male) were identified, with mean (S.D.)
age 26 (8.0) years. 14 patients isolated S. aureus, mean
number of isolates 3.2 (2.9), during 1999. Seven patients
had 3 or more isolates during the year. In the group with
S. aureus infection there was no age or sex difference com-
pared to those with no infection. The difference in BMI
between the 2 groups was not statistically significant, in
those infected 22.6 (3.9) kgym versus 21.8 (3.5) kgym2 2
in uninfected (Ps0.49). Patients with S. aureus had a mean
FEV1 71.0 (27.5) %predicted compared with mean FEV1
71.5 (27.4) %predicted in those not infected (Ps0.95).
Patients without P. aeruginosa did not have a significantly
increased risk of S. aureus infection (x s0.40, P)0.10).2
In this population of adult CF patients, S. aureus infection
could not be predicted by the variables age, sex, BMI,
FEV1 value and P. aeruginosa status.
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BURKHOLDERIA CEPACIA INFECTION IN
CYSTIC FIBROSIS PATIENTS; IS IT ALWAYS
THE SAME?
L. Pereira , T. Bandeira , C. Barreto1 1 1
Cystic Fibrosis Centre, Paediatric Department, University1
of Hospital Santa Maria, Lisbon, Portugal
Pulmonary infection with Burkholderia cepacia in patients
with Cystic Fibrosis is usually associated with poor prog-
nosis and fast deterioration of pulmonary function.
To better understand the pathogenicity of this microorgan-
ism 19 patients with sputum cultures positive for B. cepacia
(21.6% of total followed) were assessed for pertinent var-
iables: pulmonary function, number of antibiotic treatments
for exacerbation during both the year before and the year
after infection by B. cepacia.
Ten patients had transient infection (B.c. eradicated after
antibiotic treatment) and 9 persistent colonization ()6
months). Among the 10 patients with transient infection the
age of infection varied between 3 months and 39 years old,
2 had isolates of B. cepacia at the time of diagnosis at 3
months old, and all but one of the remaining had already
been colonized with P. aeruginosa. None of the patients
showed deterioration of FEV1)3%. Only 2 patients
showed an increase of admissions over the last year by
more than one.
Of the permanently infected patients the age at first isolate
varied between 4 months and 20 years old, all but 2 were
already colonized with P. aeruginosa. Two patients died in
the year following colonization, one with the cepacia syn-
drome and the other with a Klebsiella sepsis. A third patient
deteriorated and died during the 2nd year after infection.
Four other patients deteriorated lung function, increased
pulmonary exacerbation andyor were in serious condition
after B.c. colonization. Surprisingly the 2 remaining
patients did not deteriorate and remain colonized 3 and 7
years, respectively, after the first isolate.
Our study suggests that B. cepacia pathogenicity is varia-
ble. Transient infection does not deteriorate patients con-
dition. Permanent colonization in the majority of cases is
associated with a poor prognosis.
It would be important to characterize B. cepacia species by
genomovar or exopolysaccharide production in order to
correlate these findings with clinic.
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EVALUATION OF A NEW SELECTIVE MEDIUM
FOR RECOVERY B. CEPACIA COMPLEX, S.
MALTOPHYLIA, A. XYLOSOXIDANS AND
OTHERS TOBRAMYCIN-RESISTANT
ORGANISMS IN THE AIRWAYS SPECIMENS OF
CYSTIC FIBROSIS (CF) PATIENTS (PTS)
E. Ugolotti , M.L. Belli , M.L. Fenu , S. Piana , G.1 1 1 2
Pittaluga , S. Ottolino , G. Manno1 1 1
Infectious Diseases Research and Diagnosis Laboratory,1
Cystic Fibrosis Center, Department of Pediatrics, G.2
GasliniInstitute, Genova, Italy
Aim: To evaluate a new selective medium designed to
improve the isolation rate of tobramycin resistant (To-R)
microorganisms from CF specimens.
Methods: BAS (Burkholderia, Achromobacter, Stenotro-
phomonas) selective medium (eosin methylene blue agar
base supplemented with lactose, 20 mcgyml of To, vanco-
mycin and amphotericine B) was compared from 22-08-
2001 to 25-01-2002, with MacConkey agar (MC), OFPBL
agar, PC medium and BCSA medium. Specimens were
processed with standard procedures, a colony count was
performed. Cultures were observed after 48, 72 h and dis-
carded after 6 days. Strains were identified at species level
with conventional methods (oxidase test, temperature
growth condition, biochemical reactions (API NE,
API20E). Strains were assigned to the B. cepacia complex
(Bcc) by molecular analysis. To was tested by microdilu-
tions from 0.12 to 256 mcgyml.
Results: A total of 319 sputa or throat swabs from 199 pts
were cultured. By all media a total of 38 Bcc, 33 A. xylo-
soxidans (Ax) and 42 S. maltophilia (Sm) were isolated.
The rate (%) of recovered strains in the different media
was: in MC Bcc 42, Ax 45 and Sm 59; in BAS Bcc 100,
Ax 94, Sm 83; in OFPBL Bcc 82, Ax 39, Sm 12; BCSA
Bcc 92, Ax 9 and Sm 7; PC Bcc 82, Ax 9, Sm 4.8. A total
of 249 mucoid and non-mucoid P. aeruginosa (Pa) with
different antibiotic susceptibility profile were found in all
media: of these 194 in MC and 55 in BAS, 14 in OFPBL,
10 in BCSA and 2 in PC. The Pa mediane colony count
were 10=5 CFUyml in MC and 10=3 CFUyml in BAS.
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MIC50–MIC90 of To for Pa were 2–128 mcgyml in strains
recovered from MC and 128 to )256 mcgyml in strains
from BAS. The rate of growth of Candida, Aspergillus and
Gram positives was: 0.6, 4, 0% in BAS and 34, 7, 22% in
OFPBL.
Conclusions: Our data show that BAS is superior than MC,
OFPBL, BCSA and PC in recovering To-R nonfermenters
in CF and is useful in monitoring the emergence of small
subpopulation of To-R Pa in pts treated with inhaled To.
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EVALUATION OF BURKHOLDERIA CEPACIA
SELECTIVE AGAR (BCSA) ON SUPPORTING
GROWTH OF B. CEPACIA COMPLEX BACTERIA
RECOVERED FROM CYSTIC FIBROSIS (CF)
PATIENTS AND FROM ENVIRONMENTAL
SOURCES IN ITALY
M.L. Belli , S. Piana , S. Ottolino , C. Dalmastri , A.1 2 1 3
Bevivino , L. Chiarini , S. Tabbacchioni , G. Manno3 3 3 1
Infectious Diseases Research and Diagnosis Laboratory,1
Cystic Fibrosis Center, G. Gaslini Institute, Genova, Italy,2
Biotechnology and Agriculture Division, ENEA Casaccia,3
Rome, Italy
We evaluated a new selective medium, BCSA (BioMerieux
Italy), with others commercial prepared selective media in
their ability to support the growth of BC complex strains
from CF and environmental sources. A collection of 68
strains isolated from sputa of 53 pts from different Italian
regions attending the CF center of Genova and 75 strains
isolated from the maize rhizosphere in three Italian regions
was studied. Strains were assigned to the BC complex by
polyphasic analysis employing (i) conventional tests: API
20 E, API NE Systems (BioMerieux), OF basal medium
(Difco) for 6 sugars, oxidase test, growth at 420C, pigment
and haemolysis production; (ii) genus and species-specific
polymerase chain reaction assays (Bevivino JCM 2002, in
press). BCSA plates were compared with OFPBL and
Cepacia Medium (CM) (both from BBL, Cockeysville).
Growth study was carried out by a subculture of strains on
blood agar for 24–48 h and aliquots of a bacterial suspen-
sion (1=10 to 1=10 CFUyml) placed on BCSA, OFPBL3 4
and CM. Recovery efficiency for strains was determined
after incubation at 300 and 350 C for 72 h. BC complex
status of studied strains was: 2 % gvr I, 68% gvr III, 3.5
% B. stabilis, 19.6% B. ambifaria, 5.6% B. pyrrocinia.
Conventional tests were able to recognize B. stabilis but
failed to discriminate BC gvr I to BC gvr III and to B.
ambifaria. 100% of studied strains grown on BCSA and
OFPBL and 97% on CM (3 CF strains of BC gvr IIIA and
1 CF gvr III failed to growth on CM). All strains displayed
good growth on BCSA and OFPBL after 48 h at 350 8C
but on 24 h incubated BCSA plates the colony growth was
yet detectable. CM needed an increased incubation time for
72 h to improve the optimum growth rate.
In conclusion, our results show that BCSA is superior to
OFPBL and CM for rapidity and quality of growth of Ital-
ian BC complex strains of CF and environmental origins.
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COMPARISON OF BURKHOLDERIA CEPACIA
SELECTIVE AGAR (BCSA) TO OXIDATION
FERMENTATION AGAR POLYMYXIN
BACITRACIN LACTOSE AGAR (OFPBL) FOR
THE ISOLATION OF BURKHOLDERIA CEPACIA
COMPLEX IN PATIENTS WITH CYSTIC
FIBROSIS
M.L. Garlaschi , E. Scarazzati , L. Cariani , G. Clarizia ,1 1 1 1
P. Russo , M.L. Fenu , M.L. Belli , G. Manno1 2 2 2
Microbiology Laboratory, Istituti Clinici di-1
Perfezionamento, Milano, Italy, Infectious Diseases2
Research and Diagnosis Laboratory, University Department
of Pediatrics, G.Gaslini Institute, Genova, Italy
Rapid isolation and identification of bacteria belonging to
the Burkholderia cepacia complex is important for appro-
priate treatment of cystic fibrosis (CF) patients. A newly
described media, BCSA, provides a selective and enriched
environment to support the growth of B. cepacia Complex
isolates. We compared BCSA (manufactured by Bio-
Merieux Italia S.p.A.), to OFPBL (from BBL Cockeys-
ville), in two Italian clinical microbiology laboratories
(Istituti Clinici di Perfezionamento of Milan and G. Gaslini
Institute of Genova).
Methods: In the period 7y7y2001–25y01y2002 we eval-
uated prospectively specimens of respiratory secretions
from adults and pediatrics CF patients. The plates of BCSA
and OFPBL were included as part of the routine and selec-
tive media used by the individual laboratories for the cul-
ture of CF respiratory pathogens. Bacterial strains were
identified at species level by conventional biochemical
method, the B. cepacia Complex status was assessed by
genus and species-specific polymerase chain reaction
assays (Agodi JCM 2001,Bevivino JCM 2002, in press).
Results: A total of 586 respiratory specimens were proc-
essed. 337y586 (57.5%) cultures had no microorganisms
growth on any selective agar for B. cepacia complex; on
51y586 (8.7%) cultures grew B. cepacia complex on both
media; on 73y586 (12.5%) cultures grew other than B.
cepacia complex on BCSA and 264y586 (45.0%) on
OFPBL. Other microorganisms that grew on BCSA and
OFPBL agar included: 124 Staphylococcus aureus (1 on
both media, 123 on OFPBL only); 57 moulds (23 on both
media, 40 on OFPBL only); 27 Achromobacter xylosoxi-
dans (17 on both media, 10 on OFPBL only); 122 yeasts
(6 on both media, 116 on OFPBL only); 16 Pseudomonas
aeruginosa (10 on both media, 6 on OFPBL only).
Conclusions: BCSA provided more rapid isolation and
identification of B. cepacia Complex isolates from cystic
fibrosis respiratory cultures when compared to OFPBL.
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Diagnosis Laboratory, University Department of Pediatrics,
G.Gaslini Institute, Genova, Italy
Rapid isolation and identification of bacteria belonging to
the Burkholderia cepacia complex is important for appro-
priate treatment of cystic fibrosis (CF) patients. A newly
described media, BCSA, provides a selective and enriched
environment to support the growth of B. cepacia complex
isolates. We compared BCSA (manufactured by Bio-
Merieux Italia S.p.A.), to OFPBL (from BBL Cockeys-
ville), in two Italian clinical microbiology laboratories
(Istituti Clinici di Perfezionamento of Milan and G. Gaslini
Institute of Genova).
Methods: In the period 7y7y2001–25y01y2002 we eval-
uated prospectively specimens of respiratory secretions
from adults and pediatrics CF patients. The plates of BCSA
and OFPBL were included as part of the routine and selec-
tive media used by the individual laboratories for the cul-
ture of CF respiratory pathogens. Bacterial strains were
identified at species level by conventional biochemical
method, the B. cepacia Complex status was assessed by
genus and species-specific polymerase chain reaction
assays (Agodi JCM 2001, Bevivino JCM 2002, in press).
Results: A total of 586 respiratory specimens were proc-
essed. 337y586 (57.5%) cultures had no microorganisms
growth on any selective agar for B. cepacia complex; on
51y586 (8.7%) cultures grew B. cepacia complex on both
media; on 73y586(12.5%) cultures grew other than B.
cepacia complex on BCSA and 264y586 (45.0%) on
OFPBL. Other microorganisms that grew on BCSA and
OFPBL agar included: 124 Staphylococcus aureus (1 on
both media, 123 on OFPBL only); 57 moulds (23 on both
media, 40 on OFPBL only); 27 Achromobacter xylosoxi-
dans (17 on both media, 10 on OFPBL only); 122 yeasts
(6 on both media, 116 on OFPBL only); 16 Pseudomonas
aeruginosa (10 on both media, 6 on OFPBL only).
Conclusions: BCSA provided more rapid isolation and
identification of B. cepacia Complex isolates from cystic
fibrosis respiratory cultures when compared to OFPBL.
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DISTRIBUTION OF BURKHOLDERIA CEPACIA
COMPLEX ISOLATES FROM PATIENTS WITH
CYSTIC FIBROSIS
G. Golini , F. Favari , R. Fontana1 2 1
Dipartimento di Patologia, Universit‘ di Verona, Servizio1 2
di Microbiologia, Azienda Ospedaliera di Verona, Italy
Aims: To confirm all isolates obtained from patients with
cystic fibrosis (CF) as Burkholderia cepacia (Bc) Complex
and to identify the genomovar of Bc isolates.
Methods: Ninety-seven isolates, identified by Api 20NE as
Bc, were subjected to a PCR-based identification by ampli-
fication of 16S rDNA and recA genes. We studied the pro-
file obtained from RFLP analysis of these genes.
Results: Eighty-three (85.6%) isolates were identified as
Bc Complex. Eight (9.6%) isolates were found to be Bc
genomovar I, 32 (38.5%) isolates to be Bc genomovar III-
A, 42 (50.6%) isolates to be Bc genomovar III-B and one
(1.0%) isolate to be Bc genomovar V. We found 14
(14.4%) isolates, misidentified by biochemical tests, to be
Pseudomonas aeruginosa (three isolates, 3%), Alcaligenes
xilosoxidans (five isolates, 5.1%), Stenotrophomonas mal-
tophilia (three isolates, 3%), Ralstonia pickettii or Com-
momonas acidovorans (one isolate, 1%). Two strains were
not identified (2.1%).
Conclusions: All isolates obtained from CF patients, iden-
tified by commercial test, should be further confirmed using
genotyping methods.
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BURKHOLDERIA CEPACIA DETECTION AND
SUBCLASSIFICATION INTO GENOMOVARS
USING SPUTUM AS A SOURCE OF DNA
P. Drevinek , H. Hrbackova , O. Cinek , F. Prusik , P.1 2 1 2
Pohunek1
2nd Department of Pediatrics, 2nd Medical School of1
Charles University, Prague, Department of Clinical Micro-2
biology, University Hospital Motol, Prague
In order to improve sensitivity and specificity of B. cepacia
detection from sputum of children with cystic fibrosis (CF),
we modified previously used non-nested PCR on the recA
gene of B. cepacia complex, adding a second PCR round.
While the first round detects B. cepacia complex and
preamplifies the target sequence, the second round of nested
PCR increases sensitivity of detection and is used for the
bacteria subclassification by a set of genomovar-specific
reactions. In a pilot study, we compared results of our nest-
ed PCR with culture, examining 103 clinical samples of 78
Czech CF children and young adults. PCR positive finding
was seen in 55 (53%) samples, while routine microbiolog-
ical techniques diagnosed B. cepacia in 44 (43%) samples.
Out of the 55 PCR positive samples, seven yielded positive
signal only in the second round of nested PCR. The major-
ity of B. cepacia infected CF patients were colonized with
S128 Journal of Cystic Fibrosis 1 (2002) S81–S180
genomovar III, recA group III-A (93%), two with recA
group III-B (5%) and one patient was colonized with B.
multivorans (2%). In conclusion, we demonstrate higher
sensitivity of nested PCR compared to both culture, and
non-nested PCR. The present preliminary results from the
Czech CF population indicate almost total B. cepacia gen-
omovar III-A uniformity, which might partly contribute to
the perceived clinical problems caused by this pathogen.
Supported by the Czech Ministry of Health (grant 6568)
and Education (grant 111300003).
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SPECIES AND GENOMOVAR DISTRIBUTION OF
BURKHOLDERIA CEPACIA COMPLEX IN
ITALIAN CYSTIC FIBROSIS PATIENTS
C. Dalmastri , G. Manno , A. Materazzo , S.1 2 1
Tabacchioni , L. Chiarini , S. Piana , P. Vandamme , A.1 1 3 4
Bevivino1
Biotechnology Unit, ENEA C. R. Casaccia, 00060 S.1
Maria di Galeria, Rome, Italy, Infectious Diseases2
Research and Diagnosis Laboratory, Department of Pedi-
atrics, University of Genoa, Gaslini Children’s Hospital
Genoa, Genoa, Italy, Cystic Fibrosis Centre, Department3
of Pediatrics, University of Genoa, Gaslini Children’s Hos-
pital Genoa, Genoa, Italy, Laboratory for Microbiology,4
University of Gent, B-9000 Gent, Belgium
The Burkholderia cepacia complex actually comprises nine
distinct species or genomovars: B. cepacia genomovar I, B.
multivorans, B. cepacia genomovar III, B. stabilis, B. viet-
namiensis, B. cepacia genomovar VI, B. ambifaria, B.
anthina, and B. pyrrocinia. Although they are all capable
of human infection, B. multivorans and especially B. cepa-
cia genomovar III seem the best adapted to the lungs of
Cystic Fibrosis (CF) patients, accounting for the majority
of CF isolates and epidemic clones. Differences of patho-
genicity among B. cepacia strains may result in different
distribution of distinct species and genomovars in nosocom-
ial infections. Indeed, the exact identification of each bac-
terial isolate represents a critical framework to refine
current management strategies of CF patients. The aim of
the present study was to show an exhaustive picture of the
distribution of B. cepacia complex species and genomovars
in one of the most important Italian CF Centres, the CF
Centre of Gaslini Hospital (Genoa, Italy). From 117 FC
patients living in different Italian regions, who attended the
Centre from 1985 to 2001, approximately 1.000 B. cepacia
complex isolates were recovered. Speciesygenomovar iden-
tification was performed in at least one isolate from each
CF patient, by a combination of PCR-based techniques,
such as Restriction Fragment Lenght Polymorphism Anal-
ysis (RFLP) of Amplified 16S rDNA (ARDRA) and recA
gene, and genomovar specific PCR tests of the recA gene.
Preliminary results indicate a highly disproportionate dis-
tribution of the different species and genomovars, with
more than the 50% of the isolates belonging to B. cepacia
genomovar III. Other species, such as B. cepacia geno-
movar I, B. cepacia genomovar IV, and B. pyrrocinia were
rarely found. Furthermore, the presence of some candidate
virulence determinants was also investigated in all of the
strains to evaluate their potential pathogenicity in relation
to their species or genomovar.
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EVALUATION OF BURKHOLDERIA CEPACIA
SELECTIVE AGAR (BCSA) ON SUPPORTING
GROWTH OF B. CEPACIA COMPLEX BACTERIA
RECOVERED FROM CYSTIC FIBROSIS (CF)
PATIENTS AND FROM ENVIRONMENTAL
SOURCES IN ITALY
S. Piana , M.L. Belli , S. Ottolino , A. Bevivino , C.1 1 1 2
Dalmastri , L. Chiarini , S. Tabbacchioni , M.L. Fenu , G.2 2 2 1
Manno1
Infectious Diseases Research and Diagnosis Laboratory,1
University Department of Pediatrics, G.Gaslini Institute,
Genova, Italy, Biotechnology and Agriculture Division,2
ENEA Casaccia, Rome, Italy
We evaluated a new selective medium, BCSA (BioMerieux
Italy), with others commercial prepared selective media in
their ability to support the growth of BC complex strains
from CF and environmental sources. A collection of 68
strains isolated from sputa of 53 pts from different Italian
regions attending the CF center of Genova and 75 strains
isolated from the maize rhizosphere in three Italian regions
was studied. Strains were assigned to the BC complex by
polyphasic analysis employing (i) conventional tests: API
20 E, API NE Systems (BioMerieux), OF basal medium
(Difco) for 6 sugars, oxidase test, growth at 420 8C, pig-
ment and haemolysis production; (ii) genus and species-
specific polymerase chain reaction assays (Bevivino JCM
2002, in press). BCSA plates were compared with OFPBL
and Cepacia Medium (CM) (both from BBL, Cockeys-
ville). Growth study was carried out by a subculture of
strains on blood agar for 24–48 h and aliquots of a bacterial
suspension (1=10 to 1=10 CFUyml) placed on BCSA,3 4
OFPBL and CM. Recovery efficiency for strains was deter-
mined after incubation at 300 and 350 8C for 72 h. BC
complex status of studied strains was: 2 % gvr I, 68% gvr
III, 3.5 % B. stabilis, 19.6% B. ambifaria, 5.6% B. pyrro-
cinia. Conventional tests were able to recognize B. stabilis
but failed to discriminate BC gvr I to BC gvr III and to B.
ambifaria. 100% of studied strains grown on BCSA and
OFPBL and 97% on CM (3 CF strains of BC gvr IIIA and
1 CF gvr III failed to growth on CM). All strains displayed
good growth on BCSA and OFPBL after 48 h at 350 8C
but on 24 h incubated BCSA plates the colony growth was
yet detectable. CM needed an increased incubation time for
72 h to improve the optimum growth rate. In conclusion,
our results show that BCSA is superior to OFPBL and CM
S129Journal of Cystic Fibrosis 1 (2002) S81–S180
for rapidity and quality of growth of Italian BC complex
strains of CF and environmental origins.
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CROSS-INFECTION WITH GENOMOVARS OF
BURKHOLDERIA CEPACIA COMPLEX OTHER
THAN GVIII AT A LARGE UK CF CENTRE
L.R. Macfarlane , A. Qureshi , L. Mooney , V. Keer , M.1 1 1 2
Denton , K.G. Kerr , D. Peckham , K. Brownlee , S.P.2 1 3 4
Conway3
Division of Microbiology, University of Leeds, Leeds, UK,1
Department of Micribiolgy, The Leeds teaching Hospitals2
NHS Trust, Leeds, UK, Regional Adult CF Unit, Seacroft3
Hospital, Leeds, UK, Regional Paediatric CF Unit, St.4
James’ University Hospital, Leeds, UK
Cross-infection with Burkholderia cepacia complex is
reported from cystic fibrosis (CF) units world-wide but is
usually associated with genomovar (gv) III strains. Forty-
three isolates of B. cepacia complex were obtained from 31
CF patients attending the Regional Paediatric (9 patients)
and Regional Adult (22 patients) CF Units in Leeds, UK.
All were confirmed as B. cepacia complex by the Labo-
ratory of Hospital Infection, Central Public Health Labo-
ratory, London, UK. Isolates were identified to genomovar
level using a published PCR-based method and were gen-
otyped using a published RAPD-PCR method. A large clus-
ter of indistinguishable gvIII strains was identified at the
Regional Adult CF Unit. Three patients at the Regional
Paediatric CF Unit shared an indistinguishable strain of
Burkholderia multivorans. Four patients at the Adult Unit,
two of whom were siblings, shared a different strain of B.
multivorans. Two patients, one from the Paediatric Unit and
one who had moved recently to the Adult Unit, shared the
same strain of Burkholderia vietnamiensis. Further discrim-
ination using pulsed-field gel electrophoresis (PFGE) sug-
gested that the three Paediatric Unit isolates of B.
multivorans were indistinguishable, but not all of the four
Adult Unit B. multivorans isolates were related and the two
B. vietnamiensis isolates were clearly unrelated. None of
these patients suffered any acute clinical deterioration.
PFGE was more discriminatory than RAPD-PCR. The three
paediatric patients with the same B. multivorans strain had
no overlapping in-patient admissions, clinical appointments
or social contact suggesting that patient-to-patient trans-
mission was unlikely. The routes of transmission of non-
gvIII B. cepacia complex strains may be different to those
of epidemic gvIII strains. This has implications for infec-
tion control strategies within CF units and highlights the
value of systematic genomovar identification and genotyp-
ing of B. cepacia complex isolates.
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MICROBIOLOGICAL CHARACTERIZATION,
EPIDEMIOLOGY AND CLINICAL OUTCOME OF
ACHROMOBACTER XYLOSOXIDANS (AX) IN
CYSTIC FIBROSIS (CF)
G. Manno , L. Minicucci , E. Ugolotti , M.L. Belli , S.1 2 1 1
Piana , M.L. Fenu , G. Pittaluga , L. Romano3 1 1 3
Infectious Diseases Research and Diagnosis Laboratory,1
2nd Pediaric Clinic, Cystic Fibrosis Center, University2 3
Department of Pediatrics, G.Gaslini Institute, Genova, Italy
Aim: At present, an increase of Ax prevalence and inci-
dence is described in several CF centers although the path-
ogenic role in pts is still unclear. To investigate the
influence of Ax colonization we reviewed, data of pts
attending our Center from 1982 to 2001.
Methods: Ax isolation was obtained with conventional
methods and, from 1993, a selective medium for tobra-
mycin intrinsically resistant organisms (Eosin Methylene
Bleu agar with antibiotics) was included. Species identifi-
cation was obtained by temperature growth condition, bio-
chemical tests (API NE) and enzymatic profile (API
ZYM). DNase, protease, elastase, lecitinase, lipase, coag-
ulase and haemolysin production were studied and strains
were genetically typed by RAPD analysis. Antibiotics sus-
ceptibility patterns were assessed by a microdilution meth-
od. Anti-Ax IgGs were tested by EIA on 129 sera of 75
pts (53 Ax positives), proteic-soluble standard antigen was
used. Correlation between Ax colonization, lung function
evolution (FEV1) and clinical outcome were evaluated.
Results: All Ax strains studied were negative for exoen-
zymes production and the antibiotics susceptibility patterns
did not vary significantly in the years. In the study period
Ax was recovered from 127 pts: 53 (41.7%) were persist-
ently colonized (mean 4.7 years"3.7 S.D.) and 74
(58.3%) in a transient way. The Ax colonized pts preva-
lence ranged from 10% in 1982, 18% in 1994 and 13% in
2001. In a group of 26 Ax persistently colonized pts mean
FEV1 changed from 61% 1 yr before AX acquisition, to
51.5% 3 yrs after. High level of anti-Ax IgGs were present
in 88.5% of persistently colonized pts.
Conclusions: The routine use of a selective media for mul-
tiresistant nonfermenters enhance the recovery rate of Ax.
A limited evidence of Ax role in the morbidity of CF pts
was found. The antibiotic resistance, above all to tobra-
mycin, seems to be the most important Ax pathogenic trait.
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PRELIMINARY RESULTS FROM A MULTIPLE
DOSE STUDY OF THE SAFETY,
PHARMACOKINETICS, AND ANTIMICROBIAL
ACTIVITY OF INHALED PA1806 IN CYSTIC
FIBROSIS (CF) PATIENTS
R.M.J.L. van der Heijde , R.P.M. Asfazadour , H.A.W.M.1 2
Tiddens1
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Heart Lung CentreyUniversity Medical Centre Utrecht,1
Paediatric PulmonologyySophia Children’s Hospital Eras-2
mus Medical Centre Rotterdam, The Netherlands
PA1806 is a synthetic monobactam antibiotic active in vitro
against a variety of Gram-negative bacteria, including Pseu-
domonas aeruginosa, Burkholderia cepacia, and Stenotro-
phomonas maltophilia. Intravenous and inhaled PA1806
safety has been studied in normal volunteers. This multiple-
dose open study of the safety, pharmacokinetics (PK), and
antimicrobial activity of inhaled PA1806 was conducted in
CF patients. Patients inhaled 300 mg PA1806 twice daily
for 2 weeks and were followed for 2 weeks after dosing.
Enrollment of 26 patients was planned. Safety and PKs
from the first 8 patients are presented here.
The 8 patients were aged 18–31 years, with screening
FEV1% predicted (Knudson) ranging from 43.9 to 75.2
and sputum culture positive for P. aeruginosa ()105 CFUy
g). Safety evaluations included adverse events (AEs),
FEV1 airway response to inhalation, oxygen saturation,
blood chemistry and hematology. Blood and urine samples
were collected for PK analysis.
6y8 patients completed the study. Two were withdrawn
after 8 days due to exacerbations of CF. One withdrawn
patient was hospitalised with severe pyrexia and dyspnoea
(a serious AE). Severe AEs reported by the remaining 7
patients were: cough (1), yellow discoloration of the tongue
(1), and dyspnoea (1). No patients experienced bronchos-
pasm (defined as drop in FEV1 of )20%) or desaturation
(SO -92%) up to 4 h post-dosing. Maximum plasma con-2
centration (C ) was 471"235 (day 1) and 515"259 ngymax
ml (day 14). Plasma concentration–time curve (AUC)
values were 1264"636 and 1062"663 ng hyml, respec-
tively (day 1 and 14). These C and AUC values weremax
50% of those previously measured in normal volunteers.
Conclusion: PA1806 inhalation was tolerated well and
resulted in low plasma levels in CF patients. These prelim-
inary safety results indicate that multiple doses of inhaled
PA1806 can safely be delivered to CF patients.
This study was supported by Chiron Corporation, Seattle
WA.
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LOW-DOSE AZITHROMYCIN THERAPY
REACHES SPUTUM DRUG LEVELS OF
POTENTIAL ANTIPSEUDOMONAL ACTIVITY IN
CYSTIC FIBROSIS PATIENTS
U. Baumann , E. App , M. King , J. Fischer , T.1 2 3 1
Zimmermann , W. Sextro , H. von der Hardt4 5 1
Department of Paediatric Pulmonology and Neonatology,1
Hanover Medical School, Germany, CF-Outpatient Clinic,2
Department of Pneumology, UniversityHospital Freiburg,
Germany, Pulmonary Research Group, University of3
Alberta, Edmonton, Canada, Pfizer Pharmaceutical Group,4
R&D Illertissen, Illertissen, Germany, Altona Paediatric5
Hospital, Hamburg, Germany
Aims: Low-dose long-term therapy with macrolides has
been proven effective in diffuse panbronchiolitis, a disease
sharing with cystic fibrosis (CF) chronic pulmonary infec-
tion with Pseudomonas aeruginosa as a feature. Since long-
term exposure with azithromycin (AZM) at levels of 1 to
10 mgyml were shown to inhibit alginate production and
biofilm formation of P. aeruginosa in vitro, we investigated
whether these drug levels can be reached by a low dose
therapy in CF patients in vivo.
Methods: In an open, prospective study, we assessed tol-
erability and drug levels in serum and sputum under long-
term azithromycin (AZM) treatment in ns15 CF patients
with two different dosages (low dose: 250 mg AZM 2=y
week, high dose: 250 mg AZMyday) over a period of 3
months. Samples were assayed by HPLC with electrochem-
ical detection (HPLC-ECD).
Results: AZM therapy was well tolerated in all patients.
Mean (S.E.M.) serum drug levels were comparable in both
dosage groups with 0.03 (0.01) and 0.06 (0.03) mgyml in
the low and high dose group, respectively. Sputum drug
levels, however, showed a considerable accumulation over
a period of 4 weeks. In the following steady state, mean
sputum AZM concentrations were 1.0 (0.2) 5 gyml in the
low dose group and 23.8 (0.6) mgyml in the high dose
group.
Conclusions: We conclude, that long-term AZM therapy in
CF is tolerable and that low-dose AZM therapy leads to
sputum drug levels of potential antipseudomonal activity.
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EVALUATION OF THE PREDICTIVE
PERFORMANCE OF DIFFERENT
PHARMACOKINETIC MODELS FOR
PIPERACILLIN DURING CONTINUOUS
INTRAVENOUS INFUSION
M. Kuck , M. Perz-y-Perez , M. Brouwer , H. Heijerman ,1 2 1 2
D. Touw1
Central Hospital Pharmacy The Hague, The Hague, Hos-1 2
pital Leyenburg, The Hague, The Netherlands
Objective: Home intravenous antibiotic treatment pro-
gram—lactam antibiotics are increasingly administered by
continuous intravenous infusion (CII) to cystic fibrosis
(CF) patients to treat pulmonary exacerbation. The aim of
this study was to develop a pharmacokinetic model (PM)
of piperacillin (P), which is valid to predict the serum con-
centrations of P during CIV in CF patients.
Methods: 7 adult CF patients with a pulmonary exacer-
bation were once-only treated with a short intravenous infu-
sion (SII) of 4 g P (and 0.5 g tazobactam (T)) in 30 min.
Up to 6 h after the administration of P (T) blood samples
were collected. CII of 12 g P (1.5 g T) during 24 h was
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started immediately after collecting the last blood sample.
During and up to 6 h after stopping the CII blood samples
were collected. The serum concentration data obtained after
the SII of P (T) were used to describe PMs. The serum
concentration data obtained during and after the CII were
used to test the predictive performance (Sheiner and Beal,
1981) of the described PMs.
Results: Average pharmacokinetic parameters (S.D.) of P
for a 1-compartment (1c) model were obtained with the
standard-two-stage (STS) method. Population models were
developed for a 1c, 2c and Michaelis–Menten (MM) mod-
el. The predictive performance of the models was expressed
in precision (root of the mean squared prediction error),
and bias (mean prediction error). The MM population mod-
el turned out to be the most precise (10.4 mgyl, 95% con-
fidence limits (cl) 7.0–12.9 mgyl) and the less biased (y
7.7 mgyl, 95% cly10.7 toy4.7 mgyl) model. If the mod-
el was applied to serum concentrations of P the precision
and bias improved to 4.7 mgyl (95% cl 2.2–6.3 mgyl),
respectively, 0.3 (95% cl y1.1 to 1.6 mgyl).
Conclusion: It is possible to describe the pharmacokinetics
of P in CF patients in a PM. The predictive performance
can be optimized by measuring a P serum concentration.
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INTRAVENOUS BOLUS COLISTIN IN CHILDREN
WITH CYSTIC FIBROSIS
P. Burr , C. Daman-Willems , L. Dennard , G. Hinson , J.1 1 1 1
Stroobant , M. Goldman1 2
Children’s Hospital Lewisham, London, UK, Forest Lab-1 2
oratories Europe, Bexley, UK
Background: Colistin, a polymixin antibiotic with activity
against gram negative organisms, has been used since 1985
as an inhalation for eradication and control of Ps. aerugi-
nosa (PA) in patients with cystic fibrosis (CF). Colistin is
also used intravenously typically as a slow infusion. It has
the added advantage that PA resistance to it is rare.
Increasingly, patients are able to complete courses of intra-
venous antibiotics at home, minimising disruption to family,
work and school life. Whilst infusions of antibiotics can be
administered by means of syringes pumps or deflation
devices such as the side-kick or elastomeric infusion sys-
tem, many patients prefer the advantages of antibiotics
administered as a bolus (given over 5 min) which further
reduces the inconvenience associated with intravenous anti-
biotics. Experience with colistin given as a bolus to children
has not previously been reported.
Aims: A retrospective review of the use of colistin admin-
istered as a bolus with respect to side effects, haematolog-
ical and biochemical parameters, and ease of use.
Methods: Children with cystic fibrosis who had received a
course of colistin by intravenous bolus over a 15 month
period August 1999 to December 2000 were studied. Notes
maintained by the CF clinical nurse specialist (PB) were
reviewed for adverse events, practical difficulties, ease of
administration and patient acceptance, and laboratory data
abnormalities.
Results: 5 children aged between 12 and 16 yrs received
courses of colistin 14 days. There were no adverse affects
noted during therapy by parents or members of the CF team
on routine visits to these children whilst on or after treat-
ment. There were no significant differences in laboratory
data in any patients before or after a course of colistin.
Conclusion: Intravenous colistin can be safely given to
children with cystic fibrosis as a bolus minimising the
inconvenience to patients needing a course of intravenous
anti-PA antibiotics.
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EXPERIENCE OF A NOVEL
ANTIPSEUDOMONAL ANTIBIOTIC,
FOSFOMYCIN, IN ADULT CYSTIC FIBROSIS
PATIENTS
A. Mirakhur , M. Ledson , M. Gallagher , C.A. Hart , M.1 1 1 1
Walshaw1
Regional Adult CF Unit
Many adult patients with cystic fibrosis are chronically
colonised by Pseudomonas aeruginosa, which requires
intravenous antibiotic treatment. However, increasing resis-
tance is occurring to these antibiotics, and we have there-
fore looked for other agents which might be active against
this organism. One such antibiotic is fosfomycin, which has
a unique bactericidal action against Pseudomonas aerugi-
nosa with an MIC of 64 mgyl. Whilst it has been available
on the Continent for 31 years, it is not licensed for use in
the UK. We have an increasing number of adult CF patients
who are chronically colonised with resistant Pseudomonas
aeruginosa, and we have therefore explored the possibility
of using fosfomycin as part of their treatment for acute
exacerbations. Over the last 4 years, 15 patients (mean age
23 years wrange 18–37x, mean BMI 20.3 w15–27x, 6 male)
chronically colonised with Pseudomonas aeruginosa were
given a total of 30 courses of fosfomycin (mean 2 courses
w1–3x, mean course length 17 days w7–36x) for pulmonary
exacerbations. Fosfomycin was obtained from suppliers in
Germany on a named patient basis and given intravenously
at a dose of 5 g tds in conjunction with other antipseudo-
monal antibiotics. During treatment, one patient had nausea
which was attributed to fosfomycin and the antibiotic was
withdrawn. All the remaining patients had clinical resolu-
tion and spirometry improved following treatment (mean
FEV1% predicted: day 0 41 w14–96x, course end 49 w16–
97x; P-0.001). There was no change in renal parameters
with treatment (mean serum creatinine: day 0 85 mmolyl
w61–197x, course end 78 w49–109x, PsN.S.; mean urea:
day 0 3.9 wrange 1.1–7.0x, course end 4.3 w2.3–8.5x, Ps
N.S.). Thus, fosfomycin was well tolerated and had clinical
efficacy. We recommend that other units consider adding
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this antibiotic to their antibiotic formulary for the treatment
of Pseudomonas aeruginosa.
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EFFECTS OF LINEZOLID IN TWO CF PATIENTS
WITH CHRONIC S. AUREUS INFECTION NOT
RESPONDING TO STANDARD THERAPY
F. Napoli, L. Romano, R. Casciaro, F. Guerriero, D. Gian-
otti, R. Lorini
CF Centre, Gaslini Institute, Genoa, Italy
Linezolid is a member of a new class of antibacterial
agents: the oxazolidinones. It is a bacteriostatic agent indi-
cated for the treatment of infections caused by Gram-pos-
itive pathogens including S. aureus. Our experience on
linezolid effects in CF is here reported.
Case 1: 10 yr, girl. In the previous 19 months, she had
been admitted repeatedly for intravenous combined admin-
istration of glycopeptides, beta-lactams and aminoglyco-
sides. Sputum cultures grew S. aureus only. Lung function
and chest radiological picture deteriorated despite repeated
hospitalizations. Few days after every antibiotic course, the
patient showed increased cough, thicker and darker sputum,
fever, weight loss. No oral or inhaled antibiotic could pre-
vent clinical deterioration at home, the only showing some
effect being intramuscolar teicoplanine. Inhaled vancomy-
cin was not tolerated. On December 2001, combined intra-
venous therapy with linezolid 300 mg bid (10 mgykgydie)
and teicoplanine (9.8 mgykgydie) was administered.
Marked reduction of inflammatory markers and improve-
ment of lung function tests were observed after 14 days of
treatment (ESR from 101 to 69 mmyh, CRP from 9.9 to
0.9 mgydl, FEV1 from 54 to 72%). Subsequently, oral line-
zolid was effective in controlling airways infection at home.
Case 2: 25 yr, male; persistent MRSA bronchopulmonary
colonization caused recurrent fever despite oral and inhaled
antibiotic treatments administered at home. Inhaled vanco-
mycin was not tolerated. Intermittent oral treatment with
linezolid (600 mg bid; 8.8 mgykgydie) 15 daysymonth was
started on September 2001 and turned out to be effective
in controlling infection symptoms.
Our preliminary data show that linezolid, due to its almost
complete bioavailability and good tolerability profile, line-
zolid could represent a useful alternative to other anti-S.
aureus agents, especially when prolonged duration of anti-
microbial therapy is required.
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ANTIBIOTIC USE AND PSEUDOMONAS
AERUGINOSA (PA) SUSCEPTIBILITY PROFILE
IN THE CYSTIC FIBROSIS CENTER OF
GENOVA, ITALY: A SIX-YEAR ANALYSIS
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Background: Limited data about antimicrobial use and
antimicrobial resistance in CF pts exist. We performed a
retrospective analysis on PA susceptibility profile and anti-
biotic use in a CF center between 1993 and 1998.
Methods: Data on 224 CF pts and 1315 PA isolates (717
non-mucoid, 598 mucoid) were analyzed. Antibiotic sus-
ceptibility by broth microdilution panels (Pasco Gram Neg-
ative Breakpoint, Difco) was tested for amikacin (AK),
tobramycin (NN), netilmicin (NET), ciprofloxacin (CIP),
ceftazidime (CAZ), cefepime (FEP), piperacillin (PIP),
PIPytazobactam (PyT), ticarcillin (TIC), TICyclavulanic
acid (TIM), imipenem (IMP), meropenem (MEM), and
aztreonam (ATM). The prescribed antibiotics were given
as defined daily dosesy1000 pts-days (DDDs).
Results: The number of DDDs ranged from 358 to 484;
while the use of inhaled antibiotics increased during the
study period, the prescription of systemic antibiotics
remained fairly constant (range 240–275). The most fre-
quently used drugs were nebulized colistin (110.7), CIP
(98.9), NN (55.0), CAZ (31.8), NET (24.7), AK (18.4),
PIP (18.2), carbapenems (12.6). CAZ was the most active
agent (86% of strains susceptible), followed by IMP
(83.1), PyT (81.7), ATM (80.3), MEM (79), NN (76.5),
CIP (73.7), TIC (72.4), AK (69.5), NET (56.5). Non-
mucoid strains were significantly more susceptible than
mucoid strains to aminoglycosides (75.5 vs 61.8%; P-
0.0001) and CIP (79 vs 69.2%, P-0.0001), but showed a
comparable patterns of susceptibility towards the other
agents. MIC50 and 90 did not increase during the time. An
overall decrease of aminoglycosides use (from 127.3 to
78.1) was observed; by contrast the use of CAZ increased
from 22.8 to 41.8. However, there was not significant cor-
relation between antibiotic use and resistance to any indi-
vidual agent.
Conclusion: In this study, the antibiotic susceptibility pat-
terns in PA isolates from CF pts did not change significantly
over the years from 1993 and 1998.
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IN VITRO ACTIVITIES OF ANTIBIOTIC
COMBINATIONS AGAINST BURKHOLDERIA
CEPACIA-COMPLEX STRAINS USING E-TEST
G. Manno , E. Ugolotti , M.L. Belli , M.L. Fenu , S.1 1 1 1
Piana , G. Pittaluga , M. Cruciani2 1 3
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Background: Treatment of Burkholderia cepacia-complex
(Bc) infections in cystic fibrosis patients is problematic,
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since the microorganism is often resistant to most individual
antimicrobial agents.
Aim: To evaluate the Epsilometer test (E-test) technique to
assess the activity of antimicrobial combinations against
Bc.
Methods: In a preliminary evaluation, we compared E-test
to checkerboard method on 10 test organisms. Synergy test-
ing by E-test was then performed with various antimicrobial
combinations on 131 strains recovered from 53 cystic fibro-
sis patients (23 males, 30 females) and assigned to the BC
complex by polyphasic analysis employing (i) conventional
tests: API 20 E, API NE Systems (BioMerieux), OF basal
medium (Difco) for 6 sugars, oxidase test, growth at
420XC, pigment and hemolysis production; (ii) genus and
species-specific polymerase chain reaction assays (Bevivi-
no JCM 2002, in press).
Results: An agreement of 90% between E-test and check-
erboard was found. Resistance to individual antimicrobial
agents ranged from 48% for meropenem to 100% for tobra-
mycin, chloramphenicol, and rifampin. On the whole, in
71.6, 15.6, and 12.6% of instances the various combinations
tested resulted in additivityyindifference, synergism, and
antagonism, respectively. The highest rates of synergy were
observed with combinations of ciprofloxacin-piperacillin
(44%), rifampin-ceftazidime (33%), chloramphenicol-cef-
tazidime (22%), cotrimoxazole-piperacillinytazobactam
(22%), and ciprofloxacin-ceftazidime (21%). Rates of
antagonism for cotrimoxazole and chloramphenicol in com-
bination with Beta-lactams were higher than those observed
for ciprofloxacin-beta-lactams. For most isolates that were
affected synergistically, Minimal Inhibitory Concentrations
(MICs) of beta-lactams in any of these combinations and
MICs of ciprofloxacin in combination with piperacillin or
ceftazidime were decreased into the susceptibility ranges.
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ANTIBIOTIC RESISTANCE OF BURKHOLDERIA
CEPACIA IN REGIONAL CYSTIC FIBROSIS
CENTER OF PALERMO: REPORT OF 1999–2001
RESULTS
M.L. Furnari , L. Termini , A. Collura , T. Pensabene , F.1 1 2 2
Pardo1
Regional Cystic Fibrosis Center, Children Hospital, Paler-1
mo, Microbiology Department, Children Hospital, Palermo2
Cystic Fibrosis (CF) is a chronic disease in which the out-
come is based on lung function caused by viruses and many
bacteria; important is aggressive early treatment against
intermittent colonisation and maintenance chemotherapy
against chronic infection remain the main objective to
decrease the lung damage.
In the last years Burkholderia cepacia (Bc) has become the
most important pathogen of infection and it is associated
with a poor clinical prognosis. Nowadays we know 9 gen-
omovars and the isolates associated with acute clinical
decline belong to genomovar III. Bc is resistant to a lot of
antimicrobial agents. In this study were retrospectively
examined the resistance of 516 BC strains isolated from 56
patients (1999–2001). Selective media (OFPBL) and a
commercial identification assay, API 20, were used for
identification.
6.2% of strains were resistant to piperacillinytazobactam,
8.5% to ceftazidime, 28.5% to carbepenem, 41% to cefe-
pime, 38.1% to aztreonam, 98.6% to amikacin, 95.3% to
tobramicin, 41.6% to CAF, 73.1% to cotrimoxazole, 40.8%
to ciprofloxacin, 46.8% to levofloxacin. These resistances
have increased during last 3 years. Ceftazidime from 0 to
11.7%, piperacillinytazobactam from 5 to 10%, carbape-
nem from 13.6 to 41.1%, aztreonam from 27.2 to 44.7%,
cefepime from 31.8 to 50%, CAF from 31.8 to 49.4%, cip-
rofloxacin from 40.9 to 46.4%, cotrimoxazole from 68.1 to
80%.
In view of the fact that Bc develops resistance to a lot of
antimicrobial agents ceftazidime and piperacillinytazobac-
tam remain the most potent agents and should be the drugs
of choice. Moreover the Bc strains develop the most resis-
tance to aminoglycoside. It is important to follow the resis-
tances during the years, to use different drugs during
intravenous courses in the same patient and to use a com-
bination of antibiotics to reduce the risk of selection of
resistant mutants.
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RISK ASSESSMENT OF CROSS-INFECTION IN
‘NEWLY’ PSEUDOMONAS AEROGINOSA
COLONIZED PATIENTS IN A CF CENTRE
S. Vandaele , P. Schelstraete , F. Haerynck , M.1 1 1
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Introduction: The means, by which Pseudomonas aero-
ginosa (P.a.) in CF patients is acquired and transmitted, are
not well understood. The majority of P.a. types seems to be
acquired from the environment and not from other CF
patients or from the hospital. However, CF centres need to
be vigilant that cross-colonization does not develop
amongst their patients. Therefore P.a. colonized patients are
segregated in our CF centre.
Aim: To assess the pseudomonas genotypes of ‘newly’ col-
onized Cf patients in our centre. These patients are consid-
ered as P.a. negative, and show, at a certain time, a regular
culture of the organism, on three or more occasions extend-
ing over six months, despite therapeutic efforts to eradicate
the organism. These patients exclusively attend our centre.
Methods: Sputum samples were obtained of these patients.
The genotype of P.a. strains was identified by random
amplified polymorphic DNA fingerprinting technique.
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Results: 17 of 34 (50%) colonized patients are considered
as becoming ‘newly’ colonized, while attending only our
CF centre. 13y17 (76%) harboured a unique genotype.
Since there is evidence that siblings commonly share the
same genotype, we excluded the siblings. 13y15 still had a
unique genotype (86.5%). The 2 unrelated children with
the same genotype lived in close contact (the same class-
room, the same physiotherapist, the same transport when
coming together to the consultation ward). The mean age
of colonization is 10 year.
Conclusion: ‘Newly’ Pseudomonas aeroginosa colonized
CF patients do not seem to acquire P.a. from other CF
patients, when exclusively attending our centre.
Cross-infection seems to occur only between siblings or
patients with close contact outside the CF centre.
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DECREASING PREVALENCE OF CHRONIC P.
AERUGINOSA INFECTION IN DANISH CF
PATIENTS
B. Frederiksen, N. Høiby, C. Koch
The Copenhagen CF Centre (Rigshospitalet), Denmark
Earlier studies (1974–1995) predicted a decreasing preva-
lence of chronic P. aeruginosa lung infection among CF
patients treated at the Copenhagen CF Centre.
This follow-up study shows that the prevalence did
decrease significantly from 45% in 1995 to 36% in 2000
(P-0.05).
The mortality and number of new patients were unchanged
during 1996–2000 compared with 1991–1995.
The yearly incidence of CF patients developing chronic P.
aeruginosa infection also decreased from an average of
3.4% in 1991–1995 to an average of 1.9% in 1996–2000.
The yearly incidence of CF patients with intermittent P.
aeruginosa colonisation decreased from an average of
20.6% in 1991–1995 to an average of 14.6% in 1996–
2000.
Patients with intermittent P. aeruginosa colonisation have
since 1989 been treated with colistin inhalations and orally
ciprofloxacin, from ultimo 1997 for 3 months. In very few
patients the sensitivity to colistin have been reduced, and
these patients have been treated with tobramycin
inhalations.
The prevalence of patients with B. cepacia was unchanged
and still below 5%.
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BURKHOLDERIA CEPACIA EPIDEMIOLOGY IN
PATIENTS OF THE CYSTIC FIBROSIS CENTRE,
PRAGUE, CZECH REPUBLIC
J. Bartosova , P. Drevinek , K. Kotikova , A. Zapletal , O.1 1 1 1
Nyc , O. Cinek , D. Zemkova , V. Vavrova2 1 1 1
2nd Paediatric Department, Charles University 2nd1
MedicalSchool and University Hospital Motol, Prague,
Czech Republic, Institute of Microbiology, University2
Hospital Motol, Prague, Czech Republic
Chronic infection by Burkholderia cepacia in patients with
Cystic fibrosis (CF) has been associated with increased
morbidity and mortality.
The aim of this study was to investigate the epidemiology
of B. cepacia infection among patients attending CF centre
in Prague and to evaluate its influence upon clinical course
of the disease.
At present, 290 CF patients from different parts of Czech
Republic attend our CF centre. 62 of all patients (21.4%)
are infected by B. cepacia. Since 1994 B. cepacia has been
isolated in 91 cases (mean age at first positive culture
14.8"4.8 yrs). 29 of these patients have died from respi-
ratory failure (mean age at death 20.04"4.7 yrs).
After colonization, the forced expiratory volume in one sec-
ond (FEV1) decreased from 63.2"20.4 to 53.4"25% p.v.,
mean deterioration per year was 3.9"10% p.v. Deteriora-
tion of lung function in patients infected by cepacia was
not dependent on nutritional status, duration of cepacia
infection or age.
In 2001 B. cepacia was detected directly from sputum sam-
ples by PCR based method. 91.2% of the PCR examined
patients were infected with genomovar IIIa. Genomovar
IIIb has been found in two patients (siblings) and geno-
movar II in one patient.
Strict policy of segregation of the CF patients colonized
with B. cepacia from the non-colonized ones was intro-
duced in our CF centre in 1997 but did not lead to an
expected decrease in the number of newly infected patients
(53 in 1994–1997, 35 in 1998–2001). No positive culture
of B. cepacia has been found in a search for a nosocomial
source.
In conclusion, high prevalence of B. cepacia with predom-
inance of strain IIIa proves cross-infection in our CF center.
Improvement of early diagnosis of B.c. infection by regular
checks at least every 3 month and early expectoration train-
ing may increase the efficacy of segregation measures.
Supported by IGA MZCR NMy6568-3 and MSMT
111300003.
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LONGITUDINAL ANALYSES OF MICROBIAL
ECOLOGY IN TWO ANTIBIOTIC-TREATED
CYSTIC FIBROSIS PATIENTS
D. VanDevanter, S. Anderson, L. Barker, R. Shawar
Chiron Corporation, Seattle, WA, USA
CF patients are prone to chronic polymicrobial lung infec-
tions that significantly contribute to lung inflammation and
destruction. Once chronic infections have been established
in CF lungs, they are rarely (if ever) eradicated by antibi-
otic therapy. Nonetheless, acute and chronic antibiotics are
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routinely administered to chronically infected CF patients
in an attempt to mitigate the consequences of infection. An
anticipated (but not well-characterized) result of repeated
selective antibiotic pressure in the absence of eradication is
the emergence of diverse bacterial populations within indi-
vidual patients. This increased diversity complicates the use
of traditional clinical microbiologic techniques to charac-
terize the antibiotic susceptibility of infecting organisms. In
this study, we systematically analyzed every colonial phe-
notypic Pseudomonas aeruginosa (PA) variant isolated
from 2 CF patients during their participation in the 6-month
tobramycin solution for inhalation (TOBI) clinical trial. A
total of 60 PA isolates collected during 11 clinical visits
were characterized with respect to morphotype (mucoidy
nonmucoid), genotype (using RAPD PCR typing), meta-
bolic status (auxotrophyprototroph), antibiotic
susceptibility, and sputum density. Bacterial population
dynamics were correlated with antibiotic regimens and also
with pulmonary function (FEV1% predicted). These anal-
yses demonstrated a much higher degree of microbial diver-
sity than had been previously appreciated; 16 variants of 8
distinct PA genotypes were identified among the 60 sputum
culture isolates. No obvious relationships were observed
between changes in sputum bacterial density and antibiotic
therapies, or between sputum bacterial density and pulmo-
nary function test results. These data suggest that routine
clinical microbiologic methods are inadequate to character-
ize CF lung infections and are insufficient to predict either
microbiologic or clinical outcomes of specific antibiotic
therapies.
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ANTIBIOTIC RESISTANCE OF BACTERIA
ISOLATED FROM SPUTUM CULTURES OF
PATIENTS WITH CYSTIC FIBROSIS: A
PEDIATRIC CF CARE CENTER EXPERIENCE
V. Lucidi, S. Bella, T. Salerno, E. Fiscarelli, L. Massenzi,
G. Ricciotti, M. Castro
Ospedale Pediatrico Bambino Gesu, Rome, Italy
Antibiotical treatment represents one of the most important
aspect of CF patients care.
In our CF Center, according to the international protocols
of treatment, the first isolation of Pseudomonas aeruginosa
(PA) is treated with an aggressive antibiotical regimen, in
order to delay colonization and chronic infection; further-
more i.v. antibiotics are administered when we record clin-
ical, biochemical, functional and radiological features of
pulmonary exacerbation as defined by Ramsey et al. We
perform i.v. antibiotical treatment quarterly only in patients
who have chronic infection, severe respiratory insufficiency
or severe bronchorrhea.
In a series of 143 pediatric CF patients (MyF 69y74, mean
age 11.8&61617; 7.2 years) we isolated from sputum cul-
tures or swab throat SA in 70% pts, PA in 53% (mean age
at first isolation 8.5&61617; 6.2 years), SM in 11%, BC
in 4.5%.
Drug resistance of the 678 strains isolated (37% PA, 31%
SA, 4% BC) is highlighted: we evaluated the percentage
of resistance to beta-lactamics, amynoglycosides, chinolon-
ics, sulphamidics, carbopenem, polypeptidics, macrolides.
Results are reported in table
Beta latt
(%)
Carbopen (%) Aminoglic (%) Chinolon (%)
Sulfamid
(%)
Polipept
(%)
Macrol
(%)
PA
(254)
17.7 5.9 12.5 7.4 37.7 2.7 0
XM
(112)
33 24.1 16 14.2 0.8 10.7 0
SA
(214)
5.6 0.4 0.4 7.4 2.8 0 29
Alcal 33 0 33 28 0 4 0
Percentages of resistance are similar to those reported in
national and international series, while the percentage of
multiresistant strains (defined as resistance to beta-
lactamics and amynoglycosidea) is extremely low.
It is probably due to the low mean age of our series.
The percentage of resistance, that is similar to other
series, is in contrast with this datum.
Further longitudinal, prospective, multicentric studies are
necessary to identify risk factors of drug resistance,
comparing the different protocols of antibiotical
treatment strategies adopted.
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FINAL RESULTS OF LONGITUDINAL STUDY:
BACTERIOLOGIC COURSES OF CHILDREN
WITH CYSTIC FIBROSIS IN LITHUANIA
S. Dumcius
Kaunas Med. University, Lithuania
Longitudinal study of bacteriological courses of children
with cystic fibrosis (CF) was performed in one of CF cen-
ters in Lithuania for better understanding relations between
specific bacteriological isolates and clinical process of dis-
ease especially in case of late diagnosis. Continuance of
this study was 6 years.
The diagnosis of CF often is established late in our country.
Only approximately 50% of children CF is diagnosed
before age 5 years. Mean age of patients with CF is only
approximately 15 years.
The aim of this study was to understand possible connec-
tion between severity of lung disease and bacteriologic iso-
lates of children with CF when disease was diagnosed late.
Prospective evaluation during the period of 6 years included
history, physical examination, chest radiographs, and spu-
tum cultures for bacteria of 57 children with CF. Mean age
was 4.8 years when disease was diagnosed first.
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In 6 (10.5%) cases cultures were negative during all period
of observation. S. aureus and H. influenzae were the iso-
lates most frequently recovered 40 (70.2%).
8 (14.0%) of the children had serial cultures positive for
Pseudomonas aeruginosa and 2 (3.5%) for Stenotropho-
monas maltophilia. 2 (3.5%) children of the study had
mucoid P. aeruginosa. All children with Pseudomonas
aeruginosa had previous isolates of S. aureus and H.
influenzae. In 6 (10.5%) cases atypical isolates were recov-
ered (Klebsiella pneumoniae, E. coli, S. pyogenes, M.
catarhalis).
Conclusion: The results of prospectively performed lon-
gitudinal study in our CF center enable us conclude that
initial recovery of Pseudomonas aeruginosa is preceded by
the onset of chronic respiratory signs, more frequent daily
cough, lower chest radiograph scores and, etc, however S.
aureus and H. influenzae are most frequently recovered
from children with CF even if disease was diagnosed late.
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DEVELOPMENT OF ANTIBIOTIC RESISTANCE
IN CYSTIC FIBROSIS PATIENTS COLONIZED BY
PSEUDOMONAS AERUGINOSA: A
RETROSPECTIVE STUDY
S. Campana, G. Taccetti, G. Mergni, S. Farina, M.L. Cioni,
F. Festini, T. Repetto
Cystic Fibrosis Center of Tuscany, Department of Pediat-
rics, University of Florence, Meyer Hospital, Florence,
Italy
Cystic fibrosis (CF) patients chronically colonized by Pseu-
domonas aeruginosa (PA) require frequent courses of anti-
biotic treatment. The development of resistance to
antibiotics occurs frequently in CF due to the intensive
selective pressure provided by the large amount of antibi-
otics used in these patients. The present study shows the
evolution of antimicrobial susceptibility of PA during a 5-
year period.
PA was isolated from 60 (37.9%) out of 158 patients
attending the CF Regional Centre of Florence.
We retrospectively studied the susceptibility to antibiotics
(Ceftazidime, Ticarcillin, Imipenem, Tobramycin, Netilmi-
cin, Ciprofloxacin, Meropenem) of 546 PA strains isolated
from CF patients seen on a regular basis at our clinic from
1996 to 2000. Two positive culture a year were analyzed
for each patient. Different susceptibility patterns in relation
to PA morphotypes were also tested.
Analysis revealed that PA strains resistance increased over
a period of 5 years for most of the antibiotics tested. Among
b-lactams, ceftazidime and ticarcillin showed the higher
increase of the percentage of resistant strains (from 3.2 to
19.3% from 1996 to 2000 for ceftazidime and from 7.5 to
25.3% for ticarcillin). Fluoroquinolones susceptibility rates
(tested for ciprofloxacin as representative of the group)
decreased during the period of the study. The percentage of
strains resistant to tobramycin, netilmicin and imipenem
remained stable along the period of observation.
In conclusion, the most frequently used anti PA beta-lac-
tams showed an increase of resistance during a 5-year peri-
od. Aminoglycosides were frequently used in combined
therapy of PA infection. In spite of that, a high percentage
of strains remained fully susceptible.
Aggressive antibiotic treatment contributes to the emer-
gence of strains resistant to multiple antibiotics, therefore a
follow-up surveillance to determine changes in susceptibil-
ity of PA isolates is required.
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FALSELY ELEVATED SERUM
AMINOGLYCOSIDE LEVELS IN A PATIENT
RECEIVING NEBULISED ANTIBIOTIC
Simon Struthers , Thomas Nicholson , Graeme Jones ,1 1 2
Gary Connett1
Department of Paediatrics, Southampton General Hospital,1
UK, Department of Microbiology, Southampton General2
Hospital, UK
It is common when treating children with respiratory exac-
erbations of cystic fibrosis to treat with both nebulised and
intravenous (IV) antibiotics. Antibiotic drug levels are
often measured from finger-prick blood samples. We
describe a case of a 14-year-old girl treated simultaneously
with IV and nebulised. Tobramycin in whom drug levels,
measured from finger prick blood samples, were errone-
ously high due to finger contamination by the nebulised
drug.
The child was receiving regular medication with nebulised
tobramycin (TOBI) 300 mg twice daily and was admitted
for a course of IV ceftazidime plus tobramycin 10 mgykgy
day given in 3 divided doses. Tobramycin levels taken from
finger prick specimens around her fourth dose were elevat-
ed with trough levels of 2.5 mgyl (our target range -1
mgyl) and a peak of 12.5 mgyl (target range 7–10 mgyl).
As a result the tobramycin dosage was reduced and the
dosage interval increased. To assess subsequent renal clear-
ance a further tobramycin level was measured before the
next dose of intravenous antibiotic. The level was 27.6 mgy
l despite no parenteral tobramycin having been given in the
preceding 18 h. Sample contamination was suspected. To
confirm this a series of tobramycin levels following the
next nebulised tobramycin dose (but no further IV dose)
were collected. A venous blood level from the right ante-
cubital fossa was -1 mgyl. A blood level from a right
index finger prick was 18.5 mgyl. Saline washings (1 ml)
from the end of the right middle finger gave a level of 77
mgyl. After handwashing with soap and water, a repeat
right index finger prick blood level remained falsely high
at 6.8 mgyl. Resumption of our standard IV tobramycin
regime resulted in optimal serum levels according to assays
from further venous samples.
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This case highlights the need for care when interpreting
finger-prick drug levels in patients receiving the same ami-
noglycoside both IV and nebulised.
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THE INCREASED INTESTINAL PERMEABILITY
IN CF IS PROBABLY DUE TO PANCREATIC
INSUFFICIENCY
E. Faber, R.M. van Elburg, J.E. Dankert-Roelse, C.M.F.
Kneepkens
Vrije Universiteit Medical Centre, Department Pediatrics,
Amsterdam, The Netherlands
Aims: Disturbances of the intestinal integrity, reflected by
an increased intestinal permeability, are reported in cystic
fibrosis (CF). We investigated whether the increased intes-
tinal permeability is due to CF itself or a consequence of
the concomitant exocrine pancreatic insufficiency (PI).
Methods: We measured intestinal permeability by the sugar
absorption test in 7 CF patients: 4 with pancreatic suffi-
ciency (CF-PS, fat absorption coefficient )95%) and 3
with pancreatic insufficiency (CF-PI, fat absorption coef-
ficient -95%). In the sugar absorption test, the lactulosey
mannitol (LyM) ratio is measured in 5-h urine after oral
ingestion of a lactulose and mannitol solution, hyperos-
molar by the addition of sucrose.
Results: The mean LyM ratio was lower in CF-PS than in
CF-PI (0.057 versus 0.123, Ps0.065). This difference is
mainly due to a lower permeability for lactulose in CF-PS
versus CF-PI (83.8 and 235.6, respectively, Ps0.13).
Conclusion: Our conclusion is that an increased intestinal
permeability in CF is probably a consequence of the exo-
crine pancreatic insufficiency and not due to CF itself. The
cause of the increased intestinal permeability in the pres-
ence of PI is still unclear.
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ACUTE PANCREATITIS IN CYSTIC FIBROSIS. A
REPORT IN PATIENTS WITH PANCREATIC
SUFFICIENCY AND INSUFFICIENCY
D. Fuentes, L. Suarez, L. Maiz, H Escobar.
Cystic Fibrosis Unit. Hospital Ramon y Cajal, Universidad
Alcala de Henares, Madrid, Spain
Acute pancreatitis (AP) is an unusual complication of cys-
tic fibrosis (CF) with estimated prevalence of 1–2% and
mainly reported in patients with sufficient pancreatic func-
tion (PS).
Patients: We report 4 CF patients (sweat chloride )60
mEqyl) with associated pancreatitis. Two of them had only
one acute episode associated with wine and beer (low alco-
hol content 1–2%). The first with a homozygous I507del
and the latter an heterozygous F508delyN mutation. Each
of the remaining had four documented episodes of AP, one
with a R334WyQ890Xq7Ty7T mutation and a highly sus-
pected triggered relation to administration of antibiotics
through oral or IV route. Possible triggers in the last patient,
as well as the mutations remain unidentified. All but one
patient had PS. Pancreatic insufficiency in this patient (PI)
was determined based on fecal fat excretion quantified
between 5.6 and 12.4 gyday while receiving substitution
therapy with pancreatic enzymes.
Initial presentation included acute abdominal pain (100%)
and vomiting (40%). All patients had raised pancreatic
amylase (rs270–3000 Uyl) and lipase (rs458–1000 Uy
l). All cases had abnormal findings on USG and CAT scan
imaging suggestive of pancreatitis.
Discussion: Further research is needed to determine the
exact mechanisms of AP and related risk factors in CF. We
underline the relevance of early recognition of pancreatitis
in CF patients avoiding further complications. It must be
mandatory to perform serum analysis of amylaseylipase
and pancreatic imaging studies in patients with history of
abdominal pain of acute onset regardless of their genotype
or whether they have a preserved pancreatic function or not,
since there are few reported cases in patients with PI.
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EVIDENCE OF FATS MALABSORPTION IN CF-
PATIENTS WITHOUT GASTROINTESTINAL
SYMPTOMS OF LIPIDS LOSS
T. Kapoustina , N. Kashirskaya , N. Kapranov1 2 2
Russian State Medical University and Research Center for1 2
Medical Genetics RAMS, Moscow, Russia
Aim: To reveal that the absence of gastrointestinal symp-
toms in CF-patients is not always indicative that malab-
sorption is controlled.
We investigated lipids absorption in 35 CF-patients (age
from 9 to 15 years; 18 boys and 17 girls). They were divid-
ed into two groups. Group 1—16 patients with liver cir-
rhosis. Group 2—18 patients without it. All CF-patients
received basic treatment (antibiotics, mucolitics, enzyme
replacement therapy, UDCA, vitamins). Control data was
taken from healthy children of the same age.
Methods: (1) Quantitative and qualitative structure of fae-
ces lipids were analysed by gas–liquid chromatography. (2)
Faecal microscopy. (3) Presence of gastrointestinal symp-
toms. (4) Bodyweight and growth.
Results: All CF-patients in our study had not gastrointes-
tinal symptoms of malabsorption. At faecal microscopy the
neutral fat was not found out. It was shown in our study
that dietary fat in CF-patients is completely digested to free
fatty acids, phospholipids, monoglycerides, diglycerides
and free cholesterol. However total lipid loss in faeces in
both groups was increased by three times compared to the
control group (P-0.001). Big amount of free fatty acids,
phospholipids and cholesterol was lost with stool in both
groups (P-0.001). In group of patients with liver cirrhosis
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loss of cholesterol was more then in group without it (P-
0.05). Coprostanol—microbe derivate of cholesterol—was
below the control level in both groups. This observation
may suggest that CF patients have disturbance of the
growth of colon anaerobic bacteria. We have found out
return correlation between bodyweight and contents in fae-
ces free fatty acids.
Conclusion: The investigation of faeces lipid and phos-
pholipid composition revealed the prevalence of malab-
sorbtion instead of maldigestion in both groups. So this
shows the necessity of new therapeutic approaches for the
improvement of lipid absorption in CF patients (probably,
the special dietary supplements will be useful). Also this
research can help with selection of an adequate and safe
dose of pancreatic enzymes.
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FECAL PANCREATIC ELASTASE, FECAL
CHIMOTRIPSIN AND SERUM LIPASE LEVELS IN
CF-PS, PI PATIENTS
L. Iapichino , G. Traverso , L. Termini , C. Di girgenti , S.1 1 1 2
Teresi , E. Guicciardini3 3
20 U.O. di Pediatria Centro Regionale Fibrosi Cistica1
ARNAS, Laboratorio Biologia molecolare ARNAS Paler-2
mo, Laboratorio Analisi G. di Cristina ARNAS Palermo3
Augarten et al. reported that serum lipase levels in CF are
genetically determined and are useful to establish the diag-
nosis of CF. Human pancreatic elastase 1 remains unde-
graded during intestinal transit and it s concentration in
feces reflects exocrine pancreatic function. Fecal chymo-
trypsin is normally used to monitorize pancreatic function
in CF-PS patients and to perform the diagnosis of CF-PI
patients. The study we present, was aimed to assess (1)
The relationship between serum lipase, fecal pancreatic
elastase and chymotrypsin in CF-PS and PI patients. (2)
Which of these may be considered parameter of shift from
PS to PI. We examined 3 groups of patients: PS, PI and
Normal subjects.
All PI patients had low levels (-10) of serum lipase and
fecal elastase (-100), 3 of them had serum lipase level
ranged 16–24, one of them (39 years old) was PS until 1
year ago. We consider him a PI–LC (Late Conversion).
The other 2 were children and we consider these borderline
values as effect of ending regurgitation of lipase into the
circulation, all had low levels of fecal chymotrypsin. All
the patients but one had two severe mutations. PS patients
can be divided in 2 groups:
1. PS™PI Late Conversion: They had normal values of
elastase and chymotrypsin and high levels of serum lip-
ase and we presume they will become PI. Some harbored
almost one mild splice mutation (3849q10 kb C™T,
2789q5G™A, 1341q18A–C)
2. PS they had normal values of elastase, lipase and chy-
motrypsin. Same of them harbored 5T splice mutation.
All normal subjects have normal lipase elastase and chy-
motrypsin levels. From this preliminary study, lipase is a
predictive index of PS–PI conversion, fecal elastase and
chymotrypsin seem to be the best parameters of PS–PI con-
version and indicate when it is necessary to begin pancre-
atic enzyme therapy.
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PROPER INTERPRETATION OF ELASTASE 1
ACTIVITIES IN STOOL: EXPERIENCE OF THE
PRAGUE CF CENTRE
H. Tomasova , D. Zemkova , J. Bartosova , V. Skalicka ,3 2 2 1
S. Kolouskova , J. Nevoral , M. Macek Jr. , V. Vavrova2 1 4 2
1st Paediatric Department, 2nd Paediatric Department,1 2
Institute of Biochemistry Institute of Biology and Medical3 4
Genetics, Charles University 2nd Medical School, Prague,
Czech Republic
We studied E-1 stool activities in our patients (pts) with
CF and insulin dependent diabetes mellitus (IDDM), com-
pared to random controls, to validate E-1 examinations as
a laboratory indicator of the pancreatic status.
Seventy-eight CF (mean age 9.8"6.1 years), 22 IDDM
(12.2"4.8) pts and 40 controls without pancreaticyintes-
tinal disorders (8.7"5.5) were examined (E-1 Bioserv kit;
D). Obtained results were compared to their nutritional stat-
us (NS), duration of IDDM (D-IDDM) and in CF pts to
their CFTR genotype.
In controls mean E-1 activities were 549.7"227.0 mgyg
(median, 555.0; range, 72.0–1020.0; 3. percentile ypct.y,
100.0; 10 pct, 230.0), while the usual ‘cut-off’ value of
200.0 ugyg was at the 7.5 pct. Three controls, with normal
sweat Cl , were below the cut-off: 1 case was obese, whiley
2 had acute infection without any NS deterioration. In CF
the mean was 63.7"134.4 (range 0.0–900.0) and E-1
activities positively correlated with the sweat Cl . How-y
ever, there was no E-1 association with NS due to pancre-
atic substitution. E-1 activities )200 were found in pts
with F508dely3849q10 kb C™T (2=), F508delyR347P
and CFTRdele2.3 (21 kb)yunk (1= each) genotypes. Gen-
erally lower E-1 activities were also found in IDDM—mean
304.5"188, with 6 cases -200. There was a non-signifi-
cant correlation with body weight (Ps0.06) and with D-
IDDM (Ps0.07). The latter observation is in agreement
with the fact that in adult IDDM patients the exocrine pan-
creas is also affected and requires further study.
In summary, lower E-1 activities do not automatically indi-
cate pancreatic insufficiency. When sweat Cl are normal,y
we recommend repeating E-1 examinations after respective
treatment. Therapeutic interpretations of E-1 activities in
CF patients should also take into account the overall clin-
ical status, stool lipid examination and the CFTR genotype.
Supported by MZCR: 5067-3, LN00A079, ME457,
00000064203.
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USEFULNESS OF FECAL ELASTASE 1 TEST IN
CHILDREN WITH CYSTIC FIBROSIS
S. Dumcius
Kaunas University of Medicine
There are not many data concerning the various aspects of
clinical value of fecal elastase-1 (E1) test in children with
cystic fibrosis (CF). The aim of this study was to evaluate
usefulness of E1 test for assessing exocrine pancreatic func-
tion in children with CF and gastrointestinal non-pancreatic
disorders.
We used ELISA kit for determination of E1 in faces
(ScheBO Tech GmbH).
A total of 58 children (30 girls and 28 boys) were evaluated
(31 with CF and 27 with gastrointestinal non-pancreatic
disorders). Median age was 11.16 yrs (range 6.21–15.2
yrs). In all patients E1 concentration was measured.
Among patients with CF according to fecal fat excretion 26
(83.9%) were clinically classified as pancreatic insufficient
(PI) and 5 (16.1%) pancreatic sufficient (PS).
For 28 children with CF (all 26 PI and 2 PS patients) E1
concentrations were below 200 mgE1yg stool. 8 (25.8%)
children with CF had no detectable E1 (-15 mgE1yg) and
3 (9.6%) had normal levels (E1 concentration )500
mgE1yg stool). All of them were clinically evaluated as
pancreatic insufficient. In the group of children with non-
pancreatic gastrointestinal disorders E1 concentration was
normal.
Conclusion: The differences of E1 concentration in stool
between children with and without CF were significant
(P-0.001). Determination of E1 in faces is reliable method
for assessing level of pancreatic insufficiency in children
with CF.
P239
INCREASE IN GASTROINTESTINAL SYMPTOMS
IN PATIENTS WITH CYSTIC FIBROSIS
FOLLOWING INTRODUCTION OF CREON 10000
L. Wilson, M. Chilvers, W. Stannard, C. O’Callaghan
University Hospitals of Leicester Cystic Fibrosis Centre,
Leicester, UK
Background: Enzyme replacement is needed for optimum
nutrition in the majority of patients with cystic fibrosis.
Close monitoring of enzyme requirements is needed to pre-
vent the occurrence of gastrointestinal symptoms. Recently,
the most commonly used enzyme preparation has changed
from 8000 to 10 000 units lipaseycapsule. In our centre, 70
children were switched to Creon 10000 and 10 were
observed to have increased gastrointestinal symptoms.
Aim: To analyse the symptoms and enzyme requirements
of patients who experienced gastrointestinal symptoms
when taking Creon 10000.
Method: Notes were reviewed before and after enzyme
supplement change from Creon 10000 to Pancrease for the
10 patients (4 male, mean age 10.6 yrs, range: 5–19 yrs).
Symptoms of abdominal pain, loose stools, distal intestinal
obstruction syndrome (DIOS) and patients lipase (Unitsy
kgyday) requirements were recorded.
Results: Prior to the change to Creon 10000, the mean
("95% Confidence Intervals (CI)) daily lipase require-
ment of Creon 8000 was 8900.0 UykgyDay ("2635.0 Uy
kgyDay). No children experienced significant
gastrointestinal symptoms. No significant difference in lip-
ase requirement was observed between the dose of Creon
8000 or Creon 10000 (Ps0.82).
Creon 10000 Pancrease
Abdominal pain (%) 9 (90) 1 (10)
Loose stools (%) 7 (70) 0 (0)
DIOS (%) 5 (50) 0 (0)
Mean daily lipase 8660.0 ("679.1) 6450.0 ("1225.7)
Dose (UykgyDay (95% CI))
On introduction of Creon 10000 patients experienced an
increased frequency of abdominal pain, loose stools and
DIOS. This resolved on changing to Pancrease. A
significant reduction in mean daily lipase requirement
was observed (2210.0"667.7 UykgyDay (P-0.001)).
Summary: On introduction of Creon 10000 we
observed an increase in gastrointestinal symptoms in
15% of children attending our cystic fibrosis clinic. This
resolved on changing pancreatic supplement.
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PANCREATIC ENZYME SUPPLEMENTATION IN
ENTERAL TUBE FEEDING IN CHILDREN WITH
CYSTIC FIBROSIS
J.M. Roze , R.H.M.A. van Lieshout , J.E. Dankert-1 1
Roelse , A.M. Stok2 3
University of Professional Education Arnhem and Nijme-1
gen, Department of Nutrition and Dietetics, VU University2
Medical Center Amsterdam, Department of Pulmonology,3
VU University Medical Center Amsterdam
Introduction: In cystic fibrosis (CF) pancreatic enzymes
are orally supplied as capsules enteric coated microspheres.
To infants also pancreatine powder is given. No consensus
exists as to the moment of supplementation of pancreatic
enzymes in children with CF given nocturnal tube feeding
1.
Objective: To investigate the way and moment of pancre-
atic enzyme supplementation in tube-fed CF children aged
0 to 18 years.
Method: A questionnaire was sent to paediatric dietitians,
gastroenterologists and pulmonologists, all members of a
CF-team, of 12 hospitals that lend specialised CF-care in
The Netherlands (8) and Belgium (4).
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Results: The response was 71%. Different answers were
given to:
– the way of administration (orally or by tube) (table)
– the advised nutrition to take the supplements with
– the moment of enzyme supplementation (table).
Way of administration of pancreatic enzyme supplements
in continuous nocturnal enteral feeding
Enzyme administration
discipline
Oral By
tube
Oral or
by tube
Not
applicable
(%) (%) (%) (%)
Dietitian 8 8 16 12
Gastroenterologist 8 0 16 0
Pulmonologist 8 4 16 4
Total 24 12 48 16
Moment of enzyme supplementation in continuous
nocturnal enteral feeding
Discipline Dietitian Gastroenterologist Pulmonologist Total
Moment ns11 ns6 ns8 ns24
Before start 0 0 1 1
(4%)
Before and
during
7 3 3 13
(52%)
Before and
after
2 2 2 6
(24%)
Before, during
and after
2 0 2 4
(16%)
Not applicable 0 1 0 1
(4%)
Conclusion: The policy of pancreatic enzyme
supplementation in tube-fed children with cystic fibrosis
differs between hospitals. The responses from different
specialists within one hospital are unequivocal.
Consensus on this topic is desirable.
Laag J. van der, M. Sinaasappel, H.G.M. Heijerman.
CBO Consensusbijeenkomst: Diagnostiek en
behandeling van cystic fibrosis. 1e druk, Alphen aan den
Rijn, 1998 (Consensus Statement in Dutch).
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PITFALLS IN THE USE OF C13 MIXED
TRIGLYCERIDE BREATH TEST
E. Robberecht, S. Van Biervliet, M. Vanderkerken
Cystic Fibrosis centre, Ghent, Belgium
The C13 mixed triglyceride (MTG) breath test is a non-
invasive method to evaluate fat absorption. Different cen-
tres recommend this test to optimise pancreatic enzyme
replacement therapy (PERT) in cystic fibrosis (CF)
patients. The test is however influenced by gastrointestinal
motility as will be clearly shown in this case report.
Case: A 9-year-old girl with CF and exocrine pancreatic
insufficiency progressively developed abdominal discom-
fort. She had steatorrhea and a weight loss despite a vora-
cious appetite. She spontaneously increased her dose of
lipase to 500.000 U a day without any effect on her com-
plaints. MTG breath tests were performed with different
dosages of Creon. The cumulative percentage dose recov-
ered (cPDR) was 6% without enzymes, 7.6% with 15.000
U and 10.3% with 40.000 U lipase. Since the acid environ-
ment of the duodenum in CF can impair the activation of
coated enzymes, the girl was started on 20 mg Omeprazole
a day. A MTG breath test was performed after 4 weeks of
treatment with 50.000 U lipase. The cPDR was 5.8%. As
the time-curve did not reach a peak within the 6 h of the
test, cisapride (3=10 mg) was added to the treatment reg-
imen to accelerate gastric emptying. The child clinically
improved and gained weight. The MTG breath test was
repeated. A normal curve was achieved with this treatment
regimen and 50.000 U lipase. The cPDR was 31.3%.
Conclusion: Apart from digestive and absorptive mecha-
nisms intestinal motility should be taken into account in the
interpretation of a MTG breath test. The presented case sug-
gests that, if the latter is disturbed Cisapride can help in
improving fat absorption.
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GROWTH AND PULMONARY FUNCTION OF CF
CHILDREN PRESENTING WITH MECONIUM
ILEUS
M. Nathan , S. Suresh , H.C. Ryley , I.J.M. Doull1 1 2 1
Department of Child Health, Department of Medical1 2
Microbiology, Univeristy of Wales, Cardiff, Wales, UK
Aim: To determine if infants presenting with meconium
ileus (MI) have a more severe clinical course than those
who do not.
Subjects and methods: Prospective, longitudinal follow up
of 3 groups of patients with CF; Grp 1, 22 subjects pre-
senting at birth with MI; Grp 2, 25 subjects detected
through newborn screening for CF; Grp 3, 27 subjects with
CF diagnosed following clinical presentation. Outcome
measures include weight, height and body mass index at
age 5, 10 and 15 yrs and pulmonary function (FEV1, FVC
and FEF25-75) at age 6, 10 and 15 yrs. Analysis of vari-
ance was used to determine differences between groups.
Results: Data were available at 5, 10 and 15 yrs in 20, 14
and 7 group 1 subjects, respectively; 24, 21 and 5 group 2
subjects; and 24, 14 and 7 group 3 subjects. Apart from a
small difference in FEF25-75 between groups at age 6
years, there was no significant difference in any parameter
between the 3 groups.
Conclusion: Infants who present with MI do not have a
more severe clinical course than either those who are
detected through newborn screening, or those who present
clinically.
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LONG TERM FOLLOW-UP OF CF PRESENTING
AS MECONIUM ILEUS: AN EXPOSED–
UNEXPOSED MATCHED COHORT STUDY
A. Munck , M. Gerardin , C. Alberti , C. Ajzenman , M.1 1 2 1
Lebourgeois , Y. Aigrain , J. Navarro1 3 1
Gastroenterology, Hospital Robert Debre, ParisyFrance,1
Public health, Hospital Robert Debre, ParisyFrance, SUR-2 3
GERY, Hospital Robert Debre, ParisyFrance
This retrospective study compares the outcome of CF
patients with or without a positive history of meconium
ileus (MI).
Method: 26 children older than 7 with MI have been
matched for sex, birth date, youngest CF diagnosis and
assessed in one CF center (1978–1994). CFTR genotype,
birth weight, age at CF diagnosis, survival, complications
have been recorded; nutritional status (BMI), lung function
tests (LFT) (FVC, FEV1) and SatO2 have been evaluated
at 1, 3, 6, 10 and 15 years (y). Results have been expressed
as count (%) for qualitative variables and median (first-
third quartiles) for quantitative variables. Comparisons used
x or Fisher’s exact test and Kruskal–Wallis’ test.2
Patients: 26 MI (13 F–13 M) were matched with 26
nonMI (nMI) CF and followed for a median of 12.5 y (10–
17). MI management was medical for 31% and surgical for
69%. A nutritional support was prescribed for all surgical
patients. All the patients are alive.
Results: Genotype, median birth weight, pancreatic insuf-
ficiency were similar in both groups. Age at CF diagnosis
was younger in the MI group (m) 1 (0–3) vs 3.5 (2–23)
(Ps0.003). Considering complications we did not find any
difference in the occurrence of chronic infection by Pseu-
domonas aeruginosa, aspergillosis, diabetes, pancreatitis,
liver alterations (steatosis MI 42%, nMI: 18% (Ps0.07),
cirrhosis (MI 1, nMI 0). Nutritional status assessed by BMI
showed no significant differences between groups at 10
(ns23) (MI:16.1 (14.9–17.6) nMI:16.1 (14.9–17)) and
even at 15 y old (ns11) (MI:19.0 (16.6–21.3) nMI:19.4
(17.3–19.9)). LFT did not differ significantly with regard
to FVC at 10 (ns23) (MI:90 (78–104) nMI:100 (87–
107)) and 15 y old (ns11) (MI:76 (75–93) nMI:80 (62–
87)), FEV 1 at 10 (ns23) (MI:76 (69–98) nMI:94 (78–
101)) and 15 y old (ns11) (MI:66 (56–92) nMI:74 (54–
81) and SatO2.
Conclusion: MI does not represent a risk factor for patient
s life. Adequate nutritional and medical management of MI
allow similar nutritional status and LFT in comparison with
other CF patients.
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SOMATIC DEVELOPMENT ANALYSIS OF
CZECH CF CHILDREN AGED 0–3 YEARS (1998–
2001)
V. Skalicka , D. Zemkova , Z. Vancikova , J. Bartosova ,1 2 1 2
V. Vavrova2
1st Department of Paediatrics, Charles University, 2nd1
Medical School, University Hospital Motol, Prague, Czech
Republic, 2nd Department of Paediatrics, Charles Univer-2
sity, 2nd Medical School, University Hospital Motol,
Prague, Czech Republic
Introduction: The age of 0–3 years is a very critical period
for the future development of patients with CF. Early diag-
nosis and intensive treatment are essential.
Aim of study: Analyse the correlation of the development
of anthropometrical parameters versus age of diagnosis,
caloric intake, microbiological colonization and
complications.
Patients and methods: 29 patients aged 0–3 were
observed for at least 6 months, 24 of them for more than
1 year. 27 (93%) were pancreatic insufficient and 2 (7%)
pancreatic sufficient. Supervised anthropometrical parame-
ters (height, weight, weight-to-height, mid-arm circumfer-
ence, head circumference, abdominal circumference) were
considered: at the time of diagnosis, at 6 months and 12
months after diagnosis. Contemporarily, caloric intake, air-
way colonization and complications were monitored.
Results: Marked improvement occurs in the first 6 months
of treatment after diagnosis. Weight improved from
"2.211.3 S.D. to "1.311.2 S.D., P-0.001. Improvement
is more significant in patients with more severe weight defi-
ciency at diagnosis (Ps0.002), it is dependent on caloric
intake and independent on the age of diagnosis. Progress is
less significant between 6th–12th months of treatment
(weight: from "1.311.2 S.D. to "111.9 S.D.), it is indi-
rectly dependent on the weight at 6 months of treatment
(Ps0.002) and not significantly dependent on caloric
intake; the energy need is individual, depending on the clin-
ical status. 12 patients had Pseudomonas aeruginosa airway
colonization; no difference in supervised parameters was
found if compared with non-colonized ones.
Conclusions: Improved therapy led to the decrease of mor-
tality to zero and to the nutritional and developmental
improvement in patients 0–3 years in our center.
Supported by MSMT 111300003.
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AUDIT OF DIETETIC ANNUAL REVIEW
S. Williams, J. Barrett, D. Honeybourne, D. Stableforth
Birmingham Heartlands Hospital, Bordesley Green East,
Birmingham, UK, B95SS
Annual assessment of all adult cystic fibrosis (CF) patients
has been introduced as a means of ensuring all patients are
assessed routinely to provide the best possible multidisci-
plinary care. An audit of this dietetic annual review was to
assess efficacy, nutritional status, the dietary practices of
our patients and to assess protocol design. Dietetic records
were reviewed and data were recorded. These data were
analysed using Microsoft Excel. 135y225 (60%) patients
had undergone at least one annual dietetic review. 35y135
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(26%) of patients had a diagnosis of cystic fibrosis related
diabetes. 52y135 (39%) of patients used nutritional sup-
plements. 9y135 (7%) used overnight feeding. The mean
body mass index (BMI) for males (ns71) was 21.6 kgy
m and for females (ns64) was 21.3 kgym . 19 patients2 2
(14%) had a BMI-19 kgym . 123y135 (91%) of patients2
were pancreatic insufficient 22 of these patients took doses
in excess of 10 000 ulipaseykgbody weightyday. 94y135
patients (69%) had vitamin levels assessed. Mean serum
vitamin A was 1.61 mmolyl, vitamin D 17.2 mgyl and vita-
min E 19.6 mmolyl.20 patients (21%) had vitamin levels
below the reference range. 96y13 (71%) patients had arm
anthropometry measured. Males mean MAC 24.4 cm-5th
percentile mean TSF7.25 mm -25th percentile, mean
midarm muscle circumference (MAMC) 24.2 cm -10th2
percentile. Females had a mean MAC 25.1 cm and mean
TSF 13.7 mm both -25th percentile, mean MAMC 22.7
cm -75th percentile. 82% of the sample had BMI within2
the healthy range (20–25 kgym ). Arm anthropometry2
showed an improvement with increasing BMI. 94% had
MAMC values-50th percentile which supported the need
for exercise in combination with nutritional advice, to pro-
mote weight gain as muscle. We have developed a protocol
for patients on lipase dose)10 000 uykg and are currently
writing a vitamin policy to improve levels. A specific doc-
ument for annual nutritional assessment facilitates a com-
prehensive dietetic review, highlights suboptimal therapy
and allows advice to be focuses on the individuals
assessment.
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DEVELOPMENT OF A BEHAVIOURAL
NUTRITION EDUCATION STRATEGY FOR
ADULTS WITH CYSTIC FIBROSIS
H. Watson , D. Bilton , H. Truby1 1 2
Adult CF Centre, Papworth Hospital, Cambridge, UK,1
University of Surrey, UK2
Chronic pulmonary disease is the main cause of morbidity
and mortality in cystic fibrosis. Recent research has shown
a significant relationship between good nutrition and sur-
vival. A meta analysis of nutrition intervention for weight
gain in CF recommended a randomised controlled trial of
a nutrition education and behavioural intervention. Phase 1
involved the development of a programme, a pilot study
and peer review. Phase 2 evaluates its effectiveness on
nutritional status and dietary intake compared to standard
dietary management. The programme was developed fol-
lowing qualitative analysis of focus groups. This enabled
an informed approach to developing a suitable model. The
programme ‘Eat well with CF’ comprises of modules of
learning that are structured to take 30–40 min per week to
complete over a 10 week period. It includes weekly chal-
lenges which are based on social learning theory. This was
adopted as a framework for establishing new behaviours.
The programme was peer reviewed by 5 UK CF specialist
dietitians and 1 international CF specialist dietitian. The
aim of the review was to assess validity of the programme
and gain expert opinion on content and age appropriateness.
The peer review showed dietitians rated the pack highly,
although the appendix was rated poorly and was subse-
quently removed. The comments were otherwise positive
and have confirmed the unique nature of ‘Eat well with
CF’. This was confirmed in a pilot study at an independent
matched CF centre. All participants felt their nutrition
knowledge would be improved by completing the pro-
gramme and that their eating habits would change as a
result of such an intervention.
The results of the pilot study demonstrated that the overall
structure of the programme was good and contained suffi-
cient motivators to enable successful recruitment and
retention.
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ASSESSMENT OF ENERGY AND NUTRIENT
INTAKE OF GERMAN CF-PATIENTS
U. Mueller , B. Palm , G. Dockter , H.G. Posselt , J.1 2 2 1
Bargon3
University Hospital Frankfurt, Department of Pediatrics,1
University of Saarland, Clinic for Children and Adoles-2
cents CF Department, Homburg, St. Elisabethen Hospital,3
Department of Internal Medicine
Introduction: When growing older, osteoporosis is seen in
many CF-patients. Osteoporosis itself is promoted by mal-
nutrition and insufficient calcium-intake. The target of this
investigation was to examine, whether CF-patients are
reaching the common reference values of Germany, Austria
and Switzerland, corrected for the need of CF-patients for
energy (130%), fat (40%), carbohydrates (40%), protein
(20%) and calcium.
Method: 131 males and 122 females from 11 German CF-
treatment-centers have been included (age: 0–61 yrs). With
the help of weight and height wyh-ratio was calculated.
Mean intake of calories, fat, carbohydrates, protein and cal-
cium was determined by dietary records and compared with
reference values according to age for CF-patients. The
patients were classified in 4 age-groups (g1: 0–-4 yrs, g2:
4–-10 yrs, g3: 10–-16 yrs, g4: )16 yrs).
Results: Normal wyh-ratio was seen in 2y3 of the patients
(g1: range 76.1–173.3; g2: range 80.4–121; g3: range
77.9–110.8; g4: range 67.6–126.5), but in older patients
there was a significant drop in wyh-ratio (Ps0.008). Wy
h-ratio became significantly worse in males than in females
(P-0.005). Likewise intake of energy, fat and carbohy-
drates decreased markedly. None of the CF-patients
received calcium supplement.
Discussion: Although normal wyh-ratio was seen in 2y3 of
the patients none of the age-groups reached the reference
values for energy intake for CF-patients. The worsened wy
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h-ratio in older patients correlated with decreased intake of
energy, fat and carbohydrates. Calcium-intake has been
nearly 100% referred to reference values. However refer-
ence values for calcium were not corrected for needs of
CF-patients, because reference values for CF are missing.
Conclusion: Possibly CF-patients have an additional
requirement for calcium. To assess this requirement further
studies are needed. Furthermore dietary advice should be
focused more on older CF-males than now.
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TRENDS IN THE NUTRITIONAL STATUS OF A
COHORT OF CHILDREN WITH CYSTIC
FIBROSIS
J. Lowdon, K.J. Walker, H. Anthony, I.J.M. Doull
Cystic Fibrosis Unit, UHW, Cardiff, UK
Aim: To identify trends in the nutritional status of a cohort
of children with CF.
Subjects: 186 (103 m) analysed cross-sectional at mean
ages of: Set I 11.1 yrs (0.11), Set II 7.0 yrs (0.17), Set III
11.0 yrs (0.19), Set IV 14.0 yrs (0.18).
Method: Mean Wt, Ht, Body Mass Index (BMI) and %Ide-
al Wt for Ht (%IWH) at annual assessment, over 15 yrs,
were analysed. Cohort was split by gender.
Results: Mean Ht Z score Set I 0.7 (1.2), Set II 0.6 (1.1),
Sets III and IV had mean scores of 0.6 (0.9) and 0.9 (1.1),
respectively. No significant differences between the sexes.
Mean Wt Z scores Set I 0.6 (1.1), Set II 0.4 (1.2), Set III
0.3, Set IV 0.7. No significant differences between the sex-
es. Overall, Wt Z scores for each set increased to above
average and then began to decrease below the average of
healthy children, demonstrating an overall decline in nutri-
tional status with age. BMI Z score Set I 0.34 (0.9), Set II
0.03 (1.0), Set III 0.03 (1.1), Set IV 0.05 (1.08). No sig-
nificant differences were found between the sexes. Overall,
BMI Z scores of each set increased from below to above
average in males and from below to above average and then
a decrease in females. Mean %IWH Set I 95.2 (8.9), Set
II 98.5 (12.7), Set III 99.5 (18.2), Set IV 95.0 (16.4). No
significant differences between the sexes. In each set the
children achieved weights below that required for their
height. The percentages increase approximately 11 yrs but
decline in adolescence.
Conclusion: This confirms the results of previous findings
that children with CF have below average nutritional status
compared to a healthy population and worsens as they enter
puberty. Although there were no differences between gen-
ders the decline observed occurred to a greater extent in
females.
Lai H.C., Kosorok S.A., Farrell P.M.(1998) Growth status
in children with CF based on national CF patient registry
data: evaluation of various criteria used to identify malnu-
trition. J Pediatr 132:478–485.
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A COMPARISON OF ANTHROPOMETRIC
MEASUREMENTS IN A COHORT OF INFANTS
WITH CYSTIC FIBROSIS
J. Lowdon, K.J. Walker, H. Anthony, I.J.M. Doull
Cystic Fibrosis Unit, UHW, Cardiff, Wales, UK
Aim: To determine the relative value of different measures
of nutritional status for use in infants with cystic fibrosis
less than 2 years of age.
Subjects: 86 infants (47 m), mean age 1.05 yrs (0.114,
1.0–1.99), divided into 3 categories of graded nutritional
state (Table 1).
Method: Mean weight and height, Body Mass Index
(BMI) and %Ideal Weight for Height (%IWH) at annual
assessment, over 15 yrs was analysed.
Results: (1) Measurements of height and weight Z scores
were highly correlated (P-0.001, rs0.685). (2) BMI Z
scores showed significant correlations with all growth
measurements, (weight P-0.001, rs0.687, %IWH P-
0.001, rs0.882), except height Z scores, where it was
found to have no correlation. (3) %IWH showed significant
correlations with weight (P-0.001, rs0.939), height (P-
0.001, rs0.397) and BMI Z scores (P-0.001, rs0.882),
but no categorical agreement with BMI.
Conclusions: (1) The agreement and correlation found
between the measurements of height and weight indicate
that these provide reliable methods in the measurement of
nutritional status for this age group. However, they should
be used in conjunction with each other to avoid a biased
view. (2) There is no agreement between the categories of
BMI and %IWH in the ability to classify nutritional status;
therefore suggesting that using the particular anthropomet-
ric measures would classify subjects differently in this age
group.
Categories of nutrition %Ideal weightyheight Z Score
1 -85% y4.0 to 1.04
2 86–100% y1.039 to 1.03
3 )101% 1.031 to 4.0
Ramsay B.W., Farrell P.M. Pencharz. (1992) Consensus
Committee. Nutritional assessment and management in
cystic fibrosis: a consensus report. Am J Clin Nutr. 55
108–116.
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BODY COMPOSITION ASSESSMENT IN
ADULTS WITH CYSTIC FIBROSIS:
COMPARISON OF DUAL ENERGY X-RAY
ABSORPTIOMETRY (DEXA) WITH SKINFOLDS
AND BIOELECTRICAL IMPEDANCE ANALYSIS
(BIA)
S. King , J. Wilson , T. Kotsimbos , M. Bailey , I.1 2 2 3
Nyulasi1
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Nutrition Department, Alfred Hospital, Melbourne, Aus-1
tralia, Cystic Fibrosis Service, Alfred Hospital, Melbourne,2
Australia, Department of Epidemiology and Preventive3
Medicine, MonashUniversity, Melbourne, Australia
Poor nutrition is associated with poor survival in cystic
fibrosis (CF). In order to assess body composition and to
be able to evaluate the effect of nutritional supplementation,
it is important to use reliable and accurate methods.
Aim: To compare body composition in adults with CF
using two non-invasive methods (skinfolds and BIA), with
DEXA, which is a reliable and accurate method.
Methods: Seventy-six adults with CF (61% male, mean
age 29.9 years (range 19–59 years), mean BMI 21.5 kgy
m (range 17.2–28.8)) were studied. Body composition2
was measured to calculate %body fat using (1) DEXA
(Lunar); (2) Skinfold thicknesses at four sites using stan-
dardised Harpenden callipers (British Indicators Ltd) with
%fat calculated using the equations of Durnin and Wor-
mersley and (3) BIA using a SEAC Multiple Frequency
Bioimpedance Meter (Uniquest Ltd) with %fat calculated
using the equations of Segal.
Results: Mean (S.D.) %fat measured using DEXA was
12.4 (6.5)% in males and 24.1 (6.6)% in females. Mean
(S.D.) %fat measured using skinfolds was lower: 9.0
(4.3)% in males and 21.7 (5.3)% in females. Mean (S.D.)
%fat measured using BIA was 15.4 (5.1) for males and
21.0 (5.4)% in females (P-0.001 for comparisons with
DEXA %fat using paired t-tests).
Skinfolds in males and females and BIA in women signif-
icantly underestimated %fat, while BIA in men signifi-
cantly overestimated %fat. The 95% limits of agreement
(1) with DEXA %fat were 9.7 to 3.7 for skinfolds; and
10.5 to 11.1 for BIA (Segal), suggesting that both skinfolds
and BIA will incorrectly predict %fat in many adults with
CF.
Conclusion: %fat measured using skinfolds and BIA sig-
nificantly differs from %fat measured using DEXA. There-
fore the use of DEXA is recommended for the assessment
of body composition in adults with CF.
Supported by the Australian Cystic Fibrosis Research Trust.
1. Bland, J.M. and Altman, D.G. (1986) Statistical methods
for assessing agreement between two methods of clinical
measurement, Lancet, I, 307–310.
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THE IMPROVED NUTRITIONAL STATUS AS AN
INDICATOR FOR BETTER MANAGEMENT OF
CYSTIC FIBROSIS PATIENTS IN MACEDONIA
S. Fustik, N. Slaveska, L. Spirevska
Pediatric Clinic, Clinical Centre, Skopje, Macedonia
Malnutrition and growth retardation are common compli-
cations of cystic fibrosis (CF), adversely affecting prog-
nosis of the disease. Therefore, the maintenance of adequate
nutritional status is one of the priorities of the CF
management.
In 1996 a specialised CF centre was established at the Pedi-
atric Clinic in Skopje with the goal of providing up-to-date
forms of CF treatment. To assess the impact of the newer
therapeutic approaches on nutritional status of CF individ-
uals, we have analyzed the anthropometric indexes of the
patients such as z score for weight—zW, z score for
height—zH, z score for weight for height—zWyH, and
body mass index—BMI (for patients older than 9 years) in
two different periods: 1995 and 2001. Data from 43 patients
(23 males, 20 females) in 1995 and 53 patients (32 males,
21 females) in 2001, aged from 1 to 18 years, were includ-
ed in study. Mean values of the anthropometric indexes and
standard deviation (in parentheses) of the CF patients in
1995 and 2001 were, respectively: zWsy1.58 (1.00) to
y0.67 (0.99), zHsy1.11 (0.95) to y0.43 (1.05), zWy
Hsy1.25 (1.02) to y0.38 (0.69), and BMIs14.32
(1.12) to 17.2 (2.74).
Statistical comparisons between two studied groups (Stu-
dent’s t-test) showed significantly higher mean values of
all anthropometric indexes (P-0.0001 and P-0.001) in
2001 vs. 1995.
In conclusion, the results from the study suggest that the
development of specialised CF centre and the improvement
of overall treatment of CF (mainly the regular patients’
controls, the aggressive treatment of pulmonary infections,
and the meticulous attention to nutrition) are associated
with the important improvement of the nutritional status
and growth of CF patients in Macedonia.
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FRUIT AND VEGETABLE INTAKE OF SCHOOL
AGE CHILDREN WITH CYSTIC FIBROSIS
ATTENDING A REGIONAL CF CENTRE IN THE
UK
F. Bartlett , J. Price1 2
Department of Nutrition and Dietetics, Department of1 2
Child Health, Kings College Hospital, London, UK
There is increasing interest in the role that phytochemicals,
of which fruit and vegetables are a rich source, might play
in chronic lung diseases. Nothing is known about the fruit
and vegetable intake of British children with Cystic
Fibrosis.
Aims: To establish the amounts and types of fruit and veg-
etables regularly eaten by children with CF and compare
them to data from the recently published, National Diet and
Nutrition Survey of British school age children.
Methods: Food diaries of children between the ages of 4
and 18 years, invited for annual review at a large regional
CF centre in the South East of England, during the years
1995–2000, were audited for fruit and vegetable intake.
The food was not weighed and no attempt was made to
estimate the size of the servings. Data was compared to the
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NDNS. NDNS data were collected from the diets of chil-
dren UK wide, from weighed 7 day diaries in January–
December 1997.
Results: 79 CF patients had completed at least one food
diary over this period (mean no of days recorded per child,
8.3, range 3–15). The mean average intake of servings of
fruit and vegetables per day (inclusive of fruit juice) was
1.7 (0.1–0 6.4) compared to 2.2 servings for NDNS chil-
dren. 1 in 3 CF children, had not eaten any whole fruit
during the data collection period, compared to 1 in 5 of the
NDNS children. Apples followed by bananas were the most
commonly consumed fruits in both groups. The most com-
monly consumed vegetables were, respectively; peas, car-
rots, baked beans, broccoli, sweetcorn and tomatoes. Nutsy
nut products were consumed by 32% of children with CF,
compared to only 15% of children in the NDNS. There was
no correlation between weight for height percentage and
daily intake of fruit and vegetable intake (Ps0.724).
Conclusions: Children with CF eat less fruits and vegeta-
bles than children without CF. The consequences of this are
not known. There appears to be no correlation between fruit
and vegetable intake and nutritional status.
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FAT SOLUBLE VITAMIN STATUS OF A COHORT
OF ADULT CF PATIENTS
J. Al-Siaidi , N.A. Jarad1 2
Adult CF Unit Bristol Royal Infirmary Bristol BS2 8HW1
UK, Adult CF Unit Bristol Royal Infirmary Bristol BS22
8HW UK
Aims of study: Malabsorption of fat-soluble vitamins is
common in most patients with C.F. It has become part of
routine practice to supplement patients with vitamins A, D
and E and to monitor their plasma levels annually.
The aim of this retrospective study was to determine the
prevalence of sub-optimal serum vitamin levels in this
group and whether levels correlated with age, Body Mass
Index (BMI) or haemoglobin (Hb).
Methods: At annual review 54 patients (24 female), mean
age 23.7 years, (range 17–40) had their serum vitamins A,
E, 25 OHD and blood Hb measured. For those with pan-
creatic insufficiency, fat soluble vitamins were routinely
prescribed according with National Guidelines. Age and
BMI were also recorded. This study reflects over a 2-year
period, evaluating the most recent annual review. The cor-
relation between vitamin levels, age, BMI and Hb (vit E
only) was evaluated by simple regression analysis.
Results: For Vit A, Vit E and Vit D, 30%, 21% and 40%
of patients, respectively, had sub-optimal vitamin levels.
There was a correlation between serum levels of Vit A and
Vit E (rsq0.39, Ps0.004). BMI correlated with Vit A
levels (rsq0.3, Ps0.03), but not with Vit E level (rs
q0.23, Ps0.1). Vitamin E level correlated with the blood
Hb (rsq0.32, Ps0.02).
Vit D levels did not correlate with any of the factors inves-
tigated. There was no correlation between Vitamin levels
and age.
Levels of Vits A, D and E remain low in 20–40% of
patients despite supplementation.
Conclusion: This study confirms that there is a correlation
between Vit A and E levels. Vitamin A level correlates with
BMI whereas Vit E level correlates with blood haemoglo-
bin. Compliance with vitamins and the level of supplemen-
tation warrants further study.
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CIRCULATING PLASMA RETINOL
CONCENTRATIONS AND INFECTION IN
PATIENTS WITH CYSTIC FIBROSIS
A.L. Cawood , J.L. Murphy , M.P. Carroll , D. Serisier , J.1 1 2 2
Jackson , P. Afolabi , S. Wootton1 1 1
Institute of Human Nutrition, University of Southampton,1
Department of Respiratory Medicine, Southampton2
UniversityHospitals Trust, Southampton, UK
Aim: To investigate the extent to which infection influences
circulating retinol concentrations in Cystic Fibrosis.
Methods: Complete clinical records and plasma retinol
concentrations were available from 44 patients with cystic
fibrosis that attended the CF centre between 1999 and 2001
for annual assessment. Of these, 6 patients had circulating
plasma retinol and C-reactive protein (CRP) measured dur-
ing treatment following infective exacerbation.
Results: From the clinical records the mean plasma retinol
concentration of the group was 1.79"0.9 mmolyl ranging
from 0.4–4.8 mmolyl. Tertile analysis of results revealed
that the patients with the lowest plasma retinol concentra-
tions (0.4–1.2 mmolyl) had significantly greater IgG (mean
20 gyl) and CRP (mean 25 mgyl) concentrations than those
with the highest circulating plasma retinol (1.9–4.2 mmoly
l) (P-0.05). Plasma retinol was negatively associated with
serum IgG (rsy0.41; P-0.01) and CRP concentrations
in patients with a CRP)6 mgyl (rs0.41; Ps0.07). In
addition, there was a significant increase in plasma retinol
during treatment following infective exacerbations. Mean
plasma retinol concentrations on admission were
0.92"0.26 mmolyl and rose to 1.27"0.67 mmolyl and
1.65"0.31 mmolyl by day 7 and 14, respectively. Plasma
retinol concentrations at day 14 were significantly different
from those at admission (P-0.01). Concurrently, mean
CRP concentrations fell from 22.6"16.7 mgyl to 5"3.9
mgyl (Ps0.07).
Conclusion: This work reinforces the view that plasma ret-
inol concentrations should be monitored with a marker of
infective status in order to differentiate between infection-
induced hyporetinolaemia or a problem associated with stat-
us, before any adjustment to vitamin A supplementation is
made.
Work supported by the CF trust.
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HOW MUCH VITAMIN E IS ENOUGH?
D. Tjesic-D, D. T.-Drinkovic, A. Votava-Raic, D. Puzevski,
T. Voskersensky, J. Kelecic, D. Richter
Department of Pediatrics, University Hospital Center,
Zagreb
Patients with cystic fibrosis (CF) have significantly
decreased plasma levels of vit. E, an antioxidant, due to fat
malabsorption and chronic pulmonary inflammation. Rec-
ommendations for vitamin supplementation vary widely.
Our patients are advised to take 200 I.U. per day. The aim
of this study was to evaluate the efficacy of this supple-
mentation dose.
17 children taking 200 I.U. of vit. E for at least 6 months
have been investigated (10 girls, 7 boys; median age: 3
years, all PI and on enzyme therapy). Mean plasma vit. E
level was low: 4.22"2.56 mgyl (normal range: 5.8–16.8
mgyl); only 3 children (18%) were within the normal
range. Expressed per gram of total lipid (cholesterolqtrig-
liceridesqphospholipids), which is a better indicator of
stores, the mean vit. E:lipid ratio was 1.19"0.66 mgyg, i.e.
above the reported lower limit of normal, with 71% of
patients (12 out of 17) within the normal range. No patient
developed values above normal for vit. E.
To evaluate usefulness of different doses on vit. E status
for the same child, a subgroup of 10 subjects that formerly
took 100 I.U. vit. E daily was additionally studied. Results
are as follows (for 100 I.U. and 200 I.U., resp.): mean
plasma vit. E level was 2.86"0.91 mgyl and 4.69"1.93
mgyl; mean vit. E:lipid ratio was 0.83"0.34 mgyg and
1.38"0.64 mgyg. Plasma concentration was low in both
measurements, but significantly lower while taking 100 I.U.
(Ps0.002). Vit. E:lipid ratio was borderline while on 100
I.U. and increased significantly to normal value during 200
I.U. supplementation (Ps0.002); 8 patients out of 10
(80%) reaching normal ratio.
We believe these data support our recommendation to start
vit. E supplementation with 200 I.U. daily. It is safe and
useful for the majority of CF patients, while 100 I.U. is
insufficient in more than 50% of cases. Nevertheless,
;30% of patients would need a higher dose to reach vit.
E normal values, so periodic checkups and individual dose
titration is necessary.
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STATUS OF BONE MINERAL CONTENT IN A
GROUP OF CHILDREN WITH CYSTIC FIBROSIS
J. Lowdon, M. Nathan, I.J.M. Doull
Paediatric CFyRespiratory unit, Department of Child
Health, University Hospital of Wales, Cardiff, Wales
Aim: To determine the bone mineral content (BMC) in a
paediatric CF population and its associated risk factors.
Subjects: 25 children with CF (15 m), age 6–17 years and
58 normal controls (29 m) age 6–18 years. The subjects
with CF had a mean wt SDS 0.15 (y1.76–2.49), mean ht
SDS y0.73 (y3.0–1.84), mean BMI SDS 0.62 (y1.19–
2.4), mean %wtyht 114% (84–143%). Four have gastros-
tomy feeds, 6 use nutritional supplements and 4 are on
long-term oral corticosteroids. Baseline anthropometric data
and 3 day food intakes were collected on each CF subject.
Method: Duel-energy X-ray absorptiometry (DEXA) of
lumbar spine (LS) and total hip BMC (TH) was performed
using a Hologic QDR 1000yW densitometer. Normal ref-
erence ranges were generated from the normal controls with
corrections for bone area, age, sex, height, weight and
pubertal status.
Results: The mean standard deviation score (SDS) for the
CF subjects was y0.33 for LS (range y3.03 to 1.65),
while mean SDS for TH wasy0.27 (rangey1.79 to 2.57).
Only 2 subjects had BMC values outside 2 SDS, both for
LS. Both are on long-term oral corticosteroids and one has
associated diabetes. Mean energy intake for the CF subjects
was 130% EAR (range 77–182%), with Calcium meeting
254% RNI (range 94–453%) and Vitamin D 3.82 ugyday
(range 0.6–11.0). There was no correlation between dietary
intake or nutritional parameters and BMC.
Conclusion: In our population the vast majority of subjects
had normal BMC.
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HYPERCALCIURIA IN CYSTIC FIBROSIS
S. Nousia-Arvanitakis , M. Fotoulaki , A. Makedou1 1 2
Fourth Department of Pediatrics, Aristotle University,1
Biochemical Laboratory, Fourth Department of Pediatrics,2
Greece
Abnormal CFTR in the cystic fibrosis (CF) apical epithelial
membranes is responsible for an ion transport defect. The
kidney is an organ most exquisitely adapted for ion trans-
port. The aim of this study was to measure urinary calcium
(Ca) excretion as an indirect parameter for Ca transport in
the kidney.
Methods: Forty CF patients, 35 having well-controlled
pancreatic insufficiency and 5 pancreatic sufficient, with an
age range of 5–35 years and clinical scores between 45 and
97 were investigated. Forty normal individuals matched for
age and sex served as controls. Measurements of 24-h uri-
nary Ca and creatinine (Cr) exertion were made. The Cay
Cr ratio was calculated. Urine was examined for the
presence of erythrocytes. Blood levels of Cr, Ca, phospho-
rus (P), potassium (K), bicarbonates (HCO ) and hydrogen2
ion concentration were obtained.
Results: In the controls, Ca exertion ranged from 0.30 to
3.90 (mean: 2.09"1.15) mgyKgy24 h and CayCr ranged
from 0.02 to 0.25 (mean: 0.08"0.05). In CF, Ca exertion
ranged from 0.30 to 10.20 (mean: 3.02"2.26) mgyKgy24
h and CayCr ranged from 0.04 to 0.60 (mean:
0.18"0.14).There was significant difference in the Ca
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excretion (t: 4.443, P-0.001) and CayCr ratio (t: 7.431,
P-0.001) between the two groups. Ten CF patients had
urine Ca exceeding 4 mgykgy24 h and CayCr ratio)0.2
(upper normal limit). There was no difference between pan-
creatic insufficient and pancreatic sufficient CF patients.
Serum values of Cr, Ca, P, K and HCO were normal.2
Hematuria or acidosis was not detected.
Conclusions: Increased Ca excretion was demonstrated in
25% of CF patients. Conditions associated with hypercal-
ciuria including malabsorption were eliminated. The
absence of hematuria may be attributed to a pathogenic
mechanism different from that of idiopathic hypercalciuria
or to the presence of protective factors. These data suggest
that a renal defect of Ca transport may be involved in CF.
This finding needs further elucidation with more specific
Ca transport studies in the kidney tubule.
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BONE MINERAL AND BODY COMPOSITION IN
CHILDREN WITH CYSTIC FIBROSIS
S. Conway , B. Oldroyd , K. Brownlee , S. Wolfe , S.1 2 1 1
Evans J. Truscott1 2
Regional Paediatric Cystic Fibrosis Unit, St James’s Uni-1
versity Hospital, Leeds, UK, Centre for Bone and Body2
Composition Research, The General Infirmary, Leeds, UK
We have previously shown that osteopeniayosteoporosis is
prevalent in adolescents and adult patients with cystic fibro-
sis (CF).
This study was initiated to determine if low bone mineral
density (BMD) was prevalent in prepubertalypubertal CF
children, who may have impaired growth and development
due to malnutrition, corticosteroid therapy, delayed puberty
and reduced physical activity. Interpretation of BMD meas-
urements in growing children is complicated as results are
dependent on age, pubertal stage and body size. It may be
necessary therefore to normalise for body size in children
with CF.
Currently (107) CF and (100) control children, age range
5 to 16 years have been recruited. The two groups were
sub-divided by gender into (3) groups according to pubertal
stage: prepubertal (stage 1), early pubertal (stages 2 and 3)
and late pubertal (stages 4 and 5). Measurements of BMD
were made at the lumbar spine (L2–L4) and total body
using a GeyLunar Prodigy Absorptiometer (Analysis ver-
sion 2.26). Age matched Z-scores were derived from the
manufacturers USA white children reference ranges. Body
composition consisting of total body lean tissue (TBLean),
fat (TBF), bone mineral content (TBBMC) and %TBF
were obtained from the total body scan. Height (Ht),
weight (Wt) and body mass index (BMI) age matched Z-
scores were derived from the 1990 British reference
standards.
The CF group had only mild growth impairment, Z-scores,
mean (s.d.), for Ht, Wt and BMI were y0.45 (1.0), y0.6
(1.1) and y0.5 (1.2). The same parameters for the control
group were: 0.3 (1.1), 0.4 (1.1) and 0.3 (1.1). Age matched
Z-scores at the lumbar spine and total body indicated low
BMD (-y1 s.d.) for CF: 40%, 20% and controls 21, 5%,
respectively. %TBF had increased values in controls com-
pared to CF for all groups. The effect of normalisation for
body size utilising TBLean is being studied and will be
reported.
This study was supported by a grant from the Cystic Fibro-
sis Trust.
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BONE TURNOVER IN CHILDREN WITH CYSTIC
FIBROSIS
S. Conway , B. Oldroyd , K. Brownlee , S. Wolfe , S.1 2 1 1
Evans , W. Fraser , J. Truscott1 3 2
Regional Paediatric Cystic Fibrosis Unit, St James’s Uni-1
versity Hospital, Leeds, UK, Centre for Bone and Body2
Composition Research, Leeds General Infirmary, Leeds,
UK, Department of Clinical Chemistry, University of Liv-3
erpool, Liverpool, UK
The aim of the study was to assess bone turnover in a group
of children with cystic fibrosis (CF) and to evaluate the
relationship between bone turnover and bone
mineralisation.
Bone mineral density (BMD) was measured at the lumbar
spine, L2-L4 (SBMD) and total body (TBBMD) by dual-
energy X-ray absorptiometry in 47 pre-pubertal children
(19 females, 28 males) and 49 pubertal children (26
females, 23 males). Serum levels of bone-specific alkaline
phosphatase (BALP) and carboxyterminal crosslinked tel-
opeptide of type 1 procallagen (P1CP) were measured as
markers of bone formation. Urine levels of cross-linked N-
telopeptides of type 1 collagen expressed as bone collagen
equivalents (NTXBCEyCr), pyridinoline (PYDyCr) and
deoxypyridinoline (DPDyCr) were measured as markers of
bone resorption corrected for urinary creatinine (Cr).
The only significant deficit in BMD was observed at the
lumbar spine in the pubertal group, age-matched Z-scores
y1.0 (1.7), P-0.001. Correlation between bone markers
and BMD were highly significant for PYDyCr and DPDy
Cr (rsy0.65 to y0.75, P-0.0001). A weak correlation
was observed between BALP and BMD (rsy0.26 to y
0.28, P-0.01). For bone formation markers BALP values,
75% were above the upper limit of the normal ranges, while
P1CP values were within the normal ranges. Bone resorp-
tion markers PYDyCr and DPDyCr had values 50 and
35%, respectively, above the upper limit of the reference
ranges.
The initial analysis of the data indicates that abnormalities
of bone metabolism occur in children with CF. Additionally
the effects of gender and pubertal stage are being evaluated.
This study was supported by a grant from the Cystic Fibro-
sis Trust, UK.
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OSTEOPOROSIS IN PATIENTS WITH CYSTIC
FIBROSIS
I. Loukou, P. Nikolaidou, E. Georgouli, A. Antoniou, E.
Tsapra, A. Kalostou, S. Doudounakis
Aghia Sophia Children’s Hospital, Athens, Greece
Cystic fibrosis (CF) is frequently associated with osteo-
porosis. A lot of factors are supposed to increase risk of
osteoporosis like severe respiratory disease, steroid therapy,
hypogonadism and deficiency of vitamin D. Aim of the
study was (a) to investigate osteoporosis in our patients and
(b) to evaluate its appearance in correlation with 25 (OH)
D deficiency. We studied 25 CF patients (10 boys and 15
girls) aged 6–18 years and 19 healthy children in the same
age. All patients were receiving 800 I.U. vitamin D per day.
In both patient and control group the bone formation index
as carboxy- and amino-terminal propeptides of procollagen
type I (PICP and PINP, respectively), bone fragment of
alkaline phoshatase and osteocalcin were estimated. Also
bone resorption index were estimated such as deoxypyrin-
idoline (dPYR) in urine specimen and C telopeptide
(ICTP) in blood specimen. Also 25 (OH) D and parathor-
mone (PTH) were estimated. In the CF group the bone
mineral density (BMD) was also estimated using dual ener-
gy X-ray absorpiometry (DEXA) in lumbar vertebrae. The
investigation revealed (1) The PINP in patient group
(386.71329.6 lgyl) was significantly diminished (Ps
0.003) compared with that of the control group (8541460
lgyl). (2) The bone fragment of alkaline phosphatase
(446120.9 lgyl) was significantly lower (Qs0.034) than
that of the control group (71129.4 lgyl). (3) The serum 25
(OH) D level (1911111.27 ngyml) was lower than that of
the control group. (4) Reduction in bone density was pres-
ent in 10 CF patients (40%) (T score -y2.5).
Conclusions: (1) Significant percentage (40%) of CF
patients have osteoporosis. (2) The daily dose of 800 I.U.
vitamin D is insufficient for some of CF patients.
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SEVERE OSTEOPENIA IN CFTR-NULL MICE
F. Dif , V. Geoffroy , M.C. de Vernejoul , G. Levi1 2 2 3
Laboratoire de Physiologie, MNHN CNRS UMR8572, 71
rueCuvier, 75005 Paris, France, INSERM U349, Centre2
Viggo Petersen, Hopital Lariboisiere, Paris, France, Mor-3
fogenesi Molecolare, IST, largo Rosanna Benzi 10, Genova,
Italy and CNRS UMR857
Aim: One common complication of cystic fibrosis (CF) is
low bone mineral density (BMD) with increased risk of
fractures compared to the general population. Patients with
more severe forms of the disease are most at risk of devel-
oping osteopenia and osteoporosis. Many factors such as
nutrition status, weight, calcium and vitamin D intake,
hypogonadism, chronic inflammation and age have been
suggested as significant etiologic factors. However findings
are not consistent between different reports. A recent report
suggests uncoupling of osteoblastic and osteoclastic activity
in young adults with CF with an imbalance of bone resorp-
tion over bone formation. The purpose of this study is to
determine if there is a direct relation between the genetic
defect in the CF transmembrane conductance regulator
(CFTR) and osteoporosis.
Method: We have examined bones of mice in which CFTR
has been inactivated by homologous recombination and
compared them to those of matched controls. Dual energy
X-ray aborptiometry (DXA) was used to measure BMD
and bone mineral content of the total body.
Results: Both parameters were strongly decreased in
CFTR-null mice. These results were correlated with histo-
mophometric analyses of bone tissues. The results indicated
an evident osteopenia over all the bone volume, especially
in cortical bone in CFTR mutant mice.
We conclude that absence of CFTR leads to osteopenia; the
relation could however be indirect. Further studies are
ongoing to determine why CFTR-null mice present this
severe bone defect.
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BONE MINERAL DENSITY IN ADULTS WITH
CYSTIC FIBROSIS.
G. Taccetti , T. Repetto , S. Campana , E. Procopio , S.1 1 1 1
Farina , M.L. Cioni , F. Festini , M. de Martino , M.L.1 1 1 1
Brandi2
Cystic Fibrosis Center of Tuscany, Department of Pediat-1
rics, University of Florence, Meyer Hospital, Florence, Ita-
ly, Department of Internal Medicine, University of2
Florence, Florence, Italy
Osteoporosis is an increasingly recognized problem in
adults with cystic fibrosis (CF) and its etiopathogenesis is
thought to be multifactorial. The aim of the present study
was to evaluate the prevalence of osteopenia and osteopo-
rosis in CF patients over age 18 and to correlate bone min-
eral density (t-score) with nutritional status, expressed as
BMI (kgym ), and pulmonary function (FEV1). In all2
patients we determined body mass index (BMI), FEV1, and
serum concentrations of calcium and 25-hydroxyvitamin
D3 (25-OHD). Bone density (BMD) was measured using
dual energy X-ray absorptiometry (DEXA) at the lumbar
spine in 43 CF adults w26 males and 17 females (mean age
of 27.04 years, range 19–50 years, median 25 years)x. Thir-
ty-three out of 43 (76.7%) patients showed clinical evi-
dence of pancreatic insufficiency and 37 (86%) were
chronically colonized by Gram negative nonfermentative
roads.
BMD was significantly reduced in CF patients, with 19 out
of 43 patients (44.18%) showing osteopenia (T-score
S149Journal of Cystic Fibrosis 1 (2002) S81–S180
between y1 and y2.5) and 5 out of 43 (11.6%) osteo-
porosis. The 25-OHD levels were low only in 2 cases
(4.6%). We did not found any correlation between BMD
and FEV1 and between BMD and BMI. The prevalence of
osteopenia or osteoporosis in CF patients is relevant
(55.8%), while the prevalence of patients with levels of 25-
OH-vitD below the normal range is 5%.
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MALE CF BODY BUILDERS AND EFFECTS OF
THE USE OF MUSCLE ENHANCING
SUBSTANCES
S Pandya , M Ledson , M Walshaw1 1 1
Regional Adult CF Unit
Against our advice, were aware that some male CF patients
were attending commercial gyms and using both legal mus-
cle enhancing supplements such as creatine and also illegal
anabolic steroids, in an attempt to increase body weight and
improve upper body muscle mass. The long-term effect of
these muscle-building products in chronic disease is
unknown. We therefore surveyed our 16 male CF patients
(mean age 22 years wrange 18–36x) who are regular com-
mercial gym users to see whether they used any of the
above substances and if it improved their weight and mus-
cle mass. Fat and protein stores were measured by mid arm
circumference (mac), triceps skin fold thickness (tsf), cal-
culated mid arm muscle circumference (mamc), and BMI.
Two patients (12%) were diabetic, and 14 (87%) took
enzymes (average daily dose 4682 lipaseykg wrange 1327–
11364x). Only 1 (6%) admitted to taking anabolic steroids,
2 (12.5%) to creatine and 6 (37.5%) to nutritional supple-
ments, but we suspected the real number was much greater.
All 16 undertook both aerobic and anaerobic exercise (aver-
age 381 minysession, 2.4 timesyweek). The average weight
was 67 kg (range 56–96) and BMI 23. The average tsf was
4.2 mm (range 3–5.5) (5th centile), average mac was 27
cm (range 25–33) (25th centile), and average mamc was
27 cm (range 23–31.7) (50th centile).
Thus, we have shown that a group of male CF adults who
attend commercial gyms have maintained good protein
stores as reflected in their average weight, BMI and mamc.
Although their fat stores are low, this may be due to chronic
malabsorption in those who require enzymes. Whether cre-
atine and anabolic steroid use has contributed to the
increase in protein stores and decrease in fat stores in these
patients is unclear, but increasing use of commercial gyms
will expose CF patients to such substances. Members of the
CF team should be aware of this and closer monitoring of
these patients and further research may be required to deter-
mine any long-term effects.
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SERUM SELENIUM CONCENTRATION IN
PATIENTS WITH CYSTIC FIBROSIS IN
COMPARISON TO AGE RELATED
REFFERENCE VALUES
M. Kappler , T. Lang , A. C. Muntau , M. Streiter , P.1 1 1 1
Schramel , H.-K. Harms , R.-M. Bertele-Harms2 1 1
Childrens University Hospital, 80337 Munich, GSF,1 2
85758 Neuherberg
A sufficient nutritional supply with the essential trace ele-
ment selenium is necessary to maintain the function of
selenoenzymes such as glutathione peroxidase, an impor-
tant enzyme in the antioxidative system. Because of
increased need for this antioxidans in CF and because of
the possible malabsorption, a relative selenium deficiency
has been suggested in CF-patients. We therefore analysed
the serum selenium concentration in CF-patients and com-
pared the results with age related reference values of 1010
healthy children.
Patients: ns155 (f 76), 16.2"8.2 (1–38) years of age,
FEV-1 82.9"23.4%.
Results:
(I) Age 1–5
years
ns14 Selenium 0.64"0.17
mmolyl
(n: 0.43–
1.63)
(II) Age 5–18
years
ns91 Selenium 0.79"0.29
mmolyl
(n: 0.53–
1.57)
(III) Age )18
years
ns50 Selenium 0.79"0.22
mmolyl
We found low serum selenium concentrations in 16% of
the patients. Data were nearly normally distributed,
serum selenium concentrations were significantly lower
than in controls. Within group II we compared CF-
patients with low selenium concentrations to patients
with normal selenium concentrations: No difference was
found concerning age, FEV-1, nutritional status,
genetics, vitamin-E or IgG levels. Low selenium
concentrations significantly correlated to elevated
erythrocyte sedimentation rate (ESR) and low
supplementation with pancreatic enzymes.
Conclusions: The serum selenium concentration in CF-
patients is lower than in controls. Surprisingly we found
no correlation between serum selenium concentration
and lung function testing results or nutritional status.
Low selenium concentrations in patients with low
enzyme supplementation can possibly be explained by
the relatively high amount of selenium contained in these
pancreatic enzyme preparations. The daily selenium
intake by enzyme supplementation was up to 30% of the
recommended supply in our patients. The low selenium
concentrations in patients with elevated ESR may reflect
the increased need for selenium in infections.
S150 Journal of Cystic Fibrosis 1 (2002) S81–S180
P276
CRITERIA TO INDICATE INTERVENTION WITH
ENTERAL FEEDING IN CHILDREN WITH CYSTIC
FIBROSIS
J.M. Roze , R.H.M.A. van Lieshout , J.E. Dankert-1 1
Roelse , A.M. Stok2 3
University of Professional Education Arnhem and Nijme-1
gen, Department of Nutrition and Dietetics, VU University2
Medical Center Amsterdam, Department of Pulmonology,3
VU University Medical Center Amsterdam
Introduction: Moderate or severe malnutrition is an indi-
cation for starting enteral nutrition in CF children. How-
ever, literature does not describe unambiguous which
specific criteria indicate this way of alimentation.
Several norms of anthropometic, biochemical and function-
al parameters and also psychosocial aspects are mentioned.
Objective: To define which criteria are used to indicate
intervention with enteral feeding in children with cystic
fibrosis.
Method: A questionnaire was sent to 35 paediatric dieti-
tians, gastro-enterologists and pulmonologists, all members
of a CF-team, of 12 hospitals that lend specialised CF-care
in The Netherlands (8) and Belgium (4).
Results: 71% of the approached specialists responded. 44%
of the respondents answered that no specific norms of nutri-
tional parameters are used to start enteral feeding in CF
children. 52% did mention to use one or more ultimate
values of nutritional parameters. Growth failure in spite of
food supplements was the incentive mentioned most fre-
quently to start enteral feeding. 56% mentioned that psy-
chosocial factors weigh heavily in the decision to start tube
feeding.
Mentioned norms of parameters that indicate intervention
with enteral feeding
Parameter Dietitian Gastroenterologist Pulmonologist
Growth failure 6 4 11
Growth curve (y2
S.D.
6 1 0
Conclusion: Among the participating institutes, there is
concurrence about the criteria that indicate intervention
with enteral feeding. However, the possibility to use
clearly defined criteria remains open to question. Limit
values of nutritional parameters can probably only be
used as guideline when this way of feeding is being
considered.
In practice exclusive antropometric parameters of the
nutritional status are being used to indicate intervention
with tube feeding. ‘Growth failure’ has been mentioned
the most.
Ever more, psychosocial aspects of tube feeding in
children play an important part in the decision whether
or not to start this way of alimentation.
1. Taminiau J.A.J.M., K. de Meer, C.M.F. Kneepkens,
e.a. Werkboek enterale voeding bij kinderen.
Amsterdam, 1997.
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THE EFFECT AND ACCEPTANCE OF
GASTROSTOMY FEEDING IN CHILDREN WITH
CYSTIC FIBROSIS
S. Van Biervliet , M. Genetello , E. Robberecht1 2 1
UZ Ghent Cystic Fibrosis Centre, Ghent, Belgium
Malnutrition is an important negative prognostic factor in
cystic fibrosis (CF) patients. Maintaining a good nutritional
status is one of the key features of optimal CF care. When
all other measures fail, we propose additional tube feeding
via a gastrostomy to attain this goal. In a retrospective study
we describe the follow-up results in 11 patients with CF
and gastrostomy tube feeding. We submitted them a ques-
tionnaire concerning the problems they encountered and
their personal view on the gastrostomy.
Patients: 9 female, 3 male, at the time of the PEG insertion
the median age was 9.4 y (7 m–14.8 y); the median follow
up is 1.9 y (5 m–8.5 y). The PEG tube is systematically
changed into a button gastrostomy after 6 weeks. The indi-
cation for the gastrostomy was stunting in 9 and feeding
problems in 2 patients. The median weight for height%
(WFH%) was 83% (67–90%). They received approxi-
mately 30% of their daily caloric needs via the gastrostomy.
Results: There is a significant weight gain within 3 m
(median WFH% 96% (75–112%)). The BMI z score also
significantly improves within 3 m. A further slower
increase in BMI z score and WFH% is seen from 3 m until
2 years. They start to grow within 6 m (median growth in
6 m increases from 1.5 to 5.5 cm). The height z score
significantly improves within 6 m. In the patients able to
perform a pulmonary function test, there was no significant
change in pulmonary function. There was no correlation
between the result of the tube feeding and the remaining
FEV1 at the start of tube feeding. The acceptance of the
gastrostomy by parents and patients was good. The most
frequently encountered problem is local irritation and the
survival of the button gastrostomy was very variable (2–9
m).
Conclusion: We can confirm that long-term overnight gas-
trostomy feeding improves the nutritional status of CF
patients. The pulmonary function remained stable. It is in
general well accepted. But more important for the stunted
patients, the growth velocity increases.
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HEPATOBILIARY LESIONS IN CHILDREN WITH
CYSTIC FIBROSIS
I.L. Indrejaityte , I. Skurvydiene , A. Valiulis1 2 1
Vilnius university children hospital, Vilnius, Lithuania,1
Taurage regional hospital, Taurage, Lithuania2
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The aim of the study was to define early markers of hepa-
tobiliary lesions in children with cystic fibrosis of various
severity.
89 children (mean age 10.7 years) were examined physi-
cally, their blood was tested for the liver enzymes (ami-
notransferases, alkaline phohphatase,
gamaglutamyltranspepetidase) and their liver was examined
by ultrasound.
Liver abnormalities were found in 27 out of 89 (30 perc.)
of examined patients, mostly in boys (63 perc.). The prom-
inent liver abnormality was palpable liver enlargement (70
perc.), mostly found in children up to 5 years old (63
perc.).
We did not find any statistically significant differences of
liver enzymes activity between children with hepatic abnor-
malities (27) and children with no evidence of hepatic
abnormalities (62).
We diagnosed liver enlargement by ultrasound in 70.4 perc.
of children with liver abnormalities, found on physical
examination, and in 40.3 perc. Of children with no physical
signs of liver abnormality.
The majority of children with enlarged liver showed chang-
es on liver ultrasound examination: in 78 perc. of cases was
observed totally hyperechogenic liver, in 28 perc. of cases
hyperechogenic periportal zones of liver were seen, the
signs of liver steatosis were seen in 18.5 perc. Of infants
and younger children, and in 18.5 perc. of cases the signs
of multifocal biliary cirrhosis and hepatic fibrosis were
seen.
The results of our study showed that liver enzymes blood
assay was not informative in diagnosing early hepatic
lesions in children with cystic fibrosis.
The results of our study suggest that hepatobiliary lesions
in children with cystic fibrosis are more common than it
was thought previously, especially in male patients, and liv-
er ultrasound examination is an informative diagnostic
method to define early signs of hepatic lesions even in the
youngest children with cystic fibrosis, especially in those
with palpable liver enlargement.
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URSODEOXYCHOLIC ACID IN THE TREATMENT
OF HEPATOPATHY IN CYSTIC FIBROSIS
I. Popa , N. Tudose , L. Pop , Z. Popa , L. Berinde , Z.L.1 1 1 2 1
Popa1
University of Medicine and Pharmacy Timisoara, Roma-1
nia, CF Centre Timisoara, Romania2
The aim of the paper is the assessment of the efficiency in
the treatment with ursodeoxycholic acid in the CF cases
with severe liver disease. Lot of study: 20 children (12
female and 8 male) with their age between 1 month and
18 years (average: 12.4 years), to whom we administered
ursodeoxycholic acid, 20 mgykg bodyyday in two doses),
during 12 months. The witness lot: 10 children (4 female
and 6 male), average: 10.5 years, to whom we administered
adjuvant liver medications. Criteria used for the lot selec-
tion: hepathomegaly, increased alkaline phosphatase, dense
image at ultrasound examination, the increased pressure in
the portal vein. Other investigations according to the case:
classical biological parameters related to the hepatic func-
tion, liver needle biopsy in 3 cases (2 cases that associated
ascites and another one with hepatic cytolysis). We found
no case with hepatic cirrhosis. We assessed the results at 6
and 12 months from the beginning of the treatment. The
values of the alkaline phosphatase ameliorated, but they
maintained over the superior limit in all the cases. The
majority of the other biological parameters became normal,
excepting the prothrombin indices that maintained values
of 70–80% from normal in 5 cases (25%). In the cases
with ascites the liquid resorption occurred, involution of
hepatomegaly but with preservation of an echodense image
of the liver and values of the pressure within the portal
system at the superior limit of normality. We mention that
during the first 6 months from the beginning of the therapy,
the evolution ameliorated significantly. In the witness lot
we did not find positive significant changes.
Conclusions: ursodeoxycholic is beneficial even in the cas-
es with severe liver disease; the treatment has to be done
for at least 12 months; the efficiency proved in the cases
with portal hypertension suggests the ursodeoxycholic effi-
ciency even in the cases with severe focal cirrhosis.
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SHORT-TERM THERAPY OF CF LIVER DISEASE
WITH TRANSMETIL (S-ADENOSYL-L-
METHIONINE)
I. Galeva, A. Kufardjieva
Pediatric Clinic, Alexander’s State University Hospital,
Sofia, Bulgaria
Aims: Liver cellular dysfunction, as well as, cholestasis and
fibrosis are common and life threatening CF complications.
As it is known, S-adenosyl-L-methionin participates in two
important liver metabolic pathways—transmethylation and
transsulfuration and thus influences many cell activities. It
modulates hepatic Na yK yATPase and improvesq q
membrane fluid and bile flow, overcomes the cell deficien-
cy of cystine, taurine and glutathione and protects against
cellular toxicity, decreases liver fibrogenesis and prevents
from cirrhosis among others.
This study is a first attempt to assess the benefit and drug
tolerance of Transmetil in young CF patients with CF liver
disease.
Methods: Five CF patients (1 male and 4 females) aged
from 11 to 18 years (mean age 16 years) received orally,
once a day 500 mg of Transmetil for a period of 2 months
in addition to their regular CF therapy. A strong clinical
and biochemical evidence for a severe liver disease was
found in all of the patients. Drug tolerance, as well as, liver
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sizes (clinical and ultrasound data), serum liver enzyme
values, bilirubin levels, lung functional parameters and
nutritional status in the beginning and in the end of the 2-
month period were compared.
Results: In all patients tolerance towards the drug and some
improvement in liver clinical and biochemical parameters
were observed. Three of the patients slightly gained in
weight and in four no lung exacerbation or any decline in
lung function were found.
Conclusions: A short-term therapy of young CF patients
with liver complications using Transmetil showed encour-
aging results and good drug tolerance. A more thorough
study is considered appropriate.
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IMPORTANCE OF YEARLY ULTRASOUND
SCREENING OF ASYMPTOMATIC CFLD:
EXPERIENCE OF THE PRAGUE CF CENTRE
V. Vavrova , D. Zemkova , Z. Hribal , J. Bartosova , V.2 2 4 2
Skalicka , H. Vanicek , M. Macek Jr. , O. Pozler1 5 3 5
2nd Paediatric Department, Charles University 2nd School
of Medicine and University Hospital Motol, Prague 5,
Czech Republic
Although CF-related liver disease (CFLD) increases mor-
tality in CF, it is initially asymptomatic and manifests only
at later stages. Therefore, we compared the utility of clin-
ical-ybiochemical markers and ultrasonographic examina-
tion of liver, spleen and portal veins (US) in its early
diagnosis.
Between 1946–2000 278 CF patients (pts) died at our CF
center and 16 (5.8%) had their liver cirrhosis (C) con-
firmed by necropsy. Currently, we longitudinally monitor
226 CF pts and US was done in 109y226 pts (48.2%; 56
My53 F; mean age 10.3"6.0 yrs). Based on US pts were
divided into: 1ynormal (N), 2yinitial periportal fibrosis
(IPF), 3ydiffuse parenchymal changes (DPC) or 4yirreg-
ular liver edge, nodular changes and severe periportal fibro-
sis (C) cohorts. US was correlated with hepato andyor
splenomegaly, biochemical liver function tests (BTs; AST,
ALT, GMT, ALP, bilirubine), nutritional status (NS), pul-
monary function tests (PFT) and the CFTR genotype. In
45 pts with normal BTs US detected 4x IPF and 5= DPC,
while in 33 pts with transient (-6 months, )1.5 normal
value) elevation of BTs US found 9= IPF and 14= DPC.
In 25 pts with permanent elevation of BTs ()12 m). US
revealed 9= N, 3= IPF, 12= DPC and 1= C. Abdominal
pain supported by US-DPC lead to new dg. of CF in 1 pt.
In the period of US screening already 5 pts head repeatedly
confirmed C by this examination. In one of them there was
severe varical hemorrhage and 15 m. after TIPS he got
transplanted. C and DPC are predominantly associated with
Class I–III. CFTR alleles. IPF was associated in 13 pts with
2 ‘severe’ CF alleles, with an exception of 3849q10 kb
C™TyF508del. Interestingly, C negatively influenced
growth and NS, but PFTs were not affected.
In conclusion, for early diagnosis of CFLD BTs are an inac-
curate marker and year US examinations in all CF pts are
necessary.
Supported by MZCR: 5067-3, LN00A079, ME457,
00000064203 and MSMT 111300003.
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SERUM A-GLUTATHIONE S-TRANSFERASE AS
AN EARLY BIOCHEMICAL MARKER FOR THE
DETECTION OF CYSTIC FIBROSIS LIVER
DISEASE
K. Sidlova , V. Skalicka , K. Kotaska , M. Pechova , M.1 1 2 2
Chada , J. Bartosova , Z. Hribal , V. Vavrova , R. Prusa2 3 4 3 2
1st Department of Paediatrics, Charles University, 2nd1
Medical School, University Hospital Motol, Prague, Czech
Republic, Department of Clinical Biochemistry and Patho-2
biochemistry, 2nd Medical School, University Hospital
Motol, Prague, Czech Republic, 2nd Department of Pae-3
diatrics, Charles University, 2nd Medical School, Univer-
sity Hospital Motol, Prague, Czech Republic, Clinic for4
Imaging Methods, Charles University, 2nd Medical School,
University Hospital Motol, Prague, Czech Republic
Aim of the study was to evaluate serum a-glutathione S-
transferase (s-GSTA) levels in patients with cystic fibrosis
(CF) and compare s-GSTA with other liver function tests
and with hepatic ultrasound scan (US). The cytosolic
enzyme, a-glutathione S-transferase is predominantly found
in the liver and distributed uniformly in the liver lobule. s-
GSTA concentrations have been found to provide a more
sensitive indication of hepatocellular damage than conven-
tional liver tests.
S-GSTA levels were measured in 37 CF patients aged 1 to
28 years (mean age 10.4, 24 males). The control group had
27 patients aged 2 to 17 years (mean age 8.5 yrs, 18 males).
The presence of hepatobiliary abnormalities was assessed
by clinical examination, ultrasonic scan, s-GSTA, and con-
ventional liver enzymes: alanine aminotransferase (ALT),
alkaline phosphatase (ALP), aspartate aminotransferase
(AST) and g-glutamyl transferase (GMT).
The calculated 5–95% range of s-GSTA for the control
group was 0.098–2.54 mgyl, for the CF group 0.43–9.76
mgyl. Mean s-GSTA level in control group was 1.55 mgy
l (S.D.s1.57), in CF group 2.05 mgyl (S.D.s2.60). No
significant correlations existed in the CF group between s-
GSTA and conventional liver tests (ALT, AST, ALP and
GMT). 4 patients from the CF group had hepatobiliary
abnormalities detectable by conventional liver tests, s-
GSTA and US. An additional 4 patients had abnormal s-
GSTA, while conventional liver tests and US were normal.
One other patient had abnormal hepatic US, but normal
standard liver tests and s-GSTA.
S153Journal of Cystic Fibrosis 1 (2002) S81–S180
The study has suggested that a raised s-GSTA level might
be a marker of possible liver disease in CF patients. s-
GSTA seems to be a more sensitive marker than transam-
inases for the assessment of hepatocellular integrity
monitoring and an early predictor of hepatic damage, but
more studies should be performed. Further monitoring of
patients with elevated s-GSTA is essential.
Supported by IGA MZCR Nk 6447-3 and MSMT
111300003.
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ORTHOTOPIC LIVER TRANSPLANTATION
(OLT) IN CYSTIC FIBROSIS (CF) PATIENTS
P. Canuzzi , M. Rossi , M. Rolla , P. Berloco , A.1 2 1 2
Grzejdziak , M. Zaccagnini , S. Quattrucci1 1 1
Cystic Fibrosis Center, Department of Pediatrics, Univer-1
sity of Rome ‘‘La Sapienza’’, Department of Surgery Sur-2
gical Specialities TransplantationParide Stefanini, Rome,
Italy
Introduction: CF liver disease interests biliary duct cells
and not hepatocytes. It can remain stable for decades or
evolve in focal biliary cirrhosis (FBC). Portal hypertension
increases the risk of death and OLT can be the only treat-
ment if lung function is only moderately impaired. Indica-
tions for OLT are: portal hypertension, hepatic failure and
hypersplenism. Contraindications are: FEV1-40%, lung
panresistant infections, PaCO )45 mmHg, severe lung2
fibrosis at CT, HIV or HBsAg positivity, creatinine clear-
ance -60 mlymin.
Methods: From 1996 to 2001, 6 CF pts received OLT
(mean age 18.5 years—5 M, 1 F). Clinical features were:
FEV1: 53.5%, BMI 17.6, Shwachmann score 72. Waiting
time ranged between 1 week and 1 year. All pts had portal
hypertension and oesophageal varices bleeds. Sclerotherapy
for oesophageal varices bleeds was carried out in 2 pts and
TIPPS in 1. Pancytopenia was present in 4 pts, PT)19 s
in 2 pts.
Results: Mean time in ICU was 12 h (range 6–24 h). We
had no operative mortality and the following complications:
acute rejection (2 pts), viral infections (CMV—5 pts,
EBV—1 patient), respiratory bacterial infection (Ps. ae.—
4 pts, St. au.—1 patient, B. cepacia—1 patient), post-anas-
tomotic biliary strictures (1 patient). All complications
were treated successfully except one. One patient died after
37 months for B. cepacia panresistant pneumonia. Respi-
ratory and nutritional conditions improved in 5 pts.
Conclusions: OLT should be considered a viable therapeu-
tic option when CF liver disease becomes a life-threatening
condition. Lung function improves for: resolution of dia-
phragmatic splinting, decreasing of intrapulmonary shunts
and antiinflammatory action of immunosuppressive therapy.
Timing remains still an open question.
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EPIDEMIOLOGY OF FIBROSING
COLONOPATHY: US VERSUS UK 1991–2001
M. Bakowski , P. Prescott1 2
Solvay Healthcare Limited, Southampton UK SO18 3JD,1
University of Southampton, Southampton UK SO17 1BJ2
Different approaches have been used in the US and the UK
in an attempt to eradicate fibrosing colonopathy (FC), an
iatrogenic disease first seen in 1991 in children with cystic
fibrosis. The US removed high strength pancreatic enzymes
()20 000 units of lipase per capsule) from the market in
1994 and advocated reduction of enzyme intake to less than
10 000 lipase unitsykgyday (2500 unitsykgymeal). In the
UK, advice on intake was similar but the three high strength
enzyme brands coated with methacrylic acid copolymer
(MAC) were singled out as being associated with FC and
were contraindicated for use in children with cystic fibrosis.
Whilst the approach taken in the UK appears to have erad-
icated the disease, the epidemic is continuing in the US. 35
FC cases were reported in the US between 1991 and 1994
and an additional 37 between 1995 and 1999 (1). Further
cases were reported in 2000 and 2001. In the UK, 14 cases
were reported between 1991 and 1994, but only four
between 1995 and 2001, the last in 1997 (2). All cases in
both countries received more than 10 000 lipase unitsykgy
day (average 40–50 000 unitsykgyday) and all had been
treated with MAC-coated brands or with both MAC and
non MAC-coated brands. No FC case had ever exclusively
received non-MAC coated brands alone, which are by far
the most commonly used enzymes in the UK ()98% mar-
ket share in 2001). Furthermore, in 1999–2000 the dose of
these non-MAC coated enzymes still exceeded the guide-
lines in approximately two-thirds of UK patients on high
strength (Creon 25 000) and one-third of patients on low
strength (Creon and Pancrease) brands (3).
We suggest that the success of the UK in controlling FC
can be attributed to the move away from the use of MAC-
coated enzymes. The US policy of attempting to control the
disease by simply reducing enzyme doses has failed.
References
1. Stevens JC et al. Pediatr Pulmonol 2001; Suppl 22: abstr
501.
2. Bansi DS et al. Gut 2000; 46: 283–285.
3. Mehta A. Lancet 2001;358: 1546–1547.
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CLOSTRIDIUM DIFFICILE-ASSOCIATED
PSEUDOMEM BRANOUS COLITIS IN A YOUNG
PATIENT WITH CYSTIC FIBROSIS
M. Laurans, M. Toulemonde, J.F. Duhamel
Department of Pediatrics, Clemenceau Hospital, Caen,
France
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Clostridium difficile associated pseudomembranous colitis
(PMC) is a common affliction of post operative patients.
Risk factors include antibiotic therapy, recent surgery and
hospitalization.
We report a case of PMC in a 10-year-old woman with
cystic fibrosis (DF 508, 1677 delTA). She had been treated
for pharyngitis with amoxicilline and josamycine and had
improved. Two weeks later, she presented with abdominal
pain, diarrhea and fever. Emergency laparotomy was per-
formed; only inflammatory liquid in the peritoneum was
found. The white blood cell count was 29 000. She was
asymptomatic for one day but later presented with refrac-
tory diarrhea. Colonoscopy showed left-side pseudomem-
branous colitis. After vancomycine administration and
parenteral nutrition, complete resolution of pseudomem-
branous colitis occured.
Because cystic fibrosis patients may have a wide spectrum
of gastrointestinal symptoms, disease caused by C difficile
must be considered when these patients have acute abdom-
inal pain, diarrhea or severe leukocytosis.
Despite high carrier rates of Clostridium difficile in patients
with CF, pseudo membranous colitis is distinctly rare, but
severe cases complicated by toxic megacolon have been
reported. CF patients with refractory or unexplained intes-
tinal symptoms merit thorough investigations.
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CLOSTRIDIUM DIFFICILE COLITIS IN FIVE CF
PATIENTS
R. Ziebach, A. Busch, M. Stern
University Childrens’ Hospital Tuebingen, Germany
Introduction: Hospitalization and antibiotic therapy are
risk factors for Clostridium difficile (CD) colitis. Neonates
and CF patients are the only populations reported in which
CD toxin is frequently recovered from asymptomatic indi-
viduals (1). However, some cases of severe CD colitis in
CF patients have been described (2–4). Since abdominal
pain and abnormal stools are not unusual in CF patients,
mild or atypical courses of CD-infection might be
underestimated.
Patients: We report on 5 patients (age 10 months to 5
years) with CD colitis during or within 4 weeks after anti-
biotic therapy. None of them had been hospitalized within
the preceding 6 months. One patient had severe colitis with
watery, bloody diarrhea, protein and electrolyte loss, and
elevated inflammatory parameters. The others had symp-
toms like diarrhea, vomiting and abdominal pain. Antibiotic
treatment preceding CD infection were: cotrimoxazol, ceph-
alosporins, amoxicillinqclavulanic acid, ceftazidimeq
tobramycin. Interestingly the CD strain of the patient who
received amoxicillinqclavulanic acid was sensitive in vitro
to exactly these antibiotics.
Therapy: All patients have been treated with metronidazole
(20 mgykg for 7 days). Two patients had further CD infec-
tion episodes under antibiotic therapies. One of them now
receives metronidazole and saccharomyces boulardii when-
ever antibiotic therapy is needed, the other one takes
metronidazole only when gastrointestinal symptoms occur
under antibiotics.
Conclusion: Gastrointestinal symptoms (diarrhea, abdom-
inal pain) are suspicious for CD in CF patients during anti-
biotic therapy. Recurrent episodes of CD colitis may require
additional therapy with metronidazole. Saccharomyces bou-
lardii may be helpful, but no studies on probiotics in CF
patients with antibiotic-associated diarrhea exist so far.
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A RE-AUDIT OF SCREENING FOR CYSTIC
FIBROSIS RELATED DIABETES (CFRD)
A. Verma, A. Claridge, T. Havelok, J. Biesty, D. McKenna,
D. Clough, J. Redfern, A. Webb
Adult Cystic Fibrosis Unit, Wythenshawe Hospital,
Manchester
Introduction: The prevalence of CFRD is 5–6%. By the
2nd to third decade of life this has increased to nearer 35%
(Moran, 1999). The average age of onset is 18–21 years
and is associated with a 6-fold increase in mortality and
associated co-morbidity. However, if diagnosed early, insu-
lin therapy reduces morbidity and mortality. An earlier audit
(Verma, 2001) to assess whether the selective screening
criteria for oral glucose tolerance testing (OGTT) (Yung,
1999) found that, the identified incidence of 1.9% was sta-
tistically significantly less than the expected (4–6). Con-
cluding that only 52% of patients with CFRD would be
identified by selective screening. Hence all patients were
offered routine annual OGT testing.
Aims: To assess the true incidence of CFRD in our popu-
lation. To identify the CFRD patients who would have been
‘missed’ if the old screening protocol was still in place.
Method: A retrospective review of case notes using the
OGTT and HbA1c databases. 242 patients were identified
but 91 patients excluded between 1.3.00 and 29.2.01.
Results: 89 OGTT were performed on 151 patients (preg-
nant women had OGTTs every trimester up to 30 weeks).
The incidence was found to be 4.4% and the prevalence
26.9%. This is in line with data from the North American
registry. Had the selective screening protocol been imple-
mented we would have 6 patients would have been missed
with CFRD and 10 patients with impaired glucose
tolerance.
Conclusions: In view of the need for early diagnosis and
treatment of CFRD, annual OGT testing is essential for all
CF centres especially for adult patients. Selective screening
does not identify all patients who need to be tested. This
audit also identified of a new group of patients who are
hypoglycaemic after a glucose load.
Future work: To plot the natural history of CFRD in our
population.: To identify hypoglycaemic patients at 120 min
and look at subsequent years OGTTs.
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CONTRIBUTION OF AUTOIMMUNITY TO
ETIOPATHOGENESIS OF CFRD—PRELIMINARY
RESULTS
S. Kolouskova, O. Cinek, J. Bartosova, M. Pechova, Z.
Sumnik, M. Snajderova, D. Zemkova, V. Vavrova
2nd Dept of Pediatrics of 2nd Medical School of Charles
University and University Hospital Motol, Prague
Aim: Etiopathogenesis of cystic fibrosis related diabetes
(CFRD) has not yet been elucidated. To disclose possible
autoimmune component of CFRD, we examined children
and young adults with CF for Type 1 diabetes mellitus
(DM)-associated HLA-DQ polymorphisms, and for auto-
antibodies to GAD (glutamic acid decarboxylase) and IA-
2 (tyrosine phosphatase).
Patients and methods: HLA-DQ genotypes were com-
pared between 88 CF patients aged 13.715.6 (mean"S.D.),
and 289 healthy unrelated children. The HLA-DQA1, -
DQB1 were genotyped by polymerase chain reactions with
sequence-specific primers. All CF patients were screened
for anti-GAD and anti-IA2 autoantibodies using RIA meth-
ods with the positivity threshold at the 99th percentile of
healthy children. Glucose tolerance in CF patients was
investigated in an oGTT (oral glucose tolerance test): in
patients with impaired glucose tolerance (IGT) or with dia-
betes mellitus we performed intravenous glucose tolerance
test (ivGTT) to assess first-phase insulin response (insuli-
nopaenia was defined as the sum of insulin release in min-
ute 1q3 lower than 22 mIUyl).
Results: Diabetes mellitus was diagnosed in 12y88 CF
patients (all with insulinopaenia), while IGT with insuli-
nopenia -22 mIUyl was present in further 4y88 patients.
The distribution of HLA-DQB1, -DQA1 alleles in the 16
insulinopaenic patients did not significantly differ either
from the remaining CF patients, or from healthy children.
Anti-GAD were positive in 5y88 (5.7%), anti-IA-2 in 1y
88 (1.1%) CF patients. In CF patients with diabetes, 3y12
(25%) had at least one autoantibody.
Conclusions: We did not observe increased prevalence of
Type 1 DM-related HLA-DQA1,-DQB1 alleles in insuli-
nopaenic CF patients, or in CF patients as a whole. How-
ever, our finding of anti-GAD andyor anti-IA-2 positivity
in 25% CFRD patients suggests heterogeneity of this con-
dition and merits further analysis.
Support: Ministry of Health (6461-3) and Education
(111300003), the Czech Republic.
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A SIMPLE TOOL FOR RECOGNITION AND
MANAGEMENT OF CF RELATED DIABETES
S. Bell, G. Hooper, C. Mayer, A. Walker, P. Smith, C. Pan-
tin, C. Campbell, W. Lenny
North Staffordshire CF Centre, Stoke-on Trent ST4 7PA, UK
Introduction: CF patients are reviewed 2 monthly. Chil-
dren over 10 yrs and adult have routine blood sugars at
each clinic visit and an Oral Glucose Tolerance Test
(OGTT) at annual review. Some results have been misin-
terpreted causing anxiety to both staff and patients. A tool
for interpretation of blood sugars was decided to help alle-
viate these problems.
Aims: To produce a simple tool for health professionals to
interpret random blood sugars and OGTTs which will lead
to rapid identification and management of their needs.
Methods: The CF Team met with a Paediatric Diabetolo-
gist an Adult Diabetologist and a Biochemist to plan the
contents of the tool based on current research on CF related
diabetes.
Results: A compact 2 sided A 4 guide was produced.
Sheet one has 2 tables with actions to be taken for: Random
blood sugars of: -7.8 mmolyly7.8–11.0 mmoly)11.1
mmolyl OGTT Test.
The OGTT results are interpreted with actions dependant
upon results at 0 miny60 miny120 min.
Sheet two describes the Recognition, Assessment, Treat-
ment and Monitoring of CF Related Diabetes.
Conclusions: Since the implementation of this tool a more
effective method of management has been obtained through
consistent interpretation of blood sugar results with the clin-
ical condition of each individual CF patient.
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GESTATIONAL DIABETES IN CYSTIC
FIBROSIS: THE NEED FOR CLOSE LINKS WITH
OBSTETRIC AND DIABETIC TEAMS
A. Verma , M. Das , A. Ahluwalia , R. Rowe , A. Jones ,1 2 2 3 1
M. Dodd , A. Webb1 1
Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Man-1
chester, Obstetric Unit, Wythenshawe Hospital, Manches-2
ter, Diabetology Unit, Wythenshawe Hospital, Manchester3
Introduction: With increasing numbers of pregnancies, an
increase in prevalence of diabetes and routine oral glucose
tolerance (OGT) testing at our CF Centre we have devel-
oped close links with obstetric and diabetic teams.
Aims: To assess maternal and foetal outcome prior to and
after developing links with the obstetric and diabetic teams.
Methods: A retrospective review of medical notes for preg-
nancies booked in wGroup Ax after links were formed in
year 2000 (ns6) and wGroup Bx 1995–2000 (ns7). We
initiated OGT testing in each trimester for group A.
Results: Prior to pregnancy, no patients in either group
were identified as having diabetes. There were no differ-
ences between the 2 groups for microbiological status, spi-
rometry, weight and height. 4y6 patients in group A and 7y
7 in group B were pancreatic insufficient. We identified 5y
6 patients in group A but 0y7 in group B as having CFRD
or gestational diabetes (GD). Patients in group A were
diagnosed as having GD at a mean (range) of 26 (20–29)
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weeks and required a mean (range) max. insulin dose of
44 (22–86) I.U.yday. Mean wS.E.Mx patient weights (i)
pre-delivery and (ii) 6 months post-partum were (i) 60.2
kg w3.5x (ii) 60.2 kg w3.7x for group A, and (i) 50.1 kg
w2.6x (ii) 42.0 kg w1.1x for group B (P-0.05). There was
no difference in mean FEV1 pre-delivery and 6 months
post-partum between the 2 groups. Patients in group A
received a mean of 2.8 courses of i.v. antibiotics for a mean
of 42.8 days whilst those in group B had 3.4 courses for a
mean of 40.9 days. For groups A and B, the mean duration
of gestation was 35.6 and 33.0 weeks and mean birth
weights were 2.7 and 2.1 kg, respectively. 2y6 babies in
group A and 6y7 babies in group B required SCBU care.
Conclusions: Gestational diabetes is common in CF. Diag-
nosis improves maternal nutritional outcome. We recom-
mend OGT testing for all pregnant women in each trimester
up to 30 weeks and specialist care from joint clinics with
CF, obstetric and diabetic teams.
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THE BELGIAN CYSTIC FIBROSIS REGISTRY
1998–2000
C. Sevens, N. Desloover
Academisch Ziekenhuis Vrije Universiteit Brussel, Belgium
Background and method: The Belgian CF Registry
(BMR-RBM) was created in 1998 to bridge an epidemio-
logical gap. An annual inquiry is held by means of a ques-
tionnaire filled in by physicians in charge of the patient.
The informed consent is detained by the physician. The
questionnaire consists of two sections: basic data and obser-
vational data to be collected annually, at the last clinical
contact for that year. The content of the forms has not
undergone any major change throughout a 3 years period.
Minor modifications were introduced in order to rationalize
the answering patterns. The data were computed in a central
Access database.
Results: The population studied from 1998 to 2000
involved, respectively 534, 604 and 735 patients with CF,
an increase of 27.4%. The results are available in annual
reports and expressed, on purpose, only in numerical tables
to avoid misinterpretation of not yet stabilized data. The
median age of the population in 2000 was 15.6 yrs, 39.1%
patients were 18 years or older, 52.1% were males. At DNA
analysis (93% of the patients) 75.4% of the chromosomes
carried the DF508 mutation, 56.9% of the patients were
homozygotes DF508. The observational data-pulmonary
and digestive status, infection patterns, complications, treat-
ment, social and educational levels are quite extensive.
Some striking features over the observation period were:
slow but steady decrease of Pseudomonas aeruginosa
infections, 8.2 to 9% of the patients required insulin, ther-
apy with ursodeoxycholic acid increased significantly,
91.2% of the patients were on antibiotics in 2000. At epi-
demiological level the registration increased from 1 CF per
18 071 inhabitants to 1y13 847 (Belgian population 10 mil-
lions). Missing data decreased over time.
Conclusion: The Belgian CF Registry, of recent existence,
shows a high registration rate. The results are comparable
to those from other countries and can already be considered
as a quality of care measurement system.
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FACTORS AFFECTING AGE AT DEATH IN
CYSTIC FIBROSIS PATIENTS
THE ITALIAN REGISTRY 1988–2000
L. Viviani , A. Bossi , Assemblea dei direttori dei Centri1 2
Istituto di Statistica Medica e Biometria, Universita degli1 `
Studi di Milano, Centri Regionali di Riferimento e di Sup-2
porto per la cura della Fibrosi Cistica
Background: The improvement of the knowledge of Cystic
Fibrosis (CF) pathophisiology, as well as the advances in
centralised medical care have allowed a marked increase in
life expectancy. Now the majority of CF children are
expected to survive until adulthood.
Objectives: The aim of this poster is to compare age at
death of CF patients classified by gender, region of resi-
dence, diagnosis procedures, pancreatic insufficiency, DNA
analysis, and to evaluate its variation from 1988 to 2000.
Patients and methods: All patients included in the Italian
Registry and dead from CF after 1988 (when the Registry
started). Clinical and demographic data were entered into
a computerised database and processed with ‘SAS’ system.
Results: 512 patients (12%) died during the period under
study (approx. 40 per year). Data show a small difference
in age at death between genders: median age at death is
18.4 years for females and 19.8 years for males. Age at
death distribution has a maximum peak between 16 and 20
years of age, and deaths within the first year of life repre-
sent approximately 3% of total deaths (more than the half
of these patients presented meconium ileus at birth). Medi-
an age at death increased progressively from 14.3 (1988–
1990) to 22 years (1997–2000). This increasing trend
emerged also for patients diagnosed within the first year of
life. There was no difference in age at death between
deltaF508 homozygotes and patients not carrying the
deltaF508 allele.
Comments: Since only 31 deaths occurred among patients
born after 1988, survival curves cannot be drawn at present.
Nevertheless, a large increase in expectancy of life was
observed during the last decade. Neonatal screening pro-
grams could be one of the reasons for this fact.
S157Journal of Cystic Fibrosis 1 (2002) S81–S180
P297
QUALITY ASSESSMENT OF DATA FROM THE
EPIDEMIOLOGIC REGISTER OF CYSTIC
FIBROSIS (ERCF) RELATING TO NORTH OF
ENGLAND CENTRES
J. Strobl, I. Enzer, A. Bagust, T. Walley, A. Haycox
Prescribing Research Group, Department of Pharmacology,
University of Liverpool
Purpose: The purpose of the work described was to assess
the quality of data from the Epidemiologic Registry of Cys-
tic Fibrosis (ERCF), a multicentre, longitudinal follow-up
project of patients with cystic fibrosis (CF), prior to using
the data for a cost-effectiveness analysis of rhDNase (dor-
nase alfa).
Methods: Data relating to 1184 patients from seven UK
CF centres were cleaned, and data of five of these centres
were subjected to an on-site Data Quality Review (DQR)
of key variables. The review compared ERCF reported data
from 28% of the registered patients with that from original
data sources in the centres. In addition, centre staff were
questioned about their clinical as well as recording practices
to elicit differences which may be relevant in the interpre-
tation of the results of any data analysis and to give an
indication of the representativeness of the study group.
Finally, a comparison of summary data with other published
reports from the entire European dataset of the ERCF as
well as other studies was also possible for some variables.
Results: Corrections of key variables following the DQR
were generally minor, e.g. in the case of adjustments of
reported spirometry readings. Twenty-four accidental re-
registrations of transferred patients in another centre were
identified, and 8% of deaths had not been previously
recorded. There are centres differences in recording practice
which are relevant to the interpretation of the data and their
analyses.
Conclusions: The data quality of some key variables found
in the current sample is encouraging. The DQR provided
an additional opportunity to check key data, and partly
complete it, even where omissions could not have been
noticed during data cleaning. Data analysis should allow
for centre differences, given the identified (and possible
unidentified) practice variations. Data protection issues
seriously affect the ability to assess the quality of secondary
data.
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COMPARISON OF ADULT CYSTIC FIBROSIS
POPULATIONS IN BELFAST AND CORK
J. Courtney , T. O’Connor , C. Short , C. Bredin , S.1 2 2 2
Elborn1
Adult Cystic Fibrosis Unit, Belfast City Hospital, Belfast,1
Cystic Fibrosis Unit, University Hospital, Cork2
It is known that cystic fibrosis populations vary in para-
meters such as genotype, frequency of Gram negative infec-
tion and socio-economic status. The aim of this study was
to assess if there is any difference in age, sex, microbiology
and genetics between the Belfast and Cork adult cystic
fibrosis populations.
113 subjects registered in Belfast in December 2000 were
compared with 49 subjects in Cork. There was a significant
difference in FEV1 (% predicted) between the two groups,
mean (SE) in Belfast 74.9 (2.3) and Cork 64.4 (4.4), Ps
0.02. There was no difference in age 24.9 (0.6) and 24.9
(0.8) years, Ps0.99 or BMI 21.8 (3.8) kgym and 21.22
(3.0) kgym , respectively, Ps0.43. There was no differ-2
ence in sex distribution with 57 (50.4%) males in Belfast
compared to 27 (55.1%) in Cork, x s0.4, Ps0.5. The2
proportion of patients with Pseudomonas aeruginosa infec-
tion was significantly different between Belfast (57
patients, 50.4%) and Cork (35 patients, 71.4%), x s6.1,2
Ps0.01. No patients in Cork had Burkholderia cepacia
infection in comparison with 20 in Belfast, x s9.9, Ps2
0.002. Patients with deltaF508 homozygous mutation were
in greater proportion in Cork (31 patients, 65.9%) com-
pared to Belfast (30 patients, 37.5%), x s9.6, Ps0.0022
but there was no significant difference found in the pro-
portion of those who were heterozygous for deltaF508. The
difference in the proportion of patients with R117H or
G551D mutations in Belfast w10 patients (12.5%) and 7
patients (8.8%)x compared with Cork w4 patients (8.5%)
and 8 patients (17%)x was not statistically significant, x s2
0.5, Ps0.5 and x s1.9, Ps0.2, respectively.2
This study showed that there were significant differences
between Belfast and Cork adult cystic fibrosis populations
in lung function, microbiology and genetics. The better
FEV1 seen in patients from Belfast may be due to the lower
proportion of individuals who were homozygous for
deltaF508.
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SURVIVAL OF CYSTIC FIBROSIS PATIENTS
FROM BRITTANY, FRANCE (1970–2000)
D. Gillet , V. Scotet , I. Dugueperoux , G. Bellis , C.1 2 1 3´ ´
Ferec , M. Roussey , G. Rault , M. De Braekeleer , Reseau2 4 5 1´ ´
Mucoviscidose Bretagne Pays de Loire
Department of Cytogenetics, Cytology, and Reproduction1
Biology, CHU Morvan and Faculty of Medecine, UBO,
Brest, France, INSERM EMI 01–15, Laboratory of2
Molecular Genetics, Brest, France, Institut National d-3
’Etudes Demographiques, Paris, France, CHRU, Hopital4´ ˆ
Sud, Rennes, France, Centre de Perharidy, Roscoff, France5
The aim of this study was to analyse the survival of CF
patients in a region where the disease is frequent.
We registered retrospectively all the patients born since
1970 in Brittany (Western France), by cross-checking dif-
ferent data sources. Councils of the region were contacted
in order to consult patients’ birth certificate, which allowed
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us to document patients’ exact birth date, birth residence
place, and death date when applicable. Survival probability
at different ages for both genders was estimated with Kap-
lan–Meier method.
We collected complete information for 419 patients of
whom 218 were females (52%) and 201 were males (48%).
The mean follow-up time was 13.14 (ranges0.01–30.24)
years. At the end of the study, the overall mortality rate was
28.4% (ns119). The median age at death for the whole
cohort was 8.35 years (8.35 for males, 9.20 for females).
The estimates probability for survival after 20 years from
birth was 63% for men and 68% for women. The median
survival time was 22.84 years for the former group and
27.99 for the other; the difference was not significant.
Whereas it is usually admitted with literature, we failed to
observe a higher mortality in women group. In our cohort,
the female survival seems as good as the male one. These
unexpected findings could be explained by a better ascer-
tainment of CF girls born in Brittany between 1970 and
1979.
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DISTRIBUTION OF THE INCIDENCE OF CF
WITHIN TUSCANY (ITALY): ARE
GEOGRAPHICAL FACTORS RELEVANT?
F. Festini , T. Repetto , G. Taccetti , S. Campana , G.F.1 1 1 1
Mergni , C. Di Bilio , E. Procopio , S. Farina , E. Pelo ,1 1 1 1 2
M. de Martino1
Cystic Fibrosis Center of Tuscany, Department of Pediat-1
rics, University of Florence, Meyer Hospital, Florence, Ita-
ly, Cytogenetic and Genetic Unit, Careggi Hospital,2
Florence, Italy
Since 1991 the Tuscan CF Center has carried out an IRTq
lactase neonatal screening project on all the newborns of
Tuscany, a geographic and administrative region of Italy
inhabited by 3.5 million people on a 23 000 km area. The2
Center also performs genetic counselling and prenatal diag-
nosis for CF.
We surveyed the data of a ten and a half year period of the
neonatal screening (from July 1st 1991 to Dec. 31st 2001)
in order to analyze the incidence of CF in Tuscany.
In the considered period 275 520 children were born in Tus-
cany. Among them, 64 who resulted positive to neonatal
screening were diagnosed CF with sweat test. Three other
children were diagnosed because of symptoms. Seven pre-
natal diagnosis were followed by abortion. The incidence
of CF in Tuscany in the given period is therefore 1y3723.
We successively divided the region’s territory into zones
with homogenous and distinct geographical and historical
features and we calculated the incidence of CF in each area.
The results show that the incidence of CF is not uniform
within the entire region and that there are marked differ-
ences between the considered zones (range 1y2040–1y
5423).
In particular we found that:
– CF incidence is much higher in rural areas and lower in
urban areas;
– it is higher in mountainous zones and lower in the sea
coastline and in the Arno River Valley;
– it is higher in areas with a low population density and
lower in areas with a high population density.
The lowest incidence of CF was found in the metropolitan
area of the capital, Florence, where one third of Tuscan
population is concentrated.
These data allow us to hypothesize that geographical and
historical factors may influence the incidence of CF in a
given zone and, specifically, that in geographically and his-
torically more isolated areas the CF gene carrier status may
be more frequent due to less contacts with other
communities.
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SPATIAL AND TEMPORAL DISTRIBUTION OF
CYSTIC FIBROSIS AND OF ITS MUTATIONS IN
BRITTANY, FRANCE: A RETROSPECTIVE
STUDY FROM 1960
V. Scotet , D. Gillet , I. Dugueperoux , M.P. Audrezet , G.1 2 2 1
Bellis , B. Garnier , M. Roussey , G. Rault , M. De3 3 4 5
Braekeleer , C. Ferec6 1
INSERM EMI 01-15, Department of Molecular Genetics,1
Brest, France, Department of Cytogenetics, Brest, France,2
INED, Paris, France, CHRU, Hopital Sud, Rennes,3 4
France, Centre de Perharidy, Roscoff, France, INSERM5 6
EMI 01-15, Department of Cytogenetics, Brest – INED,
Paris, France
Aim: The aim of this study was to define the spatial and
temporal distribution of cystic fibrosis (CF) and of its
mutations in Brittany (western France) where the disease
is frequent.
Method: We retrospectively registered all the patients born
in Brittany since 1960, by crosschecking different data
sources (medical care centres, genetics laboratories, hos-
pital archives, etc.). We contacted councils in order to
obtain patients’ residence place.
Results: A total of 520 patients were registered. We
assessed CF incidence according to administrative (depart-
ment, district, canton) and ecclesiastic (bishopric) divisions
and analysed its evolution over decades. Incidence was 1y
2630, with a westyeast gradient which was confirmed over
time (Finistere: 1y2071 vs. Ille-et-Vilaine: 1y3286). This
high frequency may result from founder effects and genetic
drift. Currently, incidence is decreasing mainly because of
prenatal diagnosis. Moreover, we determined the spectrum
of CFTR mutations and their spatial distribution in this
region. We obtained an excellent detection rate (99.7%).
Western Brittany presented a specific mutations spectrum:
1078delT (9.4% of mutated alleles in bishopric of Cor-
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nouaille), G551D (7.7% in Leon), 4005q1G)A (2.9% in
Cornouaille) and W846X (1.5% in western Brittany). On
the other hand, the eastern part show a spectrum more sim-
ilar to the French one.
Conclusions: This study relates the regional specificities of
the CFTR gene and highlights the disparities that existed
in Brittany, both in incidence and in mutations distribution.
This results from different isolation degrees and population
movements between the two parts of this region. It is the
first time that a so detailed study of the CFTR gene is
performed in a large population. This better knowledge of
CF epidemiology allows to improve the diagnosis strategies
and to refine genetic counselling.
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VALIDATION OF A SIMPLE AND INEXPENSIVE
METHOD FOR ESTIMATION OF SWEAT
CHLORIDE
S.K. Kabra, M. Kabra, S. Gera, Sridevi, J. Mathew, R.
Lodha
All India Institute of Medical Sciences, New Delhi 110029,
India
We validated a simple and inexpensive method for esti-
mation of sweat chloride.
Methods: Sweat collection and estimation of chloride was
based on principles of quantitative pilocarpine iantophores-
is. Two layers of filter paper soaked in 1% pilocarpine
placed under positive electrode and five layers of filter
paper soaked in tape water was put under negative electrode
over the skin of fore-arm and arm of same side and secured
firmly. Iantophoresis performed for 5–7 min by using 9 V
battery.
Sweat was collected in Whatman 42 filter paper kept in pre
weighed screw capped plastic bottle for 30 min. The filter
paper soaked in sweat was replaced in the plastic bottle,
weight and eluted in 8 ml distilled water overnight. A titra-
tion on 2 ml of the eluted solution and known strength of
saline was performed with mercuric nitrate using diphenyl
carbazone as indicator. Sweat chloride was calculated by
using equation N V sN V . For validation of method the1 1 2 2
test was performed on 50 samples containing known
strengths of saline in different weight and 50 sweat samples
collected from patients by two observers independently.
Results: Sweat weight of )100 mg could be collected in
first attempt in 450y600 (75%). After second attempt sweat
of )100 mg could be collected in 540y600 (90%). The
mean difference in chloride estimation on known strength
by first observer was 0.88 1 6.9 (95% CI 1.03–2.79) and
by second observer was 2.81 5.9 (95% CI 1.17–4.4). The
inter observer variability between two observers was
2.8616.1 (95% CI 1.2–4.4) The cost of equipment was 7
US$ and cost per test was 0.5 US$.
Conclusion: This inexpensive method of sweat chloride
estimation gives acceptable accuracy and repeatability and
can be used in resource poor countries for diagnosis of CF.
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RETROSPECTIVE AUDIT OF THE MACRODUCT
SWEAT COLLECTION SYSTEM AND
CONDUCTIVITY ANALYSER AFTER ITS
INTRODUCTION TO A DISTRICT GENERAL
HOSPITAL
R. Jayaraj, D. Lacy, D. Neithercut
Wirral Hospital NHS Trust, Arrowe Park Hospital, Arrowe
Park Road, Upton, Wirral, UK
Aims: To audit the results of sweat tests following the intro-
duction of the macroduct sweat collection system and con-
ductivity analyser in a district general hospital.
Methods: Data was collected on all sweat tests performed
from September 2000 to August 2001. Using this method
Hammond et al. (1) recommended that if the equivalent
conductivity was greater than 50 mmolyl NaCl the result
should be regarded as equivocal and if greater than 90
mmolyl as positive. We therefore identified any patient with
a result )50 mmolyl and further investigations and out-
come were documented.
Results: 79 sweat tests were performed on 74 patients. In
one patient insufficient sweat was obtained on two
attempts. One patient had a sweat conductance of 134
mmolyl and was confirmed on genotype to have CF.
14y73 had results)50 and-90 mmolyl. Two patients had
results just above 50 mmolyl and these were lower on
repeat macroduct test and no further tests were performed.
9y73 (12%) eqivicals had normal repeat sweat test meas-
uring Na and Cl ion concentrations by the quantitative pilo-
carpine iontophoresis test (QPIT) at the Regional CF Unit
(Liverpool) whereas 3y73 (4%) had a repeat QPIT that was
also equivical. One of these patients on genotype had 2 CF
mutations and was confirmed as having CF, but the remain-
ing 2 patients had only one identifiable CF mutation and
the diagnosis is still undetermined.
Conclusion: The macroduct system and conductivity ana-
lyser was easy to use and reliable. Although 12% needed
a second sweat test using the QPIT system, the majority
were able have their investigation locally and were saved
the journey to the Regional CF Centre. Furthermore we
were able to provide a same day result. The material costs
for the macroduct system is more expensive than the QPIT
but this maybe offset by lower labour costs. Overall we
would recommend this system provided it is in conjunction
with QPIT for equivical and positive results.
1. Hammond et al., J Pediatrics, Feb 1994, 255–260.
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URIC ACID METABOLISM IN CYSTIC FIBROSIS
M. Fotoulaki , A. Makedou , S. Nousia-Arvanitakis1 2 1
Fourth Department of Pediatrics, Aristotle University,1
Biochemical Laboratory, Fourth Department of Pediatrics2
Hyperuricosuria, previously reported in cystic fibrosis
(CF), has been attributed to the ingestion of high dose
purine-rich pancreatic extracts. High-energy, high protein
diets proposed to CF patients may also increase uric acid
production. The aim of this study was to investigate uric
acid metabolism in CF patients receiving reasonable dosage
of pancreatic extracts, as previously recommended.
Methods: Thirty-nine CF patients having an age range of
4.5–19 (mean 10.3q3.3) years, pancreatic insufficiency,
controlled with -10 000 I.U. lipaseykgyday, and clinical
scores ranging from 50 to 97 points were investigated. Thir-
ty-nine normal individuals matched for age and sex served
as controls. Glomerular filtration rate (GFR), serum uric
acid, urine uric acidykgy24 hrs and the ratio of uric acid
per 100 ml GFR wurine uric acid x serum creatinine (Cr)y
urine Crx were calculated. Fresh urine samples were exam-
ined for the presence of uric acid crystals. Data were
expressed as mean 1 standard deviation (S.D.) and statis-
tical analysis was performed using 2-tailed t-test. The
results are tabulated.
Cystic fibrosis Controls P value
Cr clearance
mlyminy1.73 91.43"37.53 95.17"55.60 0.79
Serum uric acid mgydl 4.71"1.3 4.44"1.25 0.36
Urine uric acid mgykgy24 h 14.43"7.17 15.43"7.39 0.54
Uric acid ydl GFR (mgydl) 0.75"0.69 0.62"0.35 0.31
Renal function was normal and the parameters of uric
acid metabolism were comparable in CF patients and the
control group. The ratio of uric acid per 100 ml GFR
was high in both groups (normal -0.56 mgydl). Uric
acid crystals were detected in one CF urine sample.
Conclusion: Pancreatic extract substitution in dosage
not exceeding 10 000 I.U.ykgyday is associated with
normal uric acid excretion in CF. Hyperuricosuria
previously demonstrated in CF patients is most likely
related to the catabolism of purine-rich pancreatic
extracts consumed in excessive doses.
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NASAL IRRIGATION AFTER ENDOSCOPIC
SINUS SURGERY (ESS) IN CYSTIC FIBROSIS
M. Di Cicco , C. Castagna , D. Costantini , A. Brivio , D.1 1 2 3
Brusa3
Department E.N.T., University of Milan, Italy, Depart-1 2
ment Pediatrics-CF Centre, University of Milan, Italy,
Physiotherapy CF Centre, University of Milan, Italy3
Nasal irrigation improves symptoms and health status of
patients with sinonasal disease. After ESS, often compli-
cated by thickening of secretions, nasal stenosis with crust-
ing, infections with purulent discharge and nasal bleeding,
the use of NaCl solution is a common treatment.
The effectiveness of nasal irrigation with a new available
device (Lavonase) was compared to simple nasal washing
using isotonic saline solution in a study involving 30 CF
patients (mean age 12.5 yy. Range 5–18 yy) who under-
went ESS, randomly assigned to either treatment.
Lavonase treatment is a continuous soft shower in which
the pressure of the water is due to the difference of height
between the head of the patient and a 250 ml sack of saline
solution (NaCl 0.9%). The connection to the nose is guar-
anteed by an oval silicone adapter that fits the anatomy of
the nostril.
The second group received simple nasal washing with 20
ml of saline solution (NaCl 0.9%) via a normal syringe.
Both therapies were performed twice a day for 4 weeks.
Patients rated postoperative blood loss, postnasal drip,
crusting, thickness of secretions and purulent discharge by
a self-administered questionnaire at follow up and by an
objective endoscopic evaluation of the nasal cavities.
Mucociliary clearance by saccharine–charcoal method was
evaluated in both groups.
We found the two methods equally effective as far as clin-
ical amelioration, endoscopic findings and mucociliary
transport time reduction are concerned.
Patients who used continuous soft shower experienced sig-
nificant improvement in 4 of the 5 nasal symptoms queried;
90% of these patients found this treatment easier to perform
and with no side effects. The control group experienced less
positive results.
We conclude that nasal irrigation with continuous soft
shower is an effective and well-tolerated method in the
management of ESS in CF patients.
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PEDIATRIC PARANASAL SINUS MUCOCELE IN
CYSTIC FIBROSIS: A CONSERVATIVE
SURGICAL APPROACH (ESS)
M. Di Cicco , C. Castagna , S. Portaleone , D.1 1 1
Costantini , R. Padoan , A. Bassotti2 2 2
Department ENT, University of Milan, Italy, Department1 2
Pediatrics-CF centre, University of Milan, Italy
Mucoceles are benign mucus-secreting cysts lined with res-
piratory epithelium that can occur in paranasal sinuses. In
Cystic Fibrosis (CF), the congenital epithelium alterations
causing excessively viscous mucus, bacterial overgrowth
and infection, lead to paranasal sinuses obstruction. This
condition in rare cases evolves in a slow concentric expan-
sion named mucocele, that displaces and destroys surround-
ing structures and can cause local, orbital and intracranial
complications.
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The ENT evaluation of CF patients with nasal endoscopy
and CT scan, led us to a correct early diagnosis.
We treated 6 CF patients with mucocele (3 male and 3
female), the age of the patients ranges from 7 months to 5
years (mean age 3.16 years). All patients presented with
persistent rhinorrhea, snoring since birth with SaO2
decrease, respiratory distress in absence of other rhino-oro-
pharyngeal pathologies.
In two patients the neoformation was located at the naso-
lacrymal duct, two had maxillary mucoceles and two had
monolateral ethmoido-maxillary mucocele.
Since that the gold standard in nasal surgery is actually
ESS, we consider external sinus procedures inappropriate
to approach CF mucoceles.
The patients received seven days of systemic i.v. antibiotic
therapy, vitamin K, respiratory physiotherapy and nebulized
corticosterids prior to surgery.
We have not been faced with particular intraoperative com-
plications during surgery and it has been always possible
to remove completely the neoformation, infected in three
cases (pyomucocele) by Pseudomonas.
At surgery of nasolacrymal duct mucoceles only thick
fibrous tissue separated the content of the mass from orbital
fat showing that in these cases ESS is essential to avoid
orbital involvement.
All symptoms and particularly SaO decrease dramatically2
regressed after mass removal and no recurrency was
observed after 12 months at endoscopic follow up.
Pediatric sinus mucocele occurs almost exclusively in CF
patients, therefore respirator.
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POSTURAL ASSESSMENT BY QUANTEC.
SCANNING IN ADULT CYSTIC FIBROSIS (CF)
PATIENTS
R. Tattersall, D. Groves, M. Ledson, M. Walshaw
Regional Adult CF Unit
Patients with cystic fibrosis may develop postural problems,
due to progressive lung disease, malnutrition, or poor bone
mineralisation. To investigate this further, we studied the
posture of 63 adult CF patients (mean age 24 years wrange
15–53x, 29 female) by noninvasive assessment of their
back topography, using the validated Quantec. scanning
technique in both normal and a standardised corrected pos-
ture. Compared to 33 control individuals (mean age 23
years wrange 18–54x), CF patients were more kyphotic both
in normal (P-0.0001) and corrected posture (P-0.001).
CF females had a greater angle of lordosis than CF males
in normal posture (mean 47.5 v 41, P-0.01), but were less
kyphotic in both postures (normal posture: mean angle 46.6
v 52.0, P-0.05; corrected posture: mean 41.3 v 50.5, P-
0.02). In normal posture, there was a correlation between
diminishing vital capacity and worsening back asymmetry
(Suzuki index: rs0.25; P-0.05; POTSI: rs0.31, P-
0.05; Cobb angle: rs0.31, P-0.05), and diminishing
FEV1 and increasing kyphotic angle (rs0.40, P-0.01). In
corrected posture, back asymmetry (Cobb angle) correlated
with increasing age (rs0.42, P-0.001) and diminishing
FEV1 (rs0.35, P-0.01), and diminishing spirometry cor-
related with increasing angle of kyphosis (rs0.37, P-
0.01). Thus, we have shown that worsening spinal
deformity is associated with deteriorating lung function.
Furthermore, when the kyphotic angle in corrected posture
was compared to the corrected-to-normal ratio (an indica-
tion of the mobility of the thoracic spine) there was a strong
correlation (rs0.75, P-0.0001), suggesting that the pos-
tural abnormalities may be reversible. These results confirm
that most CF adult patients have spinal deformities, some
of which may be corrected by postural advice. Further stud-
ies need to be performed to assess the value of postural
therapy and spinal mobilisation exercises in patients with
cystic fibrosis.
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RELATIONSHIP BETWEEN POSTURE AND
AUTONOMIC FUNCTION IN ADULT CF
PATIENTS
R. Tattersall, A. Mirakhur, D. Groves, M. Ledson, M.
Walshaw
Regional Adult CF Unit
We have already shown that adult CF patients may have
abnormalities of autonomic function (24th European CF
Meeting Vienna 2001), and that many CF patients also have
musculoskeletal problems and an abnormal posture (23rd
European CF Meeting Stockholm 2000). We speculated
that dysfunction of the autonomic nervous system may play
a part in overall neuromuscular control and thus contribute
to postural abnormality. In order to investigate this further,
we have compared parameters of autonomic function with
posture in a group of 17 adult CF patients (mean age 25
years wrange 17–53x, 11 male). The Quantec scanning
method was used to make measurements of back asym-
metry, including the angles of kyphosis and lordosis, in both
normal and corrected (forced) posture. The validated Var-
iacardio TF4 device, employing a modified orthostatic load,
was used to measure cardiovascular autonomic response,
and this was taken as an indication of overall autonomic
function. There were significant correlations between wors-
ening autonomic function and increasing postural abnor-
mality in terms of the angle of lordosis in both normal and
corrected postures (rs0.51, P-0.05), and with the angle
of kyphosis in normal posture (rs0.59, P-0.01). Fur-
thermore, in normal posture measures of back asymmetry
showed that as autonomic system functioned worsened,
back asymmetry increased (Cobb angle: rs0.48, P-0.05;
Suzuki index: rs0.54, P-0.05). These correlations were
abolished in corrected posture, suggesting an interaction
between the degree of autonomic function and the patient
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s normal habitus. Thus, we have shown that there is a rela-
tionship between worsening posture and deteriorating auto-
nomic function in a group of adult CF patients. Whether
there is a causal link or this merely reflects the overall level
of CF disease requires further investigation.
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RELATIONSHIP BETWEEN POSTURE AND
SYMPTOMS IN ADULT PATIENTS WITH CYSTIC
FIBROSIS
R. Tattersall, T. El-Safi, B. Govin, M. Ledson, M. Walshaw
Regional Adult CF Unit
We have shown using the Quantec scanner that most CF
adults have spinal deformities. To investigate this further,
we surveyed 63 patients (mean age 24 wrange 15–53x, 29
female) using a structured questionnaire paying attention to
back pain (0–10 VAS), sputum expectoration, breathless-
ness, and perceived posture, and correlated these with the
postural abnormality observed. We made measurements in
both a normal and forced (corrected) posture. 51 patients
(83%) had chronic back pain (24 w38%x severe), 44 w86%x
in the lower back. The intensity of pain correlated with the
degree of abnormal lordosis both in normal (rs0.28, P-
0.05) and corrected posture (rs0.26, P-0.05). The degree
of thoracic kyphosis correlated with sputum productiony
day (rs0.35, P-0.01). Furthermore, patients with severe
pain produced more sputum (rs0.25, P-0.05). 31 (49%)
considered their posture to be poor, were more kyphotic in
both normal and corrected posture than the remainder
(angle of kyphosis: normal posture mean 52.8 v 46.2 wP-
0.01x, corrected posture mean 53.5 v 38.9 wP-0.001x), and
more lordotic in corrected posture (angle of lordosis: mean
44.5 v 39.9, P-0.04). They had more chronic back pain
(pain score: mean 5.3 v 3.6, P-0.02) and were more
breathless on exercise (Borg score: mean 2.5 v 1.5, P-
0.02). They also had a greater corrected-to-normal kyphosis
ratio (mean 1.00 v 0.85, P-0.005), indicating a greater
degree of spinal flexibility suggesting that their postural
abnormalities may be reversible. Thus, we have shown that
many CF patients are aware that their posture is poor and
that some abnormalities may be reversible. Furthermore,
back pain is very common poor posture, coupled with
increased expectoration, may play a part. We speculate that
the flexed position often adopted whilst coughing may
exacerbate chest pain. We are now evaluating the effect of
postural therapy and spinal mobilisation on CF patients
posture and back pain.
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FABRICATED ILLNESS IN CYSTIC FIBROSIS: A
ROLE FOR AIRWAY ION TRANSPORT
STUDIES?
K.W. Southern , E.F. Burrows , J.J. Cottrell , H.L.1 2 2
Wallace , P.M. Barker1 3
Department of Paediatrics, University of Liverpool, UK,1
Regional Paediatric CF Unit, Alder Hey Children’s Hos-2
pital, UK, University of North Carolina at Chapel Hill,3
North Carolina, USA
Aims: To highlight a potential role for airway ion transport
studies in suspected cases of Munchausen Syndrome by
Proxy (MSP). MSP is a complex disorder in which a parent
(generally the mother) fabricates chronic illness in their
child by giving false history, altering tests or causing phys-
ical injury.
Methods: We report two cases, one in the UK and one in
the USA.
Results: Case 1: Child referred, at parent’s request, to a
Paediatric CF Unit following lower respiratory tract infec-
tion. Repeated sweat electrolytes high (range 140–1000
mmolyl). Extended genetic screen negative. Pancreatic suf-
ficient with good weight gain. Frequent telephone calls
made to the CF team reporting symptoms of persistent
cough, resulting in 4 admissions for IV antibiotics. Exam-
ination and chest X-ray normal. After 12 months (because
of diagnostic uncertainty) nasal potential difference (PD)
measurement and two sweat tests were performed under
GA. Nasal PD (basal PD, y30 mV; Delta amiloride, 12
mV; Delta zero Cl and isoprenaline, y10 mV) and sweaty
test results were normal. Subsequent sweat test under super-
vision was normal. Family counselled and referred to Social
Services.
Case 2: History of failure to thrive and fatty stools. Repeat-
ed sweat electrolytes variable with large differences
between simultaneous samples from left and right forearms.
Results generally very high (e.g.,)1000 mmolyl). Extend-
ed genetic screen negative. Nasal PD under sedation, nor-
mal (basal PD, y15.5 mV; Delta amiloride, 7.8 mV; Delta
zero Cl and isoprenaline, y12.5 mV). Subsequent sweaty
test under supervision, normal. Family currently under
supervision of local Paediatrician.
Discussion Cases of factitious CF have been reported. Phy-
sicians and CF teams should be aware that unusual sweat
electrolytes (high)160 or varied) may be associated with
the addition of salt to the test. Airway ion transport studies
(nasal PD) under controlled circumstances may aid the
diagnosis of MSP in these difficult cases.
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DRUG-INDUCED HYPERPROLACTNAEMIA IN
CYSTIC FIBROSIS ADULTS
R. Bright-Thomas, J. Redfern, D. Clough, A. Verma, A.
Webb, A. Jones
Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Man-
chester, UK
Background: Prolactin initiates and maintains lactation and
is known to regulate dopamine turnover and affect gonad-
otrophin secretion in the hypothalamus. Physiological ele-
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vation of serum prolactin occurs during pregnancy and
lactation. Pathological elevation of prolactin may be caused
by pituitary tumours, primary hypothyridism, polycystic
ovary syndrome and renal failure. A number of drugs
including antiemetics, which are frequently used for nausea
and as pro-motility agents in CF patients, modulate dopa-
mine levels and are known to cause hyperprolactinaemia.
Clinical features include galactorrhoea, oligoyamenorrhoea
and subfertility in women, decreased libido in both sexes,
delayed or arrested puberty and secondary hypogonadism.
Method and results: Over the past 2 years we have
assayed prolactin levels in 135 CF patients attending our
centre. Serum prolactin was found to be greater than 1000
mUyl (normal range: men -450 mUyl, women -600
mUyl) in 16 patients (12%). 13 are female. No patient was
pregnant or lactating and no patient has been found to be
hypothyroid or have evidence of polycystic ovary syn-
drome. 14y16 patients were on antiemetics when hyperpro-
lactinaemia was identified. Prolactin levels have returned to
normal with cessation of the drug in 6 patients, 5 patients
await repeat assay, 2 have died and 1 has been lost to fol-
low-up. 2y16 patients have chronic renal failure following
heart-lung transplantation and take antiemetics; 1 of these
patients is also on verapamil for hypertension which
decreases dopaminergic tone.
Conclusion: CF physicians need to be aware of possible
drug-induced hyperprolactinaemia in their patients and
withdraw the causative drug. The side effects of subfertility,
decreased libido, delayed or arrested puberty and secondary
hypogonadism (which may result in reduced bone mineral
density) may exacerbate already significant problems in the
CF population.
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LIVER GLYCOGEN SYNTHASE DEFICIENCY IN
A CHILD WITH CYSTIC FIBROSIS
E. Raeder , T. Luecke , A. Das , F.Tegtmeyer , M.1 1 1 2
Ballmann1
Medical School Hannover, Pediatric Department, Hanno-1
ver, Germany, Park Schoenfeld Children Hospital, Kassel,2
Germany
We report a girl with cystic fibrosis (CF) (delta F508
homozygous) who had suffered from postprandial hyper-
glycaemia, an HbA1c at the upper normal range and occa-
sional morning drowsiness and fatigue since the age of 5
6y12 years. The oral glucose tolerance test (OGT) at that
time was normal. Since diabetes or impaired glucose tol-
erance (IGT) is common in CF, the tentative diagnosis was
an unspecified abnormality in glucose homeostasis. At the
age of 6 6y12 years further metabolic profiles showed fast-
ing hypoglycaemia, hyperketonaemia and normal lactate.
She was admitted to our hospital at the age of 7 3y12 years
for further investigation. She was 109 cm tall, weight 15.5
kg (both below the 3rd centile). Beside hepatosplenome-
galia no other abnormal physical signs were detected. Her
lung function test was normal. Routine screening showed
an elevated HbA1c, postprandial hyperglycaemia and fast-
ing hypoglycaemia. The OGT at that time demonstrated
IGT. Because metabolic studies detected IGT but did not
explained the severe fasting hypoglycaemia and an addi-
tional metabolic disease was suspected. Metabolic profiles
considered characteristic for hepatic glycogen synthase
deficiency. Diagnosis was proven by low liver glycogen
content and deficiency of glycogen synthase in liver biopsy.
Liver glycogen synthase deficiency is likely to be more
common than believed nowadays. Symptoms may be mild
for years and therefore diagnosis may be delayed or missed.
Seven families have been described with 14 affected chil-
dren. Here, we report an additional patient with this enzyme
deficiency. Diagnosis was complicated by CF, because
interfering with glucose homeostasis. We compare this case
with previously published cases to draw the attention to this
disorder. Further therapeutic problems might develop with
the occurrence of CF-dependent diabetes mellitus.
P313
2-YEAR FOLLOW-UP OF PATIENTS WITH CF
AND IATROGENIC ADRENAL INSUFFICIENCY
CAUSED BY IN VIVO INTERACTION OF
ITRACONAZOLE AND BUDESONIDE
M. Skov , K. Main , I.B. Sillesen , J. Muller , C. Koch ,1 2 3 2 1¨
S. Lanng ,1
CF Center, Department of Growth and Reproduction,1 2
National University Hospital, Copenhagen, Clin. Pharm.3
Unit, Gentofte Hospital, Denmark
Introduction: Iatrogenic adrenal insufficiency was recently
observed in patients with cystic fibrosis (CF) receiving itra-
conazole because of allergic bronchopulmonary aspergil-
losis (ABPA) and who were also on inhaled budesonide.
Development of Cushing9s syndrome in one patient led to
diagnosis of several other patients with this complication.
Both agents were discontinued in all patients on itracona-
zole, followed by hydrocortisone substitution at a dose of
15 mgym (or prednisolone) of insufficient patients.2
Aim: To evaluate the degree and duration of adrenal
insufficiency.
Patients and methods: 31 patients with ABPA had been
on long-term treatment with high-dose itraconazole (400–
600 mgyday); 25 in combination with high-dose budeson-
ide (800–1600 mgyday, as anti-inflammatory agent); and
11 of these were found to have adrenal insufficiency (sup-
pressed spontaneous ACTH and stimulated cortisol).
ACTH test: after i.v. injection of 250 mg tetracosactid plas-
ma-cortisol was measured after 30 and 60 min.
Results: After 2 years, 2y11 patients have normalised adre-
nal function and corticosteroid substitution has been dis-
continued. 7y11 patients have subnormal adrenal function.
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Two patients were not tested because of treatment with
prednisolone.
Discussion and conclusion: Itraconazole inhibits CYP3A
interfering with steroidogenesis and—since budesonide is
metabolised by hepatic CYP3A—leads to increased relative
systemic concentration of budesonide. High systemic ster-
oid concentration, dose and duration of treatment or indi-
vidual receptor susceptibility are suggested to cause the
serious side effect. Inter-individual differences in steroid
receptor susceptibility may account for differences in the
degree of adrenal suppression. This follow-up study shows
that adrenal function is slowly regained but clearly sup-
pression may last for several years after cessation of the
causative agents and permanent damage in some patients
cannot be ruled out.
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PSEUDO-BARTTER’S SYNDROME: A
SPECTRUM OF DISORDERS ASSOCIATED
WITH CYSTIC FIBROSIS
V. Hresic-Krsulovic, M. Percl, I. Golmajer-Vlahovic, J.
Cepin-Bogovic
Children’s Hospital Zagreb, Klaiceva 16, University of
Zagreb, Medical School, Department of Pediatrics, Croatia
Bartter’s syndrome is a congenital abnormality character-
ized by metabolic alkalosis, hypokalemia and hyper aldos-
teronism. Acute dehydration unith hypochloronatremic
metabolic alkplosis is a classical complication of cystic
fibrosis (cf) this symptoms associated with hypokacemia in
cystic fibrosis represent pseudo-bartter’s syndrome. The
clinical presentation pseudo-bartter’s syndrome of 4 chil-
dren with CF in children’s hospital are presented. Two chil-
dren were girls and two were boys. All the patients had the
deltaF508 mutation either in homozygosity or compound
heterozygosity with another CF mutation. The children
were in age between 4 to 21 months. Clinical symptoms
which were precedent condition of pseudo-bartter’s syn-
drome were in all cases vomiting during 2–14 days. Two
patients had reduced appetite and in 2 children respiratory
symptoms increased. Investigations showed metabolic alka-
losis (BE q5.2 to q26) hyponatremia (115–137 mmoly
l), hypochloremia (70.5–95.7 mmolyl) and hypokalemia
(2–3.5 mmolyl).
All our patients were dehydrated with paradoxically normal
diuresis.
Children with symptoms of bartter’s syndrome must be fol-
lowed by examination for cystic fibrosis.
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PSEUDO BARTTER-SYNDROME IN TURKISH
CYSTIC FIBROSIS CHILDREN
Ebru Yalcin , Ilker Cetin , Mustafa Koyun , Deniz1 1 1
Dogru , Nural Kiper , Ugur Ozcelik , Ayhan Gocmen2 3 4 3
Pediatrician, Assistant Professor of Pediatrics, Professor1 2 3
of Pediatrics, Associate Professor of Pediatrics, Ankara,4
Turkey
Aim: Acute dehydration with hypochloremic, hyponatremic
metabolic alkalosis (Pseudo Bartter-syndrome) is a well-
known complication of cystic fibrosis (CF). The aim of this
study was to determine the clinical and laboratory features
of Pseudo Bartter-syndrome (PB) in children with CF.
Methodology: We reviewed the medical records of 40 chil-
dren with CF who were under follow-up in our department
from 1979 to 2001.
Results: Pseudo Bartter-syndrome was observed in 40 of
296 CF patients (13.5%) (19 boys, 21 girls) with a mean
age of 5.2 months (1–18 months) at the first attack. All
patients experienced vomiting, sweating, loss of appetite,
irritability and dehydration findings during PB episodes.
Most of the PB attacks were diagnosed during the summer
months (ns15). Mean plasma sodium, potassium and
chloride levels (mEqyl) were 136 (106–143), 3.6 (1.6–
6.1), 82 (60–110), respectively. Metabolic alkalosis was
detected in all patients, mean blood pH and HCO levels3
were 7.49 (7.31–7.61) and 37 mmolyl (25–62), respec-
tively. In all patients, chronic lung disease and malabsorp-
tion findings accompanied PB. All the patients were
managed with intravenous fluids and NaCl solutions in
addition to oral salt supplementation. Mean treatment dura-
tion was 11.5 days (2–43). During the follow-up, 18
patients (45%) required hospital admissions due to recur-
rent PB attacks, total attacks number was 68 in 40 patients.
The F508 mutation was the most common mutation detect-
ed with a frequency of 50% in our CF patients with PB
(homozygosity in 5 and heterozygosity in 15 patients).
Conclusion: Cystic fibrosis should be included in the dif-
ferential diagnosis of hypochloremic, hyponatremic meta-
bolic alkalosis in children. Children with CF are at risk of
developing PB particularly in hot weather and after vom-
iting. Vomiting and abrupt diminution of oral intake are
important signs alerting the physician to be suspicious for
the development of Pseudo Bartter-syndrome.
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SUBMANDIBULAR SIALOLITHIASIS IN A
PATIENT WITH CYSTIC FIBROSIS
I. Adams , D. Rostalski , V. Sollich1 2 1
Department of General Paediatrics and Neonatology, Med-1
ical Faculty, Otto von Guericke University, Department of2
Otorhinolarynology, Medical Faculty, Otto von Guericke
University, Magdeburg, Germany
Paediatric cases of sialolithiasis are very uncommon. Due
to their abnormal salivary secretions with elevated calcium
and phosphate levels, cystic fibrosis patients are predis-
posed for stone formation in the salivary glands. However,
sialolithiasis in cystic fibrosis patients is very rarely
described.
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We report on a 13 year old boy, who was diagnosed with
CF (F508dely2143del) at the age of eleven when he was
hospitalized for further diagnostic since he presented with
increased liver enzymes during a routine investigation. In
his past medical history he underwent nasal and paranasal
sinus surgery three times because of recurrent polyposis
nasi et sinuum. He has normal pulmonary function
parameters.
Actually he presented with painful postprandial swelling of
the left regio submandibularis. Sonography showed multi-
ple concrements and postprandial dilation of salivary ducts.
Therefore the entire left submandibular gland was extirpat-
ed. At that time the histopathological investigation revealed
a chronic-nonspecific fibrosing sialadenitis.
This case displays an unusual presentation of cystic fibrosis
with manifestation of symptoms mainly in the upper res-
piratory and digestive tract. The typical pulmonary disease
is missing.
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FAVOURABLE OUTCOME OF MULTIPLE
CEREBRAL ABSCESSES IN A CYSTIC
FIBROSIS PATIENT
M.A. Monti , G. Pizzamiglio , N. Gervasini , A. Giunta ,1 1 1 2
G.C. Secchi1
Centro Fibrosi Cistica Regione Lombardia – Sezioni1
Adulti – I.C.P, Milano, Centro Fibrosi Cistica Regione2
Lombardia, Italy.
Brain abscess (BA) is a rare pathology and few cerebral
abscesses are reported in patients with Cystic Fibrosis (CF).
We present a case of multiple brain abscesses in a CF
patient with favourable outcome.
Male, 36 yrs, CF diagnosed at the age of 12, sweat test
positive, DeltaF 508y1717-1G™A, chronic S. aureus res-
piratory infection, severe broncopulmonary involvement
(FEV1s22%, O2LT since 1996), admitted to our CF Cen-
tre on 15y06y01 for fever and respiratory deterioration after
surgical treatment of malleolar fracture. The patient was
treated with three sequential antibiotic scheduleqitracona-
zole for recurrent broncopneumonia. Fever disappeared
since 05y07y01.
08y07y01: A transient sensorimotor right emisyndrome
induced fall and skull contusion. Cerebral MRI (CMRI)
showed a little hyperintense area in frontomesial left cor-
tical region, another area of doubtful signal in posterior
right thalamic region.
19y07y01 and 22y07y01: Paresthaesias and myoclonic sei-
zures at the right extremities occurred: antiepileptic therapy
was started and the patient did not have any more neuro-
logical symptoms.
23y07y01: CMRI with gadolinium showed the enlargement
of the frontal left lesion, the thalamic one was unchanged.
Thrombosis, autoimmune vasculitis, lymphoma, primitive
or secondary tumor were ruled out. Cultures, viral PCR,
Aspergillus fumigatus antigen in CSF were negative. Diag-
nostic or therapeutic neuro-surgical intervention was
refused.
25y07y01: Empirical therapy with ceftriaxone 4 gydie i.v.,
metronidazole 2 gydie i.v. was started (qitraconazole).
27y08y01: CMRI: frontal lesion 30% reduction, thalamic
lesion reduction.
04y12y01: CMRI: further frontal left lesion reduction; no
thalamic lesion.
The i.v. long-term antibiotic and antimycotic therapy was
discontinued only in January, 2002 without any remarkable
clinical or biochemical negative effect. The patient is now-
adays asympomatic.
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MENINGITIS BY FLAVOBACTERIUM
MENINGOSEPTICUM (FM) IN AN INFANT WITH
CYSTIC FIBROSIS (CF)
P. Canuzzi, M. Rolla, S. Bertasi, M. Zaccagnini, S.
Quattrucci
Centro Fibrosi Cistica Regione Lazio, Istituto di Clinica
Pediatrica, Universit‘ degli Studi di Roma ‘‘La Sapienza’’
Introduction: Meningitis is a rare complication of CF,
especially by FM. FM is an oxidase positive, Gram nega-
tive fermentative bacillus which has high virulence in the
newborn and causes high mortality meningitis. The infec-
tion is attributed to contaminated hospital equipment and
solutions and is highly resistant to antibiotic therapy. Typ-
ically infants with FM meningitis have temperature below
normal.
Case report: A CF newborn (Male, IRT positive, sweat
test: Cl s70 mmolyl) without respiratory symptoms buty
with severe pancreatic insufficiency, during third day of life
underwent surgery for meconium ileus without bowel resec-
tion. After surgery he received ten days of parenteral nutri-
tion. He had anaemia, intermittent fever and a negative
abdomen. Reactive C Protein resulted positive, chest X-ray
negative and white blood count was 24.000ymmc. The sur-
gical wound was infected by St. aureus and treatment with
teicoplanine was started. General conditions improved,
fever vanished, but the patient occasionally presented vom-
iting without others symptoms. Oesophagus ultrasonogra-
phy proved a mild gastro-oesophagus reflux. After ten days
the infant presented intracranic hypertension with repeated
vomiting episodes, tension of antherior fountain, hypotonia,
fixed look, seizures of lower limbs. Liquor culture showed
panresistant FM. Combined therapy with vancomycine and
ciprofloxacine i.v. was started and infection was controlled.
The patient underwent laser-ventricularscopic operation and
no more episodes of intracranic hypertension occurred. Five
months later clinical conditions are improved.
Conclusions: Although meningitis due to FM is a rare
complication in CF patient, it should nevertheless be sus-
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pected after surgery for meconium ileus and when the clin-
ical picture is not clear.
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SUCCESSFUL PREGNANCY AFTER IN VITRO
FERTILISATION WITH SPERM OBTAINED FROM
TESTIS BIOPSY FROM A YOUNG ADULT WITH
CYSTIC FIBROSIS
K. Holics , R. Ujhelyi , V. Forgacs , P. Wiegand , M.1 1 2 2
Nagy2
Heim Pal Hospital for Children, CF Centre, Budapest,1
Institut of Forgacs Budapest, Hungary2
It is well known that approximately 97% of men affected
by cystic fibrosis (cf) are infertile caused mostly by con-
genital bilateral absence of vas deferens (CBAVD). Now-
days the newly developed assisted reproductive techniques
make it possible also for the male cf patients to father
children.
In our cf centre, after genetic counselling we offer for all
adolescent patients an andrological examination’s possibil-
ity. In the last 3 year 5 young adults underwent this exam-
ination and in all of them obstructive azoospermia was
found.
At the end of 2000 one of the five patients—who has a
healthy wife—requested assistance for his family planning.
The 26 years old male patient was diagnosed with cf at the
age of 3 and was cared in the Cf Centre of the Heim Pal
Hospital for Children. He is homozygous dF 508. The res-
piratory and digestive manifestations can be balanced with
proper treatment, however the FEV 1 is only 36% of pre-
dicted. He has been colonised with staph, aureus, therefore
requires regular intravenous antibiotic treatment and anti-
biotic inhalation.
The couple planned a normal family life, therefore they
requested referral to an Assisted Fertility Institute.
Three in vitro fertilisation (IVF) cycles have been per-
formed. The first time sperms were obtained from testis
biopsy, good quality embryos were transferred, but the
women did not become pregnant. Second time we used fro-
zen testis tissue, obtained from the first attempt. We had
good fertilisation rate, but no pregnancy. The third time we
used fresh testis tissue, 8 oocytes were fertilized, four
embryos transferred. Three weeks later the ultrasound
examination showed two gestational sacs. Two weeks later
one embryo development could observed. The pregnancy
was without complication and resulted in full term delivery.
It was the first case in Hungary with which we wanted to
show that the prospects for fatherhood in cf are excellent
with this technology. Risks and ethical aspects are under
consideration.
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THE LATE DIAGNOSIS OF CYSTIC FIBROSIS
P. Kohout , K. Vonkova1 2
IInd Department of Internal Medicine, Department of1 2
Pneumology, Charles University Hospital, Hradec Kralove,
Czech Republic
Introduction: Cystic fibrosis is a disease of various organs
with the variable spectrum of manifestations. The diagnosis
in most patients is done in first 2 years of their life, more
often when steatorrhea is present.
In patients with mild symptoms the diagnosis is made most-
ly at a later age, 7% of patients from Genoa CF Center in
1992 were diagnosed when 13 years or older, 3 patients at
31, 39, 40 years of age, respectively. When the diagnosis
is done later, the danger of complications rises.
Case report: 42 years old female was admitted for recur-
rent pulmonary infections.
History: 24 years of age, insulin-dependent diabetes mel-
litus; 35 years of age, recurrent infections of upper airways;
since 38 years of age, recurrent pneumonia. No dyspeptic
problems, no steatorrhoe.
Objective: height 1.62 m, weight 40 kg, BMI 15.2.
Laboratory: Hemoglobin 92, hematocrite 0.32, WBC 8.2;
S-Glucose 12 28 mmolyl, ALT 0.37, AST 0.37, ALP 2.5,
GMT 5.2. Total protein 64 gyl, albumine 31 gyl. Feces
fat—negat., fatty acids—mild positive. Sweat test—positive
(86.8).
Sonography: Hepatomegaly, steatosis, atrophic pancreas.
Pulmonary functions: FVC 73%, FEV1 69%.
Bone density: 53% of the appropriate value.
Genetics: dF508 heterozygous.
Diagnosis: Cystic fibrosis.
Conclusion: In the patients with the mild symptoms of cys-
tic fibrosis the diagnosis is made often very late. It is nec-
essary to have a suspicion on the cystic fibrosis also in adult
patients with combination of recurrent pulmonary infection
associated with malnutrition (even without dyspeptic syn-
dromes andyor steatorrhoe), insulin-dependent diabetes
mellitus and other problems (hepatopathy).
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MEDICAL AND SOCIAL PROVISION OF CYSTIC
FIBROSIS PATIENTS
A. Kapranov, Z. Biistinova, I. Osipova, A. Voronkova, N.
Kapranov, N. Kashirskaya
Research Centre for Medical Genetics RAMS, Moscow,
Russia
A positive experience of the cooperation between the Rus-
sian CF Centre, the Moscow Department of Public Health
and an Association of CF Children’s Parents made possible
to develop individual treatment schemes and organize time-
ly outpatient observation of these patients, provide a treat-
ment continuity of CF patients between the Russian CF
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Centre and paediatric outpatient departments as well as
Adult CF Patients’ Centre. It also permitted to arrange a
distinct scheme for the full medicine provision and reha-
bilitation of CF patients and to improve their quality of life,
to control precisely and to diminish financial expenses for
cystic fibrosis patients’ treatment; to train doctors and nurs-
es of Moscow outpatient departments in CF patients’ man-
agement and to improve a quality of outpatient medical care
for CF patients.
Since February 1996 the Russian CF Centre has been prac-
ticing an antibacterial therapy at home. The presence of an
intravenous catheter did not disturb a normal life activity
of a child and his family, including attendance a school. In
2000 the Moscow Department of Public Health and the
Russian CF Centre performed the nurse s training in 163
paediatric outpatient clinics regarding a care for a peripheral
intravenous catheter and infusing through it.
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WEIGHT GAIN AND RESPIRATORY FUNCTION
IN RELATION TO SCHOOL HOLIDAYS FOR
CHILDREN WITH CYSTIC FIBROSIS
Alan Cade, Maggie O’Connell, Steven P. Conway, Keith G.
Brownlee
Regional Paediatric Cystic Fibrosis Unit, St. James’ Uni-
versity Hospital, Beckett Street, Leeds LS9 7TF, UK
Introduction: There is a complex inter-relationship
between body weight, lung function, morbidity and mor-
tality in cystic fibrosis. It is not known if children with CF
have seasonal fluctuations in weight gain, related to levels
of physical activity, viral respiratory tract infections, school
terms or other factors. A previous study has demonstrated
peaks in paediatric asthma admissions during school terms
suggesting a viral aetiology for exacerbations (1).
Aims: To investigate the seasonal fluctuations in weight
gain, particularly with respect to school holidays, in a
cohort of 90 school age children with CF over a 2 year
period. The relationship between weight changes and FEV1
changes have also been studied.
Results: The study has identified an acceleration in weight
gain around the major school holidays that may be
explained by reduced exposure to and decreased incidence
of respiratory tract infections. Respiratory function analysis
has demonstrated a remarkable correlation with weight
changes.
Conclusions: This study confirms that a fall in weight gain
is associated with a worsening of respiratory function and
cannot be considered a normal phenomenon associated with
seasonal changes in physical activity, diet, etc. Episodes of
poor weight gain must be investigated and treated appro-
priately, particularly during school holidays when acceler-
ated weight gain is anticipated.
1. Storr J. and Lenney W. (1989). School holidays and
admissions with asthma. Arch Dis Child 64: 103–107.
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CYSTIC FIBROSIS—WHO CARES?
K. Deem, F. Thornhill, A. Dewar
Paediatric Department, Poole Hospital NHS Trust, UK
National guidelines for standards of care for cystic fibrosis
patients suggest that health and survival are improved
where care is delivered by a multidisciplinary team led by
a consultant and nurse specialist. We have undertaken a
retrospective review of paediatric patients at our hospital.
The study covered a defined period from January 1995 to
December 2000, which represents three 2-year periods. In
1995 and 1996 care to CF patients was delivered by a gen-
eral paediatrician; 1997 and 1998 reflected introduction of
a consultant with a specialist interest in CF; 1999 and 2000
a CF nurse specialist joined the team.
Guidelines suggest at least 4 routine clinic visits per patient
per year, and an annual review by a specialist CF consult-
ant. Over the study period, hospital attendance for routine
visits increased from 3.6 to 6.6 per patient and annual
reviews rose from 50 to 97.2%. Number of intravenous
antibiotic courses increased from 21 to 44, but proportion
administered at home rose from 46 to 60%. Interestingly
from 1995 to 2000 our patient numbers increased from 17
to 42 patients. The regional database for South and West
England showed a stable paediatric population from 1995
to 2000, suggesting that our clinic has grown for reasons
other than CF population trends. Introduction of a specialist
CF consultant and a multidisciplinary team has certainly
improved our compliance with national guidelines. Spe-
cialist knowledge may also have led to a lowering of our
threshold for suspicion of CF as a diagnosis, and migration
of CF families into our area. This review confirms that an
increase in service provision can lead to an increase in serv-
ice uptake better for our patients, better for us?
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UNEXPECTED OUTPATIENT RESOURCE
DEMANDS ASSOCIATED WITH A LARGE
ADULT CF UNIT
B. Govin, C. Cowperthwaite, D. Russell, M. Ledson, M.
Walshaw
Regional Adult CF Unit
To maintain good health, CF individuals require more
healthcare attention than do other chronically ill patients
and grouping them into appropriately funded CF centres
provides the best outcome. In our large CF centre (150
adult patients), we provide a number of consultant based
weekly clinics (including for B. cepacia), which patients
attend as necessary and at least every two months. This
arrangement allows a focused and efficient use of personnel
and facilities. We have noticed however, that even after CF
nurse contact, some patients attend the service unplanned
outside clinic times, when the resources are uncoordinated.
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To investigate this, we have audited the number of and rea-
sons for out-of-hours consultations to our outpatient serv-
ice, over 1 year when there were 900 routine CF
consultations in-hours at clinics. Excluding direct admis-
sions to the wards, there were 222 out-of-hours attendances
(24.6% of the total), 78 by males. 93 cases (42%) were
for acute chest exacerbations: 45 (48%) started home IV
antibiotics, 18 (19%) home oral antibiotics, and the remain-
ing 30 (33%) were admitted. 45 cases (20%) were for other
acute problems (24 w54%x abdominal pain, 9 w20%x chest
pain, 6 w13%x IV line problems, and 6 w13%x vomiting).
In 30 cases (13%), out-of-hours visits were for segregation
to prevent cross infection, mainly non-epidemic B. cepacia.
In 36 cases (16%), visits were for social reasons (fitting in
with workycollege, returning from holiday, or ease of trans-
port). Finally, the remaining 18 cases (8%) were inappro-
priate, when patients attended with routine problems for no
apparent reason.
Thus, this survey shows that the demands upon an adult
CF outpatient service are continuous, and a significant pro-
portion of attendances are unplanned and outside normal
clinic times. Whilst most are unavoidable, a quarter of cases
they could have been prevented. We are now working with
patients to ensure that our scarce outpatient resources are
utilised most appropriately.
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DO CF PATIENTS UNDERSTAND THEIR DRUG
THERAPY?
J. Crawley, M. Ledson, M. Walshaw
Regional Adult CF Unit
Patients with CF need to take many different routine drug
treatments, either as therapy for CF complications or to
replace deficiencies associated with the condition. It is well
known that compliance with complicated drug therapy is
poor, and to investigate the reasons for this we audited the
drug knowledge of a group of 24 consecutive CF patients
admitted to our adult CF unit over a 1-month period. All
were interviewed by the CF pharmacist who recorded the
different medications taken and elucidated whether they
understood the reasons for each therapy.
In terms of replacement therapy, 23 (96%) were taking pan-
creatic enzymes and all knew the reasons for this. 22 (92%)
were taking multivitamin capsules BPC and 13 of these
(59%) did not know why. Also, 16 were taking vitamin E
supplements and 10 of these (62%) did not know why.
In terms of treatment for disease, of the 22 (92%) who took
regular antistaphylococcal antibiotics, only 7 (32%) under-
stood why. 9 (38%) were using dornase alfa, and all under-
stood the reason for using it and when to use it in relation
to physiotherapy. 16 (67%) were on regular short acting
bronchodilator therapy (inhalers or nebulisers), and only 1
(6%) did not know the reason for such therapy.
Conversely, 11 (46%) were using inhaled steroids, and only
3 (27%) of these knew what they were for and why they
were taking them. Furthermore, of the 10 (42%) on regular
oral steroids, only 7 (70%) knew what it was for.
Thus, we have shown that frequently adult CF patients are
not aware of the reasons for many of the therapies that they
are taking, and this may in part explain why compliance is
often poor. It may be of relevant that patients appeared to
understand the need and use of rescue therapies (such as
inhaled bronchodilators and pancreatic enzymes) rather
than those with a prophylactic role (such as vitamin sup-
plements). Our CF pharmacist has now embarked upon an
active program of patient education into their routine drug
treatment.
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CYSTIC FIBROSIS: HOW ARE THE PARENTS
COPING?
M.C. Samaan, B.J. Watson
CF unit, Department of Paediatrics and Child Health, Cork
University Hospital, Wilton, Cork, Ireland
Aims:
– To assess if there were differences between mothers and
fathers in coping with CF
– To identify stressors that affect these parents
– See if lone parents experience more stress than 2-parent
families.
Methods: we conducted an anonymous, self-administered
postal survey.
Subjects: we included all families (Ns73) of children on
the patient register in a regional CF unit affiliated to a Uni-
versity Hospital.
Insruments: we used the GHQ-version 28, a well validated
instrument to detect psychiatric disorders in non-psychiatric
settings. Higher scores (5 or above) indicate poor psycho-
logical health.
We also used a purpose-designed questionnaire for collect-
ing demographic data and various factors that parents find
stressful in dealing with CF we posted a copy to each parent
to fill in and a stamped addressed envelope was provided
SPSS statistical package was used to analyze the results the
ethics committee in hospital approved the project.
Results: response rate was 60% (Ns45), rate of lone par-
ents is 15.6%. 75% of respondents scored less than 5 on
GHQ for both mothers and fathers. Lone parents did not
differ from two parent families. Mothers spent significantly
more time caring for CF child (1.62 hyday) compared to
fathers (0.6 hyday). While 86% of fathers are in fulltime
employment, only 12.5% of mothers are.
Mothers smoking rates are significantly higher than fathers
(28 vs 14.3%, respectively).
Stressful factors identified for both parents include:
Clinic visits, admission to hospital, prognosis, expecting
bad news on clinic visits and coping with work.
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Conclusions: As a group, parents of CF children are mak-
ing good psychological adjustment. However, these fami-
lies are under significant pressures and mothers seem to be
more affected by this taking the role of the primary carer.
There seems to be significant stress attached to dealing with
health care services. We feel that more focus is needed to
provide additional support to these families, especially
mothers.
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TRADITIONAL HOSPITALISATION VERSUS
HOME CARE: ANALYSE OF CHOICE AND ITS
REPERCUSSIONS ON THE CYSTIC FIBROSIS
CHILD’S FAMILY. THE CASE OF THE
INTRAVENOUS ANTIBIOTIC TREATMENT,
FROM THE MATERNAL POINT OF VIEW
L. Lebarrois Gueganton , G. Rault , I. Dugueperoux , C.1 1 2
Ferec , M. De Braekeleer3 2
Centre de Perharidy, 29684 Roscoff, Laboratoire de cyto-1 2
genetique, Faculte de medecine, Universite de Bretagne´ ´ ´ ´ ´
Occidentale, 29200 Brest, Service de genetique molecu-3 ´ ´ ´
laire, Centre hospitalier universitaire Morvan, 29200 Brest
The treatment of intravenous antibiotherapy, marking a
dreaded stage in the evolution of the disease, can be carried
out in traditional hospitalisation (TH) or in home care
(HC). The objective is identify psychological elements
leading CF children’s mothers to prefer TH or HC, then
consequences of their choice. After having recalled the
medical and psychological aspects of cystic fibrosis, a
library search on the topic of the hospitalisation of the chil-
dren makes it possible to pose some starting assumptions.
The method used to verify them is based on semi-directing
talks in the local setting (Ns14), and on a questionnaire
at the national level (Ns115), targeted to mothers of chil-
dren aged from 2 to 14 years. The analysis by themes of
the contents of the talks and the comparative statistic anal-
ysis of the results of the questionnaires make it possible to
pose various results: the choice is strictly depending on the
mother’s age, on the paternal level of study, on the syste-
matisation of the treatments, on the number of previous
IAT, on the home’s fitting out, on the information about
the disease. The choice has consequences on the feelings
of anguish and depression, on the friendly network, on the
leisure activities, on the relations between mothers and sib-
lings. Motivations are essentially based on practical consid-
erations. They are depending on the child and his family’s
well-being, on better care, on a easier organization, on the
desire of investment, on the representation of the disease.
Conclusion: no psychological profile distinguishes mothers
choosing the TH of those opting for the HC. The repercus-
sions of IAT do not differ fundamentally according to the
chosen modality. TH often appears as a period pre-HC.
These types of study, as well as the intervention, on the
field, of psychologists, are major keys to make a real advan-
tage of the chosen modality for all the protagonists, espe-
cially in term of quality of life.
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QUALITY OF LIFE IN CYSTIC FIBROSIS: ARE
CLINICAL MANIFESTATIONS AND TREATMENT
REGIMENS INFLUENTIAL?
L. Gee , J. Abbott , S.P. Conway , C. Etherington , A.K.1 1 2 2
Webb3
Faculty of Health, University of Central Lancashire, Pres-1
ton, PR2 2TQ, UK, Adult CF Unit, Seacroft Hospital,2
Leeds, L514 6UH, Adult CF Unit, Wythenshawe Hospital,3
Manchester, M23 9LT
The progression of cystic fibrosis (CF) is marked by
increased clinical manifestations and interventions within
treatment regimens. The influence of different clinical man-
ifestations and treatment regimens on health related quality
of life (HRQoL) has not been assessed. The study aims to
measure HRQoL across different groups within the CF pop-
ulation using the *Cystic Fibrosis Quality of Life (CFQoL)
questionnaire. The CFQoL is a disease specific measure
consisting of 9 domains: physical functioning, social func-
tioning, chest symptoms, treatment issues, emotional
responses, body image, interpersonal relationships, career
issues and future concerns. HRQoL data, age, gender,
FEV1 and BMI was collected from 223 adolescents and
adults with CF. Participants were case matched for gender,
age, FEV1 and BMI across the following groups: intrave-
nous (IV) access device and no IV device, cepacia and non-
cepacia, non-diabetic and insulin dependent diabetic, lung
transplantation status and nutritional intervention status.
Using Mann–Whitney tests for 2 way comparisons and
Kruskal–Wallis tests for 3 way comparisons, the following
significant differences between groups were found: IV
access groups career issues (Ps0.003), physical function-
ing (Ps0.01) and body image (Ps0.08), cepacia groups
no significant differences, diabetic vs non-diabetics career
issues (Ps0.02), physical functioning (Ps0.04) and body
image (Ps0.07), transplant status chest symptoms (Ps
0.001), emotional functioning (Ps0.03), physical func-
tioning (Ps0.0007), social functioning (Ps0.005),
treatment issues (Ps0.003) and career issues (Ps0.09),
nutritional status body image (Ps0.02). Differences in
HRQoL varied between groups with the majority apparent
between lung transplantation groups. Across group com-
parisons, no differences emerged for future concerns, which
remained low irrespective of group membership.
*For copies of the CFQoL and scoring equations contact J
Abbott (e-mail jabbott@uclan.ac.uk).
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QUALITY OF LIFE (QOL) AFTER LUNG
TRANSPLANTATION (LTX): ARE CYSTIC
FIBROSIS (CF) PATIENTS DIFFERENT FROM
PATIENTS WITH INTERSTITIAL LUNG
DISEASES (ILD)?
G. Ullrich , E. Scharf , J. Penkert , H. Jdnsch , W.1 2 2 3
Schulz , A. Freihorst , J. Niedermeyer2 1 3
Hannover Medical School, Department Pediatric Pulmon-1
ology and Neonatology, University of Braunschweig, Psy-2
chological Institute, Department Clinical Psychology,
Hannover Medical School, Department Internal Medicine3
and Pulmonology
LTx is now considered a well established life saving meas-
ure in patients with terminal lung disease. The clinical
impression is that CF patients often seem to recover partic-
ularly well. However, comparative data are rare.
Method: We intended to study 37 CF patients and 29
(matched for age) ILD patients of whom 18y28 participat-
ed (ageCF 19 to 41 y; mean age 31.6 yyage LD 23 to 41
y; mean age 32.8 y). Time since LTx had to be at least 12
months (median survival 57 y for CFy71 y for ILD
patients, respectively). To assess aspects of QoL we used
the MNnchner Lebensqualitdts Dimensionen Liste (MLDL),
a standardized questionnaire which lists 19 domains of QoL
calculated as 4 scale scores (cf. Heinisch et al. 1991). The
MLDL was administered with three different instructions:
(a) changes in the respective domains; (b) changes in per-
ceived importance of the domain (results not shown here);
(c) satisfaction with the respective domain at present.
Results: The results are summarized in table 1 and show
significant improvement for both groups but no differences
between them.
Improvement of QoL after LTx and satisfaction at present
in 18 ILD patients and 28 CF patients, respectively wmean
score (standard deviation); approx. valuesx. Instruction
form
MLDL scales Improvement* Satisfaction**
Physical 4 (3) vs. 5 (3) 15 (4) vs. 16 (4)
Psychological 4 (3) vs.5 (3) 14 (4) vs. 15 (3)
Social 3 (3) vs. 2 (2) 17 (3) vs. 16 (4)
Everyday life 3 (2) vs. 5 (3) 15 (3) vs. 14 (3)
*A score of 0 indicates no change, the maximum change
is 10 and 10, respectively; **Calculated as 0–20 (20s
max. of satisfaction); Ps0.08.
Conclusions: Transplanted CF patients are usually
younger than ILD patients. If the latter are matched for
age there are no sign. Differences as regards QoL.
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QUALITY OF LIFE (QOL) IN CYSTIC FIBROSIS
(CF) PATIENTS AFTER LUNG
TRANSPLANTATION (LTX): WHAT IS
IMPORTANT APART FROM IMPROVED TOTAL
SCORES?
G. Ullrich , H. Jdnsch , E. Scharf , W. Schulz , A.1 3 2 2
Freihorst , J. Niedermeyer1 3
Hannover Medical School, Department Pediatric Pulmon-1
ology and Neonatology, University of Braunschweig, Psy-2
chological Institute, Department Clinical Psychology,
Hannover Medical School, Department Internal Medicine3
and Pulmonology
LTx is now an established life saving measure in terminal
lung disease. Apart from time of survival studies also
addressed aspects of QoL. Irrespective of the particular
assessment of QoL it is always assumed that the patients
internal standard remains unaffected and that only the
amount of perceived QoL changes pre to post LTx.
Method: As a part of a larger study on psychological
aspects of LTx in CF patients versus patients with intersti-
tial lung disease we asked 37 CF patients to participate of
whom 28 returned the questionnaires (age 19–41 years;
mean age 31.6 y). Time since transplantation ranged from
1.1–10.5 years (median survival 4.8 y; 1 y survival request-
ed minimum for participation). To assess aspects of QoL
we used the MNnchner Lebensqualitdts Dimensionen Liste
(MLDL), a standardized questionnaire which lists 19
domains of QoL summarized and calculated as 4 scale
scores (cf. Heinisch et al. 1991). The MLDL was admin-
istered with three different instructions: (a) changes in the
respective domains; (b) changes in the perceived impor-
tance of the respective domain; (c) satisfaction with the
respective domain at present (results not shown).
Results: Table 1 shows that there not only is a significant
improvement of QoL after LTx but that there are corre-
sponding shifts in perceived importance of QoL, too.
Perceived improvement and perceived importance of QoL
wmean (99% CI)x in 28 CF patients
Instruction
MLDL scale* Improvement Importance
Physical 4.5 (3.0–6.0) 3.9 (2.4–4.4)
Psychological 4.8 (3.2–6.4) 2.1 (0.5–3.7)
Social 2.3 (1.2–3.4) 1.5 (0.0–3.0)
Everydaylife 4.7 (3.2–6.2) 3.3 (0.9–4.7)
*A score of 0 indicates no change, the maximum change
is 10 and 10, respectively.
Conclusions: After LTx there is an improvement of QoL
in CF patients but also some domains of QoL are being
valued more important which multiplies the overall
benefit of LTx.
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URAL’S CYSTIC FIBROSIS CENTER (RUSSIA):
QUALITY OF LIFE IN ADULTS
G.V. Pavlov, M.E. Devaikina
Ural Medical Academy, ul. Flotskaja 52, Ekaterinburg,
Russia
From 1972 to 2001 year 231 cystic fibrosis (CF) patients
have been followed at our center, of them 140 are alive. In
the past 30 years the median survival of our patients with
CF has increased less 6 years to more than 23 years. Patient
survival rates have increased because of new antibiotic ther-
apy and improved nutrition with pancreatic enzymes
replacements. As life expectancy improves, survival meas-
uring becomes less useful for outcome. The measurement
of quality of life (QoL) is now more important for this
patient population. The aims of the present study were to
assess QoL in a population of adults with CF, to compare
QoL with published scores from a healthy population, and
to examine the relation between QoL and other measured
clinical variables. QoL was assessed by the questionnaire
SF36 (J.E. Ware, Medical Outcomes Study Short Form).
Involved in the study were 28 CF patients of median age
20 years (range 16–39). For the patients with CF there
were significant differences from norms in following
aspects: physical activity (P-0.05), vitality (P-0.05),
general health (P-0.05). There is a strong relation between
perceived QoL and other measures of disease severity such
as FEV1 (%predicted) (P-0.05, rs0.49), breathlessness,
and the time spent on home treatment. Survival in adult-
hood has brought many additional problems such as fertil-
ity, psychological and social issues and so on. The
measurement of QoL can be used to assess these problems.
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EVALUATION OF CHANGES IN HEALTH-
RELATED QUALITY OF LIFE FOR
PARTICIPANTS IN THE ADULT CYSTIC
FIBROSIS PROGRAM
A. Quittner , M. Davis , M. Ray , A. Modi1 1 2 1
University of Florida, Gainesville, FL, USA, Abilities of1 2
Florida in Partnership with Department of Children and
Families, Gainesville, USA
Over the last 2 decades, there has been a dramatic increase
in the life expectancy of individuals with CF. Median life
expectancy is now 32 years and the majority of children
who are born with CF today can expect to live into adult-
hood. Little is known however, about the health care needs
of the adult population and how the provision of services
affects quality of life.
In response to this growing adult population, a health care
program for adults with CF (ACFP) was developed. In
2000, the ACFP was funded statewide to serve 120 adults
with CF. The objectives of the study were: (1) to evaluate
the services utilized by adults in the program and (2) to
examine how these services impacted health-related quality
of life (HRQOL).
Adults enrolled in ACFP between 1999 and 2000 were
asked to complete a HRQOL measure (the Cystic Fibrosis
Questionnaire; CFQ) once per year. The CFQ is a reliable
and valid HRQOL measure assessing functioning across a
variety of domains (e.g., Respiratory, Emotional) (Quittner
et al., 2000). Initial data on 110 adults (54% male) with
CF was analyzed. Average age of participants was 29 years,
with a mean FEV1% predicted of 52.
Preliminary analyses indicated that most participants util-
ized services, such as medical equipment, ADEK vitamins,
and nutritious food. The program also produced positive
changes in HRQOL, particularly in the areas of physical
and respiratory functioning, health perceptions, and body
image. Adults who received The VestT Airway Clearance
System were found to have higher CFQ scores on the Vital-
ity (ts2.3, P-0.05) and Respiratory scales (ts2.3, P-
0.05) compared to participants who did not receive it.
The current study expands this sample to include a total of
130 adults, with repeated assessments of HRQOL prior to
service delivery and annually over a period of 2 years.
Logistic regression and Poisson analyses will be conducted
to assess the impact of these services on HRQOL.
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‘NOW YOU SEE IT—NOW YOU DON’T’—THE
VANISHING GASTROSTOMY
G.D. Hooper, C. Mayer, S. Bell, S. Samuels, C.A. Campbell
North Staffordshire Cystic Fibrosis Centre, Stoke-on-Trent,
Staffordshire, UK
The importance of adequate nutrition in CF has been well
established, as have the higher energy requirements in CF
patients. Overnight enteral feeding often becomes necessary
in adult patients to maintain these requirements. If gastros-
tomy feeding is the chosen method, the importance of the
right choice of gastrostomy feeding tube is paramount for
the acceptance and well being of the patient. This becomes
an even bigger issue for the young attractive, fashion and
body conscious patients we all meet in our CF centres.
The now popular button gastrostomy devices are often cho-
sen to replace the more bulky tubes. However, for one of
our patients the button was not attractive due to the nec-
essary formation of a large tract, the regular changing
required, risk of the balloon bursting at inappropriate times
and the bulky appearance under fashionable clothing.
We therefore demonstrate an individual’s adaptability in her
choice of tube to fit in with her needs.
She has successfully adapted a Freka 9F gauge PEG tube
with an ingenious method of concealing the tube out of
sight enabling her to remain attractive and confident wear-
ing crop-tops and tight fitting clothing.
The small gauge of the tube means only a small residual
scar if the tube is to be removed later. We have always
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found these tubes to have excellent longevity, rarely prob-
lems with blockage, and are suitable to administer High
Energy feeds—2 kcalyml at a reasonable volume. Used
over 18 months it has not leaked or caused any other prob-
lems such as skin irritation.
In conclusion we show the importance of patients’ individ-
uality, life-style, choice and ingenuity when faced with the
prospect of long term gastrostomy feeding.
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A DIFFERENT PROJECT: HOLIDAY’S
INTERNATIONAL CENTER FOR CHILDREN
WITH CF
J.M. Roman, B. Osona, J. Figuerola, A. Rosell, J. Feliu
Department and Cystic Fibrosis Unit. Hospital Son Dureta,
Palma De Mallorca, Spain
Introduction: the center has been created by the Cystic
Fibrosis Unit of the Son Dureta University Hospital (Palma
de Mallorca), working together with the Esplai de les Illes
Foundation. Its activity aims at helping the patients and
their families at the understanding of their illness and final-
ly at fulfilling the suitable behaviours to improve it.
Aims: the main objective is to provide the affected children
with medical and sport facilities. The temperate climate on
Majorca throughout the whole year allows the center to
combine activities at the open air with specialized medical
care. The patients have on this setting a complete control
of their illness along their weekly or monthly stay in an
adequate atmosphere with suitable facilities.
We develop medical, educational, dietetic and kinesitherapy
programmes adapted to the child and adolescent pedagog-
ical and psychological needs, promoting the treatment com-
pliance and the self-care.
Center features: the center is situated 2 km far from a
hospital and 12 km from the capital city Palma de Mallorca.
Among its facilities include a gymnasium, a swimming
pool, classrooms, breathing rehabilitation rooms, lung func-
tion laboratory and outdoor sport facilities.
The staff is comprised by pediatricians, pulmonologists,
gastroenterologists, and otolaryngologists, and the para-
medical staff: kinesitherapists, psychologists, educators,
nurses and nutrition specialists.
Conclusions: the programmes developed on this center
allow a complete control of the illness guided by an expert
team, together with sport and leisure activities with the aim
of improving the quality of life in cystic fibrosis patients.
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VAGINAL DISORDERS IN CF WOMEN:
PRELIMINARY RESULTS OF A NURSE LED
STUDY
L. Longo, S. Speri, G. Sartori, R. Doro
Cystic Fibrosis Center of Veneto, Verona, Italy
The clinical course of cystic fibrosis heavily conditions the
quality of life of affected people. In order to control res-
piratory infections, CF patients often need frequent courses
of high doses antibiotics.
Little attention has been given so far by the literature to the
side effects of antibiotic therapy on the genital apparatus
of women with CF. Because of the considerable use of anti-
biotics CF women are likely to be more susceptible to gen-
ital infective disorders.
The aim of this study is:
– to provide data on the incidence of vulvo-vaginal symp-
toms in women with CF;
– to assess the influence of such symptoms on patients
quality of life.
The study was started on July 2001. Data were obtained
through a questionnaire administered by staff nurses to CF
female patients aged 10 or more, followed by the CF Centre
of Verona.
The questionnaire required patients to report:
– the number of antibiotic courses in the last year and the
route of administration;
– if they had vulvo-vaginal disorders during the courses;
– if and how the reported disorders affected their everyday
life;
– what kind of measures were taken.
Preliminary results: Ninety-four patients were examined.
All the patients received antibiotic therapy in the last year
(78% both per os and I.V.). 58% of them had more than
one antibiotic course per month. (range 13–24 courses per
year).
61% of the women reported vulvo-vaginal disorders.
The statistic analysis shows that IV administration of anti-
biotics caused a higher incidence of vulvo-vaginal symp-
toms (67% of patients who used IV administration vs. 27%
of patients who used only oral and aerosolized administra-
tion, Fisher test Ps0.007).
The effects of such symptoms were worse on sexual life
(23%) than on working life (7%).
Conclusions: The incidence of vulvo-vaginal disorders in
CF women receiving antibiotic therapy is high. Specific
nursing measures should be evaluated in order to prevent
and relieve such disorders.
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COMPLICATIONS WITH INDWELLING
CATHETERS IN CF PATIENTS FOLLOWED AT
THE UNIVERSITAL HOSPITAL IN LEUVEN
(BELGIUM)
M. Proesmans, L. Boulanger, K. De Boeck
University of Leuven, Leuven, Belgium
As in other CF centres, indwelling catheters are being used
at our centre for CF patients with difficult IV access need-
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ing frequent IV antibiotic therapy. These catheters might be
needed for many years and complications are not
infrequent.
We decided to document the type and frequency of catheter
related complications and compare our data with published
data from other CF centres.
From 1–96 until 12–2001, 42 catheters (CELSITE T205
Braun) were inserted for 36 CF patients (6 patients receiv-
ing a second catheter) out of a CF population of 160. Mean
age at the time of catheter insertion was 15 years
(s.d."4.75). 11 complications were documented, all lead-
ing to removal of the catheter: necrosis of the overlying
skin (ns1), cellulitis (ns1) and catheter infections (ns
9). Of the latter 6 catheter infections were caused by Can-
dida species alone, 2 by Candida and S epidermidis and 1
by Candida and E faecalis. In one of these patients, Candida
septicemia resulted in an ocular candida infection with par-
tial loss of vision despite intensive treatment with ampho-
tericin B. Mean insertion time for these 11 removed
catheters was 31 months (range 7–54; s.d. 13.7) which was
not significantly different from the catheters not removed
(mean 33.9; range 9–57; s.d. 15).
Compared to literature data our overall complication rate is
not higher (11 for 108 catheter years). However, most cen-
tres mainly document trombotic complications and not one
trombosis of the catheter is documented in this series. This
implies that the infectious complications are relatively more
frequent. Handling of the catheter outside our centre or
imprudent catheter handling by the patients themselves
might be involved. Re-education of our CF patients with
an indwelling catheter is warranted.
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TOTALLY IMPLANTABLE VENOUS ACCESS
DEVICE-RELATED INFECTIONS IN CYSTIC
FIBROSIS
N. Desmazes-Dufeu , D. Hubert , M.C. Douard , B.1 1 2
Delaisi , L. Agrario , C. Dupont , D. Dusser3 1 1 1
Service de Pneumologie, Hopital Cochin, Paris, France,1
Service d’Anesthisie, Hopital Saint Louis, Paris, France,2
Service de Pidiatrie Gastro-entirologie, Hopital Robert-3
Debri, Paris, France
Totally implantable venous access devices (TIVAD) have
an essential role via the frequent delivery of antibiotics in
cystic fibrosis (CF) patients. Percentage of infectious com-
plications in retrospective previous studies is between 7 and
19%. We report on 3 CF patients with TIVAD-related infec-
tion having the same clinical presentation.
Data concerning these patients are in the table below.
Patients have fever, tachycardia, sometimes hypotension
and cutaneous rash, after needle insertion into the TIVAD
and flush of saline serum on the line. These symptoms
appeared several times before the diagnosis of TIVAD-relat-
ed infection was established. Pulmonary embolism or aller-
gy were the other hypothesis. Paired quantitative blood
cultures (PQBC) obtained simultaneously from the TIVAD
and a peripheral vein lead to the diagnosis in patients 1 and
3.
In patient 2, culture from the septum and the tip after
removing the TIVAD confirmed the diagnosis. No patient
had local signs of skin infection. Infected clots ant partic-
ulate matter were found below the silicone septum of the
reservoir.
Thus infected deposits in the reservoir were, in these
patients, the source of TIVAD-related infection.
Patient Age Sex Symptoms Time
before
diagnosisa
Microorganismb
1 31 M Fever 3 Corynebacterium
2 20 M Septic shock
and cut.
rash
6 Aspergillus sp.
3 17 F Septic shock 2 Torulopsis
Glabrata
Month.a
Microorganism observed in TIVAD (tip, septum) forb
patient 2, and in PQBC for patients 1 and 3.
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THE PREVALENCE OF URINARY
INCONTINENCE IN THE ADULT MALE
POPULATION OF A REGIONAL CYSTIC
FIBROSIS CENTRE
L. Gumery , G. Hodgson , N. Humphries J. Sheldon , D.1 1 1 1
Stableforth , W. Mackenzie , D. Honeybourne , G.2 3 2
Hawkins4
Physiotherapy Department, Adult Cystic Fibrosis Centre,1
Birmingham Heartlands Hospital, Adult Cystic Fibrosis2
Centre, Birmingham Heartlands Hospital, Obstetrics and3
Gynaecology Department, Birmingham Heartlands Hospi-
tal, Physiotherapy Department, Women’s’ Health, Bir-4
mingham Heartlands Hospital
The reporting by adult cystic fibrosis males of symptoms
of urinary incontinence led to this study to identify preva-
lence and offer treatment as appropriate. Prevalence within
the normal male population ranges from 1.6%, age 15–64
years (Thomas et al., 1980) to 5.0%, age range 20–96
years (Temml, 2000). Temml states that prevalence is 1.7%
(age range 20–29), 2.7% (age range 30–39), 3.9% (age
range 40–49) increasing to 11.5% in males over 70 years.
Prevalence increases with age and predisposing factors such
as chest infection and increased cough. Data varies as prev-
alence may be under-reported and under-recognised due to
stigma. 90 CF males (age range 16–51 years, mean age 28
years) were posted a self-administered anonymous ques-
tionnaire developed from the work with females by Orr et
al. (2001). Fifty-six males (62.2%) replied and 7y90
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(7.8%) reported persistent symptoms, independent of chest
condition. Of respondents reporting symptoms, 8.6% (3y
35) were aged 20–29 and 12.5% (4y32) were aged 30–
39.
Respondents were embarrassed by symptoms and did not
realise treatment was available, therefore had not previously
reported them. Activities increasing symptoms were spi-
rometry, airway clearance techniques (ACT), coughing and
laughing. Management of symptoms may be improved by
early diagnosis and referral to professionals, including the
urologist and specialist continence physiotherapist. Advice
and exercises to minimise symptoms may increase adher-
ence to ACT due to reduced fear of leakage. Results indi-
cate that under-recognition and under-reporting of urinary
incontinence due to lack of awareness by patients and staff
is evident. An information leaflet has been developed and
a section on urinary incontinence added to the annual
assessment. Prevalence of urinary incontinence (7.8%) is
greater than normal in the adult CF male population of this
regional centre and should always be considered as treat-
ment may enhance adherence to ACT.
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AN AUDIT OF INHALER KNOWLEDGE AND
TECHNIQUE IN ADULTS WITH CYSTIC
FIBROSIS AT A REGIONAL CENTRE
R. Davies, C. Diver, L. Gumery, D. Honeybourne, D.
Stableforth
Birmingham Heartlands Hospital, Adult Cystic Fibrosis
Centre, Birmingham, UK
Inhaler therapy is widely used in cystic fibrosis (CF) treat-
ment, to deliver Bronchodilators and corticosteroids directly
to the airways. To date there has been no published docu-
mentation regarding the effects of an educational pro-
gramme on inhaler knowledge, techniques and drug usage
in adults with CF.
Extensive research has been undertaken with respiratory
diseases such as asthma and chronic obstructive pulmonary
disease. Research into these respiratory groups has shown
that poor inhaler knowledge and technique is improved
with education. The study aimed to assess knowledge and
technique of administration of inhaled bronchodilators and
corticosteroids. A review of 191 CF medical notes showed
that 67% (ns127) of patients are prescribed inhaler treat-
ment. Assessment took place at home visits, during in-
patient stays or at annual review. A questionnaire was
devised to assess patients knowledge of dosage, timing and
drug effects. Care and cleaning of the inhaler and spacer
devices were monitored. Inhaler technique was observed
and assessed using the National Asthma and Research
Training Guidelines.
Re-education of knowledge and inhaler technique took
place if found to be inadequate. 39% (ns50) patients have
undergone the assessment process.
Results showed that all patients knew the correct dosage of
prescribed medication. A total of 67 inhalers were used by
50 people. 91% (ns61) were taken at the correct time.
Patients were asked to describe the action of each inhaled
drug. 70% (ns35) were taking inhaled bronchodilators, of
which 100% knew the effect. 84% (ns42) were taking
inhaled corticosteroids, of which 44% (ns18) did not
know the effect. 70% demonstrated good inhaler technique
at the first attempt. 30% (ns15) failed at first attempt but
after re-education all succeeded. Inhaler knowledge and
technique was not optimal.
An educational programme and regular review of patients
using inhalers has been highlighted which is now part of
clinic assessment and annual review.
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THE DIAGNOSIS OF CF BEYOND INFANCY:
ARE PRESENTING FEATURES MILD OR
MISSED?
J. Leaver, M. Turner, T. David, L. Patel
Department of Child Health, University of Manchester and
Booth Hall Children’s Hospital, Manchester, UK
Background: Delayed diagnosis of CF causes distress to
families. Diagnosis beyond the 1st year of life could be
related to variation in disease pattern or inadequate recog-
nition of the typical features. We therefore assessed current
presentation patterns to a regional paediatric CF unit in
England with 100 patients.
Hypothesis: Diagnosis of CF after the 1st birthday is asso-
ciated with atypical presentation (without fat malabsorp-
tion) or mild disease (weight )10th centile).
Methods: Case-notes of new diagnoses of CF between
March 2000 and March 2001 were studied retrospectively.
We defined Infant diagnosis and Childhood diagnosis as
that made before and after the 1st birthday, respectively.
Results: There were 5 infant diagnoses (1 male; median
age 15 wk) and 5 childhood diagnoses (2 male; median age
5.2 yr). One antenatal diagnosis and 1 diagnosis in the
immediate postnatal period due to meconium ileus were
excluded. All infants and 2y5 children (P-0.05) had fat
malabsorption. Infant diagnosis was associated with per-
sistent cough (ns1), poor weight gain despite adequate
intake (ns2) or both (ns2). Childhood diagnosis was
associated with persistent cough (ns5) and clubbing (ns
1). At diagnosis all infants and 1y5 children were below
the 10th centile for weight (P-0.01). Parents had concerns
within 6 months of birth in 9y10 cases. Infants had had
symptoms for 9 to 31 wk and children for 1.7 to 6.0 yr
before diagnosis. Other features included nasal discharge (1
infant, 3 children), oedema due to hypoproteinaemia (4
infants, 1 child), macrocytic anaemia (4 infants, 1 child),
salty taste (4 infants, 1 child), chest X-ray abnormality (4
infants, 4 children), and S. aureus (5 infants, 2 children)
and P. aeruginosa (1 infant, 1 child) from cough swabs.
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Conclusions: The hypothesis was supported. The presen-
tation of CF )1 yr age can be atypical and not necessarily
with chronic lung disease plus steatorrhoea.
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IMPLEMENTATION OF KEY EDUCATIONAL
PACKAGES INTO A REGIONAL CYSTIC
FIBROSIS CENTRE
S. Hill, K. McInerney, L. Wilson, K. Davies, C.
O’Callaghan
University Hospitals of Leicester Cystic Fibrosis Centre,
Leicester, UK
Background: With advances in Cystic Fibrosis knowledge
and treatment comes improved quality and quantity of life.
This demands in-depth planning and education to meet cur-
rent and future needs of children and their families.
Currently within the Leicestershire Cystic Fibrosis centre
we care for approximately 70 patients from birth to tran-
sitional age. Despite education being provided in our centre
it was recognised that this required formalising and devel-
oping. It was apparent that education was also needed for
allied health care workers not directly involved with the
care of children with cystic fibrosis.
Aim: To implement and evaluate educational packages
within our Cystic Fibrosis centre.
Implementation: Feedback from families, children, ward
staff and team members highlighted areas of need. Trial
packages were developed and introduced in the following
areas:
● Parentycarer information and teaching evenings
● Home Intravenous Administration booklet (2000 Leics)
● Self medication programme (2000 Leics)
● Disability Living Allowance booklet (1998 Leics)
● Partnership In Care school study days (1999 Leics)
● TeachingyPlay box for longline and portacath education
● Bi-annual newsletter
Evaluation of the packages has enabled some to be incor-
porated into the CF team s ongoing educational programme.
Others remain at the pilot stage of development. All are
readily available in clinic, ward and community settings.
Our Partnership In Care study days have been attended by
228 School Carers over a 2-year period. All participants
returned evaluation questionnaires. The respondents all
found the program to be valuable.
Conclusion: We have successfully developed and imple-
mented educational packages into our service. These
encompass many areas of CF care, and have proved of ben-
efit to our children, families and allied health care workers.
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INFECTION CONTROL POLICIES IN A CYSTIC
FIBROSIS CENTRE—WHAT DO PATIENTS
WANT TO DO?
A. Bowling, M. Dodd, J. Milnes, K. Webb, A. Jones
Adult CF Centre, South Manchester University Hospitals
NHS Trust, Manchester, UK
Introduction: We have documented evidence of P. aeru-
ginosa cross-infection at our CF Centre.
(1) The CF Trust has published recommendations that
patients receive their care in single rooms and avoid visiting
each other’s rooms. (2) Our facilities comply with the rec-
ommendations but patients continue to enter each other’s
rooms. We decided to encourage patients to make an
informed decision on the guidelines. A signed questionnaire
was introduced to document patient wishes and understand-
ing of the guidelines.
Methods: The questionnaire was administered by the nurs-
ing staff on admission and audited over a 4-month period.
Microbiological status was noted.
Results: 72 questionnaires were completed by 51 patients
for 87 admissions during the 4-month period; 32 were
admitted once, 31 twice and 9 on three occasions. Most
(48y51) patients had chronic P. aeruginosa infection; 26
harboured sporadic strains, 19 a highly transmissible strain
and for 3 typing is awaited. All 51 patients reported that
the CF Trust recommendations had been discussed. Only 1
patient thought he did not understand the guidelines. 48y
51 patients agreed not enter other patients’ rooms, 2 did
not and 1 was unsure. 15y51 patients felt it was acceptable
for patients to enter their room, 34 did not and 2 would
give permission under special circumstances. On subse-
quent admissions, 5y18 patients reversed their decisions.
There was no difference in answers for patients who har-
bour sporadic and highly transmissible strains of P.
aeruginosa.
Conclusions: This questionnaire identifies lack of knowl-
edge in infection control guidelines and enables the nursing
staff to support patients in their wishes. Patients may
change their mind, so the questionnaire should be repeated.
References:
1. Jones et al., Lancet 2001.
2. CF Trust Control of Infection Group.
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STARTING SCHOOL PROGRAMME—AN
EDUCATIONAL PACKAGE AIMED AT A
TROUBLE-FREE INTRODUCTION TO SCHOOL
FOR CHILDREN WITH CYSTIC FIBROSIS
A. Mill, E. Thomson
CF Clinic, Royal Aberdeen Children’s Hospital, Aberdeen,
UK
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Starting nursery or primary school can be an anxious time
for any child and family. For the child with CF, there are
increased anxieties relating to coughing, infection, eating
and toileting. In our experience at the Royal Aberdeen Chil-
dren’s Hospital, problems have arisen due to school staff
having little or no experience of CF. The CF nurse and
dietitian designed a ‘Starting School Programme,’ to pre-
empt these issues. It includes an information pack and
school visit. The programme is aimed at making the intro-
duction to school easy and positive for the child. Other aims
of the programme are to raise awareness of CF in schools
and nurseries, educate staff, alleviate staff and parental anx-
iety, and improve communication between the school and
the CF team.
The issues mentioned above are discussed with parents and
carers at the child’s annual assessment prior to starting
school. We introduce the programme and offer to contact
the school to arrange a 30–45 min visit fitting around the
school timetable. Parents, carers and as many appropriate
school staff as possible are encouraged to attend. The
schools are given an information pack to keep with the
child’s records. The pack is individualised and includes the
child’s details and contact numbers for the local CF team.
It also contains relevant CF trust literature and a factsheet
pertaining to pancreatic enzyme therapy. Topics covered at
this visit include, a basic overview of CF and the disease
process, infection, symptoms, nutrition, enzymes and mal-
absorption, physiotherapy, exercise and class projects.
This programme has been running for a year and 8 locations
have been visited. All schools approached, welcomed a vis-
it. Attendance from all disciplines was very good and many
pertinent issues were raised. Some staff admitted to being
very anxious about having the child in their class and were
reassured at the meeting. We are in the process of following
up the programme using a questionnaire.
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ECHOGENIC BOWEL ON ULTRASOUND SCAN
LEADING TO ANTENATAL DIAGNOSIS OF CF:
THE ROLE OF THE CF TEAM
J.J. Cottrell, E.F. Burrows, D.P. Heaf
Royal Liverpool Childrens Hospital, Alder Hey, Liverpool,
UK
In the past 3 years we know of 4 cases of echogenic bowel
detected at antenatal ultrasound (US) scan at 20y40 which
have led to CF screening for the parents and amniocentesis
of the foetus. We present the 4 cases and their different
outcomes.
1 US scan 20y40 showed echogenic bowel. Mother
DF508, Father DF508, foetus DF508yDF508. Genetics
referral and CF Team informed. Outcome: male infant born
29 weeks q3 by emergency Caesarian section due to pre-
eclamptic toxaemia in the mother. Meconium Ileus, ileos-
tomy on Day 9.
2 US scan 22y40 showed echogenic bowel. Mother
DF508, Father DF508, foetus DF508yDF508. Genetics
referral and CF Team informed by Obstetric team. Out-
come: Termination of pregnancy.
3 US scan 20y40 showed echogenic bowel. Father
DF508, Mother showed to be negative of 20 mutations,
foetus DF508y? Referral to Genetics declined and referral
to CF team not offered. Outcome: female born term, spon-
taneous delivery with meconium stained liquor. Baby pre-
sented 12y52 Failure to thrive and chest symptoms.
4 US scan 20y40 showed echogenic bowel. Mother
DF508, Father DF508, foetus DF508yDF508. Genetic
referral made but CF team refferal not offered. Parents self-
referred to CF team.
Outcome: male infant born 38 weeks q2. MI, ileostomy
day 2.
All parents were seen by CF consultant and CF nurse spe-
cialist and given a detailed explanation of CF; daily treat-
ment, prognosis, impact on the family, meconium ileus and
its management. For those pregnancies which continued,
the CF nurse maintained regular contact offering support
and information. The CF nurse has a key role in the support
of the family and liaison between the Teams involved. It is
the CF nurse who provides continuity for the parents in the
antenatal and postnatal period.
Improved communication with the Specialist Midwives will
inform them that the CF Team is available to provide a
service in the antenatal period and that this can be offered
to any couple in this situation.
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AN UNUSUAL COMPLICATION OF ‘TOTALLY
IMPLANTABLE VENOUS ACCESS DEVICES’
(TIVAD) IN PATIENTS WITH CYSTIC FIBROSIS
Kerstin Herlitz , Mary Ferrell , Esa Petersson , Inger1 2 3
Erwander4
Department of Pediatrics, Gvteborg University, Depart-1 2
ment of Repiratory Medicine, Gvteborg University,
Department of Pediatrics, Karolinska Institutet Stockholm,3
Department of Pediatrics, Lund University4
The aim of the investigation was to establish how common
it is that TIVAD catheter is unable to be removed among
CF patients in the Swedish CF population. Many CF
patients require treatment with i.v. antibiotics repeatedly
and over long periods of time. The TIVAD is considered
to be a safe and effective method of administrating i.v. anti-
biotics. Patients: One hundred and fifty-two patients with
TIVAD from three of the four CF centers were included.
Which covers 85% of the total Swedish CF population.
Results: Of the patients who had complications with their
TIVAD, four (3 Fy1 M mean age 23 yr, range 10–35 yrs)
had catheters that were impossible to remove. All four have
severe genotypes, three of them are homozygous for dF508
and one is homozygout for 3659del C. All were colonized
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with Pseudomonas areguinosa. The average FEV 1.0 was
67% (range 46–85%) and over a period of 8 years or more
these patients received an average of 5 antibiotic treatments
yearly. The TIVADs were not used for parenteral nutrition
in any of the patients. Three of the TIVAD catheters had
been in situ for 9–10 years without any complications,
while the remaining one only had been in situ for 6 months.
Conclusion: Catheters that can not been removed is a new
complication for us and it is more common than we pre-
viously thought in approximately 3% of the TIVAD
patients. The underlying cause is unknown.
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A REVIEW OF THE HOMECARE SERVICE
OFFERED BY A PAEDIATRIC CYSTIC FIBROSIS
CLINIC
J. Burton
Great Ormond Street Hospital for Children NHS Trust
Aims: Our centre established a homecare service in 1998
to complement and enhance the current in and outpatient
CF service, which cares for 200 patients in the south east
of England. The aims of this review were to evaluate the
homecare service since its establishment, to identify the
patient groups seen and examine visit demographics.
Method: Details of all visits were entered into a database
including (a) number of visits; (b) reason for visits; (c)
length of visits; (d) travelling time and distance; and (e)
visits carried out with other health care professionals
(HCPs).
Results: To date 537 visits have been carried out for 98
patients. Sixteen different categories of visit types were
established, including clinical assessment, home intrave-
nous antibiotics (HIAs), newly diagnosed, psychosocial
support, teaching of new treatments, school visits and
health care professional visits. The mean number of visits
per patient was 5.5 (range 1–33) and mean visit time was
53 min. Mean travelling time was 71 min and mean mileage
was 27.8 miles. Of the 537 visits, 144 (26.8%) were for
clinical assessment, 104 (19.4%) for admission follow up,
51 (9.5%) for newly diagnosed patients, 39 (7.3%) during
HIAs, 34 (6.3%) school visits for teaching staff and 26
(4.8%) for pre admission assessment. Of the total visits, 84
(15.6%) were joint visits with another HCP.
Conclusions: Homecare visits are undertaken for a variety
of reasons. Over 25% were for clinical assessment, reduc-
ing the time spent by families attending hospital and
increasing their ability to continue with schooling and
employment. Almost 10% of visits were to newly diag-
nosed patients, to teach CF care and support the family after
the diagnosis. These two groups reflect the aims of the serv-
ice, which is to provide extended specialised care to fami-
lies and decrease the burden of attending hospital. This
audit has illustrated some difficulties in our current data
collection and a more comprehensive database is being
devised.
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AN INVESTIGATION INTO THE FACTORS
AFFECTING ADHERENCE TO DRUG
TREATMENT IN AN ADULT CYSTIC FIBROSIS
POPULATION
P. Kelly , S. Elborn , L. Stevenson , J. McElnay1 1 2 2
Department of Respiratory Medicine and Cystic Fibrosis,1
Belfast City Hospital, School of Pharmacy, Queen’s Uni-2
versity of Belfast
Aims: Adherence to therapy is an important issue in Cystic
Fibrosis as non-adherence may have a negative effect on
disease status and progression. The present study was
undertaken to determine the influence of the following fac-
tors on adherence to drug treatment in adults with cystic
fibrosis, knowledge of medication and disease state, per-
ceived positive benefits from taking medication and prob-
lems associated with taking a particular drug.
Method: Data were collected using a questionnaire and
face-to-face interviews with cystic fibrosis adults at Belfast
City Hospital. Specific questions were asked to ascertain
patient’s knowledge of disease and their medication. Per-
ceived positive benefits of medicines was assessed using
the Beliefs about Medicines Questionnaire (BMQ). Self-
reported compliance was used to assess adherence to drug
treatment. Patients were asked if they skipped doses, forget
to take medication or run out of medication.
Results: 44 patients participated in the study. No correla-
tion between compliance and patient knowledge of their
medication or disease state was observed (Ps0.678 and
Ps0.87, respectively). A higher BMQ score was found in
adherent patients with a mean of 41 compared to 37 in the
non-compliant population (ns22, Ps0.06). Scores ranged
from 26 to 49 and the most frequent score was 37. There
was a negative correlation between patients experiencing
problems taking their medication (e.g. suffering side-
effects) and adherence with these medicines (Ps0.04).
Conclusions: This study suggests that a major factor deter-
mining compliance is patients perceived benefits of medi-
cation. Increased knowledge about disease state and
medication is not related to better compliance. If a patient
experiences problems with medicines (e.g. experiences
side-effects) it has a negative effect on compliance.
Reference
1. Horne, R. Weinman, J, Hankins, M. (1999) The Beliefs
about Medicines Questionaire: The development and eval-
uation of a new method for assessing the cognitive repre-
sentation of medication. Psychology and Health 14, 1–24.
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STABILITY OF PIPERACILLIN AND
TAZOBACTAM IN A PORTABLE PUMP
RESERVOIR AND SYRINGE
M. Kuck, M. Brouwer, D. Touw
Central Hospital Pharmacy, The Hague, The Netherlands
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Objective: To assess the stability of piperacillin (P) and
tazobactam (T) in a portable pump reservoir (PPR), used
for home continuous i.v. antibiotic treatment, during storage
at y200, q50, q370 8C and in syringes used for clinical
continuous i.v. antibiotic treatment during storage at q200
8C (room temperature).
Methods: For each temperature three 100 ml PVC PPRs
were filled with a solution of P and T in water for injection;
concentrations were 120 mgPyml and 15 mg Tyml. The
concentration of P resp. T were in the syringes 40 mgyml
resp 5 mgyml. Before storage of the PPRs at y200 8C for
each measuring point samples were taken and stored at y
200 8C. During storage samples were analysed at regular
intervals over a period of 0–70 days (y200 8C), 0–28
days (q50 8C), 0–24 h (q370 8C) and 0–8 h (q200 8C).
The solutions were inspected for visual changes and drug
concentrations were determined by a stability-indicating
high-performance liquid chromatographic procedure. The
dose that could be delivered out of the PPR kept at q370
8C was calculated by using the AUC of the concentration
time plot.
Results: PyT solutions were stable (no more than 10%
reduction from initial concentration and no detectable
changes in solution colour and clarity) during 70 days at
y200 8C, 28 days at q50 8C in the PPRs and 8 h at q
200 8C in the syringes. It was calculated that during 24 h
more than 90% of the nominal dose would be delivered out
of the PPR kept at q370 8C.
Conclusions: The results of this study demonstrate that Py
T can be used in home intravenous antibiotic treatment. The
PPR can be stored in the patient s freezer (y200 8C) for
the course of the therapy. After thawing PyT can be admin-
istered by continuous intravenous infusion during 24 h. The
syringes can be used during 8 h at room temperature.
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COMPARISON OF HOSPITAL AND HOME
INTRAVENOUS ANTIBIOTIC THERAPY IN
ADULTS WITH CYSTIC FIBROSIS
G. Esmond , M. Butler , A. McCormack , D. Empey1 2 2 2
City University, London, Barts and The London adult cys-1 2
tic fibrosis centre
The concept of home intravenous antibiotic therapy for
acute respiratory exacerbations is rapidly becoming popu-
lar, in response to economic pressures and patient choice.
Comparison of hospital and home intravenous antibiotic
therapy in adults with cystic fibrosis for clinical outcomes
and quality of life was studied using a quasi-experimental
design. A pre- and post-test was used to measure clinical
outcomes of Forced Expiratory Volume in 1 s (FEV1),
Forced Vital Capacity (FVC), oxygen saturations (SaO ),2
Body Mass Index (BMI) and quality of life using the Cystic
Fibrosis Quality of Life (CFQoL) questionnaire.
Thirty adult cystic fibrosis patients (15 hospital and 15
home) were recruited to the study once they had chosen
where they undertook their treatment. There were 6 females
and 9 males in the hospital group and 9 females and 6 males
in the home group which was on average 4 years older.
When the groups were compared for clinical outcomes the
hospital group showed greater improvement in Forced Vital
Capacity (P-0.01). There were no differences in quality
of life when the hospital and home groups were compared
(P)0.05), although changes achieved with treatment
showed differences in five of the nine quality of life
domains.
Lung function improved more in the hospital group, sug-
gesting that acute respiratory exacerbations were not as
effectively treated at home. Although there were no differ-
ences in quality of life between the home and hospital
groups, the Cystic Fibrosis Quality of Life (CFQoL) ques-
tionnaire was able to detect transient changes in health stat-
us during the course of intravenous antibiotics.
If the patients right to choose where they receive treatment
is to be supported, further research is required to determine
the reasons for home care being less clinically effective in
treating acute respiratory exacerbations in cystic fibrosis
patients.
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ADHERENCE TO PHISIOTHERAPY IN C.F.
PATIENTS
M.C. Guenza , R. Pescini , M. Gremmo1 2 1
Rehabilitation Department, Cystic Fibrosis Centre, Gas-1 2
lini Institute, Genoa, Italy
In defining the word ‘compliance’ we mean the adherence
to therapeutic regimens with the correct knowledge and
proper application of the treatment programme. This defi-
nition synthesizes the way in which the behaviour of the
patient coincides with the general medical protocols con-
nected with health. In C.F. patients, the reported percentage
of non-compliance is 50%. This has led us to analyse the
situation, putting the concept of compliance itself, and the
factors which influence it under discussion. There are dif-
ferent aspects relative to therapeutic regimens which may
influence the adherence. Every factor has its own impact
and, for this reason, it is essential to see the problem as a
whole and to view the relationships that interact from all
perspectives. The breathing rehabilitation of a C.F. patient
is a fundamental element in the proper management of the
disease. The rehabilitation programme must be tailored for
every individual patient, on the basis of their capacity and
clinical needs, attempting to gain the highest level possible
of adherence to the programme. The C.F. patient often
underestimates the complexity of the pathology whilst over-
estimating their capacity of controlling the disease itself.
This mechanism can cause enormous difficulty in com-
munication. If, in the carrying out of the medical rehabili-
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tation model, the physiotherapy programme and the
relationship between the therapist and patients are two sep-
arate entities, which seem apparently distant, the result in
the ‘bio-psycho-social’ rehabilitation model will assume a
different significance. In our study we have chosen two
different tools to evaluate the patient’s adherence to the
treatment in order to compare two different sets of results.
These results can be used not only for statistical purposes,
but, above all, to reach the objective of improving compli-
ance in physiotherapeutic programmes.
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PHYSIOTHERAPY OF CF ADULT PATIENTS IN
THE CZECH REPUBLIC
L. Smolikova , V. Vavrova , D. Zemkova1 2 2
UH Motol, Clinic of Rehabilitation, 2nd Medical Faculty1
of Charles University, Prague, UH Motol, 2nd Pediatric2
Clinic, 2nd Medical Faculty of Charles University, Prague
Modern physiotherapy techniques of CF patients are fully
practiced since 1990. The elementary basis for their imple-
mentation is closely connected with the end of information
embargo and the beginning of intensive international coop-
eration in CF Physiotherapy branch.
Aims: Physiotherapy of CF adults-training programmes in
the Czech Republic.
Methods: following methods are currently used in physi-
otherapy of CF: inhalation therapy includes mucolytics,
antiobiotics and rhDNase, bronchodilators. ACT-autogenic
drainage, flutter, breathing techniques with cough control,
active cycle of breathing techniques, huffing, expectoration
with cough control, mobilisation and relaxation techniques,
physical training and exercises, non-invasive ventilation.
Physiotherapy is practiced for in- and out-patients as prac-
tical consulting sessions. For the last 2 years physiotherapy
has been concentrated on patients on the Lung Transplan-
tation waiting list as well as patients after lung transplan-
tation. One part of physiotherapy is concentrated on
oxygen-dependent patients and patients in the CF end stage
stadium.
Complex database in UH Motol comprises all patients treat-
ed since 1985. We have data of 384 living CF patients, 158
died after 1985, 12 were lost from evidence. 28.5% of these
patients are older than 18 years. 263 of CF patients are
treated in UH Motol CF Center. Physiotherapy is given to
all these patients in daily practice by 3–5 physiotherapists
in Prague CF Center as well as in smaller centers of 4
University Hospitals in our country.
Conclusions: In the last 10 years physiotherapy as well as
all system of treatment of CF patients in Czech Republic
was improved and completely rebuilt. Also thanks to those
changes in physiotherapy the life expectancy in 2001 was
29.22 years. Median age at death increased from 12.2 years
for 48 patients who died between 1985 and1990 to 19.04
years for 60 patients who died 1991–1999 (Ps0.029).
Supported by Grant VZ 111300003 MSMT.
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MUSCULOSKELETAL PROBLEMS IN AN ADULT
CF UNIT
R. McVean, H. Langman, A. Orr, A. Webb, M. Dodd
Adult CF Unit, Wythenshawe Hospital, Manchester, UK
With improved survival, musculoskeletal (MS) problems in
CF are increasingly reported. 1. We have appointed a CF
physiotherapist designated to assess MS problems. This
report analyses the referrals over the first 18 months of the
post.
Twenty-two patients (5 with multiple problems) were
assessed. The mean (range) age, FEV1 and BMI were 28
(18 39) years, 57 (17 91)% predicted, and 22.3 (17.5 27.7)
Most referrals were for low back pain (LBP) (8) and tho-
racic pain (TP) (7). The remainder were for joint problems;
knee pain (2), shoulder pain (2), cervical pain (2), hip pain
(1), wrist pain (1), leg pain (1) and multiple joint pain (1)
and postural advice (3). 14 had acute and 11 had chronic
pain.
Most patients with LBP and TP had poor posture. Symp-
toms improvedyresolved over 13 days (1–51) (median,
range) in 10y15. Treatment included joint mobilisation,
exercise and postural advice. Others have reported a high
incidence of back pain and postural abnormalities in CF
that can be corrected with postural therapy.1. Bone mineral
density was normal in 8y15, osteopenic in 2y15 and osteo-
porotic in 5y15.
2 peripheral joint problems were related to CF. These
patients presented with chronic shoulder pain whose symp-
toms were worse following weight training performed as
part of their treatment regimen. One had supraspinatus ten-
dinitis and the second had shoulder instability, probably due
to muscle imbalance related to overtraining of the anterior
muscles of the shoulder.
Initial results from analysis of this new service support the
importance of the post for treatment of acute pain and its
necessary quick resolution in relation to airway clearance
and mobilityyexercise. Further work is needed to investi-
gate the aetiology of spinal pain and assess the value of
postural exercise therapy in the prevention of spinal
problems.
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THE INFLUENCE OF BRONCHODILATORS ON
CHEST PHYSIOTHERAPY EFFECT IN
CHILDREN WITH CF
T. Orlik, D. Sands, L. Kluba
Institute of Mother and Child, Warsaw, Poland
The aim of our study was to estimate the influence of bron-
chodilators on chest physiotherapy effect in children with
CF. We studied 35 patients with CF (mean age 11.26 yrs;
range 7–17; 19 F) randomly selected into three groups.
Group A patients inhaling bronchodilator (Salbutamol)
before PT. Group B patients inhaling placebo before PT.
Group C patients without bronchodilator. In the first phase
of the study the patients were performing bronchial revers-
ibility test. On this ground we selected patients with bron-
chial hyperactivity. In second phase each patient was
performing PT. We measured: FEV1, FVC, FEV1yVC,
MEF25, 50, 75%, PEF before and after PT and weight of
coughed-up sputum during PT.
Results: In 15 patients we observed BHR. In this group we
found statistically significant decrease in FEV1, FVC, MEF
25% after PT. In patients without HBR we found significant
decrease in MEF 25% only. The application of bronchodi-
lator before PT increased all study parameters in both
groups. In case of FEV1, FVC, FEV1yVC, PEF the dif-
ferences were statistically significant in patients with HBR
and in PEF in group without BHR. However, analysis of
variance have not shown statistical differences between
both groups inhaling bronchodilator before PT. The biggest
quantity of sputum determined by its coughed-up weight
was in patients with BHR inhaling bronhodilator before PT
(xy12.41 g). However, analysis of variance have not dem-
onstrated significant differences in coughed-up sputum
between groups A, B, and C. In group without BHR only
patients inhaling bronchodilator before PT coughed-up xy
0.146 g sputum.
Conclusion: (1) Bronchodilators increase effectiveness of
PT determined by coughed-up sputum weight in patients
with BHR. (2) Bronchodilators do not increase effective-
ness of PT in patients without BHR. The conclusions
require confirmation by greater number of patients study.
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ADHERENCE TO PHYSIOTHERAPY AND
QUALITY OF LIFE IN CYSTIC FIBROSIS—
LITERATURE REVIEW
C. Ireland , M. Carroll1 2
Physiotherapy Department, Adult Cystic Fibrosis Unit,1 2
Southampton University Hospitals Trust, UK
With increasing age, care has become more complex pre-
senting patients with the dilemma of adhering to time con-
suming treatments which have a considerable impact on
their quality of life (QoL). Adherence to physiotherapy
(PT) has been reported in several studies as being poor in
spite of the recognised benefit of PT in reducing lung dam-
age and increasing exercise tolerance. There is little
research on adherence to PT and the impact it has on QoL.
Carr et al.’s (1996) study focused on the need to understand
the patient’s health beliefs when planning treatment.
Cross-sectional studies have focused on the reasons why
PT is not done. No longitudinal studies have been con-
ducted giving recognition to the possible variation in adher-
ence throughout disease progression. Recently attention has
been paid to defining adherence and recognising that 100%
adherence is abnormal (Lask 1997). If no discernible
improvement in QoL is evident then adherence is unlikely,
irrespective of medical advice. Studies have been conducted
to establish the impact of the disease and its treatment on
patients’ QoL. Validated Cystic Fibrosis (CF) disease spe-
cific questionnaires were not used until recently. In the USA
Quittner et al. (2000) validated a CF Questionnaire (CFQ),
based on the French CFQ, while Gee et al. (2000) have
validated one in the UK.
Conclusion: The review highlights the need for physioth-
erapists to do longitudinal studies on individually tailored,
evidence based treatments, accommodating the patients’
health beliefs in order to improve adherence to PT and
potentially their QoL.
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